Search Result
Results for "
antitumor+activity
" in MedChemExpress (MCE) Product Catalog:
2770
Inhibitors & Agonists
17
Biochemical Assay Reagents
66
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-13669
-
-
-
- HY-16568
-
|
(+)-Irinotecan hydrochloride trihydrate; CPT-11 hydrochloride trihydrate
|
Topoisomerase
Autophagy
|
Cancer
|
|
Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate) is a topoisomerase I inhibitor with antitumor activity .
|
-
-
- HY-17574
-
-
-
- HY-P99455
-
|
EMB-01
|
EGFR
c-Met/HGFR
|
Cancer
|
|
Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity .
|
-
-
- HY-N0865
-
|
(-)-Ingenol
|
PKC
|
Cancer
|
|
Ingenol is a PKC activator, with a Ki of 30 μM, with antitumor activity.
|
-
-
- HY-14798
-
-
-
- HY-16059
-
|
(+)-Arglabin
|
NOD-like Receptor (NLR)
Farnesyl Transferase
Autophagy
|
Inflammation/Immunology
Cancer
|
|
Arglabin ((+)-Arglabin), a natural product isolated from Artemisia glabella, is a NLRP3 inflammasome inhibitor. Arglabin shows anti-inflammatory and antitumor activities . The antitumor activity of Arglabin proceeds through its inhibition of farnesyl transferase which leads to the activation of RAS proto-oncogene .
|
-
-
- HY-101275
-
-
-
- HY-B0063
-
|
ST1481
|
Topoisomerase
|
Cancer
|
|
Gimatecan (ST1481) is a potent topoisomerase I inhibitor. Gimatecan is an orally bioavailable camptothecin analogue with antitumor activity .
|
-
-
- HY-135152
-
|
|
Reactive Oxygen Species (ROS)
|
Cancer
|
|
CYPMPO is a spin-trapping reagent. CYPMPO, a cyclic DEPMPO-type nitrone, is evaluated for spin-trapping capabilities toward hydroxyl and superoxide radicals. anti-oxidant and anti-tumor?activity .
|
-
-
- HY-111652
-
|
|
Drug Derivative
|
Cancer
|
|
S-Gboxin is a functional analog of the oxidative phosphorylation (OXPHOS) inhibitor Gboxin and has antitumor activity. S-Gboxin inhibits the growth of mouse and human glioblastoma with an IC50 of 470 nM. S-Gboxin has antitumor activity .
|
-
-
- HY-100453
-
|
|
STAT
Apoptosis
|
Cancer
|
|
HO-3867 is a selective and potent STAT3 inhibitor and shows good antitumor activity.
|
-
-
- HY-16513
-
VAL-083
2 Publications Verification
Dianhydrodulcitol; Dianhydrogalactitol
|
DNA Alkylator/Crosslinker
|
Cancer
|
|
VAL-083 is an alkylating agent that creates N7 methylation on DNA, with antitumor activity.
|
-
-
- HY-112570
-
|
|
ERK
|
Cancer
|
|
CC-90003 is an irreversible and selective inhibitor of ERK 1/2 with antitumor activity.
|
-
-
- HY-14846
-
|
LY2523355
|
Kinesin
Mitosis
|
Cancer
|
|
Litronesib (LY2523355) is a selective mitosis-specific kinesin Eg5 inhibitor, with antitumor activity .
|
-
-
- HY-P99108
-
-
-
- HY-132868
-
-
-
- HY-N7994
-
|
|
Others
|
Cancer
|
|
Hellebrigenol is a metabolite of bufadienolides with antitumor activity .
|
-
-
- HY-B0733
-
-
-
- HY-111411
-
IZCZ-3
2 Publications Verification
|
c-Myc
Autophagy
|
Cancer
|
|
IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity .
|
-
-
- HY-117244
-
AZD7507
2 Publications Verification
|
c-Fms
|
Cancer
|
|
AZD7507 is a potent and orally active CSF-1R inhibitor, with antitumor activity.
|
-
-
- HY-10818
-
|
|
Antifolate
|
Cancer
|
|
LY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase (GARFT), with a Ki of 6.5 nM, and has antitumor activity.
|
-
-
- HY-107549
-
|
|
HDAC
|
Cancer
|
|
KD 5170 is a pan inhibitor of histone deacetylases (HDACs) and exhibits broad spectrum antitumor activity in vitro and in vivo .
|
-
-
- HY-P99630
-
|
MM-302 antibody
|
EGFR
|
Cancer
|
|
Gancotamab antibody (MM-302) is a HER2-targeted antibody with antitumor activity .
|
-
-
- HY-159846
-
|
|
MEK
|
Cancer
|
|
Luvometinib is a mitogen-activated protein kinase (MEK) inhibitor with antitumor activity .
|
-
-
- HY-145716
-
|
Nafoxidene
|
Estrogen Receptor/ERR
|
Cancer
|
|
Nafoxidine, a nonsteroidal estrogen antagonist, is shown to possess antitumor activity against breast cancer.
|
-
-
- HY-N7595
-
|
|
Others
|
Cancer
|
|
Microhelenin C is a sesquiterpene lactone that can be isolated from Helenium microcephalum, with antitumor activity .
|
-
-
- HY-101007A
-
|
Tyrphostin AG 835; Tyrphostin B 50
|
EGFR
|
Cancer
|
|
(+)-Tyrphostin B44 (Tyrphostin AG 835) (Compound B50) is an EGRF inhibitor with antitumor activities .
|
-
-
- HY-116849
-
|
|
Others
|
Cancer
|
|
LY181984 is a compound in a series of orally active diarylsulfonylureas. LY181984 shows antitumor activity .
|
-
-
- HY-159844
-
-
-
- HY-103223
-
|
NSC 710305
|
Cytochrome P450
|
Cancer
|
|
Phortress is a high affinity AhR ligand that elicits antitumor activity by inducing transcription of CYP1A1 .
|
-
-
- HY-133571
-
|
AHGDM
|
HSP
ADC Payload
|
Cancer
|
|
Aminohexylgeldanamycin (AHGDM), a Geldanamycin derivative, is a potent HSP90 inhibitor. Aminohexylgeldanamycin shows antiangiogenic and antitumor activities .
|
-
-
- HY-13656
-
|
KOS-1803
|
Microtubule/Tubulin
|
Cancer
|
|
Isofludelone (KOS-1803) is a potential microtubule stabilizer for the study of solid tumors. Isofludelone has antitumor activity .
|
-
-
- HY-136486
-
|
|
Others
|
Cancer
|
|
Lasiocarpine N-oxide is a natural compound with antitumor activity .
|
-
-
- HY-159833
-
-
-
- HY-32364
-
|
|
Drug Derivative
|
Cancer
|
|
3-arylisoquinolinamine derivative is a 3-arylisoquinolinamine derivative with antitumor activity.
|
-
-
- HY-N4257
-
|
|
Others
|
Cancer
|
|
Yadanziolide A, a quassinoid glycoside from Brucea javanica, has antitumor activity .
|
-
-
- HY-177633
-
|
LY 2181308
|
Survivin
|
Cancer
|
|
Gataparsen is an antisense oligonucleotide directed against survivin mRNA with potential antitumor activity.
|
-
-
- HY-121895
-
|
|
Aurora Kinase
|
Cancer
|
|
BI 831266 is a potent and selective inhibitor of Aurora kinase B with antitumor activity .
|
-
-
- HY-147359
-
|
|
Antibiotic
Apoptosis
|
Cancer
|
|
Boanmycin is an antibiotic with antitumor activity that induces cellular senescence and apoptosis .
|
-
-
- HY-131374
-
|
|
CXCR
|
Cancer
|
|
TN14003 is a CXCR4 inhibitor. TN14003 has antitumor activity .
|
-
-
- HY-143359
-
|
|
Ras
|
Cancer
|
|
COTI-219 is an orally active inhibitor of KRAS. COTI-219 has antitumor activity .
|
-
-
- HY-133571A
-
|
AHGDM hydrochloride
|
HSP
ADC Payload
|
Cancer
|
|
Aminohexylgeldanamycin (AHGDM) hydrochloride, a Geldanamycin derivative, is a potent HSP90 inhibitor. Aminohexylgeldanamycin hydrochloride shows antiangiogenic and antitumor activities .
|
-
-
- HY-P99799
-
|
CX-072
|
PD-1/PD-L1
|
Cancer
|
|
Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity .
|
-
-
- HY-114248
-
|
|
CDK
|
Cancer
|
|
AGM-130 is a cyclin-dependent kinase (CDK) inhibitor. AGM-130 exhibits antitumor activity .
|
-
-
- HY-119626
-
-
-
- HY-13548
-
-
-
- HY-164039
-
|
|
Ras
|
Cancer
|
|
Talorasib (compound 1-2) has antitumor activity .
|
-
-
- HY-N7235
-
|
|
Others
|
Cancer
|
|
Lanatoside E is a cyclic triterpene saponin with antitumor activity .
|
-
-
- HY-121245
-
-
- HY-N7685
-
-
- HY-101604
-
|
Bestrabucil; KM2210
|
Drug Derivative
|
Cancer
|
|
Atrimustine is a conjugate of chlorambucil and β-estradiol benzoate with the antitumor activity.
|
-
- HY-P2157
-
|
|
Ras
|
Cancer
|
|
Ras Inhibitory Peptide (VPPPVPPRRR) is a Ras inhibitor with antitumor activity .
|
-
- HY-122146
-
-
- HY-129339
-
|
|
Fungal
|
Infection
Cancer
|
|
Akrobomycin is an anthracycline antibiotic. Akrobomycin shows antimicrobial and antitumor activities .
|
-
- HY-105035
-
|
Cytorhodin S; HLB 817
|
Drug Derivative
|
Cancer
|
|
Rodorubicin (Cytorhodin S) is a tetraglycosidic anthracycline with preclinical antitumor activity .
|
-
- HY-126651
-
|
NSC-56654
|
mGluR
|
Cancer
|
|
Azotomycin is an L-glutamine analog. Azotomycin has antitumor activity .
|
-
- HY-N4304
-
|
|
Others
|
Cancer
|
|
Gambogellic acid is an xanthone isolated from the processed gamboge, with antitumor activity .
|
-
- HY-10084
-
|
|
Kinesin
|
Cancer
|
|
CK0106023 is a potent and specific allosteric inhibitor of KSP with a Ki value of 12 nM, showing antitumor activity. CK0106023 causes mitotic arrest and growth inhibition in several tumor cell lines. CK0106023 exhibits antitumor activity in tumor-bearing mice .
|
-
- HY-149547
-
-
- HY-162410
-
|
|
MDM-2/p53
|
Cancer
|
|
Fluplatin is a prodrug composed of cisplatin and fluvastatin. Fluplatin has antitumor activity .
|
-
- HY-N14832
-
-
- HY-105890
-
-
- HY-177633A
-
|
LY 2181308 sodium
|
Survivin
|
Cancer
|
|
Gataparsen sodium is an antisense oligonucleotide directed against survivin mRNA with potential antitumor activity.
|
-
- HY-163137
-
|
|
Telomerase
|
Cancer
|
|
Telomerase-IN-6（6f）is a telomerase inhibitor with antitumor activity .
|
-
- HY-105164
-
|
BBR 3576
|
Drug Derivative
|
Cancer
|
|
Topixantrone (BBR 3576) is an antitumor agent, and shows antitumor activity on prostate carcinoma .
|
-
- HY-136728
-
|
|
Caspase
|
Cancer
|
|
Ac-YVAD-AOM is the inhibitor of caspase-1 that shows antitumor activity .
|
-
- HY-19943
-
-
- HY-N5122
-
|
|
Others
|
Cancer
|
|
Vindolinine is a natural alkaloide that can be found in Catharanthus roseus . Vindolinine has antitumor activity.
|
-
- HY-119675
-
|
|
Bacterial
|
Infection
Cancer
|
|
Albonoursin, a microbial secondary metabolite, is an antibacterial peptide. Albonoursin displays antibacterial and antitumor activities .
|
-
- HY-144028
-
|
|
Trk Receptor
|
Cancer
|
|
Compound cpd-1 is a small molecule Trks inhibitor with good antitumor activity .
|
-
- HY-N13900
-
-
- HY-123363
-
|
F-11782
|
Topoisomerase
|
Cancer
|
|
Tafluposide (F-11782) is a DNA topoisomerase inhibitor. Tafluposide has antitumor activity .
|
-
- HY-139096
-
|
|
Phosphodiesterase (PDE)
|
Cancer
|
|
4-Pentadecylbenzylphosphonic acid is an Autotaxin (ATX) inhibitor. 4-Pentadecylbenzylphosphonic acid has antitumor activity .
|
-
- HY-143659
-
|
|
Others
|
Cancer
|
|
QW30 (Compound 19) shows potent antitumor activity with an IC50 value of 0.33 μM.
|
-
- HY-N8975
-
|
|
Others
|
Cancer
|
|
Antitumor agent-137 (Compound M12) is a linear diarylheptanoid compound with antitumor activity .
|
-
- HY-142681
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity .
|
-
- HY-153941
-
|
|
RET
|
Cancer
|
|
RET-IN-24 (Compound 26) is a selective RET tyrosine kinase inhibitor with antitumor activity .
|
-
- HY-125395
-
-
- HY-W040046
-
|
Nafoxidene hydrochloride
|
Estrogen Receptor/ERR
|
Cancer
|
|
Nafoxidine hydrochloride is a non-steroidal estrogen receptor antagonist with antitumor activity for breast cancer .
|
-
- HY-146970
-
|
|
Antibiotic
|
Cancer
|
|
Lankacyclinone C is a lankacidin C congener lacking the δ-lactone moiety, with antitumor activity .
|
-
- HY-N12145
-
|
Ao58A; NSC 66645
|
Bacterial
|
Infection
Cancer
|
|
Streptimidone (Ao58A) is a bacterial metabolite found in Streptomyces. Streptimidone has antitumor activity .
|
-
- HY-169500
-
|
9a-O-Demethylmitomycin G
|
Drug Derivative
|
Cancer
|
|
Mitomycin Z (9a-O-Demethylmitomycin G) is a member of the mitomycin family with an antitumor activity .
|
-
- HY-168111
-
-
- HY-132900
-
|
|
ROR
|
Cancer
|
|
RORγ agonist 1 is a potent and orally bioavailable RORγ agonist (EC50 = 21 nM) with antitumor activity.
|
-
- HY-126878
-
|
|
Antifolate
|
Infection
Cancer
|
|
11-Oxahomoaminopterin shows antifolate activity and inhibits Lactobacillus casei DHFFZ with antimicrobial and antitumor activities .
|
-
- HY-121350
-
|
|
Apoptosis
|
Cancer
|
|
Merodantoin has significant antitumor activity in vitro and in vivo, and has less toxicity to normal cells and tissues .
|
-
- HY-P5955
-
|
|
Caspase
|
Cancer
|
|
Ac-AAVALLPAVLLALLAP-LEVD-CHO is a cell-permeable caspase-4 inhibitor that has antitumor activity .
|
-
- HY-123191
-
|
|
PAI-1
|
Cancer
|
|
CJ-463 is a potent and selective uPA inhibitor. CJ-463 has antitumor activity .
|
-
- HY-129728
-
-
- HY-N3268
-
|
|
Apoptosis
|
Cancer
|
|
Methyl pseudolarate A is a diterpenoid compound that exerts its antitumor activity by inhibiting cell proliferation and inducing apoptosis .
|
-
- HY-117253
-
|
|
Drug Metabolite
|
Cancer
|
|
PHA-782584 is a metabolite of sunitinib. Sunitinib is an oral multitargeted tyrosine kinase inhibitor with antitumor activities .
|
-
- HY-15493
-
|
NRC-AN-019
|
Bcr-Abl
|
Cancer
|
|
AN-019 is a Bcr-Abl kinase inhibitor. AN-019 has antitumor activity .
|
-
- HY-P5938
-
|
|
Caspase
|
Cancer
|
|
Ac-AAVALLPAVLLALLAP-YVAD-CHO is a cell-permeable caspase-1 inhibitor that has antitumor activity .
|
-
- HY-117679
-
|
|
Endogenous Metabolite
|
Cancer
|
|
LY 135114 free base is a metabolite with antitumor activity. LY 135114 free base is a metabolite of LY 195448, a phenylethanolamine compound with antitumor activity. LY 135114 free base has shown potential biological activity in research and may be used for cancer inhibition .
|
-
- HY-105164A
-
|
BBR 3576 dihydrochloride
|
Antibiotic
|
Cancer
|
|
Topixantrone (BBR 3576) dihydrochloride is an antitumor agent, and shows antitumor activity on prostate carcinoma .
|
-
- HY-179314
-
|
|
Ras
|
Cancer
|
|
RAS-IN-4 (example DA123) is a RAS inhibitor with antitumor activity .
|
-
- HY-158793
-
|
|
Endogenous Metabolite
|
Cancer
|
|
Lentztrehalose A is a trehalose analog.Lentztrehalose A can be isolated from actinomycetes. Lentztrehalose A has antitumor activity .
|
-
- HY-N17754
-
|
|
Others
|
Others
|
|
Astin J is an acyclic peptide present in the roots of Aster tataricus. Astin J exhibits no antitumor activity .
|
-
- HY-125420
-
|
|
Drug Derivative
|
Cancer
|
|
5-Deazaisofolic acid is an isofolate analogue with antitumor activity. 5-Deazaisofolic acid can be utilized in cancer research .
|
-
- HY-119859
-
-
- HY-N2623
-
|
Prangenidin
|
Others
|
Cancer
|
|
Alloimperatorin (Prangenidin), a coumarin compound, is extracted from Angelica dahurica. Alloimperatorin (Prangenidin) has antitumor activity .
|
-
- HY-156393
-
|
|
ERK
|
Cancer
|
|
Laxiflorin B, a herbal compound, is a novel selective ERK1/2 inhibitor that has antitumor activity .
|
-
- HY-N2322
-
|
|
Others
|
Cancer
|
|
Khasianine is a steroidal glycoalkaloid which is obtained from black nightshade (Solanum Nigrum L.), which displays antitumor activity.
|
-
- HY-123887
-
-
- HY-120638
-
|
|
Topoisomerase
|
Cancer
|
|
BMS-250749 is a topoisomerase I (Top I) inhibitor of the fluoroglycosyl-3,9-difluoroindolecarbazole class. BMS-250749 exhibits potent cytotoxicity and selectivity, and shows curative antitumor activity against Lewis lung cancer. BMS-250749 exhibits broad-spectrum antitumor activity superior to CPT-11 in certain preclinical xenograft models. .
|
-
- HY-N14410
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Clecarmycin C is an antitumor antibiotic. Clecarmycin C shows cytotoxicity and antitumor activity. Clecarmycin C shows antimicrobial activity .
|
-
- HY-129673
-
-
- HY-130201
-
|
|
Drug Derivative
|
Cancer
|
|
Deacetylsaptomycin D is a deacetylated saptomycin with in vitro antitumor activity. Deacetylsaptomycin D inhibits the growth of mouse methoxy-A fibrosarcoma cells .
|
-
- HY-U00248
-
|
MJ-III65; NSC706744
|
Topoisomerase
|
Cancer
|
|
LMP744 (MJ-III65) is a DNA intercalator and Topoisomerase I (Top1) inhibitor with antitumor activity .
|
-
- HY-105060
-
|
|
Drug Derivative
|
Cancer
|
|
TA 077 is a nitrosourea derivative with antitumor activity. TA 077 can be used for the research of cancer, such as lung cancer and leukemia .
|
-
- HY-142678
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-21 is a potent EGFR inhibtior with an IC50 of 0.38 nM. EGFR-IN-21 has antitumor activity .
|
-
- HY-P1808
-
|
|
GnRH Receptor
|
Cancer
|
|
LGnRH-III, lamprey, an isoform of GnRH isolated from the sea lamprey, is a weak GnRH agonist with antitumor activities .
|
-
- HY-121569
-
|
|
Kinesin
|
Cancer
|
|
Syntelin is a selective centromere protein E (CENP-E) inhibitor with IC50 at 160 nM. Syntelin has antitumor activity .
|
-
- HY-172879
-
|
|
Aminopeptidase
|
Cancer
|
|
Aminopeptidase N inhibitor 2 (Compound 2k) is an APN inhibitor (IC50: 4.3 μM) and has antitumor activity.
|
-
- HY-162911
-
|
|
Phosphodiesterase (PDE)
|
Cancer
|
|
Enpp-1-IN-22 is an orally bioavailable prodrug of the potent ENPP1 inhibitor paraformaldehyde with antitumor activity .
|
-
- HY-U00248A
-
|
MJ-III65 hydrochloride; NSC706744 hydrochloride
|
Topoisomerase
|
Cancer
|
|
LMP744 hydrochloride (MJ-III65 hydrochloride) is a DNA intercalator and Topoisomerase I (Top1) inhibitor with antitumor activity .
|
-
- HY-119696
-
-
- HY-101773
-
|
|
c-Met/HGFR
|
Cancer
|
|
c-Met-IN-2 is a potent, selective and orally available c-Met inhibitor, with an IC50 of 0.6 nM, with antitumor activity.
|
-
- HY-157133
-
-
- HY-N15371
-
|
|
Others
|
Infection
Inflammation/Immunology
Cancer
|
|
Barbinine is a diterpene alkaloid with antibacterial, antioxidant, anti-inflammatory and antitumor activities. Barbinine is a phytotoxin found in several Delphinium species .
|
-
- HY-162773
-
|
|
c-Met/HGFR
|
Cancer
|
|
MET-IN-1 (Compound 13) is an orally active MET inhibitor. MET-IN-1 has antitumor activity .
|
-
- HY-130072
-
|
|
Fungal
|
Cancer
|
|
Bivittoside B is a non-sulfated hexoside analog derived from Bovine sea cucumber, exhibiting antifungal and potential antitumor activities.
|
-
- HY-129291
-
|
AM 6201
|
Antibiotic
Bacterial
Fungal
|
Infection
Cancer
|
|
Reductiomycin is an antibiotic, which exhibits antimicrobial activity against gram positive bacteria and fungi. Reductiomycin exhibits antitumor activity .
|
-
- HY-15961
-
|
|
Drug Derivative
|
Cancer
|
|
Antitumor agent-3 is a potent compound which comprises a new imidazopyridine having excellent antitumor activity as an active ingredient.
|
-
- HY-123675
-
|
|
Mps1
|
Cancer
|
|
CFI-400936 is a potent TTK inhibitor with an IC50 of 3.6 nM. CFI-400936 has antitumor activity .
|
-
- HY-112588
-
-
- HY-101031
-
|
|
c-Met/HGFR
|
Cancer
|
|
c-met-IN-1 (compound 16) is a potent and selective c-Met inhibitor, with IC50 of 1.1 nM, with antitumor activity. .
|
-
- HY-125158A
-
|
|
Aurora Kinase
|
Cancer
|
|
(E/Z)-HOI-07 is a potent and selective Aurora B inhibitor. HOI-07 has antitumor activity .
|
-
- HY-160992
-
-
- HY-15184
-
|
Azalomycin B; Gopalamicin; Efomycin E
|
Autophagy
Antibiotic
|
Cancer
|
|
Elaiophylin (Azalomycin B; Gopalamicin; Efomycin E) is an autophagy inhibitor, exerts antitumor activity as a single agent in ovarian cancer cells .
|
-
- HY-107363
-
|
|
mTOR
|
Cancer
|
|
FT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity.
|
-
- HY-112167A
-
|
ARRY-575 dihydrochloride; RG7741 dihydrochloride
|
Checkpoint Kinase (Chk)
|
Cancer
|
|
GDC-0575 dihydrochloride (ARRY-575 dihydrochloride) is an orally bioavailable CHK1 inhibitor, with an IC50 of 1.2 nM, and has antitumor activity.
|
-
- HY-145852
-
-
- HY-N8449
-
|
|
Others
|
Inflammation/Immunology
Cancer
|
|
Ailanthoidol is a natural occurring neolignan, with anti-inflammatory and antitumor activities. Ailanthoidol has chemopreventive activity against tumor promotion .
|
-
- HY-144102
-
|
|
HDAC
|
Cancer
|
|
HDAC-IN-29 (compound 13b) is a potent pan-HDAC inhibitor. HDAC-IN-29 shows antitumor activity .
|
-
- HY-109104
-
|
MEDI9197; 3M-052
|
Toll-like Receptor (TLR)
|
Cancer
|
|
Telratolimod (MEDI9197) is a potent toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity .
|
-
- HY-112805
-
-
- HY-128425
-
|
Ureidosuccinic Acid
|
Endogenous Metabolite
|
Metabolic Disease
Cancer
|
|
N-Carbamoyl-DL-aspartic acid (Ureidosuccinic acid) is a precursor of nucleic acid pyrimidines. N-Carbamoyl-DL-aspartic acid has antitumor activities .
|
-
- HY-161025
-
|
|
c-Fms
VEGFR
|
Cancer
|
|
SYHA1813 is a dual inhibitor of CSF1R and VEGFR. SYHA1813 has potent antitumor activity against GBM .
|
-
- HY-164382
-
|
|
TAM Receptor
|
Cancer
|
|
ER-851 is a selective AXL inhibitor with oral activity with IC50 of 100 nM. ER-851 has antitumor activity .
|
-
- HY-128798
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
Menin-MLL inhibitor 20 is an irreversible menin-MLL interaction inhibitor with antitumor activities (WO2020142557A1, Intermediate 6) .
|
-
- HY-163365
-
-
- HY-124584
-
|
|
Apoptosis
|
Cancer
|
|
Minnelide is a prodrug of triptolide that shows potent antitumor activity in a number of tumor types, particularly in pancreatic cancer. Minnelide promotes apoptosis .
|
-
- HY-156818
-
|
|
Ser/Thr Protease
|
Cancer
|
|
TNIK-IN-7 (Compound 8) is an inhibitor of Traf2 and Nck-interacting kinase (TNIK), with IC50 of 11 nM, that has antitumor activity .
|
-
- HY-148059
-
|
B-Raf IN 10
|
Raf
|
Cancer
|
|
Uplarafenib (B-Raf IN 10) (Compound C09) is a BRAF inhibitor with an IC50 between 50 and 100 nM. Uplarafenib shows antitumor activity .
|
-
- HY-155341
-
|
|
FLT3
Haspin Kinase
|
Cancer
|
|
HSK205 is a dual FLT3 and haspin inhibitor, with IC50 of 0.187 nM for FLT3. HSK205 has antitumor activity .
|
-
- HY-N2283
-
|
|
ERK
Akt
Endogenous Metabolite
|
Cancer
|
|
Deltonin, a steroidal saponin, isolated from Dioscorea zingiberensis, has antitumor activity; Deltonin inhibits ERK1/2 and AKT activation.
|
-
- HY-111999A
-
|
|
STING
|
Cancer
|
|
E7766 diammonium salt is a macrocycle-bridged STING agonist with a Kd of 40 nM. E7766 diammonium salt shows potent pan-genotypic and antitumor activities .
|
-
- HY-139735
-
|
|
Drug Intermediate
|
Cancer
|
|
Antitumor agent-29 is a novel hepatocyte-targeting antitumor proagent, which exhibits good antitumor activity and low toxic side effects.
|
-
- HY-162799
-
|
|
Choline Kinase
|
Cancer
|
|
ChoKα inhibitor-6 (compound Fa22) is a less specific ChoKα1 inhibitor with antitumor activity .
|
-
- HY-N1166
-
|
Deguelinol I; Hydroxydeguelin
|
EGFR
|
Cancer
|
|
Tephrosin is a natural rotenoid which has potent antitumor activities. Tephrosin induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors .
|
-
- HY-124762
-
|
|
Ser/Thr Protease
|
Cancer
|
|
TNIK-IN-1 (Compound 1) is an inhibitor of Traf2 and Nck-interacting kinase (TNIK), with IC50 of 65 nM, that has antitumor activity .
|
-
- HY-N11654
-
|
Cardol monoene
|
Insecticide
|
Infection
Cancer
|
|
Bilobol is a potent insecticide against Aedes aegypti with a LC50 of 7.67 mg/L. Bilobol also has antitumor activity .
|
-
- HY-N0661
-
-
- HY-111999B
-
|
|
STING
|
Cancer
|
|
E7766 disodium is a macrocycle-bridged STING agonist with a Kd of 40 nM. E7766 disodium shows potent pan-genotypic and antitumor activities .
|
-
- HY-105530
-
|
CL 286558
|
Biochemical Assay Reagents
|
Cancer
|
|
Zeniplatin is a third-generation, water-soluble platinum compound that has shown broad antitumor activity. Zeniplatin can be used for cancer research .
|
-
- HY-101486
-
|
|
β-catenin
|
Cancer
|
|
LF3 is an antagonist of the β-Catenin/TCF4 interaction with antitumor activity; has an IC50 of 1.65 μM .
|
-
- HY-N9844
-
|
|
Others
|
Others
|
|
Jaspolyanthoside is a trimeric iridoid glycoside can be found in the stems of Jasminum nervosum Lour. (Oleaceae). It lacks anti-inflammatory, antioxidant, and antitumor activities .
|
-
- HY-Y0247
-
|
6-Chloro-9H-purine
|
Drug Intermediate
|
Cancer
|
|
6-Chloropurine is a building block in chemical synthesis. Intermediate in the preparation of 9-alkylpurines and 6-rnercaptopurine. Antitumor activities .
|
-
- HY-113102B
-
|
|
Endogenous Metabolite
|
Cancer
|
|
9(Z),11(Z)-octadecadienoic acid is an isomer of linoleic acid and has antitumor activity (EC 50 = 446.1 µM) .
|
-
- HY-W781271
-
|
|
Drug Derivative
|
Cancer
|
|
Antitumor agent-160 (compound Ia) is a derivative of the antifungal agent PHENALENONE (HY-W286805) and has antitumor activity .
|
-
- HY-136327
-
|
|
DNA Alkylator/Crosslinker
|
Cancer
|
|
Phenylacetic acid mustard is the major metabolite of the cancer chemotherapeutic agent Chlorambucil (HY-13593). Chlorambucil is an alkylating agent with antitumor activity .
|
-
- HY-132001
-
|
KO-539
|
Epigenetic Reader Domain
|
Cancer
|
|
Ziftomenib (KO-539) is an orally active menin-MLL interaction inhibitor with antitumor activities (WO2017161028A1, compound 151) .
|
-
- HY-159846S
-
|
|
Isotope-Labeled Compounds
MEK
|
Cancer
|
|
Luvometinib-d is the deuterium labeled Luvometinib (HY-159846). Luvometinib is a mitogen-activated protein kinase (MEK) inhibitor with antitumor activity .
|
-
- HY-161326
-
|
|
FGFR
|
Cancer
|
|
CXF-007 is a potent and specific FGFR4 inhibitor with a IC50 value of 7 nM. CXF-007 has antitumor activity .
|
-
- HY-162163
-
|
|
Toll-like Receptor (TLR)
|
Cancer
|
|
TLR7 agonist 19 (Compound 14) is a Toll-like receptor 7 (TLR7) agonist with excellent pharmacokinetic properties and synergistic antitumor activity.
|
-
- HY-136582
-
|
Androgen receptor-IN-2
|
Androgen Receptor
|
Cancer
|
|
Masofaniten (Androgen receptor-IN-2) is a potent and orally active androgen receptor inhibitor. Masofaniten has antitumor activity against prostate cancer .
|
-
- HY-113799
-
-
- HY-15359
-
-
- HY-B1071
-
-
- HY-18931A
-
|
|
Arp2/3 Complex
|
Cancer
|
|
NSC305787 hydrochloride is an inhibitor of ezrin with a Kd of 5.85 μM, inhibits the phosphorylation of ezrin caused by PKCΙ with an IC50 of 8.3 μM, has antitumor activity.
|
-
- HY-U00097
-
|
|
Fungal
|
Infection
Cancer
|
|
L-4-Oxalysine hydrochloride is a natural product isolated from the culture media of Streptomyces roseovirdofuscus in China which has shown antitumor activities.
|
-
- HY-117481
-
|
|
Apoptosis
|
Cancer
|
|
NSC-639829 is a Benzoylphenylurea (BPU) analogue which has antitumor activity. NSC-639829 is promising for research of refractory metastatic cancer .
|
-
- HY-17574R
-
-
- HY-W018800
-
-
- HY-W701673
-
-
- HY-N9292
-
|
|
Others
|
Cancer
|
|
Friedelin-3,4-lactone (Compound 4) is a triterpene can be isolated from the leaves of Garcia parViflora with weak antitumor activity .
|
-
- HY-105136A
-
|
|
Drug Derivative
|
Infection
Cancer
|
|
Dezaguanine is a purine analog. Dezaguanine exhibits antitumor activity in leukemia and breast cancer cells. Dezaguanine can be used in cancer-related research .
|
-
- HY-10824B
-
|
PT523 ammonium
|
Dihydrofolate reductase (DHFR)
Antifolate
|
Cancer
|
|
Talotrexin ammonium is a nonpolyglutamatable antifolate. Talotrexin ammonium improves antitumor activity in a broad spectrum of cancer models by targeting DHFR to inhibit tumor growth .
|
-
- HY-160829
-
|
Cositecan-NH2; BNP 1350-NH2
|
Drug Derivative
|
Cancer
|
|
Karenitecin-NH2 (Cositecan-NH2) (DB-173) is a Camptothecin (HY-16560) analogue with antitumor activity .
|
-
- HY-W002277
-
|
|
Drug Derivative
|
Infection
Cancer
|
|
1,8-Naphthyridine is a heterocyclic compound with antibacterial and antitumor activities. 1,8-Naphthyridine is promising for research of antibacterial agents and cancers .
|
-
- HY-153499
-
|
|
Smo
|
Cancer
|
|
SMO-IN-4 (Compound 24) is a potent and orally active smoothened antagonist (IC50: 24 nM). SMO-IN-4 has antitumor activity .
|
-
- HY-167828
-
|
|
Ras
|
Cancer
|
|
ARN25062 (compound 27) is a CDC42/RHOJ inhibitor with antitumor activity. ARN25062 is a novel trisubstituted pyrimidine derivative .
|
-
- HY-172935
-
|
|
Antifolate
|
Cancer
|
|
FR-β ligand 1 (III), a folate receptor-targeting ligand, possesses antitumor activity, high selectivity, and stronger affinity for folate receptor .
|
-
- HY-101604R
-
|
Bestrabucil (Standard); KM2210 (Standard)
|
Reference Standards
Others
|
Cancer
|
|
Atrimustine (Standard) is the analytical standard of Atrimustine. This product is intended for research and analytical applications. Atrimustine is a conjugate of chlorambucil and β-estradiol benzoate with the antitumor activity.
|
-
- HY-N10391
-
|
Cleistenolide
|
Bacterial
|
Infection
Cancer
|
|
(-)-Cleistenolide is a α,β-unsaturated δ-lactone isolated from Cleistochlamys kirkii Oliver. (-)-Cleistenolide has antibacterial and antitumor activity .
|
-
- HY-161695
-
|
|
VEGFR
|
Cancer
|
|
Angiogenesis inhibitor 6 (Compound 8) is a non-tyrosine kinase inhibitor with effective antiangiogenic properties. Angiogenesis inhibitor 6 has antitumor activity .
|
-
- HY-18931
-
|
|
Arp2/3 Complex
|
Cancer
|
|
NSC305787 is an inhibitor of ezrin with a Kd of 5.85 μM, inhibits the phosphorylation of ezrin caused by PKCΙ with an IC50 of 8.3 μM, has antitumor activity.
|
-
- HY-169101
-
|
|
Apoptosis
|
Cancer
|
|
KSRP-IN-1 (compound 8) is a KSRP inhibitor that induces Apoptosis and cell cycle arrest. KSRP-IN-1 has antitumor activity .
|
-
- HY-12045
-
HMN-214
3 Publications Verification
IVX-214
|
Polo-like Kinase (PLK)
|
Cancer
|
|
HMN-214, an orally bioavailable proagent of HMN-176, is an inhibitor of polo-like kinase-1 (plk1), with antitumor activity.
|
-
- HY-111502
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
Y06036 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with Kd value of 82 nM . Antitumor activity .
|
-
- HY-134900
-
-
- HY-164263
-
|
NAPS
|
Apoptosis
|
Cancer
|
|
N-Acetylphytosphingosine (NAPS) is a sphingolipid derivative. N-Acetylphytosphingosine induces mitochondria-dependent Apoptosis by activating Bak. N-Acetylphytosphingosine has antitumor activity .
|
-
- HY-139796
-
|
|
HDAC
|
Cancer
|
|
ZYJ-34v is an orally active histone deacetylase inhibitor. ZYJ-34v has antitumor activity .
|
-
- HY-175316
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-168 (Compound 9a) is a potent EGFR inhibitor with an IC50 of 0.069 μM. EGFR-IN-168 has antitumor activity .
|
-
- HY-W018800R
-
-
- HY-13669R
-
-
- HY-W131305
-
|
|
Drug Intermediate
|
Cancer
|
|
Naphthohydroquinone is a compound featuring a naphthalene ring structure with two hydroxyl groups. Naphthohydroquinone exhibits significant cytotoxicity and antitumor activity in some of its derivatives .
|
-
- HY-122486
-
|
Lophirochalcone
|
EBV
|
Cancer
|
|
Lophirachalcone (Lophirochalcone) is an inhibitor of the activation of EB virus (EBV) induced by tumor promoter teleocidin B-4. Lophirachalcone has antitumor activity .
|
-
- HY-136718
-
|
|
Apoptosis
|
Cancer
|
|
CLEFMA is a curcuminoid with antitumor activity. CLEFMA inhibits tumor growth is associated with NF-κB-regulated anti-inflammatory and anti-metastatic effects .
|
-
- HY-110335A
-
|
|
ROCK
|
Cancer
|
|
OXA-06 is a pharmacologic inhibitor of ROCK, possessing antitumor activity by impairing cell migration and MYPT1 phosphorylation in PANC-1 cells.
|
-
- HY-N12371
-
|
|
Others
|
Others
|
|
5,8-Dihydroxy-6,7-dimethoxyflavone, isolated from aerial parts of Gnaphalium gaudichaudianum, has antitumor activity .
|
-
- HY-W285243
-
-
- HY-161051
-
|
|
NAMPT
DNA Alkylator/Crosslinker
|
Cancer
|
|
Anticancer agent 177 (Compound 11b) is a NAMPT inhibitor and DNA alkylating agent. Anticancer agent 177 has antitumor activity in vitro and in vivo .
|
-
- HY-149951
-
|
|
Others
|
Cancer
|
|
Anticancer agent 107(Compd 11jc) has significant antitumor activity and can be used as an anticancer agent in the study of pulmonary metastatic melanoma .
|
-
- HY-W052750
-
|
|
Biochemical Assay Reagents
|
|
|
5-Carboxy-2-thiouracil is a compound with antitumor activity that can form complexes with metal ions, thereby exhibiting significant biological effects.
|
-
- HY-113793
-
|
|
Ras
|
Cancer
|
|
BPH-742 (compound 9) is a Geranylgeranyl diphosphate synthase inhibitor with IC50 of 0.1 μM. BPH-742 has antitumor activity .
|
-
- HY-B1000
-
|
Seleno-DL-methionine; DL-Selenomethionine
|
Autophagy
Keap1-Nrf2
|
Cancer
|
|
Selenomethionine is a naturally occurring amino acid containing selenium that has oral activity and is a common natural food source. Selenomethionine has antitumor activity .
|
-
- HY-N0174
-
|
Cryptotanshinon; Tanshinone c
|
STAT
Autophagy
|
Cancer
|
|
Cryptotanshinone is a natural compound extracted from the root of Salvia miltiorrhiza Bunge that shows antitumor activities. Cryptotanshinone inhibits STAT3 with an IC50 of 4.6 μM.
|
-
- HY-144903
-
|
GDC-1971
|
SHP2
Phosphatase
p38 MAPK
ERK
|
Cancer
|
|
Migoprotafib (GDC-1971) (compound 199) is a SHP2 inhibitor. Migoprotafib inhibits the MAPK/ERK signaling pathway, and exhibits antitumor activity .
|
-
- HY-14573
-
-
- HY-156602
-
|
OKI-179
|
HDAC
|
Cancer
|
|
Bocodepsin (OKI-179) is an orally active and selective HDAC inhibitor, with antitumor activity. Bocodepsin can be used for suppression on solid tumor and hematologic malignancies .
|
-
- HY-P10418
-
|
|
c-Myc
|
Cancer
|
|
VGN50 is a bioactive molecule that mimics the function of K-Rta and down-regulates MYC-mediated gene transcription. VGN50 has antitumor activity .
|
-
- HY-149290
-
|
|
Prostaglandin Receptor
|
Cancer
|
|
AMX12006 is a potent, selective and orally active EP4 antagonist with an IC50 value of 4.3 nM. AMX12006 shows cytotoxic and antitumor activity .
|
-
- HY-129679
-
|
|
JAK
|
Cancer
|
|
NMS-P953 (compound 28) is an orally active JAK2 inhibitor (IC50=0.008 μM) with antitumor activity .
|
-
- HY-146141
-
|
|
Ephrin Receptor
|
Cancer
|
|
EphA2 agonist 2 (Lead compound) is a selective EphA2 agonist with antitumor activities. EphA2 agonist 2 can cross the BBB .
|
-
- HY-123351
-
|
|
Fungal
|
Infection
Cancer
|
|
Kievitone, an isoflavanone, could be isolated from hypocotyls of Phaseolus vulgaris L. infected with Rhizoctonia solani Kühn. Kievitone has antifungal activity and antitumor activity .
|
-
- HY-163965
-
|
|
Toll-like Receptor (TLR)
|
Cancer
|
|
Antitumor agent-185 (compound 3) shows antitumor activity that could effectively reduce the growth of tumors and prolong the survival time of mice in vivo .
|
-
- HY-112897
-
|
|
Autophagy
PI3K
Apoptosis
|
Cancer
|
|
IITZ-01 is a potent lysosomotropic autophagy inhibitor with single-agent antitumor activity, with an IC50 of 2.62 μM for PI3Kγ.
|
-
- HY-P99539
-
|
REGN4018
|
CD3
|
Cancer
|
|
Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and CD3. Ubamatamab demonstrates potent antitumor activity .
|
-
- HY-164402
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
NSC-124854 is a DNA polymerase β (Pol-β) inhibitor with an IC50 of 5.3 μM. NSC-124854 has antitumor activity .
|
-
- HY-126740
-
|
|
Antibiotic
Fungal
|
Infection
Cancer
|
|
Anguinomycin A is an antibiotic that exhibits good inhibitory activity against G. boninense with an MIC value of 5 µg/disk. Anguinomycin A has antitumor activity .
|
-
- HY-111636
-
|
|
Apoptosis
|
Cancer
|
|
VSW1198 is an inhibitor for geranylgeranyl diphosphate synthase (GGDPS) with an IC50 of 45 nM. VSW1198 reveals antitumor activity in myeloma- and prostate cancer with liver toxicity .
|
-
- HY-156275
-
|
|
Others
|
Cancer
|
|
OSBP-IN-1(compound 12) is a Schweinfurthins analogues targeted of oxysterol-binding protein (OSBP). OSBP-IN-1 has antitumor activity .
|
-
- HY-162627
-
|
|
Lactate Dehydrogenase
|
Cancer
|
|
LDHA-IN-6 (compound 6) is an oral bioactive inhibitor of lactate dehydrogenase-A (LDHA), with the IC50 of 46 nM. LDHA-IN-6 has antitumor activity .
|
-
- HY-P99969
-
|
CMAB-302; Cipterbin
|
EGFR
|
Cancer
|
|
Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities .
|
-
- HY-B1071A
-
|
Lasalocid-A sodium; Ionophore X-537A sodium; Antibiotic X-537A sodium
|
Antibiotic
Bacterial
Autophagy
Parasite
Apoptosis
|
Infection
Cancer
|
|
Lasalocid sodium (Lasalocid sodium-A) is an antibacterial and anticoccidial agent that can be used as feed additives. Lasalocid sodium exhibits antitumor activity. Lasalocid sodium is orally active .
|
-
- HY-177450
-
|
|
Phospholipase
|
Cancer
|
|
DS07551382 is a potent phosphatidylserine synthase 1 (PTDSS1) inhibitor, thereby blocking intracellular phosphatidylserine synthesis. DS07551382 has antitumor activity .
|
-
- HY-Z3832
-
|
|
Apoptosis
p38 MAPK
Autophagy
|
Cancer
|
|
N-Methylparoxetine is a derivative of Paroxetine that induces Apoptosis NSCLC cells by activating mitogen-activated protein kinase ( MAPK). N-Methylparoxetine has antitumor activity .
|
-
- HY-101568
-
|
FGF-401
|
FGFR
|
Cancer
|
|
Roblitinib (FGF-401) is an orally active and highly selective FGFR4 inhibitor with an IC50 of 1.9 nM . Roblitinib has antitumor activity .
|
-
- HY-N11010
-
|
|
Others
|
Cancer
|
|
Eclalbasaponin IV is a triterpenoid that can be isolate from the aerial parts of Eclipta prostrata. Eclalbasaponin IV shows antitumor activity in human ovarian cancer cells .
|
-
- HY-119113
-
|
|
Drug Derivative
|
Cancer
|
|
C 175 is a nitroacridine derivative with antitumor activity. C 175 inhibits the growth of HeLa cells monolayer (ED50=0.49 μM) .
|
-
- HY-156602A
-
|
OKI-179 hydrochloride
|
HDAC
|
Cancer
|
|
Bocodepsin hydrochloride (OKI-179) is an orally active and selective HDAC inhibitor, with antitumor activity. Bocodepsin hydrochloride can be used for suppression on solid tumor and hematologic malignancies .
|
-
- HY-116592
-
|
|
c-Met/HGFR
|
Cancer
|
|
SOMCL-863 is a selective and orally active c-Met inhibitor with antitumor activity in vitro and in vivo. SOMCL-863 can be utilized in cancer research .
|
-
- HY-N0585
-
|
(Rac)-NCTD
|
Apoptosis
|
Cancer
|
|
(Rac)-Norcantharidin ((Rac)-NCTD) is the racemic form of Norcantharidin. Norcantharidin is a demethylated derivative of Cantharidin (HY-N0209) and has antitumor activity .
|
-
- HY-167737
-
|
|
Cytochrome P450
|
Cancer
|
|
(-)-Vorozole is an orally active non-steroidal aromatase inhibitor with potent and selective properties. (-)-Vorozole demonstrates antitumor activity in in vivo experiments. (-)-Vorozole is utilized in the study of breast cancer.
|
-
- HY-N11777
-
|
NHAP
|
NF-κB
|
Cancer
|
|
(−)-N-Hydroxyapiosporamide (NHAP), an alkaloid, is an NF-κB inhibitor with potent antitumor activity in vitro and in vivo. (−)-N-Hydroxyapiosporamide can be used for the research of colorectal cancer (CRC) .
|
-
- HY-168982
-
|
|
FLT3
IRAK
|
Cancer
|
|
Lomonitinib is a highly potent and selective pan-FLT3/IRAK4 inhibitor with antitumor activity. Lomonitinib is promising for research of myeloid leukemia .
|
-
- HY-13745
-
|
MEN 10755
|
Topoisomerase
|
Cancer
|
|
Sabarubicin is a doxorubicin disaccharide analogue with striking antitumor activity. Sabarubicin is more effective than doxorubicin as a topoisomerase II poison and stimulated DNA fragmentation at lower intracellular concentrations.
|
-
- HY-135751
-
|
|
Antibiotic
Bacterial
DNA/RNA Synthesis
|
Infection
Cancer
|
|
Holomycin is an antibiotic with dithiolopyrrolone structure. Holomycin can inhibit bacterial RNA synthesis. Holomycin has antitumor activity. Holomycin can be used for the research of bacterial infection .
|
-
- HY-15794A
-
|
Methoxymorpholinyl doxorubicin hydrochloride; FCE 23762 hydrochloride; PNU 152243A
|
G-quadruplex
|
Cancer
|
|
Nemorubicin hydrochloride is a derivative of doxorubicin, and has antitumor activity. Nemorubicin hydrochloride, not only intercalate into the duplex DNA, but also result in significant ligands for G-quadruplex DNA segments, stabilizing their structure.
|
-
- HY-W451275
-
HG106
2 Publications Verification
|
Apoptosis
|
Cancer
|
|
HG106 is an effective SLC7A11 inhibitor. HG106 mediates apoptosis by increasing oxidative stress and endoplasmic reticulum stress, and it has antitumor activity .
|
-
- HY-162008
-
|
|
HSP
Bcl-2 Family
|
Cancer
|
|
S1g-10 is a Hsp70/Bim inhibitor, and shows antitumor activity in chronic myeloid leukemia cells .
|
-
- HY-W698934
-
-
- HY-136293
-
|
|
Apoptosis
|
Cancer
|
|
Mechercharmycin A is a cytotoxic substance isolated from marine-derived Thermoactinomyces sp. YM3-251. Mechercharmycin A exhibits relatively strong antitumor activity .
|
-
- HY-162314
-
|
|
Wnt
|
Cancer
|
|
TNIK-IN-8 (Compound 35b) is a potent, orally active TNKI inhibitor with a IC50 value of 6 nM. TNIK-IN-8 has antitumor activity .
|
-
- HY-N7611
-
|
|
Others
|
Cancer
|
|
7-Prenyloxyaromadendrin is a flavonoid from Pterocaulon alopecuroides with antitumor activity. 7-Prenyloxyaromadendrin shows good antiproliferative activity in tumor cell lines .
|
-
- HY-120590
-
|
SKLB1028
|
EGFR
FLT3
Bcr-Abl
|
Cancer
|
|
Ruserontinib (SKLB1028) is an orally active multikinase inhibitor of EGFR, FLT3 and Abl, with an IC50 value of 55 nM for human FLT3, and has antitumor activity .
|
-
- HY-N3378
-
|
|
Farnesyl Transferase
Parasite
|
Infection
|
|
Lipiferolide is an antiplasmodial agent (IC50: 1.8 μg/mL) that can be isolated from Liriodendron tulipifera. Lipiferolide also inhibits FPTase, and has antitumor activity .
|
-
- HY-109146
-
|
PT-112
|
Apoptosis
DNA Alkylator/Crosslinker
|
Cancer
|
|
Imifoplatin (PT-112) is a platinum-based active molecule and a member of the phosphaplatins family. Imifoplatin can induce Apoptosis and exhibits antitumor activity .
|
-
- HY-129577
-
|
|
Necroptosis
|
Inflammation/Immunology
Cancer
|
|
Aplysin is a brominated sesquiterpene with an isoprene backbone that exhibits hepatoprotective, immunomodulatory, and antitumor activities. Aplysin effectively prevents spontaneous pancreatic necrosis and inflammatory responses in NOD mice .
|
-
- HY-115907A
-
|
|
Drug Isomer
|
Cancer
|
|
(rac)-K20 is the racemate of K20, a KRas G12C inhibitor with an IC50 of 1.16 μM. K20 has antitumor activity .
|
-
- HY-P10201A
-
|
|
STAT
|
Cancer
|
|
Ac-GpYLPQTV-NH2 acetate is a STAT3 inhibitor with an IC50 value of 0.33 μM. Ac-GpYLPQTV-NH2 acetate has antitumor activity .
|
-
- HY-144817
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 27 (DYT-1) is a tubulin polymerisation inhibitor with an IC50 of 25.6 μM. Tubulin inhibitor 27 shows anti-angiogenesis and antitumor activities .
|
-
- HY-169284
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
Polθ-IN-5 (Compound 139) is a DNA polymerase theta (Polθ) inhibitor. Polθ-IN-5 has antitumor activity .
|
-
- HY-127067
-
|
|
Akt
EGFR
mTOR
|
Inflammation/Immunology
Cancer
|
|
Yuanhuadin, extracted from Genkwa Flos Daphne genkwa, has antitumor activity through inhibiting Akt/mTOR and EGFR pathways, induce cell-cycle arrest and abortion .
|
-
- HY-111783
-
|
|
DNA-PK
ATM/ATR
PI3K
Apoptosis
|
Cancer
|
|
AZD-7648 is a potent, orally active, selective DNA-PK inhibitor with an IC50 of 0.6 nM. AZD-7648 induces apoptosis and shows antitumor activity .
|
-
- HY-146511
-
|
|
Others
|
Cancer
|
|
Anticancer agent 41 is a potent anticancer agent, shows a potent antitumor activity against MDA-MB-231 cell with an IC50 of 3.99 μM[1].
|
-
- HY-139132
-
|
|
Apoptosis
|
Cancer
|
|
Met-F-AEA is a metabolically stable anandamine analogue. Met-F-AEA inhibits cell growth by activating apoptosis. Met-F-AEA has antitumor activity .
|
-
- HY-120787
-
|
Theasapogenol B; Jegosapogenol A
|
Biochemical Assay Reagents
|
Cancer
|
|
Barringtogenol C (Theasapogenol B) is one of seeds sapogenols of Thea sinensis L. Barringtogenol C is a type of barrigenol triterpenoid. Barringtogenol C derivatives exhibits antitumor activity .
|
-
- HY-132295
-
|
ZN-c3
|
Wee1
|
Cancer
|
|
Azenosertib (ZN-c3) is a selective, orally active inhibitor for Wee1 inhibitor (IC50=3.9 nM). Azenosertib exhibits antitumor activity .
|
-
- HY-115568
-
|
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
|
BETd-246 is a second-generation and PROTAC-based BET bromodomain (BRD) inhibitor connected by ligands for Cereblon and BET, exhibiting superior selectivity, potency and antitumor activity .
|
-
- HY-106389
-
|
ZK 98299
|
Progesterone Receptor
|
Cancer
|
|
Onapristone is a progesterone receptor antagonist, with Kds of 11.6 nM and 11.90 nM for human endometrium and myometrium progesterone receptor in saturation analysis. Onapristone has antitumor activity .
|
-
- HY-16568R
-
|
(+)-Irinotecan hydrochloride trihydrate (Standard); CPT-11 hydrochloride trihydrate (Standard)
|
Reference Standards
Topoisomerase
Autophagy
|
Cancer
|
|
Irinotecan (hydrochloride trihydrate) (Standard) is the analytical standard of Irinotecan (hydrochloride trihydrate). This product is intended for research and analytical applications. Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate) is a topoisomerase I inhibitor with antitumor activity .
|
-
- HY-138645A
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
5-Iminodaunorubicin hydrochloride is a quinone-modified anthracycline that retains antitumor activity . 5-Iminodaunorubicin hydrochloride produces protein-concealed DNA strand breaks in cancer cells .
|
-
- HY-102087
-
JPM-OEt
3 Publications Verification
|
Cathepsin
|
Cancer
|
|
JPM-OEt is a broad spectrum cysteine cathepsin inhibitor. JPM-OEt binds covalently in the active site, and irreversibly inhibits the cysteine cathepsin family. Antitumor activity .
|
-
- HY-126218
-
|
|
HSV
|
Cancer
|
|
HSV-TK substrate is a substrate for HSV-TK, and induces multi-log cytotoxicity in HSV-TK-expressing and bystander cells. HSV-TK substrate shows antitumor activity .
|
-
- HY-138645
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
5-Iminodaunorubicin is a quinone-modified anthracycline that retains antitumor activity . 5-Iminodaunorubicin produces protein-concealed DNA strand breaks in cancer cells .
|
-
- HY-129156
-
|
|
Apoptosis
|
Cancer
|
|
HS-1793 is a Resveratrol (HY-16561) analogue with antitumor activities in a variety of cancer cell lines . HS-1793 induces cell apoptosis .
|
-
- HY-12825
-
-
- HY-160414
-
|
(R,R)-TRX-COBI; TRX-cobimetinib
|
MEK
|
Cancer
|
|
TRX-COBI ((R,R)-TRX-COBI; Trx-cobimetinib) is a MEK inhibitor targeting TRX fragments based on Fe 2+. TRX-COBI has antitumor activity .
|
-
- HY-P10201
-
|
|
STAT
|
Cancer
|
|
Ac-GpYLPQTV-NH2 is a STAT3 inhibitor with an IC50 value of 0.33 μM. Ac-GpYLPQTV-NH2 has antitumor activity .
|
-
- HY-N10469
-
|
Phleomycin F
|
Antibiotic
|
Cancer
|
|
Bleomycin B4 (Phleomycin F) is an antibiotic. Bleomycin B4 has antitumor activity. Bleomycin B4 can be used for the research of cancer .
|
-
- HY-N14781
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
10-Decarbamoyloxy-9-dehydromitomycin B is a mitomycin. 10-Decarbamoyloxy-9-dehydromitomycin B has antibacterial and antitumor activity .
|
-
- HY-N12364
-
|
|
Others
|
Cancer
|
|
Bufoserotonin C is a new indole alkaloid from the traditional Chinese medicine Chansu that has antitumor activity, with IC 50 of 34.3 μM in A549 cells .
|
-
- HY-101414
-
-
- HY-161074
-
|
|
FAP
|
Cancer
|
|
PNT6555 is a fibroblast activation protein-α (FAP) inhibitor. PNT6555 has antitumor activity. PNT6555 can be used for imaging of FAP-positive tumors .
|
-
- HY-153950
-
|
|
CDK
|
Cancer
|
|
CDK7-IN-22 (compound 101) is an CDK7 inhibitor with antitumor activity. CDK7-IN-22 shows selectivity on CDK7 .
|
-
- HY-156780
-
|
|
Cuproptosis
|
Cancer
|
|
NSC 689534 can form copper chelate with Cu 2+. NSC 689534/Cu 2+ complex is a potent oxidative stress inducer, and has antitumor activity .
|
-
- HY-169285
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
Polθ-IN-6 (Compound 89) is a DNA polymerase theta (Polθ) inhibitor. Polθ-IN-6 has antitumor activity .
|
-
- HY-136499
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
DI-82 is a potent deoxycytidine kinase (dCK) inhibitor with an IC50 app of 27.8 nM and Ki app of 9.2 nM. DI-82 has antitumor activity .
|
-
- HY-P2322
-
-
- HY-122474
-
|
|
Drug Derivative
|
Cancer
|
|
Acetylaranotin is a metabolite produced by the fungus Arachniotus aureus, exhibiting antitumor activity. Acetylaranotin is utilized in research within the field of oncology for its potential in anti-cancer applications .
|
-
- HY-132891
-
-
- HY-124944
-
|
|
Ras
|
Cancer
|
|
APS6-45 is an orally active tumor-calibrated inhibitor (TCI). APS6-45 inhibits RAS/MAPK signaling and exhibits antitumor activity .
|
-
- HY-131065
-
|
|
c-Met/HGFR
|
Cancer
|
|
MET kinase-IN-2 is a potent, selective, orally bioavailable MET kinase inhibitor with an IC50 of 7.4 nM. MET kinase-IN-2 has antitumor activity .
|
-
- HY-179105
-
|
|
TAM Receptor
|
Cancer
|
|
Axl-IN-20 (Compound w11) is a selective, orally active AXL inhibitor, with an IC50 of 5 nM. Axl-IN-20 has antitumor activity against hematological malignancies .
|
-
- HY-W070294
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
8-Azahypoxanthine is a purine analog and an inhibitor of hypoxanthine-guanine phosphoribosyltransferase (HGPRT). 8-Azahypoxanthine exhibits antitumor activity and can be used in the research of tumors such as adenocarcinoma .
|
-
- HY-101414A
-
-
- HY-B0431A
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Phenoxybenzamine hydrochloride is a nonselective, irreversible, orally active α-adrenoceptor antagonist that is commonly used for the research of hypertension, specifically caused by pheochromocytoma. Phenoxybenzamine hydrochloride also shows antitumor activity .
|
-
- HY-N6074
-
|
|
Autophagy
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Soyasapogenol B is a component of soy that has oral activity. Soyasapogenol B promotes autophagy and apoptosis. Soyasapogenol B has anti-inflammatory, antioxidant and antitumor activities .
|
-
- HY-107366
-
SGN-2FF
2 Publications Verification
|
Glycosyltransferase
|
Cancer
|
|
SGN-2FF is a potent and orally active inhibitor of fucosylation, directly inhibits fucosyltransferase activity. SGN-2FF possesses antitumor activity .
|
-
- HY-N1265
-
|
|
Others
|
Cancer
|
|
Scutebata A is a diterpenoid isolated from Scutellaria barbata that exhibits antitumor activity. Scutebata A is weakly cytotoxic against SK-BR-3 with an IC50 value of 15.2 μM .
|
-
- HY-160284
-
|
|
CDK
|
Cancer
|
|
CDK12/13-IN-1 (Compound 4) is a CDK12/13 inhibitor. CDK12/13-IN-1 has antitumor activity .
|
-
- HY-19599
-
|
(+)-Vorozole; R83842
|
Cytochrome P450
|
Cancer
|
|
Vorozole is a potent and selective, orally active non-steroidal aromatase inhibitor . Vorozole shows antitumor activity in vivo. Vorozole has the potential for the research of mammary cancer .
|
-
- HY-16111A1
-
|
|
Farnesyl Transferase
|
Cancer
|
|
BMS-214662 mesylate is a potent and selective farnesyl transferase inhibitor with an IC50 of 1.35 nM. BMS-214662 mesylate exhibits potent antitumor activity and can be utilized in cancer research .
|
-
- HY-N14677
-
|
|
Bacterial
|
Infection
Cancer
|
|
Pillaromycin A has anti-mycobacteria, Gram-positive bacteria and Gram-negative bacteria effects, but the effect of anti-Gram-negative bacteria is weak. Pillaromycin A also has antitumor activity .
|
-
- HY-136350
-
|
|
Phosphodiesterase (PDE)
|
Cancer
|
|
BRD9500 is an orally active phosphodiesterases 3 (PDE3) inhibitor with IC50s of 10 and 27 nM for PDE3A and PDE3B, respectively. Antitumor activity .
|
-
- HY-168847
-
|
|
Ras
|
Cancer
|
|
INCB159020 is an orally active KRAS G12D inhibitor with a KRAS G12D SPR value of 2.2 nM. INCB159020 has antitumor activity .
|
-
- HY-162683A
-
|
|
CDK
Drug Isomer
|
Cancer
|
|
(R)-PHA533533 is an inactive enantiomer (S)-PHA533533 (active enantiomer) (HY-162683). (S)-PHA533533 is a CDK2 inhibitor with antitumor activity .
|
-
- HY-137450A
-
|
IMP4297 hydrochloride; JS109 hydrochloride
|
PARP
|
Cancer
|
|
Senaparib hydrochloride (IMP4297 hydrochloride) is an oral, selective PARP1/2 inhibitor with potent anti-tumor activity. Senaparib hydrochloride shows antitumor activity against advanced ovarian cancer .
|
-
- HY-128957
-
|
Duocarmazine
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Vc-seco-DUBA (Duocarmazine) is a agent-linker conjugate for ADC with potent antitumor activity by using DUBA (DNA alkylating agent), linked via the ADC linker Vc-seco .
|
-
- HY-14429
-
|
MGI 114; 6-Hydroxymethylacylfulvene; NSC 683863
|
DNA Alkylator/Crosslinker
Apoptosis
|
Cancer
|
|
(-)-Irofulven (MGI 114), an Illudin S analog, is a DNA alkylating agent. (-)-Irofulven inhibits the replication of DNA, induces tumor cells apoptosis, and has potent antitumor activity .
|
-
- HY-106689A
-
-
- HY-N7022
-
|
|
Others
|
Cancer
|
|
Eclalbasaponin I is isolated from Eclipta prostrata L with antitumor activity. Eclalbasaponin I inhibits the proliferation of hepatoma cell smmc-7721 with an IC50 value of 111.1703 μg/ml .
|
-
- HY-126494
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
DM4-SMCC is a agent-linker conjugate for ADC with antitumor activity by using DM4 (an antitubulin agent), linked via the non-cleavable SMCC linker .
|
-
- HY-N6656
-
|
|
Fungal
Bacterial
|
Inflammation/Immunology
Cancer
|
|
6-Hydroxycoumarin is a coumarin which has anti-inflammatory, anti-pyretic, anti-oxidant, vasodilator, anti-amoebic, anti-bacterial, anti-fungal, bacteriostatic and antitumor activity .
|
-
- HY-P99208
-
|
IPH2102
|
Transmembrane Glycoprotein
|
Cancer
|
|
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research .
|
-
- HY-N8253
-
|
Quercetin 4′-O-glucoside
|
Reactive Oxygen Species (ROS)
|
Inflammation/Immunology
Cancer
|
|
Spiraeoside, an orally active natural compound, exerts antioxidant activity, inhibits reactive oxygen species (ROS) and malondialdehyde production. Spiraeoside possesses antiallergic, anti-inflammatory and antitumor activities .
|
-
- HY-151404
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-76 (Compound TP-P1) is an orally active, rapid-release and water-soluble Triptolide (HY-32735) proagent with antitumor activity .
|
-
- HY-19068
-
|
|
Drug Derivative
|
Cancer
|
|
FO-152 monohydrochloride is a derivative of 5-Fluorouridine (HY-107856). FO-152 monohydrochloride exhibits more favorable antitumor activity and lower toxicity .
|
-
- HY-149011
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
CA IX-IN-1 (compound 12g) is an effective and selective inhibitor of hCA IX with IC50 value of 7 nM. CA IX-IN-1 exhibits antitumor activity .
|
-
- HY-115729A
-
-
- HY-126692
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Mal-VC-PAB-ABAEP-Azonafide is a agent-linker conjugate for ADC with with potent antitumor activity by using Azonafide (a cytotoxin), linked via the ADC linker Mal-VC-PAB .
|
-
- HY-P99286
-
|
PRO 95780; rhuMAb-DR 5; Anti-Human DR5 Recombinant Antibody
|
Apoptosis
|
Cancer
|
|
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma .
|
-
- HY-106689
-
-
- HY-138799
-
|
|
HDAC
|
Cancer
|
|
KA2507 is a potent, orally active and selective HDAC6 inhibitor, with an IC50 of 2.5 nM. KA2507 shows antitumor activities and immune modulatory effects in preclinical models .
|
-
- HY-B0431
-
-
- HY-169763
-
|
|
IRE1
Apoptosis
|
Cancer
|
|
D-F07 is a prodrug with an aldehyde shielding group and an IRE-1 inhibitor that induces Apoptosis. D-F07 has antitumor activity .
|
-
- HY-119696S1
-
-
- HY-137450
-
|
IMP4297; JS109
|
PARP
|
Cancer
|
|
Senaparib (IMP4297) is a highly potent, selective and orally active PARP1/2 inhibitor. Senaparib (IMP4297) exhibits strong antitumor activity in animal models .
|
-
- HY-111381
-
BI-3812
3 Publications Verification
|
BCL6
|
Cancer
|
|
BI-3812, a chemical probe, is a highly efficient BCL6 inhibitor that is capable of suppressing the BTB domain of BCL6, with an IC50 value of ≤ 3 nM, exhibiting antitumor activity .
|
-
- HY-158845
-
|
|
Apoptosis
|
Cancer
|
|
8Br-HA is a potent FHIT inhibitor with an IC50 of 0.12 μM. 8 BR-HA can induceApoptosis. 8Br-HA has antitumor activity .
|
-
- HY-149015
-
|
|
Farnesyl Transferase
|
Cancer
|
|
FTase-IN-1 (compound 17a) is a potent and specific inhibitor of fanesyl transferase (FTase) with an IC50 of 0.35 μM. FTase-IN-1 displays cytotoxicity potential and antitumor activity .
|
-
- HY-162569
-
|
|
Apoptosis
Necroptosis
|
Cancer
|
|
Ru-TRZ2 is a potent ruthenium-based chemotherapeutic agent. Ru-TRZ2 induces apoptosis and necroptosis. Ru-TRZ2 shows antitumor activity .
|
-
- HY-13810
-
|
|
Raf
|
Cancer
|
|
PF-04880594 is a potent and selective RAF inhibitor. PF-04880594 inhibits both wild-type and mutant BRAF and CRAF. PF-04880594 shows antitumor activity .
|
-
- HY-146014
-
-
- HY-148091
-
|
|
DNA Alkylator/Crosslinker
|
Cancer
|
|
Duocarmycin analog-2 is a potent DNA alkylating agent. Duocarmycin analog-2 can be used of synthetic immunoconjugate. Duocarmycin analog-2 has antitumor activity .
|
-
- HY-130233
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
S516 (Compound 22) is an active metabolite of CKD-516 and a potent tubulin polymerization inhibitor with an IC50 of 4.29 μM. S516 has marked antitumor activity .
|
-
- HY-145859
-
-
- HY-162366
-
|
|
Ras
|
Cancer
|
|
KRAS G12D inhibitor 20 (Compound 14) is a selective G12D KRAS inhibitor. KRAS G12D inhibitor 20 has antitumor activity .
|
-
- HY-139612
-
|
JDQ-443; NVP-JDQ443
|
Ras
PERK
|
Inflammation/Immunology
Cancer
|
|
Opnurasib (JDQ-443) (NVP-JDQ443) is an orally active, potent, selective, and covalent KRAS G12C inhibitor. Opnurasib shows antitumor activity .
|
-
- HY-136317
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-betaglucuronide-MMAE-1 is a agent-linker conjugate for ADC with potent antitumor activity by using MMAE (a tubulin polymerization inhibitor), linked via the cleavable ADC linker MC-betaglucuronide.
|
-
- HY-163351
-
|
|
PDI
|
Cancer
|
|
PDI-IN-2 (Compound 22) is a PDI or recombinant PDI inhibitor with IC50 values of 0.62 and 0.63 μM, respectively. PDI-IN-2 has antitumor activity .
|
-
- HY-160549
-
|
|
c-Myc
|
Cancer
|
|
c-Myc inhibitor 14 (Compound 13A) is a c-Myc protein inhibitor. The IC50 value of HL60 inhibitor is <100 nM. c-Myc inhibitor 14 shows antitumor activity .
|
-
- HY-145330
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
NSC639828 is a potent inhibitor of DNA polymerase α with an IC50 of 70 μM. NSC639828 has high antitumor activity. NSC639828 has the potential for researching cancer disease .
|
-
- HY-136321
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-betaglucuronide-MMAE-2 is a agent-linker conjugate for ADC with potent antitumor activity by using MMAE (a tubulin polymerization inhibitor), linked via the cleavable ADC linker MC-betaglucuronide.
|
-
- HY-122108
-
|
LL-Z 1272-alpha
|
Apoptosis
|
Cancer
|
|
Ilicicolin A is a potent anticancer agent. Ilicicolin A induces apoptosis. Ilicicolin A inhibits cell growth and colony formation. Ilicicolin A shows antitumor activity. Ilicicolin A has the potential for the research of prostate cancer .
|
-
- HY-147993
-
|
|
Aurora Kinase
|
Cancer
|
|
Aurora kinase inhibitor-10 (Compound 6c) is an orally active Aurora B inhibitor with an IC50 of 8 nM. Aurora kinase inhibitor-10 shows antitumor activity .
|
-
- HY-161012
-
|
|
Apoptosis
|
Cancer
|
|
RB-07-16 is a C6-PyraP-BP inhibitor of human geranylammate pyrophosphate synthase (hGGPPS). RB-07-16 has antitumor activity .
|
-
- HY-N0878
-
|
|
Apoptosis
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Bufotalin is a steroid lactone isolated from Venenum Bufonis with potently antitumor activities. Bufotalin induces cancer cell apoptosis and also induces endoplasmic reticulum (ER) stress activation .
|
-
- HY-145828
-
|
|
Microtubule/Tubulin
Ferroptosis
|
Cancer
|
|
Microtubule inhibitor 2 is a potent and selective, orally active microtubule inhibitor. Microtubule inhibitor 2 triggers cell death through ferroptosis . Microtubule inhibitor 2 shows antitumor activity .
|
-
- HY-128968
-
-
- HY-10231
-
-
- HY-132001A
-
|
(R)-KO-539
|
Epigenetic Reader Domain
|
Cancer
|
|
(R)-Ziftomenib ((R)-KO-539) is the R-enantiomer of Ziftomenib (HY-132001). Ziftomenib (KO-539) is an orally active menin-MLL interaction inhibitor with antitumor activities .
|
-
- HY-N13894
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Auramycin A, an anthracycline antibiotic that shows marked antibacterial activity against Gram-positive bacteria. Auramycin A also exhibits antitumor activity against P388 and L1210 leukemia in mice .
|
-
- HY-123269
-
-
- HY-185372
-
|
Liposomal mitoxantrone
|
Liposome
Topoisomerase
PKC
|
Cancer
|
|
Mitoxantrone hydrochloride liposome is a liposome-encapsulated Mitoxantrone hydrochloride (HY-13502A) (a topoisomerase II inhibitor). Compared to regular Mitoxantrone hydrochloride, Mitoxantrone hydrochloride liposome enhances antitumor activity and prolongs drug circulation time in the body.
|
-
- HY-106090
-
|
CI-937; DUP 937
|
DNA/RNA Synthesis
|
Cancer
|
|
Teloxantrone (CI-937; DUP 937) is a DNA synthesis inhibitor (IC50: 0.33 μM). Teloxantrone has antitumor activity and can be used in colorectal cancer research .
|
-
- HY-148466
-
|
|
Aldehyde Dehydrogenase (ALDH)
|
Cancer
|
|
IGUANA-1 is a potent and selective ALDH1B1 inhibitor. IGUANA-1 shows no significant mitochondrial toxicity. IGUANA-1 has antitumor activity .
|
-
- HY-144804
-
|
|
VEGFR
|
Cancer
|
|
VEGFR-2-IN-17 (Compound 15a) is a potent VEGFR-2 inhibitor with an IC50 of 67.25 nM. VEGFR-2-IN-17 shows antitumor activities .
|
-
- HY-P9905
-
Cetuximab
Maximum Cited Publications
53 Publications Verification
C225; IMC-C225
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
|
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
|
-
- HY-161573B
-
|
|
YAP
GGTase
|
Cancer
|
|
BAY-593 (hydrochloride) is an orally active GGTase-I inhibitor. BAY-593 (hydrochloride) can block YAP1/TAZ signaling in animals and has antitumor activity .
|
-
- HY-126491
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
SPP-DM1 is a agent-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker SPP .
|
-
- HY-N0878R
-
-
- HY-118712
-
|
|
mTOR
|
Cancer
|
|
WYE-23 is a mTOR inhibitor, and IC50 is 0.45 nM. It is selective to PI3Kα and IC50 is 661 nM. WYE-23 has antitumor activity .
|
-
- HY-147327
-
|
|
Drug Metabolite
|
Cancer
|
|
N-Formylsarcolysine has antitumor activity, and inhibits leukemia by increasing the Hb and erythrocyte levels and decreasing the number of leukocytes. N-Formylsarcolysine also involves in glioblastoma and other diseases research .
|
-
- HY-169129
-
|
ILX-295501
|
Drug Derivative
|
Cancer
|
|
LY-295501 is a sulfonylurea compound that has demonstrated in-vivo antitumor activity against a broad spectrum of solid tumors. LY-295501 can be utilized in cancer research .
|
-
- HY-12823
-
|
|
FGFR
|
Cancer
|
|
BLU9931 is a potent, highly selective, and irreversible fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 3 nM and a Kd of 6 nM. BLU9931 has significant antitumor activity .
|
-
- HY-132891A
-
-
- HY-107324
-
|
(-)-β-Elemene; Levo-β-elemene
|
Apoptosis
|
Cancer
|
|
β-Elemene ((-)-β-Elemene; Levo-β-elemene) is isolated from natural plant Curcuma aromatica with an antitumor activity. β-Elemene can induce cell apoptosis.
|
-
- HY-161573
-
|
|
YAP
GGTase
|
Cancer
|
|
BAY-593 is an orally active GGTase-I inhibitor. BAY-593 can block YAP1/TAZ signaling in animals and has antitumor activity .
|
-
- HY-124584A
-
|
|
Apoptosis
|
Cancer
|
|
Minnelide free base is a prodrug of Triptolide (HY-32735) that shows potent antitumor activity in a number of tumor types, particularly in pancreatic cancer. Minnelide free base promotes apoptosis .
|
-
- HY-128961
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Alkyl-Hydrazine Modified MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the Modified MMAF (a tubulin inhibitor), linked via the noncleavable MC-Alkyl-Hydrazine .
|
-
- HY-N10387
-
|
|
Others
|
Cancer
|
|
Glucodichotomine B (Compound 13) is a natural product which can be isolated from the roots of Chinese medicinal plant Stellaria dichotoma L. var. lanceolata. Glucodichotomine B shows antitumor activity .
|
-
- HY-128906
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-Retapamulin is a agent-linker conjugate for ADC with potent antitumor activity by using Retapamulin (a ribosome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
|
-
- HY-108488
-
|
|
Src
|
Cancer
|
|
KB SRC 4 is a potent, and highly selective c-Src inhibitor, with a Ki of 44 nM and a Kd of 86 nM, and shows no inhibition on c-Abl up to 125 μM; KB SRC 4 has antitumor activity.
|
-
- HY-125645
-
|
|
HDAC
|
Cancer
|
|
M122 is a potent inhibitor of HDAC1 and HDAC2, with the IC50 values of 0.48 μM and 0.47 μM, respectively, respectively. M122 has antitumor activity .
|
-
- HY-150036
-
|
|
Antibiotic
Cholecystokinin Receptor
|
Cancer
|
|
Anthramycin, a member of the pyrolobenzodiazepine (PBD) family, is a potent antibiotic. Anthramycin has potent antitumor activity. Anthramycin can act as an potent antagonist of cholecystokinin in the central nervous system in mice .
|
-
- HY-136289
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MB-VC-MGBA is a agent-linker conjugate for ADC with potent antitumor activity by using MGBA (minor-groove-binding DNA-alkylating agent), linked via the ADC linker MB-VC .
|
-
- HY-P99906
-
|
DKN-01; LY-2812176
|
β-catenin
|
Cancer
|
|
Sirexatamab (DKN-01) is a humanized IgG4 monoclonal antibody that can bind to and neutralize circulating DKK1. Sirexatamab exhibits antitumor activity in tumor models expressing DKK1 .
|
-
- HY-119324
-
|
|
Apoptosis
|
Others
|
|
Anticancer agent 254 (compound 10) is a dichloroacetic acid-loaded compound with enhanced antitumor activity against leukemia cells in vitro and better stability in vivo, and can be considered for preclinical evaluation of cancer inhibition.
|
-
- HY-144697
-
-
- HY-158195
-
|
|
Apoptosis
|
Cancer
|
|
DPP23 exerts antitumor activity through ROS-mediated apoptosis in cancer cells, but does not play a role in healthy cells. DPP23 can up-regulate the expression of ATF4 .
|
-
- HY-161350
-
-
- HY-W326094
-
|
GOE 1734; PD 104 208; NSC 328786
|
DNA/RNA Synthesis
|
Cancer
|
|
Dinaline (GOE 1734; PD 104 208; NSC 328786) is a potent and orally activity anticancer agent. Dinaline shows cytotoxicity and antitumor activity. Dinaline has the potential for the research of colorectal cancer .
|
-
- HY-106662
-
|
Chloroquinoxaline; NSC-339004
|
Molecular Glues
Topoisomerase
Parasite
|
Infection
Cancer
|
|
Chloroquinoxaline sulfonamide (Chloroquinoxaline), a structural analogue of sulfaquinoxaline, is a topoisomerase II alpha/beta poison. Chloroquinoxaline sulfonamide is used to control coccidiosis in poultry, rabbit, sheep, and cattle . Antitumor activity .
|
-
- HY-163893
-
|
|
Apoptosis
|
Cancer
|
|
Apoptosis inducer 23 (compound 6e) is an apoptosis inducer with antitumor activity. Apoptosis inducer 23 plays an important role in lung cancer research by inducing apoptosis through mitochondrial damage .
|
-
- HY-128907
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-clindamycin is a agent-linker conjugate for ADC with potent antitumor activity by using clindamycin (a protein synthesis inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
|
-
- HY-N15597
-
|
NSC 34757
|
Topoisomerase
|
Cancer
|
|
Melicopidine (NSC 34757) is a DNA topoisomerase inhibitor, which is an acridone alkaloid found in the bark of Medicosma subsessilis. Melicopidine exerts potential antitumor activity by binding to DNA or inhibiting related enzyme activity .
|
-
- HY-P99758
-
|
CS1003
|
PD-1/PD-L1
|
Cancer
|
|
Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab shows antitumor activity and can be used for the research of unresectable or metastatic hepatocellular carcinoma .
|
-
- HY-N14822
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
4-O-Demethyl-11-deoxydoxorubicin is an anthracycline antibiotic with antibacterial and antitumor activities. 4-O-Demethyl-11-deoxydoxorubicin is cytotoxic to Hela cells .
|
-
- HY-128902
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-vinblastine is a agent-linker conjugate for ADC with potent antitumor activity by using vinblastine (an microtubule protein inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
|
-
- HY-144803
-
|
|
VEGFR
|
Cancer
|
|
VEGFR-2-IN-16 (Compound 15b) is a potent VEGFR-2 inhibitor with an IC50 of 86.36 nM. VEGFR-2-IN-16 shows antitumor activities .
|
-
- HY-19095
-
|
|
Antifolate
|
Cancer
|
|
TNP-351 is an antifolate. TNP-351, a dihydrofolate reductase (DHFR) inhibitor, has potent antitumor activity against not only leukemia cells but also solid tumor cells in vitro and in vivo .
|
-
- HY-27787
-
|
cis-Eleostearic acid
|
Apoptosis
Ferroptosis
|
Metabolic Disease
Cancer
|
|
α-Eleostearic acid (cis-Eleostearic acid), a conjugated linolenic acid, is an apoptosis inducer. α-Eleostearic acid is also a ferroptosis inducer. α-Eleostearic acid exhibits antioxidant and antitumor activity .
|
-
- HY-N2322R
-
|
|
Reference Standards
Others
|
Cancer
|
|
Khasianine (Standard) is the analytical standard of Khasianine. This product is intended for research and analytical applications. Khasianine is a steroidal glycoalkaloid which is obtained from black nightshade (Solanum Nigrum L.), which displays antitumor activity.
|
-
- HY-P990028
-
|
|
ADC Antibody
Transmembrane Glycoprotein
|
Cancer
|
|
Raludotatug is a humanized anti-CDH6 IgG1 monoclonal antibody. Raludotatug has antitumor activity and can be used to synthesize the ADC molecule Raludotatug deruxtecan (HY-164734) .
|
-
- HY-P991605
-
|
|
LAG-3
|
Cancer
|
|
HLX26 is a humanised anti-LAG-3 monoclonal antibody. HLX26 has antitumor activity especially advanced solid tumours. HLX26 can be used for lymphoma research .
|
-
- HY-N9488
-
|
Girinimbin
|
Apoptosis
Bacterial
Parasite
|
Infection
Inflammation/Immunology
Cancer
|
|
Girinimbine (Girinimbin) is a carbazole alkaloid with a variety of biological effects. Girinimbine can induce apoptosis, and has antitrypanosomal, antiplatelet activity, antibacterial activity, anti-inflammatory, antioxidant and antitumor activities .
|
-
- HY-P991140
-
|
|
Claudin
|
Cancer
|
|
Garetatug is a humanized monoclonal antibody targeting human CLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity .
|
-
- HY-162752
-
|
|
Apoptosis
|
Cancer
|
|
Anticancer agent 250 (compound 104) has antitumor activity, inducing apoptosis, slowing proliferation, and degrading key oncogenic proteins (such as aRaf, CDK4 ) without inducing a heat shock response .
|
-
- HY-P99202
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research .
|
-
- HY-155343
-
|
|
Phospholipase
|
Cancer
|
|
A4333 is biotinylated compound of A3373 (HY-155342) that inhibits Phospholipase D1 (PLD1), but not PLD2. A4333 plays an important role in antitumor activity .
|
-
- HY-156336
-
|
|
Polo-like Kinase (PLK)
|
Cancer
|
|
PLK1-IN-7 (compound 30e) is a potent PLK1 inhibitor, with an IC50 of 0.66 nM. PLK1-IN-7 exhibits antiproliferative and antitumor activities .
|
-
- HY-115937
-
|
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
c-Met-IN-9, a 4-phenoxypyridine derivative, is a c-Met kinas inhibitor with an IC50 of 12 nM. c-Met-IN-9 induces cells apoptosis, and has antitumor activities .
|
-
- HY-177614
-
|
AD3133 sodium
|
VEGFR
|
Cancer
|
|
ALN-3133 sodium is a siRNA that targets VEGF, and it is one of the siRNAs in ALN-VSP.ALN-VSP is a lipid nanoparticle formulation containing two siRNAs for kinesin spindle protein (KSP) and VEGF with potential antitumor activity.
|
-
- HY-103694
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Nebularine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-135176
-
|
|
Endogenous Metabolite
|
Cancer
|
|
13-Dihydrocarminomycin (compound D788-12) is the major metabolite of the antitumor antibiotic Carminomycin (HY-B2171). 13-Dihydrocarminomycin has weak antitumor activity .
|
-
- HY-125132
-
|
(-)-Agelastatin A; AglA
|
Apoptosis
|
Cancer
|
|
Agelastatin A ((-)-Agelastatin A; AglA), a tetracyclic alkaloid isolated from the sponge Agelas dendromorpha, induces apoptosis and arrests cells in the G2/M phase of the cell cycle, exhibiting antitumor activity .
|
-
- HY-119696R
-
|
|
Reference Standards
Drug Metabolite
|
Neurological Disease
Cancer
|
|
MTIC (Standard) is the analytical standard of MTIC. This product is intended for research and analytical applications. MTIC, the active metabolite of Temozolomide (TMZ), is a DNA alkylating agent. MTIC has antitumor activity
[1][2][3][4].
|
-
- HY-12808
-
|
|
NAMPT
AMPK
mTOR
|
Cancer
|
|
STF-118804 is a highly specific NAMPT inhibitor. STF-118804 activates AMPK and inhibits mTOR pathways. STF-118804 has antitumor activity against pancreatic cancer .
|
-
- HY-160854
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin inhibitor 43 (Compound 29) has significant antitumor activity. Tubulin inhibitor 43 inhibits the proliferation and growth of cancer cells by inhibiting the activity of β-microtubulin, and finally induces apoptosis .
|
-
- HY-P991726
-
|
|
Orphan GPCR
|
Cancer
|
|
Vemzatatug is a humanized IgG1κ monoclonal antibody inhibitor targeting GPRC5D. Vemzatatug has an antitumor activity. Vemzatatug can be used for cancers like multiple myeloma (MM) research .
|
-
- HY-152995
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Confidential is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-158005
-
|
|
Apoptosis
|
Cancer
|
|
Anticancer agent 195 (Compound 10) is an inhibitor for ELF3-MED23 PPI with Ki of 0.68 μM. Anticancer agent 195 induces apoptosis and exhibits antitumor activity .
|
-
- HY-41940
-
|
|
Bcr-Abl
|
Cancer
|
|
Dasatinib intermediate-1 is an intermediate in the synthesis of Dasatinib (HY-10181). Dasatinib Is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity .
|
-
- HY-132262
-
|
IMGN-901; BB-1090
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Lorvotuzumab mertansine is an ADC consisting of a humanized N901 monoclonal antibody against CD56 bound to maytansinoid DM1 via a stable disulfide linker. Lorvotuzumab mertansine has antitumor activity .
|
-
- HY-B1071R
-
|
Lasalocid-A (Standard); Ionophore X-537A (Standard); Antibiotic X-537A (Standard)
|
Reference Standards
Bacterial
Autophagy
Antibiotic
Parasite
Apoptosis
|
Infection
Cancer
|
|
Lasalocid (Standard) is the analytical standard of Lasalocid. This product is intended for research and analytical applications. Lasalocid (Lasalocid-A) is an antibacterial and anticoccidial agent that can be used as feed additives. Lasalocid exhibits antitumor activity. Lasalocid is orally active.
|
-
- HY-148900
-
|
|
E1/E2/E3 Enzyme
|
Cancer
|
|
SCFSkp2-IN-2 (Compound AAA-237) is a Skp2 inhibitor with a KD of 28.77 μM. AAA-237 induces apoptosis of NSCLC cells and shows antitumor activities .
|
-
- HY-136315
-
-
- HY-164527
-
|
|
Src
FAK
EGFR
|
Cancer
|
|
Si306 is a Src inhibitor with antitumor activity. Si306 reduces the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), and inhibits the invasion of human glioblastoma (GBM) .
|
-
- HY-128955
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-VC-PABC-Aur0101 is a agent-linker conjugate for ADC with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the ADC linker MC-VC-PABC.
|
-
- HY-145989
-
|
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
|
Aminobenzenesulfonic auristatin E is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .
|
-
- HY-162249
-
|
|
Ras
|
Cancer
|
|
ASP6918 is a potent and orally active KRAS G12C inhibitor with an IC50 value of 0.028 µM. ASP6918 inhibits cell growth. ASP6918 shows antitumor activity .
|
-
- HY-168104
-
|
|
VEGFR
|
Cancer
|
|
VEGFR-2-IN-55 (Compound 30) is a potent VEGFR-2 kinase inhibitor with an IC50 value of 1.24 nM . VEGFR-2-IN-55 has antitumor activity .
|
-
- HY-177613
-
|
AD12115
|
Kinesin
|
Cancer
|
|
ALN-12115 is a siRNA that targets kinesin spindle protein (KSP), and it is one of the siRNAs in ALN-VSP.ALN-VSP is a lipid nanoparticle formulation containing two siRNAs for KSP and VEGF with potential antitumor activity.
|
-
- HY-128893
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Sq-Cit-PAB-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using Gefitinib (an EGFR tyrosine kinase inhibitor), linked via the ADC linker MC-Sq-Cit-PAB.
|
-
- HY-162301
-
-
- HY-176708
-
|
|
Phosphodiesterase (PDE)
|
Cancer
|
|
ISM5939 is an orally active and selective ENPP1 inhibitor with an IC50 of 0.63 nM for 2,3-cGAMP degradation and 9.28 nM for ATP hydrolysis. ISM5939 has antitumor activity .
|
-
- HY-154269
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Confiden is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-15717
-
|
|
Ras
|
Cancer
|
|
Kobe2602 is a Ras-Raf interaction inhibitor. Kobe2602 inhibits the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki of 149 μM. Kobe2602 has antitumor activity .
|
-
- HY-185371
-
|
Irinotecan hydrochlorid liposomee; Liposomal irinotecan
|
Liposome
Topoisomerase
|
Cancer
|
|
Irinotecan liposome is a liposome-encapsulated form of Irinotecan hydrochlorid (HY-16562A) (a topoisomerase I inhibitor). Compared with Irinotecan, Irinotecan liposome enhances antitumor activity, reduces drug release rate, and avoids neutropenia.
|
-
- HY-117288A
-
|
BCL201 hydrochloride
|
Bcl-2 Family
|
Cancer
|
|
S55746 hydrochloride (BCL201 hydrochloride) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 hydrochloride (BCL201 hydrochloride) has antitumor activity with low toxicity .
|
-
- HY-128903
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-carfilzomib iodide is a agent-linker conjugate for ADC with potent antitumor activity by using carfilzomib (an irreversible proteasome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
|
-
- HY-163270
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
PM534, tubulin targeting agent, inhibits tubulin assembly with IC50 values of 0.8-3.2 nM. PM534 binds to the colchicine site of tubulin, which has high antitumor activity .
|
-
- HY-147981
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin polymerization-IN-31 (Compound 4c) is a tubulin polymerization inhibitor with an IC50 of 3.64 μM. Tubulin polymerization-IN-31 induces cancer cell apoptosis and shows antitumor activity .
|
-
- HY-N10093
-
|
Chamaejasmin
|
Apoptosis
AMPK
Autophagy
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Chamaejasmine is a biflavonoid that can be isolated from the roots of Stellera chamaejasme L. Chamaejasmine has antitumor activity. Chamaejasmine induces cell apoptosis, autophagy and ROS production, and activates the activity of AMPK/mTOR signal pathway .
|
-
- HY-150507
-
|
JNJ-78394355
|
Bcl-2 Family
|
Cancer
|
|
JNJ-4355, a chemical probe, is a highly potent MCL-1 (myeloid cell leukemia-1) inhibitor, with KI of 18 pM. JNJ-4355 shows antitumor activity .
|
-
- HY-177613A
-
|
AD12115 sodium
|
Kinesin
|
Cancer
|
|
ALN-12115 sodium is a siRNA that targets kinesin spindle protein (KSP), and it is one of the siRNAs in ALN-VSP.ALN-VSP is a lipid nanoparticle formulation containing two siRNAs for KSP and VEGF with potential antitumor activity.
|
-
- HY-N13895
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Auramycin B, an anthracycline antibiotic that shows marked antibacterial activity against Gram-positive bacteria. Auramycin B also exhibits antitumor activity against P388 and L1210 leukemia in mice .
|
-
- HY-N2380
-
|
|
Others
|
Cancer
|
|
N-Benzoyl-(2R,3S)-3-phenylisoserine is a Taxol C-13 Side Chain and crucial for the strong antitumor activity of Taxol .
|
-
- HY-160702
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
DMBA-SIL-Mal-MMAE is a cytotoxin-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked DMBA-SIL-Mal .
|
-
- HY-162849
-
|
|
Wee1
|
Cancer
|
|
PKMYT1-IN-3 (compound 8ma) is a potent and selective PKMYT1 inhibitor with an IC50 value of 16.5 nM. PKMYT1-IN-3 has antitumor activity .
|
-
- HY-154270
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Confident is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-117288
-
S55746
1 Publications Verification
BCL201
|
Bcl-2 Family
|
Cancer
|
|
S55746 (BCL201) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 (BCL201) has antitumor activity with low toxicity .
|
-
- HY-16513R
-
|
Dianhydrodulcitol (Standard); Dianhydrogalactitol (Standard)
|
DNA Alkylator/Crosslinker
Reference Standards
|
Cancer
|
|
VAL-083 (Standard) is the analytical standard of VAL-083. This product is intended for research and analytical applications. VAL-083 is an alkylating agent that creates N7 methylation on DNA, with antitumor activity.
|
-
- HY-19474
-
|
Ansamitocin P-0
|
Microtubule/Tubulin
ADC Payload
Apoptosis
|
Cancer
|
|
Maytansinol (Ansamitocin P-0) is a derivative of Maytansine. Maytansinol can inhibit tubulin polymerization and induce apoptosis. Maytansinol has antitumor activity. Maytansinol can be used in cancer drug research .
|
-
- HY-124092
-
|
935U83
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Raluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-128908
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-Indibulin is a agent-linker conjugate for ADC with potent antitumor activity by using Indibulin (an orally applicable inhibitor of tubulin assembly), linked via the ADC linker MC-Val-Cit-PAB.
|
-
- HY-10981A
-
|
E7080 mesylate
|
VEGFR
FGFR
PDGFR
RET
c-Kit
|
Cancer
|
|
Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
|
-
- HY-128899
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-Auristatin E is a agent-linker conjugate for ADC with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker MC-Val-Cit-PAB.
|
-
- HY-N8533
-
|
|
DNA/RNA Synthesis
|
Infection
Cancer
|
|
Sodium Camptothecin is a plant alkaloid, with antitumor activity. Sodium Camptothecin is a reversible inhibitor of RNA synthesis. Sodium Camptothecin is an effective inhibitor of adenovirus replication. Sodium Camptothecin inhibits DNA synthesis and causes breaks in intracellular preformed viral DNA .
|
-
- HY-113574
-
|
|
HSP
|
Cancer
|
|
HSP90-IN-29 (Compound 13), a benzoxazole derivative, is a potent and selective HSP-90 inhibitor with an IC50 value of 30 nM. HSP90-IN-29 has antitumor activity .
|
-
- HY-116446
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Pironetin is an α/β unsaturated lactone isolated from Streptomyces species. Pironetin binds to α-tubulin and is a potent inhibitor of microtubule polymerization, and has cell cycle arrest and antitumor activity .
|
-
- HY-126492
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Vat-Cit-PAB-Monomethyl Dolastatin 10 is a agent-linker conjugate for ADC with potent antitumor activity by using Monomethyl Dolastatin 10 (a potent tubulin inhibitor), linked via the ADC linker Vat-Cit-PAB.
|
-
- HY-B1071AR
-
|
Lasalocid-A sodium (Standard); Ionophore X-537A sodium (Standard); Antibiotic X-537A sodium (Standard)
|
Reference Standards
Bacterial
Autophagy
Antibiotic
Parasite
Apoptosis
|
Infection
Cancer
|
|
Lasalocid (sodium) (Standard) is the analytical standard of Lasalocid (sodium). This product is intended for research and analytical applications. Lasalocid sodium (Lasalocid sodium-A) is an antibacterial and anticoccidial agent that can be used as feed additives. Lasalocid sodium exhibits antitumor activity. Lasalocid sodium is orally active.
|
-
- HY-156796
-
|
|
ADC Payload
|
Neurological Disease
Cancer
|
|
Akt/ROCK-IN-1 (B12) is a dual inhibitor for Akt and ROCK, with the IC50s of 0.023 nM and 1.47 nM, respectively. Akt/ROCK-IN-1 has antitumor activity for neuroblastoma .
|
-
- HY-126693
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
SC-VC-PAB-DM1 is a agent-linker conjugate for ADC with with potent antitumor activity by using DM1 (Mertansine, a tubulin inhibitor) , linked via the ADC linker SC-VC-PAB .
|
-
- HY-10981
-
|
E7080
|
VEGFR
FGFR
PDGFR
c-Kit
RET
|
Cancer
|
|
Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
|
-
- HY-155079
-
|
|
EGFR
|
Cancer
|
|
DZD1516 is a potent and selective HER2 inhibitor (IC50=0.56 nM) with good blood-brain permeability. DZD1516 exhibits antitumor activity in CNS and subcutaneous xenograft mouse models .
|
-
- HY-Q25865
-
|
|
VISTA
|
Cancer
|
|
MG-V-53 is a potent small molecule V domain T-cell activating immunoglobulin suppressor (VISTA) inhibitor with IC50 value of 121 nM. MG-V-53 has antitumor activity .
|
-
- HY-12019
-
|
|
c-Met/HGFR
|
Cancer
|
|
SGX523 is a exquisitely selective and ATP-competitive MET inhibitor. SGX523 potently inhibits MET with an IC50 of 4 nM and is >1,000-fold selective versus other protein kinases. Antitumor activity .
|
-
- HY-147812
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
POLA1 inhibitor 1 (Compound 12) is an orally active POLA1 inhibitor. POLA1 inhibitor 1 shows antitumor activity against several tumor histotypes and Adarotene-resistant cell line .
|
-
- HY-125117
-
|
|
DNA/RNA Synthesis
Bacterial
|
Infection
Cancer
|
|
Simocyclinone D8 is an anthracycline antibiotic with antibacterial and antitumor activity against Gram-positive bacteria. Simocyclinone D8 inhibits DNA gyrase and thus has an inhibitory effect on a variety of tumor cell lines .
|
-
- HY-P991126
-
|
YH003
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy .
|
-
- HY-128897
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-VC-PABC-DNA31 is a agent-linker conjugate for ADC with potent antitumor activity by using DNA31 (a potent RNA polymerase inhibitor), linked via the ADC linker MC-VC-PABC.
|
-
- HY-169111
-
|
|
SHP2
|
Cancer
|
|
SHP2-IN-32 (compound C6) is an orally active, allosteric SHP2 inhibitor with an IC50 value of 0.13 nM. SHP2-IN-32 exhibits antitumor activity .
|
-
- HY-163541
-
SMS121
3 Publications Verification
|
Scavenger Receptor Class B type I (SR-BI）
|
Cancer
|
|
SMS121 is a CD36 inhibitor with a KD values of about 5 µM. SMS121 reduces the uptake of lipids and inhibits cell viability in acute myeloid leukemia cells. SMS121 has antitumor activity .
|
-
- HY-160409
-
|
|
Topoisomerase
Apoptosis
|
Cancer
|
|
TopBP1-IN-1 is a TopBP1 inhibitor. TopBP1-IN-1 has a synergistic effect with PARP inhibitors. TopBP1-IN-1 has antitumor activity .
|
-
- HY-B1056
-
|
Propazol; 2-Benzimidazolepropionic acid
|
Bacterial
Parasite
Antibiotic
Carbonic Anhydrase
|
Infection
Cancer
|
|
Procodazole is an orally active enhancer and a non-specific active immune protector against viral and bacterial infections. Procodazole also exhibits antiparasitic activity. In addition, Procodazole is a carbonic anhydrase inhibitor with antitumor activity .
|
-
- HY-161927
-
|
|
EGFR
Apoptosis
|
Cancer
|
|
EGFR-TK-IN-4 (compound 10k) is a potent and selective EGFR-TK inhibitor. EGFR-TK-IN-4 can induce apoptosis . EGFR-TK-IN-4 has antitumor activity .
|
-
- HY-154668
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'- Homocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-105293
-
|
|
DNA/RNA Synthesis
Topoisomerase
|
Cancer
|
|
NSC 727357 is a DNA intercalator and topoisomerase inhibitor with antitumor activity. NSC 727357 can inhibit cells proliferation and induce G1 phase arrest. NSC 727357 can be used for the research of cancer, such as melanoma .
|
-
- HY-N2227
-
|
Luteoside
|
Others
|
Others
|
|
Isorhamnetin 3-glucoside-7-rhamnoside (Luteoside) is a flavonoid that can be isolated from the aerial parts of B. tripartita . It has weaker antitumor activity, and it also has antiplatelet and anticoagulant activity.
|
-
- HY-139784
-
|
(R)-2-Hydroxyoleic acid; (R)-2-OHOA; (R)-LAM561
|
Endogenous Metabolite
|
Cancer
|
|
Idroxioleic acid ((R)-2-Hydroxyoleic acid; (R)-2-OHOA), the R enantiomer of (Rac)-Idroxioleic acid, is an orally active fatty acid that modulates the lipid composition and structure of the membranes. Idroxioleic acid has antitumor activities .
|
-
- HY-148127
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
TAM558 is a payload molecule used for the synthesis of OMTX705. OMTX705 is a humanized anti-fibroblast-activating protein (FAP) antibody conjugated to the cytolysin TAM470 (HY-148128), with antitumor activity .
|
-
- HY-163195
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 40 (compound 45) is a tubulin inhibitor with IC50 of 1.2 μM. Tubulin inhibitor 40 shows selective cytotoxicity towards cancer cells. Tubulin inhibitor 40 processes antitumor activity .
|
-
- HY-P9922
-
|
IMC-3G3; LY3012207
|
PDGFR
|
Cancer
|
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .
|
-
- HY-P9956
-
|
CNTO-328
|
Interleukin Related
|
Cancer
|
|
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research .
|
-
- HY-141602
-
-
- HY-16446
-
|
|
c-Met/HGFR
PI3K
Akt
MEK
Apoptosis
|
Cancer
|
|
SAR125844 is a potent, selective, and ATP-competitive MET kinase inhibitor with the value of IC50 is 4.2 nM and Ki is 2.8 nM. SAR125844 has antitumor activity and can be used for the research of cancer .
|
-
- HY-128909
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-rifabutin is a agent-linker conjugate for ADC with potent antitumor activity by using rifabutin (an DNA-dependent RNA polymerase inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
|
-
- HY-143460
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
CAXII-IN-1 (Compound 17) is a selective CA XII inhibitor with Ki values of 3.8 nM and 56.0 nM against hCA XII and hCA IX, respectively. CAXII-IN-1 shows antitumor activity .
|
-
- HY-P10951
-
|
(R)-PSMA I&T; (R)-PNT-2002
|
PSMA
|
Cancer
|
|
Zadavotide guraxetan (PSMA I&T; PNT-2002) is a prostate-specific membrane antigen (PSMA) inhibitor. Zadavotide guraxetan has antitumor activity and can be used in prostate cancer-targeted research .
|
-
- HY-155172
-
|
|
Cyclophilin
|
Cancer
|
|
ZX-J-19j (Compound ZX-J-19j) is a cyclophilin J inhibitor. ZX-J-19j showes potent antitumor activity .
|
-
- HY-152599
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-Methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-13598
-
|
CKD-516
|
Microtubule/Tubulin
|
Cancer
|
|
Valecobulin (CKD516) is a valine proagent of (S516) and a vascular disrupting agent (VDA). Valecobulin is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors .
|
-
- HY-152546
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Allyloxyguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-111407A
-
|
SCH900353 hydrochloride; MK-8353-001
|
ERK
|
Cancer
|
|
MK-8353 (SCH900353) hydrochloride is a potent, selective, orally active ERK1/2 inhibitor with IC50 values of 23.0 nM and 8.8 nM, respectively. MK-8353 exhibits antitumor activity .
|
-
- HY-164497
-
|
|
DNA/RNA Synthesis
Histone Methyltransferase
|
Cancer
|
|
NSC 641396 is a ribonucleotide reductase (RNR) inhibitor with an IC50 value of 1.2 μM. NSC 641396 is also a protein arginine N-methyltransferase 9 (PRMT9) inhibitor. NSC 641396 has antitumor activity .
|
-
- HY-17411
-
-
- HY-152654
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4′-Thiocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-134295
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Chloroinosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152617
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’-Thioinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154732
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Thiopseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-170865
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
OncoFAP-GlyPro-MMAF is a Drug-Linker Conjugate for ADC with potent antitumor activity. OncoFAP-GlyPro-MMAF consists of Monomethylauristatin F (HY-15579) and a linker. OncoFAP-GlyPro-MMAF can be used for synthesis of ADCs .
|
-
- HY-157339
-
-
- HY-154242
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Methylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152643
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Methylpseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N2113
-
|
|
Autophagy
|
Cancer
|
|
Glaucocalyxin B is an ent kaurane diterpenoid isolated from the Chinese traditional medicine Rabdosia japonica with anticancer and antitumor activity; decreases the growth of HL-60 cells with an IC50 of approximately 5.86 μM at 24 h.
|
-
- HY-161696
-
|
|
Apoptosis
|
Cancer
|
|
AN5777 is a GSPT1 degrader. AN5777 significantly reduces GSPT1 through the ubiquitin-proteasome system. AN5777 induces G1 block and Apoptosis. AN5777 has antitumor activity .
|
-
- HY-154535
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Alpha-inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-106052
-
|
ICIG 1105; NSC 279194; RFCNU
|
DNA/RNA Synthesis
|
Cancer
|
|
Bofumustine (ICIG 1105) is a nitrosourea compound with antitumor activity. Bofumustine can interfere with the replication and division of tumor cell DNA through alkylation, leading to the death of tumor cells. Bofumustine can be used in the field of cancer research .
|
-
- HY-154329
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W244398
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Thiocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-105019A
-
|
Melphalan flufenamide hydrochloride
|
DNA Alkylator/Crosslinker
Apoptosis
|
Cancer
|
|
Melflufen (Melphalan flufenamide) hydrochloride, a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen hydrochloride shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen hydrochloride induces irreversible DNA damage and cytotoxicity in MM cells .
|
-
- HY-128904
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-duocarmycin chloride is a agent-linker conjugate for ADC with potent antitumor activity by using Duocarmycin (a DNA minor groove binding alkylating agent), linked via the ADC linker MC-Val-Cit-PAB.
|
-
- HY-111207
-
|
|
CDK
Apoptosis
|
Cancer
|
|
CA224 (Compound 1) is a selective and orally active Cdk4–cyclin D1 inhibitor with an IC50 of 6.2 µM. CA224 induces cell apoptosis and shows antitumor activity .
|
-
- HY-W011581
-
|
|
Drug Intermediate
|
Infection
Cancer
|
|
6,9-Dichloro-2-methoxyacridine is an aromatic heterocyclic compound. 6,9-Dichloro-2-methoxyacridine is a precursor of ACS03, which exhibits antileishmanial and antitumor activities .
|
-
- HY-W587829
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Thiothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N9647
-
|
|
Wnt
β-catenin
Apoptosis
|
Cancer
|
|
Dalbinol is a rotenoid compound. Dalbinol can inhibit Wnt/β-catenin signaling pathway and promote β-catenin degradation. Dalbinol inhibits tumor cells proliferation and induces apoptosis. Dalbinol has antitumor activity .
|
-
- HY-152615
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-Methylguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-145989A
-
|
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
|
Aminobenzenesulfonic auristatin E TFA is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E TFA has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .
|
-
- HY-131795
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Methylthioadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152383
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Difluoromethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152682
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
Cancer
|
|
5-Ethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152368
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Hydrazinoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-117613
-
|
|
Topoisomerase
|
Cancer
|
|
A-74932 hydrochloride is a potent Top II inhibitor with antitumor activity. A-74932 hydrochloride inhibits the catalytic activity of mammalian DNA topoisomerase II. A-74932 hydrochloride can be used for cancer research .
|
-
- HY-128894
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Sq-Cit-PAB-Dolastatin10 is a agent-linker conjugate for ADC with potent antitumor activity by using Dolastatin10 (a tubulin polymerization inhibitor), linked via the ADC linker MC-Sq-Cit-PAB.
|
-
- HY-W022290
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Bromocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-134294
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Chloroguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-105019
-
|
Melphalan flufenamide
|
DNA Alkylator/Crosslinker
Apoptosis
|
Cancer
|
|
Melflufen (Melphalan flufenamide), a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen induces irreversible DNA damage and cytotoxicity in MM cells .
|
-
- HY-111407
-
MK-8353
5 Publications Verification
SCH900353
|
ERK
|
Cancer
|
|
MK-8353 (SCH900353) is a potent, selective and orally available ERK1/2 inhibitor, with IC50s of 23.0 nM and 8.8 nM, respectively; MK-8353 has antitumor activity.
|
-
- HY-154536
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Alpha-Guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-137193
-
|
|
Drug Metabolite
|
Cancer
|
|
5,6-Dihydroabiraterone is the metabolism of Abiraterone (HY-70013). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, and shows antitumor activity in CRPC (castration-resistant prostate cancer) .
|
-
- HY-152544
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Allylthioguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152807
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-Thioadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W609639
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxyisocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N9987
-
-
- HY-129167
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction extracted from patent WO2017214367, compound example 1. Menin-MLL inhibitor 4 has antitumor activity .
|
-
- HY-154268
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Confidential-2 is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-128759
-
|
|
DYRK
|
Cancer
|
|
DYRKs-IN-2 (Example 132) is a potent DYRKs inhibitor with IC50s of 30.6 nM and 12.8 nM for DYRK1B and DYRK1A, respectively. DYRKs-IN-2 has antitumor activity .
|
-
- HY-12643
-
-
- HY-126682
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Mal-VC-PAB-DM1 is a agent-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker Mal-VC-PAB .
|
-
- HY-112581
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N0661R
-
-
- HY-152462
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Azaguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N7028
-
-
- HY-N10542
-
|
|
Others
|
Cancer
|
|
Aplyronine C is an active compound. Aplyronine C shows potent antitumor activity and has cytotoxicity against HeLa-S3 cells with an IC50 values of 22 nM. Aplyronine C can be used for the research of cancer .
|
-
- HY-142740
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Rha-PEG3-SMCC (compound 13) is a agent-linker conjugate for ADC with potent antitumor activity by using SMCC (a protein crosslinker), linked via the noncleavable ADC linker Rha-PEG3.
|
-
- HY-16475
-
|
|
Hedgehog
|
Cancer
|
|
TAK-441 is a highly potent and orally active hedgehog (Hh) signaling inhibitor with an IC50value of 4.4 nM. TAK-441 has strong antitumor activity in solid tumors .
|
-
- HY-15324
-
|
P505-15 acetate; PRT-2607 acetate; BIIB-057 acetate
|
Syk
Src
Mixed Lineage Kinase
PAK
Pyk2
FAK
Apoptosis
|
Cancer
|
|
PRT062607 (P505-15) acetate is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 acetate exerts potent antitumor activity in tumor xenograft mouse models . .
|
-
- HY-154670
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Homoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154534
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Alpha-Adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W048500
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Thiothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-145856
-
|
|
VEGFR
Apoptosis
|
Cancer
|
|
VEGFR-2-IN-11 (Compound 8h) is a potent VEGFR-2 inhibitor with an IC50 of 60.27 nM. VEGFR-2-IN-11 shows antitumor activity and induces cell apoptosis .
|
-
- HY-151414
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3'-Deoxyinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-15323
-
|
P505-15 Hydrochloride
|
Syk
Mixed Lineage Kinase
PAK
Pyk2
FAK
Apoptosis
Src
|
Cancer
|
|
PRT062607 (P505-15) Hydrochloride is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 Hydrochloride exerts potent antitumor activity in tumor xenograft mouse models .
|
-
- HY-131792
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloroinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-10818R
-
|
|
Reference Standards
Antifolate
|
Cancer
|
|
LY309887 (Standard) is the analytical standard of LY309887 (HY-10818). This product is intended for research and analytical applications. LY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase (GARFT), with a Ki of 6.5 nM, and has antitumor activity.
|
-
- HY-103223R
-
|
NSC 710305 (Standard)
|
Reference Standards
Cytochrome P450
|
Cancer
|
|
Phortress (Standard) is the analytical standard of Phortress (HY-103223). This product is intended for research and analytical applications. Phortress is a high affinity AhR ligand that elicits antitumor activity by inducing transcription of CYP1A1 .
|
-
- HY-152314
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Cyanoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W100215
-
|
5-Methylcyclocytidine hydrochlorine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Methylcyclocytidine hydrochloride is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-171135
-
-
- HY-154275
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’-Methylthymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152740
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Pyrrolidinomethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W009163
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Bromouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-18957C
-
|
BGB-283 hydrochloride
|
Endogenous Metabolite
|
Cancer
|
|
Lifirafenib hydrochloride (BGB-283 hydrochloride) is a novel, reversible B-RAFV600E inhibitor with antitumor activity. Lifirafenib has shown potent antitumor activity against solid tumors with B-RAFV600E mutations, such as melanoma, thyroid cancer, and low-grade serous ovarian cancer. Lifirafenib exhibits selective cytotoxicity in vitro, preferentially inhibiting the proliferation of cancer cells with B-RAFV600E and EGFR mutations/amplification. Lifirafenib can achieve dose-dependent inhibition of tumor growth in animal models, accompanied by partial and complete tumor shrinkage .
|
-
- HY-N0379
-
-
- HY-154421
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,5’-Dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-149072
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
TLR7 agonist 11 is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P992110
-
|
DB-1311 Antibody; BNT324 Antibody
|
CD276/B7-H3
|
Cancer
|
|
Elfetabart is a humanized monoclonal antibody targeting CD276 with antitumor activity. The antibody isotype of Elfetabart is human IgG1κ, and the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-125665
-
|
|
Apoptosis
|
Cardiovascular Disease
Cancer
|
|
Pheophorbide A is an intermediate product in the chlorophyll degradation pathway. Pheophorbide A can be used as a photosensitizer. Pheophorbide A is a lymphatic vascular activator. Pheophorbide A has antitumor activity. Pheophorbide A can be used for human lymphatic vascular insufficiencies research .
|
-
- HY-10537
-
|
VNP40101M
|
DNA/RNA Synthesis
|
Cancer
|
|
Laromustine (VNP40101M) is a compound with antitumor activity. The mechanism of action of Laromustine mainly involves DNA alkylation and DNA repair inhibition. Laromustine can be used for bone marrow transplantation in patients with acute myeloid leukemia and cancer .
|
-
- HY-N2389R
-
|
|
Reference Standards
Apoptosis
|
Cancer
|
|
Formosanin C (Standard) is the analytical standard of Formosanin C. This product is intended for research and analytical applications. Formosanin C is a diosgenin saponin isolated from Paris polyphylla and an immunomodulator with antitumor activity. Formosanin C induces apoptosis .
|
-
- HY-N10541
-
|
|
Others
|
Cancer
|
|
Aplyronine B is an active compound. Aplyronine B shows potent antitumor activity and has cytotoxicity against HeLa-S3 cells with an IC50 values of 2.9 nM. Aplyronine B can be used for the research of cancer .
|
-
- HY-W014306R
-
|
|
Nucleoside Antimetabolite/Analog
Reference Standards
|
Cancer
|
|
2',3'-Dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-10991
-
|
|
c-Met/HGFR
VEGFR
Apoptosis
|
Cancer
|
|
MGCD-265 analog is a potent and oral active inhibitor of c-Met and VEGFR2 tyrosine kinases, with IC50s of 29 nM and 10 nM, respectively. MGCD-265 analog has significant antitumor activity .
|
-
- HY-W013259
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Methylmercaptopurine riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-12442
-
|
|
STAT
Apoptosis
|
Cancer
|
|
LY5 is a STAT3 inhibitor with an IC50 value of 0.5 μM. LY5 induces apoptosis and inhibits STAT3 phosphorylation. LY5 shows antitumor activity in vivo, it can be used for the research of cancer .
|
-
- HY-152375
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Hydroxy-xyloguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-147158
-
|
|
Molecular Glues
|
Cancer
|
|
ZXH-1-161 is a potent CRBN modulator that selectively induces the degradation of GSPT1 in a CRBN-dependent manner. ZXH-1-161 can inhibit the proliferation of multiple myeloma cells and exhibits antitumor activity .
|
-
- HY-147834
-
|
|
STING
|
Cancer
|
|
STING agonist-9 (Compound 45) is a potent STING agonist with an EC50 of 1.2 nM and 32.82 μM against h-STING and m-STING, respectively. STING agonist-9 shows antitumor activity .
|
-
- HY-152327
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Methylthio isopentenyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-D2095
-
|
|
Fluorescent Dye
|
Cancer
|
|
Medical fluorophore 33 is a novel quinoline-isoquinoline salt. Medical fluorophore 33 exhibits a strong fluorescent signal, good microsomal stability and high biocompatibility in vivo. Medical fluorophore 33 has antitumor activity in colorectal cancer mice .
|
-
- HY-115436
-
|
|
Apoptosis
|
Cancer
|
|
LYG-202, a flavonoid, has potent anti-angiogenic and antitumor activity. LYG-202 inhibits VEGF-stimulated HUVEC migration and tube formation. LYG-202 induces cancer cell apoptosis .
|
-
- HY-W154568
-
|
6-MPR
|
Nucleoside Antimetabolite/Analog
|
Others
Cancer
|
|
6-Methylpurine riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-130806
-
|
H2dUrd
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Dihydrodeoxyuridine (H2dUrd) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-159811
-
|
|
Drug Derivative
|
Cancer
|
|
Antitumor agent-187 (compound I) is an isoflavone derivative with antitumor activity. Antitumor agent-187 shows IC50 values of 5.23 μM and 2.63 μM on A2780 and SKOV3, respectily .
|
-
- HY-152602
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,3'-Dimethylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152441
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Aminomethyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152387
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Chloro-arabinoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154131
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3-Deaza-xylouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-148810
-
|
BI 1810631
|
c-Met/HGFR
|
Cancer
|
|
Zongertinib (BI 1810631) is a potent and selective HER2 and EGFR tyrosine kinase inhibitor with IC50 values of 13 nM and 579 nM, respectively. Zongertinib has antitumor activity and can be used in the study of multiple solid tumors .
|
-
- HY-122315
-
|
NSC-741909
|
JNK
Apoptosis
|
Cancer
|
|
Oncrasin-60 (NSC-741909) is a compound with antitumor activity that is active against multiple cancer cell lines in vitro and can induce tumor regression in vivo, with its mechanism involving JNK activation and STAT3 inhibition.
|
-
- HY-W014306
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',3'-Dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-130805
-
|
OHUrd
|
Nucleoside Antimetabolite/Analog
|
Others
Cancer
|
|
5-Hydroxyuridine (OHUrd) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W412546
-
|
4-[1-[(2-Methylphenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152321
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Hydroxy-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-108441
-
|
|
Wnt
β-catenin
|
Cancer
|
|
CCT 031374 hydrobromid is a potent inhibitor of β-catenin/transcription factor (TCF) complex signaling. CCT031374 inhibits TCF-dependent transcription of genes of Wnt signaling pathway. CCT 031374 has antitumor activity .
|
-
- HY-124439
-
|
|
Antibiotic
Bacterial
SARS-CoV
|
Infection
Cancer
|
|
Setomimycin is a potent antibiotic. Setomimycin inhibits the SARS-CoV-2 Mpro enzyme with an IC50 value of 12.02 µM. Setomimycin shows anti-inflammatory and antioxidant properties. Setomimycin shows antiproliferative and antitumor activity .
|
-
- HY-149071
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
TLR7 agonist 10 is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152869
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-(Trifluoromethyl)cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152510
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(Aminomethyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152794
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-Methyl wyosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-105006
-
|
2-Methoxyadenosine; 2-O-Methylisoguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Spongosine (2-Methoxyadenosine) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152420
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Trifluoromethyl adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154474
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,4-Dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-14815
-
|
Combretastatin A4 phosphate
|
Apoptosis
Microtubule/Tubulin
|
Cancer
|
|
Fosbretabulin (Combretastatin A4 phosphate) is a vascular disruptor with antitumor activity against atypical thyroid carcinoma (ATC) cell lines and xenografts. Fosbretabulin inhibits tumor growth by inhibiting microtubule polymerization, inducing apoptosis, and suppressing angiogenesis in tumors .
|
-
- HY-152586
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2′,3′-Anhydroadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152867
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-(Trifluoromethyl)uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-128920
-
|
|
Cytochrome P450
|
Cancer
|
|
Phortress free base (NSC 710305) is a P450 CYP1A1-activated antitumor prodrug with antitumor activity . Phortress free base leads to DNA damage and cell cycle arrest .
|
-
- HY-P991143
-
|
TORL-1-23 Antibody
|
Claudin
|
Cancer
|
|
Ixotatug is a monoclonal antibody targeting human CLDN6 (claudin-6). Ixotatug specifically binds to CLDN6, interfering with relevant signaling pathways in tumor cells and exerting antitumor activity. Ixotatug is promising for research of cancers .
|
-
- HY-153832
-
|
|
RAR/RXR
NO Synthase
|
Cancer
|
|
MSU-42011 is an orally active retinoid X receptor (RXR) agonist. MSU-42011 inhibits the iNOS activity and reduces the expression of p-ERK protein. MSU-42011 has immunomodulatory and antitumor activity .
|
-
- HY-P11211A
-
|
|
Bacterial
|
Infection
Cancer
|
|
D2A21 TFA is an antimicrobial peptide with significant antimicrobial activity against Pseudomonas and bactericidal effect on burn scabs. D2A21 TFA has antitumor activity and can be used in prostate cancer research .
|
-
- HY-N6952
-
-
- HY-161116
-
|
|
Acetyl-CoA Carboxylase
|
Cancer
|
|
AD-5584 is an ACSS2 inhibitor with blood-brain permeability. AD-5584 can significantly reduce lipid storage, reduce colony formation, and increase cell death. AD-5584 has antitumor activity .
|
-
- HY-154537
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P991145
-
|
|
SLC39 (Zinc Transporter)
|
Cancer
|
|
Laventatug is a humanized monoclonal antibody targeting human SLC39A6. Laventatug specifically binds to SLC39A6, interfering with the intracellular zinc ion transport process and thus exerting antitumor activity. Laventatug is promising for research of cancers .
|
-
- HY-13744
-
|
RFS 2000; 9-Nitrocamptothecin
|
Topoisomerase
|
Cancer
|
|
Rubitecan (RFS 2000), a Camptothecin derivative, is an orally active topoisomerase I inhibitor with broad antitumor activity, and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells .
|
-
- HY-154616
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Phthalimidopropyl uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-147057
-
|
FAP-2286
|
FAP
|
Cancer
|
|
Rofapitide tetraxetan (FAP-2286) is a potent and selective FAP-binding peptide with a mean IC50 value of 2.7 nM for binding to FAP. Rofapitide tetraxetan can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan has antitumor activity .
|
-
- HY-W108399
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-t-Bulyldimethylsilylthymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W107935
-
|
|
HSP
|
Cancer
|
|
Hsp90-IN-37 (Z-2) is a heat shock protein 90 (Hsp90) inhibitor that inhibits Hsp90 enzymatic activity by 69%. Hsp90-IN-37 has antitumor activity .
|
-
- HY-123979
-
ζ-Stat
3 Publications Verification
NSC37044
|
PKC
Apoptosis
|
Cancer
|
|
ζ-Stat (NSC37044) is a specific and atypical PKC-ζ inhibitor, with an IC50 of 5 μM. ζ-Stat can reduce melanoma cell lines proliferation and induce apoptosis, and has antitumor activity in vitro .
|
-
- HY-152594
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Uridine-5-oxyacetic acid is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154530
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
DMTr-TNA-C(Bz)-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152318
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Adenosine-2-carboxamide is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-100506
-
|
|
Integrin
|
Cancer
|
|
GLPG0187 is a broad spectrum integrin receptor antagonist with antitumor activity; inhibits αvβ1-integrin with an IC50 of 1.3 nM . GLPG0187 inhibits migrasome biogenesis without cytotoxicity .
|
-
- HY-152613
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-Ethylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-147057A
-
|
FAP-2286 acetate
|
FAP
|
Cancer
|
|
Rofapitide tetraxetan (FAP-2286) acetate is a potent and selective FAP-binding peptide with a mean IC50 value of 2.7 nM for binding to FAP. Rofapitide tetraxetan acetate can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan acetate has antitumor activity .
|
-
- HY-152649
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Cyclopropylmethylpseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154620
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-O-Hexadecyl-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N6949
-
-
- HY-149959
-
|
|
Mps1
|
Cancer
|
|
Mps1-IN-6 is a potent Mps1 inhibitor with an IC50 value of 2.596 nM. Mps1-IN-6 shows antiproliferative activity. Mps1-IN-6 shows antitumor activity .
|
-
- HY-154674
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Allylpseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154626
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Hexadecanyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P10656
-
|
|
Apoptosis
Pyroptosis
|
Cancer
|
|
Ac-DEVDD-TPP is a porphyrin derivative that can be converted into D-TPP by caspase-3 cleavage and laser irradiation. The formed porphyrin nanofibers can effectively induce Apoptosis and Pyroptosis. Ac-DEVDD-TPP has antitumor activity .
|
-
- HY-161897
-
|
|
Kinesin
|
Cancer
|
|
CENP-E-IN-2 (compound 3) is a photoswitchable CENP-E inhibitor, with the pIC50 of 6.82 without light illumination and 5.85 with 365 nm light illumination. CENP-E-IN-2 has antitumor activity .
|
-
- HY-152384
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5’(R)-C-Methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152837
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1,3-Dimethyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154109
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Aminopseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P99250
-
|
MetMAb
|
c-Met/HGFR
|
Cancer
|
|
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity .
|
-
- HY-107777
-
|
|
Histone Methyltransferase
|
Cancer
|
|
LLY-283, a chemical probe, is a potent, selective and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, with an IC50 of 22 nM and a Kd of 6 nM for PRMT5:MEP50 complex, and shows antitumor activity .
|
-
- HY-126683
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Mal-C6-α-Amanitin is a agent-linker conjugate for ADC with potent antitumor activity by using α-Amanitin (an RNA polymerase II inhibitor), linked via the ADC linker Mal-C6.
|
-
- HY-112030
-
|
Potassium tetrachloroplatinate(Ⅱ)
|
Biochemical Assay Reagents
|
Cancer
|
|
Dipotassium tetrachloroplatinate (Potassium tetrachloroplatinate (Ⅱ)) is an important reagent for the preparation of other platinum coordination complexes. Dipotassium tetrachloroplatinate acts as a radiosensitizer to enhance the killing effect of hyperthermia. Dipotassium tetrachloroplatinate serves as a catalyst. Dipotassium tetrachloroplatinate exhibits antitumor activity .
|
-
- HY-154528
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Phthalimidopropyl cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W550365
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(alpha-L-Threofuranosyl)thymine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-163469
-
|
|
Src
|
Cancer
|
|
SRC-3-IN-2 (SI-12 6c)is an orally active steroid receptor coactivator 3 (SRC-3) inhibitor. SRC-3-IN-2 has antitumor activity .
|
-
- HY-152871
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Uridine 5-oxyacetic acid methyl ester is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154110
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-Aminopseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154453
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Deoxy-xylo-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154187
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Pivaloyloxymethyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N6011
-
|
|
Topoisomerase
Apoptosis
|
Cancer
|
|
9-Methoxycamptothecin (MCPT), isolated from Camptotheca acuminata, has antitumor activities through topoisomerase inhibition. 9-Methoxycamptothecin (MCPT) induces strong G2/M arrest and apoptosis in cancer .
|
-
- HY-75161
-
-
- HY-148128
-
|
|
Microtubule/Tubulin
ADC Payload
|
Cancer
|
|
TAM470 is a novel cytolysin, inhibiting tubulin polymerization and microtubule depolymerization. TAM470 can be used in the synthesis of OMTX705 as payload molecule, OMTX705 is a novel FAP-targeting antibody-drug conjugates (ADCs) with antitumor activity .
|
-
- HY-154356
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(alpha-L-Threofuranosyl)cytosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-177081
-
|
|
MEK
|
Cancer
|
|
Envometinib (Compound B) is a dual-MEK inhibitor that works through Deep Cyclic Inhibition (DCI). Envometinib has antitumor activity in various in vivo models. Envometinib can be studied in RAS and RAF mutated cancer such as colorectal cancer and melanoma .
|
-
- HY-W556301
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′,3′-O-Isopropylideneisocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N0174R
-
|
Cryptotanshinon (Standard); Tanshinone c (Standard)
|
Reference Standards
STAT
Autophagy
|
Cancer
|
|
Cryptotanshinone (Standard) is the analytical standard of Cryptotanshinone. This product is intended for research and analytical applications. Cryptotanshinone is a natural compound extracted from the root of Salvia miltiorrhiza Bunge that shows antitumor activities. Cryptotanshinone inhibits STAT3 with an IC50 of 4.6 μM.
|
-
- HY-152313
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Bromoadenosine, antimalarial agent is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N2682
-
|
|
Others
|
Cancer
|
|
(7R,8S)-Dehydrodiconiferyl alcohol is a natural product that can be isolated from the thorns of Gleditsia sinensis. (7R,8S)-Dehydrodiconiferyl alcohol shows antitumor activity .
|
-
- HY-144217
-
|
|
ATM/ATR
|
Cancer
|
|
SKLB-197 showed an IC50 value of 0.013 μM against ATR but very weak or no activity against other 402 protein kinases. It displayed potent antitumor activity against ATM-deficent tumors both in vitro and in vivo.
|
-
- HY-130812
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Gemcitabine-O-Si(di-iso)-O-Mc is a agent-linker conjugate for ADC with potent antitumor activity by using Gemcitabine (a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent; HY-17026), linked via the ADC linker .
|
-
- HY-W128112
-
|
alpha-D-Ribofuranoside,2,4(1H,3H)-pyrimidinedione-1
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(a-D-ribofuranosyl)uracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-163308
-
|
|
Bcl-2 Family
|
Cancer
|
|
Bcl-2-IN-18 (Compound 23) is a breast cancer Bcl-2 inhibitor with a IC50 value of 4.7 μM for MCF-7. Bcl-2-IN-18 has antitumor activity .
|
-
- HY-108230
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
ALK-IN-12 is a potent and orally active ALK inhibitor with an IC50 of 0.18 nM. ALK-IN-12 also inhibits IGF1R and InsR (IC50=20.3 and 90.6 nM). Antitumor activities .
|
-
- HY-152454
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-α-C-Methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-137589
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Dimethyldeoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N13571
-
|
|
Others
|
Cancer
|
|
Adenostemmoic acid G is a kaurane-type diterpenoid compound, and other diterpenoid compounds in the plant extract containing it exhibit cytotoxic and antitumor activity. Adenostemmoic acid G can be naturally extracted from the fresh whole plant of Adenostemma lavenia O. KUNTZE .
|
-
- HY-15575
-
|
MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE; Vedotin
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
|
VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
|
-
- HY-W083376A
-
|
|
Keap1-Nrf2
|
Inflammation/Immunology
Cancer
|
|
4-Methoxychalcone is a naturally occurring chalcone compound. 4-Methoxychalcone has antioxidant activity, anti-inflammatory activity, antitumor activity and antibacterial activity. 4-Methoxychalcone can be used to study inflammation and tumor models .
|
-
- HY-154398
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Aza-xylo-cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152767
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Ethylpseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-163374
-
|
|
CDK
|
Cancer
|
|
Cdc7-IN-20 (EP-05) is an orally effective and selective Cdc7 inhibitor with IC50 and Ki values of 0.93 and 0.11 nM, respectively. Cdc7-IN-20 has antitumor activity .
|
-
- HY-W006474
-
|
5H-Pyrido[4,3-b]indole
|
Flavivirus
Drug Intermediate
|
Infection
Cancer
|
|
γ-Carboline is a skeleton and antiviral agent. γ-Carboline shows anti-BVDV activity, with an EC50 of 2.0 μM. γ-Carboline derivatives show anti-BVDV, antibacterial, antifungal, antitumor activity .
|
-
- HY-154621
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Hexadecanyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152344
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-β-C-Methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152795
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N4-Desmethyl wyosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W130204
-
|
N4-Acetyl-2'-deoxycytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N-Acetyl-2′-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N12534
-
|
|
Apoptosis
|
Cancer
|
|
Monaspin B is a natural product produced by the co-culture of Monascus purpureus and Aspergillus oryzae. Monaspin B exerts anti-proliferation activity by inducing apoptosis of HL-60 cells, IC50 160 nM. Monaspin B has antitumor activity .
|
-
- HY-144232
-
|
|
Others
|
Cancer
|
|
Anticancer agent 28 shows good antitumor activity in H22 allogeneic mice in vivo. Anticancer agent 28 has inhibitory potency in K562 cells of 50 times than oridonin, and its IC50 value is 0.09 μM.
|
-
- HY-152608
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-iso-Propyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152814
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2′-β-C-Methyl isoguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152725
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Benzyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154354
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Methyl 3’-O-benzyl xyloriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-20142
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-(t-Butyldiphenylsilyl) thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N15458
-
|
|
Apoptosis
|
Cancer
|
|
5,6,7,8,4'-Pentahydroxyflavone (Compound 2b) is a flavonoid with antitumor activity. 5,6,7,8,4'-Pentahydroxyflavone exerts cytotoxic effects via inhibiting cell proliferation and inducing apoptosis .
|
-
- HY-B1000R
-
|
Seleno-DL-methionine (Standard); DL-Selenomethionine (Standard)
|
Reference Standards
Autophagy
Keap1-Nrf2
|
Cancer
|
|
Selenomethionine (Standard) is the analytical standard of Selenomethionine. This product is intended for research and analytical applications. Selenomethionine is a naturally occurring amino acid containing selenium that has oral activity and is a common natural food source. Selenomethionine has antitumor activity[1][2][3].
|
-
- HY-123502
-
|
AZD-6738 formate
|
ATM/ATR
|
Cancer
|
|
Ceralasertib formate is a potent, selective and orally active ATR inhibitor with an IC50 value of 1 nM. Ceralasertib formate inhibits cell viability and induces DNA damage. Ceralasertib formate induces cell senescence. Ceralasertib formate shows antitumor activity .
|
-
- HY-170314
-
-
- HY-B0342
-
|
Methylglucamine; Meglumin; Methylglucamin
|
Biochemical Assay Reagents
|
Cancer
|
|
Meglumine (Methylglucamine) is an orally active amino sugar derived from sorbitol. Meglumine has anti-inflammatory and antitumor activity. Meglumine is often used as an excipient in active molecules and with iodinated compounds in contrast agents such as meglumine and meglumine iodide .
|
-
- HY-W011102
-
|
NSC 83265; S-Tritylcysteine; 3-Tritylthio-L-alanine
|
Kinesin
Apoptosis
|
Cancer
|
|
S-Trityl-L-cysteine (NSC 83265) is a selective and allosteric kinesin Eg5 inhibitor with an IC50 of 1 μM for the inhibition of basal ATPase activity and 140 nM for the microtubule-activated ATPase activity. S-Trityl-L-cysteine has antitumor activities .
|
-
- HY-B0431S
-
|
|
Adrenergic Receptor
|
Cancer
|
|
Phenoxybenzamine-d5 is the deuterium labeled Phenoxybenzamine . Phenoxybenzamine is a nonselective, irreversible, orally active α-adrenoceptor antagonist that is commonly used for the research of hypertension, specifically caused by pheochromocytoma. Phenoxybenzamine also shows antitumor activity .
|
-
- HY-N11435
-
|
Forbesoside
|
Others
|
Others
|
|
6'-O-trans-Feruloylnodakenin is a marker compound used for HPLC fingerprint of N. forbesii . 6'-O-trans-Feruloylnodakenin has antitumor activities (IC50 = 7.5x10-7 mol/L) in vitro.
|
-
- HY-152345
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Ethoxymethyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152464
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-arabinoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-128758
-
|
|
DYRK
|
Cancer
|
|
DYRKs-IN-1 is a potent DYRKs (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC50s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 has antitumor activity .
|
-
- HY-137848
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Thymine 1-β-D-arabinofuranoside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-144656
-
|
|
Steroid Sulfatase
|
Cancer
|
|
Steroid sulfatase-IN-1 is a potent and orally active Steroid sulfatase inhibitor with an IC50 of 1.71 nM. Steroid sulfatase-IN-1 shows antitumor activity in vivo. Steroid sulfatase-IN-1 has the potential for the research of breast cancer .
|
-
- HY-152598
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methylxylo-guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-163194
-
|
|
E1/E2/E3 Enzyme
|
Cancer
|
|
Cbl-b-IN-16 (compound 31) is an orally active Cbl-b inhibtor with IC50 of 30 nM and induces IL-2 production in Hu-T-cells with EC50 of 230 nM. Cbl-b-IN-16 exhibits antitumor activity .
|
-
- HY-156814
-
|
|
Hedgehog
|
Cancer
|
|
HPP-9 is a Proteolysis-Targeting Chimeras （PROTACs） based on Hedgehog Pathway Inhibitor-1 (HPI-1), with the pIC50 of 6.71, that can degrade BET bromodomains. HPP-9 has antitumor activity [1[.
|
-
- HY-154722
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Dimethylaminomethylidene isoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152417
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N3-Ethyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-128758A
-
|
|
DYRK
|
Cancer
|
|
DYRKs-IN-1 hydrochloride is a potent DYRKs (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC50s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 hydrochloride has antitumor activity .
|
-
- HY-17422B
-
|
|
DNA/RNA Synthesis
HSV
Antibiotic
|
Infection
Cancer
|
|
Acyclovir monophosphate is a potent anti-herpes simplex virus (HSV) agent. Acyclovir monophosphate blocks DNA synthesis through the inhibition of the viral DNA polymerase and terminates the chain elongation of the viral DNA. Acyclovir monophosphate shows antitumor activity .
|
-
- HY-15528
-
|
|
PKD
|
Cancer
|
|
kb NB 142-70 is a potent PKD inhibitor, with IC50s of 28.3, 58.7 and 53.2 nM for PKD1, PKD2, and PKD3, respectively. kb NB 142-70 also has antitumor activity.
|
-
- HY-152346
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Benzoyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152459
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-(n-Propylidene hydrazino) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-168611
-
-
- HY-172146
-
|
|
CDK
|
Cancer
|
|
CDK4/6-IN-24 (Compound A) is the inhibitor for CDK4/6. CDK4/6-IN-24 exhibits board-spectrum antitumor activity that inhibits multi cancer cells with IC50 of submicromolar levels .
|
-
- HY-B1320
-
-
- HY-119261
-
|
|
Antibiotic
|
Cancer
|
|
Ruboxyl is an anthracycline antibiotic with antitumor activity. Ruboxyl inhibits colorectal cancer (CRC) liver metastasis in mice by 84%, suppresses B16 melanoma growth, and increases the survival rate of mice with L1210 or L5178Y leukemia .
|
-
- HY-152609
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Cyanomethyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154553
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,5’-Di-O-acetylthymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-145758
-
|
|
Endonuclease
|
Cancer
|
|
FEN1-IN-SC13 is a potent DNA fragmentation endonuclease 1 (FEN1) inhibitor with antitumor activity. FEN1-IN-SC13 interferes with DNA replication and repair in vitro and in cells .
|
-
- HY-152411
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Beta-C-Methyl-inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-117361
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
LY207702 is a difluorinated purine nucleoside with antitumor activity and cardiotoxicity. LY207702 is cytotoxic to CEA-positive LS174T cells (IC50=0.302 μg/mL). LY207702 can be used in the study of colon cancer .
|
-
- HY-152323
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Methylsulfonyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152342
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Methoxymethyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-157122
-
-
- HY-119458
-
|
|
Topoisomerase
TMV
Fungal
|
Infection
|
|
Luotonin A is an antiviral and antiphytopathogenic fungus agent. Luotonin A has good antiviral activity against tobacco mosaic virus (TMV). Luotonin A also has certain inhibitory activity on topoisomerase I and topoisomerase II. Luotonin A shows antitumor activity .
|
-
- HY-129545
-
|
|
Isocitrate Dehydrogenase (IDH)
|
Cancer
|
|
DS-1001b is an orally active, blood-brain permeable, potent IDH-1 (isocitrate dehydrogenase-1) mutant inhibitor. DS-1001b has antitumor activity .
|
-
- HY-152385
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5,6-Dihydro-ara-uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-10080
-
|
GMX1777; EB-1627
|
NAMPT
|
Cancer
|
|
Teglarinad chloride (GMX1777) is a proagent of GMX1778 (a nicotinamide phosphoribosyl transferase inhibitor). Teglarinad chloride exhibits antitumor activity in mice can be attributed to inhibition of NAMPT. Teglarinad chloride also enhances radiation efficacy, mediated by interference with DNA repair and antiangiogenesis .
|
-
- HY-159130
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
AO-022 is a potent TALDO1 allosteric inhibitor. AO-022 decreases the expression of vimentin and snail. AO-022 shows antiproliferative activity and antitumor activity. AO-022 has the potential for the research of breast cancer .
|
-
- HY-77644
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'-Deoxy-5'-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-13598A
-
|
CKD-516 hydrochloride
|
Microtubule/Tubulin
|
Cancer
|
|
Valecobulin hydrochloride (CKD-516 hydrochloride) is a valine proagent of S516 (HY-130233) and a vascular disrupting agent (VDA). Valecobulin hydrochloride is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors .
|
-
- HY-154717
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Deoxy-2’-fluoroisocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P991556
-
|
|
TNF Receptor
|
Cancer
|
|
TQB2916 is a humanized IgG2 monoclonal antibody agonist targeting CD40. TQB2916 has a significant antitumor activity with CD40 occupancy and immune activation. TQB2916 can be used for advanced solid tumors and lymphomas research .
|
-
- HY-105166A
-
|
NSC-659687
|
Drug Derivative
|
Cancer
|
|
S 16020-2 is a new Olivacine derivative. S 16020-2 shows antitumor activity S 16020-2 has anti-cancer activity against leukemia, sarcoma, lung cancer, non-small cell lung cancer, and breast cancer .
|
-
- HY-16106
-
|
BMN-673; LT-673
|
PARP
|
Cancer
|
|
Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity .
|
-
- HY-111554
-
-
- HY-152298
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Fluoro-4’-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152701
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Aminocarbonylmethyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152743
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Aza-7-deazguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-482934
-
|
2'-Fluoro-2'-deoxyinosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoroinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152622
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154559
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-2-hydrazinyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-115983
-
|
|
CD47
Apoptosis
|
Cancer
|
|
DMUP is a potent CD47-SIRPα axis inhibitor. DMUP induces apoptosis and increases the macrophage phagocytosis in A549 cells. DMUP decreases the expression of CD47 and SIRPα protein. DMUP shows antitumor activity .
|
-
- HY-19064
-
-
- HY-154241
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Methyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154347
-
|
|
Apoptosis
|
Cancer
|
|
5′-Deoxy-5′-iodothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152540
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methoxy-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152505
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methyl-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152731
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3′-Deoxy-3′-methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154491
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-14907
-
|
MPC 6827
|
Microtubule/Tubulin
|
Cancer
|
|
Verubulin (MPC-6827) is a highly potent and broad-spectrum microtubule blocker. Verubulin has antitumor activity against breast cancer, melanoma, and ovarian cancer. Verubulin can be used in non-small cell lung cancer research .
|
-
- HY-113341
-
-
- HY-154011
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Amino-2′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152666
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methyl-4’-thiocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154153
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Methyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154088
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′-Deoxy-3′-iodothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W460267
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2,2'-O-Dimethylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-149160
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5′-Amino-5′-deoxythymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152367
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Hydroxy-3’-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-119969
-
|
NSC 182986
|
DNA Alkylator/Crosslinker
|
Cancer
|
|
Diaziquone (NSC 182986), an aziridinylbenzoquinone, is a DNA alkylating agent. Diaziquone shows a broad antitumor activity against numerous transplantable murine tumors including curative activity against several intracerebrally implanted tumors. Diaziquone crosses the blood brain barrier .
|
-
- HY-155338
-
|
|
YAP
|
Cancer
|
|
SWTX-143 is an orally active YAP/TAZ-TEAD inhibitor that binds to the palmitoylation pocket of all four TEAD isoforms. SWTX-143 causes irreversible and specific inhibition of the transcriptional activity of YAP/TAZ-TEAD and shows antitumor activity .
|
-
- HY-176495
-
|
|
DNA Alkylator/Crosslinker
DNA/RNA Synthesis
|
Cancer
|
|
SG3683 is a DNA-targeted cytotoxic agent belonging to pyrrolobenzodiazepine (PBD) dimers. SG3683 exerts antitumor activity with an IC50 value of 0.74 nM in MDA-MB-436 cells. SG3683 is promising for research of cancers, such as breast cancer .
|
-
- HY-P991125
-
|
YH-002
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy .
|
-
- HY-152630
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-5-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-B0431AS
-
|
|
Isotope-Labeled Compounds
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Phenoxybenzamine-d5 (hydrochloride) is the deuterium labeled Phenoxybenzamine hydrochloride. Phenoxybenzamine hydrochloride is a nonselective, irreversible, orally active α-adrenoceptor antagonist that is commonly used for the research of hypertension, specifically caused by pheochromocytoma. Phenoxybenzamine hydrochloride also shows antitumor activity[1][2][3].
|
-
- HY-152771
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3′-Deoxy-3′-fluorocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154364
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-5-trifluoromethyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154327
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
DMTr-dH2U-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154214
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-(3-Methyln-propylidene hydrazino) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154025
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Azido-2′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154589
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3',5'-Di-O-benzoyl fialuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154520
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-3′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154467
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-6-thioinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-163720
-
|
|
Ras
Apoptosis
|
Cancer
|
|
KRAS G12C inhibitor 63 (K45) is a KRAS G12C inhibitor. KRAS G12C inhibitor 63 can induce Apoptosis. KRAS G12C inhibitor 63 has antitumor activity .
|
-
- HY-136270
-
|
VX-803; M4344; ATR inhibitor 2
|
ATM/ATR
|
Cancer
|
|
Gartisertib (VX-803) is an ATP-competitive, orally active, and selective ATR inhibitor, with a Ki of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC50 of 8 nM. Antitumor activity .
|
-
- HY-154243
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Methyl-2’-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-171443
-
|
Lyso-GM3
|
EGFR
Drug Derivative
|
Cancer
|
|
Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analogue of Ganglioside GM3 (HY-114456) with antitumor activities. Lyso-Monosialoganglioside inhibits EGF-induced increases in EGFR kinase activity in A431 epithelial cancer cells .
|
-
- HY-152445
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Amino-3’-deoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152354
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Benzyloxy-3’-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-161840
-
|
|
FGFR
|
Cancer
|
|
Antitumor agent-176 (Compound 22), an antitumor agent, can effectively bind to FGF2 and inhibit the activation of fibroblast growth factor receptor (FGFR) in multiple myeloma (MM) cells, exhibiting significant antitumor activity both in vivo and in vitro against MM .
|
-
- HY-N15263
-
|
|
Antibiotic
Fungal
|
Infection
Cancer
|
|
Cepafungin III is an acylpeptide antibiotic that can be isolated from the culture broth of Pseudomonas species. Cepafungin III exhibits inhibitory activity against yeast and fungi, and antitumor activity against P388 leukemia in mice, when mixed with Cepafungin I and II .
|
-
- HY-154200
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-5-methycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P99306
-
|
DS 1024; Zatuximab
|
EGFR
|
Cancer
|
|
Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo .
|
-
- HY-152452
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2′-Amino-2′-deoxycytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-158006
-
|
|
MetAP
|
Cancer
|
|
SDX-7539 is a selective inhibitor for Methionine aminopeptidase type 2 (MetAP2). SDX-7539 inhibits proliferarion of HUVECs with an IC50 of 120 μM. SDX-7539 exhibits antitumor activity in NSCLC xenograft athymic nude mice .
|
-
- HY-148391
-
|
SBF-1
|
DNA/RNA Synthesis
|
Cancer
|
|
23-Oxa-OSW-1 (SBF-1), a derivative of OSW 1 (HY-101213), is a potent osterol-binding protein (OSBP) inhibitor. 23-Oxa-OSW-1 has antitumor activity .
|
-
- HY-106218A
-
|
5-Fluorocyclocytidine hydrochloride; 5'-Fluorocyclocytidine hydrochloride
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Flurocitabine hydrochloride (5-Fluorocyclocytidine hydrochloride; 5'-Fluorocyclocytidine hydrochloride) is the hydrochloride form of Flurocitabine (HY-106218). Flurocitabine hydrochloride exhibits antitumor activity through hydrolysation in vivo into two active antitumor substances arabinosyl-tluorocytosine (ara-FC) and arabinosyl-fluorouracil (ara-FU) .
|
-
- HY-101275R
-
|
|
Hippo (MST)
Reference Standards
TGF-beta/Smad
Wnt
|
Cancer
|
|
EMT inhibitor-1 (Standard) is the analytical standard of EMT inhibitor-1 (HY-101275). This product is intended for research and analytical applications. EMT inhibitor-1 is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities.
|
-
- HY-152821
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methoxy-4’-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154540
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Alpha-5-Methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-145602
-
|
CPI-0209
|
Histone Methyltransferase
|
Cancer
|
|
Tulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor that targets and inhibits the EZH2 enzyme.Tulmimetostat has antitumor activity and is used in a variety of solid tumor studies .
|
-
- HY-152628
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3-deazauridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152465
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Carboxymethyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P992125
-
|
HFB-200603
|
CD28
|
Cancer
|
|
Radanstobart is a humanized monoclonal antibody targeting CD272 with antitumor activity. Radanstobart is of the human IgG4κ isotype, and the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-135765
-
|
|
Others
|
Cancer
|
|
Micordilin is a complex Elemanolide-like compound isolated from the medicinal plant Mikania cordifolia. Micordilin is an endogenous hemiacetal of C-14-acetylated dialdehyde elemanolide. Micordilin has antitumor dilactone properties and can be used in the study of antitumor activity .
|
-
- HY-154554
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,5’-Di-O-benzoyl thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152700
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methoxy-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-109019
-
|
CM082; X-82
|
VEGFR
PDGFR
|
Cardiovascular Disease
Cancer
|
|
Vorolanib (CM082) is an orally active, potent multikinase VEGFR/PDGFR inhibitor. Vorolanib is a potent ATP-binding cassette (ABC) transporter inhibitor. Vorolanib is an angiogenesis inhibitor and has antitumor activity combined with ZD1839 (HY-50895) .
|
-
- HY-154215
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-(P-Cyanophenyl methylidene hydrazino) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-160096
-
|
|
ATM/ATR
|
Cancer
|
|
M3541 is a potent, ATP-competitive and selective ATM inhibitor with an IC50 of 0.25 nM. M3541 shows remarkable selectivity against other protein kinases. M3541 suppresses double-strand breaks (DSB) repair and has antitumor activities .
|
-
- HY-152320
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Adenosine-2-carboxy methyl amide is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-16399
-
|
|
Apoptosis
SF3B1
|
Cancer
|
|
Pladienolide B is a potent cancer cell growth inhibitor that targets the SF3B1 subunit of the spliceosome. Pladienolide B exerts antitumor activities mediated through the inhibition of pre-mRNA splicing. Pladienolide B induces apoptosis .
|
-
- HY-N0697
-
-
- HY-154087
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′-Bromo-3′-deoxythymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152519
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(Aminomethyl)-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154443
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Rev dC(Bz)-5'-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154300
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N-Benzoyl-3′-O-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W154172
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Chloro-2′-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152533
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Ethyl-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-137600
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1,N6-Ethenoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152631
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-5-methoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-177989
-
|
SGI-078
|
EGFR
|
Cancer
|
|
ER121 (SGI-078) is an orally active non-toxic small molecule ErbB2 kinase inhibitor. ER121 shows potent antitumor activity can be used for the research of HER2-related breast cancer .
|
-
- HY-154470
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Aza-2’-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152351
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Bromo-3’-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154001
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2'-Deoxy-8-methylthioguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-149220
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'-Protected 2,2'-anhydrouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-144805
-
|
|
VEGFR
Apoptosis
|
Cancer
|
|
VEGFR-2-IN-18 (Compound 15d) is a potent VEGFR-2 inhibitor with an IC50 of 60 nM. VEGFR-2-IN-18 induces cell apoptosis. VEGFR-2-IN-18 shows antitumor activities .
|
-
- HY-W004520
-
|
5-Methylphenazinium methylsulfate
|
Bacterial
Antibiotic
Apoptosis
|
Cancer
|
|
Phenazine methylsulfate is a free radical generator that can act as an electron transfer reactant in cell viability assays. It also has insecticidal properties. Furthermore, Phenazine methylsulfate induces oxidative DNA damage and cell apoptosis, showing antitumor activity .
|
-
- HY-154114
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-2-iodoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152295
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-2’-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152334
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Chloro-2’-deoxyadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W141338
-
|
2'-Bromo-2'-deoxy-D-uridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Bromo-2′-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W114787
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-2’-O-methylcytidine is a natural cytidine nucleoside analog. Cytidine analogs have the mechanism of inhibiting DNA methyltransferase (such as Zebularine (HY-13420)) and have potential antimetabolite and antitumor activities .
|
-
- HY-102018
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
Cancer
|
|
3'-Deoxy-3'-fluoroadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-169326S
-
-
- HY-148742
-
|
|
RET
|
Cancer
|
|
RET-IN-21 (compound 5) is a selective RET V804M inhibitor with the IC50 of 0.02 μM. RET-IN-21 does not inhibit the wild type isoforms of RET or KDR. RET-IN-21 has antitumor activity .
|
-
- HY-161317
-
-
- HY-154324
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152591
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-Methyl-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152730
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoroinosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154740
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′-Chloro-3′-deoxythymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W039275
-
|
5'-Iodo-5'-deoxyguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'-Deoxy-5'-iodoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152765
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
Cancer
|
|
3′-Deoxy-3′-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152710
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methoxycarbonylmethyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154692
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-5-methylisocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152440
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Amino-3’-deoxycytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152793
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-Cyano-7-deazaguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154294
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl ara-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154120
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Aza-2'-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W141127
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
1-(Bromomethyl)pyrene is a Br compound with antitumor activity. 1-(Bromomethyl)pyrene is widely used in the synthesis of fluorophores for the fluorescent sensing of variety of analytes. 1-(Bromomethyl)pyrene can be also used in the synthesis of photoinitiators (PIs) .
|
-
- HY-W251781
-
|
2′-Deoxy-4-thiouridine; 4-Thiodeoxyuridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Thio-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W013052
-
|
8-Bromo-9-(2-deoxypentofuranosyl)-9H-purin-6-amine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Bromo-2'-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152739
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-(N-Isopentenyl-N-trifluoroacetyl) aminomethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P10705
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
KGFRWR is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. KGFRWR can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .
|
-
- HY-N4227
-
|
|
Endogenous Metabolite
|
Cancer
|
|
Conicasterol is a 4-mercaptosteroid with significant cytotoxic activity. Conicasterol showed an IC50 value of 6.23 μg/mL in a test on a human breast adenocarcinoma cell line (MCF-7). Conicasterol's antitumor activity makes it a potential bioactive lead molecule .
|
-
- HY-154399
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Aza-3’-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-168504
-
|
|
Histone Demethylase
Apoptosis
|
Cancer
|
|
LSD1-IN-36 is a potent LSD1 inhibitor with an IC50 value of 0.8 nM. LSD1-IN-36 induces apoptosis and arrests the cell cycle. LSD1-IN-36 shows antitumor activity .
|
-
- HY-108697
-
|
|
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
PT2399 is a potent and selective HIF-2α antagonist, which directly binds to HIF-2α PAS B domain with an IC50 of 6 nM. PT2399 displays potent antitumor activity in vivo .
|
-
- HY-154232
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4′,5′-Didehydro-5′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-B0431AR
-
|
|
Reference Standards
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Phenoxybenzamine (hydrochloride) (Standard) is the analytical standard of Phenoxybenzamine (hydrochloride). This product is intended for research and analytical applications. Phenoxybenzamine hydrochloride is a nonselective, irreversible, orally active α-adrenoceptor antagonist that is commonly used for the research of hypertension, specifically caused by pheochromocytoma. Phenoxybenzamine hydrochloride also shows antitumor activity .
|
-
- HY-152759
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-xylocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154012
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2'-Deoxy-8-methylamino-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152308
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’,5-difluorocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154248
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-3’,2-anhydrouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154147
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N1-methylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154624
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Hexadecanyl-2-aminoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152662
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Dideoxy-5-fluorocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154038
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′,3′-Dideoxy-3′-fluoroadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154400
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Aza-3’-beta-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152707
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-2′-C-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154239
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-Triphenylmethyl-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152593
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N1-methylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152379
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-methyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154374
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Azido-2’,5’-dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W603690
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2'-Deoxy-N6-phenoxyacetyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W550918
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Bromo-2’-O-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152433
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-(1,1-Difluoroethyl)pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-181547
-
|
|
Btk
|
Cancer
|
|
HBC-12551 is an orally active BTK inhibitor (IC50 in HEK293 cells: 1.31 nM for BTK; 2.18 nM for BTK C481S). HBC-12551 has antitumor activity against diffuse large B-cell lymphoma .
|
-
- HY-P99010
-
|
|
FGFR
|
Cancer
|
|
Bemarituzumab is a humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer .
|
-
- HY-10824
-
|
PT523
|
Antifolate
Dihydrofolate reductase (DHFR)
|
Cancer
|
|
Talotrexin (PT523), an analog of Aminopterin (HY-14518), is a nonpolyglutamatable classic antifolate. Talotrexin is a RFC (reduced folate carrier) specific inhibitor and selectively inhibits RFC transport. Talotrexin shows antitumor activity by targeting DHFR to inhibit tumor growth .
|
-
- HY-152752
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’,3’-Dideoxy-3’-fluorocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154333
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-8-(phenylmethoxy)guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W560803
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'-DMTr-2,2'-anhydrothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154625
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Hexadecanyl-2-aminoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152551
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-C-Methyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154569
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-furfurylamino thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-77645
-
|
1-(5-Deoxy-beta-D-erythro-pent-4-enofuranosyl)uracil
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4',5'-Didehydro-5'-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154564
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-N-methylaminothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152836
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-O-Methyl-5-hydroxymethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-126681
-
|
NHS-VC-PAB-MMAE
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
SC-VC-PAB-MMAE (NHS-VC-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB .
|
-
- HY-154289
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Isopropylidene-5-hydroxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152516
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-(2-Methoxyethyl) inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154420
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Bis-(O-t-butyldimethylsilyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-106787
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
HO 221 is an orally active benzoylphenylurea derivative with antitumor activity. HO 221 can inhibit the activity of mammalian DNA polymerase alpha. HO 221 can induce G1 phase arrest. HO 221 can be used for the research of cancer, such as leukemia .
|
-
- HY-158412
-
|
|
Proteasome
Apoptosis
|
Cancer
|
|
BT317 is a blood-brain transmissible mitochondrial Lon peptidase I (LonP1) and CT-L proteasome inhibitor. BT317 can increase the production of reactive oxygen species (ROS) and induce apoptosis in astrocytoma cells. BT317 has antitumor activity .
|
-
- HY-181789
-
|
|
PROTACs
Histone Methyltransferase
|
Cancer
|
|
DOT1L808 is a potent and highly selective DOT1L PROTAC degrader with a DC50 value of 5 nM. DOT1L808 can promote the ubiquitination and degradation of DOT1L. DOT1L808 exhibits antitumor activity in an orthotopic leukemia model .
|
-
- HY-154026
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Amino-2'-deoxyuridine (monohydrochloride) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N8253R
-
|
Quercetin 4′-O-glucoside (Standard)
|
Reference Standards
Reactive Oxygen Species (ROS)
|
Inflammation/Immunology
Cancer
|
|
Spiraeoside (Standard) is the analytical standard of Spiraeoside. This product is intended for research and analytical applications. Spiraeoside, an orally active natural compound, exerts antioxidant activity, inhibits reactive oxygen species (ROS) and malondialdehyde production. Spiraeoside possesses antiallergic, anti-inflammatory and antitumor activities .
|
-
- HY-152717
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-O-Methyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152499
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-Methyl-2'-O-methylinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-147322
-
|
|
YAP
|
Cancer
|
|
YAP/TAZ inhibitor-2 is a potent and orally active TEAD-YAP/TAZ inhibitor with an EC50 value of 3 nM. YAP/TAZ inhibitor-2 shows anti-proliferative activity. YAP/TAZ inhibitor-2 shows antitumor activity .
|
-
- HY-154303
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Levulinyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-126534A
-
|
LSN3106729 hydrochloride
|
Ligands for Target Protein for PROTAC
CDK
|
Cancer
|
|
Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .
|
-
- HY-154204
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoroarabino inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152996
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-8-(methylthio)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152854
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(Hydroxymethyl)cytidine is a purine nucleoside analog that can be used in oligonucleotide synthesis. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-101030
-
|
|
NEKs
Apoptosis
|
Cancer
|
|
MBM-17 is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 3 nM. It effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55 shows antitumor activities, and no obvious toxicity to mice .
|
-
- HY-154602
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
2’-dG (iBu)-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N10188
-
|
|
Others
|
Cancer
|
|
Nidurufin is a potent cell cycle inhibitor with antitumor activity.Nidurufin induces in vitro cell cycle arrest at G2/M transition in the K562 cell line in a concentration and time dependent manner(IC50=12.6 μM) .
|
-
- HY-152584
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-xyloguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N4251
-
|
(-)-Periplocoside M
|
Others
|
Cancer
|
|
Periplocoside M (compound 8) is a natural product isolated from the root bark of Periploca sepium. Periplocoside M shows antitumor activity against human A-549 and HepG2 cell lines, with the IC50 of 4.84 and 7.06 μM .
|
-
- HY-123979A
-
|
NSC37044 trisodium
|
PKC
Apoptosis
|
Cancer
|
|
ζ-Stat trisodium (NSC37044 trisodium) is a specific and atypical PKC-ζ inhibitor, with an IC50 of 5 μM. ζ-Stat trisodium can reduce melanoma cell lines proliferation and induce apoptosis, and has antitumor activity in vitro .
|
-
- HY-124615
-
|
|
p38 MAPK
PI3K
|
Cancer
|
|
ST-162 is a MAPK/PI3K dual antagonist. ST-162 exhibits antitumor activity and can increase the efficacy of immune checkpoint blockers. ST-162 can be used for the research of cancer, such as melanoma .
|
-
- HY-12743A
-
|
|
Proteasome
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
K-7174 dihydrochloride is an orally active proteasome and GATA inhibitor. K-7174 dihydrochloride is a cell adhesion inhibitor. K-7174 dihydrochloride induces cell apoptosis. K-7174 dihydrochloride shows antitumor activities, it can be used for the research of cancer .
|
-
- HY-152336
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-(2-Methyl)propyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-101486R
-
|
|
β-catenin
Reference Standards
|
Cancer
|
|
LF3 (Standard) is the analytical standard of LF3 (HY-101486). This product is intended for research and analytical applications. LF3 is an antagonist of the β-Catenin/TCF4 interaction with antitumor activity; has an IC50 of 1.65 μM .
|
-
- HY-152590
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N6-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154372
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′,5′-Dideoxy-5′-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154496
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N3-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154558
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-6-O-methylinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-126534
-
|
LSN3106729
|
Ligands for Target Protein for PROTAC
CDK
|
Cancer
|
|
Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .
|
-
- HY-152316
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-N6-isopropyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W700392
-
|
|
IMPDH
|
Cancer
|
|
IMPDH-IN-2 (compound 2) is an inhibitor of inosine monophosphate dehydrogenase (IMPDH) with IC50Values are 0.15 and 0.17 μM, respectively. IMPDH-IN-2 has antitumor activity .
|
-
- HY-152866
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N,N-Dimethyl-2’-O-methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154052
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5′-Amino-2′,5′-dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-149364
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin inhibitor 34 (compound b5) is a potent anticancer agent. Tubulin inhibitor 34 can inhibit tubulin polymerization and induce G2/M arrest and apoptosis. Tubulin inhibitor 34 exhibits significant antivascular and antitumor activity .
|
-
- HY-153697
-
|
|
FAK
|
Cancer
|
|
FAK-IN-10 is an inhibitor of FAK with an IC50 of 76.3 μM. FAK-IN-10 exhibits antitumor activity against MCF-7 and A431 cell lines with IC50s of 4.23 and 0.78 μM,respectively .
|
-
- HY-101568R
-
|
FGF-401 (Standard)
|
FGFR
Reference Standards
|
Cancer
|
|
Roblitinib (Standard) is the analytical standard of Roblitinib (HY-101568). This product is intended for research and analytical applications. Roblitinib (FGF-401) is an orally active and highly selective FGFR4 inhibitor with an IC50 of 1.9 nM . Roblitinib has antitumor activity .
|
-
- HY-154392
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-2’-deoxy inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W392809
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methyl-2′-O-methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154533
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Acetyl-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-131345
-
|
|
PI3K
|
Cancer
|
|
PI3Kα-IN-4 is a potent, selective and orally active inhibitor of PI3Kα, with an IC50 of 1.8 nM. PI3Kα-IN-4 has antitumor activity .
|
-
- HY-129393
-
|
AB928
|
Adenosine Receptor
|
Inflammation/Immunology
Cancer
|
|
Etrumadenant (AB928) is an orally bioavailable, selective dual adenosine receptor (A2aR/A2bR) antagonist. Etrumadenant relieves adenosine-mediated immune suppression. Etrumadenant has immunomodulatory and antitumor activities .
|
-
- HY-162781
-
|
|
HDAC
|
Cancer
|
|
HDAC1/6-IN-2 (I-c4) is the inhibitor of HDAC1 and HDAC6, with the IC50s of 3.1 nM and 2.95 nM, respectively. HDAC1/6-IN-2 has antitumor activity .
|
-
- HY-157387
-
|
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
c-Met-IN-22 (compound 51am) is an orally active inhibitor against c-Met with an IC50 value of 2.54 nM. c-Met-IN-22 has antiproliferative and antitumor activities. c-Met-IN-22 induces cell apoptosis .
|
-
- HY-154456
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N6-cyclopentyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154237
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-3’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154556
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′,3′-Dideoxy-5-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152548
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-C-Methyl-4-deoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152377
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Hydroxy-2’-O-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152865
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-(N-Acetylaminomethyl)-7-deazaguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154697
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3-epi-Azido-3-deoxythymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-100760S
-
|
Xanthothricin-13C4; Toxoflavine-13C4; PKF-118-310-13C4
|
Isotope-Labeled Compounds
β-catenin
Bacterial
Antibiotic
|
Infection
Cancer
|
|
Toxoflavin- 13C4 is the 13C-labeled Toxoflavin. Toxoflavin (Xanthothricin) is an antagonist of transcription factor 4 (TCF4)/β-catenin complex, also acts as an inhibitor of KDM4A, with antitumor activity . Antibiotic properties.
|
-
- HY-152640
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Fluoro-4’-thio-cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W415119
-
|
acetic acid 4-acetoxy-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2-hydroxymethyl-tetrahydrofuran-3-yl ester
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',3'-Di-O-acetyl-D-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-142772
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
Y08284 is a potent, selective, oral active CBP bromodomain inhibitor with an IC50 of 4.21 nM. Y08284 suppresses the proliferation of prostate cancer cell lines LNCaP, C4-2B, and 22Rv1. Antitumor activity .
|
-
- HY-12743
-
|
|
Proteasome
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
K-7174 is an orally active proteasome and GATA inhibitor. K-7174 is a cell adhesion inhibitor. K-7174 induces cell apoptosis. K-7174 shows antitumor activities, it can be used for the research of cancer .
|
-
- HY-14220
-
|
|
Apoptosis
Sigma Receptor
|
Cancer
|
|
CB-184 is a selective ligand for sigma-2 (σ2), with Ki values of 7436 nM for σ1 and 13.4 nM for σ2. CB-184 promotes apoptosis and has antitumor activity .
|
-
- HY-152607
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N,N-Dimethyl-2′-O-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-156244
-
|
|
PROTACs
|
Cancer
|
|
PROTAC GDI2 Degrader-1 (compound 21) is a potent PROTAC GDI2 degrader. PROTAC GDI2 Degrader-1 exhibits excellent in vivo antitumor activity in the GDI2-overexpressing pancreatic xenograft models .
|
-
- HY-152307
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-N6-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-149674
-
|
|
VEGFR
|
Cancer
|
|
VEGFR-2/c-Met-IN-1 is a dual inhibitoe of VEGFR-2 and c-Met with IC50s of 138 nM and 74 nM, respectively. VEGFR-2/c-Met-IN-1 has antitumor activity .
|
-
- HY-155950
-
|
|
Methylenetetrahydrofolate Dehydrogenase (MTHFD)
Apoptosis
|
Cancer
|
|
TH9619 is a potent inhibitor of dehydrogenase and cyclohydrolase activities in both MTHFD1 and MTHFD2 with a IC50 value of 47 nM, and selectively kills cancer cells. TH9619 induces apoptosis by blocking the S phase. TH9619 has antitumor activity .
|
-
- HY-154293
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N6-ethyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P10286
-
|
|
MDM-2/p53
|
Cancer
|
|
Phage-derived 12/1 peptide exhibits antitumor activity by targeting MDM2 and MDMX, an thus disrupt the MDM2-p53 and MDMX-p53 interaction, with IC50 of 0.15 and 1.25 μM .
|
-
- HY-137548
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′,3′-Dideoxy-3′-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152577
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-(2-Methoxyethyl) inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152554
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-xyloadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-128995A
-
|
Glycyl-DX-8951 TFA; Exatecan analog 2 TFA
|
Drug Derivative
|
Cancer
|
|
Glycyl-Exatecan TFA (Glycyl-DX-8951 TFA), a derivative of Exatecan (HY-13631), is an anticancer agent. Glycyl-Exatecan TFA has significantly antitumor activity. Glycyl-Exatecan TFA can be used for cancers like solid tumors research .
|
-
- HY-154510
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N4-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152638
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-3’-O-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-134673A
-
UZH1a
3 Publications Verification
|
Apoptosis
|
Cancer
|
|
UZH1a is a potent and selective METTL3 inhibitor, with an IC50 of 280 nM. UZH1a can be used for epitranscriptomic modulation of cellular processes. UZH1a has antitumor activity. UZH1a also can be used as a chemical probe for studying METTL3 .
|
-
- HY-152588
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N1-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152325
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-(N,N-Dimethylaminocarbonyl)-pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W347492
-
|
O6-Methyl-2′-deoxyguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
O6-Methyldeoxy guanosine; DNA adduct is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152425
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Methylamino-N6-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152513
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-O-Methyl-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-165375
-
|
|
Others
|
Cancer
|
|
Plenolin is an anticancer agent. Plenolin exhibits inhibitory activity against human epidermoid carcinoma cells. Plenolin shows in vivo antitumor activity against ascites carcinosarcoma and lymphocytic leukemia in rodent models. Plenolin can be used for research related to ascites tumors and leukemia .
|
-
- HY-127130
-
|
|
Bcl-2 Family
Apoptosis
Fungal
Antibiotic
|
Infection
Cancer
|
|
Spicamycin, an adenine nucleoside antibiotic with antifungal and antitumor activities. Spicamycin is also a potent inducer of differentiation of myeloid leukemia cells. Spicamycin induces apoptosis in NB4 cells via down-regulation of Bcl-2 expression and modulation of PML protein .
|
-
- HY-112582S
-
|
1-Methylpseudouridine-d3; N1-methyl-pseudouridine-d3
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methylpseudouridine-d3 is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-169106
-
|
|
Topoisomerase
Apoptosis
|
Cancer
|
|
Topoisomerase inhibitor 4 (compound 45) is a potent Topoisomerase1/2 inhibitor. Topoisomerase inhibitor 4 causes cell cycle arrest in the G2/M phase by inducing Apoptosis. Topoisomerase inhibitor 4 has antitumor activity .
|
-
- HY-136630
-
|
SHR110008
|
Drug Derivative
|
Others
|
|
Felotaxel (SHR110008) is a derivate of Docetaxel (HY-B0011), with antitumor activity and specific pharmacokinetic properties in rats. Felotaxel is rapidly distributed to normal tissues. The kidney is the major excretion organ, and its plasma protein binding capacity is nearly linearly related to concentration.
|
-
- HY-19829
-
|
|
ADC Payload
Bacterial
Antibiotic
|
Infection
Cancer
|
|
Sandramycin ia a cyclic depsipeptide antibiotic isolated from cultured broth of a Nocardioides sp. Sandramycin is also a DNA intercalator that potently binds DNA and is an ADC cytotoxin. Sandramycin is active against Gram-positive bacteria and has potent antitumor activity .
|
-
- HY-154544
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
3’-O-MOE-U-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152561
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5’(R)-C-Methyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W357202
-
|
PMO Thymidine Precusor
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
7’-OH-N-trityl morpholinothymine (PMO Thymidine Precusor) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152397
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N6-isopentenyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-10981S1
-
|
E7080-d5
|
VEGFR
FGFR
PDGFR
c-Kit
RET
|
Cancer
|
|
Lenvatinib-d5 is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
|
-
- HY-149016
-
|
|
Microtubule/Tubulin
Farnesyl Transferase
|
Cancer
|
|
Tubulin polymerization-IN-25 (compound 17f) is a dual inhibitor of tubulin polymerization and farnesyl transferase (FTase) with IC50s of 1.11 μM and 0.39 μM, respectively. Tubulin polymerization-IN-25 displays cytotoxicity and excellent antitumor activity .
|
-
- HY-152317
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Methyl-2-thio-xylo-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-151588
-
|
|
Virus Protease
|
Cancer
|
|
Anticancer agent 90 is a benzothiazole-2-thiophene S-glycoside derivative with antitumor activity. Anticancer agent 90 has high inhibition against the two cell line from ovarian cancer (OVCAR-4), renal cancer (A498) .
|
-
- HY-154136
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Fluoro-3’-beta-C-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-107363R
-
|
|
Reference Standards
mTOR
|
Cancer
|
|
FT-1518 (Standard) is the analytical standard of FT-1518 (HY-107363). This product is intended for research and analytical applications. FT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity.
|
-
- HY-105064C
-
|
CP-597396 dihydrochloride
|
Na+/H+ Exchanger (NHE)
|
Cancer
|
|
Zoniporide dihydrochloride (CP-597396 dihydrochloride) is a potent and selective inhibitor of highly water-soluble sodium hydrogen exchange type 1 (NHE-1). Zoniporide dihydrochloride inhibits NHE1 dependent 22Na + uptake in vitro with an IC50 of 14 nM. Zoniporide has antitumor activity .
|
-
- HY-152715
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-C-β-Methyl-4-deoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152749
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-β-C-methyl-5-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-16261
-
|
INNO-206; DOXO-EMCH
|
Topoisomerase
ADC Payload
|
Cancer
|
|
Aldoxorubicin (INNO-206) is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. Aldoxorubicin (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.
|
-
- HY-154130
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(b-D-Xylofuranosyl)-5-trifluoromethyluracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154292
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N1-Methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-165473
-
|
|
Calcium Channel
|
Cancer
|
|
Hexadecylphosphoserine is a phospholipid molecule that contains a long-chain alkyl (hexadecyl) and a phosphoserine group, giving it a high affinity for the cell membrane. Hexadecylphosphoserine can exert antitumor activity by modulating [Ca ++]i and its related signaling pathways, making it useful for research in the field of breast cancer .
|
-
- HY-154262
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Ethyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152635
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Chloro-2’-O-methyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152467
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Aza-2’-beta-C-methylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152880
-
|
T 70179
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Deoxy-2’-fluoro-arabino-tubercidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154468
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-O-Methyl-2’-O-methylinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154129
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(b-D-Xylofuranosyl)-5-methoxyuracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154348
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’,5’-Didehydro-5’-deoxy thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152530
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-beta-C-Methyl-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154296
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-ara-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152729
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-(2-Amino-2-oxoethyl)uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154018
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154161
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(2-Hydroxyethyl)-2’-deoxy uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152721
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-O-Methyl-4-deoxy uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152497
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-β-C-Methyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152629
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-β-C-Methyl-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152428
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-α-C-methylguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154600
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-3’-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-103266
-
|
|
Aurora Kinase
|
Cancer
|
|
TC-A 2317 hydrochloride is an orally active Aurora A kinase inhibitor (Ki=1.2 nM). TC-A 2317 hydrochloride exhibits excellent selectivity to Aurora B kinase (Ki=101 nM) and other 60 kinases, good cell permeability and good PK profile. Antitumor activity .
|
-
- HY-152768
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-(1,1,1-Trifluoroethyl)pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-143692
-
-
- HY-152651
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’(R)-C-Methyl-3-deazauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-162326
-
|
|
VEGFR
Apoptosis
|
Cancer
|
|
VEGFR-2 IN-41 (Compound 8) is a VEGFR-2 inhibitor with an IC50 of 0.0554 μM. VEGFR-2 IN-41 can induce apoptosis. VEGFR-2-IN-41 has antitumor activity .
|
-
- HY-152745
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-β-C-Methyl-5-trifluoromethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154430
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N2-cyclopentyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-111388
-
|
|
CDK
|
Cancer
|
|
SEL120-34A is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
|
-
- HY-W008615
-
|
5-Iodo-D-cytidine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Iodo-cytidine (5-Iodo-D-cytidine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-16261C
-
|
INNO-206 hydrochloride; DOXO-EMCH hydrochloride
|
Topoisomerase
ADC Payload
|
Cancer
|
|
Aldoxorubicin (INNO-206) hydrochloride is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. Aldoxorubicin hydrochloride (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.
|
-
- HY-W010681A
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
3’-O-DMTr-thymidine 5’-CE phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W355463
-
|
|
Microtubule/Tubulin
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
3-Demethylthiocolchicine is a colchicine (HY-16569) analog with broad-spectrum antitumor activity. 3-Demethylthiocolchicine has the same effects and activities as colchicine in blocking casein-induced amyloidosis, microtubule binding, and anti-inflammatory effects, with significantly lower toxicity .
|
-
- HY-160818
-
MC3138
2 Publications Verification
|
Sirtuin
|
Cancer
|
|
MC3138 is a selective SIRT5 activator. MC3138 has antitumor activity on human PDAC cells, with IC50 values of 25.4-236.9 μM. MC3138 combined with Gemcitabine (HY-17026) significantly inhibits tumor growth in mice .
|
-
- HY-B1714
-
|
|
Drug Derivative
|
Cancer
|
|
NSC 601980 analog is an analogue of NSC601980. In yeast screening experiments, NSC 601980 exhibited antitumor activity, effectively inhibiting cell proliferation in both COLO 205 and HT29 cell lines, with Log GI 50 values of -6.6 and -6.9, respectively.
|
-
- HY-W394419
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
3’-dC(Bz)-2’-phosphor amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152322
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-N6-iso-pentenyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W675573
-
|
|
DNA/RNA Synthesis
Parasite
|
Infection
Cancer
|
|
VF-149 is a Ribonucleotide reductase inhibitor. VF-149 significantly inhibits Plasmodium falciparum growth with an IC50 of 6.4 μM. VF-149 has antimalarial and antitumor activities. VF-149 can be used for malarial infections and cancers research .
|
-
- HY-105188A
-
|
|
TNF Receptor
|
Cancer
|
|
ONO-4007 is an antitumor lipid A analogue. ONO-4007 exhibits strong antitumor activity in several animal models via intratumoral production of tumor necrosis factor-alpha production (TNF-α). ONO-4007 can be used for the research of cancer .
|
-
- HY-161136
-
|
|
EGFR
STAT
|
Cancer
|
|
EGFR/STAT3-IN-1 (Compound 5k) is a dual inhibitor of EGFR/STAT3 with IC50 values for EGFR and STAT3 are 41 and 3.34 nM, respectively. EGFR/STAT3-IN-1 has antitumor activity .
|
-
- HY-154373
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4′,5′-Didehydro-2′,5′-dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154138
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-beta-C-Methyl-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152501
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Chloro-2’-O-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-19137
-
|
KW 2189 free base
|
Antibiotic
|
Infection
Cancer
|
|
Pibrozelesin (KW 2189 free base) is the derivative of antibiotic Duocarmycin B2. Pibrozelesin exhibits antitumor activity, inhibits proliferation of cell H69 with an IC50 of 1.9 μM. Pibrozelesin induces the DNA strand breaks upon activation via carboxyl esterase .
|
-
- HY-152500
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Deoxy-3’-β-C-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-49200
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
DMT-2'-F-dC(Bz)-CE-Phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-147710
-
|
|
MicroRNA
|
Cancer
|
|
PIN1 inhibitor 2 (compound 12) is a potent PIN1 inhibitor. PIN1 inhibitor 2 shows antitumor activity with an IC50 of 9.55 µM for MCF7 cells. PIN1 inhibitor 2 has the potential for the research of breast cancer .
|
-
- HY-148494
-
|
FLX475
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Tivumecirnon (FLX475) is an orally active, selective CCR4 antagonist. Tivumecirnon blocks the binding of CCR4 to its ligands, CCL17 and CCL22, thereby reducing Treg infiltration into the tumor microenvironment. Tivumecirnon has antitumor activity .
|
-
- HY-154201
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-O6-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-132003
-
|
|
Akt
|
Cancer
|
|
Wortmannin-Rapamycin Conjugate 1 (compound 7c) is a furan ring-opened derivative of wortmannin-rapamycin conjugate with potent antitumor activities and a fine water solubility. Wortmannin-Rapamycin Conjugate 1 can inhibit the AKT phosphorylation in the tumor and can be used for cancer research .
|
-
- HY-177347
-
|
|
Ribosomal S6 Kinase (RSK)
|
Cancer
|
|
RSK2-IN-5 (compoud C2) is a p90 ribosomal S6 kinase 2 (RSK2) inhibitor with a Kd of 856 nM. RSK2-IN-5 exhibits antitumor activity against breast cancer and melanoma cancer cells .
|
-
- HY-W013728
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,3,5-Tri-O-benzoyl-a-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152326
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-β-C-Methyl-6-azauridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N7850
-
|
1-Hydroxy-8-methoxyanthraquinone
|
Endogenous Metabolite
|
Cancer
|
|
6PGD-IN-1 (compound S3) is an inhibitor of 6-phosphogluconate dehydrogenase (6PGD). IC50 and Kd the value of 17.8μM and 17.1 μM respectively. 6PGD-IN-1 has antitumor activity .
|
-
- HY-175256
-
|
|
Ribosomal S6 Kinase (RSK)
|
Cancer
|
|
RSK2-IN-5 (compoud C24) is a p90 ribosomal S6 kinase 2 (RSK2) inhibitor with a Kd of 317 nM. RSK2-IN-5 exhibits antitumor activity against breast cancer and melanoma cancer cells .
|
-
- HY-154568
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-(4-morpholinyl)thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-144841A
-
|
(Rac)-CFT7455
|
Molecular Glues
|
Cancer
|
|
(Rac)-Cemsidomide ((Rac)-CFT7455) is the racemate of Cemsidomide (HY-144841) with antitumor activity . Cemsidomide is a ubiquitin ligase pathway Ikaros/Aiolos degrader with molecular glue activity. Cemsidomide has a GI50 of 0.05 nM for NCIH929.1 cells.
|
-
- HY-148019
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-2′-fluoro-N-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154472
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Ethyl-2’-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154233
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-TBDPS-2,2’-anhydrouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154428
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N2-isopropyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-19356A
-
|
|
Eukaryotic Initiation Factor (eIF)
Apoptosis
|
Cancer
|
|
Didesmethylrocaglamide, a derivative of Rocaglamide, is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. Didesmethylrocaglamide has potent growth-inhibitory activity with an IC50 of 5 nM. Didesmethylrocaglamide suppresses multiple growth-promoting signaling pathways and induces apoptosis in tumor cells. Antitumor activity .
|
-
- HY-157385
-
|
|
HDAC
Apoptosis
|
Cancer
|
|
HDAC-IN-67 (compound 27f) is an HDAC inhibitor against HDAC1 and HDAC6, with IC50 values of 22 nM and 8 nM, respectively. HDAC-IN-67 inhibits cell proliferation and induces cell apoptosis. HDAC-IN-67 exhibits antitumor activity .
|
-
- HY-154496A
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N3-methylcytidine hydriodide is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154128
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(b-D-Xylofuranosyl)-5-fluorouracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-111388B
-
|
SEL120-34A hydrochloride
|
CDK
|
Cancer
|
|
SEL120-34A hydrochloride is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
|
-
- HY-154495
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-Methyl-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W377454
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-Beta-D-arabinofuranosyl-5-iodouracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152369
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1,N6-Etheno-ara-adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154330
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3'-beta-Azido-2',3'-dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152863
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N6-Furfuryl-2-aminoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W048512
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',3'-Didehydro-2',3'-dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-101414R
-
|
L-2,4-Diaminobutyric acid (Standard)
|
Reference Standards
GABA Receptor
Endogenous Metabolite
|
Neurological Disease
Cancer
|
|
L-DABA (Standard) is the analytical standard of L-DABA. This product is intended for research and analytical applications. L-DABA (L-2,4-Diaminobutyric acid) is a week GABA transaminase inhibitor with an IC50 of larger than 500 μM; exhibits antitumor activity in vivo and in vitro.
|
-
- HY-152741
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-β-C-Methyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P991141
-
|
|
VEGFR
|
Cancer
|
|
Inlecitug is a chimeric monoclonal antibody targeting human KDR (kinase insert domain receptor). Inlecitug specifically binds to KDR, blocking the binding of vascular endothelial growth factor (VEGF) to KDR and inhibiting angiogenesis, thus exerting antitumor activity. Inlecitug is promising for research of cancers .
|
-
- HY-135299
-
|
|
Src
|
Cancer
|
|
CH6953755 is a potent, orally active and selective YES1 kinase (a member of the SRC family) inhibitor with an IC50 of 1.8 nM. CH6953755 inhibits YES1 kinase, leading to antitumor activity against YES1 Gene -amplified cancers in vitro and in vivo .
|
-
- HY-152644
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-β-C-Methyl-5-methoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N8473
-
|
(+)-Pericosine A
|
Topoisomerase
|
Cancer
|
|
Pericosine A ((+)-Pericosine A) is a topoisomerase II (Topoisomerase II) inhibitor that can be isolated from the Periconia byssoides strain. Pericosine A has significant antitumor activity in vitro and in vivo and can be used in cancer research. Pericosine A also inhibits the protein kinase epidermal growth factor receptor .
|
-
- HY-177540
-
|
|
Drug Isomer
Bacterial
Parasite
|
Infection
Cancer
|
|
ent-Rhizocarpic acid is an enantiomer of Rhizocarpic acid. ent-Rhizocarpic acid has more potent antibacterial and antiparasitic activity against Staphylococcus aureus (ATCC 25923) and Giardiaduodenalis 713 compared to Rhizocarpic acid. ent-Rhizocarpic acid also has a weak but selective antitumor activity against NS-1 cells .
|
-
- HY-154432
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-deoxyinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152415
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-α-C-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P10709A
-
|
|
Biochemical Assay Reagents
|
Cardiovascular Disease
Cancer
|
|
CREKA peptide acetate is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. CREKA peptide acetate can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .
|
-
- HY-152466
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Methyl-N1-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152343
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1-(β-D-Xylofuranosyl)-2-thiouracil is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-10981S
-
|
E7080-d4
|
VEGFR
FGFR
PDGFR
c-Kit
RET
|
Cancer
|
|
Lenvatinib-d4 is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
|
-
- HY-B0508
-
|
Ro 7-0207
|
Bacterial
Parasite
Antibiotic
Hedgehog
|
Infection
Cancer
|
|
Ornidazole (Ro 7-0207) is a nitroimidazole derivative with anti-trichomonad activity and in vitro activity against a variety of anaerobic bacteria. Ornidazole inhibits Sonic hedgehog (Shh) signaling pathway, exhibits antitumor activity. Ornidazole can be used in research of Crohn’s disease .
|
-
- HY-W047393
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Methyl 2,3,5-tri-O-benzyl-D-ribofuranoside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154231
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-alpha-D-arabinoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154081
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-2’-OMeU-methyl phosphonamidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-173350
-
|
|
Arf Family GTPase
Apoptosis
|
Cancer
|
|
Ran-IN-1 is a specific inhibitor of Ran GTPase. Ran-IN-1 selectively induces cytotoxicity and apoptosis in aneuploid ovarian cancer cells and also inhibits DNA repair. Ran-IN-1 exhibits antitumor activity and is useful for research on tumors such as epithelial ovarian cancer .
|
-
- HY-W040293
-
|
PE(6:0/6:0); 1,2-Dihexanoyl-sn-glycero-3-phosphoethanolamine
|
Apoptosis
|
Cancer
|
|
06:0 PE (PE(6:0/6:0)) is a water-soluble phospholipid characterized by its short acyl chains, exhibiting notable antitumor activity and the ability to inhibit tumor progression in vivo, alongside antiproliferative and proapoptotic effects, while serving as a precursor for phosphatidylcholine and phosphatidylethanolamine.
|
-
- HY-122241
-
|
|
PKC
|
Cancer
|
|
MT477 is a potent protein kinase C (PKC) inhibitor. MT477 induces apoptosis and necrosis. MT477 decreases the protein expression of Ras-GTP, p-Erk1/2, p-Elk1. MT477 shows antitumor activity .
|
-
- HY-154457
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N6-(4-methoxybenzyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154406
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N2-methylguanosine, DNA adduct is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-146575
-
|
|
Aldose Reductase
17β-HSD
|
Cancer
|
|
AKR1C3-IN-8 (Compound 5) is a potent, selective AKR1C3 inhibitor with an IC50 of 0.069 μM. AKR1C3-IN-8 shows antitumor activity .
|
-
- HY-152650
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N6-Methyl-2-methyl thioadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152400
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Bromo-9-(β-D-xylofuranosyl) guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-114311
-
|
|
FGFR
Discoidin Domain Receptor
|
Cancer
|
|
FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoindin domain receptor 2 (DDR2), with IC50 values of 31.1 nM and 3.2 nM, respectively. Antitumor activity .
|
-
- HY-13703
-
-
- HY-123325
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Kapurimycin A1 is an anbitiotic that can be isolated from Streptomyces. Kapurimycin A1 has a significant inhibitory effect on Gram-positive bacteria, exhibits cytotoxicity to cultured mammalian cells, and shows strong antitumor activity against the mouse leukemia P388 cell line .
|
-
- HY-152872
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Uridine-5-oxo-acetyl-(9-fluorenylmethyl) ester is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154261
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Rev 2’-O-MOE-A(Bz)-5’-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-157750
-
|
|
MEK
Raf
|
Cancer
|
|
MEK1/C-Raf-IN-1 (Compound 14d) is a MEK1/C-Raf inhibitor with IC50 values of 97 and 23 nM, respectively. MEK1/C-Raf-IN-1 has antitumor activity .
|
-
- HY-152675
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Amino-2’-deoxy-β-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152624
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Methyl-4’-thio-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N6074R
-
|
|
Reference Standards
Autophagy
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Soyasapogenol B (Standard) is the analytical standard of Soyasapogenol B. This product is intended for research and analytical applications. Soyasapogenol B is a component of soy that has oral activity. Soyasapogenol B promotes autophagy and apoptosis. Soyasapogenol B has anti-inflammatory, antioxidant and antitumor activities .
|
-
- HY-14833
-
|
TP300
|
Topoisomerase
|
Cancer
|
|
Atiratecan (TP300) is a proagent of camptothecin analog CH0793076 (HY-107096). Atiratecan does not inhibit acetylcholinesterase (AChE) activities. Atiratecan shows antitumor activity against both breast cancer resistance protein (BCRP)-positive and -negative xenografts in mouse xenograft models .
|
-
- HY-152508
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Chloro-2’-beta-C-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-125827
-
|
13-Methylberberinium chloride
|
Interleukin Related
|
Metabolic Disease
Cancer
|
|
13-Methylberberine chloride (13-Methylberberinium chloride), a berberine analogue, has anti-adipogenic and antitumor activities. 13-Methylberberine chloride (13-Methylberberinium chloride) increases production of IL-12 and inhibits the expression of iNOS at posttranscriptional level in macrophages activated with LPS .
|
-
- HY-154323
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-DMTr-3’dA(Bz)-methylphosphonami dite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154566
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-N,N-diethylamino thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152339
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N4-Amino-2'-C-methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152606
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Ethyl-2’-C-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P99175
-
|
|
CD47
|
Cancer
|
|
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research .
|
-
- HY-154516
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-9-(beta-D-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-150752
-
|
|
Btk
Pyroptosis
|
Cancer
|
|
BTK-IN-15 (compound 42) is a potent Bruton's tyrosine kinase (BTK) inhibitor with high oral absorption. BTK-IN-15 inhibits BTK with an IC50 value of 0.7 nM. BTK-IN-15 displays excellent kinase selectivity, antitumor activity, and induces apoptosis .
|
-
- HY-172104
-
|
|
EGFR
Apoptosis
|
Cancer
|
|
EGFR-IN-143 (Compound 5f) is a potent EGFR inhibitor with an IC50 value of 0.15 μM. EGFR-IN-143 induces apoptosis by arresting the cell cycle in the G2/M phase. EGFR-IN-143 has antitumor activity .
|
-
- HY-114334
-
|
CB839 derivative
|
Glutaminase
|
Cancer
|
|
Glutaminase-IN-1 (CB839 derivative), a CB839 derivative, is an allosteric inhibitor of 1,3,4-selenadiazole-containing kidney-type glutaminase (KGA), with an IC50 of 1 nM. Glutaminase-IN-1 (CB839 derivative) shows improved cellular uptake and antitumor activity.
|
-
- HY-N13163
-
|
|
Others
|
Cancer
|
|
2-Epitripdiolide is a diterpenoid compound derived from Tripterygium hypoglaucum with significant antitumor activity. Its IC50 values against A549, KB, KBvin, and MDA-MB-231 cells are 1.34, 0.4, 4.4, and 1.2 nM, respectively .
|
-
- HY-152621
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Ethyl-4’-thio-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P3627
-
|
|
Drug Derivative
|
Cancer
|
|
Nagrestipen, a human macrophage inflammatory protein-1 alpha (MIP-1α) variant, also known as ECI 301. Nagrestipen has antitumor activity and can be used in therapeutic trials to study cancer, tumors, metastases, radiation oncology, and tumor metastasis .
|
-
- HY-152413
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Furfuryl-2’-C-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152461
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-(3-Trifluoromethylbenzyl)-3’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154458
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N6-(3-methoxybenzyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152738
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-β-C-Methyl-3-deazauri dine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152648
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Ethyl-2’-O-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P1791
-
|
Lactoferricin B; Lfcin B
|
Bacterial
Fungal
Apoptosis
|
Infection
Cancer
|
|
Lactoferrin 17-41 (Lactoferricin B), a peptide corresponding to residues 17-41 of bovine lactoferrin, has antimicrobial activity against a wide range of microorganisms, including Gram-positive and Gramnegative bacteria, viruses, protozoa, and fungi. Lactoferrin 17-41 has antitumor activities .
|
-
- HY-154481
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
3’-O-Me-C(Bz)-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152324
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-N6-(2-hydroxyethyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-12643R
-
-
- HY-138294
-
|
|
Ras
Raf
|
Cancer
|
|
RAS/RAS-RAF-IN-1 is a potent RAS and RAS-RAF inhibitor. RAS/RAS-RAF-IN-1 has a KD of 5.0 μΜ-15 μΜ for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity .
|
-
- HY-154064
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
3’-O-MOE-A(Bz)-2’-CED-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-146574
-
|
|
Aldose Reductase
17β-HSD
|
Cancer
|
|
AKR1C3-IN-7 (Compound 13) is a potent, selective AKR1C3 inhibitor with an IC50 of 0.19 μM. AKR1C3-IN-7 shows antitumor activity .
|
-
- HY-133980
-
|
|
Drug Metabolite
|
Cancer
|
|
O-Demethyl Lenvatinib is a metabolite of Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
|
-
- HY-152805
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(2-β-C-Methyl-β-D-ribofuranosyl)purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154198
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5′-O-[Bis(4-methoxyphenyl)phenylmethyl]cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![5′-O-[Bis(4-methoxyphenyl)phenylmethyl]cytidine](//file.medchemexpress.com/product_pic/hy-154198.gif)
- HY-128425R
-
|
Ureidosuccinic acid (Standard)
|
Reference Standards
Endogenous Metabolite
|
Metabolic Disease
Cancer
|
|
N-Carbamoyl-DL-aspartic acid (Standard) (Ureidosuccinic acid (Standard)) is the analytical standard of N-Carbamoyl-DL-aspartic acid (HY-128425). This product is intended for research and analytical applications. N-Carbamoyl-DL-aspartic acid is a precursor of nucleic acid pyrimidines. N-Carbamoyl-DL-aspartic acid has antitumor activities.
|
-
- HY-154257
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-iso-Butyryl-8-azaguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-13680
-
|
Dian III; N-Methylisoindigotin; Natura-α
|
Apoptosis
|
Cancer
|
|
Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity .
|
-
- HY-139642
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Mal-(CH2)5-Val-Cit-PAB-Eribulin is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB .
|
-
- HY-N0611
-
|
α-Boswellic acid
|
Others
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
alpha-Boswellic acid (α-Boswellic acid) is an orally active pentacyclic triterpenoid compound that can be extracted from frankincense. alpha-Boswellic acid has anti-inflammatory and antitumor activities. alpha-Boswellic acid can be used in Alzheimer's disease (AD) research .
|
-
- HY-154529
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-3’-O-phthalimidopropyl cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N2232
-
|
N-trans-Feruloyloctopamine
|
Akt
p38 MAPK
Apoptosis
Cadherin
|
Cancer
|
|
N-Feruloyloctopamine (N-trans-Feruloyloctopamine) is an antioxidant component that can be isolated from garlic skin. N-Feruloyloctopamine can inhibit tumor cell proliferation and invasion, and induce apoptosis. N-Feruloyloctopamine has antitumor activity and can be used in the research of tumors such as hepatocellular carcinoma .
|
-
- HY-154565
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-N,N-dimethylamino thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154395
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-2′-deoxy-N,N-dimethyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152421
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Benzyloxy-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N12137
-
|
|
Others
|
Cancer
|
|
Glycoside St-J (Compound 2) is a triterpenoid saponin. Glycoside St-J has antitumor activity and inhibits HeLa cell proliferation. Glycoside St-J Isolates from natural Anemone flaccida. Glycoside St-J can be used in the development of new anticancer agents .
|
-
- HY-154297
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Dimethylamino methylidene-2’-deoxyisoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P1791B
-
|
Lactoferricin B acetate; Lfcin B acetate
|
Bacterial
Fungal
Apoptosis
|
Infection
Cancer
|
|
Lactoferrin 17-41 (Lactoferricin B) acetate, a peptide corresponding to residues 17-41 of bovine lactoferrin, has antimicrobial activity against a wide range of microorganisms, including Gram-positive and Gramnegative bacteria, viruses, protozoa, and fungi. Lactoferrin 17-41 acetate has antitumor activities .
|
-
- HY-145791
-
|
2′,3′-Didehydro-2′,3′-dideoxycytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Dideoxycytidinene (2′,3′-Didehydro-2′,3′-dideoxycytidine) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W128788
-
|
4-amino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)pyrimidin-2(1H)-one
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-b-D-arabinocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152494
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Methyl-9-(β-D-xylofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N7022R
-
|
|
Reference Standards
Others
|
Cancer
|
|
Eclalbasaponin I (Standard) is the analytical standard of Eclalbasaponin I. This product is intended for research and analytical applications. Eclalbasaponin I is isolated from Eclipta prostrata L with antitumor activity. Eclalbasaponin I inhibits the proliferation of hepatoma cell smmc-7721 with an IC50 value of 111.1703 μg/ml .
|
-
- HY-154082
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Caroxy uracil-1-yl acetic acid benzyl ester is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152804
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Iodo-2’-β-C-methyl cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-169232
-
|
|
PROTACs
|
Cancer
|
|
PCC16 chloride is a CRBN-based cp-PCC with an IC50 value of 102 nM for the degradation of DHHC3. PCC16 chloride has antitumor activity. (Target protein ligand: HY-169235, linker: HY-169236, E3 ligase ligand: HY-10984) .
|
-
- HY-154417
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Bis(O-t-butyldimethylsilyl)-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154170
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',3',5'-Tri-O-acetyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P99633
-
|
BGB-A333
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity .
|
-
- HY-152873
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Uridine-5-(N-Fmoc-methylamino)-acetyl (9-fluorenylmethyl) ester is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152747
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-β-D-Ribofuranosyl-2(1H)-pyridinone is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152332
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Chloro-N6-(4-methoxy)benzyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-146407
-
|
|
Apoptosis
|
Cancer
|
|
Anticancer agent 53 is a potent anticancer agent. Anticancer agent 53 shows in vitro cytotoxicity. Anticancer agent 53 induces apoptosis and cell cycle arrest in S/G2/M phases. Anticancer agent 53 shows antitumor activity with no apparent toxicity .
|
-
- HY-154418
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Bis(O-(t-butyldimethylsilyl)-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154595
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-benzoyl-4-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154344
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5′-Deoxy-5′-iodo-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-128775
-
|
|
Drug Derivative
|
Cancer
|
|
JHU395 is an orally-bioavailable and a plasma stable lipophilic glutamine antagonists (GA) proagent. JHU395 delivers 6-diazo-5-oxo-L-norleucine (DON) to malignant peripheral nerve sheath tumor (MPNST) in vitro and in vivo, and has antitumor activity in MPNST .
|
-
- HY-154609
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Bromo-2’-deoxy-5-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-15779
-
|
|
SphK
Apoptosis
|
Cancer
|
|
K145 is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC50 of 4.3 µM and a Ki of 6.4 µM. K145 is inactive against SphK1 and other protein kinases. K145 induces cell apoptosis and has potently antitumor activity .
|
-
- HY-N17781
-
|
3-Acetyl-11-methoxy-α-BA
|
Others
|
Inflammation/Immunology
Cancer
|
|
3-O-Acetyl-11-methoxy-α-boswellic acid (3-Acetyl-11-methoxy-α-BA) is a triterpenoid α-boswellic acid derivative with potential anti-inflammatory and antitumor activity, which can be isolated from frankincense of the Boswellia genus.
|
-
- HY-154646
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-benzoyl-4’-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-161351
-
|
|
Akt
STAT
Apoptosis
|
Cancer
|
|
STAT3/AKT-IN-1 is a dual inhibitor for the signal transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT) signalling pathway, exhibits antitumor activity against gastric cancer and induces cell apoptosis in SGC-7901 cells .
|
-
- HY-128871
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
VCP-Eribulin is a bioactive molecule-linker conjugate designed for ADCs (Drug-Linker Conjugates for ADC), formed by conjugating an ADC linker (VCP) with Eribulin (HY-13442). Eribulin is a unique microtubule inhibitor exhibiting antitumor activity. VCP-Eribulin can be utilized for antibody conjugation .
|
-
- HY-119937
-
|
|
ROCK
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
ROCK inhibitor-2 (compound 6) is a selective dual inhibitor of ROCK1 and ROCK2, with IC50 values of 160 nM and 21 nM, respectively. ROCK inhibitor-2 inhibits pMYPT1 with IC50 of 75 nM. ROCK inhibitor-2 exhibits antitumor activity .
|
-
- HY-152723
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-N,N-dimethyl-2′-C-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152330
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Chloro-N6-(3-methoxy)benzyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-126803
-
|
|
Antibiotic
|
Infection
Cancer
|
|
Saquayamycin B (compound 3) is a new angucycline antibiotic. Saquayamycin B has antitumor activities against a human lung (H-460) and a human breast cancer cell line (MCF-7) with GI50 values of 12.2 and 15.2 µM respectively .
|
-
- HY-162104
-
|
|
RAD51
|
Cancer
|
|
BRCA2-RAD51-IN-1 (Compound 46) is a BRCA2-RAD51 inhibitor with an EC50 value of 28 μM. BRCA2-RAD51-IN-1 has antitumor activity .
|
-
- HY-152302
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-3’-fluoro-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154396
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Chloro-2’-deoxy-2’-fluoroadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152362
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Hydroxy-3’-deoxy-3’-fluoroguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W002016
-
|
|
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Phthalazine is a substrate for human aldehyde oxidase 1, which can lead to the production of ROS and subsequent enzyme inactivation. Phthalazine is a nitrogen-containing organic heterocyclic compound. Phthalazine exhibits antitumor activity in blood cancer, breast cancer, colon cancer, lung cancer and renal cancer .
|
-
- HY-N0585R
-
|
(Rac)-NCTD (Standard)
|
Reference Standards
Apoptosis
|
Cancer
|
|
(Rac)-Norcantharidin (Standard) is the analytical standard of (Rac)-Norcantharidin (HY-N0585). This product is intended for research and analytical applications. (Rac)-Norcantharidin ((Rac)-NCTD) is the racemic form of Norcantharidin. Norcantharidin is a demethylated derivative of Cantharidin (HY-N0209) and has antitumor activity .
|
-
- HY-154599
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
5-Me-3’-dU-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-153384
-
|
|
Apoptosis
Microtubule/Tubulin
Mitosis
|
Cancer
|
|
EAPB 02303 is a microtubule-disrupting agent and inhibitor. EAPB 02303 induces mitosis arrest and impairment of spindle assembly. Thus, EAPB 02303 induces apoptosis and exhibits antitumor activity. EAPB 02303 also exhibits a potent synergy with Paclitaxel (HY-B0015) at lower concentrations .
|
-
- HY-19343
-
|
BMS-908662
|
Raf
|
Cancer
|
|
XL-281 (BMS-908662) is an orally active inhibitor for RAF kinase, with IC50s of 2.6, 4.5 and 6 nM, for CRAF, B-RAF, and B-RAFV600E, respectively. XL-281 exhibits antitumor activity .
|
-
- HY-152803
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Iodo-3’-deoxy-3’-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W010917
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′,3′,5′-Tri-O-acetyl-6-chloroguanosine diacetate is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154288
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-benzoyl-5-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-163515
-
|
|
Ras
|
Cancer
|
|
Anticancer agent 207 (compound 10b) is a potent anticancer agent. Anticancer agent 207 bounds to the NRAS rG4 with a KD value of 2.31 µM. Anticancer agent 207 shows cytotoxicity and decreases the expression of NRAS protein. Anticancer agent 207 shows antitumor activity .
|
-
- HY-154066
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-3’-flluoro-3-deazauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-114338A
-
|
SHR-6390 hydrochloride
|
CDK
|
Cancer
|
|
Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC50 values of 12.4 nM and 9.9 nM, respectively . Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esophageal squamous cell carcinoma .
|
-
- HY-164376
-
|
|
CDK
|
Cancer
|
|
CDK4/6-IN-21 (compound I-52) is a CDK4/6 inhibitor with IC50 values of 3.88 and 3.31 nM for CDK4 and CDK6, respectively. CDK4/6-IN-21 has antitumor activity .
|
-
- HY-W054074
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Bromo-2',3',5'-tri-O-acetyluridine diacetate is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-169581
-
|
|
Reactive Oxygen Species (ROS)
Mitosis
|
Cancer
|
|
DIM-C-pPhtBu is an orally active endoplasmic reticulum stress activator. DIM-C-pPhtBu induces mitochondrial and lysosome dysfunction, excessive mitosis, ROS production, and unfolded protein response-mediated cell death in neck cancer cells. DIM-C-pPhtBu has antitumor activity .
|
-
- HY-154573
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-O6-[2-(4-nitrophenylethyl)]guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2’-Deoxy-O6-[2-(4-nitrophenylethyl)]guanosine](//file.medchemexpress.com/product_pic/hy-154573.gif)
- HY-139981
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Microtubule destabilizing agent-1 (Compound 12b) acts as a microtubule destabilizing agent (MDA) based on hydroxamic acid, could serve as a potential MDA for further investigation. Microtubule destabilizing agent-1 shows favorable metabolism stability, high bioavailability, and potent antitumor activity .
|
-
- HY-152761
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-5-methoxyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154642
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Bromo-2’-deoxy-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152359
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Benzyloxy-3’-deoxy-3’-fluoroguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-163134
-
|
|
DNA-PK
|
Cancer
|
|
DNA-PK-IN-12 (compound 31t) is an oral active DNA-PK inhibitor with the IC50 of 0.1 nM. DNA-PK-IN-12 inhibits cell growth and Hct116 cell colony formation with the IC50 of 33.28 μM, and shows antitumor activity in vivo .
|
-
- HY-152335
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Chloro-N6-(3-trifluoromethyl)benzyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-147515
-
|
|
FGFR
|
Cancer
|
|
FGFR4-IN-11 (Compound 30) is a potent, selective, covalent FGFR4 inhibitor with an IC50 of 2.1 nM. FGFR4-IN-11 significantly inhibits the FGF19/FGFR4 signaling pathway and shows antitumor activity .
|
-
- HY-170610
-
-
- HY-152439
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Amino-3’-deoxy-5-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-132233
-
|
|
WDR5
|
Cancer
|
|
DDO-2093 is a potent MLL1-WDR5 protein-protein interaction inhibitor (IC50=8.6 nM; Kd=11.6 nM) with antitumor activity. DDO-2093 selectively inhibits the catalytic activity of MLL complex .
|
-
- HY-N14959
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Deacetylravidomycin N-oxide is an antibiotic that can be produced by Streptomyces ravidus S50905. Deacetylravidomycin N-oxide is active against Gram-positive bacteria but inactive against Gram-negative bacteria. Deacetylravidomycin N-oxide has antitumor activity against P388 leukemia and methamphetamine A fibrosarcoma .
|
-
- HY-161861
-
|
|
VEGFR
Akt
|
Cancer
|
|
VEGFR-2/AKT-IN-1 (compound 17) is a dual inhibitor of VEGFR-2 and AKT, with the IC50s of 0.164 μM and 0.452 μM, respectively. VEGFR-2/AKT-IN-1 has antitumor activity .
|
-
- HY-154513
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-5,N4-dimethylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152482
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-(2-Methoxyethyl)-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W004284
-
|
|
Environmental Pollutants
Apoptosis
PI3K
Akt
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Heptadecanoic acid is an odd-chain saturated fatty acid (OCS-FA) with oral activity. Heptadecanoic acid can inhibit cell proliferation and induce Apoptosis. Heptadecanoic acid has antitumor activity. Heptadecanoic acid is associated with a number of diseases, including coronary heart disease, pre-diabetes and type 2 diabetes, and multiple sclerosis .
|
-
- HY-152329
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-6-azauridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-131902
-
|
|
MALT1
|
Cancer
|
|
MLT-231 is a potent, highly selective allosteric MALT1 Inhibitor with an IC50 of 9 nM. MLT-231 specifically prevents endogenous BCL10 cleavage with IC50 of 160 nM. MLT-231 shows antitumor activity in an ABC-DLBCL type xenograft model in mouse .
|
-
- HY-P2282
-
|
|
STAT
|
Cancer
|
|
APTSTAT3-9R, a specific STAT3-binding peptide, inhibits STAT3 activation and downstream signaling by specifically blocking STAT3 phosphorylation. APTSTAT3-9R exerts antiproliferative effects and antitumor activity .
|
-
- HY-154156
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoroadenosine 5’-monophosphate (triethylammonium) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152712
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Bromo-3’-deoxy-3’-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152653
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-iso-Propyl-2’-O-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154578
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2'-deoxyadenosine, DNA adduct is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152457
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-3’-fluoro-beta-D-xylo-inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-50846
-
SCH772984
Maximum Cited Publications
182 Publications Verification
|
ERK
|
Cancer
|
|
SCH772984 is a highly selective and ATP-competitive ERK inhibitor, with IC50s of 4 and 1 nM for ERK1 and ERK2, respectively. SCH772984 has antitumor activity in MAPK inhibitor-na?ve and MAPK inhibitor-resistant cells containing BRAF or RAS mutations .
|
-
- HY-152757
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-5-trifluoromethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-115949
-
|
|
HSP
|
Cancer
|
|
Antitumor agent-47 (Compound 3e) is a silibinin derivative with an antitumor activity. Antitumor agent-47 shows cytotoxic activity against NCI-H1299 and HT29 cells with IC50 values of 8.07 µM and 6.27 µM, respectively .
|
-
- HY-W551974
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-benzoyl-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154415
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-benzoyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154213
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-5-MedC (Ac)-methyl phosphonamidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154085
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
(2’,3’,5’-Tri-O-acetyl)uridine 5-carboxylic acid is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-B1000S1
-
|
|
Isotope-Labeled Compounds
Autophagy
Keap1-Nrf2
|
Cancer
|
|
Selenomethionine- 77Se (Seleno-DL-methionine- 77Se) is the 77Se- labeled Selenomethionine (HY-B1000). Selenomethionine is a naturally occurring amino acid containing selenium that has oral activity and is a common natural food source. Selenomethionine has antitumor activity .
|
-
- HY-W048487
-
|
N6-Benzoyl-7'-OH-Morpholino adenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Benzoyl-7’-OH-morpholino adenine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152455
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N6-(m-methoxy benzyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152549
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-O-(2-Methoxyethyl)-2-aminoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152693
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N4-Methyl-2’-O-methyl-cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152611
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-5-methyl ara-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152754
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152487
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-3’-deoxy-3’-fluoroadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-164376A
-
|
|
CDK
|
Cancer
|
|
CDK4/6-IN-21 maleate (compound I-52) is a CDK4/6 inhibitor with IC50 values of 3.88 and 3.31 nM for CDK4 and CDK6, respectively. CDK4/6-IN-21 maleate has antitumor activity .
|
-
- HY-152753
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152760
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-5-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-15779A
-
|
|
SphK
Apoptosis
|
Cancer
|
|
K145 hydrochloride is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC50 of 4.3 μM and a Ki of 6.4 μM. K145 hydrochloride is inactive against SphK1 and other protein kinases. K145 hydrochloride induces cell apoptosis and has potently antitumor activity .
|
-
- HY-W539754
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2'-Deoxy-2'-fluoro-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-132233A
-
|
|
Histone Methyltransferase
|
Cancer
|
|
DDO-2093 dihydrochloride is a potent MLL1-WDR5 protein-protein interaction inhibitor (IC50=8.6 nM; Kd=11.6 nM) with antitumor activity. DDO-2093 dihydrochloride selectively inhibits the catalytic activity of MLL complex .
|
-
- HY-154230
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Rev 2’-O-MOE-C(Bz)-5’-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152337
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Chloro-N6-(4-trifluoromethyl)benzyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152664
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(2,3-Dideoxy-β-D-erythro-hexo pyranosyl)cytosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-165473A
-
|
|
Calcium Channel
|
Cancer
|
|
Hexadecylphosphoserine TFA is a phospholipid molecule that contains a long-chain alkyl (hexadecyl) and a phosphoserine group, giving it a high affinity for the cell membrane. Hexadecylphosphoserine TFA can exert antitumor activity by modulating [Ca ++]i and its related signaling pathways, making it useful for research in the field of breast cancer .
|
-
- HY-152778
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Chloro-3’-deoxy-3’-fluoroadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152356
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Bromo-3’-deoxy-3’-fluoroguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-133980A
-
|
|
Drug Metabolite
|
Cancer
|
|
O-Demethyl Lenvatinib hydrochloride is a metabolite of Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET. Lenvatinib shows potent antitumor activities .
|
-
- HY-152306
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1,N3-Bis(cyanomethyl)pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154190
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',3',5'-Tri-O-benzoyl-6-azauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-137139
-
|
|
Antibiotic
Bacterial
Farnesyl Transferase
|
Infection
Cancer
|
|
10'-Desmethoxystreptonigrin is an inhibitor for Ras Farnesyltransferase with an IC50 of 21 μM. 10'-Desmethoxystreptonigrin is a broad-spectrum antibiotic with antibacterial activity. 10'-Desmethoxystreptonigrin exhibits antitumor activity against P388 leukemia, without significant cytotoxicity (LD50 is 8.8 mg/kg) .
|
-
- HY-114338
-
|
SHR-6390
|
CDK
|
Cancer
|
|
Dalpiciclib (SHR-6390) is an orally active and highly selective inhibitor of CDK4 and 6 with IC50 values of 12.4 nM and 9.9 nM, respectively . Dalpiciclib shows antitumor activity against breast cancer and esophageal squamous cell carcinoma .
|
-
- HY-N0189
-
|
Rhabarberone; 3-Hydroxymethylchrysazine
|
mTOR
Influenza Virus
Apoptosis
Autophagy
|
Cancer
|
|
Aloe emodin (Rhabarberone) is a natural hydroxyanthraquinone with antitumor activities. aloe-emodin can bind with mTORC2 and inhibit its kinase activity. Aloe emodin exerts antiproliferation effects and induces cellular apoptosis . Aloe emodin also exhibits antiviral activity that against influenza A virus .
|
-
- HY-154259
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Rev 2’-O-MOE-G(iBu)-5’-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-B1000S
-
|
Seleno-DL-methionine-76Se; DL-Selenomethionine-76Se
|
Isotope-Labeled Compounds
Autophagy
Keap1-Nrf2
|
Cancer
|
|
Selenomethionine- 76Se (Seleno-DL-methionine- 76Se) is the 76Se- labeled Selenomethionine (HY-B1000). Selenomethionine is a naturally occurring amino acid containing selenium that has oral activity and is a common natural food source. Selenomethionine has antitumor activity .
|
-
- HY-151587
-
|
|
Others
|
Cancer
|
|
Anticancer agent 89 is a benzothiazole-2-thiophene S-glycoside derivative with antitumor activity, has high inhibition against the three cell line from ovarian cancer (OVCAR-4), renal cancer (A498), and melanoma (SK-MEL-5) .
|
-
- HY-152456
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Amino-2’-deoxy-5-methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-B0719
-
|
Ingenol 3-angelate; PEP005
|
PKC
|
Inflammation/Immunology
Cancer
|
|
Ingenol Mebutate is an active ingredient in Euphorbia peplus, acts as a potent PKC modulator, with Kis of 0.3, 0.105, 0.162, 0.376, and 0.171 nM for PKC-α, PKC-β, PKC-γ, PKC-δ, and PKC-ε, respectively, and has antiinflammatory and antitumor activity.
|
-
- HY-152733
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Aza-7-bromo-7-deazaguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-149879
-
|
|
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Npx-Au is a NSAID–Au(I) complex with antitumor activity. Npx-Au can be used for the research of ovarian cancer . Npx-Au is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-149424
-
|
|
PI5P4K
|
Cancer
|
|
PI5P4K-β-IN-2 (compound d5) is a PI5P4K-β inhibitor (IC50 = 0.35 μM) with antitumor activity.
|
-
- HY-154271
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
TLR7 agonist 12 (example 20) is a TLR7 agonist, also is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-156681A
-
|
(S)-STX-478; (S)-STX-478-101; (S)-LY4064809
|
PI3K
|
Cancer
|
|
(S)-STX-478 is the S-enantiomer of STX-478. STX-478 is a selective inhibitor of PI3Kα mutants, preventing metabolic dysfunction and demonstrating antitumor activity in xenograft mouse models with PI3Kα mutant tumors .
|
-
- HY-183253
-
|
|
Drug-Linker Conjugates for ADC
Eukaryotic Initiation Factor (eIF)
EGFR
|
Cancer
|
|
DL149 is a component of an antibody-drug conjugate (ADC) formed by conjugating the eIF4A inhibitor FD236 (HY-186186) with an ADC linker, and exhibits potential antitumor activity. DL149 can bind to an anti-HER2 antibody to form a complete ADC molecule, which precisely binds to the HER2 receptor on the surface of tumor cells. After internalization into cells, it releases the eIF4A inhibitor payload. DL149 irreversibly blocks the mRNA translation process in tumor cells, thereby inhibiting tumor cell proliferation and inducing their death. DL149 exhibits in vivo antitumor activity in the SK-OV-3 xenograft tumor model, and can be used for the research of HER2-positive solid tumors .
|
-
- HY-P99914
-
|
GNC-038
|
PD-1/PD-L1
CD19
TNF Receptor
CD3
Interleukin Related
IFNAR
|
Inflammation/Immunology
Cancer
|
|
Emfizatamab (GNC-038) is a monoclonal antibody against CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3 and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia .
|
-
- HY-10981R
-
|
E7080 (Standard)
|
Reference Standards
VEGFR
FGFR
PDGFR
c-Kit
RET
|
Cancer
|
|
Lenvatinib (Standard) is the analytical standard of Lenvatinib. This product is intended for research and analytical applications. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
|
-
- HY-124116
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
PD 121373 is a DNA complexing agent with antitumor activity. PD 121373 can bind tightly to DNA and RNA and inhibit the synthesis of DNA and RNA. The IC50 values of PD 121373 for inhibiting DNA and RNA synthesis in L1210 cells are 0.5 μM and 0.3 μM, respectively .
|
-
- HY-154121
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-(2-Methoxyethyl)guanosine 5’-triphosphate (ammonium) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W397503
-
|
2'-Deoxy-5'-O-DMT-5-iodouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-5-iodo-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154167
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-(4,4’-Dimethoxytrityl)-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152566
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N7-Methyl-2’-beta-C-methyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154526
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(3’-O-[4,4’-dimethoxytrityl]-alpha-L-threofuranosyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![1-(3’-O-[4,4’-Dimethoxytrityl]-alpha-L-threofuranosyl)uridine](//file.medchemexpress.com/product_pic/hy-154526.gif)
- HY-154545
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
3’-O-MOE-5MeU-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154473
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N4-ethyl-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152563
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-beta-C-methyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154291
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-3’-fluoro-N1-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154133
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-3’-fluoro-xylo-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-143296
-
|
|
SphK
|
Cancer
|
|
SphK1-IN-1 (compound 48) is a SphK1 inhibitor with effective antitumor activity. SphK1-IN-1 inhibits SphK1 ATPase with an IC50 value of 4.02 μM. SphK1-IN-1 can be used for the research of cancer .
|
-
- HY-154059
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluorouridine 5’-monophosphate triethyl ammonium is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-131818
-
|
NH2dAdo; Nsc 238990
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'-Amino-5'-deoxyadenosine (NH2dAdo; Nsc 238990) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152340
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Amino-2’-deoxy-5-fluoro-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-101246
-
|
|
RET
|
Cancer
|
|
RPI-1 is a specific, orally available 2-indolinone Ret tyrosine kinase inhibitor. RPI-1 inhibits proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCgamma, ERKs and AKT in human medullary thyroid carcinoma TT cells. Antitumor activity .
|
-
- HY-152507
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-beta-C-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-100748
-
|
CXD101
|
HDAC
|
Cancer
|
|
Zabadinostat (CXD101) is a potent, selective and orally active class I HDAC inhibitor with IC50s of 63 nM, 570 nM and 550 nM for HDAC1, HDAC2 and HDAC3, respectively. Zabadinostat has no activity against HDAC class II. Zabadinostat has antitumor activity .
|
-
- HY-154465
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
3’-F-3’-dG(iBu)-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154319
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(3’-O-[4,4’-Dimethoxytrityl]-alpha-L-threofuranosyl)-thymine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![1-(3’-O-[4,4’-Dimethoxytrityl]-alpha-L-threofuranosyl)-thymine](//file.medchemexpress.com/product_pic/hy-154319.gif)
- HY-152633
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N6,N6-dimethyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-146711
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 24 is a potent tubulin inhibitor. Tubulin inhibitor 24 inhibits tubulin polymerization. Tubulin inhibitor 24 induces cell cycle arrest at the G2/M phase in a concentration-dependent manner. Tubulin inhibitor 24 shows antitumor activity with no obvious toxicity .
|
-
- HY-154394
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-N6-methyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-130430
-
|
(-)-Neplanocin A
|
Antibiotic
Orthopoxvirus
|
Infection
Cancer
|
|
Neplanocin A ((-)-Neplanocin A) is an antitumor antibiotic with significant antitumor activity against murine L1210 leukemia. Neplanocin A is also an irreversible inhibitor of AdoHcy hydrolase (Ki=8.39 nM). Neplanocin A also has antiviral activity and is effective against vaccinia virus. Neplanocin A is obtained from Ampulariella regularis .
|
-
- HY-129252
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Prothracarcin is an antibiotic with antitumor activity that exerts its tumor cell toxicity by covalently binding to the C-2 amino group of guanine residues in the minor groove of DNA. Prothracarcin also shows antibacterial activity against Gram-positive bacteria and some Gram-negative bacteria such as Escherichia coli .
|
-
- HY-161123
-
|
|
WDR5
|
Cancer
|
|
WDR5-IN-8 is a WDR5 inhibitor with IC50 value of 15.5 nM. WDR5-IN-8 shows good anti-proliferative activity in two human acute leukemia cell lines. WDR5-IN-8 has antitumor activity .
|
-
- HY-154407
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N2,N2-dimethylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154511
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N4,N4-dimethylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-161573A
-
|
|
YAP
GGTase
|
Cancer
|
|
(7S)-BAY-593 is the S-enantiomer of BAY-593 (HY-161573). BAY-593 is an orally active GGTase-I inhibitor. BAY-593 can block YAP1/TAZ signaling in animals and has antitumor activity .
|
-
- HY-154295
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N1-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154159
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O,4’-C-Methyleneadenosine 5’-monophosphate (triethylammonium) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N8253S
-
-
- HY-154391
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-O-(tert-Butyldiphenylsilyl)-2,3-isopropylidene-D-ribonolactone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-10981AR
-
|
E7080 mesylate (Standard)
|
Reference Standards
VEGFR
FGFR
PDGFR
RET
c-Kit
|
Cancer
|
|
Lenvatinib (mesylate) (Standard) is the analytical standard of Lenvatinib (mesylate). This product is intended for research and analytical applications. Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
|
-
- HY-131847
-
|
2,6-Dichloro-9-(2’,3’,5’-tri-O-acetyl-β-D-ribofuranosyl)purine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2,6-Dichloro-2',3',5'-triacetyl-purine riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152518
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-O-Methyl-5-methyl-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152817
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2′-β-C-Methyl-beta-D-6-methylpurine riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152301
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-N6-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152489
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Chloro-2’-deoxy-2’-fluoro inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-175750
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
MOMA-341 is a selective Werner RecQ like helicase (WRN) inhibitor. MOMA-341 binds to WRN at cysteine 727 through an allosteric and ATP-competitive binding mechanism. MOMA-341 has antitumor activity and can be used for advanced and metastatic solid tumors research .
|
-
- HY-N15497
-
|
|
Reactive Oxygen Species (ROS)
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
Terpestacin is found in Phoma exigua var. heteromorpha. Terpestacin binds to UQCRB to inhibit the production of mitochondrial ROS and HIF-1α. Terpestacin inhibits tumor angiogenesis in the FM3A breast cancer cell xenograft mouse model. Terpestacin has antitumor activity and phytotoxicity .
|
-
- HY-149017
-
|
|
Apoptosis
|
Cancer
|
|
Apoptosis inducer 7 (Compound 5I) induces apoptosis in cancer cells. Apoptosis inducer 7 inducrs cleavage of PARP, caspases, down-regulation of anti-apoptotic protein c-Flip and up regulation of pro-apoptotic protein Noxa. Apoptosis inducer 7 exhibits antitumor activity .
|
-
- HY-154370
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Bis-O-(t-butyldimethylsilyl)-N1-methylpseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152403
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-3’-fluoro-xylo-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152504
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N1-methyladensoine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-102087R
-
|
|
Reference Standards
Cathepsin
|
Cancer
|
|
JPM-OEt (Standard) is the analytical standard of JPM-OEt (HY-102087). This product is intended for research and analytical applications. JPM-OEt is a broad spectrum cysteine cathepsin inhibitor. JPM-OEt binds covalently in the active site, and irreversibly inhibits the cysteine cathepsin family. Antitumor activity .
|
-
- HY-154355
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-N6-cyclopentyl 2’-deoxy- adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152444
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Hydroxymethyl-2’-O-(2-methoxyethyl)uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154531
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′,3′-Dideoxy-3′-fluoro-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154203
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Deoxy-3’-deoxy-3’-fluoro uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-19474R
-
|
Ansamitocin P-0 (Standard)
|
Reference Standards
Microtubule/Tubulin
ADC Payload
Apoptosis
|
Cancer
|
|
Maytansinol (Standard) is the analytical standard of Maytansinol. This product is intended for research and analytical applications. Maytansinol (Ansamitocin P-0) is a derivative of Maytansine. Maytansinol can inhibit tubulin polymerization and induce apoptosis. Maytansinol has antitumor activity. Maytansinol can be used in cancer drug research[1][2].
|
-
- HY-136350B
-
|
|
Phosphodiesterase (PDE)
|
Cancer
|
|
(S)-BRD9500 is the isomer of BRD9500 (HY-136350), and can be used as an experimental control. BRD9500 is an orally active phosphodiesterases 3 (PDE3) inhibitor with IC50s of 10 and 27 nM for PDE3A and PDE3B, respectively. Antitumor activity .
|
-
- HY-149240
-
|
|
P-glycoprotein
|
Cancer
|
|
Anticancer agent 108 (Compound 3.10) is a potent P-gp inhibitor with significant antitumor activity and less toxicity to normal and pseudonormal cells. Anticancer agent 108 (Compound 3.10) had no acute toxic effect on С57BL/6 mice .
|
-
- HY-106662R
-
|
|
Molecular Glues
Topoisomerase
Parasite
|
Infection
Cancer
|
|
Chloroquinoxaline sulfonamide (Standard) is the analytical standard of Chloroquinoxaline sulfonamide. This product is intended for research and analytical applications. Chloroquinoxaline sulfonamide (Chloroquinoxaline), a structural analogue of sulfaquinoxaline, is a topoisomerase II alpha/beta poison. Chloroquinoxaline sulfonamide is used to control coccidiosis in poultry, rabbit, sheep, and cattle . Antitumor activity .
|
-
- HY-149070
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′-Azido-2′,3′-dideoxy-5-hydroxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152813
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2′-Deoxy-2′-fluoro-4-deoxy-arabinouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-13582A
-
|
|
Fungal
Parasite
|
Infection
Cancer
|
|
Carbendazim hydrochloride is a potent and orally active broad-spectrum?benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria,?Fusarium?and?Sclerotina . Carbendazim hydrochloride is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma .
|
-
- HY-13582
-
|
|
Environmental Pollutants
Fungal
Parasite
|
Infection
Cancer
|
|
Carbendazim is a potent and orally active broad-spectrum benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria, Fusarium and Sclerotina . Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma .
|
-
- HY-175230
-
|
|
Lactate Dehydrogenase
Apoptosis
|
Cancer
|
|
ZG-2492 is an orally active LDHA inhibitor with an IC50 of 156 nM. ZG-2492 can reduce lactate production and induce cell cycle arrest and apoptosis in pancreatic cancer cells . ZG-2492 has antitumor activity and can be used in the research of tumors such as pancreatic cancer .
|
-
- HY-154218
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-O-Benzoyl-3-O-t-butyldiphenylsilyl-L-threono lactone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152435
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Amino-2’-deoxy-5-methyl uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152509
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-beta-C-methyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152618
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-N-Acetyl-3’-amino-3’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152424
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-(4-Methoxybenzyl)-2’-C-methyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-128905
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-dimethylDNA31 is a agent-linker conjugate for ADC with potent antitumor activity by using dimethylDNA31, linked via the ADC linker MC-Val-Cit-PAB. DimethylDNA31 has effective bactericidal activity against persisters and stationary-phase S. aureus.
|
-
- HY-152815
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2′-Deoxy-2′-fluoro-3-deaza-arabinouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-162967
-
|
|
PROTACs
Cyclic GMP-AMP Synthase
STING
|
Inflammation/Immunology
Cancer
|
|
MS8588 is a deubiquitinase-targeting chimera (DUBTAC) against cGAS. MS8588 induces targeted stabilization of cGAS, thereby activating downstream signaling pathways. MS8588 activates the cGAS/STING/IRF3 innate immune signaling pathway. MS8588 exhibits antitumor activity .
|
-
- HY-154132
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(b-D-Xylofuranosyl)-N6-(p-methoxybenzyl) adenine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154246
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Fluoro-2’-deoxy-arabinoadenosine 5’-triphosphate (triethylamine) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152311
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-N6,N6-dimethyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-111170
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
STA-9584 is a potent vascular disrupting agent (VDA) that targets tubulin. STA-9584 exhibits potent antitumor activity in mouse xenograft model by selectively targeting microvasculature at both the center and periphery of tumors. STA-9584 can be used for research in prostate and breast cancer .
|
-
- HY-154404
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-benzyl-4’-thio-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154345
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4′,5′-Didehydro-5′-deoxy-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154134
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-3’-fluoro-xylo-5-trifluoromethyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154158
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoroguanosine 5’-monophosphate triethyl ammonium is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154306
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-iodo-2’-O-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-106176
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
BMS-184476 is a selective microtubule inhibitor with potent antitumor activity. BMS-184476 induces G2/M phase arrest and promotes tumor cell apoptosis. BMS-184476 is promising for research of solid tumors, such as non-small cell lung cancer .
|
-
- HY-152390
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Fluoro-2’-deoxy-N6-methylarabinoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154238
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
5’-O-DMTr-3’-deoxyuridine 2’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-111934
-
|
|
Parasite
Potassium Channel
|
Others
Cancer
|
Cymarin, a cardiac glycoside, potently inhibits the Palytoxin (PTX)-induced K + release (IC50=0.42 μM). Cymarin reveals an antitumor activity against breast cancer and pancreatic cancer. Cymarin exhibits antifeedant and growth inhibitory effects as crop protectant .
|
-
- HY-154660
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-2’-deoxy-5-iodocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154266
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-2’-deoxy-N6-ethyl-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-120763
-
|
|
Farnesyl Transferase
|
Cancer
|
|
LB42908 is a potent, selective and orally active farnesyltransferase inhibitor. LB42908 inhibits farnesylation of H-Ras, K-Ras with IC50 values of 0.9 nM, 2.4 nM for H-Ras, K-Ras, respectively. LB42908 shows antiproliferative activity. LB42908 shows antitumor activity .
|
-
- HY-P99836
-
|
IBI101
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
|
Cudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research .
|
-
- HY-18986
-
|
MI-77301
|
MDM-2/p53
E1/E2/E3 Enzyme
Apoptosis
|
Cancer
|
|
SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective MDM2-p53 interaction inhibitor. SAR405838 binds to MDM2 with a Ki of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity .
|
-
- HY-17411R
-
-
- HY-152484
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N7-Methyl-2’-deoxy-2’-fluoroarabinoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-145989S
-
|
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
|
Aminobenzenesulfonic auristatin E-d8 is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .
|
-
- HY-154205
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoroarabino-O6-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154235
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-iBu-2’,3’-bis-O-TBDMS guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-185561
-
|
RC88
|
Mesothelin
|
Cancer
|
|
Misitatug blivedotin (RC88) is an antibody-drug conjugate (ADC) targeting mesothelin (MSLN). Misitatug blivedotin binds to mesothelin and exhibits dose‐dependent antitumor activity. Misitatug blivedotin can be used for the research of ovarian cancer, non-squamous non-small-cell lung carcinoma, cervical cancer .
|
-
- HY-W457757
-
|
1,2-O-Isopropylidene-3-O-Methyl-D-ribofuranose
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,2-Di-O-isopropylidene-3-O-methyl-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-I0100
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Methyl 2-deoxy-3,5-di-O-toluoyl-D-ribofuranoside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152634
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Chloro-2’-deoxy-2’-fluoro-arabino adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N0446
-
|
|
ADC Payload
|
Cancer
|
|
10-Methoxycamptothecin is a natural bioactive derivative of camptothecin (CPT) isolated from Camptotheca acuminata, and has been confirmed to possess high anti-cancer properties. 10-Methoxycamptothecin has higher cytotoxicity than 10-hydroxycamptothecin by testing antitumor activity against 2774 cell lines .
|
-
- HY-172496
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .
|
-
- HY-154307
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4′,5′-Didehydro-5′-deoxy-2′-O-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P99422
-
|
SHR-1316
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .
|
-
- HY-156920
-
|
|
Necroptosis
RIP kinase
|
Inflammation/Immunology
Cancer
|
|
VDX-111 is an analog of vitamin D. VDX-111 exhibits cytotoxicity in ovarian cancer cells through upregulation of RIPK1/RIPK3 pathway and induction of necroptosis. VDX-111 promotes expressions of cytokines and exhibits antitumor activity in mouse model .
|
-
- HY-W357201
-
|
N-[1-(6-Hydroxymethyl-4-trityl-morpholin-2-yl)-2-oxo-1,2-dihydro-pyrimidin-4-yl]-benzamide
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-7’-OH-N-trityl morpholino cytosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N6775
-
|
PX-866
|
PI3K
|
Cancer
|
|
Sonolisib (PX-866), an improved Wortmannin analogue, is an oral, irreversible, and pan-isoform inhibitor of PI3K (IC50=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)). Antitumor activity .
|
-
- HY-103439A
-
|
|
Tyrosine Hydroxylase
EGFR
|
Cancer
|
|
GW583340 is an orally active ErbB-2/EGFR tyrosine kinase inhibitor. GW583340 exhibits antitumor activity in xenograft models with EGFR overexpression or ErbB-2 overexpression. GW583340 is applicable to research related to head and neck cancer, breast cancer, and gastric cancer .
|
-
- HY-154050
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′-Chloro-3′-deoxy-5′-O-(triphenylmethyl)thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-18203
-
|
|
Apoptosis
Akt
mTOR
|
Cancer
|
|
HBF-0079 is a selective anti-hepatocellular carcinoma agent. HBF-0079 induces cell cycle arrest and Apoptosis. HBF-0079 modulates cell-growth and anti-apoptotic signaling through AKT and mTOR. HBF-0079 exhibits antitumor activity against hepatocellular carcinoma .
|
-
- HY-N12209
-
|
|
Others
|
Cancer
|
|
Neohelmanthicin A (compound 3A) is a phenylpropanoid compound with antitumor activity. The IC50s of Neohelmanthicin A for inhibiting leukemia cell line EL4, breast cancer cell line S180 and breast cancer cell line MCF7 are 0.13 μM, 7 μM and 23 μM respectively .
|
-
- HY-154331
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(5-O-Methoxytrityl-2-deoxy-β-D-xylofuranosyl)uracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154343
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′-Azido-3′-deoxy-5′-O-(triphenylmethyl)thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W045998
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,2-O-Isopropylidene-5-O-p-toluoyl-a-D-xylofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-100862
-
|
|
PARP
|
Cancer
|
|
BRCA1-IN-2 (compound 15) is a cell-permeable protein-protein interaction (PPI) inhibitor for BRCA1 with an IC50 of 0.31 μM and a Kd of 0.3 μM, which shows antitumor activities via the disruption of BRCA1 (BRCT)2/protein interactions .
|
-
- HY-152647
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Methoxypurine-9-beta-D-(3-methoxy riboside) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-146357
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Anticancer agent 48 (compound 48) is a broad spectrum anticancer agent. Anticancer agent 48 inhibits tubulin polymerization. Anticancer agent 48 shows antiproliferative activity. Anticancer agent 48 shows antitumor activity in vivo. Anticancer agent 48 has the potential for the research of solid and hematological tumors .
|
-
- HY-152412
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-α-C-methyl-5-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-172498
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .
|
-
- HY-149638
-
|
|
Sirtuin
HSP
|
Cancer
|
|
HSP70/SIRT2-IN-2 (Compounds 1a) is a dual inhibitor for SIRT2 and HSP70, with IC50 of 45.1±5.0 μM for SIRT2. HSP70/SIRT2-IN-2 has antitumor activity .
|
-
- HY-129880
-
|
Deacetylvinblastine hydrazide; DAVLBH
|
Microtubule/Tubulin
|
Cancer
|
|
Desacetylvinblastine hydrazide (Deacetylvinblastine hydrazide; DAVLBH) is an active component of EC145, a folate-targeted drug conjugate. Desacetylvinblastine hydrazide interferes with the formation of the mitotic spindle, and thus inhibits cell division and leads to cell death. Desacetylvinblastine hydrazide exhibits antitumor activity against folate receptor (FR)-positive tumor .
|
-
- HY-152492
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N1-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-161141
-
|
|
c-Met/HGFR
|
Cancer
|
|
EGFR/ C-Met-in-2 (Compound H-22) is a dual inhibitor of EGFR/c-Met. EGFR/c-Met-IN-2 inhibits cell proliferation by arresting G2/M phase. EGFR/c-Met-IN-2 has antitumor activity .
|
-
- HY-172497A
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG3400-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG3400-CREKA can be used for drug delivery .
|
-
- HY-152393
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-α-C-methyl-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W555976
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Hydroxymethyl-2',3'-O-isopropylidene-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-180111
-
|
|
Polo-like Kinase (PLK)
|
Neurological Disease
Cancer
|
|
PLK4-IN-7 is a selective and orally active PLK4 inhibitor with an IC50 value of 7.9 nM. PLK4-IN-7 exhibits potent antitumor activity and favorable metabolic stability. PLK4-IN-7 can be used for the research of tumors such as neuroblastoma .
|
-
- HY-W564313
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',3'-O-Isopropylidene-5-pyrrolidinomethyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P99205
-
|
|
ADC Antibody
|
Cancer
|
|
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
|
-
- HY-154557
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′,3′-Didehydro-2′,3′-dideoxy-5-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-120041
-
|
|
IRAK
|
Cancer
|
|
ND-2158 is a competitive IRAK4 inhibitor, with the Ki of 1.3 nM. ND-2158 suppresses LPS-induced TNF production in human white blood cells, alleviated collagen-induced arthritis, and blocked gout formation in mouse models. ND-2158 has antitumor activity in vivo .
|
-
- HY-154382
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’,5’-Didehydro-2’-O-(2-methoxyethyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W013164
-
|
|
COX
|
Inflammation/Immunology
Cancer
|
|
SC-58125 is a potent and selective inhibitor of cyclooxygenase 2 (COX-2), with an IC50 of 0.04 μM. SC-58125 exhibits antitumor activity in vitro and in vivo. SC-58125 also can inhibit edema at the inflammatory site and has analgesic effect .
|
-
- HY-W357200
-
|
N-[9-(6-Hydroxymethyl-4-trityl-morpholin-2-yl)-9H-purin-6-yl]-benzamide
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Benzoyl-7’-OH-N-trityl morpholino adenine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P5702
-
|
|
Bacterial
Apoptosis
Fungal
|
Infection
|
|
EP3 is an antimicrobial peptide. EP3 has antibacterial and antifungal activities. EP3 inhibits E. gallinarum, P. pyocyanea, A. baumanii, K. terrigena with a MIC value of 12.85 μg/mL. EP3 also shows antitumor activity against cancer cells, and induces cell apoptosis .
|
-
- HY-154234
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-TBDPS-5-methyl-2,2’-anhydrouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-173252
-
|
|
Ligands for Target Protein for PROTAC
Ras
|
Cancer
|
|
KRASG12C ligand-1 is a PROTAC target protein ligand that can be used to synthesize the PROTAC YN14-H (HY-173250). YN14-H is a PROTAC degrader targeting KRAS G12C and has antitumor activity .
|
-
- HY-154376
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’,5’-Didehydro-2’-O-methyl-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W342904
-
|
5'-O-[Bis(4-methoxyphenyl)phenylmethyl]-5-iodo-2'-O-methyl-uridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Methyl-5’-O-DMTr-5-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154304
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’,5’-Didehydro-2’,5’-dideoxy-2’-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-149637
-
|
|
Sirtuin
HSP
|
Cancer
|
|
HSP70/SIRT2-IN-1 (Compounds 2a) is a dual inhibitor for SIRT2 and HSP70, with IC50 of 17.3±2.0 μM for SIRT2. HSP70/SIRT2-IN-1 has antitumor activity .
|
-
- HY-112786
-
|
Vc-MMAF
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-Val-Cit-PAB-MMAF (Vc-MMAF) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF (HY-15579), linked via cathepsin cleavable MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB-MMAF shows antitumor activity .
|
-
- HY-154429
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N2,N2-diethyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154612
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-4’-thio-a-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152796
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Furan-2-yl-2’-O-methyl uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-131349
-
|
|
CCR
|
Cancer
|
|
CCR4-351 is an orally active, potent and selective CCR4 antagonist. CCR4-351, featuring a novel piperidinyl-azetidine motif, has IC50s of 22 nM and 50 nM in the calcium flux and CTX assay. CCR4-351 has antitumor activity .
|
-
- HY-154371
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-Benzoyl-2’-O,4’-C-methyleneuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-107324R
-
|
(-)-β-Elemene (Standard); Levo-β-elemene (Standard)
|
Reference Standards
Apoptosis
|
Cancer
|
|
β-Elemene (Standard) is the analytical standard of β-Elemene. This product is intended for research and analytical applications. β-Elemene ((-)-β-Elemene; Levo-β-elemene) is isolated from natural plant Curcuma aromatica with an antitumor activity. β-Elemene can induce cell apoptosis.
|
-
- HY-152486
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-deoxy-2’-fluoroarabinoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152736
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-5-methyl-xylo-uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-146260
-
|
|
PI3K
|
Cancer
|
|
NVP-CLR457 (compound 40) is an orally active, potent and balanced pan-class I PI3K inhibitor. NVP-CLR457 shows a clear dose-dependent PK/PD/efficacy relationship. NVP-CLR457 has antitumor activity .
|
-
- HY-172497
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .
|
-
- HY-152481
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-deoxy-2’-fluoroarabinoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154408
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
2’-O-Me-5-I-U-3’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W013164R
-
|
|
Reference Standards
COX
|
Inflammation/Immunology
Cancer
|
|
SC-58125 is a potent and selective inhibitor of cyclooxygenase 2 (COX-2), with an IC50 of 0.04 μM. SC-58125 exhibits antitumor activity in vitro and in vivo. SC-58125 also can inhibit edema at the inflammatory site and has analgesic effect .
|
-
- HY-N7028R
-
|
|
Reference Standards
Notch
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Withanolide A (Standard) is the analytical standard of Withanolide A. This product is intended for research and analytical applications. Withanolide A is an orally active extract from the Indian herb Ashwagandha. Withanolide A can induce apoptosis. Withanolide A has anti-inflammatory and antitumor activity. Withanolide A can be used in the study of neurodegenerative diseases .
|
-
- HY-41793
-
|
2'-Deoxy-3'-O-[(1,1-dimethylethyl)dimethylsilyl]-2'-fluorouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3'-O-(t-Butyldimethylsilyl)-2'-deoxy-2'-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154258
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Rev 2’-O-MOE-5MeU-5’-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154677
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Aminopurine-9-beta-D-(2’-deoxy)riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-129040A
-
|
MIBG sulfate; Iobenguane sulfate
|
Adrenergic Receptor
|
Cancer
|
|
m-Iodobenzylguanidine sulfate (MIBG sulfate) is an analogue of the neurotransmitter norepinephrine with antitumor activity. Radioiodinated m-Iodobenzylguanidine sulfate is clinically used as a tumor-targeted radiopharmaceutical in the diagnosis and treatment of adrenergic tumors. m-Iodobenzylguanidine sulfate is a high-affinity substrate for cholera toxin that interferes with cellular mono(ADP-ribosylation) .
|
-
- HY-154123
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Benzoyl-2’-chloro-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154263
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-N6-ethyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154567
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-N-(2-chloroethyl)amino thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-103439
-
|
|
Tyrosine Hydroxylase
EGFR
|
Cancer
|
|
GW 583340 dihydrochloride is an orally active ErbB-2/EGFR tyrosine kinase inhibitor. GW 583340 dihydrochloride exhibits antitumor activity in xenograft models with EGFR overexpression or ErbB-2 overexpression. GW 583340 dihydrochloride is applicable to research related to head and neck cancer, breast cancer, and gastric cancer .
|
-
- HY-154575
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-[(3-Pyridyl) pyrrolidin-1-yl]-2’-deoxyinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2-[(3-Pyridyl) pyrrolidin-1-yl]-2’-deoxyinosine](//file.medchemexpress.com/product_pic/hy-154575.gif)
- HY-131349A
-
|
|
CCR
|
Metabolic Disease
Cancer
|
|
CCR4-351 hydrochloride is an orally active, potent and selective CCR4 antagonist. CCR4-351 hydrochloride, featuring a novel piperidinyl-azetidine motif, has IC50s of 22 nM and 50 nM in the calcium flux and CTX assay. CCR4-351 hydrochloride has antitumor activity .
|
-
- HY-147270
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
MC-VA-PAB-Exatecan is a agent-linker conjugate for ADC. MC-VA-PAB-Exatecan contains the ADC linker (peptide MC-VA-PAB) and a DNA topoisomerase I inhibitor Exatecan (HY-13631). MC-VA-PAB-Exatecan synthesized ADC shows good antitumor activity .
|
-
- HY-154086
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-2’,2’-difluoro-dC(Bz)-methyl phosphonamidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-163697
-
|
|
Wee1
Apoptosis
|
Cancer
|
|
WEE1-IN-7 (compound 12h) is a potent and orally activeWEE1 inhibitor with an IC50 value of 2.1 nM. WEE1-IN-7 induces apoptosis and cell cycle arrest at the S phase. WEE1-IN-7 shows antitumor activity .
|
-
- HY-13533
-
|
NSC 682691; 4-Demethylpenclomedine
|
Drug Metabolite
|
Cancer
|
|
DMPEN (NSC 682691) (4-Demethylpenclomedine) is an alkylating metabolite of Penclomedine (HY-106401). DMPEN has an antitumor activity. DMPEN does not induce Purkinje cells loss with no significant neurocerebellar toxicity in rat cerebellum models. DMPEN can be used for cancers like breast and brain cancer research .
|
-
- HY-145908
-
|
|
NO Synthase
|
Cancer
|
|
Antitumor agent-49 (Compound 10) is a Harmine derivative-furoxan hybrids containing NO donor, with antitumor activities. Antitumor agent-49 shows cytotoxic activity against HepG2 cells with an IC50 of 1.79 µM. Antitumor agent-49 produces high levels of NO in vitro .
|
-
- HY-154779
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5′-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![5′-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine](//file.medchemexpress.com/product_pic/hy-154779.gif)
- HY-152503
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N6-Benzoyl-3’-O-(2-methoxyethyl)adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P1613
-
|
Cyclo(RGDfV); C(RGDfV)
|
Integrin
Apoptosis
|
Cancer
|
|
Cyclo(Arg-Gly-Asp-D-Phe-Val) (Cyclo(RGDfV)) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia .
|
-
- HY-152706
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-O-Methyl-N2,N2-dimethyl-guanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154442
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Rev 2’-O-MOE-5MeC(Bz)-5’-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154037
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Benzoyl-3'-fluoro-2',3'-dideoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152571
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-O-(2-methoxyethyl) inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154309
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
3'-O-tert-Butyldimethylsilyl-5'-O-DMT-2'-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-139612B
-
|
(Rac)-JDQ-443; (Rac)-NVP-JDQ443
|
Drug Derivative
Ras
PERK
|
Cancer
|
|
(Rac)-Opnurasib ((Rac)-JDQ-443; (Rac)-NVP-JDQ443) is the levorotomer of Opnurasib (HY-139612). Opnurasib is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). Opnurasib shows antitumor activity .
|
-
- HY-152378
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Deoxy-2’-fluoro-β-D-arabino-6-azauridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152569
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-O-(2-methoxyethyl) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154024
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-2’-O-(2-methoxyethyl)cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P992005
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
DS-1055a is an anti-human GARP antibody. DS-1055a effectively depletes GARP-positive regulatory T cells in the tumor microenvironment, and activates effector T cells. DS-1055a exhibits antitumor activity and can be used for the research of cancer, such as colon cancer .
|
-
- HY-154148
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Isopentenyl-2’-deoxy adenosine, 2’-deoxy riboprine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-111555
-
-
- HY-154240
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-2’,3’-bis-O-(2-methoxyethyl) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152350
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-4’-thio-β-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152570
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Methyl-2’-O-(2-methoxyethyl) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152864
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Methylpurine-2’-deoxy-2’-fluoro-beta-D-arabinoriboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W553730
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-iodouridine; 2’-Iodo-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W394293
-
|
2-Thio-5-methyluridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methyl-2-thiouridine (2-Thio-5-methyluridine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-120027
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Kribb3 is an inhibitor for microtubule. KRIBB3 inhibits the proliferation of cancer cells with GI50 of 0.2-2.5 μM, arrests cell cycle at G2/M phase, and induces apoptosis in HCT-116. Kribb3 exhibits antitumor activity in mouse models .
|
-
- HY-16214
-
|
LDHA Inhibitor FX11
|
Lactate Dehydrogenase
Apoptosis
Reactive Oxygen Species (ROS)
|
Cancer
|
|
FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a Ki of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts .
|
-
- HY-W395015
-
|
5'-O-(DIMETHOXYTRITYL)-2'-O-METHYLINOSINE
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
5’-O-(4,4-Dimethoxytrityl)-2’-O-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152567
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-O-(2-methoxyethyl) guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154587
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-[6-(Diethoxyphosphinyl)-2-O-methyl-β-D-ribo-hexofuranosyl]uracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![1-[6-(Diethoxyphosphinyl)-2-O-methyl-β-D-ribo-hexofuranosyl]uracil](//file.medchemexpress.com/product_pic/hy-154587.gif)
- HY-107365
-
|
|
PI3K
mTOR
|
Cancer
|
|
PQR530 is a potent, ATP-competitive, orally bioavailable and brain-penetrant dual pan-PI3K/mTORC1/2 inhibitor, with a subnanomolar Kd toward PI3Kα and mTOR (0.84 and 0.33 nM, respectively). Antitumor activity .
|
-
- HY-100429
-
CAN508
1 Publications Verification
|
CDK
|
Cancer
|
|
CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity .
|
-
- HY-154546
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
3’-O-MOE-5Me-C(Bz)-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154325
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(2-Deoxy-β-D-erythro-pentofuranosyl)-4(1H)-pyrimidinone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154499
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Methyl 4-C-hydroxymethyl-2,3-O-isopropylidene-beta-D-ribofuranoside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154220
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-2’-deoxy-2’,2’-diflurocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152349
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Deoxy-2’-fluoro-β-D-arabino-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N1984
-
|
Qing Hao acid; Artemisinic acid; Arteannuic acid
|
JNK
Interleukin Related
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Artemisinic acid (Qing Hao acid) is a sesquiterpene that can be isolated from Artemisia annua L. Artemisinic acid is also an important precursor for the synthesis of Artemisinin (HY-B0094). Artemisinic acid has various pharmacological activities, such as antimalarial activity, antitumor activity, antipyretic effect, antibacterial activity, allelopathic effect, and anti-adipogenic effect .
|
-
- HY-179628
-
|
|
Drug Derivative
|
Cancer
|
|
STING agonist-49-CO-C2-mal-Cys (compound 2), the derivative of STING agonist-49-CO-C2-mal (HY-179627), is the product of ADC catabolism and payload release, exhibits antitumor activity in vivo .
|
-
- HY-154454
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-2’,5’-di-O-acetyl-8-hydroxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-43426A
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-O-Benzoyl-1,2-di-O-isopropylidene-alpha-D-xylofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-125300
-
|
|
Fungal
Antibiotic
|
Cancer
|
|
Oligomycin E is a antitumor antibiotic that can be isolated from Streptomyces. Oligomycin E has significant antifungal activity, showing minimal inhibitory concentrations (MICs) values between 2 and 75μg/mL. Oligomycin E has strong antitumor activity against HeLa cells, with an IC50 of 0.014 μg/mL .
|
-
- HY-156243
-
|
|
ROCK
|
Cancer
|
|
GDI2-IN-1 (compound (+)-37) is a GDP-dissociation inhibitor beta (GDI2) inhibitor with an IC50 of 2.87 μM and a KD of 36 μM. GDI2-IN-1 exhibits excellent in vivo antitumor activity in GDI2-overexpressing pancreatic xenograft models .
|
-
- HY-152619
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6,N6-Dimethyl-4’-thio-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154588
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-[6-Phosphono-2-O-methyl-β-D-ribo-hexofuranosyl]uracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![1-[6-Phosphono-2-O-methyl-β-D-ribo-hexofuranosyl]uracil](//file.medchemexpress.com/product_pic/hy-154588.gif)
- HY-154680
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N3-(4-nitrobenzyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154727
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N3-(3-aminopropyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-18213
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-9 (Compound 8) is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity .
|
-
- HY-154541
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2,N2-Dimethylamino-6-deamino adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154363
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3-Cyanovinyl-9-(5’-O-DMT-2’-deoxyribofuranosyl)carbazole is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152587
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-3’-O-(2-methoxyethyl) inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P10841
-
|
|
Amino Acid Derivatives
|
Cancer
|
|
CyPep-1 is a novel cationic lytic peptide with antitumor activity. CyPep-1 is highly cytotoxic by interacting with the negatively charged cell membrane of cancer cells. CyPep-1 has strong cytolytic activity on cancer cells both in vivo and in vitro, and can be used in the study of solid tumors .
|
-
- HY-B0305A
-
|
HOE 760
|
Histamine Receptor
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Roxatidine Acetate Hydrochloride is a potent, selective, competitive and orally active histamine H2-receptor antagonist. Roxatidine Acetate Hydrochloride has antisecretory potency against gastric acid secretion. Roxatidine Acetate Hydrochloride can also suppress inflammatory responses and can be used for gastric and duodenal ulcers research. Roxatidine Acetate Hydrochloride has antitumor activity .
|
-
- HY-154251
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Methoxy-9-β-D-ribofuranosyl-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-12941
-
|
|
MDM-2/p53
|
Cancer
|
|
AM-7209 is a potent and selective MDM2-p53 interaction inhibitor with a Kd of 38 pM. AM-7209 inhibits the MDM2 amplified SJSA-1 osteosarcoma cell line with an IC50 of 1.6 nM. AM-7209 shows antitumor activities .
|
-
- HY-15575S
-
|
MC-Val-Cit-PAB-MMAE-d8; mc-vc-PAB-MMAE-d8
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
|
VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .
|
-
- HY-154605
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-iso-Butyroyl-2’-fluoro-2’-deoxyarabinoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152769
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Methoxy-2’-deoxy-2’-fluoro-beta-D-arabinoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W782079
-
|
|
Apoptosis
Fungal
Bacterial
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Geraniol-d6 (Major) is the deuterated labeled Geraniol (Major). Geraniol is an olefin terpene with oral activity. Geraniol inhibits cell proliferation and promotes apoptosis. Geraniol has antibacterial, antifungal, antioxidant, anti-inflammatory and antitumor activities. Geraniol can be used to study diabetes .
|
-
- HY-154729
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Methyl-2’-O-acetyl-5’-O-benzoyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152575
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Methyl-3’-O-(2-methoxyethyl) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-157068
-
|
|
Ferroptosis
Glutathione Peroxidase
|
Cancer
|
|
icFSP1 is a potent ferroptosis suppressor protein-1 (FSP1) inhibitor. icFSP1 triggers subcellular relocalization of FSP1 from the membrane and FSP1 condensation, in synergism with GPX4 inhibition. icFSP1 induces ferroptosis. icFSP1 shows antitumor activity against melanoma. .
|
-
- HY-N3862
-
|
|
Others
|
Cancer
|
|
Erythrodiol 3-O-palmitate is a natural product isolated from Dicranostigma leptopodum (Maxim) Fedde, Gentiana rhodantha Franch or Swertia kouitchensis. Erythrodiol 3-O-palmitate has antitumor activity, and inhibits the proliferation of K562 cells with the inhibition rate of 47% at 100 ug/mL .
|
-
- HY-152874
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-N-(t-Butyloxycarbonylmethyl)-N-trifluoro acetyl-aminomethyl-2’-O-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152371
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1,N6-Etheno-9-(β-D-xylofuranosyl)adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154224
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
2’-O-Me-2-thio-U-3’-phos phoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154682
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N3-(n-dodecyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154489
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Bromo-2’-deoxy-2’-fluoro-β-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154723
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N3-(4-hydroxybenzyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-148923
-
|
|
STAT
|
Cancer
|
|
MC0704 is a STAT3 inhibitor with an IC50 value of 2.13 μM. MC0704 induces cell apoptosis and cell cycle arrest. MC0704 shows antitumor activity in mouse breast cancer models. MC0704 can be used for the research of metastatic triple-negative breast cancer (mTNBC) .
|
-
- HY-154326
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Deoxy-2’-deoxy-5’-(4,4’-dimethoxytrityl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-139612A
-
|
(S)-JDQ-443; (S)-NVP-JDQ443
|
Drug Isomer
Ras
PERK
|
Inflammation/Immunology
Cancer
|
|
(S)-Opnurasib ((S)-JDQ-443; (S)-NVP-JDQ443) is an isomer of Opnurasib (HY-139612). Opnurasib is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). Opnurasib shows antitumor activity .
|
-
- HY-B0305
-
|
|
Histamine Receptor
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Roxatidine acetate is a potent, selective, competitive and orally active histamine H2-receptor antagonist. Roxatidine acetate has antisecretory potency against gastric acid secretion. Roxatidine acetate can also suppress inflammatory responses and can be used for gastric and duodenal ulcers research. Roxatidine acetate has antitumor activity .
|
-
- HY-152426
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1-Amino-8-benzyloxy-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N3028
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Taccalonolide B is microtubule stabilizer isolated from Tacca plantaginea, with antitumor activity. Taccalonolide B is effective in vitro against cell lines that overexpress P-glycoprotein (Pgp) and multidrug-resistance protein (MRP7). Taccalonolide B inhibits growth of SK-OV-3 cells with an IC50 of 208 nM .
|
-
- HY-145627
-
|
BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Ozuriftamab vedotin (BA3021), an antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities .
|
-
- HY-152568
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N7-Methyl-2’-O-(2-methoxyethyl) guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152573
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-3’-O-(2-methoxyethyl) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-18165
-
|
|
LPL Receptor
|
Cancer
|
|
XL541 is a potent, selective S1P1 antagonist. XL541 inhibits GDP-GTP exchange. XL541 causes frank surface hemorrhaging of tumors. XL541 collaborates with Paclitaxel (HY-B0015) to exhibit antitumor activity against breast cancer and lung cancer .
|
-
- HY-152527
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Deoxy-2’-fluoro-4-thio-beta-D-arabinouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-23790
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Benzoyl-2'-O-(2-methoxyethyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W565157
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3,5-O-Ditoluoyl 6-chloropurine-9-β-D-deoxyriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-108716
-
|
CBS9106; SL-801
|
CRM1
Apoptosis
|
Cancer
|
|
CBS9106 (SL-801) is a reversible oral CRM1 inhibitor with CRM1 degrading and antitumor activities. CBS9106, inhibits CRM1-dependent nuclear export, causing arrest of the cell cycle and inducing apoptosis in a time- and dose-dependent manner for a broad spectrum of cancer cells .
|
-
- HY-154437
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-β-Amino-2’,3’-dideoxy-5’-O-methoxy trityluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152785
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(3-Deoxy-3-fluoro-beta-D-ribofuranosyl)-9H-Purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154360
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Di-O-acetyl-8-benzyloxy-3’-deoxy guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152831
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-8-aza-7-deaza-7-iodoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152735
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-[[Methyl(2,2,2-trifluoroacetyl)amino]methyl]-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![5-[[Methyl(2,2,2-trifluoroacetyl)amino]methyl]-2-thiouridine](//file.medchemexpress.com/product_pic/hy-152735.gif)
- HY-163357
-
|
|
CDK
MDM-2/p53
|
Cancer
|
|
CDK2/MDM2-IN-1 (III-13) is a dual inhibitor of CDK2/MDM2 with an IC50 value of 2.60 nM for CDK2. CDK2/MDM2-IN-1 has antitumor activity .
|
-
- HY-144793
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Deac-SS-Biotin is a potent antitumor agent with improved tumor targeting effects and reduced off-target toxicities. Deac-SS-Biotin uptakes into the cells through biotin-mediated internalization. Deac-SS-Biotin combined with DTT (Glutathione mimetic) can effectively inhibit microtubule assembly and displays greater antitumor activity .
|
-
- HY-B0431AS1
-
|
|
Isotope-Labeled Compounds
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Phenoxybenzamine (benzyl-2,3,4,5,6-d5) (hydrochloride) is the deuterium labeled Phenoxybenzamine hydrochloride. Phenoxybenzamine hydrochloride is a nonselective, irreversible, orally active α-adrenoceptor antagonist that is commonly used for the research of hypertension, specifically caused by pheochromocytoma. Phenoxybenzamine hydrochloride also shows antitumor activity[1][2][3].
|
-
- HY-B0986
-
-
- HY-172759
-
|
|
Wee1
|
Cancer
|
|
PKMYT1-IN-9 is a highly selective and orally active PKMYT1 inhibitor (IC50: 4.4 nM). PKMYT1-IN-9 shows more selective for PKMYT1 than WEE1 (IC50: 32.4 μM). PKMYT1-IN-9 exhibits antitumor activity .
|
-
- HY-N0379R
-
|
|
Reference Standards
Endogenous Metabolite
|
Others
|
|
D-Mannose (Standard) is the analytical standard of D-Mannose. This product is intended for research and analytical applications. D-Mannose is a C-2 superpolymer of glucose that occurs naturally in many plants and fruits. D-Mannose has anti-inflammatory and antitumor activity. D-Mannose plays an important role in immune regulation .
|
-
- HY-154023
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-Benzoyl-2’,3’-di-O-acetyl-4’-C-fluoromethyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154514
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-5,N4,N4-trimethylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154667
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,2-Di-O-acetyl-3,5-di-O-benzyl-D-xylofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-176534
-
|
|
Histone Methyltransferase
|
Cancer
|
|
PRMT5-IN-52 (Compound 17) is a non-nucleoside Protein Arginine Methyltransferase 5 (PRMT5) inhibitor with inhibitory rates of 20.2% at 10 μM. PRMT5-IN-52 has potent antitumor activity, promising for research of cancers, including lung, prostate cancer, and colorectal carcinoma .
|
-
- HY-154469
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-2’-O-MOE inosine 3’-P-methyl phosphonamidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-149024
-
|
|
VEGFR
Apoptosis
MDM-2/p53
|
Cancer
|
|
VEGFR-2-IN-23 (compound 11b) is a potent and selective VEGFR-2 inhibitor with an IC50 value of 0.34 nM. VEGFR-2-IN-23 shows antitumor activity. VEGFR-2-IN-23 induces apoptosis and cell cycle arrest at G1 phase .
|
-
- HY-171187
-
|
CL 13580
|
Carbonic Anhydrase
|
Cancer
|
|
Chlorzolamide (CL 13580) is a carbonic anhydrase (CA) inhibitor. Chlorzolamide has an effect on the skeletal muscle of rats, which can reduce the tetanic contraction force of soleus and extensor digitorum longus and prolong the relaxation time and peak time of muscle contraction. In addition, Chlorzolamide inhibits tumor cell proliferation and has antitumor activity .
|
-
- HY-12643S
-
|
MK-397-d3
|
Isotope-Labeled Compounds
|
Infection
Cancer
|
|
Eprinomectin-d3 (MK-397-d3) is the deuterium-labeled Eprinomectin (HY-12643). Eprinomectin is a type of avermectin. Eprinomectin, as a broad-spectrum fungicide, has insecticidal, insecticidal and acaricidal activities. Eprinomectin induces apoptosis and autophagy in prostate cancer cells and has antitumor activity .
|
-
- HY-157388
-
|
|
Histone Methyltransferase
HDAC
|
Cancer
|
|
CARM1/HDAC2-IN-1 (compound CH-1) is a dual inhibitor against CARM1 and HDAC2, with IC50 values of 3.71 nM and 4.07 nM, respectively. CARM1/HDAC2-IN-1 possesses antitumor activity .
|
-
- HY-119789
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Albofungin (Antibiotic P-42-1) is isolated from the culture filtrate of Actinomyces tumemacerans strain INMI.P-42. Albofungin shows highly active on a wide variety of gram-positive bacteria and fungi. Albofungin shows cytotoxic to HeLa cell cultures and exhibited antitumor activity on EHRLICH ascites tumor in mice.
|
-
- HY-19551
-
|
ApoG2
|
Bcl-2 Family
Apoptosis
Autophagy
Fungal
ROS Kinase
|
Infection
Cancer
|
|
Apogossypolone (ApoG2) is an orally active Bcl-2 family proteins inhibitor with Ki values of 35, 25 and 660 nM for Bcl-2, Mcl-1 and Bcl-XL, respectively. Apogossypolone shows antitumor activities, induces cell apoptosis and autophagy . Apogossypolone also has antifungal activity .
|
-
- HY-168903
-
|
|
STAT
|
Cancer
|
|
STAT3-IN-41 (Compound 16) is a prodrug of compound 1. STAT3-IN-41 slowly releases compound 1 inhibiting STAT3 signaling pathway. STAT3-IN-41 shows antitumor activity against lung cancer, hepatocellular carcinoma and pancreatic cancer .
|
-
- HY-154610
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Amino-9-[2-deoxy-β-D-ribofuranosyl]-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![6-Amino-9-[2-deoxy-β-D-ribofuranosyl]-9H-purine](//file.medchemexpress.com/product_pic/hy-154610.gif)
- HY-152994
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,2-Di-O-acetyl-3,5-di-O-benzoyl-D-xylofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154412
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-2’-deoxy-2’-fluoro-β-D-arabinocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154622
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Bz-5’-O-DMTr-2’-O-hexadecanyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152877
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-1-β-D-ribofuranosyl-4(1H)-pyrimidinone is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154206
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzo yl-5’-O-(4,4’-dimethoxytrityl)-aracytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152555
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Amino-2’-deoxy-β-D-arabino-5-methyl uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-168460
-
|
|
RIBOTAC
DNA/RNA Synthesis
|
Cancer
|
|
RNA recruiter 2 is a QSOX1 mRNA ligand. RNA recruiter 2 can serve as a ligand for target RNA (Ligands for Target RNA for RIBOTAC) for the development of RIBOTAC RNA degraders with antitumor activity. RNA recruiter 2 can be used for the synthesis of F1-RIBOTAC (HY-171148) .
|
-
- HY-N3149
-
|
|
STAT
Apoptosis
Reactive Oxygen Species (ROS)
|
Cancer
|
|
(E)-2-Hydroxycinnamaldehyde is an aldehyde that can be separated from the stem bark of cinnamon. (E)-2-Hydroxycinnamaldehyde inhibits cell proliferation and induces apoptosis by inhibiting signal transduction of STAT3 and reactive oxygen species production. (E)-2-Hydroxycinnamaldehyde has antitumor activity .
|
-
- HY-169084
-
|
|
Glycosyltransferase
|
Cancer
|
|
ST-IN-1 (compound (R)-1) is a selective ST inhibitor (Ki=70 nM, rat a-2,6-ST; Ki=19 nM, hST6GAL1) with antitumor activity. ST-IN-1 inhibits tumor growth and metastasis by delipidating the surface of tumor cells .
|
-
- HY-176508
-
|
|
Casein Kinase
|
Cancer
|
|
KDX1381 is a bivalent CK2α inhibitor (IC50: 17 nM, KD: 54 nM). KDX1381 has antitumor activity in mouse 786-O and A375 tumor xenograft models. KDX1381 combined with VEGFR inhibitors or DNA damaging agents enhances antitumor efficacy in mouse hepatocellular carcinoma and glioma models .
|
-
- HY-152661
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Hydroxy-2’-de oxy-2’-fluoro-beta-D-arabino adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154276
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-O-Acetyl-2-O-benzoyl-3-O-tert-butyldiphenylsilyl-L-threofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-181274
-
|
|
Apoptosis
Reactive Oxygen Species (ROS)
Mitochondrial Metabolism
|
Cancer
|
|
Apoptosis inducer 59, a camphorsulfonamide-based thiazolylhydrazone derivative, is a apoptosis inducer with antitumor activity. Apoptosis inducer 59 can inhibit cell migration and invasiveness, cause S phase arrest, induce ROS production and depolarise mitochondrial membrane potential. Apoptosis inducer 59 can be used for the research of cancer, such as breast cancer .
|
-
- HY-152660
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-6-O-methyl-2’-O-methyl purine riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N0171B
-
|
β-Sitosterol (purity>75%); 22,23-Dihydrostigmasterol (purity>75%)
|
Apoptosis
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Beta-Sitosterol (purity>75%) is a phytosterol with oral activity. Beta-Sitosterol (purity>75%) interferes with a variety of cell signaling pathways, including the cell cycle, apoptosis and cell proliferation. Beta-Sitosterol (purity>75%) has anti-inflammatory, antioxidant, and antitumor activities .
|
-
- HY-W354644
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(β-D-Ribofuranosyl)-5-nitropyrine-2(1H)-one is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154607
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-3’-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-49198
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2'-Deoxy-2'-fluoro-N4-benzoyl-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154381
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-iodo-2’-O-(2-methoxyethyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-19018
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
CGP-6809 is an orally active DNA inhibitor. CGP-6809 exhibits antitumor activity against various transplantable tumors in mice and rats, including melanoma, prostate cancer, and rectal cancer. CGP-6809 can be used in research on various cancers, including melanoma, prostate cancer, and rectal cancer .
|
-
- HY-13454
-
|
|
PKD
|
Cancer
|
|
CID 2011756 is an ATP competitive PKD inhibitor, with an IC50 of 3.2 µM for PKD1 in cell free assay, and also shows cellular pan-PKD inhibitory activity against PKD2 and PKD3 (IC50, 0.6 and 0.7 µM, respectively). CID 2011756 also has antitumor activity.
|
-
- HY-160094
-
|
|
Ligands for Target Protein for PROTAC
|
Cancer
|
|
BCN-sulfonamide-PEG2-sulfonamide-N-bis ethanol (compound 71) is a Ligands for Target Protein for PROTAC that contains a sulfonamide linker to increase the solubility of the linker-conjugate. BCN-sulfonamide-PEG2-sulfonamide-N-bis ethanol can be used to synthesize PROTACs with antitumor activity .
|
-
- HY-176142
-
|
|
CDK
c-Myc
Apoptosis
Bcl-2 Family
|
Cancer
|
|
YX0798 is a selective and orally active CDK9 inhibitor (Kd: 0.28 nM). YX0798 downregulates the oncoprotein c-MYC and pro-survival protein MCL-1. YX0798 disrupts the cell cycle and results in transcriptomic reprogramming, eventually leading to cell apoptosis. YX0798 has antitumor activity .
|
-
- HY-147202
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BRD4 Inhibitor-24 (compound 3U) is a potent BRD4 inhibitor, BRD4 Inhibitor-24 shows antitumor activity against MCF7 and K652 cells, with IC50 values of 33.7 and 45.9 μM, respectively (extracted from patent CN107721975A) .
|
-
- HY-152392
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Fluoro-2’-deoxy-N6,N6-dimethylarabinoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152998
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-acetyl-5-methoxycarbonylmethyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152655
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Ethoxy-9-beta-D-(2-C-methyl-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152711
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Chloro-2’-β-C-methyl-6-N,N-dimethyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154478
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Acetyl-N2-iso-Butyroyl-2’-deoxy-guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-157888
-
|
|
SHP2
Phosphatase
|
Cancer
|
|
SHP2-IN-26 (Compound 4b) is a highly selective SHP2 allosteric inhibitor with a IC50 value of 3.2 nM. SHP2-IN-26 inhibits the phosphorylation of ERK and AKT in NCI-H358 cells. SHP2-IN-26 has antitumor activity .
|
-
- HY-B0342R
-
|
Methylglucamine (Standard); Meglumin (Standard); Methylglucamin (Standard)
|
Biochemical Assay Reagents
Reference Standards
|
Cancer
|
|
Meglumine (Standard) is the analytical standard of Meglumine. This product is intended for research and analytical applications. Meglumine (Methylglucamine) is an orally active amino sugar derived from sorbitol. Meglumine has anti-inflammatory and antitumor activity. Meglumine is often used as an excipient in active molecules and with iodinated compounds in contrast agents such as meglumine and meglumine iodide .
|
-
- HY-143412
-
|
|
HDAC
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
MIR002 is a potent and orally active DNA polymerase α (POLA1) and HDAC 11 dual inhibitor. MIR002 induces acetylation of p53, activation of p21, G1/S cell cycle arrest, and apoptosis. MIR002 shows significant antitumor activity in vivo .
|
-
- HY-159964
-
|
|
Deubiquitinase
|
Cancer
|
|
USP7-IN-16 (Compound 61) is a selective USP7 inhibitor with IC50 values of 5.5 nM in the FLINT assay and 2.1 nM in MM.1S cells. USP7-IN-16 exhibits antitumor activity in mice and is a promising candidate for research in the field of oncology .
|
-
- HY-122092
-
|
|
Telomerase
|
Cancer
|
|
FJ-5002 is a telomerase inhibitor with an IC50 of 2 μM. FJ-5002 can induce telomere shortening, increased chromosomal abnormalities, and senescence/crisis-like features in the human leukemia cell line U937. FJ-5002 exhibits antitumor activity and can be used in the study of cancer .
|
-
- HY-145584
-
|
JPI-547/OCN-201
|
PARP
Wnt
β-catenin
|
Neurological Disease
Cancer
|
|
Nesuparib (JPI-547) is the orally active inhibitor for PARP 1/2 and Tankyrase 1/2 that inhibits tankyrases 1, tankyrases 2, and PARP 1 with IC50s of 5, 1 and 2 nM, respectively. Nesuparib exhibits antitumor activity and can be used in research of advanced solid tumor .
|
-
- HY-154627
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-iBu-5’-O-DMTr-2’-O-hexadecanyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-168733
-
|
|
Lactate Dehydrogenase
Apoptosis
|
Cancer
|
|
LDHA-IN-9 (Compound 1g) is an inhibitor for LDH-A with an IC50 of 25 nM. LDHA-IN-9 inhibits the proliferation of DLD-1 cell (GI50 of 27 μM) through apoptosis induction. LDHA-IN-9 exhibits antitumor activity in mouse model without significant toxicity (25 mg/kg) .
|
-
- HY-152689
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Deoxy-2’-fluoro-N3-(4-nitrobenzyl)-beta-D-arabinouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-170827
-
|
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
E3 Ligase Ligand-linker Conjugate 159 is an E3 ligase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 159 can be used for the synthesis of SMD-3236 (HY-170824), a PRAOTAC that targets the degradation of SMARCA2, exhibiting long-lasting antitumor activity in vivo .
|
-
- HY-105019AR
-
|
Melphalan flufenamide hydrochloride (Standard)
|
Reference Standards
DNA Alkylator/Crosslinker
Apoptosis
|
Cancer
|
|
Melflufen hydrochloride (Standard) is the analytical standard of Melflufen hydrochloride (HY-105019A). This product is intended for research and analytical applications. Melflufen (Melphalan flufenamide) hydrochloride, a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen hydrochloride shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen hydrochloride induces irreversible DNA damage and cytotoxicity in MM cells .
|
-
- HY-154463
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-iso-Butyroyl-3’-deoxy-3’-fluoro guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W559353
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(3-Beta-amino-2,3-dideoxy-beta-d-threopenta-furanosyl)thymine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-168868
-
|
|
RET
Ligands for Target Protein for PROTAC
|
Cancer
|
|
RET ligand-2 is a selective RET inhibitor. RET ligand-2 can serve as a ligand for target protein (Ligands for Target Protein for PROTAC) for the development of PROTAC RET degraders with antitumor activity. RET ligand-2 can be used for the synthesis of RD-23 (HY-168867) .
|
-
- HY-152762
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-phenylpurine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-B1320R
-
-
- HY-139348
-
PFI-90
1 Publications Verification
|
Histone Demethylase
Apoptosis
|
Cancer
|
|
PFI-90 is a selective inhibitor of histone demethylase (KDM3B) that inhibits PAX3-FOXO1 action. PFI-90 induces apoptosis and myogenic differentiation, resulting in the cell death increased. PFI-90 has the potential for the antitumor activity. (patent WO2021101929A1).
|
-
- HY-154298
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N-Benzoyl-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-3′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![N-Benzoyl-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-3′-deoxyadenosine](//file.medchemexpress.com/product_pic/hy-154298.gif)
- HY-116532
-
|
|
Bcl-2 Family
|
Cancer
|
|
YCW-E11 is a Bcl-2, and Mcl-1 inhibitor with Ki values of 0.83 and 0.33 μM, respectively. YCW-E11 induces cell apoptosis through the mitochondrial pathway and exhibits antitumor activity. YCW-E11 can be utilized in cancer research .
|
-
- HY-152780
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(2’-Deoxy-2’-fluoro-β-D-arabinofuranosyl)-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W340190
-
|
5-Iodo-2'-O-methyluridine
|
Nucleoside Antimetabolite/Analog
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
2’-O-Methyl-5-iodouridine (5-Iodo-2'-O-methyluridine) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154594
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(Aminomethyl)-2′,3′-O-(1-methylethylidene)-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154725
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N3-[3-(tert-butoxycarbonyl) amino]propyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2’-Deoxy-2’-fluoro-N3-[3-(tert-butoxycarbonyl) amino]propyluridine](//file.medchemexpress.com/product_pic/hy-154725.gif)
- HY-164107
-
|
|
ADC Payload
Microtubule/Tubulin
|
Cancer
|
|
Auristatin S is an Auristatin payload with potent antitumor activity. Auristatin S attenuates bystander activity with improved off-target toxicity. Auristatin S has excellent tolerability in Karpas/KarpasBVR cell models. Auristatin S can be used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types .
|
-
- HY-152374
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-N6,N6-dimethyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-153390
-
|
|
Histone Methyltransferase
|
Cancer
|
|
AMG 193 is an orally active MTA-cooperative PRMT5 inhibitor with antitumor activity. AMG 193, when complexed with MTA, preferentially inhibits the growth of MTAP-deficient tumor cells by inhibiting PRMT5 (IC50=0.107 μM), thereby protecting normal cells with wild-type MTAP .
|
-
- HY-154366
-
|
N1-Methylpseudouridine CEP
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
5'-DMT-2'-O-TBDMS-N1-Methyl-PseudoUridine-CE-Phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154160
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(2-Hydroxyethyl)-2’,3’-di-O-toluoyl-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-103224
-
|
|
PI3K
|
Cancer
|
|
PIT-1 is a selective PIP3 (phosphatidylinositol 3,4,5-trisphosphate) antagonist. PIT-1 inhibits cancer cell survival and induces apoptosis by inhibition of PIP3 dependent PI3K / Akt signaling. PIT-1 exhibits antitumor activity in vivo .
|
-
- HY-151999
-
|
|
Ras
|
Cancer
|
|
KRAS G12C inhibitor 65 is a potent and covalent KRAS G12C inhibitor that traps KRAS G12C in the GDP-bound state. KRASG12C IN-1 exhibits potent antitumor activity against KRAS-mutant non-small cell lung cancer .
|
-
- HY-154267
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
5'-O-DMT-2-thio-2'-dU-3'-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P5703
-
|
|
Bacterial
Apoptosis
Fungal
|
Infection
|
|
EP5-1 is an antimicrobial peptide. EP5-1 has antibacterial and antifungal activities. EP5-1 also shows antitumor activity against cancer cells, and induces cell apoptosis. EP5-1 has antiviral activity against pseudorabies virus (PRV) .
|
-
- HY-152808
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-(2-Furanyl)-9-β-D-ribofuranosyl-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154385
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’,5’-Didehydro-2’-O-(2-methoxyethyl)-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-139279
-
|
TPX-0131
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
Zotizalkib (TPX-0131) is a potent, selective, CNS-penetrant and orally active inhibitor of wild-type ALK (IC50 of 1.4 nM) and ALK-resistant mutation, e.g. G1202R (IC50 of 0.3 nM), L1196M (IC50 of 0.3 nM). Zotizalkib has strong antitumor activities .
|
-
- HY-10231R
-
|
|
Reference Standards
HIF/HIF Prolyl-Hydroxylase
Autophagy
|
Cancer
|
|
PX-478 (Standard) is the analytical standard of PX-478 (HY-10231). This product is intended for research and analytical applications. PX-478 is an orally active HIF-1α inhibitor with potent antitumor activities. PX-478 can cross the blood-brain barrier .
|
-
- HY-154561
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,5’-Di-O-acetyl-2’-deoxy-N3-methyl uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-108488R
-
|
|
Reference Standards
Src
|
Cancer
|
|
KB SRC 4 (Standard) is the analytical standard of KB SRC 4 (HY-108488). This product is intended for research and analytical applications. KB SRC 4 is a potent, and highly selective c-Src inhibitor, with a Ki of 44 nM and a Kd of 86 nM, and shows no inhibition on c-Abl up to 125 μM; KB SRC 4 has antitumor activity.
|
-
- HY-154340
-
|
2’-Deoxy-3’,2-anhydro-5-methyluridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2,3’-Anhydrothymidine; 2’-Deoxy-3’,2-anhydro-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-174418
-
-
- HY-174161
-
|
|
Trk Receptor
|
Cancer
|
|
Type II TRK inhibitor 3 (Compound 18d) is a Type II TRK inhibitor with IC50 values of 0.82, 1.82, and 0.12 nM for TRKAWT/G595R/G667C, respectively. Type II TRK inhibitor 3 exhibits antitumor activity .
|
-
- HY-106218
-
|
5-Fluorocyclocytidine; 5'-Fluorocyclocytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Flurocitabine (5-Fluorocyclocytidine) is a fluorinated anlydride analog of cytosine arabinoside, partially hydrolysecl in vivo into two active antitumor substances (arabinosyl-tluorocytosine (ara-FC) and arabinosyl-fluorouracil (ara-FU)). Flurocitabine (5-Fluorocyclocytidine) has antitumor activity during phase I studies in acute leukemia and solid tumors .
|
-
- HY-15735
-
|
|
c-Met/HGFR
|
Cancer
|
|
c-Met inhibitor 1 is an orally active c-Met inhibitor. c-Met inhibitor 1 can inhibit c-Met phosphorylation with an IC50 of 0.010 μM. c-Met inhibitor 1 has antitumor activity and can be used for the research of tumors such as gastric cancer, pancreatic cancer and malignant glioma .
|
-
- HY-117183
-
|
T-2636 F
|
Antibiotic
|
Cancer
|
|
Lankacidinol (T-2636 F) is an antibiotic. Lankacidinol and its related metabolites 2,18-seco-lankacidinol A (1) and 2,18-seco-lankacidinol B (2) have significant biological activities and potential medicinal value. In addition, 2,18-seco-lankacidinol A exhibits potent antitumor activity.
|
-
- HY-173253
-
|
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
E3 Ligase Ligand-linker Conjugate 173 is an E3 Ligase Ligand-Linker Conjugate. E3 Ligase Ligand-linker Conjugate 173 can be used to synthesize YN14-H (HY-173250) to induce apoptosis and inhibits migration, and exert antitumor activity in vivo .
|
-
- HY-146040
-
|
|
Apoptosis
|
Cancer
|
|
Anticancer agent 47 (compound 4j) is a potent anticancer agent. Anticancer agent 47 shows antiproliferative activities. Anticancer agent 47 induces apoptosis and cell cycle arrest at G0/G1 phase. Anticancer agent 47 shows shows antitumor activities in vivo .
|
-
- HY-152437
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Amino-3’-deoxy-5-methyl uridine, Anticancer antiviral agent is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154135
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-3’-fluoro-xylo-N6-(p-methoxybenzyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-145584A
-
|
JPI-547/OCN-201 hydrochloride
|
PARP
Wnt
β-catenin
|
Cancer
|
|
Nesuparib (JPI-547) hydrochloride is the orally active inhibitor for PARP 1/2 and Tankyrase 1/2 that inhibits tankyrases 1, tankyrases 2, and PARP 1 with IC50s of 5, 1 and 2 nM, respectively. Nesuparib hydrochloride exhibits antitumor activity and can be used in research of advanced solid tumor .
|
-
- HY-154375
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-iodo-2’-O-methyl-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-159489
-
|
|
SHP2
|
Cancer
|
|
SDUY038 is a SHP2 allosteric inhibitor, with an IC50 of 1.2 μM and KD of 0.29 μM, respectively. SDUY038 exhibits pan-antitumor activity (IC50 = 7-24 μM) by suppressing pERK expression. SDUY038 exhibits t1/2 of 3.95 h by oral administration .
|
-
- HY-152404
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-3’-fluoro-xylo-N6-(m-methoxybenzyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N6949R
-
-
- HY-154236
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-3’,5’-bis-O-TBDMS-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-157443
-
|
|
Wee1
|
Cancer
|
|
Myt1-IN-4 (21) is an orally active and selective membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor, with an IC50 of 2.6 nM. Myt1-IN-4 (21) possesses antitumor activity .
|
-
- HY-154045
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-1,2-O-isopropylidene-5-O-(p-toluoyl)-L-arabinofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154290
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3,5-Dimethyl-2’-O-(2-methoxyethyl) uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-43426
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
(R)-5-O-Benzoyl-1,2-di-O-isopropylidene-alpha-D-xylofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152380
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1,2,4-Triazine-3,5-dione 2-β-D-xylopyranoside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154512
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-N4,N4-dimethyl-5-fluorocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-163737
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
ST-401, a microtubule-targeting agent (MTA), is a brain-penetrant microtubule (MT) assembly inhibitor. ST-401 disrupts microtubule (MT) function through gentle and reverisible reduction in MT assembly that triggers mitotic delay and cell death in interphase. ST-401 shows a potent antitumor activity .
|
-
- HY-155492
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
ERα degrader 7 (compound B1) is a potent ERα degrader with an IC50 of 14.6 nM and a DC50 of 9.7 nM, respectively. ERα degrader 7 shows excellent antitumor activity, indicating its potential to evolve as a promising selective estrogen-receptor degrader (SERD) for breast cancer research .
|
-
- HY-101494
-
|
LY3214996
|
ERK
|
Cancer
|
|
Temuterkib (LY3214996) is a highly selective inhibitor of ERK1 and ERK2, with IC50 of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.
|
-
- HY-152347
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-Amino-3’-deoxy-7,8-dihydro-8-oxoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-157148
-
|
|
c-Met/HGFR
Trk Receptor
|
Cancer
|
|
1D228 is a c-Met/TRK inhibitor with antitumor activity. 1D228 inhibits cyclin D1 to induce G0/G1 arrest and inhibit cancer cell proliferation and migration. 1D228 can be used in the study of gastric, liver and vascular tumors .
|
-
- HY-152579
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-(1-Piperazinyl)-9-β-D-ribofuranosyl-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154542
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-Acetyl-2’,3’-dideoxy-2’,3’-didehydro-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152878
-
|
NSC 529488
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-1-β-D-arabinofuranosyl-4(1H)-pyrimidinone is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152572
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-(4-Morpholinyl)-9-β-D-ribofuranosyl-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154222
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
5’-O-DMTr-2’,2’-difluoro-dC(Bz)-3’-CED-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N6656R
-
|
|
Fungal
Reference Standards
Bacterial
|
Inflammation/Immunology
Cancer
|
|
6-Hydroxycoumarin (Standard) is the analytical standard of 6-Hydroxycoumarin (HY-N6656). This product is intended for research and analytical applications. 6-Hydroxycoumarin is a coumarin which has anti-inflammatory, anti-pyretic, anti-oxidant, vasodilator, anti-amoebic, anti-bacterial, anti-fungal, bacteriostatic and antitumor activity .
|
-
- HY-W555583
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,5’-Di-O-acetyl-2’-deoxy-2’-fluoro-5-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W556276
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,4-Anhydro-2,3-di-O-isopropylidene-4-thio-D-ribitol is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152824
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
(R)-N-(2,3-Dihydro-1H-indenyl)-2-amino adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-112581S
-
|
|
Isotope-Labeled Compounds
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Methoxyuridine-d3 is the deuterium labeled 5-Methoxyuridine (HY-112581). 5-Methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-B0508S
-
|
Ro 7-0207-d5
|
Isotope-Labeled Compounds
Bacterial
Parasite
Antibiotic
Hedgehog
|
Infection
Cancer
|
|
Ornidazole-d5 is deuterium labeled Ornidazole. Ornidazole (Ro 7-0207) is a nitroimidazole derivative with anti-trichomonad activity and in vitro activity against a variety of anaerobic bacteria. Ornidazole inhibits Sonic hedgehog (Shh) signaling pathway, exhibits antitumor activity. Ornidazole can be used in research of Crohn’s disease .
|
-
- HY-155526
-
|
|
Histone Demethylase
|
Cancer
|
|
FY-21 is a selective inhibitor of LSD1 (IC50=340 nM), with anti-proliferation and anti-colony formation activities. FY-21 enhances p53 expression, down-regulates HOXA9 and MEIS1 expression. FY-21 also induces leukemia cell differentiation to exhibts antitumor activity .
|
-
- HY-151066
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BMS-1233 is an orally active inhibitor for programmed cell death-ligand 1 (PD-L1), with IC50 of 14.5 nM. BMS-1233 promotes cell death of HepG2 in a Jurkat T cell and HepG2 cell co-culture model, exhibits antitumor activity against melanoma in mouse model .
|
-
- HY-19564
-
|
|
PDHK
Apoptosis
|
Cancer
|
|
JX06 is a potent, selective and covalent inhibitor of PDK. JX06 inhibits PDK1, PDK2 and PDK3 with IC50s of 49 nM, 101 nM, and 313 nM, respectively. JX06 inhibits PDK1 activity via covalently binding to a cysteine residue in an irreversible manner. JX06 shows significant antitumor activity .
|
-
- HY-114233
-
|
MC-GGFG-DX8951
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
MC-GGFG-Exatecan (MC-GGFG-DX8951) is a agent-linker conjugate for ADC. MC-GGFG-Exatecan is a DX8951 (a DNA topoisomerase I inhibitor) derivative with protease cleavable MC-GGFG linker. MC-GGFG-Exatecan shows antitumor activity and can be used to prepare DX8951 antibody conjugate (ADC) .
|
-
- HY-W394793
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-6-chloropurine-9-beta-D-(2’-deoxy)riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-10981S2
-
|
E7080-15N,d4
|
VEGFR
c-Kit
FGFR
RET
PDGFR
Isotope-Labeled Compounds
|
Cancer
|
|
Lenvatinib- 15N,d4 is 15N and deuterated labeled Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
|
-
- HY-154264
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
5’-O-DMTr-N6-ethyl-2’-deoxyadenosine 3’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-123587
-
|
|
Proteasome
Apoptosis
|
Cancer
|
|
PR-924 is a selective tripeptide epoxyketone immunoproteasome subunit LMP-7 inhibitor with an IC50 of 22 nM. PR-924 covalently modifies proteasomal N-terminal threonine active sites. PR-924 inhibits growth and triggers apoptosis in multiple myeloma (MM) cells. PR-924 has antitumor activities .
|
-
- HY-154424
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Amino-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2′-Amino-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxyuridine](//file.medchemexpress.com/product_pic/hy-154424.gif)
- HY-154490
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(Furan-2-yl)-2’-O-methyl-5’-O-DMTr-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-173141
-
|
|
mTOR
|
Cancer
|
|
mTOR inhibitor-26 (Compound HPT-11) is an inhibitor of mTOR with an IC50 of 0.7 nM. It effectively inhibits the proliferation of AML cell lines Molm-13 and MV-4-11. mTOR inhibitor-26 exhibits antitumor activity and favorable metabolic stability, making it a promising candidate for cancer research .
|
-
- HY-100789
-
|
|
Apoptosis
Polo-like Kinase (PLK)
Mitosis
|
Cancer
|
|
ON1231320 is a highly specific polo like kinase 2 (PLK2) inhibitor with an IC50 of 0.31 μM. ON1231320 blocks tumor cell cycle progression in the G2/M phase in mitosis, causing apoptotic cell death. ON1231320, an arylsulfonyl pyrido-pyrimidinone, has antitumor activity .
|
-
- HY-141523
-
|
RMC-4630; SHP2-IN-7
|
SHP2
Phosphatase
|
Cancer
|
|
Vociprotafib (RMC-4630) is an orally active, selective and potent phosphatase SHP2 inhibitor, which blocks activation of the RAS-RAF-MEK-ERK signaling pathway with antitumor activity. Vociprotafib accelerates the time to, and increases the magnitude of, tumor regressions in Osimertinib (HY-15772)-sensitive EGFR-mutant tumors of mice .
|
-
- HY-154683
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3',5'-Di-O-benzoyl-2'-deoxy-2'-fluoro-beta-D-arabinocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154654
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(2-β-C-Methyl-2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154583
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,5’-Bis-O-benzoyl-2’-deoxy-2’-fluoro-β-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154154
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3,5-Bis-O-(4-methylbenzoyl)-2-C-methyl-D-ribonic acid gama-lactone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W011577
-
|
Dibenz[a,c]anthracene
|
Photosensitizer
|
|
|
Benzo[f]tetraphene (Dibenz[a,c]anthracene) is a polycyclic aromatic hydrocarbon with significant antitumor activity. Benzo[f]tetraphene is used as a luminescent probe in cell biology research and can effectively detect reactive oxygen species in biological systems. Benzo[f]tetraphene can also be used as a potential photosensitizer and shows good application prospects in photodynamic inhibition.
|
-
![Benzo[f]tetraphene](//file.medchemexpress.com/product_pic/hy-w011577.gif)
- HY-121893
-
|
|
MDM-2/p53
NF-κB
|
Cancer
|
|
p53-MDM2-IN-3 (Compound 5s) is an orally active p53-MDM2 inhibitor with a Ki value of 0.25 μM. p53-MDM2-IN-3 exerts antitumor activity by inhibiting NF-κB pathway .
|
-
- HY-154229
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
3’-O-DMT-N2-isobutyryl-2’-O-(2-methoxyethyl)guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154543
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-(4,4’-Dimethoxytrityl)-3’-O-(2-methoxyethyl) uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154681
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N3-[(pyrid-4-yl)methyl]uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2’-Deoxy-2’-fluoro-N3-[(pyrid-4-yl)methyl]uridine](//file.medchemexpress.com/product_pic/hy-154681.gif)
- HY-162380
-
|
|
Topoisomerase
|
Cancer
|
|
Topoisomerase II inhibitor 18 (Compound IV) is a Quinoxaline derivative, which inhibits topoisomerase II with IC50 of 7.5 μM. Topoisomerase II inhibitor 18 inhibits proliferation, cell cycle at S phase and induces apoptosis in PC-3 cells. Topoisomerase II inhibitor 18 reveals antitumor activity against cancer .
|
-
- HY-172280C
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG3400-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG3400-Octreotide can be used for drug delivery .
|
-
- HY-154571
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-acetyl-6-S-methyl-6-thio-guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154611
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-5-methyl-4’-thio-a-D-arabino uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152423
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-α-C-methyl-N6,N6-dimethyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-155249
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
KGP591 is a tubulin polymerization inhibitor (IC50 0.57 µM). KGP591 induces significant G2/M stagnation, inhibits cell migration, disrupts microtubule structure and cell morphology in MDA-MB-231 cells. KGP591 shows antitumor activity in orthotopic model of kidney cancer (RENCA) .
|
-
- HY-N0284
-
|
|
PI3K
Akt
|
Inflammation/Immunology
Cancer
|
|
Esculetin is an active ingredient extracted mainly from the bark of Fraxinus rhynchophylla. Esculetin inhibits platelet-derived growth factor (PDGF)-induced airway smooth muscle cells (ASMCs) phenotype switching through inhibition of PI3K/Akt pathway. Esculetin has antioxidant, antiinflammatory, and antitumor activities .
|
-
- HY-154721
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
5’-O-DMTr-5-iodo-2’-dU-3’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N0697R
-
|
Crocin I (Standard)
|
Reference Standards
Endogenous Metabolite
JAK
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Crocin (Standard) is the analytical standard of Crocin. This product is intended for research and analytical applications. Crocin (Crocin I) is an orally active natural product that can be isolated from the stigma of Crocus sativus. Crocin inhibits tumor cell proliferation and promotes apoptosis through JAK pathway. Crocin has anti-inflammatory, antioxidant and antitumor activities .
|
-
- HY-154720
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3-O-Benzoyl-1,2: 5,6-bis(di-O-isopropylidene)-alpha-D-galactofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154117
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',3',5'-Tri-O-benzoyl-2'-beta-C-methyl-6-azauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152695
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Methoxy purine-9-beta-D-(3’-deoxy-3’-fluoro)riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N6748
-
-
- HY-154562
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,5’-Di-O-acetyl-2’-deoxy-5,N3-dimethyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154223
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
5'-O-(4,4'-Dimethoxytrityl)-2'-O-methyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154365
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-(4,4’-Dimethoxy trityl)-2’-O-(2-methoxyethyl) inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-126083
-
|
Wortmannin-17β-ol
|
PI3K
|
Others
Cancer
|
|
17β-Hydroxywortmannin (Wortmannin-17β-ol) is an orally active inhibitor for phosphatidylinositol-3-kinase (PI-3-kinase) with an IC50 of 0.5 nM, suppresses the osteoclast resorption with an IC50 of 10 nM . 17β-Hydroxywortmannin exhibits antitumor activity .
|
-
- HY-152604
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3,4-Dihydro-3-oxo-4-β-D-ribofuranosyl-2-pyrazinecarboxamide is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-161768
-
|
|
CDK
Apoptosis
|
Cancer
|
|
VCC972839:01 is an inhibitor for cyclin dependent kinase (CDK9), with IC50 of 7 nM. VCC972839:01 inhibits the cell viability of SCLC cells in nanomolar levels. VCC972839:01 induces apoptosis through an intrinsic pathway. VCC972839:01 exhibits antitumor activity in mouse model .
|
-
- HY-154449
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-3’-O-(2-methoxyethyl)-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W357137
-
|
(3R,4S)-3,4-Dihydroxyoxolan-2-one
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
L-Threonolactone ((3R,4S)-3,4-Dihydroxyoxolan-2-one) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P991665
-
|
OBT357NF; OBT357
|
Transmembrane Glycoprotein
|
Cancer
|
|
MEN1112 (OBT357NF) is a selective humanized monoclonal antibody targeting the Bst1/CD157 antigen (EC50=1 nM). MEN1112 exerts potent antitumor activity against acute myeloid leukemia (AML) cells. MEN1112 is promising for research of hematological malignancies such as AML .
|
-
- HY-154718
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-6-chloropurine-3’,5’-di-O-acetyl-2’-deoxyriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-125037
-
|
|
Estrogen Receptor/ERR
HSP
|
Cancer
|
|
Diptoindonesin G is a 2-arylbenzofuran derivative and a modulator of estrogen receptor and HSP90 middle domain. Diptoindonesin G exhibits strong cytotoxicity against mouse leukemia P-388 cells with an IC50 of 13.2 μM. Diptoindonesin G has antitumor activity and can be used in the research of tumors such as breast cancer .
|
-
- HY-N6031
-
-
- HY-179679
-
|
|
FAK
Apoptosis
|
Cancer
|
|
FAK-IN-29 is a selective FAK inhibitor with an IC50 of 0.5 nM. FAK-IN-29 can inhibit the proliferation and colony formation of MDA-MB-231 cells, and induce cell cycle arrest and apoptosis. FAK-IN-29 exhibits antitumor activity and can be used for the research of tumors such as triple-negative breast cancer .
|
-
- HY-B0578
-
|
|
COX
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Loxoprofen is a non-steroidal, orally active anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen is a nonselective COX inhibitor with IC50s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively. Loxoprofen can reduce atherosclerosis and shows antitumor activity .
|
-
- HY-154592
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
DMTr-TNA-G(O6-CONPh2)(N2Ac)-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-13703A
-
|
ACNU
|
DNA Alkylator/Crosslinker
DNA/RNA Synthesis
Apoptosis
p38 MAPK
JNK
AP-1
|
Cancer
|
|
Nimustine hydrochloride (ACNU) is the hydrochloride salt form of Nimustine (HY-13703). Nimustine hydrochloride is an alkylating agent, which induces DNA double-strand breaks (DSBs) and inter-strand crosslinks (ICLs), thereby activating the DNA damage response (DDR) signaling pathway. Nimustine hydrochloride activates p38 MAPK/JNK signaling pathway, and exhibits antitumor activity .
|
-
- HY-122753
-
|
|
MDM-2/p53
|
Cancer
|
|
SLMP53-1 is a wild-type and mutant p53 reactivator with promising antitumor activity. SLMP53-1 mediates the reprograming of glucose metabolism in cancer cells. SLMP53-1 depletes angiogenesis, decreasing endothelial cell tube formation and vascular endothelial growth factor (VEGF) expression levels .
|
-
- HY-154030
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
N6-Benzoyl-3'-deoxy-5'-O-DMT-3'-fluoroadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-116248
-
|
|
RAR/RXR
Apoptosis
|
Cancer
|
|
Ro 41-5253 is an orally active selective retinoic acid receptor alpha (RARα) antagonist. Ro 41-5253 can bind RARα without inducing transcription or affecting RAR/RXR heterodimerization and DNA binding. Ro 41-5253 can inhibit cancer cell proliferation and induce apoptosis, has antitumor activity .
|
-
- HY-172280B
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG5000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG5000-Octreotide can be used for drug delivery .
|
-
- HY-W711474
-
|
|
Isotope-Labeled Compounds
TRP Channel
Endogenous Metabolite
|
Cancer
|
|
(-)-Menthol-d4 is the deuterium labeled (-)-Menthol (HY-75161). (-)-Menthol is a key component of peppermint oil that binds and activates transient receptor potential melastatin 8 (TRPM8), a Ca2+-permeable nonselective cation channel, to increase [Ca2+]i . Antitumor activity .
|
-
- HY-154061
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-benzoyl-2’-β-C-methyl-5-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-144894
-
|
|
Kinesin
Microtubule/Tubulin
|
Cancer
|
|
AM-5308 is the inhibitor for KIF18A (IC50=47 nM) that inhibits KIF18A-mediated microtubule ATPase activity. AM-5308 activates mitotic checkpoints, regulates cell division processes, including chromosome segregation and spindle assembly. AM-5308 exhibits antitumor activity .
|
-
- HY-149451
-
|
|
RET
VEGFR
c-Myc
|
Cancer
|
|
SYHA1815 is an orally active RET inhibitor (IC50=0.9 nmol/L) with antitumor activity. SYHA1815 is more selective for RET than KDR (IC50=15.9 nmol/L). SYHA1815 arrests the G1 cell cycle and inhibits RET-driven cell proliferation by downregulating c-Myc .
|
-
- HY-P1613A
-
|
Cyclo(RGDfV) TFA; C(RGDfV) TFA
|
Integrin
Apoptosis
|
Cancer
|
|
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .
|
-
- HY-168864
-
|
|
Ligands for Target Protein for PROTAC
HDAC
|
Cancer
|
|
POI ligand 1 is a template for the non-selective HDAC inhibitor Vorinostat (HY-10221). POI ligand 1 can serve as a ligand for target protein (Ligands for Target Protein for PROTAC) for the development of PROTAC HDAC degraders with antitumor activity. POI ligand 1 can be used for the synthesis of FF2049 (HY-168863) .
|
-
- HY-109189
-
|
BPI-7711
|
EGFR
|
Cancer
|
|
Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib exhibits high potency against the common activation EGFR and the resistance T790M mutations. Rezivertinib has excellent central nervous system (CNS) penetration and has antitumor activity .
|
-
- HY-154581
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(Furan-2-yl)-2’-O-methyl-5’-O-DMTr-cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154035
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Acetyl-5’-O-(4,4’-dimethoxytrityl)-2’-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154302
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-(4,4’-Dimethoxytrityl)-3’-O-levulinyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-B0578A
-
|
|
COX
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Loxoprofen sodium is a non-steroidal, orally active anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen sodium is a nonselective COX inhibitor with IC50s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively. Loxoprofen sodium can reduce atherosclerosis and shows antitumor activity .
|
-
- HY-119044
-
|
KT-6149
|
Drug Derivative
DNA Alkylator/Crosslinker
|
Cancer
|
|
KW-2149 (KT-6149) is a Mitomycin C (HY-13316) analogue activated by serum. KW-2149 can interact with DNA. KW-2149 exhibits antitumor activity. KW-2149 has pulmonary toxicity KW-2149 can be used for the research of cancer, such as leukemia .
|
-
- HY-181142
-
|
|
EGFR
Apoptosis
|
Cancer
|
|
Antitumor agent-213 is an antitumor agent. Antitumor agent-213 binds to epidermal growth factor receptor (EGFR) and shows antitumor activity. Antitumor agent-213 can inhibit cancer cells proliferation, migration and induces apoptosis. Antitumor agent-213 can be used for the research of cancer, such as liver cancer .
|
-
- HY-172280A
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG21000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG2000-Octreotide can be used for drug delivery .
|
-
- HY-44220
-
|
5-O-Benzoyl-1,2-O-(1-methylethylidene)pentofuranos-3-ulose
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-O-Benzoyl-1,2-di-O-isopropylidene-3-keto-alpha-D-xylofuranoside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-172280
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG1000-Octreotide can be used for drug delivery .
|
-
- HY-75161R
-
|
|
Reference Standards
TRP Channel
Endogenous Metabolite
|
Cancer
|
|
(-)-Menthol (Standard) is the analytical standard of (-)-Menthol. This product is intended for research and analytical applications. (-)-Menthol is a key component of peppermint oil that binds and activates transient receptor potential melastatin 8 (TRPM8), a Ca2+-permeable nonselective cation channel, to increase [Ca2+]i . Antitumor activity .
|
-
- HY-B0497CR
-
|
BAY2353 olamine (Standard)
|
Reference Standards
STAT
Parasite
Antibiotic
|
Infection
Cancer
|
|
Crocin (Standard) is the analytical standard of Crocin. This product is intended for research and analytical applications. Crocin (Crocin I) is an orally active natural product that can be isolated from the stigma of Crocus sativus. Crocin inhibits tumor cell proliferation and promotes apoptosis through JAK pathway. Crocin has anti-inflammatory, antioxidant and antitumor activities .
|
-
- HY-154057
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(2,3,5-Tri-O-benzyl-beta-D-ribofuranosyl)-2(1H)-pyridinone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154145
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-benzoyl-2’-β-C-methyl-5-methoxy uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N0750
-
|
Crotaline
|
Others
|
Infection
Metabolic Disease
Cancer
|
Monocrotaline is an 11-membered macrocyclic pyrrolizidine alkaloid. Monocrotaline inhibits OCT-1 and OCT-2 with IC50s of 36.8 µM and 1.8 mM, respectively. Monocrotaline has antitumor activity and is cytotoxic to hepatocellular carcinoma cells. Monocrotaline is used to induce a model of pulmonary hypertension in rodents. [2][6][8].
|
-
- HY-152532
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-6-S-Methyl-6-thio-ara-guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154359
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Acetyl-3’,5’-bis-O-benzoyl-6-aza-xylo uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-176907
-
|
|
E1/E2/E3 Enzyme
|
Cancer
|
|
ML-93 is an orally active SAE inhibitor, with an IC50 value of 0.4 μM. ML-93 inhibits the SUMOylation pathway in HCT116 cells. ML-93 shows robust antitumor activity in the HCT116 colorectal carcinoma xenograft model. ML-93 can be used for the study of colorectal cancer .
|
-
- HY-172395
-
|
|
Microtubule/Tubulin
Topoisomerase
Apoptosis
Reactive Oxygen Species (ROS)
|
Cancer
|
|
TopoII/tubulin-IN-1 (Compound 1B8) is a TopoII/tubulin inhibitor. TopoII/tubulin-IN-1 can inhibit the proliferation and the level of ROS of tumor cells, induce apoptosis and cell cycle arrest of tumor cells, but has no significant cytotoxicity to normal cells. TopoII/tubulin-IN-1 has antitumor activity .
|
-
- HY-154426
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Di-O-acetyl-8-benzyloxy-3’-deoxy-3’-fluoroguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152605
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-6-S-methyl-6-thio-arabino-inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W286906
-
|
|
Bcl-2 Family
Apoptosis
|
Cancer
|
|
Mcl1-IN-15 (Compound 7) is the inhibitor for myeloid cell leukemia 1 (Mcl-1) with an IC50 of 8.73 μM. Mcl1-IN-15 inhibits Mcl1-BH3 peptide interaction, activates the Bak/Bax-mediated apoptosis and exhibits antitumor activity .
|
-
- HY-154056
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-benzoyl-2’-β-C-methyl-3-deazauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-108713
-
|
SHR1020
|
VEGFR
PDGFR
Apoptosis
|
Cancer
|
|
Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively . Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis .
|
-
- HY-137052
-
|
N-Methyllycorine iodide
|
Drug Derivative
|
Cancer
|
|
Lycorine methiodide (N-Methyllycorine iodide) is a derivative of Lycorine (HY-N0288). Lycorine methiodide exhibits no significant in vitro antitumor activity against A549, OE21, Hs683, U373, SKMEL, and B16F10 cell lines, with all IC50 values greater than 10 μM .
|
-
- HY-132175
-
|
|
Casein Kinase
|
Cancer
|
|
CK2 inhibitor 2 is a potent, selective and orally active inhibitor of CK2, with an IC50 of 0.66 nM. CK2 inhibitor 2 shows high selectivity for Clk2 (IC50=32.69 nM)/CK2. CK2 inhibitor 2 exhibits favorable antiproliferative and antitumor activity .
|
-
- HY-W710422
-
|
|
Biochemical Assay Reagents
|
Others
|
|
1-O-Octadecyl-2-O-benzyl-rac-glycerol is a diacylglycerol that contains octadecyl alcohol at the sn-1 and benzyl alcohol at the sn-3 position. It is used in the synthesis of alkylphospholipids containing modifications of the phosphocholine moiety with antitumor activities. The hydroxyl group enables further derivatization or replacement with other reactive functional groups.
|
-
- HY-P991588
-
|
AC101
|
EGFR
Apoptosis
|
Cancer
|
|
HLX-22 is a humanized monoclonal antibody targeting HER2. HLX-22 induces apoptosis in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab (HY-P9907). HLX-22 has potent antitumor activity against advanced solid tumors .
|
-
- HY-N0750R
-
|
Crotaline (Standard)
|
Reference Standards
Others
|
Metabolic Disease
Cancer
|
Monocrotaline is an 11-membered macrocyclic pyrrolizidine alkaloid. Monocrotaline inhibits OCT-1 and OCT-2 with IC50s of 36.8 µM and 1.8 mM, respectively. Monocrotaline has antitumor activity and is cytotoxic to hepatocellular carcinoma cells. Monocrotaline is used to induce a model of pulmonary hypertension in rodents. .
|
-
- HY-124657
-
|
|
JAK
Apoptosis
|
Cancer
|
|
PRN-371 is a potent and selective JAK3 inhibitor. PRN371 effectively suppresses natural killer/T-cell lymphoma cell proliferation and induces apoptosis through abrogation of the JAK3-STAT signaling. PRN-371 exhibits antitumor activity and can be used for the research of cancer, such as hematological malignancies .
|
-
- HY-10824A
-
|
PT523 monoammonium
|
Dihydrofolate reductase (DHFR)
Antifolate
|
Cancer
|
|
Talotrexin monoammonium is the monoammonium salt form of Talotrexin (HY-10824). Talotrexin monoammonium is an analog of Aminopterin (HY-14518), and is a nonpolyglutamatable classic antifolate. Talotrexin monoammonium is a reduced folate carrier (RFC) specific inhibitor and selectively inhibits RFC transport. Talotrexin monoammonium shows antitumor activity by targeting DHFR to inhibit tumor growth .
|
-
- HY-162230
-
|
|
Apoptosis
Histone Methyltransferase
|
Cancer
|
|
PRMT5-IN-33 (compound A8) is a selective, SAM-competitve PRMT5 inhibitors with IC50 of 10.9 nM. PRMT5-IN-33 induces apoptosis and inhibits proliferation of cells Z-138 and MOLM-13. PRMT5-IN-33 exhibits an antitumor activity .
|
-
- HY-115993
-
|
|
CDK
Apoptosis
|
Cancer
|
|
CDK4/6-IN-10 is a potent, selective and orally active CDK4 and CDK6 inhibitor with IC50s of 22 nM and 10 nM, respectively. CDK4/6-IN-10 shows antitumor activity. CDK4/6-IN-10 has the potential for the research of Multiple myeloma (MM) .
|
-
- HY-12458
-
|
|
DNA/RNA Synthesis
|
Infection
Cancer
|
|
Pyrindamycin A is an antibiotic that inhibits DNA synthesis. Pyrindamycin A shows antitumor activities against murine leukemia, exhibits stronger cytotoxic activities towards murine and human tumor cell lines and especially towards doxorubicin-resistant cells, inhibits P388 and P388/ADR cells with the same IC50 of 3.9 μg/ml .
|
-
- HY-159503A
-
|
3D185; HH185
|
FGFR
c-Fms
|
Cancer
|
|
Segigratinib hydrochloride (3D185) is a potent inhibitor of FGFR1/2/3 and CSF-1R; The IC50 values for FGFR1, FGFR2, FGFR3 and CSF-1R are 0.5, 1.3, 3.6 and 3.8 nM, respectively. Segigratinib hydrochloride has antitumor activity .
|
-
- HY-W240322
-
|
|
Apoptosis
|
Cancer
|
|
PSF-IN-1 (Compound No.10-3) is a RNA-binding protein (PSF) inhibitor and can effectively inhibit the PSF-RNA interaction (IC50: 2.2 pM). PSF-IN-1 can increase histone acetylation, inhibit tumor cell proliferation and induce apoptosis. PSF-IN-1 has antitumor activity .
|
-
- HY-116052
-
|
|
MDM-2/p53
NF-κB
|
Cancer
|
|
p53-MDM2-IN-2 (Compound 5q) is an orally active p53-MDM2 inhibitor with a Ki value of 0.25 μM. p53-MDM2-IN-2 exerts antitumor activity by inhibiting NF-κB pathway .
|
-
- HY-152521
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-6-meThythio-9-(β-D-ribofuranosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-101030A
-
|
|
NEKs
Apoptosis
|
Cancer
|
|
MBM-17S is a potent NIMA-related kinase 2 (Nek2) inhibitor, with an IC50 of 3 nM. MBM-17S effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-17S shows antitumor activities, and no obvious toxicity to mice .
|
-
- HY-P2954
-
|
Polymyxin acylase
|
Biochemical Assay Reagents
|
Cancer
|
|
Polymyxin deacylase (Polymyxin acylase) is an N-myristoyl lyase. Polymyxin deacylase can deacylate polymyxin antibiotics and long-chain fatty acyl groups of proteins and peptides. Polymyxin deacylase exhibits antitumor activity against oral epithelial cancer cells. Polymyxin deacylase can be used in research on oral epithelial cancer and other cancers .
|
-
- HY-W601637
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,2-Di-O-acetyl-5-Benzoyl-3-O-Methyl-D-ribofuranose diacetate is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-113341S
-
-
- HY-146245C
-
-
- HY-120159
-
|
|
SHP2
SHP1
Phosphatase
|
Cancer
|
|
GS-493 is a selective protein tyrosine phosphatase SHP2 (PTPN11) inhibitor with an IC50 of 71 nM. GS-493 is 29- and 45-fold more active toward SHP2 than related SHP1 and PTP1B. GS-493 blocks cellular motility and growth of cancer cells. Antitumor activity .
|
-
- HY-154089
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3-Deoxy-1,2:5,6-bis-O-(1-methylethylidene)-α-D-ribo-hexofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154221
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
N4-Benzoyl-2'-deoxy-5'-O-DMT-2',2'-difluorocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-13645A
-
|
|
VEGFR
c-Kit
PDGFR
|
Cancer
|
|
Henatinib maleate is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities. Henatinib maleate inhibits the activity of VEGFR-2, c-kit, PDGFR with IC50 values of 0.6 nM, 3.3 nM and 41.5 nM, respectively. Henatinib maleate significantly inhibits VEGFR-2 phosphorylation and its downstream signal pathway .
|
-
- HY-156618
-
|
ABSK011
|
FGFR
|
Cancer
|
|
Irpagratinib (ABSK011) is an orally active FGFR4 inhibitor (IC50<10 nM). Irpagratinib inhibits FGFR4 autophosphorylation and blocks signaling from FGFR4 to downstream pathway activation. Irpagratinib has shown high exposure in PK studies in mice, rats, and dogs, and also demonstrated antitumor activity in a subcutaneous xenograft tumor model .
|
-
- HY-79490
-
|
|
ADC Payload
Topoisomerase
|
Cancer
|
|
Ac-Exatecan is acetylation-modified Exatecan (HY-13631). Exatecan is a common toxin component in ADC preparation (ADC cytotoxin) and an inhibitor of DNA topoisomerase I (IC50 = 2.2 μM). Exatecan has antitumor activity. Exatecan can be used as a payload for ADC. Exatecan is effective against P-glycoprotein mediated multi-drug resistant cells .
|
-
- HY-137092
-
|
|
SHP2
Phosphatase
|
Cancer
|
|
IACS-13909 is a selective, potent and orally active SHP2 allosteric inhibitor with an IC50 of 15.7 nM and a Kd of 32 nM. IACS-13909 is more selective for SHP2 than other phosphatases (including SHP1). IACS-13909 has antitumor activities and suppresses MAPK pathway signaling in receptor tyrosine kinases (RTK)-dependent cancers .
|
-
- HY-10971A
-
|
MLN 8237 sodium
|
Aurora Kinase
Autophagy
Apoptosis
|
Cancer
|
|
Alisertib (MLN 8237) sodium is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib sodium induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
|
-
- HY-152372
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Methyl 6-amino-9-β-D-ribofuranosyl-9H-purine-2-carboxylate is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P0036A
-
|
SMS 201-995 dihydrochloride
|
Somatostatin Receptor
Apoptosis
|
Inflammation/Immunology
Endocrinology
Cancer
|
|
Octreotide (SMS 201-995) hydrochloride is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide hydrochloride can bind to the somatostatin receptors which are mainly subtypes 2, 3 and 5. Octreotide hydrochloride increases Gi activity and reduces intracellular cAMP production. Octreotide hydrochloride has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .
|
-
- HY-162462
-
|
|
Apoptosis
|
Cancer
|
Antitumor agent-151 (7k) is a significant HsClpP agonist and an antileukemia drug candidate. Antitumor agent-151 (7k) exhibits remarkably enhanced proteolytic activity of HsClpP (EC50 = 0.79 μM) and antitumor activity in vitro (IC50 = 0.038 μM). Antitumor agent-151 (7k) induces apoptosis .
|
-
- HY-152348
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-5-methyl-4’-thio-β-D-arabino uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154601
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-5’-O-(4,4-dimethoxytrityl)-3’-deoxy cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154628
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
N2-iBu-5’-O-DMTr-2’-O-hexadecanyl guanosine 3’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152734
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-(pyridine-4-yl)purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152491
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-Cyclopropyl methyl-7,8-dihydro-8-oxo-9-(β-D-ribofuranosyl)guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154555
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-Acetyl-2’,3’-dideoxy-2’,3’-didehydro-5-fluoro-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154384
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-iodo-2’-O-(2-methoxyethyl)-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-176252
-
|
|
Apoptosis
|
Cancer
|
|
CALR ligand 1 (Compound 2a) is a calreticulin (CALR) ligand. CALR ligand 1 shows antitumor activity against triple-negative breast cancer (TNBC) cells (IC50=0.1 μM). CALR ligand 1 induces intracellular calcium overloading and triggers apoptosis in TNBC cells. CALR ligand 1 is promising for research of TNBC .
|
-
- HY-154477
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-6-chloro-9-(3-deoxy-beta-D-ribofuanosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N6961
-
|
|
Dihydroorotate Dehydrogenase
DNA/RNA Synthesis
Parasite
|
Infection
Inflammation/Immunology
Cancer
|
|
Lapachol, a natural naphthoquinone, is an orally active, potent DHODH inhibitor. Lapachol has immunosuppressive activity on lymphocytes through its direct ability to block DHODH activity and inhibit pyrimidine synthesis. Lapachol is a vitamin K antagonist with antitumor activity and can inhibit DNA and RNA synthesis in neoplastic cells. Lapachol has anti-Leishmania activity .
|
-
- HY-154439
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-β-Amino-2’,3’-dideoxy-5’-O-trityl-5-methyl uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154416
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(2,3,5-Tri-O-benzyl-beta-D-ribofuranosyl)-3-methyl-2-benzyloxypyridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154260
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
N6-Benzoyl-3'-O-DMT-2'-O-(2-methoxyethyl) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154342
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
N1-Ethyl-2’-O-TBDMS-5’-O-DMTr-3’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-108705
-
BI-3802
3 Publications Verification
|
Molecular Glues
Bcl-2 Family
|
Cancer
|
|
BI-3802, a chemical probe, is a highly potent BCL6 degrader and inhibits the Bric-à-brac (BTB) domain of BCL6 with an IC50 of ≤3 nM. BI-3802 induces the polymerization of BCL6 and promotes BCL6 degration depended on E3 ligase SIAH1. BI-3802 has antitumor activity .
|
-
- HY-N13162
-
|
|
Others
|
Cancer
|
|
Hemsleyadin D is a triterpenoid compound derived from Hemsleya penxianensis with antitumor activity. Its IC50 values against K562, MGC-803, U118, HepG2, A549, and MCF-7 cells are 93.9, 47.1, 25.9, 56.1, 66.3, and 67.6 μM, respectively .
|
-
- HY-152809
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-(furan-2-yl)purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W004520R
-
|
5-Methylphenazinium methylsulfate (Standard)
|
Reference Standards
Bacterial
Antibiotic
Apoptosis
|
Cancer
|
|
Phenazine (methylsulfate) (Standard) is the analytical standard of Phenazine (methylsulfate). This product is intended for research and analytical applications. Phenazine methylsulfate is a free radical generator that can act as an electron transfer reactant in cell viability assays. It also has insecticidal properties. Furthermore, Phenazine methylsulfate induces oxidative DNA damage and cell apoptosis, showing antitumor activity[1][2][3].
|
-
- HY-152331
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
7-n-Propyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-162783
-
|
|
Histone Methyltransferase
|
Cancer
|
|
AZ-PRMT5i-1 (Compound 28) is an effective and orally active MTAP-selective PRMT5 inhibitor. AZ-PRMT5i-1 also demonstrates MTA cooperativity and exhibits both in vitro and in vivo antitumor activities, and can be used to study MTAP-deficient cancers .
|
-
- HY-152328
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
7-Ethyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154328
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-beta-Azido-2’,3’-dideoxy-5’-O-(4-methoxy-trityl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154315
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3',5'-Bis-O-benzoyl-2'-deoxy-2'-fluoro-4-deoxy-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-176869
-
|
|
Drug Derivative
|
Cancer
|
|
EMC-AANL-DOX is a legumain-activated prodrug conjugate of Doxorubicin (DOX) (HY-15142A). EMC-AANL-DOX shows antitumor activity in mouse models of neuroblastoma (NB), breast cancer (4T1), fibrosarcoma (HT1080), and colorectal cancer liver metastases (CT26). EMC-AANL-DOX can be used for cancer research .
|
-
- HY-152531
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-6-allyl thio-9-(beta-D-ribofuranosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154422
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Amino-2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-149470
-
|
|
Histone Acetyltransferase
|
Cancer
|
|
MOZ-IN-3 (Compound 6j) is a KAT6A (MOZ) acetyltransferase inhibitor (IC50: 30 nM). MOZ-IN-3 has antitumor activity against four different myeloid leukemia cell lines (HL-60, U937, SKNO-1, K562). MOZ-IN-3 has favorable metabolic stability and pharmacokinetics .
|
-
- HY-185585
-
|
|
Drug Intermediate
|
Cancer
|
|
JNJ-27548547, Mitomycin C (HY-13316) prodrug, is a Mitomycin C and lipophilic group conjugate. JNJ-27548547 undergoes thiolytic cleavage of its dithiobenzyl linker in the presence of reducing agents to release active substance Mitomycin C. JNJ-27548547 is formulated into pegylated liposomes (PL-MLP) with high antitumor activity in mice models .
|
-
- HY-152766
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-(Thiophen-3-yl)purine-beta-D-(3’-deoxy-3’-fluoro)riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152297
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
(1S)-1,4-Anhydro-1-C-(2,4-difluorophenyl)-D-ribitol is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N8487
-
|
|
Cytochrome P450
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
7-Methoxyflavone is a flavonoid compound that can be isolated from Zornia brasiliensis. 7-Methoxyflavone can bind to human serum albumin and is an aromatase inhibitor. 7-Methoxyflavone has peripheral analgesic and certain antitumor activities. 7-Methoxyflavone is effective against chemical pain but has no significant effect on thermal pain .
|
-
- HY-50866
-
|
AEW541
|
IGF-1R
Insulin Receptor
Autophagy
|
Endocrinology
Cancer
|
|
NVP-AEW541 (AEW541 ) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC50 value of 0.15 μM. NVP-AEW541 also inhibits InsR, IC50 with a value of 0.14 μM. NVP-AEW541 has antitumor activity .
|
-
- HY-152727
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-(naphthalen-1-yl)purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-118184
-
|
|
PGE synthase
|
Cancer
|
|
AF3485 is a human mPGES-1 inhibitor that exhibits antitumor activity in vitro and in vivo. AF3485 inhibits tumor-associated angiogenesis by reducing PGE2 production, inhibiting EGFR signaling, and decreasing VEGF and FGF-2 expression. AF3485 reduced tumor growth in mice bearing human A431 xenograft tumors by subchronic administration.
|
-
- HY-50866B
-
|
AEW541 dihydrochloride
|
IGF-1R
Insulin Receptor
Autophagy
|
Cancer
|
|
NVP-AEW541 dihydrochloride (AEW541 dihydrochloride) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC50 value of 0.15 μM. NVP-AEW541 dihydrochloride also inhibits InsR, IC50 with a value of 0.14 μM. NVP-AEW541 dihydrochloride has antitumor activity .
|
-
- HY-16200
-
|
ECyD; TAS-106; 3'-C-Ethynylcytidine
|
DNA/RNA Synthesis
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Ethynylcytidine (ECyD), a nucleoside analog and a potent inhibitor of RNA synthesis, inhibits RNA polymerases I, II and II. Ethynylcytidine has robust antitumor activity in a wide range of models of cancer . Ethynylcytidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-147040
-
|
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
ABN401 is an orally active and selective ATP-competitive c-MET inhibitor with an IC50 of 10 nM. ABN401 is cytotoxic to MET-addicted cancer cells with the IC50 of 2-43 nM. ABN401 has bioavailability in rats and dogs of 42.1-56.2% and 27.4-37.7%, respectively. ABN401 has antitumor activity .
|
-
- HY-154593
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-5’-O-DMTr-2’-O-(N3-trifluoroacetyl) aminopropyl cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154686
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(3-β-Azido-2,3-dideoxy-5-O-trityl-D-threopenta-furanosyl)thymine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P991448
-
|
|
Glycoprotein VI
|
Cancer
|
|
MDX-1414 is a human IgG1 monoclonal antibody (mAb) targeting GPC3. MDX-1414 has antitumor activity in the HepG2 xenograft model. MDX-1414 can be used in liver cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P992086
-
|
|
VEGFR
|
Cancer
|
|
Anti-Mouse VEGF Antibody (G6-31) is a anti-mouse VEGF antibody. Anti-Mouse VEGF Antibody (G6-31) blocks VEGF-A-mediated angiogenesis and shows antitumor activity. Anti-Mouse VEGF Antibody (G6-31) can be used for the research of cancer, such as multiple endocrine neoplasia type 1 .
|
-
- HY-W010757
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Chloro-2-iodo-9-(2’,3’,5’-tri-O-acetyl-β-D-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154501
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-O-Benzoyl-1,2,3-tri-O-acetyl-4-C-methyl-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-B0578B
-
|
|
COX
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Loxoprofen sodium dihydrate is a non-steroidal, orally active anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen sodium dihydrate is a nonselective COX inhibitor with IC50s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively. Loxoprofen sodium dihydrate can reduce atherosclerosis and shows antitumor activity .
|
-
- HY-152460
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-N6-cyclopentyl-2’-deoxy-2’-fluoro-beta-D-arabinoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-144872
-
|
|
Drug Derivative
|
Cancer
|
|
RJ-34, an aristolactam analogue, exhibits potent antitumor activities against a broad array of cancer cell lines with GI50 values in the subnanomolar range (GI50 <0.1 nM for A431, MES-SA, MES-SA/DX5, HCT-15, and HCT-15/CLO2 cells) .
|
-
- HY-154207
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
2’-O-Acetyl-N4-benzoyl-5’-O-DMT arabinocytidine 3’-O-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-143411
-
|
|
HDAC
Apoptosis
DNA/RNA Synthesis
|
Cancer
|
|
GEM144 is a potent and orally active DNA polymerase α (POLA1) and HDAC 11 dual inhibitor. GEM144 induces acetylation of p53, activation of p21, G1/S cell cycle arrest, and apoptosis. GEM144 has significant antitumor activity in human orthotopic malignant pleural mesothelioma xenografts .
|
-
- HY-154403
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Azido-2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-148860
-
|
HIF-2α-IN-8
|
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
HIF-2α-IN-8 is a potent and orally active HIF2α inhibitor with IC50 values of 9, 37, 246 nM for HIF2α SPA, HIF2α iScript, HIF2α HRE RGA, respectively. HIF-2α-IN-8 shows antitumor activity .
|
-
- HY-152436
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-Cyclopropylmethyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl) guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154658
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N3-[(pyrid-4-yl)methyl]-beta-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2’-Deoxy-2’-fluoro-N3-[(pyrid-4-yl)methyl]-beta-D-arabinouridine](//file.medchemexpress.com/product_pic/hy-154658.gif)
- HY-154003
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
7-(2-Deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![7-(2-Deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine](//file.medchemexpress.com/product_pic/hy-154003.gif)
- HY-152853
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3-Methyl-5-β-D-ribofuranosyl-2,4(1H,3H)-pyrimidinedione is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-109019R
-
|
CM082 (Standard); X-82 (Standard)
|
Reference Standards
VEGFR
PDGFR
|
Cardiovascular Disease
Cancer
|
|
Vorolanib (Standard) is the analytical standard of Vorolanib (HY-109019). This product is intended for research and analytical applications. Vorolanib (CM082) is an orally active, potent multiKinase VEGFR/PDGFR inhibitor. Vorolanib is a potent ATP-binding cassette (ABC) transporter inhibitor. Vorolanib is an angiogenesis inhibitor and has antitumor activity combined with ZD1839 (HY-50895) .
|
-
- HY-154379
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3',5'-Di-O-acetyl-2'-O-methyl-6-chloro-2-aminopurine riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152381
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,9-Dihydro-9-β-D-xylofuranosyl-6H-purin-6-one is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152154
-
|
|
PROTACs
NAMPT
|
Cancer
|
|
Nampt degrader-2 is a fluorescent PROTAC, which efficiently degrades NAMPT with an IC50 of 41.9 nM. Nampt degrader-2 binds to NAMPT and VHL to form a ternary complex and subsequently induced NAMPT degradation via ubiquitin-proteasome system (UPS). Nampt degrader-2 leads to significant reduction of NAD + and exerts potent antitumor activities .
|
-
- HY-154623
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
N6-Bz-5’-O-DMTr-2’-O-hexadecanyl adenosine 3’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P99711
-
|
RB4v1.2
|
CD19
ADC Antibody
|
Cancer
|
|
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349) .
|
-
- HY-154643
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-9H-purin-2-amine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-174411
-
|
|
Microtubule/Tubulin
MMP
Bcl-2 Family
Reactive Oxygen Species (ROS)
Caspase
|
Cancer
|
|
Tubulin polymerization-IN-82 is a tubulin inhibitor. Tubulin polymerization-IN-82 inhibits cell migration and invasion, and triggers cell apoptosis through the mitochondria and ER stress mediated pathway. Tubulin polymerization-IN-82 exhibits antitumor activity against drug resistance cancer cells, and inhibits tumor growth, can be used for liver cancer research .
|
-
- HY-13617
-
|
CGP 30694
|
Antifolate
|
Cancer
|
|
Edatrexate (CGP 30694), as known as 10-Ethyl-10-deazaaminopterin, is Methotrexate (HY-14519) analog, exhibits antitumor activity against MTX-resistant tumors. Edatrexate is an antifolate antimetabolite, can be used for reasearch of non-small-cell lung cancer, breast cancer, non-Hodgkin's lymphoma, and cancer of the head and neck .
|
-
- HY-154515
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-9-[(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)]-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2-Chloro-9-[(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)]-9H-purine](//file.medchemexpress.com/product_pic/hy-154515.gif)
- HY-152810
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Ami no-9-(2-β-C-methyl-β-D-ribofuranosyl)-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-13680R
-
|
Dian III (Standard); N-Methylisoindigotin (Standard); Natura-α (Standard)
|
Apoptosis
Reference Standards
|
Cancer
|
|
Meisoindigo (Standard) is the analytical standard of Meisoindigo. This product is intended for research and analytical applications. Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity .
|
-
- HY-170326
-
|
|
Ligands for Target Protein for PROTAC
HSP
|
Cancer
|
|
Hsp90-in-35 (Compound 379) is an inhibitor of Hsp90. The IC50 of HSP90-IN-35 for Her2 is between 0.05 and 0.5 μM. HSP90-IN-35 has antitumor activity. HSP90-IN-35 can be used to synthesize PROTAC (HY-153881) .
|
-
- HY-154532
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(5(R)-C-Methyl-2,3,5-tri-O-benzoyl-D-ribofuranosyl)-6-chloropurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-B0508R
-
|
Ro 7-0207 (Standard)
|
Reference Standards
Bacterial
Parasite
Antibiotic
Hedgehog
|
Infection
Cancer
|
|
Ornidazole (Standard) is the analytical standard of Ornidazole. This product is intended for research and analytical applications. Ornidazole (Ro 7-0207) is a nitroimidazole derivative with anti-trichomonad activity and in vitro activity against a variety of anaerobic bacteria. Ornidazole inhibits Sonic hedgehog (Shh) signaling pathway, exhibits antitumor activity. Ornidazole can be used in research of Crohn’s disease .
|
-
- HY-152333
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
7-n-Butyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P9965
-
|
HuLuc 63; PDL 063; BMS 901608
|
Transmembrane Glycoprotein
|
Cancer
|
|
Elotuzumab (HuLuc 63) is an IgG1 monoclonal antibody targeting the SLAMF7 receptor. Elotuzumab exerts antitumor activity by activating natural killer cells and inducing antibody-dependent cell-mediated cytotoxicity. Elotuzumab can be combined with Lenalidomide (HY-A0003), Dexamethasone (HY-14648), etc., for the research of tumors such as multiple myeloma .
|
-
- HY-146245
-
-
- HY-100506R
-
|
|
Integrin
Reference Standards
|
Cancer
|
|
GLPG0187 (Standard) is the analytical standard of GLPG0187 (HY-100506). This product is intended for research and analytical applications. GLPG0187 is a broad spectrum integrin receptor antagonist with antitumor activity; inhibits αvβ1-integrin with an IC50 of 1.3 nM . GLPG0187 inhibits migrasome biogenesis without cytotoxicity .
|
-
- HY-154570
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-N-Acetyl-3’-amino-3’-deoxy-2’,5’-di-O-acetyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-13582S
-
|
|
Isotope-Labeled Compounds
Fungal
|
Infection
Cancer
|
|
Carbendazim-d4 is the deuterium labeled Carbendazim. Carbendazim is a potent and orally active broad-spectrum?benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria,?Fusarium?and?Sclerotina . Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma .
|
-
- HY-152776
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154316
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,5’-Di-O-benzoyl-2’-deoxy-2’-fluoro-3-Deaza-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154265
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-2’-deoxy-N6,N6-dimethyl-2’-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-121716
-
|
Antibiotic 2088A; LL-14I352α
|
Bacterial
|
Cancer
|
|
Pelagiomicin A is a novel phenazine antibiotic produced by the marine bacterium Pelagiobacter variabilis. The compound is unstable in water and small alcohols. The absolute structure of its major component, Pelagiomicin A, as well as the properties of minor amounts of other structures, were determined by spectroscopic data and synthesis. Pelagiomicin A is active against both Gram-positive and Gram-negative bacteria and exhibits antitumor activity in vitro and in vivo.
|
-
- HY-177710
-
|
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
MEDI4276 is a biparatopic tetravalent antibody targeting two nonoverlapping epitopes in subdomains 2 and 4 of the HER2 ecto-domain. MEDI4276 is composed of MEDI4276 Antibody (HY-P991238) and a cytotoxic payload AZ1508 (HY-128962) linked through site-specific coupling. MEDI4276 exhibits antitumor activity .
|
-
- HY-152791
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-methyl-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W061531
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-O-TBDPS-1,2-di-O-isopropy lidene-3-keto-alpha-D-xylofuranoside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-12678
-
|
NMS-E628; RXDX-101
|
ROS Kinase
Trk Receptor
Anaplastic lymphoma kinase (ALK)
Autophagy
|
Cancer
|
|
Entrectinib (NMS-E628) is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC50 values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice .
|
-
- HY-154116
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Chloro-2-hydroxy-9-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-168442
-
|
|
Ras
PERK
|
Cancer
|
|
KRAS inhibitor-40 (Compound 41) is a KRAS inhibitor that interferes with the KRAS G12C-BRAF complex. KRAS inhibitor-40 inhibits the ERK phosphorylation of KRAS downstream signaling pathway. KRAS inhibitor-40 can inhibit the proliferation of tumor cells with different KRAS mutation types and has antitumor activity .
|
-
- HY-146718
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin polymerization-IN-9 is a potent tubulin inhibitor with IC50 of 1.82 μM. Tubulin polymerization-IN-9 causes cell cycle arrest at G2/M phase, and induces cell apoptosis and depolarized mitochondria of K562 cells. Tubulin polymerization-IN-9 has potent anti-vascular and antitumor activities .
|
-
- HY-163119
-
|
|
Pim
|
Cancer
|
|
Pim-1 kinase inhibitor 9 (compound 8b) is a selective inhibitor against Pim-1 kinase with IC50 value of 0.24 µM. Pim-1 kinase inhibitor 9 inhibits cell cycle of T47D at S phase. Pim-1 kinase inhibitor 9 reveals antitumor activity .
|
-
- HY-161821
-
|
|
Interleukin Related
TNF Receptor
MMP
|
Cancer
|
|
Antitumor agent-173 (Compound 4b) is a prodrug of Cycloicaritin (HY-N1940). Antitumor agent-173 is a substrate for OATP2B1. Antitumor agent-173 selectively inhibits the growth of tumor Antitumor agent-173 significantly increases the oral bioavailability of Cycloicaritin and exerts good antitumor activity and safety .
|
-
- HY-N9093
-
|
|
Others
|
Inflammation/Immunology
Cancer
|
|
(3R,5R)-3,5-Diacetoxy-1-(3,4-dihydroxyphenyl)-7-(4-hydroxyphenyl)heptane, a diarylheptanoid from the rhizomes of Curcuma kwangsiensis, possesses a variety of biological and pharmacological activities including antioxidant, antihepa totoxic, anti-inflammatory, antiproliferative, antiemetic, and antitumor activities .
|
-
- HY-154663
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-β-D-Arabinofuranosyl-5-bromo-2,4(1H,3H)-pyrimidinedione is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152690
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Deoxy-2’-fluoro-N3-[(pyrid-2-yl)methyl]-beta-D-arabinouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2’-Deoxy-2’-fluoro-N3-[(pyrid-2-yl)methyl]-beta-D-arabinouridine](//file.medchemexpress.com/product_pic/hy-152690.gif)
- HY-122112
-
|
|
Sigma Receptor
|
Cancer
|
|
CM572 is a selective irreversible partial sigma-2 receptor agonist. CM572 has antitumor activity. CM572 induces dose-dependent cell death, with an EC50 of 7.6 μM in SK-N-SH neuroblastoma cells. CM572 can be used for the research of kinds of diseases such as neuroblastoma, breast cancer .
|
-
- HY-154312
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3,5-Di-O-benzoyl-2-deoxy-2-fluoro-5-trifluoromethyl-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152603
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-1-β-D-arabinofuranosyl-5-methyl-4(1H)-pyrimidinone is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P3116
-
|
|
Bacterial
|
Cancer
|
|
Thiocoraline is a depsipeptide that can be isolated by marine Micromonospora. Thiocoraline has antitumor activity with IC50s of 0.002, 0.002, 0.01 and 0.002 μg/mL in P388, A549, HT-29 and MEL-28 cells, respectively. Thiocoraline also a strong antimicrobial activity against Gram-positive microorganisms .
|
-
- HY-14674
-
|
|
EGFR
Apoptosis
|
Cancer
|
|
CP-724714 is a potent, selective and orally active ErbB2 (HER2) tyrosine kinase inhibitor, with an IC50 of 10 nM. CP-724714 displays a marked selectivity against EGFR kinase (IC50=6400 nM). CP-724714 potently inhibits ErbB2 receptor autophosphorylation in intact cells. Antitumor activities .
|
-
- HY-155039
-
|
|
Drug Derivative
|
Cancer
|
|
Antitumor agent-105 (Compound 37) is an antitumor agent. Antitumor agent-105 has antitumor activity against A549, H1299, H460, HCT116, MDA-MB-231 cells, with IC50 values of 6.7, 8.3, 4.3, 4.4, 6.7 μM respectively .
|
-
- HY-152407
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-Allyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl) guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-155074
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-79 (compound 21) is an EGFR inhibior with antitumor activity. EGFR-IN-79 induces ROS-independent apoptosis and EGFR/AKT/mTOR-mediated autophagy. EGFR-IN-79 induces cell death at both proliferating and quiescent zones of EJ28 spheroids. EGFR-IN-79 exhibits safety profile in the zebrafish-based model .
|
-
- HY-107366R
-
|
|
Glycosyltransferase
Reference Standards
|
Cancer
|
|
SGN-2FF (Standard) is the analytical standard of SGN-2FF (HY-107366). This product is intended for research and analytical applications. SGN-2FF is a potent and orally active inhibitor of fucosylation, directly inhibits fucosyltransferase activity. SGN-2FF possesses antitumor activity .
|
-
- HY-152431
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1-Amino-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl) guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W267446
-
|
|
Melanocortin Receptor
GSK-3
|
Metabolic Disease
Cancer
|
|
6-Methoxy-4-methylcoumarin is a 4-methylcoumarin derivative with an antitumor activity. 6-Methoxy-4-methylcoumarin activates melanin synthesis in B16F10 melanoma cells. 6-Methoxy-4-methylcoumarin is a pigmentation stimulator, and can be used for the study of skin conditions such as vitiligo .
|
-
- HY-154029
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3-β-D-Ribofuranosyl-6-hydroxymethyl-furano[2,3-d]-pyrimidin-2-one is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![3-β-D-Ribofuranosyl-6-hydroxymethyl-furano[2,3-d]-pyrimidin-2-one](//file.medchemexpress.com/product_pic/hy-154029.gif)
- HY-N1839
-
|
|
Apoptosis
Glycosidase
|
Cancer
|
|
3-Hydroxybakuchiol can be isolated from Otholobium mexicanum J. W. Grimes. 3-Hydroxybakuchiol is an electron transport chain (ETC) inhibitor. 3-Hydroxybakuchiol has antitumor activity, and induces tumor cell apoptosis. 3-Hydroxybakuchiol also has moderate inhibitory activity against α-glucosidase (IC50: 345 μM) .
|
-
- HY-147690
-
|
|
Photosensitizer
|
Cancer
|
|
Photosensitizer-2 (compound 1) is a organic D-π-A sensitizer against phototoxicity. Photosensitizer-2 contains an acrylic acid moiety that exerts high levels of phototoxicity. Photosensitizer-2 shows antitumor activity against HeLa cells, with IC50 values of 20.9 ± 4.5 μM (dark) and 0.046 ± 0.012 μM (irradiation), respectively .
|
-
- HY-P11097
-
|
|
CD47
|
Cancer
|
|
Pep-20 is a CD47/SIRPα blocking peptide with KD values of 2.91 and 3.63 μM for human and mouse CD47, respectively. IC50 values for blocking the human and mouse CD47/SIRPα interaction are 24.56 and 12.03 μM, respectively. Pep-20 has antitumor activity .
|
-
- HY-W004284R
-
|
|
Reference Standards
Apoptosis
PI3K
Akt
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Heptadecanoic acid (Standard) is the analytical standard of Heptadecanoic acid. This product is intended for research and analytical applications. Heptadecanoic acid is an odd-chain saturated fatty acid (OCS-FA) with oral activity. Heptadecanoic acid can inhibit cell proliferation and induce Apoptosis. Heptadecanoic acid has antitumor activity. Heptadecanoic acid is associated with a number of diseases, including coronary heart disease, pre-diabetes and type 2 diabetes, and multiple sclerosis[1].
|
-
- HY-W556327
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Nitro-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-2(1H)-pyridinone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-B1490
-
|
|
Serotonin Transporter
Apoptosis
Autophagy
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Imipramine hydrochloride is an orally active tertiary amine tricyclic antidepressant. Imipramine hydrochloride is a Fascin1 inhibitor with antitumor activities. Imipramine hydrochloride also inhibits serotonin transporter with an IC50 value of 32 nM. Imipramine hydrochloride stimulates U-87MG glioma cells autophagy and induces HL-60 cell apoptosis. Imipramine hydrochloride shows neuroprotective and immunomodulatory effects .
|
-
- HY-152408
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-β-D-Ribofuranosyl-2H-pyrazolo[3,4-d]pyrimidine-4,6-diamine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2-β-D-Ribofuranosyl-2H-pyrazolo[3,4-d]pyrimidine-4,6-diamine](//file.medchemexpress.com/product_pic/hy-152408.gif)
- HY-153802A
-
|
|
Apoptosis
Phosphodiesterase (PDE)
Molecular Glues
|
Cancer
|
|
Antitumor agent-100 (compound A6) hydrochloride is an orally potent apoptosis inducer and molecular gel targeting PDE3A-SLFN12 (IC50: 0.3 μM) with antitumor activity. Antitumor agent-100 hydrochloride binds to the PDE3A enzyme pocket to recruit and stabilize SLFN12, thereby preventing protein translation and leading to apoptosis .
|
-
- HY-P99777
-
|
TTI-621
|
CD47
|
Cancer
|
|
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .
|
-
- HY-154078
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Acetyl-5’-O-(p-toluoyl)-3’-deoxy-3’-fluoro-5-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154459
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-2’-deoxy-5’-O-DMTr-2’-fluoro- 5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-10181B
-
|
BMS-354825 monohydrate
|
Bcr-Abl
Src
Autophagy
Apoptosis
|
Cancer
|
|
Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib monohydrate inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib monohydrate also induces apoptosis and autophagy.
|
-
- HY-154726
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro- N3-(2S)-(2-amino-3-carbonyl)-propyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W102981
-
|
7-Oxanorborna-2-ene-5,6-dicarboxylic anhydride
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4,10-Dioxatri cyclo[5.2. 1.02.6]dec-8-ene-3,5-dione is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![4,10-Dioxatri cyclo[5.2. 1.02.6]dec-8-ene-3,5-dione](//file.medchemexpress.com/product_pic/hy-w102981.gif)
- HY-111783G
-
|
|
DNA-PK
ATM/ATR
PI3K
Apoptosis
|
Cancer
|
|
AZD-7648 (GMP) is AZD-7648 (HY-111783) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AZD-7648 is a potent, orally active, selective DNA-PK inhibitor with an IC50 of 0.6 nM. AZD-7648 induces apoptosis and shows antitumor activity .
|
-
- HY-P991311
-
|
|
LPL Receptor
Wnt
|
Cancer
|
|
GSK3178022 is a human IgG1 monoclonal antibody (mAb) targeting LRP6. GSK3178022 inhibits the expression of WNT target genes SP5 and AXIN2. GSK3178022 has antitumor activity in the RSPO fusion model of colorectal cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-19745B
-
|
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
BMS-202 hydrochloride is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 hydrochloride binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 hydrochloride has antitumor activity .
|
-
- HY-P10950
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
PD-L1 inhibitory peptide is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide is promising for research of cancers .
|
-
- HY-154369
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,4-Anhydro-2,3-O-isopropylidene-5-O-t-butyldiphenylsilyl-4-thio-D-ribitol is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154655
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Methyl-9-(2-β-C-methyl-2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154212
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Acetyl-5’-O-(4,4’-dimethoxytrityl)-5-methyl-2’-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154633
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3,5-O-[1,1,3,3-Tetrakis(1-methylethyl)-1,3-disiloxanediyl] cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![3,5-O-[1,1,3,3-Tetrakis(1-methylethyl)-1,3-disiloxanediyl] cytidine](//file.medchemexpress.com/product_pic/hy-154633.gif)
- HY-168043
-
|
|
STAT
|
Cancer
|
|
STAT3-IN-35 is a STAT3 inhibitor that binds to SH2 domain. STAT3-IN-35 inhibits the phosphorylation of STAT3 and possesses antiproliferative activities against triple-negative breast cancer (TNBC) cell lines. STAT3-IN-35 also has a toxicity and potent antitumor activity in a TNBC xenograft model .
|
-
- HY-154185
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,5’-Di-O-benzoyl-2’-deoxy-2’-fluoro-5-methyl-β-D-arabino-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154286
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-O-Acetyl-2,3,5-tri-O-benzoyl-5(R)-C-methyl-D-ribo furanose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154228
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-(4,4’-Dimethoxy trityl)-2’-O-(2-methoxyethyl)-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-100036
-
|
|
Smo
Apoptosis
Hedgehog
|
Cancer
|
|
MK-4101 is a Smoothened (SMO) antagonist (IC50 of 1.1 µM for 293 cells ) and also a potent inhibitor of the hedgehog pathway (IC50 of 1.5 µM for mouse cells; IC50 of 1 µM for KYSE180 oesophageal cancer cells). MK-4101 has robust antitumor activity that inhibits tumor cell proliferation and induces extensive apoptosis .
|
-
- HY-154040
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-Benzoyl-3’-O-(4-methoxybenzyl)-2’-O,4’-C-methyleneuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W012531
-
|
|
HIV
SARS-CoV
Endogenous Metabolite
Bacterial
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against Staphylococcus aureus and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of HIV/SARS-CoV S pseudovirus with an IC50 of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity .
|
-
- HY-152709
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-(5-phenylpyridin-3-yl)purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-173578
-
|
|
Biochemical Assay Reagents
|
Others
|
|
N-(2-Poc-ethyl)betulin amide is a triterpenoid with antiviral and antitumor activities. N-(2-Poc-ethyl)betulin amide contains a Poc (prop-2-yn-1-yloxycarbonyl) alkynyl protecting group, which allows for bioorthogonal reactions (such as click chemistry) and is used for targeted delivery and fluorescent labeling .
|
-
- HY-154440
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-6-chloro-9-(3’-O-methyl-beta-D-ribofuranosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-120436
-
|
|
Drug Derivative
|
Cancer
|
|
RM 49 is the derivative of Mitomycin C (HY-13316). RM 49 exhibits cytotoxicity in SCLC and NSCLC lung cancer cells with IC50 of 0.01-0.5 μg/mL. RM 49 exhibits high relative antitumor activity in compared with Mitomycin C, Cisplatin (HY-17394), Carboplatin (HY-17393) and Doxorubicin (HY-15142) .
|
-
- HY-143900
-
|
|
Btk
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
BTK-IN-7 is a potent and selective inhibitor of BTK (IC50=4.0 nM). BTK-IN-7 has high selectivity in both enzymatic (ITK >250-fold, EGFR >2500-fold) and cellular levels (ITK >227-fold, EGFR 27-fold). BTK-IN-7 also has potent antitumor activity .
|
-
- HY-W002016R
-
|
|
Reference Standards
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Phthalazine (Standard) is the analytical standard of Phthalazine. This product is intended for research and analytical applications. Phthalazine is a substrate for human aldehyde oxidase 1, which can lead to the production of ROS and subsequent enzyme inactivation. Phthalazine is a nitrogen-containing organic heterocyclic compound. Phthalazine exhibits antitumor activity in blood cancer, breast cancer, colon cancer, lung cancer and renal cancer .
|
-
- HY-154676
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Purine-9-b-D-(3’,5’-di-O-benzoyl-2’-deoxy-2’-fluoro)arabinoriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-13691
-
|
Ro-31-7453
|
Apoptosis
Akt
mTOR
Microtubule/Tubulin
Mitosis
|
Cancer
|
|
MKC-1 (Ro-31-7453) is an orally active and potent cell cycle inhibitor with broad antitumor activity. MKC-1 inhibits the Akt/mTOR pathway. MKC-1 arrests cellular mitosis and induces cell apoptosis by binding to a number of different cellular proteins including tubulin and members of the importin β family .
|
-
- HY-108696
-
GNE-781
5 Publications Verification
|
Epigenetic Reader Domain
Histone Acetyltransferase
|
Cancer
|
|
GNE-781 is an orally active, highly potent and selective CBP inhibitor with an IC50 of 0.94 nM in TR-FRET assay. GNE-781 also inhibits BRET and BRD4(1) with IC50s of 6.2 nM and 5100 nM, respectively. GNE-781 displays antitumor activity in an MOLM-16 AML xenograft model .
|
-
- HY-18750A
-
|
AZD3759 hydrochloride
|
EGFR
Apoptosis
|
Cancer
|
|
Zorifertinib (AZD3759) hydrochloride is a potent, orally active, BBB-penetrant, EGFR inhibitor (IC50s: 0.3, 0.2, and 0.2 nM for EGFR wt, EGFR L858R, and EGFR exon 19Del, respectively). Zorifertinib hydrochloride induces cancer cell apoptosis. Zorifertinib hydrochloride has antitumor activity, and can be used for NSCLC, HCC etc. research .
|
-
- HY-155537
-
|
YK-029A
|
EGFR
|
Cancer
|
|
YK-029A is an orally active inhibitor of mutant EGFR，targeting to both the T790M mutations (EGFR T790M) and exon 20 insertion of EGFR (EGFRex20ins). YK-029A exhibits significant antitumor activity，and results tumor regression in EGFRex20ins-driven PDX models .
|
-
- HY-154503
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3-O-(4-Methoxybenzyl)-4-C-hydroxymethyl-1,2-O-isopropylidine-alpha-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154071
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Acetyl-5’-O-(p-toluoyl)-3’-deoxy-3’-fluoro-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-161765
-
|
|
HSP
STAT
|
Cancer
|
|
iHSP110-33 is an inhibitor for heat shock protein 110 (HSP110). iHSP110-33 exhibits antitumor efficacy agaisnt large B-cell lymphoma and classical Hodgkin lymphoma. iHSP110-33 shows a synergistic effect with Selinexor (HY-17536), inhibits the STAT6 phosphorylation, and enhances its antitumor activity. .
|
-
- HY-156850
-
|
|
HDAC
NF-κB
|
Cancer
|
|
ITF 3756 is a selective, orally active HDAC6 inhibitor. ITF 3756 antagonizes TNF-α-induced activation of the NF-κB pathway. ITF 3756 reduces PD-L1 expression on human monocytes and CD8 + T cells, and exhibits antitumor activity. ITF 3756 can be used in colon cancer-related research .
|
-
- HY-19745
-
|
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity .
|
-
- HY-147798
-
|
|
EGFR
CDK
|
Cancer
|
|
EGFR/HER2/CDK9-IN-3 (Compound 10) is a potent inhibitor of EGFR/HER2/CDK9 with IC50s of 191.08, 132.65, and 113.98 nM, respectively. EGFR/HER2/CDK9-IN-3 exhibits remarkable antitumor activity .
|
-
- HY-16106S1
-
|
BMN-673-d4; LT-673-d4
|
Isotope-Labeled Compounds
PARP
|
Cancer
|
|
Talazoparib-d4 (BMN-673-d4) is deuterium labeled Talazoparib. Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity .
|
-
- HY-14392
-
|
DRB
|
CDK
Apoptosis
|
Cancer
|
|
5,6-Dichlorobenzimidazole riboside (DRB) is a nucleoside analog that inhibits several carboxyl-terminal domain kinases, including casein kinase II and cell cycle-dependent kinases (CDK). 5, 6-dichlorobenzimidazole riboside has antitumor activity. 5, 6-dichlorobenzimidazole riboside can induce apoptosis .
|
-
- HY-147796
-
|
|
EGFR
CDK
|
Cancer
|
|
EGFR/HER2/CDK9-IN-1 (Compound 4) is a potent inhibitor of EGFR/HER2/CDK9 with IC50s of 90.17, 131.39, and 67.04 nM, respectively. EGFR/HER2/CDK9-IN-1 exhibits remarkable antitumor activity .
|
-
- HY-113612A
-
|
|
Apoptosis
Phosphatase
|
Cancer
|
|
Cytostatin sodium is an effective and selective protein phosphatase 2A (PP2A) inhibitor with an IC50 value of 210 nM. Cytostatin sodium exhibits anti-metastatic properties, good antitumor activity, and can induce apoptosis. Cytostatin sodium can also prevent the adhesion of B16 melanoma cells to components of the extracellular matrix (laminin and collagen). Cytostatin sodium belongs to the family of natural product fosriecin .
|
-
- HY-117039
-
|
|
VEGFR
|
Cancer
|
|
YM-359445 dihydroxybutanedioate is an orally active VEGFR2 tyrosine kinase inhibitor, with an IC50 of 8.5 nM. YM-359445 dihydroxybutanedioate shows a complete inhibition of vascular permeability induced by VEGF. YM-359445 dihydroxybutanedioate shows antitumor activity against both lung cancer and Paclitaxel (HY-B0015)-resistant colon cancer .
|
-
- HY-N8525S
-
|
|
Isotope-Labeled Compounds
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3'-O-Acetylthymidine- 13C is the 13C-labeled 3'-O-Acetylthymidine (HY-N8525). 3'-O-Acetylthymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P1755
-
|
|
MDM-2/p53
|
Cancer
|
|
p53 (17-26) is a peptide derived from the P53 MDM2 binding domain, with a Kd of 50 nM for MDM2. p53 (17-26) causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) exhibits antitumor activity and is applicable to research related to pancreatic cancer .
|
-
- HY-13582S1
-
|
|
Isotope-Labeled Compounds
Fungal
Parasite
|
Others
|
|
Carbendazimb-d3 is the deuterium labeled Carbendazimb (HY-13582). Carbendazim is a potent and orally active broad-spectrum?benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria,?Fusarium?and?Sclerotina . Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma .
|
-
- HY-126147
-
|
|
HDAC
|
Cancer
|
|
J22352 is a PROTAC (proteolysis-targeting chimeras)-like and highly selective HDAC6 inhibitor with an IC50 value of 4.7 nM. J22352 promotes HDAC6 degradation and induces anticancer effects by inhibiting autophagy and eliciting the antitumor immune response in glioblastoma cancers, and leading to the restoration of host antitumor activity by reducing the immunosuppressive activity of PD-L1 .
|
-
- HY-125927
-
|
8-NH2-Ado
|
DNA/RNA Synthesis
Akt
mTOR
Autophagy
Apoptosis
|
Cancer
|
|
8-Aminoadenosine (8-NH2-Ado), a RNA-directed nucleoside analogue, reduces cellular ATP levels and inhibits mRNA synthesis. 8-Aminoadenosine blocks Akt/mTOR signaling and induces autophagy and apoptosis in a p53-independent manner. 8-Aminoadenosine has antitumor activity .
|
-
- HY-154335
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(3-Deoxy-3-fluoro-β-D-xylofuranosyl)-2,4(1H,3H)-pyrimidinedione is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P991606
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Infection
Inflammation/Immunology
Cancer
|
|
TRX585 is a humanised anti-immunoglobulin-like transcript 5 (ILT5) monoclonal antibody. TRX585 has a potent immunoregulatory activity. TRX585 significantly activates human T cells and upregulates NKG2D and Fas ligand, followed by enhancing antitumor activity with potent cytotoxicity. TRX585 can be used for viral infections and malignancies research .
|
-
- HY-P99249
-
|
Pogalizumab; MOXR 0916
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models .
|
-
- HY-128590
-
PHT-7.3
1 Publications Verification
|
Ras
|
Cancer
|
|
PHT-7.3 is a selective inhibitor of connector enhancer of kinase suppressor of Ras 1 (Cnk1) pleckstrin homology (PH) domain (Kd=4.7 μM). PHT-7.3 inhibits mut-KRas, but not wild-type KRas cancer cell and tumor growth and signaling. PHT-7.3 has antitumor activity .
|
-
- HY-168475
-
|
|
Apoptosis
WDR5
HDAC
|
Cancer
|
|
DD0-2363 (Compound 32d) is a dual-target inhibitor of WDR5-MLL1/HDAC. DD0-2363 inhibits cells proliferation and induces apoptosis in acute myeloid leukemia cells. DD0-2363 has antitumor activity and can be used in the research of acute myeloid leukemia .
|
-
- HY-144880
-
|
3-Aminophenyl Hemiasterlin
|
ADC Payload
Microtubule/Tubulin
P-glycoprotein
|
Cancer
|
|
SC209 (3-Aminophenyl Hemiasterlin) is a 3-aminophenyl hemiasterlin derivative that serves as a cytotoxin for ADCs, targeting tubulin. SC209 has reduced potential for drug efflux via P-glycoprotein 1 drug pump compared with other tubulin-targeting payloads. SC209 exhibits antitumor activity and can be used in the synthesis of ADC molecules .
|
-
- HY-111125
-
|
|
Parasite
Reactive Oxygen Species (ROS)
Apoptosis
|
Infection
Cancer
|
|
AMRI-59 is a potent inhibitor of PrxI used for parasitic infections. AMRI-59 can increase cellular ROS, leading to activation of signaling pathways mediated by mitochondria and apoptosis signal-regulated kinase 1, thereby leading to apoptosis in A549 human lung adenocarcinoma. AMRI-59 exhibits significant antitumor activity without apparent acute toxicity .
|
-
- HY-10181A
-
|
BMS-354825 hydrochloride
|
Bcr-Abl
Src
Autophagy
Apoptosis
|
Cancer
|
|
Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib hydrochloride inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib hydrochloride also induces apoptosis and autophagy.
|
-
- HY-154083
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Acetyl-5’-O-(p-toluoyl)-3’-deoxy-3’-fluoro-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154730
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(2’-O-Acetyl-5’-O-benzoyl-3’-O-methyl-beta-D-ribofuranosyl)-6-chloropurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-17583
-
-
- HY-152858
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Methyl 1,2,3,4-tetrahydro-2,4-dioxo-1-β-D-ribofuranosyl-5-pyrimidineacetate is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-156445
-
|
|
PI3K
mTOR
|
Cancer
|
|
PI3K/mTOR Inhibitor-14 (compound Y-2) is a potent PI3K and mTOR dual inhibitor with IC50s of 171.4 nM and 10.1 nM, respectively. PI3K/mTOR Inhibitor-14 has antitumor activities .
|
-
- HY-10971
-
|
MLN 8237
|
Aurora Kinase
Autophagy
Apoptosis
|
Cancer
|
|
Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
|
-
- HY-154124
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Benzoyl-2'-chloro-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N2274
-
|
12-Oleanene-3β,16β,23,28-tetrol; 3β,16β-12-Oleanene-3, 16,23,28-tetrol
|
Others
|
Cancer
|
|
23-Hydroxylongispinogenin (12-Oleanene-3β,16β,23,28-tetrol) is extracted from Lysimachia heterogenea Klatt. Lysimachia heterogenea Klatt is a perennial herb, which is used as a folk medicine in subduing swelling and detoxicating in China. The effective fraction LH-1 of L. heterogene has antitumor activity .
|
-
- HY-B1490A
-
|
|
Serotonin Transporter
Autophagy
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Imipramine is an orally active tertiary amine tricyclic antidepressant. Imipramine is a Fascin1 inhibitor with antitumor activities. Imipramine also inhibits serotonin transporter with an IC50 value of 32 nM. Imipramine stimulates U-87MG glioma cells autophagy and induces HL-60 cell apoptosis. Imipramine shows neuroprotective and immunomodulatory effects .
|
-
- HY-116000
-
|
Gumarontinib; SCC244
|
c-Met/HGFR
|
Cancer
|
|
Glumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive c-Met inhibitor with an IC50 of 0.42 nM. Glumetinib has greater than 2400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, TyrO3. Antitumor activity .
|
-
- HY-181071
-
|
|
DNA/RNA Synthesis
Drug Intermediate
|
Cancer
|
|
POLRMT-IN-3 is a photosensitive inhibitor of mitochondrial RNA polymerase (POLRMT). POLRMT-IN-3 is biologically inactive in the dark but rapidly releases the active parent compound LJ03 upon illumination with 405 nm light, enabling spatiotemporally precise inhibition of POLRMT. POLRMT-IN-3 exhibits antitumor activity and can be used in research on tumors such as pancreatic cancer and ovarian cancer .
|
-
- HY-152876
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Chloro-9-(2-O-methyl-beta-D-ribofuranosyl)-9H-purin-2-amine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-131454
-
|
|
STING
|
Inflammation/Immunology
Cancer
|
|
SR-717 is a non-nucleotide STING agonist with EC50s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity .
|
-
- HY-107777R
-
|
|
Reference Standards
Histone Methyltransferase
|
Cancer
|
|
LLY-283 (Standard) is the analytical standard of LLY-283 (HY-107777). This product is intended for research and analytical applications. LLY-283, a chemical probe, is a potent, selective and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, with an IC50 of 22 nM and a Kd of 6 nM for PRMT5:MEP50 complex, and shows antitumor activity .
|
-
- HY-W048245
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
(2R,3S,4R)-2-(Hydroxymethyl)tetrahydrothiophene-3,4-diol is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P1755A
-
|
|
MDM-2/p53
|
Cancer
|
|
p53 (17-26) acetate is a peptide derived from the P53 MDM2 binding domain, with a Kd of 50 nM for MDM2. p53 (17-26) acetate causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) acetate exhibits antitumor activity and is applicable to research related to pancreatic cancer .
|
-
- HY-154118
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3',5'-Bis-O-benzoyl-2'-deoxy-2'-fluoro-beta-D-arabino-6-azidouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-162608
-
|
|
PROTACs
|
Cancer
|
|
PROTAC JAK1 degrader 1 degrader 1 (compound 10c) is an effective and selective PROTAC JAK1 degrader with a DC50 of 214 nM. PROTAC JAK1 degrader 1 has antitumor activity. (Structure Note: PINK, JAK1 ligand 1 (HY-10961); Blue, VHL ligand Thalidomide (HY-14658); Black, linker) .
|
-
- HY-148696A
-
|
|
ADC Payload
Topoisomerase
|
Cancer
|
|
Gly-Cyclopropane-Exatecan involves in the synthesis of anti-B7-H4 ADC, containing Exatecan (HY-13631), a DNA Topoisomerase I inhibitor. Gly-Cyclopropane-Exatecan participated in the formation of the ADC hu2F7-Exatecan (compound 34), which showed antitumor activity in vivo and in vitro .
|
-
- HY-154498
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,2-Di-O-acetyl-3,5-di-O-benzoyl-3-beta-C-methyl-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W547585
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Hydroxy-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-2(1H)-pyridinone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-13582R
-
|
|
Parasite
Fungal
Reference Standards
|
Infection
Cancer
|
|
Carbendazim (Standard) is the analytical standard of Carbendazim. This product is intended for research and analytical applications. Carbendazim is a potent and orally active broad-spectrum benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria, Fusarium and Sclerotina . Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma .
|
-
- HY-15528R
-
|
|
PKD
|
Cancer
|
|
kb NB 142-70 (Standard) is the analytical standard of kb NB 142-70. This product is intended for research and analytical applications. kb NB 142-70 is a potent PKD inhibitor, with IC50s of 28.3, 58.7 and 53.2 nM for PKD1, PKD2, and PKD3, respectively. kb NB 142-70 also has antitumor activity.
|
-
- HY-154072
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Acetyl-5’-O-(p-toluoyl)-3’-deoxy-3’-fluoro-5-trifluoromethyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152981
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Di-O-Toluoyl-1,2-dideoxy-D-ribose-6-chloro-7-iodo-7-deazapurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152828
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-β-D-Ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![1-β-D-Ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine](//file.medchemexpress.com/product_pic/hy-152828.gif)
- HY-154475
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(2'-O-Acetyl-5'-O-benzoyl-3'-deoxy-beta-D-ribofuranosyl)-6-chloropurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-113612
-
|
|
Phosphatase
Apoptosis
|
Cancer
|
|
Cytostatin is an effective and selective protein phosphatase 2A (PP2A) inhibitor with an IC50 value of 210 nM. Cytostatin exhibits anti-metastatic properties, good antitumor activity, and can induce apoptosis. Cytostatin can also prevent the adhesion of B16 melanoma cells to components of the extracellular matrix (laminin and collagen). Cytostatin belongs to the family of natural product fosriecin .
|
-
- HY-153802
-
|
|
Apoptosis
Phosphodiesterase (PDE)
|
Cancer
|
|
Antitumor agent-100 (compound A6) is an orally available apoptosis inducer and molecular gel targeting PDE3A-SLFN12 (IC50: 0.3 μM) with antitumor activity. Antitumor agent-100 binds to the PDE3A enzyme pocket to recruit and stabilize SLFN12, thereby preventing protein translation and leading to apoptosis .
|
-
- HY-154447
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-(p-Toluoyl)-2’-O-acetyl-3’-deoxy-3’-fluoro-6-chloroinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152772
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-6-chloropurine-9-beta-D-(2’-deoxy-2’-fluoro)-arabinoriboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-105433
-
|
|
Drug Derivative
|
Cancer
|
|
Perrimustine is a cysteamine (CysA) derivative with potent antitumor activity. Perrimustine exhibits significant effect on B16 melanoma and metastasized melanoma cells by causing DNA damage. Perrimustine exhibits antitumor effects in mice bearing various cancers, including lung carcinoma, leukemia, lymphoma, melanoma, colon carcinoma, and glioma. Perrimustine can be used for cancer research, such as melanoma and leukemia .
|
-
- HY-147797
-
|
|
EGFR
CDK
|
Cancer
|
|
EGFR/HER2/CDK9-IN-2 (Compound 9) is a potent inhibitor of EGFR/HER2/CDK9 with IC50s of 145.35, 129.07, and 117.13 nM, respectively. EGFR/HER2/CDK9-IN-2 exhibits remarkable antitumor activity .
|
-
- HY-152806
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino -6-chloro-9-(2-β-C-methyl-β-D-ribofuranosyl)-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154044
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3-Deoxy-1,2-O-isopropylidene-5-p-toluoyl-a-D-glycero-pent-3-enofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-161402
-
|
|
DNA Methyltransferase
|
Cancer
|
|
METTL16-IN-1 is a potent METTL16 inhibitor with an IC50 value of 1.7 μM and a Kd value of 1.35 μM. Mettl16-in-1 inhibits the binding interaction of U6 snRNA deletion and METTL16 MTD with an IC50 value of 2.5 μM. METTL16-IN-1 has antitumor activity .
|
-
- HY-125158
-
|
|
Aurora Kinase
Apoptosis
|
Cancer
|
|
HOI-07 is a selective Aurora B kinase inhibitor. HOI-07 blocks phosphorylation of histone H3 on Ser10 in
lung cancer cells. HOI-07 induces cell-cycle arrest, and apoptosis. HOI-07 has antitumor activity, and suppresses the tumor growth of A549, 143B and KHOS xenografts .
|
-
- HY-124605
-
|
|
Syk
Btk
Apoptosis
|
Cancer
|
|
IQS-019 is a B cell receptor (BCR) kinase inhibitor. IQS-019 can inhibit the de-phosphorylation of constitutive and IgM-activated Syk, Lyn, and Btk. IQS-019 can inhibit cell proliferation, migration and induce apoptosis. IQS-019 exhibits antitumor activity and can be used for the research of cancer, such as B cell lymphoma .
|
-
- HY-124611
-
|
|
HSP
Apoptosis
|
Cancer
|
|
JG-231 is an allosteric inhibitor of heat shock protein 70 (Hsp70). JG - 231 inhibits the binding of Hsp70 and BAG family proteins, including inhibition of Hsp70 and BAG1 with a Ki of 0.11 μM. JG-231 inhibits proliferation of tumor cells and induces apoptosis. JG-231 has antitumor activity .
|
-
- HY-171489
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Mal-VC-PAB-EDA-N-Ac-Calicheamicin is a Drug-Linker Conjugate for ADC with potent antitumor activity. Mal-VC-PAB-EDA-N-Ac-Calicheamicin consists of ADC toxin Calicheamicin (HY-19609) and a linker. Mal-VC-PAB-EDA-N-Ac-Calicheamicin can be used for synthesis of ADC, PF-06647263 (HY-111965) .
|
-
- HY-152485
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-N6,N6-dimethyl-2’-deoxy-2’-fluoro-beta-D-arabino-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-18953
-
|
|
mTOR
|
Cancer
|
|
mTOR inhibitor-23 (compound DHM25) is a selective, competitive, irreversible and covalent inhibitor of mTOR. mTOR inhibitor-23 has the mechanism of inhibition occurs mainly through its capacity to covalently interact with a nucleophilic amino acid inside the ATP pocket. mTOR inhibitor-23 exerts potent antitumor activity against triple-negative breast tumor cell lines .
|
-
- HY-109189A
-
|
BPI-7711 hydrochloride
|
EGFR
|
Cancer
|
|
Rezivertinib (BPI-7711) hydrochloride is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib hydrochloride exhibits high potency against the common activation EGFR and the resistance T790M mutations. Rezivertinib hydrochloride has excellent central nervous system (CNS) penetration and has antitumor activity, such as non-small cell lung cancer (NSCLC) .
|
-
- HY-120241
-
|
K 251-1
|
Phosphodiesterase (PDE)
|
Cancer
|
|
Reticulol (K 251-1) is an inhibitor of cyclic adenosine 3', 5'-monophosphate phosphodiesterase. Reticulol shows antitumor activity independent with cell cycle arrest or apoptosis. Reticulol inhibits cell growth of murine melanoma cells and human lung tumor cells. Reticulol protects its lung metastasis via the bloodstream by inhibiting the growth of B16F10 melanoma .
|
-
- HY-17408
-
-
- HY-16491
-
|
DJ-927
|
Microtubule/Tubulin
|
Cancer
|
|
Tesetaxel (DJ-927) is an orally active and brain-penetrant taxane tubulin inhibitor. Tesetaxel inhibits tubulin depolymerization with an IC50 of 0.44 μM. Tesetaxel inhibits cancer cells proliferation and shows potent antitumor activity against P-glycoprotein-positive cancer cells. Tesetaxel can be used for the research of cancer, such as solid tumors, liver metastasis, and advanced breast cancer .
|
-
- HY-161338
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin polymerization-IN-61 (Compound 9a) is a tubulin polymerization inhibitor. Tubulin polymerization-IN-61 destroys the microtubule skeleton, blocks the cell cycle in G2/M phase, induces Apoptosis, and inhibits cancer cell migration and colony formation. Tubulin polymerization-IN-61 shows antitumor activity in vivo against 4T1 xenograft model .
|
-
- HY-152410
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Amino-4-hydrozino-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![6-Amino-4-hydrozino-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine](//file.medchemexpress.com/product_pic/hy-152410.gif)
- HY-12137A
-
|
BI 6727 trihydrochloride
|
Polo-like Kinase (PLK)
Apoptosis
|
Cancer
|
|
Volasertib (BI 6727) trihydrochloride is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.87 nM. Volasertib trihydrochloride inhibits PLK2 and PLK3 with IC50s of 5 and 56 nM, respectively. Volasertib trihydrochloride induces mitotic arrest and apoptosis. Volasertib trihydrochloride, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models .
|
-
- HY-136270S
-
|
VX-803-d8; M4344-d8; ATR inhibitor 2-d8
|
Isotope-Labeled Compounds
ATM/ATR
|
Cancer
|
|
Gartisertib-d8 (VX-803-d8) is the deuterium labeled Gartisertib (HY-136270). Gartisertib (VX-803) is an ATP-competitive, orally active, and selective ATR inhibitor, with a Ki of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC50 of 8 nM. Antitumor activity .
|
-
- HY-125147
-
|
|
NAMPT
|
Cancer
|
|
A-1293201 is a substrate-independent NAMPT inhibitor with antitumor activity. A-1293201 effectively reduces the total cellular NAD +/NADH (NADt) level, subsequently leading to ATP depletion and cancer cell death. In addition, A-1293201 can effectively overcome the acquired resistance mechanism of the NAMPT Y18 mutant to CHS-828 (HY-10079) .
|
-
- HY-154380
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Chloro-9-(3,5-di-O-acetyl-2-O-methyl-β-D-ribofuranosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-108697R
-
|
|
Reference Standards
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
PT2399 (Standard) is the analytical standard of PT2399 (HY-108697). This product is intended for research and analytical applications. PT2399 is a potent and selective HIF-2α antagonist, which directly binds to HIF-2α PAS B domain with an IC50 of 6 nM. PT2399 displays potent antitumor activity in vivo .
|
-
- HY-N2108
-
|
|
Drug Derivative
Drug Intermediate
Topoisomerase
|
Cancer
|
|
7-Ethylcamptothecin is a derivative of Camptothecin (HY-16560) and a DNA topoisomerase I inhibitor that exhibits significant antitumor activity against tumor cells. 7-Ethylcamptothecin serves as a key precursor for the synthesis of 20 (S)-O-substituted benzoyl-7-ethylcamptothecin compounds. 7-Ethylcamptothecin is widely used in various tumor-related scientific studies .
|
-
- HY-P10511
-
|
|
Apoptosis
|
Infection
Cancer
|
|
Pantinin-3 is an antimicrobial peptide with antitumor activity found in the venom of the emperor scorpion (Pandinus imperator). Pantinin-3 shows selective toxicity against breast cancer cells (MDA-MB-231) and prostate cancer cells (DU-145). Pantinin-3 can induce apoptosis in tumor cells. Pantinin-3 can be used in cancer research .
|
-
- HY-P99101
-
|
AEX-4089; MGC026 antibody
|
ADC Antibody
|
Cancer
|
|
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .
|
-
- HY-129603
-
SI-109
2 Publications Verification
|
STAT
Ligands for Target Protein for PROTAC
|
Cancer
|
|
SI-109 is a potent STAT3 SH2 domain inhibitor (Ki=9 nM) with antitumor activity. SI-109 effectively inhibits the transcriptional activity of STAT3 (IC50=3 μM). SI-109 and an analog of CRBN ligand lenalidomide have been used to design PROTAC STAT3 degrader SD-36 .
|
-
- HY-175472
-
|
|
Phosphatase
Apoptosis
|
Cancer
|
|
(GalNAc)3-CPT is a glycoconjugate prodrug that targets the asialoglyco-protein receptor (ASGR) overexpressed on hepatocytes. (GalNAc)3-CPT exhibits significant antitumor activity (IC50 value of 3.07 μM in HepG2 cells) by activating the cGAS-STING pathway and promoting CD8+ T cell infiltration into tumors, thereby inducing tumor cell apoptosis .
|
-
- HY-154679
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-6-(thiophen-3-yl)purine-beta-D-(3’-deoxy-3’-fluoro)riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-126534S
-
|
LSN3106729-d8
|
CDK
Ligands for Target Protein for PROTAC
|
Cancer
|
|
Abemaciclib metabolite M18-d8 is the deuterium labeled Abemaciclib metabolite M18. Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .
|
-
- HY-146573
-
|
|
Aldose Reductase
17β-HSD
|
Cancer
|
|
AKR1C3-IN-6 (Compound 1) is a potent, selective AKR1C3 inhibitor with IC50 values of 0.31 μM and 73.23 μM against AKR1C3 and AKR1C2, respectively. AKR1C3-IN-6 shows antitumor activity .
|
-
- HY-156286
-
|
|
Ferroptosis
|
Cancer
|
|
GPX4-IN-7 (Compound 31), indirubin derivative, is a ferroptosis inducer for colon cancer. GPX4-IN-7 has strong antitumor activity against HCT-116 cells with an IC50 value of 0.49 μM. GPX4-IN-7 can promote the degradation of GPX4, causing the accumulation of lipid ROS to induce ferroptosis .
|
-
- HY-152414
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Amino-4-hydroxyamino-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![6-Amino-4-hydroxyamino-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine](//file.medchemexpress.com/product_pic/hy-152414.gif)
- HY-152582
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-(3-Deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![7-(3-Deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine](//file.medchemexpress.com/product_pic/hy-152582.gif)
- HY-163273
-
|
|
FGFR
|
Cancer
|
|
FGFR4-IN-17 (Compound (S)-23) is a piperazinyl diflurindan derivative containing pyridinyl. FGFR4-IN-17 is a FGFR inhibitor with IC50 values of 24.2, 16.1, 78.0, and 68.0 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. FGFR4-IN-17 has antitumor activity .
|
-
- HY-113578
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
PD 116152 is a phenazine Antibiotic with antimicrobial and antitumor activity. PD 116152 possesses cytotoxic activity against L1210 lymphocytic leukemia and human colon adenocarcinoma (HCT-8) cells with IC50 values of 5.2 x 10 -7 M and 7.1 x 10 -7 M, respectively. PD 116152 is promising for research of P388 lymphocytic leukemia .
|
-
- HY-181491
-
|
|
Microtubule/Tubulin
EGFR
Akt
mTOR
Ras
Apoptosis
Autophagy
|
Cancer
|
|
Tubulin-IN-64 is a sulfonated styrylquinazoline derivative with high selectivity antitumor activity. Tubulin-IN-64 targets tubulin, inhibits the EGFR/Akt/mTOR and EGFR/Ras signaling pathways, induces cell cycle arrest, apoptosis and autophagy. Tubulin-IN-64 exhibits significant antitumor efficacy in the zebrafish GBM xenograft model. Tubulin-IN-64 can be used for the research on glioblastoma and leukemia .
|
-
- HY-P0036
-
Octreotide
Maximum Cited Publications
16 Publications Verification
SMS 201-995
|
Somatostatin Receptor
Apoptosis
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .
|
-
- HY-W026644
-
|
Acridine-9-carbaldehyde
|
Bacterial
|
Infection
Cancer
|
|
Acridine-9-carboxaldehyde (Acridine-9-carbaldehyde) is a bioactive compound with potential antibacterial and antitumor activities. Acridine-9-carboxaldehyde is widely used as a building block in compound development to synthesize various bioactive derivatives. Acridine-9-carboxaldehyde exhibits significant cytotoxicity against certain cancer cells, making it an important candidate in cancer inhibition research.
|
-
- HY-134901
-
|
|
Histone Acetyltransferase
Apoptosis
|
Cancer
|
|
WM-3835 is a potent and high-specific HBO1 (KAT7 or MYST2) inhibitor and binds directly to the acetyl-CoA binding site of HBO1. WM-3835 activates apoptosis while inhibits osteosarcoma (OS) cell proliferation, migration and invasion. WM-3835 has antitumor activity and potently inhibits pOS-1 xenograft growth in mice .
|
-
- HY-152680
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Amino-5-cyano-1- (β-D-ribofuranosyl)-7H-pyrrolo[2,3-d] pyrimidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![4-Amino-5-cyano-1- (β-D-ribofuranosyl)-7H-pyrrolo[2,3-d] pyrimidine](//file.medchemexpress.com/product_pic/hy-152680.gif)
- HY-152305
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
(1S)-1,4-Anhydro-1-C-(2,4-difluoro-5-methylphenyl)-D-ribitol is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154112
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Bromo-6-chloro-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-161967
-
|
|
FLT3
JAK
Apoptosis
|
Cancer
|
|
JAK2/FLT3-IN-3 (11r) is a dual FLT3 and JAK2 inhibitor, with IC50 values of 2.01 nM, 0.51 nM and 104.40 nM for JAK2, FLT3 and JAK3, respectively. JAK2/FLT3-IN-3 (11r) induces apoptosis and possesses antitumor activity .
|
-
- HY-111792
-
|
CRX-601
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
Cancer
|
|
GSK1795091 (CRX-601), an immunologic stimulator, is a synthetic TLR4 agonist. Antitumor activity. GSK1795091 can be used as a vaccine adjuvant to enhance both mucosal and systemic immunity to influenza virus vaccines. Not only, GSK1795091 inhibits tumor growth and increases the survival in mice model, but results in long term survival in influenza challenge model in mice .
|
-
- HY-15794
-
|
Methoxymorpholinyl doxorubicin; FCE 23762; PNU 152243
|
G-quadruplex
|
Cancer
|
|
Nemorubicin (Methoxymorpholinyl doxorubicin) is a Doxorubicin derivative with potent antitumor activity. Nemorubicin is highly cytotoxic to a variety of tumor cell lines presenting a multidrug-resistant phenotype. Nemorubicin not only intercalate into the duplex DNA, but also result in significant ligands for G-quadruplex DNA segments, stabilizing their structure. Nemorubicin requirs an intact nucleotide excision repair (NER) system to exert its activity .
|
-
- HY-12137
-
|
BI 6727
|
Polo-like Kinase (PLK)
Apoptosis
|
Cancer
|
|
Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC50s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models .
|
-
- HY-147794
-
|
|
CDK
COX
EGFR
|
Cancer
|
|
CDK9-IN-41 is a potent CDK9, EGFR, HER2, and COX-2 kinases inhibitor with IC50s of 192.81 nM, 254.03 nM, 238.81 nM, and 775 nM. COX-2-IN-18 exhibits remarkable antitumor activity against leukemia cancer cells, colon cancer cells, melanoma cells, ovarian cells and breast cells .
|
-
- HY-144497
-
-
- HY-138565
-
|
|
YAP
|
Cancer
|
|
K-975 is a potent, selective and orally active TEAD inhibitor, with a strong inhibitory effect against protein-protein interactions between YAP1/TAZ and TEAD. K-975 covalently binds to Cys359 located in the palmitate-binding pocket of TEAD via an acrylamide structure. K-975 exhibits antitumor activity on malignant pleural mesothelioma .
|
-
- HY-172170
-
|
|
Histone Demethylase
|
Cancer
|
|
LSD1-IN-39 (Compound 14) is a reversible inhibitor for LSD1 with an IC50 of 0.18 μM. LSD1-IN-39 exhibits broad-spectrum anti-proliferative activity against cancer cells, inhibits the cell migration of HepG2 and inhibits the epithelial-mesenchymal transition. LSD1-IN-39 exhibits antitumor activity in mouse models .
|
-
- HY-103257
-
|
NSC656158
|
Microtubule/Tubulin
|
Cancer
|
|
CHM-1, a microtubule-destabilizing agent, inhibits tubulin polymerization. CHM-1 is a potent and selective antimitotic antitumor activity against human hepatocellular carcinoma. CHM-1 induces growth inhibition and apoptosis via G2-M phase arrest in human hepatocellular carcinoma cells by activation of Cdc2 kinase activity .
|
-
- HY-154731
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(2’-O-Acetyl-5’-O-benzoyl-3’-O-methyl-beta-D-ribofuranosyl)-2,6-dichloropurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152687
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[6-(4-methylpiperazinyl) pyridin-3-yl]purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[6-(4-methylpiperazinyl) pyridin-3-yl]purine](//file.medchemexpress.com/product_pic/hy-152687.gif)
- HY-128995AS
-
|
Glycyl-DX-8951-d5 hydrochloride; Exatecan analog 2-d5 hydrochloride
|
Isotope-Labeled Compounds
ADC Payload
Topoisomerase
|
Cancer
|
|
Glycyl-Exatecan-d5 (Glycyl-DX-8951-d5) hydrochloride is deuterium labeled Glycyl-Exatecan (HY-128995A). Glycyl-Exatecan (Glycyl-DX-8951), a derivative of Exatecan (HY-13631), is an anticancer agent. Glycyl-Exatecan has significantly antitumor activity. Glycyl-Exatecan can be used for cancers like solid tumors research.
|
-
- HY-152685
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4-Amino-1-(β-D-ribofurano syl)-7H-pyrrolo [2.3-d] pyrimidine-5-carboxamide is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![4-Amino-1-(β-D-ribofuranosyl)-7H-pyrrolo[2.3-d]pyrimidine-5-carboxamide](//file.medchemexpress.com/product_pic/hy-152685.gif)
- HY-N0611R
-
|
α-Boswellic acid (Standard)
|
Reference Standards
Others
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
alpha-Boswellic acid (Standard) is the analytical standard of alpha-Boswellic acid. This product is intended for research and analytical applications. alpha-Boswellic acid (α-Boswellic acid) is an orally active pentacyclic triterpenoid compound that can be extracted from frankincense. alpha-Boswellic acid has anti-inflammatory and antitumor activities. alpha-Boswellic acid can be used in Alzheimer's disease (AD) research .
|
-
- HY-152827
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Methoxy-1-β-D-ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![4-Methoxy-1-β-D-ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine](//file.medchemexpress.com/product_pic/hy-152827.gif)
- HY-152578
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-(2,3-Anhydro-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![7-(2,3-Anhydro-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine](//file.medchemexpress.com/product_pic/hy-152578.gif)
- HY-172454
-
|
|
SHP2
|
Cancer
|
|
SHP2-IN-36 (Compound B8) is an allosteric inhibitor of SHP2, with an IC50 value of 9.0 nM. In addition, its IC50 for p-ERK is 40 nM. SHP2-IN-36 also exhibited significant antitumor activity in the KYSE520 xenograft mouse model. SHP2-IN-36 can be used for research in the field of anti-tumor .
|
-
- HY-B0305AR
-
|
HOE 760 (Standard)
|
Histamine Receptor
Reference Standards
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Roxatidine (Acetate Hydrochloride) (Standard) is the analytical standard of Roxatidine (Acetate Hydrochloride). This product is intended for research and analytical applications. Roxatidine Acetate Hydrochloride is a potent, selective, competitive and orally active histamine H2-receptor antagonist. Roxatidine Acetate Hydrochloride has antisecretory potency against gastric acid secretion. Roxatidine Acetate Hydrochloride can also suppress inflammatory responses and can be used for gastric and duodenal ulcers research. Roxatidine Acetate Hydrochloride has antitumor activity .
|
-
- HY-P99394
-
|
JNJ-64407564
|
CD3
|
Cancer
|
|
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .
|
-
- HY-152704
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[6-(4-morpholinyl)pyridin-3-yl]purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[6-(4-morpholinyl)pyridin-3-yl]purine](//file.medchemexpress.com/product_pic/hy-152704.gif)
- HY-115950
-
|
|
Drug Derivative
|
Cancer
|
|
Antitumor agent-48 (Compound 4a) is a 2,3-dehydrosilybin derivative with an antitumor activity. Antitumor agent-48 shows cytotoxic activity against MCF-7, NCI-H1299, HepG2 and HT29 cells with IC50 values of 8.06 µM, 13.1 µM, 16.51 µM and 12.44 µM, respectively .
|
-
- HY-N6015
-
|
|
Parasite
P-glycoprotein
|
Infection
Cancer
|
|
Bacopasaponin C is an orally active natural glycoside. Bacopasaponin C can be isolated from Bacopa monniera. Bacopasaponin C inhibits Verapamil (HY-14275)-stimulated P-gp ATPase activity with an IC50 of 57.83 μg/mL. Bacopasaponin C has antitumor activity against sarcomas. Bacopasaponin C has antiparasitic activity against Leishmania donovani .
|
-
- HY-159176
-
|
|
Cytochrome P450
|
Cancer
|
|
Antitumor agent-183 (compound 3f) has antitumor activity with metabolic stability. Antitumor agent-183 inhibits cancer cell growth, with IC50s less than 5 nM for A549, HCT116, and HS578T cells. The albumin-bound nanoparticle formulation of Antitumor agent-183 has prolonged retention in the tumor tissues .
|
-
- HY-154617
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
6-S-(2-Cyanoethyl)-2’-deoxy-5’-O-DMTr--6-thioguanosine 3’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W544504
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2,6-Dichloro-9-(2-c-methyl-2,3,5-tri-O-benzoyl-beta-D-ribofuranosyl)purine dibenzoate is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152818
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4-Chloro-7-(2-β-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d] pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![4-Chloro-7-(2-β-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d] pyrimidine](//file.medchemexpress.com/product_pic/hy-152818.gif)
- HY-W035090
-
|
(Trimethylphosphine)gold(I) chloride
|
Biochemical Assay Reagents
Endogenous Metabolite
|
|
|
Chloro(trimethylphosphine)gold(I) ((Trimethylphosphine)gold(I) chloride) is a metal complex with antitumor activity. Chloro(trimethylphosphine)gold(I) has been studied as a potential chemotherapeutic compound in cancer inhibition. Chloro(trimethylphosphine)gold(I) can also be used in organic synthesis reactions as a catalyst to improve reaction efficiency. The biocompatibility of Chloro(trimethylphosphine)gold(I) makes it promising for application in medicine and materials science.
|
-
- HY-152657
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Methyl-N3-[(2S)-2-(t-butoxycarbonyl)amino-3-(t-butoxycarbonyl)] propylpseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![N1-Methyl-N3-[(2S)-2-(t-butoxycarbonyl)amino-3-(t-butoxycarbonyl)] propylpseudouridine](//file.medchemexpress.com/product_pic/hy-152657.gif)
- HY-181764
-
|
|
Ser/Thr Protease
|
Cancer
|
|
LZL50 is an orally effective human caseinolytic protease P (hClpP) activator with an EC50 of 0.29 μM. LZL50 activates hClpP, a serine protease that mediates mitochondrial quality control by degrading damaged or misfolded mitochondrial proteins. LZL50 exhibits antitumor activity in a breast cancer xenograft mouse model. LZL50 can be used in research related to breast cancer .
|
-
- HY-146516
-
|
|
MDM-2/p53
Apoptosis
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Anticancer agent 42 (compound 10d) is an orally active anticancer agent, and shows a potent antitumor activity against MDA-MB-231 cell with an IC50 of 0.07 μM. Anticancer agent 42 can exert its anticancer activity by activating apoptotic pathway and p53 expression. Anticancer agent 42 can be used to study metastatic breast cancer .
|
-
- HY-18750
-
|
AZD3759
|
EGFR
Apoptosis
|
Infection
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Zorifertinib (AZD3759) is a potent, orally active, BBB-penetrant, EGFR inhibitor. At Km ATP concentrations, the IC50s are 0.3, 0.2, and 0.2 nM for EGFR wt, EGFR L858R, and EGFR exon 19Del, respectively. Zorifertinib induces cancer cell apoptosis. Zorifertinib has antitumor activity, and can be used for NSCLC, HCC etc. research .
|
-
- HY-147854
-
|
|
Raf
Apoptosis
|
Cancer
|
|
B-Raf IN 9 (compound 8b) is a potent B-Raf inhibitor, with an IC50 of 24.79 nM. B-Raf IN 9 induces apoptosis and shows cell cycle arrest at G2/M phase. B-Raf IN 9 exhibits potent antitumor activity against human prostate cancer PC-3 cell line, with an IC50 of 7.83 µM .
|
-
- HY-152432
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1-Amino-7-cyclopropyl methyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-144898
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
SB-216 is an BBB-penetrable tubulin polymerization inhibitor. SB-216 can inhibit the proliferation and migration, and induce apoptosis and cell cycle arrest of tumor cells. SB-216 has good in vivo metabolic stability and low toxicity, but its oral bioavailability is limited. SB-216 has antitumor activity and can be used in the research of tumors such as melanoma .
|
-
- HY-P0036B
-
|
SMS 201-995 pamoate
|
Somatostatin Receptor
Apoptosis
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Octreotide (SMS 201-995) pamoate is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide pamoate can bind to the somatostatin receptors which are mainly subtypes 2, 3 and 5. Octreotide pamoate increases Gi activity and reduces intracellular cAMP production. Octreotide pamoate has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .
|
-
- HY-174854
-
|
|
HDAC
Reactive Oxygen Species (ROS)
Apoptosis
|
Cancer
|
|
PySAHA is a multifunctional HDAC inhibitor. PySAHA can degrade intracellular HDAC via a hydrophobic tagging mechanism. PySAHA also possesses photodynamic therapeutic activity and can generate reactive oxygen species under light irradiation. PySAHA can inhibit the proliferation, migration and induce cell apoptosis of breast cancer cells. PySAHA has antitumor activity and can be used in breast cancer research .
|
-
- HY-154675
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Aminopurine-9-beta-D-(3’,5’-di-O-benzoyl-2’-deoxy-2’-fluoro)arabinoriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-15582
-
|
|
Microtubule/Tubulin
ADC Payload
|
Cancer
|
|
Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids .
|
-
- HY-B0719R
-
|
Ingenol 3-angelate (Standard); PEP005 (Standard)
|
Reference Standards
PKC
|
Inflammation/Immunology
Cancer
|
|
Ingenol Mebutate (Standard) is the analytical standard of Ingenol Mebutate. This product is intended for research and analytical applications. Ingenol Mebutate is an active ingredient in Euphorbia peplus, acts as a potent PKC modulator, with Kis of 0.3, 0.105, 0.162, 0.376, and 0.171 nM for PKC-α, PKC-β, PKC-γ, PKC-δ, and PKC-ε, respectively, and has antiinflammatory and antitumor activity.
|
-
- HY-149896
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Antitumor agent-107 (compound 5h) is an anticancer agent that shows excellent inhibitory activity against leukemia cell lines (GI50=0.32-1.34 μM). Antitumor agent-107 also shows antitumor activity against various other human cancer cell lines (GI50 range 0.35-9.43 μM) .
|
-
- HY-B0508S1
-
|
Ro 7-0207-13C2,15N2
|
Isotope-Labeled Compounds
Bacterial
Parasite
Antibiotic
Hedgehog
|
Infection
|
|
Ornidazole- 13C2, 15N2 is the 13C, 15N labeled Ornidazole. Ornidazole (Ro 7-0207) is a nitroimidazole derivative with anti-trichomonad activity and in vitro activity against a variety of anaerobic bacteria. Ornidazole inhibits Sonic hedgehog (Shh) signaling pathway, exhibits antitumor activity. Ornidazole can be used in research of Crohn’s disease .
|
-
- HY-P1812
-
AUNP-12
3 Publications Verification
NP-12
|
PD-1/PD-L1
|
Cancer
|
|
AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .
|
-
- HY-154572
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(2-O-Acetyl-3,5-di-O-benzoyl-β-D-xylofuranosyl)-6-chloro-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-144070
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
ErSO-DFP is an anticipatory unfolded protein response (a-UPR) activator. ErSO-DFP has enhanced selectivity for estrogen receptor alpha-positive (ERα+) cancer cells with a wider selectivity window than ErSO (HY-132247). ErSO-DFP displays antitumor activity against MCF-7 in mice. ErSO-DFP can cross the blood brain barrier .
|
-
- HY-152398
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Amino-4-methoxy-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![6-Amino-4-methoxy-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine](//file.medchemexpress.com/product_pic/hy-152398.gif)
- HY-146275
-
|
|
LXR
|
Cancer
|
|
LXRβ agonist-3 (compound 4-13) is a potent and selective LXRβ (liver X receptor β) agonist, with an EC50 of 0.095 μM. LXRβ agonist-3 efficiently inhibits U87EGFRvIII cell, with an IC50 of 3.75 μM. LXRβ agonist-3 shows antitumor activity, and can inhibit glioblastoma .
|
-
- HY-133492
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
DBCO-PEG4-MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the linker DBCO-PEG4. DBCO-PEG4-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-164233
-
|
|
PROTACs
HDAC
Apoptosis
|
Cancer
|
|
YX968 is a potent and selective HDAC3/8 PROTAC dual degrader with DC50 values of 1.7 and 6.8 nM. YX968 exhibits antitumor activity by promoting apoptosis .(Pink: Target protein ligand (HY-168287); Black: linker (HY-W007700); Blue: E3 ligase ligand (HY-112078))
|
-
- HY-131454A
-
|
|
STING
|
Inflammation/Immunology
Cancer
|
|
SR-717 free acid is a non-nucleotide STING agonist with EC50s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 free acid is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity .
|
-
- HY-B0342GL
-
|
Methylglucamine (GMP Like); Meglumin (GMP Like); Methylglucamin (GMP Like)
|
Biochemical Assay Reagents
|
Cancer
|
|
Meglumine (GMP Like) (Methylglucamine (GMP Like)) is the GMP Like class Meglumine (HY-B0342) that can be used as pharmaceutical excipients. Meglumine (Methylglucamine) is an orally active amino sugar derived from sorbitol. Meglumine has anti-inflammatory and antitumor activity. Meglumine is often used as an excipient in active molecules and with iodinated compounds in contrast agents such as meglumine and meglumine iodide .
|
-
- HY-105463
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Saptomycin D is an antibiotic with antitumor activity isolated from the Streptomyces sp. HP530 strain. Saptomycin D exhibits potent inhibitory effects against Gram-positive bacteria, while demonstrating weaker inhibitory activities against certain Gram-negative bacteria and yeasts. Saptomycin D also displays remarkable antitumor properties. Saptomycin D is applicable in research within the field of oncology .
|
-
- HY-154669
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(2,3-Di-O-acetyl-6-O-benzoyl-5-deoxy-D-ribo-exofuranoyl)-6-chloropurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-113341R
-
-
- HY-152686
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-6-methoxy-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152788
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Chloro-6-(furan-2-yl) purine-beta-D-(3’-deoxy-3’-fluoro)-riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W848341
-
|
NSC 338947; CIEtSoSo
|
DNA Alkylator/Crosslinker
|
Cancer
|
|
Clomesone (NSC 338947) is a compound with antitumor activity. Clomesone induces the formation of cross-links between DNA strands in cell lines. Clomesone is inactive against most human colorectal cancer solid tumor cell lines in vitro, has no significant activity against mouse tumors in vivo, and is accompanied by bone marrow suppression. Its pharmacokinetic behavior indicates that it cannot reach effective concentrations at the tumor site.
|
-
- HY-154060
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-3'-O-(2-methoxyethyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-181068
-
|
|
PARP
Apoptosis
Microtubule/Tubulin
|
Cancer
|
|
2'-Nitroflavone is a PARP1 inhibitor. 2'-Nitroflavone inhibits the proliferation, induces cell cycle arrest and apoptosis of triple-negative breast cancer cells. 2'-Nitroflavone also inhibits the migration of triple-negative breast cancer cells and endothelial cells. 2'-Nitroflavone exhibits antitumor activity and can be used in the research of tumors such as triple-negative breast cancer .
|
-
- HY-13645
-
|
|
VEGFR
c-Kit
PDGFR
|
Cancer
|
|
Henatinib is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities. Henatinib inhibits the activity of VEGFR-2, c-kit, PDGFR with IC50 values of 0.6 nM, 3.3 nM and 41.5 nM, respectively. Henatinib significantly inhibits VEGFR-2 phosphorylation and its downstream signal pathway in human umbilical vein endothelial cells (HUVECs) .
|
-
- HY-50868
-
|
INNO-406; NS-187
|
Bcr-Abl
Src
Apoptosis
|
Cancer
|
|
Bafetinib is an orally active Lyn/Bcr-Abl tyrosine kinase inhibitor. Bafetinib enhances the activity of several pro-apoptotic Bcl-2 homology (BH) 3-pure proteins (Bim, Bad, Bmf, and Bik) through intrinsic apoptotic pathways regulated by the Bcl-2 family, and induces apoptosis of Ph + leukemia cells. Bafetinib has antitumor activity .
|
-
- HY-W047478
-
|
NSC 10154
|
Fungal
Interleukin Related
|
Infection
Inflammation/Immunology
Cancer
|
|
3-Methylcarbazole (NSC 10154) is a carbazole alkaloid with an IC50 of 25 μg/mL against human fibrosarcoma cells. 3-Methylcarbazole inhibits mycelial growth and conidial germination of a variety of phytopathogenic fungi. 3-Methylcarbazole exhibits anti-inflammatory and antitumor activities. 3-Methylcarbazole can be used in studies related to fibrosarcoma, phytopathogenic fungal infections and inflammatory diseases .
|
-
- HY-N9942
-
|
|
Apoptosis
Autophagy
NF-κB
p38 MAPK
PI3K
Akt
mTOR
STAT
JAK
|
Inflammation/Immunology
Cancer
|
|
Physalin A is a biologically active withanolide. Physalin A shows anti-inflammatory, antifibrotic and ameliorative effects on autophagy in models of disc degeneration. Physalin A has antitumor activity and can induce apoptosis, ROS production and G2/M phase cell cycle arrest. Besides. Physalin A can significantly increase the activity of quinone reductase and increase the expression of detoxifying enzymesc .
|
-
- HY-147973
-
|
|
c-Myc
Apoptosis
|
Cancer
|
|
IZTZ-1, an imidazole-benzothiazole conjugate, is a c-MYC G4 ligand. IZTZ-1 is able to downregulate the c-MYC expression by stabilizing c-MYC G4. IZTZ-1 induces cell cycle arrest, apoptosis, thereby inhibiting cell proliferation in B16 cells. IZTZ-1 shows antitumor activity, and can be used for melanoma research .
|
-
- HY-154662
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N3-(2S)-(2-amino-3-carbonyl] propyl-beta-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2’-Deoxy-2’-fluoro-N3-(2S)-(2-amino-3-carbonyl] propyl-beta-D-arabinouridine](//file.medchemexpress.com/product_pic/hy-154662.gif)
- HY-144676
-
|
|
EGFR
Apoptosis
|
Cancer
|
|
pan-HER-IN-1 (Compound C5) is an irreversible, orally active pan-HER inhibitor with IC50 values of 0.38, 1.6, 2.2 and 3.5 nM against EGFR, HER4, EGFR T790M/L858R and HER2, respectively. pan-HER-IN-1 induces apoptosis and shows antitumor activities .
|
-
- HY-162616
-
|
|
HDAC
Apoptosis
|
Cancer
|
|
SelSA is a selective, orally active inhibitor for histone deacetylase 6 (HDAC6) with IC50 of 56.9 nM. SelSA inhibits the phosphorylation of ERK1/2. SelSA inhibits the proliferation of breast cancer cells and hepatocellular carcinoma cells with IC50 of 0.58-2.6 μM, inhibits cell migration and invasion of Huh7, and induces apoptosis. SelSA exhibits antitumor activity in mouse model .
|
-
- HY-181097
-
|
|
Apoptosis
EGFR
VEGFR
mTOR
HIF/HIF Prolyl-Hydroxylase
PI3K
Akt
PTEN
|
Cancer
|
|
EGFR-IN-192 is an anticancer agent. EGFR-IN-192 inhibits EGFR (IC50: 0.12 μM), downregulates the HIF-VEGF and PI3K/AKT/mTOR pathways, upregulates the tumor suppressor gene PTEN, and induces cell cycle arrest and apoptosis in tumor cells. EGFR-IN-192 exhibits antitumor activity and can be used in tumor research .
|
-
- HY-101489
-
|
|
PDGFR
Bcr-Abl
Apoptosis
|
Cancer
|
|
GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC50s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-Abl T315I inhibitor, with IC50s of 19.9 and 15.4 nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity .
|
-
- HY-P99333
-
|
M200; Eos 200-4
|
Integrin
|
Cardiovascular Disease
Cancer
|
|
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .
|
-
- HY-134673
-
UZH1
3 Publications Verification
|
Apoptosis
|
Cancer
|
|
UZH1 is a racemate of UZH1a and UZH1b. UZH1a is a potent and selective METTL3 inhibitor, with an IC50 of 280 nM. UZH1b (IC50=28 µM) is essentially inactive. UZH1 can be used for epitranscriptomic modulation of cellular processes. UZH1 has antitumor activity. UZH1 also can be used as a chemical probe for studying METTL3 .
|
-
- HY-W551230
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-6-chloropurine-9-beta-D-(2’-deoxy-3’,5’-di-O-(p-toluoyl))riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-139018
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
TLR7/8 agonist 4 hydroxy-PEG10-acid (compound 9) is a drug-linker conjugates for ADC with potent antitumor activity by using TLR7/8 agonist 4 (HY-139018; a TLR7/8 agonist), linked via the non-cleavable ADC linker hydroxy-PEG10-acid (HY-133307) .
|
-
- HY-P1812A
-
|
NP-12 TFA
|
PD-1/PD-L1
|
Cancer
|
|
AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .
|
-
- HY-153390A
-
|
|
Histone Methyltransferase
|
Cancer
|
|
(R)-AMG-193 is an isomer of AMG 193 (HY-153390). AMG 193 is an orally active MTA-cooperative PRMT5 inhibitor with antitumor activity. AMG 193, when complexed with MTA, preferentially inhibits the growth of MTAP-deficient tumor cells by inhibiting PRMT5 (IC50=0.107 μM), thereby protecting normal cells with wild-type MTAP .
|
-
- HY-154653
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(2,3,5-Tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)-9H-purin-2-amine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-135317
-
|
CA-4948
|
IRAK
Apoptosis
FLT3
NF-κB
MyD88
|
Inflammation/Immunology
Cancer
|
|
Emavusertib is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib exhibits antitumor activity in mouse model
|
-
- HY-155971
-
|
|
Autophagy
|
Inflammation/Immunology
Cancer
|
|
VISTA-IN-2 (Compound 1) is an inhibitor of V-domain Ig suppressor of T-cell activation (VISTA). VISTA-IN-2 induces VISTA degradation in cells through an autophagic mechanism. VISTA-IN-2 rescues VISTA-mediated immunosuppression, and enhances antitumor activity of immune cells. VISTA-IN-2 also activates the antitumor immunity and inhibits tumor growth in a CT26 mouse model .
|
-
- HY-162848
-
|
|
PI3K
|
Cancer
|
|
IHMT-PI3K-315 (20e) is a potent and selective PI3Kγ/δ inhibitor with IC50 values for PI3Kγ and PI3Kδ of 4.0 and 9.1 nM, respectively. IHMT-PI3K-315 has antitumor activity .
|
-
- HY-P10950A
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
PD-L1 inhibitory peptide TFA is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide TFA binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide TFA is promising for research of cancers .
|
-
- HY-130558
-
|
|
Apoptosis
Microtubule/Tubulin
|
Cancer
|
|
SL-1-73 is a tubulin ligand. SL-1-73 exhibits antitumor activity against esophageal squamous cell carcinoma (ESCC) both in vitro and in vivo by inhibiting microtubule assembly, inducing G2/M phase cell cycle arrest and apoptosis, and disrupting tumor blood vessels. SL-1-73 can be used for the research of ESCC and other tumors .
|
-
- HY-144677
-
|
|
EGFR
Apoptosis
|
Cancer
|
|
pan-HER-IN-2 (Compound C6) is a reversible, orally active pan-HER inhibitor with IC50 values of 0.72, 2.0, 8.2 and 75.1 nM against EGFR, HER4, EGFR T790M/L858R and HER2, respectively. pan-HER-IN-2 induces apoptosis and shows antitumor activities .
|
-
- HY-W016689
-
|
|
Drug Intermediate
|
Cancer
|
|
2-Amino-4-phenylthiazole is a synthetic intermediate useful for pharmaceutical synthesis. 2-Amino-4-phenylthiazole can be used to synthesize suberoylanilide hydroxamic acid (SAHA) analogs with cancer cell growth inhibitory activities. 2-Amino-4-phenylthiazole also can be used to synthesize ketone histone deacetylase inhibitors with antitumor activity in vivo .
|
-
- HY-16559A
-
|
P276-00 free base
|
CDK
|
Cancer
|
|
Riviciclib (P276-00 free base) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively .
Riviciclib shows antitumor activity on cisplatin-resistant cells .
|
-
- HY-161957
-
|
|
Topoisomerase
|
Cancer
|
|
Top1/2-IN-1 (compound 23) is an orally available dual inhibitor of Top1/2 with antiproliferative activity. Top1/2-IN-1 damages DNA with increased levels of reactive oxygen species, inducing apoptosis and cell cycle arrest in cancer cells. Top1/2-IN-1 exhibits in vivo antitumor activity in xenograft models .
|
-
- HY-172175
-
|
|
mTOR
Akt
PI3K
Apoptosis
Autophagy
|
Cancer
|
|
HYS-072 is an orally active derivative of chrysin (HY-14589) with antitumor activity. HYS-072 induces apoptosis and autophagy by inhibiting the PI3K/AKT/mTOR signaling pathway and suppresses tumor growth in vivo in xenograft models by modulating autophagy-related pathways. HYS-072 can be used in the research of triple-negative breast cancer .
|
-
- HY-14266A
-
|
|
Apoptosis
Reverse Transcriptase
Autophagy
HIV
|
Infection
|
|
Dapivirine hydrochloride is a non-nucleoside reverse transcriptase inhibitor with antitumor activity. Dapivirine hydrochloride attenuates the proliferation of glioblastoma cells and induces apoptosis. Dapivirine hydrochloride modulates autophagy and activates Akt, Bad, and SAPK/JNK signaling pathways. Dapivirine hydrochloride has shown inhibitory effects on glioma cell growth both in vitro and in vivo. Dapivirine hydrochloride is also a promising drug candidate for topical microbial agents for the prevention of sexual transmission of HIV-1 .
|
-
- HY-12248A
-
|
CB-839 hydrochloride
|
Glutaminase
Autophagy
|
Cancer
|
|
Telaglenastat (CB-839) hydrochloride is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat hydrochloride selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC50s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat hydrochloride inudces autophagy and has antitumor activity .
|
-
- HY-P991902
-
|
|
CD20
|
Cancer
|
|
NAV006 is an anti-CD20 antibody variant of Rituximab (HY-P9913) with a Kd of 30.5 nM to CD20. NAV006 exhibits reduced interaction with CA125 and demonstrates enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activity. NAV006 displays antitumor activity against lymphoma and can be used in research on non-Hodgkin lymphoma .
|
-
- HY-139018A
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride (compound 9) is a drug-linker conjugates for ADC with potent antitumor activity by using TLR7/8 agonist 4 (HY-139018; a TLR7/8 agonist), linked via the non-cleavable ADC linker hydroxy-PEG10-acid (HY-133307) .
|
-
- HY-161617
-
|
|
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
LASSBio-2052 is a derivative of N-acylhydrazone with antitumor activity against hepatocellular carcinoma (HCC). LASSBio-2052 inhibits HCC cells HepG2 and Hep3B, with IC50 of 18 and 41 μM. LASSBio-2052 arrests the cell cycle at G2/M phase, through downregulation of FOXM1. LASSBio-2052 induces apoptosis in HCC cells .
|
-
- HY-154362
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,2-Di-O-acetyl-3-deoxy-3-fluoro-5-O-(4-methyl)benzoyl-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-100748R
-
|
CXD101 (Standard)
|
HDAC
Reference Standards
|
Cancer
|
|
Zabadinostat (Standard) is the analytical standard of Zabadinostat (HY-100748). This product is intended for research and analytical applications. Zabadinostat (CXD101) is a potent, selective and orally active class I HDAC inhibitor with IC50s of 63 nM, 570 nM and 550 nM for HDAC1, HDAC2 and HDAC3, respectively. Zabadinostat has no activity against HDAC class II. Zabadinostat has antitumor activity .
|
-
- HY-154724
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N3-(2S)-[2-(tert-butoxy-carbonyl)-amino-3-carbonyl]propyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2’-Deoxy-2’-fluoro-N3-(2S)-[2-(tert-butoxy-carbonyl)-amino-3-carbonyl]propyluridine](//file.medchemexpress.com/product_pic/hy-154724.gif)
- HY-W020361
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2'-C-Ethynyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2'-C-Ethynyluridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-149974
-
|
|
Apoptosis
CDK
|
Cancer
|
|
CDK8-IN-13 is a potent, selective and orally active CDK8 inhibitor with an IC50 value of 51.9 nM. CDK8-IN-13 induces apoptosis. CDK8-IN-13 decreases the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 shows antitumor activity .
|
-
- HY-12248
-
|
CB-839
|
Glutaminase
Autophagy
|
Cancer
|
|
Telaglenastat (CB-839) is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC50s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat inuduces autophagy and has antitumor activity .
|
-
- HY-132150A
-
-
- HY-154125
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Chloro-2-fluoropurine-9-b-D-(3,5-bis-O-(p-toluoyl)-2-deoxy)riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N9666
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Chromomycin A4, a major byproduct of Chromomycin A3 (HY-W040129)'s manufacture, is an antibiotic produced by Streptomyces griseus No. 7. Chromomycin A4 exhibits cancerostatic and antitumor activity. Chromomycin A4 shows strong growth inhibition against Gram-positive bacteria and and activity against tuberculous bacilli. Chromomycin A4 can be used for the research of bacterial infection .
|
-
- HY-P10513
-
|
AP1-Z1
|
Bacterial
Fungal
Apoptosis
|
Infection
Cancer
|
|
AcrAP1 (AP1-Z1) is an antimicrobial peptide found in the venom of the Arabian scorpion (Androctonus crassicauda). AcrAP1 has antimicrobial activity and can inhibit the growth of Gram-positive and Gram-negative bacteria as well as yeast. AcrAP1 exerts antitumor activity by promoting apoptosis of cancer cells and inhibiting angiogenesis. AcrAP1 can be used in cancer therapy research .
|
-
- HY-172671
-
|
|
STING
|
Cancer
|
|
STING agonist-43 (Compound 67) is a selective STING agonist (EC50: 20.53 μM). STING agonist-43 selectively amplifies cGAMP-dependent STING pathway activation by modulating STING oligomerization. B16.F10 has antitumor activity in a mouse melanoma model. STING agonist-43 can be used for the study of cancer immunity .
|
-
- HY-P10521
-
|
|
VEGFR
|
Cancer
|
|
Apolipoprotein KV domain (67-77) is an 11-amino acid peptide identified from the KV domain of human apolipoprotein a (ApoA) with antiangiogenic and antitumor activities. Apolipoprotein KV domain (67-77) targets the angiogenic c-Src/ERK pathway by blocking activation signals received from vascular endothelial growth factor (VEGF). Apolipoprotein KV domain (67-77) can be used in cancer research .
|
-
- HY-178980
-
|
|
Casein Kinase
|
Cancer
|
|
APL-5125 (Compound 61f) is a potent, selective and orally active ATP-competitive CK2α inhibitor with an IC50 of 0.348 nM and a Ki of 0.095 nM. APL-5125 binds to CK2α in a bivalent manner, simultaneously interacting with the ATP-binding site and the αD pocket. APL-5125 exhibits antitumor activity and can be used for the research of cancer, such as colon cancer .
|
-
- HY-139609
-
|
RP-3500; ATR inhibitor 4
|
ATM/ATR
mTOR
|
Cancer
|
|
Camonsertib (RP-3500) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC50 of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC50=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity .
|
-
- HY-162312
-
|
|
Deubiquitinase
Apoptosis
|
Cancer
|
|
LLK203 is a potent USP2/USP8 dual-target inhibitor with IC50s of 0.89 μM and 0.52 μM, respectively. LLK203 leads a degradation of ERα and induces apoptosis of breast cancer MCF-7 cells. LLK203 demonstrates antitumor activities against the 4T1 tumor mice model .
|
-
- HY-150570
-
|
|
Carbonic Anhydrase
CDK
|
Cancer
|
|
Carbonic anhydrase inhibitor 14 (Compound 8b) is a carbonic anhydrase (CA) inhibitor with Ki values of 1203, 99.7, 9.4 and 27.7 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 14 can also inhibit CDK2 with an IC50 of 20.3 μM. Carbonic anhydrase inhibitor 14 shows antitumor activity .
|
-
- HY-P99055
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
|
-
- HY-P991528
-
|
|
NF-κB
|
Inflammation/Immunology
Cancer
|
|
PE0116 is a fully human CD137 agonistic monoclonal antibody generated from immunized harbor H2L2 human transgenic mice. PE0116 is a ligand block. PE0116 activates NF-κB signaling which significantly promotes T-cell proliferation and increases cytokine secretion in vitro. PE0116 exhibits robust antitumor activity in MC38 tumor model .
|
-
- HY-149085A
-
|
|
RAR/RXR
|
Cancer
|
|
(E)-XS-060 is an isomer of XS-060. XS-060 is a RXRα antagonist. XS-060 inhibits pRXRα-PLK1 interaction. XS-060 induces RXRα-dependent mitotic arrest. XS-060 exhibits good antitumor activity against breast cancer, lung adenocarcinoma, and liver cancer .
|
-
- HY-149291
-
|
|
ATM/ATR
Apoptosis
|
Cancer
|
|
ATM Inhibitor-7 is a potent and selective ataxia-telangiectasia mutated (ATM) inhibitor with an IC50 value of 1.0 nM. ATM Inhibitor-7 induces Apoptosis and cell cycle arrest at G2/M phase when combinanted with CPT-11 (HY-16562). ATM Inhibitor-7 combines with CPT-11 shows antitumor activity .
|
-
- HY-156568
-
|
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
|
SMD-3040 is a potent and selective SMARCA2 PROTAC degrader (DC50: 12 nM; Dmax: 91%). SMD-3040 can inhibit tumor cell proliferation and exhibits antitumor activity. SMD-3040 can be used in the study of tumors such as melanoma . (SMARCA2/4-ligand (HY-171765); HY-112078 VHL ligand (HY-112078))
|
-
- HY-108713A
-
|
SHR1020 malate
|
VEGFR
PDGFR
Apoptosis
|
Cancer
|
|
Famitinib (SHR1020) malate, an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib malate induces cell apoptosis. Famitinib malate exerts powerful antitumor activity in human gastric cancer cells and xenografts, it can be used for the research of cancer .
|
-
- HY-W544503
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Chloro-9-(2,3,5-tri-O-benzoyl-2-C-methyl-beta-D-ribofuranosyl)-9H-purine dibenzoate is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-B0986R
-
|
4-Hexylresorcinol (Standard)
|
Reference Standards
Parasite
Bacterial
Apoptosis
Glycosidase
Endogenous Metabolite
|
Infection
Metabolic Disease
Cancer
|
|
Hexylresorcinol (Standard) is the analytical standard of Hexylresorcinol. This product is intended for research and analytical applications. Hexylresorcinol (4-Hexylresorcinol) is a natural compound found in plants with antimicrobial, anthelmintic, antiseptic and antitumor activities. Hexylresorcinol can induce apoptosis in squamous carcinoma cells. Hexylresorcinol is a reversible and noncompetitive inhibitor of α-glucosidase. Hexylresorcinol has protective effects against oxidative DNA damage .
|
-
- HY-W654009
-
|
|
Isotope-Labeled Compounds
COX
|
Inflammation/Immunology
|
|
Loxoprofen-d3 is deuterium labeled Loxoprofen. Loxoprofen is a non-steroidal, orally active anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen is a nonselective COX inhibitor with IC50s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively. Loxoprofen can reduce atherosclerosis and shows antitumor activity .
|
-
- HY-153543
-
|
|
Toll-like Receptor (TLR)
|
Cancer
|
|
TLR7/8 agonist 8 (compound 24m) is a potent toll-like receptor 7/8 (TLR7/8) dual agonist, with EC50s of 27 and 12 nM for hTLR7 and hTLR8, respectively. TLR7/8 agonist 8 can improve the antitumor activity of PD-1/PD-L1 blockade .
|
-
- HY-N0841
-
|
Dihydrobrusatol; NSC310616
|
Parasite
NF-κB
p38 MAPK
Phosphatase
Apoptosis
|
Infection
Cancer
|
|
Bruceine A (Dihydrobrusatol) is a natural quassinoid. Bruceine A is an inhibitor of parasites, NF-κB, and PFKFB4 (Kd: 44 nM). Bruceine A is an activator of P38α MAPK. Bruceine A has antiparasitic activity. Bruceine A has antitumor activity and inhibits cancer cell migration. Bruceine A blocks the cell cycle and induces apoptosis. Bruceine A can be used in parasites, pancreatic cancer, and breast cancer research .
|
-
- HY-138293
-
|
CDK7-IN-3
|
CDK
Apoptosis
|
Cancer
|
|
SY-5609 (CDK7-IN-3) is an orally active, highly selective, noncovalent CDK7 inhibitor with a KD of 0.065 nM. SY-5609 shows poor inhibition on CDK2 (Ki=2600 nM), CDK9 (Ki=960 nM), CDK12 (Ki=870 nM). SY-5609 induces apoptosis in tumor cells and has antitumor activity .
|
-
- HY-146277
-
|
|
Histone Acetyltransferase
|
Cancer
|
|
CBP/p300-IN-19 is a potent p300/CBP HAT inhibitor with IC50s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 shows antitumor activity .
|
-
- HY-P10847
-
|
|
Ras
|
Cancer
|
|
KS-58 is a KRpep-2d (HY-P3277) derivative. KS-58 is a K-Ras (G12D) inhibitory peptide that selectively binds K-Ras. KS-58 can enter cells and block intracellular Ras interaction with effector proteins. KS-58 inhibits the proliferation of tumor cells and has antitumor activity .
|
-
- HY-130596
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
DC-86-M is an antibiotic, which can be isolated from Streptomyces luteogriseus. DC-86-M exhibits antibacterial activities against Bacillus subtilis, Staphylococcus aureus, Enterococcus faecalis, Vibrio anguillarum, and Proteus vulgaris, with MIC <1 μg/mL. DC-86-M exhibits antitumor activity against mouse sarcoma 180 with LD50 of 25 mg/kg .
|
-
- HY-152819
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4-Amino-5-iodo-7-(2-β-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![4-Amino-5-iodo-7-(2-β-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine](//file.medchemexpress.com/product_pic/hy-152819.gif)
- HY-128741
-
-
- HY-N0446R
-
|
|
ADC Payload
Reference Standards
|
Cancer
|
|
10-Methoxycamptothecin (Standard) is the analytical standard of 10-Methoxycamptothecin. This product is intended for research and analytical applications. 10-Methoxycamptothecin is a natural bioactive derivative of camptothecin (CPT) isolated from Camptotheca acuminata, and has been confirmed to possess high anti-cancer properties. 10-Methoxycamptothecin has higher cytotoxicity than 10-hydroxycamptothecin by testing antitumor activity against 2774 cell lines .
|
-
- HY-W768839
-
|
|
Isotope-Labeled Compounds
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(Hydroxymethyl)cytidine- 13C,d2 is the deuterium labeled and 13C-labeled 5-(Hydroxymethyl)cytidine (HY-152854). 5-(Hydroxymethyl)cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152474
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-β-C-Ethynylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-β-C-Ethynylcytidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-112661
-
|
Antibiotic PC-766B
|
Antibiotic
Bacterial
Fungal
|
Infection
Cancer
|
|
PC-766B is a macrolide antibiotic. PC-766B is active against Gram-positive bacteria, and some fungi and yeasts, but inactive against Gram-negative bacteria. PC-766B shows antitumor activity against murine tumor cells. PC-766B has weak inhibitory activity against Na +, K +-ATPase .
|
-
- HY-126490
-
|
|
Bacterial
Antibiotic
DNA/RNA Synthesis
|
Infection
Cancer
|
|
Phleomycin is a copper-dependent DNA damaging agent and antibiotic with antitumor activity. Phleomycin binds to DNA and produces ROS in the presence of reducing agents (such as dithiothreitol and glutathione), inducing single-strand and double-strand breaks in DNA. Phleomycin can induce cell apoptosis or mutation and is widely used in cancer inhibition, microbial genetic transformation (as a screening marker to improve fungal transformation efficiency) and DNA repair mechanism research .
|
-
- HY-125916
-
|
|
Endogenous Metabolite
|
Cancer
|
|
Pseurotin A is a secondary metabolite of Aspergillus and other fungi. Pseurotin A is a competitive inhibitor of chitin synthase and a neuritogenic agent. Pseurotin A inhibits IgE production (IC50 = 3.6 μM). Pseurotin A inhibits the PCSK9-LDLr interaction. Pseurotin A shows dose-dependent reduction of PCSK9, along with increased LDLR levels in hormone-dependent breast cancer cell lines. Pseurotin A exhibits antitumor activity .
|
-
- HY-167876
-
|
|
PI3K
|
Cancer
|
|
PQR514 is a potent PI3K inhibitor with anticancer activity. PQR514 is able to inhibit cancer cell proliferation. PQR514 showed significant antitumor activity in the OVCAR-3 xenograft model, with the required concentration being approximately one-eighth that of PQR309. PQR514 has good pharmacokinetic properties and minimal brain penetration, making it an optimized candidate compound for inhibiting systemic tumors .
|
-
- HY-B0578AR
-
|
|
Reference Standards
COX
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Loxoprofen (sodium) (Standard) is the analytical standard of Loxoprofen (sodium). This product is intended for research and analytical applications. Loxoprofen sodium is a non-steroidal, orally active anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen sodium is a nonselective COX inhibitor with IC50s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively. Loxoprofen sodium can reduce atherosclerosis and shows antitumor activity .
|
-
- HY-108713R
-
|
SHR1020 (Standard)
|
Reference Standards
VEGFR
PDGFR
Apoptosis
|
Cancer
|
|
Famitinib (Standard) is the analytical standard of Famitinib. This product is intended for research and analytical applications. Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively . Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis .
|
-
- HY-152475
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-β-C-Ethynyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-β-C-Ethynyladenosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-176738
-
|
|
Apoptosis
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Antitumor agent-204 (compound 15a) is a potent antitumor agent. Antitumor agent-204 shows cytotoxicity. Antitumor agent-204 induces nitric oxide (NO) release and reactive oxygen species (ROS) generation. Antitumor agent-204 induces apoptosis and induces cell cycle arrest at G2/M phase. Antitumor agent-204 shows antitumor activity .
|
-
- HY-107367
-
|
S-22611
|
EGFR
|
Cancer
|
|
Epertinib (S-22611) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER4 and HER2, with IC50s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib shows potent antitumor activity . Epertinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-129040AR
-
|
MIBG sulfate (Standard); Iobenguane sulfate (Standard)
|
Adrenergic Receptor
Reference Standards
|
Cancer
|
|
m-Iodobenzylguanidine (sulfate) (Standard) is the analytical standard of m-Iodobenzylguanidine (sulfate). This product is intended for research and analytical applications. m-Iodobenzylguanidine sulfate (MIBG sulfate) is an analogue of the neurotransmitter norepinephrine with antitumor activity. Radioiodinated m-Iodobenzylguanidine sulfate is clinically used as a tumor-targeted radiopharmaceutical in the diagnosis and treatment of adrenergic tumors. m-Iodobenzylguanidine sulfate is a high-affinity substrate for cholera toxin that interferes with cellular mono(ADP-ribosylation) .
|
-
- HY-176249
-
|
TNBG
|
Apoptosis
|
Cancer
|
|
Tetrazanbigen is a potent and selective antitumor agent. Tetrazanbigen exhibits strong antitumor efficacy against six human cancer cell lines with an IC50 range of 2.13-8.01 μg/mL and an IC50 of 11.25 μg/mL against normal hepatocytes. Tetrazanbigen induces S phase arrest and apoptosis in QGY-7701 cells. Tetrazanbigen exerts its antitumor activity by inducing lipid accumulation accumulation in cancer cells .
|
-
- HY-123009
-
|
|
HIF/HIF Prolyl-Hydroxylase
Histone Acetyltransferase
|
Cancer
|
|
KCN1 is a p300/HIF-1α interaction inhibitor. KCN1 inhibits HIF transcriptional activity by binding to the CH1 domain of p300 and preventing the p300/HIF-1α assembly. KCN1 exerts antitumor activities through cell cycle arrest .
|
-
- HY-P990986
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Efdelikofusp alfa is a bispecific Fc fusion protein. Efdelikofusp alfa is formed by fusing the N-terminal extracellular domain of human CD80 (B7.1) with the Fc fragment of human immunoglobulin G4 (IgG4), and is linked to an interleukin-2 variant (IL-2v) as the C-terminal part. Efdelikofusp alfa exhibits potential immunostimulatory, immune checkpoint inhibitory, and antitumor activities.
|
-
- HY-10204
-
OSI-930
4 Publications Verification
|
c-Kit
VEGFR
c-Fms
Apoptosis
|
Cancer
|
|
OSI-930 is an orally selective inhibitor of Kit, KDR and CSF-1R (c-Fms) with IC50s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits Flt-1, c-Raf, Lck and low activity against PDGFRα/β, Flt-3 and Abl. OSI-930 has antitumor activity .
|
-
- HY-B1092A
-
|
D-Gluconic acid sodium salt; Sodium D-gluconate; D-Gluconate sodium salt
|
Environmental Pollutants
ERK
NO Synthase
Endogenous Metabolite
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Gluconate sodium (D-Gluconic acid sodium salt) is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury .
|
-
- HY-168845
-
|
|
CDK
Apoptosis
|
Cancer
|
|
CDK2/9-IN-1 (compound 20a) is an orally active dual inhibitor of CDK2 and CDK9 with IC50 values are 0.004 μM and 0.009 μM respectively. CDK2/9-IN-1 induces apoptosis by regulating G2/M cell cycle arrest. CDK2/9-IN-1 has antitumor activity .
|
-
- HY-P991062
-
|
Gensci-059
|
CD47
|
Cancer
|
|
Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets CD47. Gentulizumab displays strong binding to CD47 in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-B1152
-
|
|
Dopamine Receptor
CD276/B7-H3
FOXO
|
Neurological Disease
Cancer
|
|
Piperacetazine is an orally active dopamine receptor antagonist and phenothiazine antipsychotic. Piperacetazine can directly bind to the PAX3::FOXO1 fusion protein and inhibit its transcriptional activity. Piperacetazine also exhibits antitumor activity with an IC50 of 7.627 μM against PANC-1 cells. Piperacetazine can be used for the research of diseases such as schizophrenia and pancreatic cancer and other tumors .
|
-
- HY-106109
-
|
|
DNA Alkylator/Crosslinker
DNA/RNA Synthesis
|
Cancer
|
|
FK 973 is a dihydrobenzoxazine anticancer agent. FK 973 selectively inhibits DNA synthesis and can form DNA cross-links through cytoplasmic activation. FK 973 exhibits significant antitumor activity in various animal tumor models and human tumor xenografts, with relatively weak myelosuppressive effects. FK 973 is sensitive to neural tumor cells. FK 973 can be used for DNA-targeted antitumor research .
|
-
- HY-W020420
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Chloro-9-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-183601A
-
|
|
Bcl-2 Family
Apoptosis
|
Cancer
|
|
Mcl-1-IN-22 hydrochloride is a tetrahydro-β-carboline-based Mcl-1 inhibitor with a Ki of 0.015 μM. Mcl-1-IN-22 hydrochloride shows antitumor activity, induces apoptosis and produces synergistic antitumor effects in combination with Cisplatin (HY-17394) and Paclitaxel (HY-B0015). Mcl-1-IN-22 hydrochloride can be used for the research of cancer, such as ovarian cancer .
|
-
- HY-161779
-
|
|
Molecular Glues
Epigenetic Reader Domain
Apoptosis
|
Cancer
|
|
PLX-3618 is a molecular glue, that degrades BRD4 with DC50 of 12.2 nM. PLX-3618 promotes polyubiquitination and subsequent proteasomal degradation of BRD4 by recruiting of the E3 ligase substrate receptor, DCAF11. PLX-3618 inhibits the proliferation of various cancer cells, induces apoptosis in AML cells. PLX-3618 exhibits antitumor activity against AML in mouse models .
|
-
- HY-146617
-
|
|
Glutaminase
Apoptosis
|
Cancer
|
|
GLS1 Inhibitor-4 (compound 41e) is a potent GLS1 inhibitor with an IC50 of 11.86 nM. GLS1 Inhibitor-4 shows antiproliferative activity, good metabolic stability, robust GLS1 binding affinity. GLS1 Inhibitor-4 blocks the glutamine metabolism and induce the production of ROS. GLS1 Inhibitor-4 induces apoptosis and shows antitumor activity .
|
-
- HY-124284
-
-
- HY-152718
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4-Amino-5-cyano-1-(2-β-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2.3-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![4-Amino-1-(2-C-methyl-β-D-ribofuranosyl)-1H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile](//file.medchemexpress.com/product_pic/hy-152718.gif)
- HY-173224
-
|
|
CDK
Pim
|
Cancer
|
|
CDK2/PIM1-IN-1 is an inhibitor of CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM) kinases. CDK2/PIM1-IN-1 induces apoptosis and reduces tumor-promoting TNF-α expression. CDK2/PIM1-IN-1 has antitumor activity .
|
-
- HY-175870
-
|
|
Ras
|
Cancer
|
|
Eras-4001 (Compound 14-1) is a pan-KRAS inhibitor. Eras-4001 has potent antitumor activities and significantly inhibits the proliferation of wild-type and mutant (such as KRAS G12D, KRAS G12V and KRAS G12C) cancer cells. Eras-4001 effectively inhibits tumor growth in GP2D and Panc0403 xenograft mouse models .
|
-
- HY-157419
-
|
7-(4-Ethylphenyl)-FL118
|
Apoptosis
|
Cancer
|
|
FL77-24, a FL118 analog and apoptosis inducer, possesses antitumor activity, with IC50 values of 99.4 nM, 118 nM, <6.4 nM, 28.5 nM and <6.4 nM in HCT116, HepG2, MCF-7, A549 and HeLa cells, respectively. FL77-24 mainly causes cell cycle arrest in S and G2/M phases .
|
-
- HY-106219
-
|
|
Microtubule/Tubulin
P-glycoprotein
|
Cancer
|
|
BMS 275183 is a potent, orally active analogue of Paclitaxel (HY-B0015). BMS 275183 can stabilize microtubules and exhibits antitumor activity in in vivo tumor models. BMS 275183 is active in vitro against Paclitaxel-resistant tumors including those harboring tubulin mutations or overexpressing P-glycoprotein. BMS 275183 can be used for cancer research, such as non-small cell lung cancer (NSCLC) and prostate carcinoma .
|
-
- HY-P10596
-
|
|
Bacterial
Fungal
|
Infection
Cancer
|
|
Lasioglossin-III is an antimicrobial peptide that can be isolated from the venom of wild bees. Lasioglossin-III has high antibacterial activity against Gram-positive and Gram-negative bacteria, antifungal activity and antitumor activity. Lasioglossin-III has certain cytotoxicity against three cancer cell lines (HeLa S3, CRC SW 480 and CCRF-CEM T) with IC50 values of 4, 18 and 5 μM, respectively .
|
-
- HY-12895
-
SKI V
1 Publications Verification
|
SphK
PI3K
Apoptosis
|
Cancer
|
|
SKI V is a noncompetitive and potent non-lipid sphingosine kinase (SPHK; SK) inhibitor with an IC50 of 2 μM for GST-hSK. SKI V potently inhibits PI3K with an IC50 of 6 μM for hPI3k. SKI V decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P). SKI V induces apoptosis and has antitumor activity .
|
-
- HY-W550484
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2,6-Dichloro-9-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-D-arabinofuranosyl)-9H-purine arabinoriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-168440
-
|
|
Ligands for Target Protein for PROTAC
Aurora Kinase
CDK
|
Cancer
|
|
Aurora-A ligand 1 is a high-affinity and specific Aurora-A inhibitor with a dissociation constant (Kd) value of 0.85 nM. Aurora-A ligand 1 can serve as a ligand for target protein (Ligands for Target Protein for PROTAC) for the development of PROTAC Aurora-A degraders with antitumor activity. Aurora-A ligand 1 can be used for the synthesis of HLB-0532259 (HY-168439). HLB-0532259 shows anti-tumor activity against neuroblastoma .
|
-
- HY-10181
-
-
- HY-148713
-
|
|
Apoptosis
|
Cancer
|
|
Anti-CSCs agent-1 is a potent anti-CSCs agent. Anti-CSCs agent-1 inhibits cell growth and cell migration. Anti-CSCs agent-1 induces Apoptosis. Anti-CSCs agent-1 inhibits the viability of CSCs. Anti-CSCs agent-1 enhances the production of ROS in CSCs. Anti-CSCs agent-1 shows antitumor activity .
|
-
- HY-10446
-
Pralatrexate
Maximum Cited Publications
9 Publications Verification
|
Antifolate
Apoptosis
|
Cancer
|
|
Pralatrexate is an antifolate and is a potent dihydrofolate reductasean (DHFR) inhibitor with a Ki of 13.4 pM. Pralatrexate is a substrate for folylpolyglutamate synthetase with improved cellular uptake and retention. Pralatrexate has antitumor activities and has the potential for relapsed/refractory T-cell lymphoma treatment . Pralatrexate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-167840
-
|
|
PD-1/PD-L1
|
Neurological Disease
Cancer
|
|
IMMH-010 maleate is a prodrug that serves as a novel PD-L1 inhibitor, exhibiting potential antitumor activity for the treatment of neurological disorders and advanced malignant solid tumors. IMMH-010 maleate is rapidly converted to its active form, YPD-29B, following oral administration. IMMH-010 maleate is poised for advancing research in the field of PD-L1 inhibitors and related therapeutic applications.
|
-
- HY-21978
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9H-Purine, 6-chloro-2-iodo-9-β-D-ribofuranosyl- (6-CHLORO-2-IODOPURINE-9-RIBOSIDE) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-161647
-
|
|
Reactive Oxygen Species (ROS)
Apoptosis
Autophagy
Ferroptosis
|
Cancer
|
|
Antitumor agent-156 (Compound 20) causes DNA damage and mitochondrial dysfunction, promotes reactive oxygen species
generation, activates endoplasmic reticulum stress, and induce apoptosis, autophagy and ferroptosis. Antitumor agent-156 shows superior antitumor activity against cancer cells including Cisplatin (HY-17394) resistance cells. Antitumor agent-156 displayS good liver-targeting ability .
|
-
- HY-16559
-
|
P276-00
|
CDK
Apoptosis
|
Cancer
|
|
Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively .
Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells .
|
-
- HY-177285
-
|
|
Kinesin
ADC Payload
|
Cancer
|
|
NVP-BQS481 (Compound 1) is a selective Kinesin spindle protein-5 (Eg5) inhibitor with an IC50< 0.5 nM. NVP-BQS481 has significant antimitotic and antitumor activity (IC50: 0.0.9 nM for SK-OV-3ip cells). NVP-BQS481 can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-171138
-
|
SET0568
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
Mal-VC-PAB-DMEA-PNU-159682 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-topoisomerase II agent, PNU-159682, linked via the lysosomally cleavable dipeptide, Mc-VC-PAB. Mal-VC-PAB-DMEA-PNU-159682 can be used in the synthesis of Anti-CD22-NMS249 (HY-164761) .
|
-
- HY-P1755F
-
|
|
MDM-2/p53
|
Cancer
|
|
p53 (17-26), FITC labeled is a biological active peptide. p53 (17-26) is a peptide derived from the P53 MDM2 binding domain, with a Kd of 50 nM for MDM2. p53 (17-26) causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) exhibits antitumor activity and is applicable to research related to pancreatic cancer.
|
-
- HY-P991587
-
|
|
Orphan GPCR
|
Cancer
|
|
SAR-446523 is a humanized IgG1 monoclonal antibody inhibitor targeting GPRC5D. SAR-446523 significantly induces antibody-dependent cell-mediated cytotoxicity (ADCC). SAR-446523 has potent antitumor activity with improvement of mouse survival in NK humanized NOG huIL15 transgenic mice model bearing MM cells. SAR-446523 can be used for multiple myeloma (MM) research .
|
-
- HY-W605935
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-6-chloropurine -9-beta-D-(2’-deoxy-3’,5’-di-O-benzoyl-2’-fluoro)arabinoriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N0284R
-
|
|
Reference Standards
PI3K
Akt
|
Inflammation/Immunology
Cancer
|
|
Esculetin (Standard) is the analytical standard of Esculetin. This product is intended for research and analytical applications. Esculetin is an active ingredient extracted mainly from the bark of Fraxinus rhynchophylla. Esculetin inhibits platelet-derived growth factor (PDGF)-induced airway smooth muscle cells (ASMCs) phenotype switching through inhibition of PI3K/Akt pathway. Esculetin has antioxidant, antiinflammatory, and antitumor activities .
|
-
- HY-11107
-
|
|
c-Met/HGFR
Autophagy
Apoptosis
|
Cancer
|
|
PHA-665752 is a selective, ATP-competitive, and active-site inhibitor of the catalytic activity of c-Met kinase (Ki=4 nM; IC50=9 nM). PHA-665752 exhibits >50-fold selectivity for c-Met compared with a panel of diverse tyrosine and serine-threonine kinases. PHA-665752 induces apoptosis and cell cycle arrest, and exhibits cytoreductive antitumor activity .
|
-
- HY-B0578R
-
|
|
Reference Standards
COX
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Loxoprofen (Standard) is the analytical standard of Loxoprofen. This product is intended for research and analytical applications. Loxoprofen is a non-steroidal, orally active anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen is a nonselective COX inhibitor with IC50s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively. Loxoprofen can reduce atherosclerosis and shows antitumor activity .
|
-
- HY-152556
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3-Deaza-4’-C-methyluridine, 4-Hydroxy-1-β-D-(4-C-methylribofuranosyl)-2(1H)-pyridinone is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-106364
-
|
Bleomycin PEP; Pepleomycin
|
Apoptosis
Antibiotic
|
Cancer
|
|
Peplomycin (Bleomycin PEP) is an analog of Bleomycin (HY-108345) and an antitumor antibiotic. Peplomycin exhibits potent antitumor activity and relatively low pulmonary toxicity. Peplomycin can induce various skin abnormalities and trigger apoptosis in SSCKN cells of oral squamous cell carcinoma. Peplomycin can also induce pulmonary fibrosis. Peplomycin is applicable for the research of tumors, pulmonary fibrosis and other related diseases .
|
-
- HY-101494R
-
|
LY3214996 (Standard)
|
ERK
Reference Standards
|
Cancer
|
|
Temuterkib (Standard) is the analytical standard of Temuterkib (HY-101494). This product is intended for research and analytical applications. Temuterkib (LY3214996) is a highly selective inhibitor of ERK1 and ERK2, with IC50 of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.
|
-
- HY-145768
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1-IN-18 (Compound L31) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-18 blocks PD-1/PD-L1 with the IC50 of 1.054 μM. Antitumor Activity .
|
-
- HY-P11182
-
|
|
Bacterial
|
Infection
Cancer
|
|
ChMAP-28 is an antimicrobial peptide. ChMAP-28 can be derived from goat Capra hircus. ChMAP-28 can initiate necrotic death. ChMAP-28 is effective in killing many bacteria, including strains resistant to Polymyxin and Meropenem (HY-13678). ChMAP-28 shows antitumor activity against acute promyelocytic leukemia, epidermoid carcinoma, melanoma, breast adenocarcinoma .
|
-
- HY-183513
-
|
|
FAP
|
Cancer
|
|
L-Ala-BPA is a boron delivery agent. L-Ala-BPA is transported into tumor cells via PEPT1/2 and LAT-1 (SLC7A5) pathways and is rapidly cleaved systemically by endogenous proteases including FAP to yield L-BPA (HY-W087830). L-Ala-BPA shows antitumor activity and can be used for the research of Boron Neutron Capture Therapy (BNCT) .
|
-
- HY-P990992
-
|
GI-102
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Efzilonkofusp alfa is a bispecific Fc fusion protein. Efzilonkofusp alfa is formed by fusing the N-terminal extracellular domain of human CD80 (B7.1) with the Fc fragment of human immunoglobulin G4 (IgG4), and is linked to an interleukin-2 variant (IL-2v) as the C-terminal part. Efzilonkofusp alfa exhibits potential immunostimulatory, immune checkpoint inhibitory, and antitumor activities.
|
-
- HY-119413R
-
|
|
Reference Standards
Endogenous Metabolite
|
Neurological Disease
|
|
Loxoprofen (sodium) (Standard) is the analytical standard of Loxoprofen (sodium). This product is intended for research and analytical applications. Loxoprofen sodium is a non-steroidal, orally active anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen sodium is a nonselective COX inhibitor with IC50s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively. Loxoprofen sodium can reduce atherosclerosis and shows antitumor activity .
|
-
- HY-15096
-
MKT-077
Maximum Cited Publications
16 Publications Verification
FJ-776
|
Fluorescent Dye
HSP
|
Cancer
|
|
MKT-077 (FJ-776), a highly water-soluble mitochondrial dye, has significant antitumor activity . MKT-077 exhibits low cytotoxicity, and inhibits broad-spectrum human cancer cell lines (colon cancer, breast cancer, pancreatic cancer). MKT-077 inhibits the growth of tumor in nude mice enograft tumor model. Ex/Em=488/543 nm .
|
-
- HY-107367A
-
|
S-22611 hydrochloride
|
EGFR
|
Cancer
|
|
Epertinib (S-22611) hydrochloride is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER4 and HER2, with IC50s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib hydrochloride shows potent antitumor activity . Epertinib (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-146277A
-
|
|
Histone Acetyltransferase
|
Cancer
|
|
CBP/p300-IN-19 hydrochloride is a potent and selective p300/CBP HAT inhibitor with IC50s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 hydrochloride shows antitumor activity .
|
-
- HY-169982
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-136 (compound 21v) is a potent EGFR inhibitor with IC50 values of 20.2, 1.2, 2.3, 12.5 nM for EGFR WT, EGFR LR/TM, EGFR 19D/TM/CS, EGFR LR/TM/CS, respectively. EGFR-IN-136 shows antiproliferative activity. EGFR-IN-136 shows antitumor activity and has the potential for the research of NSCLC .
|
-
- HY-P991095
-
|
APV-527; ATOR-1016
|
Transmembrane Glycoprotein
|
Cancer
|
|
ALG.APV-527 (APV-527) is a bispecific 4-1BB (CD137) and 5T4 antibody. ALG.APV-527 is designed to activate 4-1BB on T and natural killer (NK) cells only when simultaneously bound to 5T4-expressing tumor cells. ALG.APV-527 has a potent antitumor activity .
|
-
- HY-N1984R
-
|
Qing Hao acid (Standard); Artemisinic acid (Standard); Arteannuic acid (Standard)
|
Reference Standards
JNK
Interleukin Related
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Artemisic acid (Standard) (Qing Hao acid (Standard)) is the analytical standard of Artemisic acid (HY-N1984). This product is intended for research and analytical applications. Artemisinic acid (Qing Hao acid) is a sesquiterpene that can be isolated from Artemisia annua L. Artemisinic acid is also an important precursor for the synthesis of Artemisinin (HY-B0094). Artemisinic acid has various pharmacological activities, such as antimalarial activity, antitumor activity, antipyretic effect, antibacterial activity, allelopathic effect, and anti-adipogenic effect .
|
-
- HY-152405
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Amino-1,2-dihydro-2-β-D-ribofuranosyl-4H-pyrazolo[3,4-d]pyrimidin-4-one is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![6-Amino-1,2-dihydro-2-β-D-ribofuranosyl-4H-pyrazolo[3,4-d]pyrimidin-4-one](//file.medchemexpress.com/product_pic/hy-152405.gif)
- HY-174847
-
|
|
p97
|
Cancer
|
|
VCP/p97 IN-2 (Compound V13) is a VCP/p97 inhibitor with IC50 of 32 nM for p97. VCP/p97 IN-2 has excellent antitumor activities and significantly inhibits tumor growth in Molm-13 xenograft mice model. VCP/p97 IN-2 can be used for acute myeloid leukemia (AML) research .
|
-
- HY-B1490AS1
-
|
|
Serotonin Transporter
Isotope-Labeled Compounds
Apoptosis
Autophagy
|
Others
|
|
Imipramine-d4 is deuterium labeled Imipramine. Imipramine is an orally active tertiary amine tricyclic antidepressant. Imipramine is a Fascin1 inhibitor with antitumor activities. Imipramine also inhibits serotonin transporter with an IC50 value of 32 nM. Imipramine stimulates U-87MG glioma cells autophagy and induces HL-60 cell apoptosis. Imipramine shows neuroprotective and immunomodulatory effects .
|
-
- HY-159893
-
|
|
Smo
Hedgehog
Apoptosis
|
Cancer
|
|
SMO-IN-5 ((Compound 25(B31)) is a potent and competitive inhibitor of smoothened (SMO) that can inhibit Hedgehog (Hh) signaling. SMO-IN-5 interacts with Smo through hydrogen bonds, hydrophobic interactions, and electrostatic forces. SMO-IN-5 inhibits PC cell proliferation, migration, and induces apoptosis by suppressing Gli1 expression. SMO-IN-5 exhibits antitumor activity in pancreatic cancer. .
|
-
- HY-154740R
-
|
|
Nucleoside Antimetabolite/Analog
Reference Standards
|
Cancer
|
|
3′-Chloro-3′-deoxythymidine (Standard) is the analytical standard of 3′-Chloro-3′-deoxythymidine. This product is intended for research and analytical applications. 3′-Chloro-3′-deoxythymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-13502B
-
|
Mitozantrone diacetate; NSC 301739 diacetate
|
Topoisomerase
PKC
Orthopoxvirus
Apoptosis
Endogenous Metabolite
|
Infection
Cancer
|
|
Mitoxantrone diacetate is a potent topoisomerase II inhibitor. Mitoxantrone diacetate also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone diacetate induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone diacetate shows antitumor activity . Mitoxantrone diacetate also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .
|
-
- HY-163710
-
|
|
VEGFR
Carbonic Anhydrase
|
Cancer
|
|
hCA/VEGFR-2 IN-5 (compound 9) is an indolone-phenylsulfonamide and a potential dual inhibitor of cancer-related hCA IX/XII and VEGFR-2. The IC50 values of hCA/VEGFR-2-IN-5 for VEGFR-2, hCA IX and hCA XII are 0.38 μM, 40 and 3.2 nM, respectively. hCA/VEGFR-2-IN-5 has antitumor activity .
|
-
- HY-13502
-
Mitoxantrone
Maximum Cited Publications
46 Publications Verification
Mitozantrone; NSC 301739
|
Topoisomerase
PKC
Orthopoxvirus
Apoptosis
Endogenous Metabolite
|
Infection
Cancer
|
|
Mitoxantrone is a potent topoisomerase II inhibitor. Mitoxantrone also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone shows antitumor activity . Mitoxantrone also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .
|
-
- HY-156568A
-
|
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
|
SMD-3040 TFA is a potent and selective SMARCA2 PROTAC degrader (DC50: 12 nM; Dmax: 91%). SMD-3040 TFA can inhibit tumor cell proliferation and exhibits antitumor activity. SMD-3040 TFA can be used in the study of tumors such as melanoma . (SMARCA2/4-ligand (HY-171765); HY-112078 VHL ligand (HY-112078))
|
-
- HY-P990649
-
|
TRU-015
|
CD20
|
Inflammation/Immunology
|
|
PF-5212374 (TRU-015) is a humanized antibody expressed in CHO, targeting CD20/MS4A1. PF-5212374 exhibits potent direct signaling and antibody-dependent cellular cytotoxicity, with complement-mediated cytotoxicity lower than that of Rituximab (HY-P9913). PF-5212374 has antitumor activity and can be used in the research of tumors such as lymphoma and inflammatory diseases .
|
-
- HY-156568B
-
|
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
|
SMD-3040 formate is a potent and selective SMARCA2 PROTAC degrader (DC50: 12 nM; Dmax: 91%). SMD-3040 formate can inhibit tumor cell proliferation and exhibits antitumor activity. SMD-3040 formate can be used in the study of tumors such as melanoma . (SMARCA2/4-ligand (HY-171765); HY-112078 VHL ligand (HY-112078))
|
-
- HY-B1490AS
-
|
|
Isotope-Labeled Compounds
Serotonin Transporter
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Imipramine-d6 is the deuterium labeled Imipramine hydrochloride. Imipramine is an orally active tertiary amine tricyclic antidepressant. Imipramine is a Fascin1 inhibitor with antitumor activities. Imipramine also inhibits serotonin transporter with an IC50 value of 32 nM. Imipramine stimulates U-87MG glioma cells autophagy and induces HL-60 cell apoptosis. Imipramine shows neuroprotective and immunomodulatory effects .
|
-
- HY-174460
-
|
|
Drug Intermediate
|
Cancer
|
|
pCR8 is a prodrug of CR8 (HY-18340). pCR8 is amphiphilic and can self-assemble into nanoparticles. pCR8 can release CR8 under the action of high concentration of H2O2 in the tumor microenvironment. CR8 is a molecular glue degrader that can effectively degrade cell cycle-related proteins and has antitumor activity. pCR8 can be used in the research of tumors such as breast cancer .
|
-
- HY-103224R
-
|
|
Reference Standards
PI3K
|
Cancer
|
|
PIT-1 (Standard) is the analytical standard of PIT-1. This product is intended for research and analytical applications. PIT-1 is a selective PIP3 (phosphatidylinositol 3,4,5-trisphosphate) antagonist. PIT-1 inhibits cancer cell survival and induces apoptosis by inhibition of PIP3 dependent PI3K / Akt signaling. PIT-1 exhibits antitumor activity in vivo .
|
-
- HY-180241
-
|
|
Glutaminase
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Glutaminase C-IN-3 is a potent allosteric inhibitor of Glutaminase C (GAC) with an EC50 of 116 nM. Glutaminase C-IN-3 regulates cellular metabolites and increases reactive oxygen species (ROS) production by blocking glutamine metabolism. Glutaminase C-IN-3 exhibits strong antitumor activity in an A549 xenograft mouse model. Glutaminase C-IN-3 can be used for the research of non-small cell lung cancer (NSCLC) .
|
-
- HY-P99293
-
|
IDEC 114; Anti-Human CD80 Recombinant Antibody
|
CD28
Apoptosis
|
Cancer
|
|
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors .
|
-
- HY-125269
-
|
|
YAP
|
Cancer
|
|
TED-347 is a potent, irreversible, covalent and allosteric inhibitor at YAP-TEAD protein-protein interaction with an EC50 of 5.9 μM for TEAD4⋅Yap1 protein-protein interaction. TED-347 specifically and covalently bonds with Cys-367 within the central pocket of TEAD4 with a Ki of 10.3 μM. TED-347 blocks TEAD transcriptional activity and has antitumor activity .
|
-
- HY-N15614
-
|
|
Others
|
Cancer
|
|
Cassamine is a diterpenoid compound that can be isolated from the bark of Erythrophleum fordii. Cassamine exhibits certain cytotoxicity against non-small cell lung cancer cell lines, with IC50 values of 3.4, 2.1, and 1.9 μM against A549, NCI-H1975, and NCI-H1299, respectively. Cassamine has antitumor activity and can be used in the research of lung cancer and other tumors .
|
-
- HY-103441
-
|
|
EGFR
|
Cancer
|
|
JNJ28871063 hydrochloride is an orally active, highly selective and ATP competitive pan-ErbB kinase inhibitor with IC50 values of 22 nM, 38 nM, and 21 nM for ErbB1, ErbB2, and ErbB4, respectively. JNJ28871063 hydrochloride inhibits phosphorylation of functionally important tyrosine residues in both EGFR and ErbB2. JNJ28871063 hydrochloride crosses the blood-brain barrier and has antitumor activity in human tumor xenograft models that overexpress EGFR and ErbB2 .
|
-
- HY-107365R
-
|
|
Reference Standards
PI3K
mTOR
|
Cancer
|
|
PQR530 (Standard) is the analytical standard of PQR530 (HY-107365). This product is intended for research and analytical applications. PQR530 is a potent, ATP-competitive, orally bioavailable and brain-penetrant dual pan-PI3K/mTORC1/2 inhibitor, with a subnanomolar Kd toward PI3Kα and mTOR (0.84 and 0.33 nM, respectively). Antitumor activity .
|
-
- HY-16478
-
|
TAS-102; FTD/TPI
|
Nucleoside Antimetabolite/Analog
Thymidylate Synthase
|
Cancer
|
|
Trifluridine/tipiracil hydrochloride mixture (TAS-102) is a potent and orally active nucleoside antitumor agent. The composition of Trifluridine/tipiracil hydrochloride mixture (TAS-102) is a 1:0.5 mixture (on a molar basis) of alpha,alpha,alpha-tri-fluorothymidine (FTD) and thymidine phosphorylase inhibitor (TPI). Trifluridine/tipiracil hydrochloride mixture (TAS-102) shows the antitumor activity mainly via the inhibition of thymidylate synthase (TS) and incorporation into DNA .
|
-
- HY-152447
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-beta-C-Ethynyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-beta-C-Ethynyl inosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-B1490S1
-
-
- HY-B1490S
-
|
|
Serotonin Transporter
Apoptosis
Autophagy
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Imipramine-d4 (hydrochloride) is the deuterium labeled Imipramine hydrochloride. Imipramine hydrochloride is an orally active tertiary amine tricyclic antidepressant. Imipramine hydrochloride is a Fascin1 inhibitor with antitumor activities. Imipramine hydrochloride also inhibits serotonin transporter with an IC50 value of 32 nM. Imipramine hydrochloride stimulates U-87MG glioma cells autophagy and induces HL-60 cell apoptosis. Imipramine hydrochloride shows neuroprotective and immunomodulatory effects .
|
-
- HY-125135
-
|
β-Peltatin
|
Apoptosis
Bcl-2 Family
Caspase
PARP
|
Cancer
|
|
(-)-β-Peltatin is an aryltetrahydronaphthalene lignan. (-)-β-Peltatin exhibits antitumor activity and cytotoxicity against pancreatic cancer cells. (-)-β-Peltatin induces G2/M cell cycle arrest and apoptosis in pancreatic cancer cells. (-)-β-Peltatin inhibits the growth of subcutaneous xenografts of pancreatic cancer cells in nude mice. (-)-β-Peltatin can be used in pancreatic cancer-related research .
|
-
- HY-N7719
-
-
- HY-12678R
-
|
NMS-E628 (Standard); RXDX-101 (Standard)
|
Reference Standards
ROS Kinase
Trk Receptor
Anaplastic lymphoma kinase (ALK)
Autophagy
|
Cancer
|
|
Entrectinib (Standard) is the analytical standard of Entrectinib. This product is intended for research and analytical applications. Entrectinib (NMS-E628) is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC50 values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice .
|
-
- HY-174160
-
|
|
TAM Receptor
Apoptosis
|
Cancer
|
|
MerTK-IN-2 (compound 15f) is an orally active MerTK inhibitor with an IC50 of 37.5 nM. MerTK-IN-2 can induce apoptosis. MerTK-IN-2 has antitumor activity with IC50 values of 1.79, 18.32, and 2.18 μM for human ovarian cancer cells A2780, breast cancer cells MDA-MB-231, and colon cancer cells HCT116, respectively .
|
-
- HY-P991366
-
|
AL008
|
CD47
|
Cancer
|
|
IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research .
|
-
- HY-168085
-
|
|
YAP
Apoptosis
|
Cancer
|
|
CV-4-26 (Compound 22) is a covalent inhibitor of TEAD. CV-4-26 inhibits YAP/TEAD-based transcription, leading to the reduction of CTGF and CYR61 expression. CV-4-26 inhibits Huh7 and HepG2 cell colony formation, induces cell cycle arrest, and apoptosis. CV-4-26 shows antitumor activity against hepatocellular carcinoma (HCC) and hepatoblastoma (HB) .
|
-
- HY-119906
-
|
FW-04-806
|
HSP
Apoptosis
|
Cancer
|
|
Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active Hsp90 inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation. Conglobatin induces apoptosis in human breast cancer cells and esophageal squamous cell carcinoma cells, and exhibits antitumor activity in vivo .
|
-
- HY-147853
-
|
|
Raf
|
Cancer
|
|
B-Raf IN 8 (compound 7g) is a potent B-Raf inhibitor, with an IC50 of 70.65 nM. B-Raf IN 8 exhibits antitumor activity against hepatocellular carcinoma (HEPG-2), colon carcinoma (HCT-116), mammary gland (MCF-7) and human prostate cancer (PC-3) cells, with IC50 values of 9.78, 13.78, 18.52 and 29.85 µM .
|
-
- HY-N6961R
-
|
|
Reference Standards
Dihydroorotate Dehydrogenase
DNA/RNA Synthesis
Parasite
|
Infection
Inflammation/Immunology
Cancer
|
|
Lapachol (Standard) is the analytical standard of Lapachol. This product is intended for research and analytical applications. Lapachol, a natural naphthoquinone, is an orally active, potent DHODH inhibitor. Lapachol has immunosuppressive activity on lymphocytes through its direct ability to block DHODH activity and inhibit pyrimidine synthesis. Lapachol is a vitamin K antagonist with antitumor activity and can inhibit DNA and RNA synthesis in neoplastic cells. Lapachol has anti-Leishmania activity .
|
-
- HY-152625
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Beta-C-Ethynyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-Beta-C-Ethynyl inosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-146980
-
|
|
Apoptosis
GLUT
|
Cancer
|
|
GLUT4-IN-2 is a potent and selective GLUT4 inhibitor with IC50s of 11.4 µM and 6.8 µM for GLUT1 and GLUT4, respectively. GLUT4-IN-2 induces cell apoptosis and cell cycle arrest at G0/G1phase. GLUT4-IN-2 shows potent antitumor activity .
|
-
- HY-145864
-
|
|
VEGFR
|
Cancer
|
|
VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent VEGFR-2 inhibitor with an IC50 of 0.037 µM. VEGFR-2-IN-12 shows high growth inhibition against MCF-7 cells (GI50=1.6 µM). VEGFR-2-IN-12 has antitumor activity .
|
-
- HY-13502A
-
|
Mitozantrone dihydrochloride; NSC 301739 dihydrochloride
|
Topoisomerase
PKC
Orthopoxvirus
Apoptosis
Endogenous Metabolite
|
Infection
Cancer
|
|
Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .
|
-
- HY-139590
-
|
BOS-172738; DS-5010
|
RET
PDGFR
|
Cancer
|
|
Zeteletinib (BOS-172738; DS-5010) is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. Zeteletinib shows exquisite potency for the wild type RET, RET V804M/L gatekeeper mutants, and the most common oncogenic RET mutation M918T. Zeteletinib has potent antitumor activity .
|
-
- HY-106263B
-
|
|
PTEN
PDK-1
MDM-2/p53
Apoptosis
Akt
|
Cancer
|
|
Tyroserleutide hydrochloride is a tripeptide isolated from the degradation products of porcine spleen with antitumor activity. Tyroserleutide hydrochloride can upregulate the expression of the tumor suppressor gene PTEN and inhibit the activity of AKT and PDK1. Tyroserleutide hydrochloride inhibits tumor cell proliferation and MDM2 phosphorylation by inhibiting the PI3K/AKT pathway, and also upregulates P21, P27, P53, and induces mitochondrial damage and cell apoptosis .
|
-
- HY-134723
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
DBCO-PEG4-GGFG-Dxd is a agent-linker conjugate for ADC with potent antitumor activity by using Dxd (a DNA topoisomerase I inhibitor), linked via the cleavable ADC linker DBCO-PEG4-GGFG . DBCO-PEG4-GGFG-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-125780R
-
|
|
Drug Metabolite
Reference Standards
|
Cardiovascular Disease
Neurological Disease
|
|
Dasatinib (monohydrate) (Standard) is the analytical standard of Dasatinib (monohydrate). This product is intended for research and analytical applications. Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib monohydrate inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib monohydrate also induces apoptosis and autophagy.
|
-
- HY-146715
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
IDO/Tubulin-IN-2 (HT2) is a potent TDO and tubulin inhibitor. IDO/Tubulin-IN-2 also shows potent activity against U87, HepG2, A549, HCT-116, and LO2 cancer cell lines, with IC50 values of 0.43, 0.036, 0.041, 0.095 and 1.04 μM, respectively. IDO/Tubulin-IN-2 remarkably promotes the antitumor activity .
|
-
- HY-152659
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Propargylpseudouridine (see GL102032) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . N1-Propargylpseudouridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-N13115A
-
|
(E)-21-Angeloyl-protoaescigenin
|
Others
|
Cancer
|
|
Protoescigenin 21-tiglate (compound 10) is a glycosidic oleanane-type triterpenoid (BAT) that can be isolated from the acid hydrolysis product (AHP) of the crude extract of Aesculus chinensis seeds. Aesculus-derived triterpenoids (BAT) generally exhibit good antitumor, anti-inflammatory, and anti-Alzheimer's activities. However, the antitumor activity of Protoescigenin 21-tiglate is relatively weak, with IC50 values of >80 μM and 80 μM against MCF-7 and HeLa cells, respectively .
|
-
- HY-P99272
-
|
BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody
|
CXCR
|
Cancer
|
|
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .
|
-
- HY-N14221
-
|
|
Antibiotic
DNA/RNA Synthesis
|
Infection
Cancer
|
|
Eponemycin is an antibiotic that exhibits antitumor activity. Eponemycin exhibits cytotoxicity in cancer cells B16-F10, L1210, P388 and HCT-116 with IC50 of 0.0017, 0.01, 0.031 and 0.0097 µg/mL, respectively. Eponemycin inhibits the DNA synthesis in B16-F10 and Mitomycin C with IC50 of 0.1 µg/mL and 0.41 µg/mL .
|
-
- HY-N13115
-
|
(Z)-Protoescigenin 21-tiglate
|
Others
|
Cancer
|
|
21-Angeloyl-protoaescigenin (compound 11) is a glycosidic oleanane-type triterpenoid (BAT) that can be isolated from the acid hydrolysis product (AHP) of the crude extract of Aesculus chinensis seeds. Aesculus-derived triterpenoids (BAT) generally exhibit good antitumor, anti-inflammatory, and anti-Alzheimer's activities. Protoescigenin 21-tiglate has antitumor activity, with IC50 values of 38.2 μM and 33 μM against MCF-7 and HeLa cells, respectively .
|
-
- HY-149040
-
|
(S)-OBI-3424; (S)-TH-3424; AST-3424
|
17β-HSD
|
Cancer
|
|
Odafosfamide ((S)-OBI-3424) is a highly selective prodrug bis-alkylating agent activated by aldehyde-keto reductase 1C3 (AKR1C3(). Odafosfamide is highly cytotoxic to cell lines with high AKR1C3 expression. Odafosfamide exhibits antitumor activity in a variety of tumors with high AKR1C3 expression (such as liver cancer, non-small cell lung cancer, and leukemia). Odafosfamide can be used in cancer research .
|
-
- HY-152443
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Amino-3-(furan-2-yl)-4-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![6-Amino-3-(furan-2-yl)-4-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine](//file.medchemexpress.com/product_pic/hy-152443.gif)
- HY-10181R
-
|
BMS-354825 (Standard)
|
Reference Standards
Bcr-Abl
Src
Autophagy
Apoptosis
|
Cancer
|
|
Dasatinib (Standard) is the analytical standard of Dasatinib. This product is intended for research and analytical applications. Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib also induces apoptosis and autophagy.
|
-
- HY-139590A
-
|
BOS-172738 hemiadipate; DS-5010 hemiadipate
|
RET
PDGFR
|
Cancer
|
|
Zeteletinib (BOS-172738; DS-5010) hemiadipate is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. Zeteletinib hemiadipate shows exquisite potency for the wild type RET, RET V804M/L gatekeeper mutants, and the most common oncogenic RET mutation M918T. Zeteletinib hemiadipate has potent antitumor activity .
|
-
- HY-162254
-
|
|
EGFR
Ack1
|
Cancer
|
|
EGFR T790M/L858R/ACK1-IN-1 is a dual inhibitor of EGFR T790M/L858R and ACK1. IC50 values are 23 and 263 nM, respectively. EGFR T790M/L858R/ACK1-IN-1 can inhibit cell proliferation and has antitumor activity .
|
-
- HY-101570
-
|
Peposertib; M3814
|
DNA-PK
BCRP
|
Cancer
|
|
Nedisertib (Peposertib) is an orally active selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of less than 3 nM. Nedisertib also acts as a modulator of ABCG2, capable of reversing ABCG2-mediated multidrug resistance (MDR), thus providing new strategies for combination therapy. By inhibiting DNA double-strand break repair, Nedisertib can enhance the efficacy of chemotherapy and radiotherapy. Nedisertib exhibits antitumor activity .
|
-
- HY-147852
-
|
|
Raf
|
Cancer
|
|
B-Raf IN 7 (compound 6a) is a potent B-Raf inhibitor, with an IC50 of 110.23 nM. B-Raf IN 7 exhibits antitumor activity against colon carcinoma (HCT-116), mammary gland (MCF-7), hepatocellular carcinoma (HEPG-2), human cervical carcinoma (Hela) and human prostate cancer (PC-3) cells, with IC50 values of 7.50, 9.87, 10.57, 11.63 and 12.83 µM .
|
-
- HY-P992462
-
|
|
Orexin Receptor (OX Receptor)
NF-κB
|
Cancer
|
|
SHR-1806 is a OX40 agonist and a NF-κB activator, with antitumor activity. SHR-1806 mediates ADCC and CDC effects, enhances the function and expansion of effector T cells, suppresses regulatory T cells, and increases γ-interferon secretion. SHR-1806 exhibits typical pharmacokinetic characteristics and favorable safety profiles. SHR-1806 can be used in studies related to solid tumors and colon cancer .
|
-
- HY-172873
-
|
|
HDAC
Caspase
Apoptosis
|
Cancer
|
|
HDSI-18 is an orally active HDAC6 selective inhibitor (IC50: 1.6 nM). HDSI-18 is cytotoxic to K562, MV4-11, MOLM-13, THP-1, and Jurkat cells (IC50: 0.48, 0.58, 0.91, 1.79, and 4.31 μM, respectively). HDSI-18 activates Caspase-3, induces mitochondrial depolarization and apoptosis, and has antitumor activity .
|
-
- HY-120372
-
|
|
Notch
|
Cancer
|
|
BMS-871 is an orally active pan-Notch inhibitor with IC50 values of 4/1/4/3 nM for Notch1/2/3/4, respectively. BMS-871 significantly inhibited the proliferation of TALL-1 and MDA-MB-157 cells and demonstrated significant antitumor activity in T-acute lymphoblastic leukemia and triple-negative breast cancer xenograft models. BMS-871 can be used to study leukemia and breast cancer .
|
-
- HY-157396
-
|
|
Aurora Kinase
Apoptosis
Caspase
|
Cancer
|
|
JAB-2485 is an orally active and selective Aurora kinase A (AURKA) inhibitor with an IC50 value of 0.327 nM. JAB-2485 exhibits inhibitory activity against various tumor cell lines such as neuroblastoma, triple-negative breast cancer, small cell lung cancer, and epithelial ovarian cancer. JAB-2485 can induce cell cycle arrest and apoptosis in tumor cells. JAB-2485 has antitumor activity .
|
-
- HY-161629
-
|
|
Toll-like Receptor (TLR)
|
Cancer
|
|
TLR8 agonist 7 (Compound II-36) is an agonist for Toll-like receptor 8 (TLR8) with EC50 <250 nM. TLR8 agonist 7 is stable in human and murine plasma, induces secretion of cytokines TNFα, with EC50 <1 μM. TLR8 agonist 7 exhibits antitumor activity in MC38-HER2 xenograft mouse model with a tumor growth inhibition (TGI) rate of 98% .
|
-
- HY-133147
-
|
|
HDAC
Apoptosis
|
Cancer
|
|
HDAC3/6-IN-2 (compound 15) is a potent HDAC6 and HDAC3 inhibitor, with IC50 values of 0.368 and 0.635 μM, respectively. HDAC3/6-IN-2 shows antitumor activity, and induces cancer cell apoptosis. HDAC3/6-IN-2 decreases the levels of HDAC6 and HDAC3, associated with upregulation of acetylated H3 and α-tubulin .
|
-
- HY-100707
-
|
|
DNA-PK
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
IC 86621 is a potent DNA-dependent protein kinase (DNA-PK) inhibitor, with an IC50 of 120 nM. IC 86621 also acts as a selective and reversible ATP-competitive inhibitor.IC 86621 inhibits DNA-PK mediated cellular DNA double-strand break (DSB) repair (EC50=68 µM). IC 86621 increases DSB-induced antitumor activity without cytotoxic effects. IC 86621 can protects rheumatoid arthritis (RA) T cells from apoptosis .
|
-
- HY-128766A
-
|
|
Checkpoint Kinase (Chk)
|
Cancer
|
|
CHK1-IN-4 hydrochloride is a selective checkpoint kinase 1 (Chk1) inhibitor with an IC50 ≤ 1 nM. The IC50 value of CHK1-IN-4 hydrochloride against Chk2 ranges from 50 to 100 nM. CHK1-IN-4 hydrochloride inhibits cancer cell proliferation and exhibits antitumor activity in colon cancer xenograft models. CHK1-IN-4 hydrochloride can be used for the research of colon cancer and breast cancer .
|
-
- HY-18030A
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
CEP-28122 mesylate salt, a diaminopyrimidine derivative, is a potent, selective, and orally active ALK inhibitor with an IC50 value of 1.9 nM. CEP-28122 mesylate salt has antitumor activity in experimental models of ALK-positive human cancers. CEP-28122 mesylate salt has good pharmacodynamic and pharmacokinetic activity. CEP-28122 mesylate salt can be used for the study of ALK-positive anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells .
|
-
- HY-152616
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-3,7-dihydro-5-iodo-7-β-D-ribofuranosyl-4H-pyrrolo[2,3-d]pyrimidin-4-one is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2-Amino-3,7-dihydro-5-iodo-7-β-D-ribofuranosyl-4H-pyrrolo[2,3-d]pyrimidin-4-one](//file.medchemexpress.com/product_pic/hy-152616.gif)
- HY-154613
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
(2R-cis)-5-[Tetrahydro-5-(hydroxymethyl)-4-oxo-2-furanyl]-2,4(1H,3H)-pyrimidinedione is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![(2R-cis)-5-[Tetrahydro-5-(hydroxymethyl)-4-oxo-2-furanyl]-2,4(1H,3H)-pyrimidinedione](//file.medchemexpress.com/product_pic/hy-154613.gif)
- HY-173433
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
JV8 is a BRD4 PROTAC degrader. JV8 promotes the ubiquitination and degradation of BRD4 and induces apoptosis. JV8 has antitumor activity in a mouse 4T1 orthotopic tumor model. (Pink: BRD4 ligand (HY-78695); Blue: E3 ligase VHL ligand (HY-173435); Black: Linker (HY-33366); E3 ligase VHL ligand-linker conjugate (HY-173436)) .
|
-
- HY-P990534
-
|
K1-70
|
TSH Receptor
|
Endocrinology
Cancer
|
|
Anti-TSHR Antibody (K1-70) is an anti-TSHR monoclonal antibody. Anti-TSHR Antibody (K1-70) incorporates a single-chain variable fragment into a chimeric antigen receptor to redirect T cells to TSHR-expressing cells. Anti-TSHR Antibody (K1-70) shows antitumor activity with no apparent toxicity. Anti-TSHR Antibody (K1-70) can be used for the research of differentiated thyroid cancer (DTC) .
|
-
- HY-102018R
-
|
|
Reference Standards
Nucleoside Antimetabolite/Analog
|
Others
Cancer
|
|
3'-Deoxy-3'-fluoroadenosine (Standard) is the analytical standard of 3'-Deoxy-3'-fluoroadenosine (HY-102018). This product is intended for research and analytical applications. 3'-Deoxy-3'-fluoroadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-157214
-
|
|
STING
Molecular Glues
|
Cancer
|
|
NVS-STG2 is a molecular glue that targets STINGactivity of cGAMP by inducing the formation of more abundant and larger oligomers. NVS-STG2 produces antitumor activity in animal models .
|
-
- HY-123587A
-
|
|
Apoptosis
|
Cancer
|
|
(R)-PR-924 is the isomer of PR-924 (HY-123587), and can be used as an experimental control. PR-924 is a selective tripeptide epoxyketone immunoproteasome subunit LMP-7 inhibitor with an IC50 of 22 nM. PR-924 covalently modifies proteasomal N-terminal threonine active sites. PR-924 inhibits growth and triggers apoptosis in multiple myeloma (MM) cells. PR-924 has antitumor activities .
|
-
- HY-18030
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
CEP-28122, a diaminopyrimidine derivative, is a potent, selective, and orally active ALK inhibitor with an IC50 value of 1.9 nM. CEP-28122 has antitumor activity in experimental models of ALK-positive human cancers. CEP-28122 has good pharmacodynamic and pharmacokinetic activity. CEP-28122 can be used for the study of ALK-positive anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells .
|
-
- HY-181517
-
|
|
Bacterial
|
Infection
Cancer
|
|
Antitumor agent-212 is a α-exo-methylene-selenolactone derivative with prominent selective antitumor activity. Antitumor agent-212 exhibits an MIC value of 128 μg/mL against Gram-positive bacteria. Antitumor agent-212 exhibits significant antitumor effects in the U87 human glioma xenograft model. Antitumor agent-212 can be used for the study of glioma, breast cancer and non-small cell lung cancer, and antibacterial study .
|
-
- HY-123486
-
|
|
Apoptosis
Bcr-Abl
|
Cancer
|
|
HS-438 is a potent and selective BCR-ABL inhibitor. HS-438 shows antiproliferative activity. HS-438 decreases the expression of phosphorylation of BCR-ABL (Tyr177). HS-438 induces apoptosis and cell cycle arrest at G0/G1 phase. HS-438 shows antitumor activity. HS-438 has the potential for the research of chronic myeloid leukemia (CML) .
|
-
- HY-W130901
-
|
Pent-4-ynylbenzene
|
Bacterial
|
Infection
Cancer
|
|
5-Phenyl-1-pentyne (Pent-4-ynylbenzene) is a compound with antibacterial and antitumor activity, which can effectively inhibit the growth of certain cancer cells. 5-Phenyl-1-pentyne is often used as a reaction intermediate in organic synthesis to promote a variety of chemical reactions. 5-Phenyl-1-pentyne is also used in the synthesis of new compounds to improve the bioavailability and inhibitory effect of the compounds.
|
-
- HY-B1490AS3
-
-
- HY-128766
-
|
|
Checkpoint Kinase (Chk)
|
Cancer
|
|
CHK1-IN-4 is a selective checkpoint kinase 1 (Chk1) inhibitor with an IC50 ≤ 1 nM. The IC50 value of CHK1-IN-4 against Chk2 ranges from 50 to 100 nM. CHK1-IN-4 inhibits cancer cell proliferation and exhibits antitumor activity in colon cancer xenograft models. CHK1-IN-4 can be used for the research of colon cancer and breast cancer .
|
-
- HY-B0413
-
|
|
Parasite
HIF/HIF Prolyl-Hydroxylase
Microtubule/Tubulin
Antibiotic
|
Infection
Cancer
|
|
Fenbendazole is an orally active benzimidazole anthelmintic agent, with a broad antiparasitic range. Fenbendazole is a microtubule destabilizing agent and acts on helminthes primarily by binding to tubulin and disrupting the tubulin microtubule equilibrium. Fenbendazole stabilizes the transcriptional activator HIF-1α. Fenbendazole possesses an efficient anti-proliferative activity and induces apoptosis. Fenbendazole causes cell-cycle arrest and mitotic cell death, and has antitumor activity in mice xenografted with wild-type p53 .
|
-
- HY-P11076
-
|
|
Complement System
|
Cancer
|
|
CP-EPS8-NLS is a peptide with anti-AML property. CP-EPS8-NLS interferes with EPS8-associated signaling and exerts anti-AML activity in various AML cell types. CP-EPS8-NLS has potent antitumor activity in xenograft tumor models. CP-EPS8-NLS downregulates EPS8 expression and its downstream pathway .
|
-
- HY-50936S
-
|
Ecteinascidin 743-d3; ET-743-d3
|
Isotope-Labeled Compounds
Reactive Oxygen Species (ROS)
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Trabectedin D3 (Ecteinascidin 743 D3) is deuterium labeled Trabectedin. Trabectedin is a tetrahydroisoquinoline alkaloid with potent antitumor activity. Trabectedin binds to the minor groove of DNA, blocks transcription of stress-induced proteins, induces DNA backbone cleavage and cancer cells apoptosis, and increases the generation of ROS in MCF-7 and MDA-MB-453 cells. Trabectedin has tje potential for soft tissue sarcoma and ovarian cancer treatment .
|
-
- HY-128912
-
|
|
Histone Demethylase
|
Cancer
|
|
Arborinine is a potent and orally activeLSD1 inhibitor. Arborinine increases the expression of H3K4me1/2, H3K9me1/2, E-cad protein and decreases the expression of UBE2O protein level. Arborinine induces cell cycle arrest at S phase. Arborinine shows antitumor activity .
|
-
- HY-W741987
-
|
6,7-Didehydronorethisterone
|
Drug Metabolite
Fungal
Apoptosis
MDM-2/p53
|
Infection
Cancer
|
|
6,7-Dehydro Norethindrone (6,7-Didehydronorethisterone) (Compound 26) is a Norethisterone (HY-B0554) metabolite. 6,7-Dehydro Norethindrone can be produced by the biotransformation of Norethisterone using Rhizopus microsporus PT2906. 6,7-Dehydro Norethindrone induces Apoptosis, binds to p53 and inhibits the degradation of p53. 6,7-Dehydro Norethindrone selectively exhibits antitumor activity against cervical cancer .
|
-
- HY-169120
-
|
|
Telomerase
|
Cancer
|
|
FKB04 is a telomeric repeat binding factor 2 (TRF2) inhibitor that exerts its antitumor activity by disrupting the telomere maintenance mechanism in liver cancer cells, leading to T-loop defects, telomere shortening, and cellular senescence. Additionally, FKB04 can inhibit tumor growth in a human liver cancer xenograft mouse model (with Huh-7 cells implanted in BALB/c mice). FKB04 can be used in liver cancer research .
|
-
- HY-100862R
-
|
|
PARP
Reference Standards
|
Cancer
|
|
BRCA1-IN-2 (Standard) is the analytical standard of BRCA1-IN-2 (HY-100862). This product is intended for research and analytical applications. BRCA1-IN-2 (compound 15) is a cell-permeable protein-protein interaction (PPI) inhibitor for BRCA1 with an IC50 of 0.31 μM and a Kd of 0.3 μM, which shows antitumor activities via the disruption of BRCA1 (BRCT)2/protein interactions .
|
-
- HY-135960
-
BO-264
1 Publications Verification
|
FGFR
Apoptosis
|
Cancer
|
|
BO-264 is a highly potent and orally active transforming acidic coiled-coil 3 (TACC3) inhibitor with an IC50 of 188 nM and a Kd of 1.5 nM. BO-264 specifically blocks the function of FGFR3-TACC3 fusion protein. BO-264 induces spindle assembly checkpoint (SAC)-dependent mitotic arrest, DNA damage and apoptosis. BO-264 has broad-spectrum antitumor activity .
|
-
- HY-N4095
-
|
|
Aryl Hydrocarbon Receptor
Glycosidase
Reactive Oxygen Species (ROS)
GLUT
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Brevifolincarboxylic acid is a phenolic compound. Brevifolincarboxylic acid can be isolated from Duchesnea chrysantha. Brevifolincarboxylic acid inhibits α-glucosidase with an IC50 value of 323.46 μM. Brevifolincarboxylic acid has an inhibitory effect on the aryl hydrocarbon receptor (AhR). Brevifolincarbacid scavenges ROS. Brevifolincarbacid restores the glucose uptake activity of myotubes. Brevifolincarboxylic acid has antitumor activity against lung and gastric cancer. Brevifolincarbacid can be used in the study of diabetes and inflammatory diseases .
|
-
- HY-W744192
-
|
R-842
|
Drug Metabolite
IFNAR
TNF Receptor
Interleukin Related
|
Infection
Inflammation/Immunology
Cancer
|
|
2-Hydroxy Imiquimod (R-842), a hydroxylated metabolite of Imiquimod (HY-B0180), is an immunomodulating agent. 2-Hydroxy Imiquimod can induce IFN-α, TNF-α, IL-1, IL-6 and IL-8 in human blood cells. 2-Hydroxy Imiquimod exhibits antivirus and antitumor activities. 2-Hydroxy Imiquimod can be used for the researches of cancer, infection and immunology .
|
-
- HY-N6748S
-
|
|
Isotope-Labeled Compounds
P-glycoprotein
Cytochrome P450
Bacterial
c-Met/HGFR
|
Infection
|
|
Roquefortine C- 13C22 is the 13C-labeled Roquefortine C (HY-N6748). Roquefortine C is a mycotoxin that can be isolated from Penicillium species. Roquefortine C is an agonist of P-gp and an inhibitor of P450 3A and P450 1A. Roquefortine C can inhibit Gram-positive bacteria and also has certain neurotoxicity. Additionally, Roquefortine C can exert antitumor activity .
|
-
- HY-163445
-
|
|
NAMPT
|
Cancer
|
|
NAMPT activator-6 is a NAMPT activator, a regulatory molecule for the optical control system of NAMPT and NAD+. NAMPT activator-6 can be used to design efficient photoswitchable proteolysis-targeting chimeras (PS-PROTACs) to achieve up-down reversible regulation of NAMPT and NAD+ in a light-dependent manner and reduce the toxicity associated with inhibitor-based PS-PROTACs. PS-PROTAC can be used to achieve antitumor activity, NAMPT, and NAD+ modulation in vivo via optical manipulation .
|
-
- HY-181692
-
|
|
PROTACs
Epigenetic Reader Domain
E1/E2/E3 Enzyme
Apoptosis
|
Cancer
|
|
PROTAC RNF4 degrader-1 is a RNF4 PROTAC degrader (Kd = 64.5 nM) that degrades RNF4 via the ubiquitin-proteasome system. PROTAC RNF4 degrader-1 induces DNA damage, apoptosis, and exhibits antiproliferative activity in cancer cells. PROTAC RNF4 degrader-1 displays antitumor activity with no obvious side effects in mouse models. PROTAC RNF4 degrader-1 is applicable to the research of hepatocellular carcinoma .
|
-
- HY-18030B
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Others
|
|
CEP-28122 mesylate hydrochloride, a diaminopyrimidine derivative, is a potent, selective, and orally active ALK inhibitor with an IC50 value of 1.9 nM. CEP-28122 mesylate hydrochloride has antitumor activity in experimental models of ALK-positive human cancers. CEP-28122 mesylate hydrochloride has good pharmacodynamic and pharmacokinetic activity. CEP-28122 mesylate hydrochloride can be used for the study of ALK-positive anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells .
|
-
- HY-17408R
-
-
- HY-B1092
-
-
- HY-124828
-
CMLD-2
2 Publications Verification
|
HuR
|
Cancer
|
|
CMLD-2, an inhibitor of HuR-ARE interaction, competitively binds HuR protein disrupting its interaction with adenine-uridine rich elements (ARE)-containing mRNAs (Ki=350 nM). CMLD-2 induces apoptosis exhibits antitumor activity in different cancer cells as colon, pancreatic, thyroid and lung cancer cell lines. Hu antigen R (HuR) is an RNA binding protein, can regulate target mRNAs stability and translation .
|
-
- HY-100789R
-
|
|
Apoptosis
Polo-like Kinase (PLK)
Mitosis
Reference Standards
|
Cancer
|
|
ON1231320 (Standard) is the analytical standard of ON1231320 (HY-100789). This product is intended for research and analytical applications. ON1231320 is a highly specific polo like kinase 2 (PLK2) inhibitor with an IC50 of 0.31 μM. ON1231320 blocks tumor cell cycle progression in the G2/M phase in mitosis, causing apoptotic cell death. ON1231320, an arylsulfonyl pyrido-pyrimidinone, has antitumor activity .
|
-
- HY-172874
-
|
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
|
TDO-IN-2 (Compound 5c) is an orally active TDO inhibitor (IC50: 1.25 μM). TDO-IN-2 has antitumor activity in the Hepa1-6 hepatocellular carcinoma allograft mouse model. TDO-IN-2 has synergistic effects with the PD-1/PD-L1 inhibitor BMS-202 (HY-19745) and can be used to study tumor immune tolerance .
|
-
- HY-15794G
-
|
Methoxymorpholinyl doxorubicin; FCE 23762; PNU 152243
|
G-quadruplex
|
Cancer
|
|
Nemorubicin (Methoxymorpholinyl doxorubicin) GMP is a GMP-class Nemorubicin (HY-15794). Nemorubicin is a Doxorubicin derivative with potent antitumor activity. Nemorubicin is highly cytotoxic to a variety of tumor cell lines presenting a multidrug-resistant phenotype. Nemorubicin not only intercalate into the duplex DNA, but also result in significant ligands for G-quadruplex DNA segments, stabilizing their structure. Nemorubicin requirs an intact nucleotide excision repair (NER) system to exert its activity .
|
-
- HY-P991430
-
|
TB-403
|
VEGFR
|
Cancer
|
|
RO5323441 (TB-403) is a human IgG1 monoclonal antibody (mAb) targeting PlGF. RO5323441 inhibits the binding of human PlGF-1 or PlGF-2 to VEGFR-1 (IC50 values are 0.1 and 0.2 nM, respectively). RO5323441 blocks PlGF-induced VEGFR-1 phosphorylation in Flt-1-transfected HEK293 cells. RO5323441 has antitumor activity .
|
-
- HY-P10992
-
|
|
PI3K
Akt
mTOR
Caspase
Apoptosis
Bcl-2 Family
|
Cancer
|
|
YVPGP is an oligopeptide exacted from Anthopleura anjunae. YVPGP has a significant antitumor activity by mediating PI3K/AKT/mTOR signaling pathway. YVPGP arrests DU-145 cells in the S phase and induces apoptosis via mitochondrial and death receptor pathways (caspase3, 7, 8, 9). YVPGP effectively inhibits tumor growth in DU-145 xenografts mice model, promising for prostate cancer research .
|
-
- HY-182506
-
|
BM 12.531
|
Biochemical Assay Reagents
|
Inflammation/Immunology
Cancer
|
|
Azimexon (BM 12.531) is an orally active immunomodulator with radioprotective and antitumor activities. Azimexon prolongs survival in multiple mouse models, enhances immunity and hematopoiesis, and alleviates radiation injury and tumor metastasis. Azimexon causes reversible hemolytic anemia in rats and dogs, and exerts therapeutic activity against adjuvant-induced arthritis in rats. Azimexon can be used for the research of lung carcinoma, leukemia, multiple myeloma, lung tumor, arthritis, breast cancer and AIDS‑related complex .
|
-
- HY-B1490AR
-
|
|
Serotonin Transporter
Autophagy
Apoptosis
Reference Standards
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Imipramine (Standard) is the analytical standard of Imipramine. This product is intended for research and analytical applications. Imipramine is an orally active tertiary amine tricyclic antidepressant. Imipramine is a Fascin1 inhibitor with antitumor activities. Imipramine also inhibits serotonin transporter with an IC50 value of 32 nM. Imipramine stimulates U-87MG glioma cells autophagy and induces HL-60 cell apoptosis. Imipramine shows neuroprotective and immunomodulatory effects .
|
-
- HY-106364A
-
|
Bleomycin PEP sulfate; Pepleomycin sulfate
|
Apoptosis
Antibiotic
|
Infection
Cancer
|
|
Peplomycin (Bleomycin PEP) sulfate is an analog of Bleomycin (HY-108345) and an antitumor antibiotic. Peplomycin sulfate exhibits potent antitumor activity and relatively low pulmonary toxicity. Peplomycin sulfate can induce various skin abnormalities and trigger apoptosis in SSCKN cells of oral squamous cell carcinoma. Peplomycin sulfate can also induce pulmonary fibrosis. Peplomycin sulfate is applicable for the research of tumors, pulmonary fibrosis and other related diseases .
|
-
- HY-10181AR
-
|
BMS-354825 hydrochloride (Standard)
|
Reference Standards
Bcr-Abl
Src
Autophagy
Apoptosis
|
Cancer
|
|
Dasatinib (hydrochloride) (Standard) is the analytical standard of Dasatinib (hydrochloride). This product is intended for research and analytical applications. Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib hydrochloride inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib hydrochloride also induces apoptosis and autophagy.
|
-
- HY-50868R
-
|
INNO-406 (Standard); NS-187 (Standard)
|
Bcr-Abl
Src
Apoptosis
Reference Standards
|
Cancer
|
|
Bafetinib (Standard) is the analytical standard of Bafetinib. This product is intended for research and analytical applications. Bafetinib is an orally active Lyn/Bcr-Abl tyrosine kinase inhibitor. Bafetinib enhances the activity of several pro-apoptotic Bcl-2 homology (BH) 3-pure proteins (Bim, Bad, Bmf, and Bik) through intrinsic apoptotic pathways regulated by the Bcl-2 family, and induces apoptosis of Ph+ leukemia cells. Bafetinib has antitumor activity .
|
-
- HY-122130
-
|
MK-8267
|
Kinesin
Apoptosis
|
Cancer
|
|
SCH 2047069 (MK-8267) is an orally active kinesin spindle protein (KSP) inhibitor (Kd: 0.5 nM) that can cross the blood-brain barrier. SCH 2047069 exhibits an IC50 value of ≤ 5 nM against the KSP ATPase. SCH 2047069 exhibits broad-spectrum antitumor activity. SCH 2047069 can induce mitotic arrest and apoptosis in tumor cells. SCH 2047069 can be used in the research of tumors such as ovarian cancer, colon cancer, glioblastoma, and lymphoma .
|
-
- HY-144069
-
|
|
Trk Receptor
Apoptosis
|
Cancer
|
|
Pan-Trk-IN-3 (Compound 11g) is a potent inhibitor of pan-Trk and their drug-resistant mutants with IC50 values of 2, 3, 2, 21, 26, 5, 7 and 6 nM against TrkA, TrkB, TrkC, TrkA G595R, TrkA G667C, TrkA G667S, TrkA F589L and TrkC G623R, respectively. Pan-Trk-IN-3 displays excellent antitumor activity and induces apoptosis .
|
-
- HY-119016
-
SK1-I
1 Publications Verification
BML-258
|
SphK
CaMK
|
Cancer
|
|
SK1-I (BML-258), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a Ki value of 10 μM . SK1-I shows no activity at SPHK1 PKCα, PKCδ, PKA, AKT1, ERK1, EGFR, CDK2, IKKβ or CamK2β. SK1-I enhances autophagy and has antitumor activity .
|
-
- HY-152703
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-7-cyclopropyl methyl-7,8-dihydro-8-oxo-9-(beta-D-xylo furanosyl)purine (G159-82) PTPD-2 Confidential is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-182567
-
|
|
NAMPT
|
Cancer
|
|
Nampt-IN-19 is an orally active and non-substrate nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with a human Ki of 5.6 nM. Nampt-IN-19 blocks NAD + biosynthesis from Nicotinamide (HY-B0150). Nampt-IN-19 acts as an antiproliferative agent in cancer cells. Nampt-IN-19 has preclinical pharmacokinetic properties supporting oral antitumor activity in mouse xenograft models. Nampt-IN-19 can be used for the research of colorectal cancer .
|
-
- HY-162794
-
|
|
Apoptosis
Deubiquitinase
|
Cancer
|
|
YCH3124 (compound Z33) is a USP7 inhibitor (IC50=41.9 nM) with antitumor activity. YCH3124 has good in vitro antiproliferative activity against various tumor cells including LNCaP (IC50=3.6 nM) and CHP-212 (IC50=9.9 nM). In addition, YCH3124 disrupts cell cycle progression by restricting G1 phase and induces apoptosis in CHP-212 cells .
|
-
- HY-P99528
-
|
DSTP 3086S; RG 7450; MSTP2109A
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Vandortuzumab vedotin (DSTP 3086S; RG 7450) is a STEAP1-targeted antibody-drug conjugate (ADC). Vandortuzumab vedotin binds specifically to STEAP1, triggers internalization of the conjugate complex, mediates intracellular release of monomethyl auristatin E, inhibits cell division, and induces cell death. Vandortuzumab vedotin exhibits antitumor activity in preclinical prostate cancer xenografts. Vandortuzumab vedotin can be used for the research of metastatic castration-resistant prostate cancer .
|
-
- HY-117938
-
|
|
Aminoacyl-tRNA Synthetase
|
Cancer
|
|
T-3861174 is an inhibitor of prolyl-tRNA synthetase (PRS, Aminoacyl-tRNA Synthetase) without completely inhibiting its translation process. T-3861174 activates the GCN2-ATF4 pathway and induces death in multiple tumor cell lines, including SK-MEL-2. T-3861174 demonstrated significant antitumor activity in multiple xenograft models without significantly affecting body weight .
|
-
- HY-N12537
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/ PD-L1-in-38 is a PD-1/PD-L1 inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8 + T cells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity .
|
-
- HY-10819
-
|
|
Antifolate
|
Cancer
|
|
AG2034 is an inhibitor of glycinamide ribonucleotide formyltransferase (GARFT), with a Ki of 28 nM against human GARFT, and it binds with high affinity to the folate receptor (Kd of 0.0042 nM). Additionally, AG2034 is a substrate for rat liver folylpolyglutamate synthetase, with a Km of 6.4 µM. AG2034 inhibits the growth of L1210 and CCRF-CEM cells, with IC50 values of 4 nM and 2.9 nM, respectively, and it has demonstrated antitumor activity in xenograft models such as 6C3HED .
|
-
- HY-123986
-
|
|
Mitochondrial Metabolism
|
Inflammation/Immunology
Cancer
|
|
CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a KD of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity .
|
-
- HY-141601
-
|
ABBV-399
|
Antibody-Drug Conjugates (ADCs)
c-Met/HGFR
Microtubule/Tubulin
|
Cancer
|
|
Telisotuzumab vedotin (ABBV-399) (Teliso-V) is an anti-c-Met antibody-drug conjugate. Telisotuzumab vedotin consists of an anti-c-Met monoclonal antibody Telisotuzumab (ABT-700) (HY-P99391) and Monomethyl Auristatin E (HY-15162). Telisotuzumab vedotin exerts antitumor activity with acceptable toxicity in vivo. Telisotuzumab vedotin can be used for non-small cell lung cancer (NSCLC) research .
|
-
- HY-101561
-
|
BLU-285
|
c-Kit
PDGFR
|
Cancer
|
|
Avapritinib (BLU-285) is a highly potent, selective, and orally active KIT and PDGFRA activation loop mutant kinases inhibitor with IC50s of 0.27 and 0.24 nM for KIT D816V and PDGFRA D842V, respectively. Avapritinib (BLU-285) binds the active conformation of the kinase and shows antitumor activity. Avapritinib (BLU-285) attenuates the transport function of both ABCB1 and ABCG2 .
|
-
- HY-W012531R
-
|
|
Reference Standards
HIV
SARS-CoV
Endogenous Metabolite
Bacterial
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
2-Hydroxycinnamic acid (Standard) is the analytical standard of 2-Hydroxycinnamic acid. This product is intended for research and analytical applications. 2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against Staphylococcus aureus and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of HIV/SARS-CoV S pseudovirus with an IC50 of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity .
|
-
- HY-13260
-
|
|
Akt
Autophagy
Apoptosis
|
Cancer
|
|
CCT128930 is a ATP-competitive and selective inhibitor of AKT (IC50=6 nM for AKT2). CCT128930 has 28-fold selectivity over the closely related PKA kinase (IC50=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC50=120 nM). Antitumor activity.
|
-
- HY-162519
-
|
LZ90
|
NAMPT
PD-1/PD-L1
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
LZFPN-90 (LZ90) is a dual NAMPT/PD-L1 targeting compound. LZFPN-90 inhibits PD-1/PD-L1 interaction and NAMPT activity. LZFPN-90 inhibits cell growth in a NAMPT-dependent manner and blocks the cell cycle, subsequently inducing apoptosis. LZFPN-90 exerted target-dependent antitumor activities, affecting metabolic processes and the immune system .
|
-
- HY-D2380
-
|
|
G-quadruplex
|
Cancer
|
|
H2S probe 1 (compound 1NND) is a derivative of nitrobenzoxadiazole (NBD) with antitumor activity. H2S probe 1 is cytotoxic to human pancreatic cancer cell MIA PaCa-2 (IC50=77.9 nM) and has a high affinity for human telomeric G-quadruplex (G4) (Kd=1.72 μM). H2S probe 1 can be used in cancer research .
|
-
- HY-129878
-
|
AD-41
|
Endogenous Metabolite
|
Cancer
|
|
N-Trifluoroacetyladriamycin (AD-41) is a chemotherapeutic compound with antitumor activity. N-Trifluoroacetyladriamycin exhibits the highest fluorescence and radioactivity levels in the small intestine and liver, indicating its significant accumulation in these tissues. N-Trifluoroacetyladriamycin also shows significant accumulation in the kidney, spleen, large intestine, lung, and heart. N-Trifluoroacetyladriamycin is a metabolite of Valrubicin, which is used to inhibit bladder cancer. The presence of N-Trifluoroacetyladriamycin and its derivatives may be related to the biotransformation of the compound and its antitumor mechanism .
|
-
- HY-153544
-
|
|
Toll-like Receptor (TLR)
|
Cancer
|
|
TLR7/8 agonist 9 (Compound 25a) is a TLR7/8 agonist, with EC50s of 40 nM and 23 nM for hTLR7/8. TLR7/8 agonist 9 has anti-tumor activity and improves the antitumor activity of PD-1/PD-L1 blockade. TLR7/8 agonist 9 can be used for research of cancer immunotherapy .
|
-
- HY-W012531S2
-
-
- HY-203817
-
|
|
Autophagy
Apoptosis
Mitochondrial Metabolism
|
Cancer
|
|
IITZ-02 is a lysosomotropic Autophagy inhibitor. IITZ-02 enhances autophagosome accumulation but inhibits autophagosomal degradation by impairing lysosomal function, finally inducing the inhibition of autophagy. IITZ-02 abolishes mitochondrial membrane potential and induces apoptosis through the mitochondria-mediated pathway. IITZ-02 has a potent antitumor activity in MDA-MB-231 xenograft mouse models. IITZ-02 can be used for cancers research .
|
-
- HY-10181BR
-
|
BMS-354825 monohydrate (Standard)
|
Reference Standards
Bcr-Abl
Src
Autophagy
Apoptosis
|
Cancer
|
|
Dasatinib (monohydrate) (Standard) is the analytical standard of Dasatinib (monohydrate). This product is intended for research and analytical applications. Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib monohydrate inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib monohydrate also induces apoptosis and autophagy.
|
-
- HY-12137R
-
|
BI 6727 (Standard)
|
Polo-like Kinase (PLK)
Apoptosis
Reference Standards
|
Cancer
|
|
Volasertib (Standard) is the analytical standard of Volasertib. This product is intended for research and analytical applications. Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC50s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models .
|
-
- HY-116624
-
|
|
VEGFR
Apoptosis
|
Cancer
|
|
MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4) tyrosine kinase. MAZ51 inhibits VEGF-C-induced activation of VEGFR-3 without blocking VEGF-C-mediated stimulation of VEGFR2. MAZ51 had no effect on ligand-induced autophosphorylation of EGFR, IGF-1R and PDGFRβ. MAZ51 blocks proliferation and induces apoptosis in a wide variety of tumor cells. Antitumor activity .
|
-
- HY-N0542
-
|
|
Bacterial
|
Cardiovascular Disease
Infection
Neurological Disease
Cancer
|
|
Pseudoginsenoside RT5 is an orally active ocotillol-type ginsenoside and Antibacterial agent. Pseudoginsenoside RT5 can be isolated from American ginseng, transgenic American ginseng crown gall tumors and Panax japonicus. Pseudoginsenoside RT5 exerts cardioprotective effects against myocardial injury, and also possesses antibacterial and antitumor activities. Pseudoginsenoside RT5 can be used in research related to Alzheimer's disease, myocardial injury, tumors and bacterial infections .
|
-
- HY-B1490R
-
|
|
Reference Standards
Serotonin Transporter
Apoptosis
Autophagy
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Imipramine (hydrochloride) (Standard) is the analytical standard of Imipramine (hydrochloride). This product is intended for research and analytical applications. Imipramine hydrochloride is an orally active tertiary amine tricyclic antidepressant. Imipramine hydrochloride is a Fascin1 inhibitor with antitumor activities. Imipramine hydrochloride also inhibits serotonin transporter with an IC50 value of 32 nM. Imipramine hydrochloride stimulates U-87MG glioma cells autophagy and induces HL-60 cell apoptosis. Imipramine hydrochloride shows neuroprotective and immunomodulatory effects .
|
-
- HY-10971R
-
|
MLN 8237 (Standard)
|
Aurora Kinase
Autophagy
Apoptosis
Reference Standards
|
Cancer
|
|
Alisertib (Standard) is the analytical standard of Alisertib. This product is intended for research and analytical applications. Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
|
-
- HY-128952
-
|
SG3249
|
Drug-Linker Conjugates for ADC
DNA Alkylator/Crosslinker
|
Cancer
|
|
Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .
|
-
- HY-160415
-
WD6305
2 Publications Verification
|
PROTACs
Apoptosis
METTL3
|
Cancer
|
|
WD6305 is a potent and selective METTL3-METTL14 PROTAC degrader. WD6305 has DC50 values of 140 nM and 194 nM for METTL3 and METTL14, respectively. WD6305 inhibits m 6A modification and proliferation of AML cells, and induces apoptosis. WD6305 has antitumor activity .(Pink: UZH2 (HY-115717); Black: Linker; Blue: VHL ligand (HY-150803))
|
-
- HY-101029
-
|
|
NEKs
Apoptosis
|
Cancer
|
|
MBM-55 is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 1 nM. MBM-55 shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC50=5.4 nM) and DYRK1a (IC50=6.5 nM). MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55 shows antitumor activities, and no obvious toxicity to mice .
|
-
- HY-161494
-
|
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
|
XYD190 (Compound 14g) is an orally active degrader for CBP/p300. XYD190 inhibits CBP/p300 bromodomain with IC50 of 483.7 nM. XYD190 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161496)) .
|
-
- HY-130207
-
|
NSC-743380
|
Endogenous Metabolite
DNA/RNA Synthesis
|
Cancer
|
|
Oncrasin-72 (NSC-743380) is an RNA polymerase II inhibitor with activity in inhibiting growth and inducing cell death in human cancer cells. Oncrasin-72 exhibits antitumor activity through JNK activation and STAT3 inhibition. Analytical method development and validation for Oncrasin-72 is essential for quantifying its concentration in biological fluids for pharmacokinetic studies. This method was able to successfully quantify Oncrasin-72 in different dose groups when applied in rat plasma .
|
-
- HY-114778
-
|
SHR3162; Fuzuloparib
|
PARP
|
Cancer
|
|
Fluzoparib (SHR3162) is a potent and orally active PARP1 inhibitor (IC50=1.46±0.72 nM, a cell-free enzymatic assay) with superior antitumor activity. Fluzoparib selectively inhibits the proliferation of homologous recombination repair (HR)-deficient cells, and sensitizes both HR-deficient and HR-proficient cells to cytotoxic agents. Fluzoparib exhibits good pharmacokinetic properties in vivo and can be used for BRCA1/2-mutant relapsed ovarian cancer research .
|
-
- HY-154142
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Beta-C-Ethynyl-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Beta-C-Ethynyl-5-methoxyuridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-101925
-
CM-272
3 Publications Verification
|
Histone Methyltransferase
DNA Methyltransferase
Apoptosis
|
Cancer
|
|
CM-272 is a first-in-class, potent, selective, substrate-competitive and reversible dual G9a/DNA methyltransferases (DNMTs) inhibitor with antitumor activities. CM-272 inhibits G9a, DNMT1, DNMT3A, DNMT3B and GLP with IC50s of 8 nM, 382 nM, 85 nM, 1200 nM and 2 nM, respectively. CM-272 inhibits cell proliferation and promotes apoptosis, inducing IFN-stimulated genes and immunogenic cell death .
|
-
- HY-174379
-
|
|
Phosphodiesterase (PDE)
Ras
PI3K
Akt
mTOR
Apoptosis
|
Cancer
|
|
KRAS IN-44 (Compound S2C2M2) is a PDE6D degrader. KRAS IN-44 inhibits PDE6D-dependent KRAS trafficking and KRAS downstream signaling pathways. KRAS IN-44 down-regulates EGF-induced the phosphorylation of PI3K, AKT, and mTOR. KRAS IN-44 increases Apoptosis. KRAS IN-44 has antitumor activity against hepatoblastoma .
|
-
- HY-151155
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
ALK-IN-23 is a potent ALK inhibitor with IC50 values of 1.6 nM, 0.71 nM and 1.3 nM for ALK WT, ALK L1196M and ALK G1202R. ALK-IN-23 can block cell cycle in G2 phase and induce apoptosis. ALK-IN-23 inhibits cancer cell migration and colony formation in vitro. ALK-IN-23 exhibits antitumor activity in H2228 xenograft nude mice model with hypotoxicity .
|
-
- HY-113952
-
|
(-)-Actinonin
|
Aminopeptidase
Bacterial
MMP
Apoptosis
Antibiotic
|
Infection
Cancer
|
|
Actinonin ((-)-Actinonin) is a naturally occurring antibacterial agent produced by Actinomyces. Actinonin inhibits aminopeptidase M, aminopeptidase N and leucine aminopeptidase. Actinonin is a potent reversible peptide deformylase (PDF) inhibitor with a Ki of 0.28 nM. Actinonin also inhibits MMP-1, MMP-3, MMP-8, MMP-9, and hmeprin α with Ki values of 300 nM, 1,700 nM, 190 nM, 330 nM, and 20 nM, respectively. Actinonin is an apoptosis inducer. Actinonin has antiproliferative and antitumor activities .
|
-
- HY-135317E
-
|
CA-4948 maleate
|
IRAK
FLT3
NF-κB
MyD88
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Emavusertib maleate (CA-4948 maleate) is the maleate salt form of Emavusertib (HY-135317). Emavusertib maleate is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib maleate inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib maleate exhibits antitumor activity in mouse model .
|
-
- HY-13811
-
|
|
E1/E2/E3 Enzyme
Apoptosis
|
Cancer
|
|
NSC697923 is a potent UBE2N (ubiquitin-conjugating enzyme E2 N, Ubc13) inhibitor. NSC697923 induces neuroblastoma (NB) cell death via promoting nuclear importation of p53 in p53 wild-type NB cells. NSC697923 also induces cell death in p53 mutant NB cells by activation of JNK-mediated apoptotic pathway. NSC697923 inhibits DNA damage and NF-κB signaling. Antitumor activity .
|
-
- HY-100036R
-
|
|
Smo
Reference Standards
Apoptosis
Hedgehog
|
Cancer
|
|
MK-4101 (Standard) is the analytical standard of MK-4101 (HY-100036). This product is intended for research and analytical applications. MK-4101 is a Smoothened (SMO) antagonist (IC50 of 1.1 μM for 293 cells ) and also a potent inhibitor of the hedgehog pathway (IC50 of 1.5 μM for mouse cells; IC50 of 1 μM for KYSE180 oesophageal cancer cells). MK-4101 has robust antitumor activity that inhibits tumor cell proliferation and induces extensive apoptosis .
|
-
- HY-13314A
-
|
XL-647 tosylate; EXEL-7647 tosylate; KD-019tosylate
|
EGFR
VEGFR
Src
|
Cancer
|
|
Tesevatinib (XL-647) tosylate is an orally available, blood-brain barrier-penetrant inhibitor of the epidermal growth factor receptor (EGFR). Tesevatinib tosylate significantly reduces cellular viability, with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Tesevatinib tosylate also inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM). Tesevatinib tosylate can inhibit tumor proliferation and exhibits antitumor activity .
|
-
- HY-153202
-
|
|
MDM-2/p53
Apoptosis
|
Cancer
|
|
SLMP53-2 is a mutant p53 reactivator. SLMP53-2 restores wild-type-like conformation and DNA-binding ability of mutp53-Y220C by enhancing its interaction with the Hsp70, leading to the reestablishment of p53 transcriptional activity. SLMP53-2 can induce cell cycle arrest, apoptosis and endoplasmic reticulum (ER) stress. SLMP53-2 exhibits antitumor activity .
|
-
- HY-P10995
-
|
|
EGFR
IFNAR
Interleukin Related
TNF Receptor
Complement System
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
TAT-327 is cell-penetrating peptide. TAT-327 selectively inserts into cancer cell membranes and shows potent antitumor activity. TAT-327 effectively inhibits cancer cells proliferation, induces apoptosis and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. TAT-327 significantly inhibits tumor growth in HT-29 xenograft mcie models .
|
-
- HY-16270
-
|
3-Cyanopropyl carbamimidothioate; 4-Isothioureidobutyronitrile
|
Apoptosis
MDM-2/p53
|
Cancer
|
|
Kevetrin (3-Cyanopropyl carbamimidothioate; 4-Isothioureidobutyronitrile) is an apoptosis inducer that exhibits p53-dependent and p53-independent antitumor activity. In TP53 wild-type models, Kevetrin activates and stabilizes the p53 protein by altering the processing of MDM2, thereby inducing cell cycle arrest and apoptosis. Kevetrin shows higher sensitivity in mutant models. Kevetrin is applicable for the research of various cancers including acute myeloid leukemia and breast cancer .
|
-
- HY-P990981
-
|
ALPS-12; RG-6524; RO 7616789
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Clesitamig (ALPS-12) is a trispecific T cell engager with two CD3/CD137 dual-specific Fabs and one DLL3 Fab. Clesitamig engages CD3 and CD137 on T cells to activate and co-stimulate T cells, promoting their proliferation, survival, and antitumor activity. Clesitamig binds to DLL3 on tumor cells for tumor-specific recognition. Clesitamig can be used for the research of small cell lung cancer (SCLC) .
|
-
- HY-P99284
-
|
MK-0646; h7C10
|
IGF-1R
Apoptosis
|
Cancer
|
|
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo .
|
-
- HY-168072
-
|
|
Interleukin Related
Apoptosis
Autophagy
|
Cancer
|
|
GP130-IN-1 (compound 49) is a potent GP130 inhibitor with significant in vitro antitumor activity and higher selectivity than Bazedoxifene (HY-A0031). GP130-IN-1 induces ultrastructural changes in cells, causing cell cycle arrest in the G0/G1 phase in a time-dependent manner and triggering apoptosis and autophagy. GP130-IN-1 can be used in the study of triple-negative breast cancer .
|
-
- HY-186076
-
|
|
HSP
Fungal
|
Infection
Cancer
|
|
Hsp90-IN-47 (Compound C15) is a Hsp90 inhibitor and antifungal agent, with an IC50 of 0.014 μM against Hsp90α. When combined with Fluconazole (HY-B0101), Hsp90-IN-47 exerts significant synergistic antifungal effects against fluconazole-resistant Candida albicans 0304103. Hsp90-IN-47 exhibits antitumor activity against acute myeloid leukemia and non-small cell lung cancer .
|
-
- HY-N12004
-
|
|
Others
|
Cancer
|
|
19-Hydroxy-10-deacetylbaccatin III (compound 13) is a taxane with potential antitumor activity. 19-Hydroxy-10-deacetylbaccatin III has weak cytotoxicity against A498 and NCI-H226 cell lines. The study found that the inhibition rates of 30 μg/mL 19-Hydroxy-10-deacetylbaccatin III on A498, NCI-H226 and PC-3 were 16.6% and 32% respectively .
|
-
- HY-P99612
-
|
MORAb-202
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
|
-
- HY-D0162
-
|
MCCK1
|
Fungal
IKK
NF-κB
Apoptosis
|
Infection
Cancer
|
|
Malachite green hemioxalate (MCCK1) is a triphenylmethane dye which can be used to detect the release of phosphate in enzymatic reactions. Malachite green hemioxalate has antibacterial activity, which is attributed to inhibition of intracellular enzymes, insertion into DNA and/or interaction with cell membranes. Malachite green hemioxalate is also a potent and selective inhibitor of IKBKE, and inhibits its downstream targets such as IκBα, p65 and IRF3. Malachite green hemioxalate exhibits antitumor activity in vitro and in vivo .
|
-
- HY-18318
-
|
|
Raf
VEGFR
PERK
|
Cancer
|
|
Takeda-6D (compound 6d) is an orally active and potent BRAF/VEGFR2 inhibitor, with IC50 values of 7.0 and 2.2 nM, respectively. Takeda-6D shows antiangiogenesis by suppressing the VEGFR2 pathway in 293/KDR and VEGF-stimulated HUVEC cells.Takeda-6D shows significant suppression of ERK1/2 phosphorylation. Takeda-6D shows antitumor activity .
|
-
- HY-143497
-
|
|
HDAC
CDK
Apoptosis
|
Cancer
|
|
HDAC1/2 and CDK2-IN-1 (compound 14d) is a potent HDAC1, HDAC2 and CDK2 dual inhibitor, with IC50 values of 70.7, 23.1 and 0.80 μM, respectively. HDAC1/2 and CDK2-IN-1 can block the cell cycle and induce apoptosis. HDAC1/2 and CDK2-IN-1 exhibits desirable in vivo antitumor activity .
|
-
- HY-161630
-
|
|
Toll-like Receptor (TLR)
|
Cancer
|
|
TLR8 agonist 8 (Compound II-72) is an agonist for Toll-like receptor 8 (TLR8) with EC50 of 0.25-1 μM. TLR8 agonist 8 is stable in human and murine plasma, induces secretion of cytokines TNFα, with EC50 <1 μM. TLR8 agonist 8 exhibits antitumor activity in MC38-HER2 xenograft mouse model with a tumor growth inhibition (TGI) rate of 89% .
|
-
- HY-174366
-
|
|
c-Fms
PI3K
|
Cancer
|
|
JMC14 is a selective and orally active PI3Kδ and CSF1R inhibitor with IC50 values of 12 nM and 143 nM, respectively. JMC14 preferentially inhibits PI3Kδ-mediated signaling at the cellular level. JMC14 demonstrates potent antitumor activity against B-cell lymphomas and triple-negative breast cancer (TNBC) in both in vitro and vivo studies. JMC14 can be used for the study of antitumor immunity .
|
-
- HY-135317C
-
|
CA-4948 tosylate
|
IRAK
FLT3
NF-κB
MyD88
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Emavusertib tosylate (CA-4948 tosylate) is the tosylate salt form of Emavusertib (HY-135317). Emavusertib tosylate is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib tosylate inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib tosylate exhibits antitumor activity in mouse model .
|
-
- HY-152442
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-beta-C-Ethynyl-3-deazauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-beta-C-Ethynyl-3-deazauridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-19617A
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-1 hydrochloride is an orally active and irreversible L858R/T790M mutant selective EGFR inhibitor. EGFR-IN-1 hydrochloride potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR. EGFR-IN-1 hydrochloride displays strong antiproliferative activity against the H1975 cells and the first line mutant HCC827 cells. Antitumor activity .
|
-
- HY-112611
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
H3B-5942 is a selective, irreversible and orally active estrogen receptor covalent antagonist, inactivates both wild-type and mutant ERα by targeting Cys530, with Kis of 1 nM and 0.41 nM, respectively. H3B-5942 reduces ERα target gene GREB1, shows potent antitumor activity both in multiple cell lines or animals bearing ERα WT or ERα mutations .
|
-
- HY-181562
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
WRN-IN-24 is an orally active allosteric covalent Werner syndrome helicase (WRN) inhibitor with an IC50 of 201 nM. WRN-IN-24 binds to a novel allosteric cavity, forms an additional hydrogen bond with K894, and functionally inhibits WRN activity. WRN-IN-24 inhibits colorectal cancer cells proliferation and exerts dose-dependent antitumor activity in xenograft mouse models. WRN-IN-24 can be used for the research of microsatellite instability-high cancers, including colorectal cancer .
|
-
- HY-P0036S2
-
|
SMS 201-995-d8
|
Isotope-Labeled Compounds
Apoptosis
Somatostatin Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Octreotide-d8 (SMS 201-995-d8) is deuterium labeled Octreotide. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .
|
-
- HY-101117
-
|
|
Histone Methyltransferase
|
Cancer
|
|
EED226 is a polycomb repressive complex 2 (PRC2) inhibitor, which binds to the K27me3-pocket on embryonic ectoderm development (EED) and shows strong antitumor activity in xenograft mice model . EED226 is a potent, selective, and orally bioavailable EED inhibitor . EED226 inhibits PRC2 with an IC50 of 23.4 nM when the H3K27me0 peptide is used as a substrate in the in vitro enzymatic assays .
|
-
- HY-P991582
-
|
|
Fc Receptor (FcR)
|
Cancer
|
|
BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcγRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab (HY-P9907) .
|
-
- HY-108696R
-
|
|
Reference Standards
Epigenetic Reader Domain
Histone Acetyltransferase
|
Cancer
|
|
GNE-781 (Standard) is the analytical standard of GNE-781 (HY-108696). This product is intended for research and analytical applications. GNE-781 is an orally active, highly potent and selective CBP inhibitor with an IC50 of 0.94 nM in TR-FRET assay. GNE-781 also inhibits BRET and BRD4(1) with IC50s of 6.2 nM and 5100 nM, respectively. GNE-781 displays antitumor activity in an MOLM-16 AML xenograft model .
|
-
- HY-13661
-
|
UCN-01; KRX-0601
|
PKC
CDK
Apoptosis
Cadherin
|
Neurological Disease
Cancer
|
|
7-Hydroxystaurosporine (UCN-01), a derivative of Staurosporine (HY-15141), is a selective protein kinase C (PKC) inhibitor with antitumor activity. 7-hydroxystaurosporine induces apoptosis and inhibits cell proliferation in colon carcinoma and leukemia cells, suppresses invasion and migration in glioblastoma cells. 7-Hydroxystaurosporine exhibits efficacy in breast cancer xenograft mouse models. 7-Hydroxystaurosporine can be used for colon carcinoma, breast cancer, glioblastoma and leukemia research .
|
-
- HY-161372
-
|
|
PARP
c-Met/HGFR
Apoptosis
|
Cancer
|
|
PARP1/c-Met-IN-1 (Compound 16) is a selective dual inhibitor for PARP1 and c-Met, with IC50s of 3.3 and 32.2 nM, respectively. PARP1/c-Met-IN-1 induces cell apoptosis and cell cycle arrest in G2/M phase in MDA-MB-231 cells. PARP1/c-Met-IN-1 exhibits antitumor activity in mice .
|
-
- HY-108705R
-
|
|
Molecular Glues
Reference Standards
Bcl-2 Family
|
Cancer
|
|
BI-3802 (Standard) is the analytical standard of BI-3802 (HY-108705). This product is intended for research and analytical applications. BI-3802, a chemical probe, is a highly potent BCL6 degrader and inhibits the Bric-à-brac (BTB) domain of BCL6 with an IC50 of ≤3 nM. BI-3802 induces the polymerization of BCL6 and promotes BCL6 degration depended on E3 ligase SIAH1. BI-3802 has antitumor activity .
|
-
- HY-161628
-
|
|
Topoisomerase
|
Cancer
|
|
Tapcin is a dual inhibitor for topoisomerase I and topoisomerase II, with IC50 of 203 and 71 nM. Tapcin inhibits proliferations of cancer cells A-375, HeLa, Huh7.5, U2-OS, A549, Caco-2 and HT29, with IC50s of 441, 1.04, 40.5, 0.002, 0.006, 0.287 and 0.842 nM, respectively. Tapcin exhibits antitumor activity in HT29 xenograft model .
|
-
- HY-P0036S4
-
|
SMS 201-995-d8 acetate
|
Isotope-Labeled Compounds
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Octreotide-d8 (acetate) (SMS 201-995-d8 (acetate)) is deuterium labeled Octreotide. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .
|
-
- HY-W011762
-
|
|
Apoptosis
|
Cancer
|
|
VK3-OCH3 is a potent antitumor agent. VK3-OCH3 shows cytotoxicity for neuroblastoma cell lines and low cytotoxicity for normal cell lines. VK3-OCH3 induces apoptosis and cell cycle arrest at G2/M phase in IMR-32 cells. VK3-OCH3 shows antitumor activity .
|
-
- HY-161631
-
|
|
Toll-like Receptor (TLR)
|
Cancer
|
|
TLR8 agonist 9 (Compound II-77) is an agonist for Toll-like receptor 8 (TLR8) with EC50 of 0.25-1 μM. TLR8 agonist 9 is stable in human and murine plasma, induces secretion of cytokines TNFα, with EC50 <1 μM. TLR8 agonist 9 exhibits antitumor activity in MC38-HER2 xenograft mouse model with a tumor growth inhibition (TGI) rate of 97% .
|
-
- HY-154314
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-(Isopropylphenoxyacetyl)-2’-O-propargylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . N2-(Isopropylphenoxyacetyl)-2’-O-propargylguanosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-168551
-
|
|
PROTACs
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
PROTAC ALK degrader-3 (4B) is an orally active ALK degrader based on PROTACs, which can effectively induce persistent degradation of ALK fusion protein in Karpas 299 cells and strong inhibition of downstream pathways,IC50 is 119.33 nM. PROTAC ALK degrader-3 exhibits antitumor activity. (Structure Note: PINK, ALK Inhibitor (HY-15656); Blue, E3 (HY-W023573); Black, linker (HY-168552)) .
|
-
- HY-161498
-
|
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
|
XYD198 (Compound 14h) is an orally active degrader for CBP/p300. XYD198 inhibits CBP/p300 bromodomain with IC50 of 213.5 nM. XYD198 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161499))
|
-
- HY-13691R
-
|
Ro-31-7453 (Standard)
|
Apoptosis
Akt
mTOR
Microtubule/Tubulin
Mitosis
Reference Standards
|
Cancer
|
|
MKC-1 (Standard) is the analytical standard of MKC-1. This product is intended for research and analytical applications. MKC-1 (Ro-31-7453) is an orally active and potent cell cycle inhibitor with broad antitumor activity. MKC-1 inhibits the Akt/mTOR pathway. MKC-1 arrests cellular mitosis and induces cell apoptosis by binding to a number of different cellular proteins including tubulin and members of the importin β family .
|
-
- HY-10446R
-
|
|
Reference Standards
Antifolate
Apoptosis
|
Cancer
|
|
Pralatrexate (Standard) is the analytical standard of Pralatrexate. This product is intended for research and analytical applications. Pralatrexate is an antifolate and is a potent dihydrofolate reductasean (DHFR) inhibitor with a Ki of 13.4 pM. Pralatrexate is a substrate for folylpolyglutamate synthetase with improved cellular uptake and retention. Pralatrexate has antitumor activities and has the potential for relapsed/refractory T-cell lymphoma treatment . Pralatrexate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-10181S1
-
|
BMS-354825-d4
|
Isotope-Labeled Compounds
Autophagy
Bcr-Abl
Apoptosis
Src
|
Cancer
|
|
Dasatinib-d4 (BMS-354825-d4) is deuterium labeled Dasatinib. Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib also induces apoptosis and autophagy.
|
-
- HY-145851
-
|
|
HDAC
Topoisomerase
Apoptosis
|
Cancer
|
|
Top/HDAC-IN-1 (Compound 29b) is a topoisomerase/HDAC dual inhibitor with IC50s of 18, 230, 790, 87, and 5250 nM for HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8, respectively. Top/HDAC-IN-1 exhibits potent antitumor activities against the HCT116 cell line with the IC50 of 180 nM. Top/HDAC-IN-1 efficiently induces apoptosis with G2 cell cycle arrest in HCT116 cells .
|
-
- HY-161334
-
|
|
Histone Methyltransferase
Apoptosis
|
Cancer
|
|
CARM1-IN-4 (compound 11f) is a potent CARM1 inhibitor with IC50s of 9 nM and 56 nM for CARM1 and PRMT1, respectively. CARM1-IN-4 displays significant anti-proliferative effects on colorectal cancer cell lines. CARM1-IN-4 effectively inhibits the methyltransferase activity of CARM1 and prevents methylation of downstream proteins. CARM1-IN-4 induces apoptosis and shows antitumor activity .
|
-
- HY-160843
-
|
|
Apoptosis
|
Cancer
|
|
N-ω-chloroacetyl-L-ornithine (NCAO) is a potent reversible competitive ornithine decarboxylase (ODC) inhibitor that exerts cytotoxic and antiproliferative effects on tumor cell lines with EC50 values ranging from 1 to 50.6 µM. NCAO induces tumor cell Apoptosis and inhibits tumor cell migration in vitro. NCAO also exhibits a potent antitumor activity against both solid and ascitic tumors in a mouse model using the myeloma (Ag8) cell line. NCAO is promising for research of antitumor agents .
|
-
- HY-168030
-
|
|
Apoptosis
Ferroptosis
Carbonic Anhydrase
Reactive Oxygen Species (ROS)
Caspase
Mitochondrial Metabolism
|
Cancer
|
|
hCAIX-IN-23 (Compound 27) is a human carbonic anhydrase (hCA) inhibitor with Ki values of 10.4 and 8.5 nM for hCA IX and hCA XII, respectively. In addition to inhibiting hCA activity, hCAIX-IN-23 releases NO, exhibiting dual antitumor activity. hCAIX-IN-23 induces apoptosis by regulating mitochondrial caspase activity and the ferroptosis pathway (ferroptosis) through the downregulation of hCA IX and iron-regulatory protein expression. hCAIX-IN-23 is useful for renal cancer research .
|
-
- HY-106122
-
|
VP 19
|
Topoisomerase
DNA/RNA Synthesis
|
Cancer
|
|
NK-611 (VP 19) is an epipodophyllotoxin derivative. NK-611 induces DNA double-strand breaks by inhibiting topoisomerase II (IC50 = 56 μM). NK-611 does not inhibit microtubule polymerization, thus avoiding the side effects of the parent compound, Podofilox (HY-15552). NK-611 exhibits broad-spectrum antitumor activity and demonstrates potent efficacy in in vivo models of leukemia. NK-611 can be used in cancer research .
|
-
- HY-172881
-
|
|
Pyruvate Kinase
|
Cancer
|
|
PKM2-IN-10 (Compound 16) is a PKM2 inhibitor. PKM2-IN-10 inhibits the proliferation of A549 and HCC1833 cell lines with IC50 of 3.36 μM and 9.20 μM, respectively. PKM2-IN-10 exhibits antitumor activity in human non-small cell lung cancer (NSCLC) and mouse lung adenocarcinoma models. PKM2-IN-10 can be used in lung cancer research .
|
-
- HY-12248R
-
|
CB-839 (Standard)
|
Glutaminase
Autophagy
Reference Standards
|
Cancer
|
|
Telaglenastat (Standard) is the analytical standard of Telaglenastat. This product is intended for research and analytical applications. Telaglenastat (CB-839) is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC50s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat inuduces autophagy and has antitumor activity .
|
-
- HY-178325
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin-IN-57 is a Tubulin inhibitor. Tubulin-IN-57 is a potent antiproliferative agent that inhibits clonogenic formation, migration, and invasion of ovarian cancer cells. Tubulin-IN-57 inhibits tubulin polymerization, which in turn induces G2/M arrest and apoptosis in SKOV3 cells. Tubulin-IN-57 demonstrates potent antitumor activity without observable toxicity in an SKOV3 xenograft model. Y60S can be used for the study of ovarian cancer .
|
-
- HY-135317F
-
|
CA-4948 phosphate
|
IRAK
FLT3
NF-κB
MyD88
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Emavusertib phosphate (CA-4948 phosphate) is the phosphate salt form of Emavusertib (HY-135317). Emavusertib phosphate is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib phosphate inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib phosphate exhibits antitumor activity in mouse model .
|
-
- HY-157994
-
|
|
EGFR
Apoptosis
|
Cancer
|
|
EGFR WT/T790M-IN-2 (Compound 7c) is a EGFR T790M/WT inhibitor with IC50 values of 0.08 and 0.13 μM, respectively. EGFR WT/T790M-IN-2 induces apoptosis by blocking the G0-G1 phase (apoptosis). EGFR WT/T790M-IN-2 has antitumor activity .
|
-
- HY-P0036S
-
|
SMS 201-995-d8 TFA
|
Isotope-Labeled Compounds
Somatostatin Receptor
Apoptosis
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Octreotide-d8 (SMS 201-995-d8) TFA is the deuterium labeled Octreotide TFA. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly.
|
-
- HY-B0413S
-
|
|
HIF/HIF Prolyl-Hydroxylase
Parasite
Microtubule/Tubulin
Antibiotic
|
Infection
|
|
Fenbendazole-d3 is a deuterium labeled Fenbendazole. Fenbendazole-d3 is a HIF-1α agonist and activates the HIF-1α-related GLUT1 pathway. Fenbendazole is an orally active benzimidazole anthelmintic agent, with a broad antiparasitic range. Fenbendazole is a microtubule destabilizing agent. Fenbendazole causes cell-cycle arrest and mitotic cell death, and has antitumor activity in mice xenografted with wild-type p53 .
|
-
- HY-13314
-
|
XL-647; EXEL-7647; KD-019
|
EGFR
VEGFR
Src
|
Cancer
|
|
Tesevatinib (XL-647) is an orally available, blood-brain barrier-penetrant inhibitor of the epidermal growth factor receptor (EGFR). Tesevatinib significantly reduces cellular viability, with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Tesevatinib also inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM). Tesevatinib can inhibit tumor proliferation and exhibits antitumor activity .
|
-
- HY-160415A
-
|
|
PROTACs
Apoptosis
METTL3
|
Cancer
|
|
WD6305 TFA is a potent and selective METTL3-METTL14 PROTAC degrader. WD6305 TFA has DC50 values of 140 nM and 194 nM for METTL3 and METTL14, respectively. WD6305 TFA inhibits m 6A modification and proliferation of AML cells, and induces apoptosis. WD6305 TFA has antitumor activity .(Pink: UZH2 (HY-115717); Black: Linker; Blue: VHL ligand (HY-150803))
|
-
- HY-P991779
-
|
|
EGFR
|
Cancer
|
|
Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19) reacts with domain III of human and canine HER2. Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19) exerts antitumor activity in mouse oral cancer xenografts. Recommend Isotype Controls: Mouse IgG2b kappa, Isotype Control (HY-P99982) .
|
-
- HY-146494
-
|
|
Androgen Receptor
|
Cancer
|
|
Androgen receptor antagonist 5 (compound 42f) is a potent androgen receptor (AR) antagonist with an IC50 value of 6.17 μM. Androgen receptor antagonist 5 can effectively impair AR nuclear translocation, reducing the levels of nuclear AR, and disrupts AR-mediated gene regulation. Androgen receptor antagonist 5 has antiproliferative activity against LNCaP and exhibits antitumor activity in LNCaP xenograft tumor mice model. Androgen receptor antagonist 5 can be used for researching prostate cancer .
|
-
- HY-154141
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Beta-C-Ethynyl-5-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Beta-C-Ethynyl-5-fluorouridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-P991432
-
|
|
TNF Receptor
NF-κB
c-Myc
|
Cancer
|
|
VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma .
|
-
- HY-154202
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-beta-C-Ethynyl-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-beta-C-Ethynyl-5-methyluridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-W011577S1
-
|
2,3-Benzotriphenylene-13C6
|
Isotope-Labeled Compounds
Photosensitizer
|
Cancer
|
|
Dibenzo[a,c]anthracene- 13C6 (2,3-Benzotriphenylene- 13C6) is 13C labeled Benzo[f]tetraphene. Benzo[f]tetraphene (Dibenz[a,c]anthracene) is a polycyclic aromatic hydrocarbon with significant antitumor activity. Benzo[f]tetraphene is used as a luminescent probe in cell biology research and can effectively detect reactive oxygen species in biological systems. Benzo[f]tetraphene can also be used as a potential photosensitizer and shows good application prospects in photodynamic inhibition.
|
-
![Dibenzo[a,c]anthracene-13C6](//file.medchemexpress.com/product_pic/hy-w011577s1.gif)
- HY-171747
-
|
|
Antibody-Drug Conjugates (ADCs)
EGFR
Topoisomerase
Apoptosis
|
Cancer
|
|
AMT-562 is an antibody-drug conjugate (ADC) consisting of a novel anti-HER3 antibody Ab562 (HY-P991505) conjugated to the linker MC-VA-PAB and the topoisomerase I inhibitor Exatecan (HY-13631). The ADC toxic molecule and linker portion are MC-VA-PAB-Exatecan (HY-147270). AMT-562 can induce apoptosis and has antitumor activity against pancreatic, esophageal, and gastric cancers .
|
-
- HY-155163
-
|
|
Anaplastic lymphoma kinase (ALK)
ROS Kinase
FAK
Apoptosis
|
Cancer
|
|
APG-2449 is an orally active inhibitor for BCL-2 and multikinase (ALK/FAK/ROS1) with potent antitumor activities. APG-2449 reduces cell viability and enhances apoptosis in acute myeloid leukemia cells in vitro. APG-2449 decreases activation of FAK and its downstream effectors. APG-2449 can be studied in research for mesothelioma tumor, non-small cell lung cancer, ovarian cancer, hematologic and solid malignancies .
|
-
- HY-N8487R
-
|
|
Reference Standards
Cytochrome P450
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
7-Methoxyflavone (Standard) is the analytical standard of 7-Methoxyflavone (HY-N8487). This product is intended for research and analytical applications. 7-Methoxyflavone is a flavonoid compound that can be isolated from Zornia brasiliensis. 7-Methoxyflavone can bind to human serum albumin and is an aromatase inhibitor. 7-Methoxyflavone has peripheral analgesic and certain antitumor activities. 7-Methoxyflavone is effective against chemical pain but has no significant effect on thermal pain .
|
-
- HY-14572
-
|
SN 27858
|
DNA Alkylator/Crosslinker
Drug Metabolite
|
Cancer
|
|
PR-104A (SN 27858) is the alcohol metabolite of phosphate proagent PR-104. PR-104A is a hypoxia-selective DNA cross-linking agent/DNA-damaging agent and cytotoxin. Antitumor Activity . PR-104A is metabolized under hypoxia by the 1-electron NADPH:cytochrome P450 oxidoreductase. PR-104A can be used for the research of relapsed/refractory T-lineage acute lymphoblastic leukemia (T-ALL) .
|
-
- HY-P9976
-
|
ch38SB19; hu38SB19; SAR-650984
|
CD38
Apoptosis
|
Cancer
|
|
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions .
|
-
- HY-100195
-
|
|
Checkpoint Kinase (Chk)
|
Cancer
|
|
SAR-020106 is an ATP-competitive, potent, and selective CHK1 inhibitor with an IC50 of 13.3 nM for human CHK1. SAR-020106 shows excellent selectivity over CHK2. SAR-020106 significantly enhances the cell killing of Gemcitabine and SN38 by 3- to 29-fold in several colon tumor lines and in a p53-dependent fashion. SAR-020106 can enhance antitumor activity with selected anticancer agents .
|
-
- HY-135317B
-
|
CA-4948 hydrochloride
|
IRAK
FLT3
Apoptosis
NF-κB
MyD88
|
Inflammation/Immunology
Cancer
|
|
Emavusertib hydrochloride (CA-4948 tosylate) is the hydrochloride salt form of Emavusertib (HY-135317). Emavusertib hydrochloride is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib hydrochloride inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib hydrochloride exhibits antitumor activity in mouse model .
|
-
- HY-10032
-
|
PF 00477736
|
Checkpoint Kinase (Chk)
VEGFR
Src
c-Fms
Aurora Kinase
FGFR
FLT3
RET
CDK
|
Cancer
|
|
PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of Chk1, with a Ki of 0.49 nM, it is also a Chk2 inhibitor, with a Ki of 47 nM. PF 477736 shows <100-fold selectivity for Chk1 over VEGFR2, Fms, Yes, Aurora-A, FGFR3, Flt3, and Ret (IC50=8 (Ki), 10, 14, 23, 23, 25, and 39 nM, respectively). PF 477736 can enhance Gemcitabine antitumor activity in vitro and in vivo .
|
-
- HY-18986S
-
|
MI-77301-d10
|
Isotope-Labeled Compounds
|
Cancer
|
|
SAR405838-d10 (MI-77301-d10) is the deuterium labeled SAR405838 (HY-18986). SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective MDM2-p53 interaction inhibitor. SAR405838 binds to MDM2 with a Ki of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity .
|
-
- HY-14463
-
|
AT13387
|
HSP
|
Cancer
|
|
Onalespib (AT13387) is a potent and cross the blood-brain barrier heat-shock-protein-90 (Hsp90) inhibitor. Onalespib inhibits the proliferation, survival and migration. Onalespib decreases the expression of EGFR, p-EGFR, AKT, P-AKT, ERK1/2, P-ERK1/2, S6, P-S6 protein. Onalespib shows antitumor activity. Onalespib has the potential for the research of non-small cell lung cancer (NSCLC) .
|
-
- HY-173075
-
|
|
RIP kinase
Mixed Lineage Kinase
Necroptosis
|
Cancer
|
|
Anticancer agent 267 (Compound 5q) is the activator for RIPK3 and MLKL. Anticancer agent 267 inhibits the proliferation in a variety of cancer cell lines (IC50 for MDA-MB-231, MDA-MB-486 and MCF-7 is 9.79, 10.77 and 5.94 μM, respectively), arrests cell cycle at subG1 phase, and induces necroptosis in cell MDA-MB-231. Anticancer agent 267 exhibits antitumor activity in mouse xenograft models .
|
-
- HY-15582S
-
|
|
Isotope-Labeled Compounds
Microtubule/Tubulin
ADC Payload
|
Cancer
|
|
Auristatin E-d8 is the deuterium labeled Auristatin E (HY-15582). Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids .
|
-
- HY-172177
-
|
|
Apoptosis
HDAC
ROCK
|
Cancer
|
|
ROCK/HDAC-IN-2 (Compound C-9) is a ROCK/HDAC inhibitor, with IC50 values of 0.185 µM, 0.8 µM, and 0.7 µM for HDAC6, ROCK1, and ROCK2, respectively. ROCK/HDAC-IN-2 can induce apoptosis and changes in mitochondrial membrane potential in cancer cells, demonstrating significant antitumor activity. ROCK/HDAC-IN-2 can be used in the research of pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC) .
|
-
- HY-N6263
-
|
AcEGCG; Peracetylated (-)-epigallocatechin-3-gallate
|
Bacterial
PI3K
Akt
NF-κB
|
Infection
Inflammation/Immunology
Cancer
|
|
EGCG Octaacetate (AcEGCG) is a proagent of Green tea epigallocatechin-3-gallate (EGCG). EGCG Octaacetate decreases the proinflammatory mediator levels by down-regulating of PI3K/Akt/NFκB phosphorylation and p65 acetylation. EGCG octaacetate is the potential antibacterial compound for gram-positive bacteria (GPB) and gram-negative bacteria (GNB). EGCG Octaacetate exhibits antioxidant, anti-angiogenesis, anti-inflammatory and antitumor activities .
|
-
- HY-154143
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Beta-C-Ethynyl-4-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Beta-C-Ethynyl-4-deoxyuridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-W040293S
-
|
PE(6:0/6:0)-d22; 1,2-Dihexanoyl-sn-glycero-3-phosphoethanolamine-d22
|
Isotope-Labeled Compounds
|
Cancer
|
|
06:0 PE-d22 (PE(6:0/6:0)-d22) is the deuterium labeled 06:0 PE (HY-W040293). 06:0 PE (PE(6:0/6:0)) is a water-soluble phospholipid characterized by its short acyl chains, exhibiting notable antitumor activity and the ability to inhibit tumor progression in vivo, alongside antiproliferative and proapoptotic effects, while serving as a precursor for phosphatidylcholine and phosphatidylethanolamine.
|
-
- HY-15666
-
|
GZD824; HQP1351
|
Bcr-Abl
|
Cancer
|
|
Olverembatinib (GZD824) is a potent and orally active pan-Bcr-Abl inhibitor. Olverembatinib potently inhibits a broad spectrum of Bcr-Abl mutants. Olverembatinib strongly inhibits native Bcr-Abl and Bcr-Abl T315I with IC50s of 0.34 nM and 0.68 nM, respectively. Olverembatinib has antitumor activity . Olverembatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-175247
-
|
|
Large Tumor Suppressor (LATS)
E1/E2/E3 Enzyme
YAP
|
Cancer
|
|
DDO-4033 is a SPOP inhibitor (IC50 = 16.9 μM, Kd = 15.1 μM). DDO-4033 impairs the malignant migration, invasion, and proliferation of clear cell renal cell carcinoma (ccRCC) cell lines. DDO-4033 disrupts SPOP recruitment to its substrate LATS1, inhibits its polyubiquitination and subsequent degradation, and upregulates LATS1 expression. DDO-4033 has promising antitumor activity and is promising for renal cell carcinoma research .
|
-
- HY-N7175
-
|
9,11-Dehydroergosterol peroxide; 9(11)-DHEP
|
Apoptosis
Endogenous Metabolite
|
Cancer
|
|
5,8-Epidioxyergosta-6,9(11),22-trien-3-ol (9,11-Dehydroergosterol peroxide), an important steroid from medicinal mushroom, exerts antitumor activity in several tumor types. 5,8-Epidioxyergosta-6,9(11),22-trien-3-ol inhibits HT29 cell growth by inducing CDKN1A expression, thus causing cell cycle arrest and apoptosis .
|
-
- HY-135317D
-
|
CA-4948 mesylate
|
IRAK
FLT3
NF-κB
MyD88
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Emavusertib mesylate (CA-4948 mesylate) is the mesylate salt form of Emavusertib (HY-135317). Emavusertib mesylate is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib mesylate inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib mesylate exhibits antitumor activity in mouse model .
|
-
- HY-17499
-
|
|
EGFR
Apoptosis
|
Cancer
|
|
EGFR-IN-12 is a 4,6-disubstituted pyrimidine and is a potent, ATP-competitive, irreversible and highly selective EGFR inhibitor with an IC50of 21 nM. EGFR-IN-12 also inhibits mutant EGFR L858R and EGFR L861Q with IC50s of 63 nM and 4 nM, respectively. EGFR-IN-12 displays strong selectivity for EGFR over HER4 (IC50 = 7640 nM) and a panel of 55 other kinases. EGFR-IN-12 induces cells apoptosis and has antitumor activity .
|
-
- HY-157157
-
|
|
Protein Arginine Deiminase
|
Cancer
|
|
PAD4-IN-3 (compound 4B) is a PAD4 inhibitor with antitumor activity in vitro and in vivo. PAD4-IN-3 was covalently linked to RGD sequence peptide-modified chitosan (K-CRGDV), resulting in an enhanced oxidative stress-responsive nanoagent. K-CRGDV-PAD4-IN-3 can actively target tumors, inhibit PAD4 activity, block the formation of neutrophil extracellular traps (NETs), and improve the tumor immune microenvironment in response to the tumor microenvironment .
|
-
- HY-132192
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model .
|
-
- HY-P991425
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
AT-1413 is a human monoclonal antibody (mAb) targeting CD43. AT-1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. AT-1413 has antitumor activity in AML mouse models. AT-1413 can be used in Acute myeloid leukaemia, Breast cancer, Malignant melanoma and Myelodysplastic syndromes research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-150688
-
|
|
JNK
|
Cancer
|
|
JAK3-IN-13 (compound 12n) is a potent, selective and orally active JAK3 inhibitor with IC50 values of 4728, 2039, 8, 365 nM for NK1, JNK2, JNK3, Tyk2, respectively. JAK3-IN-13 shows antiproliferative activity. JAK3-IN-13 induces cell cycle arrest at G0/G1 phase. JAK3-IN-13 shows antitumor activity .
|
-
- HY-152627
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Methyl-2’-beta-C-ethynyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . N6-Methyl-2’-beta-C-ethynyl adenosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-149948
-
|
|
Epigenetic Reader Domain
PROTACs
|
Cancer
|
PROTAC BRD3/BRD4-L degrader-2 is a PROTAC molecule and can selectively degrade cellular BRD3 and BRD4-L with Ki values of 16.91 and 2.8 nM, respectively. PROTAC BRD3/BRD4-L degrader-2 also has robust antitumor activity in mouse xenograft models. PROTAC BRD3/BRD4-L degrader-2 can be used for the research of cancer .
|
-
- HY-132866
-
|
|
P-glycoprotein
|
Cancer
|
|
YS-370 (compound 44) is a potent, high selective, and orally active inhibitor of P-glycoprotein (P-gp). YS-370 stimulates the P-gp ATPase activity and has moderate inhibition against CYP3A4. YS-370 effectively reverses multidrug resistance (MDR) to paclitaxel and colchicine in SW620/AD300 and HEK293T-ABCB1 cells. YS-370 in combination with paclitaxel achieves much stronger antitumor activity .
|
-
- HY-176457
-
|
|
Small Interfering RNA (siRNA)
MDM-2/p53
PROTACs
|
Cancer
|
|
ZS3-046 is a TAF1 PROTAC degrader. ZS3-046 promotes the ubiquitination and degradation of TAF1. ZS3-046 activates p53 and induces apoptosis in acute myeloid leukemia (AML) cells. ZS3-046 has antitumor activity in an AML tumor xenograft mouse model. (Target protein ligand (HY-176467); CRBN ligase (HY-41547); Linker (HY-176469); CRBN ligase + Linker (HY-176470)) .
|
-
- HY-171477
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
Metahexestrol is an estrogen receptor (E2R) inhibitor with antitumor activity. It significantly inhibits the proliferation of estrogen receptor-positive MCF-7 human breast cancer cells (ED50 = 1.0 μM). Additionally, Metahexestrol also exhibits inhibitory effects in estrogen receptor-negative MDA-MB-231 cells, and its antiproliferative activity cannot be reversed by estrogen, suggesting that its mechanism of action may be partially independent of the E2R pathway. Metahexestrol can be used in research on estrogen-dependent breast cancer .
|
-
- HY-15196
-
TAK-285
3 Publications Verification
|
EGFR
|
Cancer
|
|
TAK-285 is a potent, selective, ATP-competitive and orally active HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, respectively. TAK-285 is >10-fold selectivity for HER1/2 than HER4, and less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. TAK-285 has effective antitumor activity . TAK-285 can cross the blood-brain barrier (BBB) .
|
-
- HY-151453
-
|
|
Topoisomerase
Apoptosis
|
Cancer
|
|
Topoisomerase IIα-IN-4 (F2) is a non-intercalative ATP-competitive human DNA topoisomerase II inhibitor with an IC50 value of 3.8 and 10.1 μM for TopoIIα and TopoIIβ, respectively. Topoisomerase IIα-IN-4 shows potent potency in apoptosis induction and cell cycle arrest in HepG2 cells. Topoisomerase IIα-IN-4 exhibits strong antitumor activities against human cancer cell lines, it can be used for the research of cancer .
|
-
- HY-128741S2
-
-
- HY-P10762
-
|
CBP-1008; LDC 10B
|
Peptide-Drug Conjugates (PDCs)
Folate Receptor (FR)
TRP Channel
|
Cancer
|
|
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .
|
-
- HY-123834
-
|
|
FLAP
ATM/ATR
|
Cancer
|
|
FEN1-IN-1 (compound 1) is a small molecule flap endonuclease 1 (FEN1) inhibitor with antitumor activity. FEN1-IN-1 binds to the active site of FEN1 and partly achieves inhibition by the co-ordination of Mg 2+ ions. FEN1-IN-1 initiaties a DNA damage response and activates the ATM checkpoint signalling pathway, the phosphorylation of histone H2AX and the ubiquitination of FANCD2 in mammalian cells. FEN1-IN-1 is promising for research of cancers .
|
-
- HY-152238
-
|
|
PI3K
mTOR
|
Cancer
|
|
PI3K/mTOR Inhibitor-12 is a potent, orally active and selective PI3K/mTOR inhibitor with IC50 values of 0.06 nM and 3.12 nM for PI3Kα and mTOR, respectively. PI3K/mTOR Inhibitor-12 has antitumor activity. PI3K/mTOR Inhibitor-12 has lower liver toxicity .
|
-
- HY-P2657
-
|
|
HIF/HIF Prolyl-Hydroxylase
Proton Pump
Endogenous Metabolite
|
Cancer
|
|
Verucopeptin is a potent HIF-1 (IC50=0.22 μM) inhibitor and decreases the expression of HIF-1 target genes and HIF-1α protein levels. Verucopeptin strongly inhibits v-ATPase activity by directly targeting the v-ATPase ATP6V1G subunit but not ATP1V1B2 or ATP6V1D. Verucopeptin exhibits antitumor activity against multidrug resistance (MDR) cancers and can be used for cancer research.
|
-
- HY-10181G
-
|
BMS-354825 (GMP)
|
Src
Bcr-Abl
Apoptosis
Autophagy
|
Cancer
|
|
Dasatinib (BMS-354825) (GMP) is a GMP-grade Dasatinib (HY-10181). GMP-grade small molecules can be used as adjuvant agents in cell therapy. Dasatinib (BMS-354825) is an orally active, ATP-competitive, dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Ki values for Src and Bcr-Abl are 16 pM and 30 pM, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50 values of less than 1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy .
|
-
- HY-13502AS
-
|
Mitozantrone-d8dihydrochloride; NSC 301739-d8 dihydrochloride
|
Endogenous Metabolite
PKC
Apoptosis
Topoisomerase
Orthopoxvirus
Isotope-Labeled Compounds
|
Infection
Cancer
|
|
Mitoxantrone-d8 dihydrochloride is deuterated labeled Mitoxantrone dihydrochloride (HY-13502A). Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .
|
-
- HY-125807
-
|
|
G Protein-coupled Receptor Kinase (GRK)
Apoptosis
Reactive Oxygen Species (ROS)
Akt
p38 MAPK
|
Cardiovascular Disease
Cancer
|
|
IS20 is a Prokineticin receptor 1 (PKR1) agonist. IS20 diminishes Doxorubicin (HY-15142A) mediated apoptosis and ROS production by activating Akt or MAPK pathways. IS20 protects the heart against Doxorubicin-induced cardiovascular toxicity and improves the survival rate and cardiac function in mouse models. IS20 does not alter the cytotoxicity and antitumor activity of acute DOX treatment in breast cancer cells and MDA-MB-231 xenograft mouse models. IS20 can be used for cancers research .
|
-
- HY-N7719R
-
|
|
Endogenous Metabolite
Reference Standards
Bacterial
Fungal
Parasite
Apoptosis
Reactive Oxygen Species (ROS)
Caspase
HSV
|
Infection
Inflammation/Immunology
Cancer
|
|
Oosporein (Standard) is the analytical standard of Oosporein (HY-N7719). This product is intended for research and analytical applications. Oosporein is a microbial metabolite and a red crystalline toxin produced by various fungi. Oosporein can promote the reproduction of fungi in host bodies by inhibiting insect immunity, and possesses multiple activities such as antibacterial, antiviral (HSV), and insecticidal effects. Oosporein can inhibit plant growth. In addition, Oosporein can also induce apoptosis, cell membrane damage, oxidative stress, and mitochondrial damage. Oosporein has certain antitumor activity .
|
-
- HY-183630
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
AZD4956 is a potent and selective DNA polymerase theta (POLQ) inhibitor. AZD4956 exhibits an IC50 value of less than 3 μmol/L against POLQ and 3.4 μmol/L against MMEJ. AZD4956 suppresses the MMEJ pathway and enhances the activity of DNA-damaging agents in HRR-deficient cellular contexts. AZD4956 shows antitumor activity in BRCA1/2-mutated triple-negative breast cancer and prostate cancer models. AZD4956 can be used for the study of homologous recombination-deficient tumors .
|
-
- HY-128741R
-
-
- HY-N0234
-
|
7-O-Methylbavachin; Bavachinin A
|
Amyloid-β
PPAR
HIF/HIF Prolyl-Hydroxylase
|
Inflammation/Immunology
Cancer
|
|
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC50 value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .
|
-
- HY-B0413R
-
|
|
Reference Standards
Parasite
HIF/HIF Prolyl-Hydroxylase
Microtubule/Tubulin
Antibiotic
|
Infection
|
|
Fenbendazole (Standard) is the analytical standard of Fenbendazole. This product is intended for research and analytical applications. Fenbendazole is an orally active benzimidazole anthelmintic agent, with a broad antiparasitic range. Fenbendazole is a microtubule destabilizing agent and acts on helminthes primarily by binding to tubulin and disrupting the tubulin microtubule equilibrium. Fenbendazole stabilizes the transcriptional activator HIF-1α. Fenbendazole possesses an efficient anti-proliferative activity and induces apoptosis. Fenbendazole causes cell-cycle arrest and mitotic cell death, and has antitumor activity in mice xenografted with wild-type p53 .
|
-
- HY-N0617
-
|
|
Phosphatase
ERK
NF-κB
Apoptosis
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Sanggenon C, a flavonoid, exerts protective effects against cardiac hypertrophy and fibrosis via suppression of the calcineurin/NFAT2 pathway. Sanggenon C inhibits mitochondrial fission to induce apoptosis by blocking the ERK signaling pathway. Sanggenon C inhibits inducible nitric oxide synthase expression in RAW264.7 cells, and TNF-α-stimulated cell adhesion and VCAM-1 expression, by suppressing NF-κB activity. Sanggenon C possesses antioxidant, anti-inflammatory and antitumor activities .
|
-
- HY-N3405
-
|
|
Glycosidase
Bcl-2 Family
Apoptosis
TGF-β Receptor
NF-κB
Fungal
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Lariciresinol is an orally active ingredient. Lariciresinol can be isolated from Arabidopsis thaliana. Lariciresinol inhibits α-glucosidase activity (IC50 of 6.97 μM; Ki of 0.046 μM). Lariciresinol dereases Bcl-2, upregulates Bax and induces Apoptosis. Lariciresinol regulates TGF-β and NF-κB pathways. Lariciresinol has antitumor activity against liver cancer, gastric cancer, and breast cancer. Lariciresinol shows antifungal activity and anti-diabetic activity .
|
-
- HY-122224
-
|
|
Sigma Receptor
|
Cancer
|
|
SW43 is a Sigma-2 selective ligand and agonist. SW43 is an ideal molecule for the development of cancer-targeted drug compounds. SW43 conjugated with DOX-L-NETA ( 89Y) exhibits antitumor activity in a VX2 cancer liver tumor allograft rabbit model. SW 43 conjugated with SW IV-52s to form SW III-123 activates the NF-κB pathway, has potent cytotoxicity against ovarian cancer cell lines, and induces apoptosis .
|
-
- HY-156816
-
|
|
Casein Kinase
DYRK
|
Cancer
|
|
ON 108600 is a inhibitor for CK2 (Casein Kinase2)/TNIK/DYRK1 , with the IC50s for DYRK1A/DYRKB, DYRK2, CK2α1/CK2α2, and TNIK of 0.016 μm/0.007 μM, 0.028 μM, 0.05 μM/0.005 μM, and 0.005 μM, respectively. ON 108600 has antitumor activity .
|
-
- HY-172100
-
|
|
Apoptosis
Reactive Oxygen Species (ROS)
p38 MAPK
|
Cancer
|
|
p38-α MAPK-IN-8 (Compound 13) is a lipophilic cationic derivative. p38-α MAPK-IN-8 is cytotoxic to various tumor cells, and can induce cell cycle arrest, apoptosis, increase reactive oxygen species (ROS) production, and induce mitochondrial membrane potential depolarization. The antitumor activity of p38-α MAPK-IN-8 may be related to p38α MAPK pathway, which can be used in the study of cancer .
|
-
- HY-128741S1
-
-
- HY-172429A
-
|
ORIC-114 hemihydrate
|
EGFR
|
Neurological Disease
Cancer
|
|
Enozertinib (ORIC-114) hemihydrate is an orally active, CNS-penetrant, highly selective and irreversible dual EGFR/HER2 inhibitor that exhibits potent and targeted inhibition of exon 20 insertion mutations. Enozertinib hemihydrate exhibits high kinome selectivity for the EGFR family of receptors to reduce off-target kinase liabilities. Enozertinib hemihydrate induces tumor regression and demonstrates antitumor activity in central nervous system and non-small cell lung cancer (NSCLC) tumor models. Enozertinib hemihydrate can be used for the research of solid tumors and NSCLC .
|
-
- HY-W012293
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
Cancer
|
|
4-Amino-1-((2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (3'-Deoxycytidine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W047478R
-
|
NSC 10154 (Standard)
|
Reference Standards
Interleukin Related
Fungal
|
Infection
Inflammation/Immunology
Cancer
|
|
3-Methylcarbazole (NSC 10154) Standard is the analytical standard of 3-Methylcarbazole (HY-W047478). This product is intended for research and analytical applications. 3-Methylcarbazole (NSC 10154) is a carbazole alkaloid with an IC50 of 25 μg/mL against human fibrosarcoma cells. 3-Methylcarbazole inhibits mycelial growth and conidial germination of a variety of phytopathogenic fungi. 3-Methylcarbazole exhibits anti-inflammatory and antitumor activities. 3-Methylcarbazole can be used in studies related to fibrosarcoma, phytopathogenic fungal infections and inflammatory diseases.
|
-
- HY-152626
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Ethyl-2’-beta-C-ethynyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . N6-Ethyl-2’-beta-C-ethynyl adenosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-50751
-
|
ABT-869; AL-39324
|
PDGFR
VEGFR
FLT3
c-Fms
c-Kit
Autophagy
Apoptosis
|
Cancer
|
|
Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib is a specific miR-10b inhibitor that blocks miR-10b biogenesis .
|
-
- HY-111508
-
|
|
PI3K
mTOR
|
Cancer
|
|
PI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/34/16/1 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ and 4.7 nM for mTOR . Antitumor activity .
|
-
- HY-10320G
-
|
BIRB 796 (GMP)
|
p38 MAPK
|
Cancer
|
|
Doramapimod GMP (BIRB 796 GMP) is an orally active inhibitor for p38 MAPK, with IC50s of 38, 65, 200 and 520 nM, for p38α, p38β, p38γ, p38δ. Doramapimod exhibits cytotoxicity and antitumor activity against multiple myeloma, synergizes with multidrug resistance protein 1 (ABCB1) and aurora kinase inhibitor VX680, promoting their antitumor efficacy against oral epidermoid carcinoma and cervical cancer. Doramapimod also exhibits anti-inflammatory activity .
|
-
- HY-13502AS1
-
|
Mitozantrone-d8 hydrochloride; NSC 301739-d8 hydrochloride
|
Isotope-Labeled Compounds
Endogenous Metabolite
Apoptosis
Orthopoxvirus
PKC
Topoisomerase
|
Infection
Cancer
|
|
Mitoxantrone-d8 (hydrochloride) (Mitozantrone-d8 (hydrochloride)) is deuterium labeled Mitoxantrone (dihydrochloride). Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .
|
-
- HY-19617B
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-1 TFA is an orally active and irreversible L858R/T790M mutant selective EGFR inhibitor. EGFR-IN-1 TFA potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR. EGFR-IN-1 TFA displays strong antiproliferative activity against the H1975 cells and the first line mutant HCC827 cells. Antitumor activity .
|
-
- HY-163307
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1-IN-39 (X 14) is an orally active PD-1/PD-L1 inhibitor with a IC50 value of 15.73 nM. PD-1/ PD-L1-in-39 has a good binding affinity for human and mouse PD-L1, with KD values of 14.62 nM and 392 nM, respectively. PD-1/PD-L1-IN-39 has antitumor activity .
|
-
- HY-N6037
-
-
- HY-13502AR
-
|
Mitozantrone dihydrochloride (Standard); NSC 301739 dihydrochloride (Standard)
|
Reference Standards
Topoisomerase
PKC
Orthopoxvirus
Apoptosis
Endogenous Metabolite
|
Infection
Cancer
|
|
Mitoxantrone (dihydrochloride) (Standard) is the analytical standard of Mitoxantrone (dihydrochloride). This product is intended for research and analytical applications. Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .
|
-
- HY-124284R
-
|
HMBA (Standard)
|
Apoptosis
p38 MAPK
Akt
NF-κB
Notch
Bcl-2 Family
MDM-2/p53
Epigenetic Reader Domain
Reference Standards
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Hexamethylene bisacetamide (Standard) is the analytical standard of Hexamethylene bisacetamide. This product is intended for research and analytical applications. Hexamethylene bisacetamide (HMBA) is a differentiation inducer and selective bromine domain inhibitor that can differentiate across the blood-brain barrier. Hexamethylene bisacetamide can induce tumor cell differentiation and inhibit cell proliferation, showing antitumor activity. Hexamethylene bisacetamide induces apoptosis by Notch1, Bcl-2 and p53 signaling pathways. In addition, Hexamethylene bisacetamide improves the obesity phenotype of mice .
|
-
- HY-172429
-
|
ORIC-114
|
EGFR
|
Neurological Disease
Cancer
|
|
Enozertinib (ORIC-114) is an orally active, CNS-penetrant, highly selective and irreversible dual EGFR/HER2 inhibitor that exhibits potent and targeted inhibition of exon 20 insertion mutations. Enozertinib exhibits high kinome selectivity for the EGFR family of receptors to reduce off-target kinase liabilities. Enozertinib induces tumor regression and demonstrates antitumor activity in central nervous system and non-small cell lung cancer (NSCLC) tumor models. Enozertinib can be used for the research of solid tumors and NSCLC .
|
-
- HY-P991610
-
|
Sym025
|
C-type Lectin-like Receptors (CTLRs)
|
Cancer
|
|
S-095029 is a humanized IgG1 monoclonal antibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells .
|
-
- HY-13260A
-
|
|
Akt
Autophagy
Apoptosis
|
Cancer
|
|
CCT128930 hydrochloride is a potent and selective inhibitor of AKT (IC50=6 nM). CCT128930 hydrochloride has 28-fold selectivity over the closely related PKA kinase (IC50=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC50=120 nM). CCT128930 hydrochloride induces cell cycle arrest, DNA damage, and autophagy. Antitumor activity .
|
-
- HY-B1022
-
Dimesna
1 Publications Verification
BNP-7787
|
Drug Derivative
|
Endocrinology
Cancer
|
|
Dimesna (BNP-7787), the disulfide form of Mesna (HY-13679), is a platinum-related toxicity protective agent. Dimesna converts to Mesna, which in turn inactivates toxic platinum substances. Dimesna does not interfere with the antitumor activity of platinum compounds. Dimesna does not affect the antiproliferative effects of Cisplatin (HY-17394) or Carboplatin (HY-17393). Dimesna counteracts Cisplatin-induced nephrotoxicity. Dimesna exerts selective protective effects on the kidneys. Dimesna can be used in studies related to ovarian cancer and Cisplatin-induced nephrotoxicity .
|
-
- HY-130559
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
SL-3-19 is a tubulin ligand. SL-3-19 exhibits antitumor activity against esophageal squamous cell carcinoma (ESCC) both in vitro and in vivo by inhibiting microtubule assembly, inducing G2/M phase cell cycle arrest and apoptosis, and disrupting tumor blood vessels. SL-3-19 has a higher activity than SL-1-73 (HY-130558). SL-3-19 can be used for the research of ESCC and other tumors .
|
-
- HY-50905
-
|
CHIR-258; TKI258
|
FLT3
c-Kit
FGFR
VEGFR
PDGFR
c-Fms
|
Cancer
|
|
Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity .
|
-
- HY-N6818
-
|
TMF
|
Apoptosis
Caspase
PARP
Endogenous Metabolite
CFTR
|
Cancer
|
|
5,7,4’-Trimethoxyflavone can be isolated from the medicinal plant Kaempferia parviflora (KP). 5,7,4’-Trimethoxyflavone is a CFTR activator and EC50 is 64 μM. 5,7,4’-Trimethoxyflavone induces apoptosis, increases proteolytic activation of caspase-3, and degradation of ADP-ribose polymerase (PARP) protein. 5,7,4’-Trimethoxyflavone has antitumor activity. 5,7,4’-Trimethoxyflavone can be used to prevent skin aging and oxidative stress .
|
-
- HY-125535
-
|
|
AMPK
mTOR
Autophagy
Atg8/LC3
|
Cancer
|
|
OSU-53 is an orally active AMPK activator (EC50: 0.3 μM) and a direct mTOR inhibitor. OSU-53 induces autophagy and increases conversion of LC3 I to LC3 II. OSU-53 also modulates energy homeostasis by suppressing fatty acid biosynthesis and shifting the metabolism to oxidation by up-regulating the expression of PGC1α and NRF-1. OSU-53 has antitumor activity in various tumor models, such as breast cancer and thyroid cancer .
|
-
- HY-174387
-
|
|
c-Met/HGFR
|
Cancer
|
|
KIN-8741 is a highly selective Type IIb c-Met inhibitor. KIN-8741 has broad activity against c-Met kinase mutations. KIN-8741 shows antitumor activity in MET gene amplified and exon 14 deleted non-small cell lung cancer models. KIN-8741 can be used in the research of c-Met driven cancers, especially advanced tumors carrying MET exon 14 jump mutations, acquired drug resistance mutations, etc .
|
-
- HY-128741S
-
|
|
Isotope-Labeled Compounds
Endogenous Metabolite
Akt
Apoptosis
Reactive Oxygen Species (ROS)
PI3K
|
Cancer
|
|
D-Allose- 13C is the 13C labeled D-Allose (HY-128741). D-Allose exhibits antitumor activity against various cancer cells. D-Allose scavenges reactive oxygen species (ROS) and reduces oxidative stress damage. D-Allose exhibits anti-inflammatory and neuroprotective through inhibition of TLR4/PI3K/AKT signaling pathway. D-Allose exhibits antihypertensive, cryoprotective, and anti-osteoporotic activities .
|
-
- HY-132192A
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride also exhibits significant in vivo antitumor activity in a CT26 mouse model .
|
-
- HY-175257
-
|
|
PARP
Reactive Oxygen Species (ROS)
Apoptosis
NF-κB
ERK
Bcl-2 Family
TGF-β Receptor
EGFR
Cadherin
|
Cancer
|
|
Theophylline-platinum(IV) prodrug-1 is a PARP-1 inhibitor. Theophylline-platinum(IV) prodrug-1 enhances DNA
damage, ROS production, mitochondrial dysfunction, apoptosis and S-phase arrest, along with reducing invasion and metastasis in cells. Theophylline-platinum(IV) prodrug-1 exhibits superior antitumor activity in the xenograft SKOV3-BRCA1-KD tumor model. Theophylline-platinum(IV) prodrug-1 can be used for the study of ovarian cancer .
|
-
- HY-120120
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
DZ-2384 is a potent microtubule-targeting agent. DZ-2384 increases the rescue frequency and preserves the microtubule network in nonmitotic cells and primary neurons. DZ-2384 acts synergistically with anti-CTLA-4 immunotherapy in Taxane-sensitive and Taxane-resistant xenograft murine models of triple-negative breast cancer (TNBC). DZ-2384 exhibits potent antitumor activity in adult acute lymphocytic leukemia (ALL) models. DZ-2384 can be used for cancer research, such as TNBC and ALL [1][2].
|
-
- HY-185430
-
|
|
TGF-β Receptor
|
Inflammation/Immunology
Cancer
|
|
HM-279 is a potent and orally active ALK5 inhibitor with an IC50 of 4.7 nM. HM-279 shows cross-reactivity with ALK7 (IC50 = 6.8 nM), but HM-279 has fair to good selectivity against other TGF-β receptor family kinases, with 4.5-693-fold selectivity. HM-279 demonstrates antitumor activity in vivo through CD8 + T cell immunity. HM-279 can be used for the research of colon cancer .
|
-
- HY-19617
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-1 (compound 24) is an orally active and irreversible L858R/T790M mutant selective EGFR inhibitor. EGFR-IN-1 potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR. EGFR-IN-1 displays strong antiproliferative activity against the H1975 cells and the first line mutant HCC827 cells. Antitumor activity .
|
-
- HY-15666A
-
|
GZD824 dimesylate; HQP1351 dimesylate
|
Bcr-Abl
|
Cancer
|
|
Olverembatinib (GZD824) dimesylate is a potent and orally active pan-Bcr-Abl inhibitor. Olverembatinib dimesylate potently inhibits a broad spectrum of Bcr-Abl mutants. Olverembatinib dimesylate strongly inhibits native Bcr-Abl and Bcr-Abl T315I with IC50s of 0.34 nM and 0.68 nM, respectively. Olverembatinib dimesylate has antitumor activity . Olverembatinib (dimesylate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-101561R
-
|
BLU-285 (Standard)
|
Reference Standards
c-Kit
PDGFR
|
Cancer
|
|
Avapritinib (Standard) is the analytical standard of Avapritinib. This product is intended for research and analytical applications. Avapritinib (BLU-285) is a highly potent, selective, and orally active KIT and PDGFRA activation loop mutant kinases inhibitor with IC50s of 0.27 and 0.24 nM for KIT D816V and PDGFRA D842V, respectively. Avapritinib (BLU-285) binds the active conformation of the kinase and shows antitumor activity. Avapritinib (BLU-285) attenuates the transport function of both ABCB1 and ABCG2 .
|
-
- HY-123045
-
|
|
CDK
|
Cancer
|
|
PNU-292137 is an orally active, potent CDK2 inhibitor with IC50s of 37 nM and 92 nM for CDK2/cyclin A and CDK2/cyclin E, respectively. PNU-292137 makes interactions with the hydrophobic pocket at the back of the CDK2 ATP pocket. PNU-292137 efficiently inhibits tumor cell proliferation in human colon and prostate tumor cell lines. PNU-292137 exhibits antitumor activity (TGI>50%) in a mouse xenograft model .
|
-
- HY-103257R
-
|
NSC656158 (Standard)
|
Reference Standards
Microtubule/Tubulin
|
Cancer
|
|
CHM-1 (Standard) is the analytical standard of CHM-1 (HY-103257). This product is intended for research and analytical applications. CHM-1, a microtubule-destabilizing agent, inhibits tubulin polymerization. CHM-1 is a potent and selective antimitotic antitumor activity against human hepatocellular carcinoma. CHM-1 induces growth inhibition and apoptosis via G2-M phase arrest in human hepatocellular carcinoma cells by activation of Cdc2 kinase activity .
|
-
- HY-B0255
-
|
GS 0840
|
HBV
Orthopoxvirus
HSV
DNA/RNA Synthesis
ATM/ATR
CDK
|
Infection
Cancer
|
|
Adefovir dipivoxil is an orally active adenosine analog and Adefovir prodrug. Adefovir dipivoxil inhibits DNA synthesis, activates the ATR signaling pathway, and disrupts the KCTD12-CDK1 interaction. Adefovir dipivoxil has antiviral activity against PRV, HBV, and orthopoxviruses. Adefovir dipivoxil has inhibitory effects on both lamivudine-resistant and wild-type strains. Adefovir dipivoxil has antitumor activity against lung and colon cancer .
|
-
- HY-13502R
-
|
Mitozantrone (Standard); NSC 301739 (Standard)
|
Reference Standards
Topoisomerase
PKC
Orthopoxvirus
Apoptosis
Endogenous Metabolite
|
Infection
Cancer
|
|
Mitoxantrone (Standard) is the analytical standard of Mitoxantrone. This product is intended for research and analytical applications. Mitoxantrone is a potent topoisomerase II inhibitor. Mitoxantrone also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone shows antitumor activity . Mitoxantrone also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .
|
-
- HY-182986
-
|
|
CDK
Apoptosis
DNA/RNA Synthesis
Aurora Kinase
|
Cancer
|
|
LS-Q2 is a highly selective CDK4/9 inhibitor with IC50 values of 1.4 nM and 6.2 nM. LS-Q2 inhibits cancer cells proliferation, induces G2/M phase arrest, apoptosis and reduces pSer2 RNA polymerase II expression. LS-Q2 interacts synergistically with BET and Bcl-2 inhibitors to drive antitumor activity. LS-Q2 can be used for the research of cancer, such as malignant solid tumors .
|
-
- HY-13554
-
|
|
Antibiotic
|
Cancer
|
|
Annamycin is an anthracycline antibiotic with antitumor activity. Annamycin interacts with topoisomerase II, induces double-strand DNA breaks, triggers cell death, and exerts cytotoxic effects. In mice, Annamycin inhibits the growth of advanced subcutaneous melanoma and subcutaneous squamous cell carcinoma, and prolongs the survival of mice with subcutaneous reticulosarcoma and in lung cancer lung metastasis models. Annamycin can be used in research related to melanoma, reticulum cell sarcoma, lung cancer, non-small cell lung cancer, small cell lung cancer .
|
-
- HY-123558
-
|
Y 14556
|
Antibiotic
|
Cancer
|
|
Bactobolin C is an antibiotic produced by Pseudomonas sp. BMG13A7, which has strong antimicrobial and antitumor activities, can also inhibit antibody production and treat autoimmune encephalomyelitis. However, its undesirable toxicity limits its medicinal application. The unique chemical structure and promising biological activities of Bactobolin C have attracted people's interest in its total synthesis and new active analogs. So far, the structural modification of Bactobolin C has mainly focused on the hydroxyl groups on the amino acid side chains and backbone.
|
-
- HY-112602
-
|
|
PI3K
mTOR
|
Cancer
|
|
PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual PI3K/mTOR inhibitor with IC50s of 20/376/204/46 nM and 186 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ and mTOR, respectively . Antitumor activity .
|
-
- HY-12678S
-
|
NMS-E628-d4; RXDX-101-d4
|
ROS Kinase
Trk Receptor
Anaplastic lymphoma kinase (ALK)
Autophagy
Isotope-Labeled Compounds
|
Cancer
|
|
Entrectinib-d4 (NMS-E628-d4; RXDX-101-d4) is the deuterium labeled Entrectinib (HY-12678). Entrectinib is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC50 values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice .
|
-
- HY-174442
-
|
|
PARP
|
Cancer
|
|
PARP1-IN-40 is a highly selectively and orally active PARP1 inhibitor (IC50: 0.19 nM for PARP1, 26 nM for PARP2). PARP1-IN-40 kills tumor cells by inhibiting PARP1, leading to accumulation of DNA damage. PARP1-IN-40 has high antitumor activity against BRCA mutant MDA-MB-436 cells. PARP1-IN-40 can be used in combination with chemotherapy for cancer-related research .
|
-
- HY-N6015R
-
|
|
Reference Standards
Parasite
P-glycoprotein
|
Infection
Cancer
|
|
Bacopasaponin C (Standard) is the analytical standard of Bacopasaponin C (HY-N6015). This product is intended for research and analytical applications. Bacopasaponin C is an orally active natural glycoside. Bacopasaponin C can be isolated from Bacopa monniera. Bacopasaponin C inhibits Verapamil (HY-14275)-stimulated P-gp ATPase activity with an IC50 of 57.83 μg/mL. Bacopasaponin C has antitumor activity against sarcomas. Bacopasaponin C has antiparasitic activity against Leishmania donovani .
|
-
- HY-N9284
-
|
|
Others
|
Cancer
|
|
5,19-Epoxy-19R,25-dimethoxycucurbita-6,23-dien-3-ol is a triterpenoid compound derived from Momordica charantia with antitumor activity, exhibiting an IC50 of 32.52 μM against U937 cells. 5,19-Epoxy-19R,25-dimethoxycucurbita-6,23-dien-3-ol shows promise for research in the field of cancer .
|
-
- HY-106031
-
|
|
Topoisomerase
DNA/RNA Synthesis
|
Cancer
|
|
F-14512 is an anticancer agent that utilizes the polyamine transport system (PTS) to selectively deliver polyamine-containing drugs to cancer cells. F-14512 enhances the affinity of polyamines for DNA, thereby inhibiting topoisomerase II and achieving selective cellular uptake. F-14512 exhibits significant cytotoxicity against cells with high PTS activity and induces DNA damage. F-14512 demonstrates potent antitumor activity in the MX1 breast tumor xenograft model. F-14512 can be used to study breast cancer .
|
-
- HY-P99109
-
|
GLS-010; AB-122; WBP-3055
|
PD-1/PD-L1
|
Cancer
|
|
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
|
-
- HY-176256
-
|
|
STING
|
Cancer
|
|
endo-S-cGAFMP (Compound 3) is a STING agonist. endo-S-cGAFMP induces the production of interferon regulatory factors and proinflammatory cytokines by activating the cGAS-STING pathway, thereby enhancing innate and adaptive immune responses. endo-S-cGAFMP has potent immunostimulatory capacity in THP1 monocytes and RAW macrophages (EC50 values of 2.45 μM and 5.54 μM, respectively). endo-S-cGAFMP has significant antitumor activity. endo-S-cGAFMP can be used as a potential cancer immunotherapeutic agent, especially for studies of systemic administration .
|
-
- HY-10204R
-
|
|
Reference Standards
c-Kit
VEGFR
c-Fms
Apoptosis
|
Cancer
|
|
OSI-930 (Standard) is the analytical standard of OSI-930 (HY-10204). This product is intended for research and analytical applications. OSI-930 is an orally selective inhibitor of Kit, KDR and CSF-1R (c-Fms) with IC50s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits Flt-1, c-Raf, Lck and low activity against PDGFRα/β, Flt-3 and Abl. OSI-930 has antitumor activity .
|
-
- HY-13404A
-
|
INC280 dihydrochloride; INCB28060 dihydrochloride
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Capmatinib (INC280; INCB28060) dihydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase .
|
-
- HY-16468
-
|
MSI-1256; ENT-01 free acid
|
Bacterial
HBV
FAK
Dengue Virus
|
Infection
Neurological Disease
Cancer
|
|
Squalamine (MSI-1256) is an aminosterol compound with broad-spectrum antiviral activity. Squalamine makes cells less conducive to certain viral replication by altering the electrostatic interactions in the inner membrane of host cells. Squalamine also has antibacterial and antitumor activities. Squalamine has broad-spectrum antibacterial activity against Gram-negative and Gram-positive bacteria, fungi and protozoa. Squalamine inhibits tumor-related angiogenesis and the growth of human breast cancer cells. Squalamine restores the function of enteric nervous system in Parkinson ,s disease mouse models .
|
-
- HY-154256
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(2-Azidoethyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5-(2-Azidoethyl)uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-157941
-
|
|
ATM/ATR
Checkpoint Kinase (Chk)
DNA/RNA Synthesis
|
Cancer
|
|
ART0380 is a potent, selective and orally active ATR kinase inhibitor. ART0380 potently inhibits human ATR-ATRIP complex with an IC50 of 51.7 nM. ART0380 binds the ATP pocket of the ATR-ATRIP complex, blocks ATR-dependent Chk1 serine 345 phosphorylation, and induces cell cycle disorder and DNA damage. ART0380 demonstrates potent and selective antitumor activity in preclinical models with varying types of ataxia-telangiectasia mutated (ATM) gene aberrancy. ART0380 can be used for the research of cancer, such as colorectal cancer and prostate cancer .
|
-
- HY-178996
-
|
|
FLT3
Apoptosis
Akt
ERK
PI3K
STAT
Mitochondrial Metabolism
|
Cancer
|
|
FLT3-IN-36 is a potent FLT3 inhibitor. FLT3-IN-36 exhibits antitumor activity against FLT3-mutated acute myeloid leukemia (AML) cells. FLT3-IN-36 induces cell cycle arrest, reduces mitochondrial membrane potential, and induces apoptosis, downregulating FLT3 and downstream protein expression (including AKT, ERK, PI3K, and STAT5). FLT3-IN-36 can be used for AML research .
|
-
- HY-156730
-
|
|
Molecular Glues
STAT
|
Cancer
|
|
KT-333 is a molecular glues that degrades STAT3 protein. KT-333 mediates the selective degradation of STAT3 through the ubiquitin-proteasome system by binding to STAT3 protein and E3 ubiquitin ligase von Hippel-Lindau protein (VHL). KT-333 has strong selectivity for STAT3 protein degradation and good antitumor activity. KT-333 can be used in the study of hematologic malignancies such as large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL) .
|
-
- HY-175603
-
|
|
Amine N-methyltransferase
|
Cancer
|
|
NCGC00685960 is a Nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 <10 nM. NCGC00685960 has potent antitumor activity. NCGC00685960 increases H3K27 trimethylation levels in ovarian cancer cells and inhibits α-SMA expression in NNMT-expressing ovarian fibroblasts. NCGC00685960 reduces 1-MNA levels, reverses SAM and H3K27 hypomethylation and significantly impairs collagen contractility in cancer-associated fibroblasts (CAFs). NCGC00685960 can be used for cancers research, such as ovarian cancer, breast cancer, colon cancer .
|
-
- HY-W394432
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
(2R,3S,5R)-2-(hydroxymethyl)-5-(6-methyl-9H-purin-9-yl)tetrahydrofuran-3-ol (9-(2-Deoxy-beta-D-ribofuranosyl)-6-methylpurine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-162873
-
|
|
MEK
Raf
|
Cancer
|
|
MEK/RAF-IN-1 (Compound 16b) is an inhibitor of both MEK and RAF. It shows potent inhibition with IC50 values of 28 nM for MEK1, and 3 nM each for BRAF and BRAFV600E. MEK/RAF-IN-1 demonstrates significant antitumor activity, effectively inhibiting cell proliferation in vitro against MIA PaCa-2 (G12C KRAS), HCT116 (G13D KRAS), and C26 (G12D KRAS) cells. Additionally, it inhibits tumor growth in xenograft mouse models of colorectal cancer .
|
-
- HY-161369
-
|
|
PROTACs
Histone Acetyltransferase
|
Cancer
|
|
CBPD-268 is a potent and orally active CBP/p300 PROTAC degrader with an DC50 value of ≤ 0.03 nM. CBPD-268 induces CBP/p300 degradation and inhibits cell growth. CBPD-268 shows antitumor activity. CBPD-268 has the potential for the research of AR-positive prostate cancer (Structure Note: Red, Androgen receptor degrader (HY-W248665A); Blue, CBP/p300 ligand (HY-161483); Black, Linker) .
|
-
- HY-P991501
-
|
HcHAb18
|
ADC Antibody
Transmembrane Glycoprotein
SARS-CoV
|
Infection
Cancer
|
|
Meplazumab (HcHAb18) is a humanized anti-CD147 IgG1 antibody a Kd of 0.47 nM. Meplazumab shows anti-SARS-CoV-2 and antitumor activity. Meplazumab conjugated with DM1 can form an antibody-conjugated drug ( HcHAb18-DM1), which induces G2/M phase cell cycle arrest and exerts antiproliferative activity in cancer cells. Meplazumab can be used for the researches of COVID-19 pneumonia and non-small cell lung cancer .
|
-
- HY-13404C
-
|
INC280 dihydrochloride hydrate; INCB-28060 dihydrochloride hydrate
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Capmatinib (INC280; INCB28060) dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase .
|
-
- HY-170855A
-
|
|
PROTACs
RET
|
Cancer
|
|
YW-N-7 (TFA) is a PROTAC that targets both the inhibition and degradation of RET kinase, with a DC50 of 88 nM. YW-N-7 (TFA) exhibits antitumor activity in a KIF5B-RET-driven xenograft mouse tumor model and can be used in the area of cancer (Structure: red part represents the target protein ligand: HY-170856; blue part represents the E3 ligase ligand: HY-1708557; black part represents the linker; E3 ligase ligand + linker: HY-170858) .
|
-
- HY-119420
-
|
|
Antibiotic
Apoptosis
Caspase
JNK
p38 MAPK
TNF Receptor
ERK
NF-κB
Mitochondrial Metabolism
|
Inflammation/Immunology
Cancer
|
|
Acetoxycycloheximide is an antibiotic with antitumor activity. Acetoxycycloheximide a protein synthesis inhibitor. Acetoxycycloheximide significantly induces activation of procaspase-3 and subsequent apoptosis mediated by the Cytochrome c from mitochondria via activation of JNK pathway. Acetoxycycloheximide triggers the downregulation of cell surface TNF-R1 via the activation of ERK and p38 MAPK, thereby preventing activation of the NF-κB signaling pathway by TNF-α. Acetoxycycloheximide is much more toxic to female rats than to males. Acetoxycycloheximide can be used for inflammatory and immune diseases and cancers research .
|
-
- HY-148290
-
|
|
PROTACs
IRAK
|
Cancer
|
|
KTX-951 is an orally active IRAK4 and IMiD (Ikaros/Aiolos) substrates PROTAC degrader (Kd = 3.5 nM). KTX-951 has DC50s of 13 nM, 14 nM and 13 nM for IRAK4, Ikaros and Aiolos, respectively. KTX-951 has IC50 of 35 nM for OCl-Ly10 CTG. KTX-951 has antitumor activity.(Pink: IRAK4 ligand-12 (HY-48932); Black: Linker (HY-W382009); Blue: CRBN Ligand Pomalidomide (HY-10984)) .
|
-
- HY-155995
-
|
MK-905
|
Biochemical Assay Reagents
|
Cancer
|
|
Pro-905 is a phosphite peptide with antitumor activity. Pro-905 delivers the active nucleotide antimetabolite thioguanosine monophosphate (TGMP) to the tumor. Pro-905 effectively prevents incorporation of purine salvage substrates into nucleic acids and inhibits colony formation in human malignant peripheral nerve sheath tumors (MPNST) cells. Pro-905 inhibits purine salvage incorporation to nucleic acids and prevents cell growth. Pro-905 inhibits the growth of MPNST and enhances the anti-tumor efficacy of JHU395 (HY-124778) .
|
-
- HY-152352
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
7,8-Dihydro-8-oxo-7-propargyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 7,8-Dihydro-8-oxo-7-propargyl guanosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-116514
-
|
|
Farnesyl Transferase
Apoptosis
Endogenous Metabolite
|
Cancer
|
|
(S)-(-)-Perillyl alcohol, a monoterpene, is an orally active farnesyl transferase and geranylgeranyl transferase inhibitor. (S)-(-)-Perillyl alcohol up-regulates the mannose-6-phosphate receptor, facilitating TGF-β1 activation and cytostasis,. (S)-(-)-Perillyl alcohol induces apoptosis in cancer cells, modulates cyclin D1 and AP-1 activity. (S)-(-)-Perillyl alcohol exhibits antitumor activity against sarcoma tumors in mice. (S)-(-)-Perillyl alcohol can be used for the research of squamous cell carcinoma of the esophagus and sarcoma 180 .
|
-
- HY-15346
-
|
BAY 80-6946
|
PI3K
Apoptosis
|
Cancer
|
|
Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .
|
-
- HY-183631
-
|
|
β-catenin
Wnt
mTOR
c-Myc
Apoptosis
|
Cancer
|
|
PM54 is an antitumor agent with activity across multiple cancer types. PM54 acts as a transcription and WNT/β-catenin signaling pathway inhibitor. PM54 suppresses oncogenic transcriptional programs, and key malignant pathways, while inducing DNA double-strand breaks, S-phase cell cycle arrest and apoptosis. PM54 enhances innate immune recognition, remodels the tumor microenvironment. PM54 exhibits antitumor activity as monotherapy or in combination in xenograft models. PM54 is applicable to research on various cancers and advanced solid tumors .
|
-
- HY-B1092AS2
-
|
D-Gluconic acid sodium salt-d6; Sodium D-gluconate-d6; D-Gluconate sodium salt-d6
|
Isotope-Labeled Compounds
Interleukin Related
ERK
NO Synthase
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Gluconate-d6 sodium (D-Gluconic acid sodium salt-d6) is the deuterium labeled Gluconate sodium (HY-B1092A). Gluconate sodium (D-Gluconic acid sodium salt) is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury .
|
-
- HY-169019
-
|
|
PI3K
Apoptosis
|
Cancer
|
XJTU-L453 is a PI3Kα inhibitor with an IC50 value of 0.4 nM. XJTU-L453 can inhibit the proliferation of breast cancer cell lines T47D and MCF7, with IC50 values of 0.2 μM and 0.5 μM, respectively. XJTU-L453 can inhibit the PI3K pathway, induce cell cycle arrest, and trigger cell apoptosis (apoptosis). XJTU-L453 also has antitumor activity in MCF7 xenograft mice .
|
-
- HY-104067
-
|
NASTRp
|
Epigenetic Reader Domain
|
Cancer
|
|
Naphthol AS-MX phosphate (NASTRp) is a small molecule inhibitor of the CREB (cyclic adenosine phosphate reaction element binding protein)-CBP (CREB binding protein) transcription factor complex. Naphthol AS-MX phosphate shows antitumor activity against lung cancer cells, inhibiting tumor cell proliferation (IC50=3.701 μmol/L), colony formation, and anchored independent growth in soft AGAR. Naphthol AS-MX phosphate can be used in the study of KRAS mutated lung cancer, especially for KRAS mutated lung cancer with poor chemotherapy resistance and prognosis .
|
-
- HY-N2187
-
|
|
Bacterial
HIF/HIF Prolyl-Hydroxylase
PI3K
Apoptosis
|
Infection
Cardiovascular Disease
Cancer
|
|
Deoxyshikonin increases the expression of VEGF-C and VEGF-A mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction and binds to specific DNA sequences targeted by HIF. Deoxyshikonin inhibited colorectal cancer (CRC) through the PI3K/Akt/mTOR pathway. Deoxyshikonin has proangiogenesis effect and antitumor activity. Deoxyshikonin is an antibacterial agent against methicillin-resistant S. aureus (MRSA) and S. pneumonia (MIC=17 μg/mL) .
|
-
- HY-182003
-
|
|
Akt
Apoptosis
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Anticancer agent 308 is an AKT inhibitor with antitumor activity. Anticancer agent 308 reduces total AKT protein levels, thereby inhibiting the pro-survival PI3K/AKT signaling pathway. Anticancer agent 308 induces apoptosis, disrupts mitochondrial membrane potential, promotes ROS accumulation in mitochondria, and induces cell cycle arrest. Anticancer agent 308 inhibits cancer cell migration. Anticancer agent 308 is applicable to research related to breast cancer, lung adenocarcinoma, cervical cancer, prostate cancer, and hepatocellular carcinoma .
|
-
- HY-13404
-
|
INC280; INCB28060
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase .
|
-
- HY-173048
-
|
|
ClpP
Apoptosis
Reactive Oxygen Species (ROS)
|
Cancer
|
|
CLPP-2068 is the orally active activator for human caseinolytic protease P (HsClpP) with an EC50 of 50.4 nM. CLPP-2068 exhibits anti-proliferative efficacy in OCI-LY10 cancer cell with an IC50 of 5.2 nM. CLPP-2068 decreases mitochondrial membrane potential, increases mitochondrial ROS levels, and induces mitochondrial dysfunction. CLPP-2068 arrests the cell cycle at G1 phase, and induces apoptosis in cell OCI-LY10. CLPP-2068 exhibits antitumor activity in mouse xenograft models .
|
-
- HY-P992012
-
|
|
Opioid Receptor
|
Neurological Disease
Cancer
|
|
CA1001 is a small-molecule ZNF74 inhibitor and a peripherally restricted κ/δ dual opioid receptor agonist. CA1001 exhibits potent antitumor activity both in vitro and in vivo. CA1001, in combination with immune checkpoint inhibitors, significantly enhances tumor regression. CA1001 activates peripherally restricted κ/δ dual opioid receptors and exerts analgesic effects under conditions of inflammatory pain, neuropathic pain, and mechanical hyperalgesia. CA1001 can be used in research related to melanoma, mechanical hyperalgesia, neuropathic pain, and inflammatory arthritis pain.
|
-
- HY-15346A
-
|
BAY 80-6946 dihydrochloride
|
PI3K
Apoptosis
|
Cancer
|
|
Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib dihydrochloride has superior antitumor activity .
|
-
- HY-19916A
-
|
BAL-101553 dihydrochloride
|
Microtubule/Tubulin
Checkpoint Kinase (Chk)
|
Cancer
|
|
Lisavanbulin (BAL-101553) dihydrochloride is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin dihydrochloride exhibits antitumor activity, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin dihydrochloride has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin dihydrochloride is also a spindle assembly checkpoint activator. Lisavanbulin dihydrochloride induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin dihydrochloride can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma .
|
-
- HY-13404B
-
|
INC280 hydrochloride; INCB-28060 hydrochloride
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Capmatinib (INC280; INCB28060) hydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib hydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib hydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib hydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase .
|
-
- HY-101029A
-
|
|
NEKs
Ribosomal S6 Kinase (RSK)
DYRK
Apoptosis
|
Cancer
|
|
MBM-55S is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 1 nM. MBM-55S shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC50=5.4 nM) and DYRK1a (IC50=6.5 nM). MBM-55S effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55S shows antitumor activities, and no obvious toxicity to mice .
|
-
- HY-175030
-
|
|
HDAC
Apoptosis
Pyroptosis
Necroptosis
PANoptosis
|
Cancer
|
|
TNI-97 is a selective and orally active HDAC6 inhibitor, with an IC50 of 0.2 nM. TNI-97 potently inhibited TNBC cell MDA-MB-453 growth and clonogenicity. TNI-97 induces PANoptosis including apoptosis, necroptosis and pyroptosis in MDA-MB-453 cells. TNI-97 shows antitumor activity in the mice carrying the MDA-MB-453 xenograft or carrying murine-derived TNBC cell allografts. TNI-97 can be used for the study of triple-negative breast cancer .
|
-
- HY-N13772
-
|
(+)-Dihydroisorhamnetin
|
Apoptosis
|
Cancer
|
|
3'-O-Methyltaxifolin ((+)-Dihydroisorhamnetin) is a dihydroflavanol found in Pulicaria jaubertii. A mixture of these alcohol compounds including 3'-O-Methyltaxifolin found in Pulicaria jaubertii exhibits antitumor activity with IC50 values of 19.1 μg, 20.0 μg, and 24.1 μg against prostate cancer (PC-3), breast cancer (MCF-7), and hepatocellular carcinoma (HepG-2) cell lines, respectively. Furthermore, 3'-O-Methyltaxifolin can induce cell apoptosis, making it a promising candidate for anticancer research. .
|
-
- HY-179617
-
|
|
E1/E2/E3 Enzyme
Interleukin Related
|
Cancer
|
|
Cbl-b-IN-30 is an orally active Casitas B-lineage lymphoma-b (CBLB) inhibitor. Cbl-b-IN-30 specifically binds to CBLB and inhibits its E3 ubiquitin ligase activity with an IC50 of 9.1 nM. Cbl-b-IN-30 can promote IL-2 secretion (EC50 = 187.5 nM) and enhance T cell activation. Cbl-b-IN-30 exerts antitumor activity and can induce immune memory. Cbl-b-IN-30 can be used for the research of colon cancer .
|
-
- HY-131710
-
|
|
Phosphodiesterase (PDE)
EGFR
Wnt
Apoptosis
|
Cancer
|
|
PDE5-IN-3 (compound 11j) is a potent PDE5 inhibitor with an IC50 of 1.57 nM. PDE5-IN-3 shows moderate EGFR inhibition with IC50 of 5.827 µM. PDE5-IN-3 significantly inhibits the Wnt/β-catenin pathway (IC50=1286.96 ng/mL). PDE5-IN-3 induces the intrinsic apoptotic mitochondrial pathway in HepG2 cells. PDE5-IN-3 has strong antitumor activity .
|
-
- HY-N0646
-
|
|
Phosphatase
Endogenous Metabolite
Tyrosinase
Apoptosis
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Silydianin is a flavonolignan. Silydianin can be obtained from Silybum marianum. Silydianin inhibits PTP1B with an IC50 of 17.38 μM. Silydianin inhibits both monophenolase and diphenolase of tyrosinase significantly, with IC50s of 2.6 μM and 16.5 μM, respectively. Silydianin induces Apoptosis and reduces cytokines (IL-4 and IL-5). Silymarin has antioxidant, cytoprotective and immunomodulatory effects. Silydianin has antitumor activity against prostate cancer. Silymarin can be used in allergic asthma research .
|
-
- HY-107367AR
-
|
S-22611 hydrochloride (Standard)
|
Reference Standards
EGFR
|
Cancer
|
|
Epertinib hydrochloride (Standard) (S-22611 hydrochloride (Standard)) is the analytical standard of Epertinib (hydrochloride) (HY-107367A). This product is intended for research and analytical applications. Epertinib (S-22611) hydrochloride is a potent, orally active, reversible, and selective tyrosine Kinase inhibitor of EGFR, HER4 and HER2, with IC50s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib hydrochloride shows potent antitumor activity . Epertinib (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-152746
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-6-chloropurine-9-(2’-O-propargyl)riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2-Amino-6-chloropurine-9-(2’-O-propargyl)riboside is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-15666R
-
|
GZD824 (Standard); HQP1351 (Standard)
|
Reference Standards
Bcr-Abl
|
Cancer
|
|
Olverembatinib (Standard) is the analytical standard of Olverembatinib. This product is intended for research and analytical applications. Olverembatinib (GZD824) is a potent and orally active pan-Bcr-Abl inhibitor. Olverembatinib potently inhibits a broad spectrum of Bcr-Abl mutants. Olverembatinib strongly inhibits native Bcr-Abl and Bcr-Abl T315I with IC50s of 0.34 nM and 0.68 nM, respectively. Olverembatinib has antitumor activity . Olverembatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-101570R
-
|
Peposertib (Standard); M3814 (Standard)
|
DNA-PK
Reference Standards
BCRP
|
Cancer
|
|
Nedisertib (Standard) is the analytical standard of Nedisertib (HY-101570). This product is intended for research and analytical applications. Nedisertib (Peposertib) is an orally active selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of less than 3 nM. Nedisertib also acts as a modulator of ABCG2, capable of reversing ABCG2-mediated multidrug resistance (MDR), thus providing new strategies for combination therapy. By inhibiting DNA double-strand break repair, Nedisertib can enhance the efficacy of chemotherapy and radiotherapy. Nedisertib exhibits antitumor activity .
|
-
- HY-113916
-
|
AT13387 lactate
|
HSP
|
Cancer
|
|
Onalespib lactate is a potent and cross the blood-brain barrier heat-shock-protein-90 (Hsp90) inhibitor with an Kd value of 0.71 nM. Onalespib lactate inhibits the proliferation, survival and migration. Onalespib lactate decreases the expression of EGFR, p-EGFR, AKT, P-AKT, ERK1/2, P-ERK1/2, S6, P-S6 protein. Onalespib lactate shows antitumor activity. Onalespib lactate has the potential for the research of non-small cell lung cancer (NSCLC) .
|
-
- HY-N4095R
-
|
|
Reference Standards
Aryl Hydrocarbon Receptor
Glycosidase
Reactive Oxygen Species (ROS)
GLUT
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Brevifolincarboxylic acid (Standard) is the analytical standard of Brevifolincarboxylic acid (HY-N4095). This product is intended for research and analytical applications. Brevifolincarboxylic acid is a phenolic compound. Brevifolincarboxylic acid can be isolated from Duchesnea chrysantha. Brevifolincarboxylic acid inhibits α-glucosidase with an IC50 value of 323.46 μM. Brevifolincarboxylic acid has an inhibitory effect on the aryl hydrocarbon receptor (AhR). Brevifolincarbacid scavenges ROS. Brevifolincarbacid restores the glucose uptake activity of myotubes. Brevifolincarboxylic acid has antitumor activity against lung and gastric cancer. Brevifolincarbacid can be used in the study of diabetes and inflammatory diseases .
|
-
- HY-W754911
-
|
BLU-285-d3
|
Isotope-Labeled Compounds
PDGFR
c-Kit
|
Cancer
|
|
Avapritinib-d3 (BLU-285-d3) is deuterium labeled Avapritinib. Avapritinib (BLU-285) is a highly potent, selective, and orally active KIT and PDGFRA activation loop mutant kinases inhibitor with IC50s of 0.27 and 0.24 nM for KIT D816V and PDGFRA D842V, respectively. Avapritinib (BLU-285) binds the active conformation of the kinase and shows antitumor activity. Avapritinib (BLU-285) attenuates the transport function of both ABCB1 and ABCG2 .
|
-
- HY-106031A
-
|
|
Topoisomerase
DNA/RNA Synthesis
|
Cancer
|
|
F-14512 hydrochloride is an anticancer agent that utilizes the polyamine transport system (PTS) to selectively deliver polyamine-containing drugs to cancer cells. F-14512 hydrochloride enhances the affinity of polyamines for DNA, thereby inhibiting topoisomerase II and achieving selective cellular uptake. F-14512 hydrochloride exhibits significant cytotoxicity against cells with high PTS activity and induces DNA damage. F-14512 hydrochloride demonstrates potent antitumor activity in the MX1 breast tumor xenograft model. F-14512 hydrochloride could be used to study breast cancer .
|
-
- HY-W768336
-
|
D-Gluconic acid-13C6 sodium; D-Gluconate-13C6 sodium
|
Isotope-Labeled Compounds
Interleukin Related
ERK
NO Synthase
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Gluconate sodium- 13C6 (D-Gluconic acid sodium salt- 13C6) is the 13C-labeled Gluconate sodium (HY-B1092A). Gluconate sodium (D-Gluconic acid sodium salt) is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury .
|
-
- HY-131906
-
|
|
JAK
FLT3
Apoptosis
|
Cancer
|
|
JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3 V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities .
|
-
- HY-174450
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
KMT9-IN-1 (Compound 8) is a KMT9 inhibitor and the ethyl ester prodrug of compound 7b. KMT9-IN-1 releases the active form 7b via esterases in cells. KMT9-IN-1 targets KMT9 in cells and reduces H4K12me1 levels. KMT9-IN-1 has antitumor activity against colon cancer. KMT9-IN-1 can be used in the research of prostate cancer and hepatocellular carcinoma .
|
-
- HY-P0036S3
-
|
SMS 201-995-13C9，15N
|
Isotope-Labeled Compounds
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Octreotide- 13C9, 15N (SMS 201-995- 13C9, 15N) is 13C and 15N labeled Octreotide. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .
|
-
- HY-179077
-
|
|
PROTACs
Btk
IKZF Family
|
Cancer
|
|
PROTAC BTK/IKZF1/3 Degrader-1 is a selective and orally active BCL6 and IKZF1/3 PROTAC degrader. PROTAC BTK/IKZF1/3 Degrader-1 exhibits antitumor activity. PROTAC BTK/IKZF1/3 Degrader-1 can be used for the research of cancer, such as lymphoma . (Structure Note: Pink: BCL6/IKZF1/3 ligand (HY-179076); Blue: CRBN ligand (HY-41547))
|
-
- HY-W013289
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
Cancer
|
|
9-((2R,3R,4R,5R)-4-Hydroxy-5-(hydroxymethyl)-3-methoxytetrahydrofuran-2-yl)-9H-purin-6-ol (2'-O-methylinosine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-158230
-
|
|
Topoisomerase
|
Cancer
|
|
SN-398 is a derivative of Camptothecin (HY-158230), which is an antitumor drug. Acting by inhibiting mammalian DNA topoisomerase I (Topo I), stabilizing the Topo I-DNA complex prevents DNA rewiring to induce Topo I mediated DNA breaks. In Hela cell tests, SN-398 shows stronger antitumor activity than SN-38 (HY-13704) (IC50=1.562 μM). SN-398 can be used to study the anti-proliferation and growth inhibition of Topo I in cancer cells .
|
-
- HY-B1092AR
-
|
D-Gluconic acid sodium salt (Standard); Sodium D-gluconate (Standard); D-Gluconate sodium salt (Standard)
|
Reference Standards
NO Synthase
Endogenous Metabolite
Interleukin Related
ERK
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Gluconate (D-Gluconic acid) (Standard) is the analytical standard of Gluconate sodium (HY-B1092A). This product is intended for research and analytical applications. Gluconate (D-Gluconic acid) sodium is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury .
|
-
- HY-136910
-
|
USP7-IN-7
|
Deubiquitinase
MDM-2/p53
|
Cancer
|
|
USP7-797 (USP7-IN-7) is an orally available, selective USP7 inhibitor (IC50=0.5 nmol/L) with antitumor activity. USP7-797 reduces the level of MDM2, thereby increasing the stability and activity of p53, leading to cell cycle arrest and apoptosis. USP7-797 has low nanomolar cytotoxicity against p53 mutant cancer cell lines, p53 wild-type hematological tumors, and neuroblastoma cell lines .
|
-
- HY-142690A
-
|
|
Apoptosis
HDAC
|
Cancer
|
|
HDAC-IN-27 dihydrochloride (Compound 11h) is a potent, orally active class I HDAC-selective inhibitor with IC50 values ranging from 0.43 to 3.01 nM against HDAC1-3. HDAC-IN-27 dihydrochloride exhibits both in vivo and in vitro antitumor activity. HDAC-IN-27 dihydrochloride demonstrates significant anti-proliferative activity against acute myeloid leukemia (AML) cell lines by inducing apoptosis and histone acetylation (AcHH3 and AcHH4). HDAC-IN-27 dihydrochloride can be used for research in acute myeloid leukemia (AML) .
|
-
- HY-119257
-
ABT-100
1 Publications Verification
|
Farnesyl Transferase
Apoptosis
|
Cancer
|
|
ABT-100, a chemical probe, is a potent, highly selective and orally active farnesyltransferase inhibitor. ABT-100 inhibits cell proliferation (IC50s of 2.2 nM, 3.8 nM, 5.9 nM, 6.9 nM, 9.2 nM, 70 nM and 818 nM for EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells, respectively), increases apoptosis and decreases angiogenesis. ABT-100 possesses broad-spectrum antitumor activity .
|
-
- HY-P991561
-
|
|
CD47
|
Cancer
|
|
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .
|
-
- HY-142690
-
|
|
HDAC
Apoptosis
|
Cancer
|
|
HDAC-IN-27 (Compound 11h) is a potent, orally active class I HDAC-selective inhibitor with IC50 values ranging from 0.43 to 3.01 nM against HDAC1-3. HDAC-IN-27 exhibits both in vivo and in vitro antitumor activity. HDAC-IN-27 demonstrates significant anti-proliferative activity against acute myeloid leukemia (AML) cell lines by inducing apoptosis and histone acetylation (AcHH3 and AcHH4). HDAC-IN-27 can be used for research in acute myeloid leukemia (AML) .
|
-
- HY-145696
-
|
|
PROTACs
JAK
|
Inflammation/Immunology
Cancer
|
|
SJ10542 is a potent and selective JAK2/3 PROTAC degrader. In PDX cells lSJBALL020589, SJ10542 has DC50 values of 14 and 11 nM for JAK2 and JAK3, respectively. SJ10542 exhibits antitumor activity and can be used for the research of hematological malignancies and autoimmune diseases . (Pink: Target protein ligand (HY-47073); Black: Linker (HY-W251248); Blue: E3 ligase ligand (HY-W890189); E3 ligase ligand+Linker (HY-176425))
|
-
- HY-114256
-
|
|
PSMA
|
Cancer
|
|
EC1169 is a cytotoxic maytansinoid conjugate that specifically binds to prostate-specific membrane antigen (PSMA). EC1169 precisely delivers the maytansinoid B hydrazide payload to PSMA-positive cells to exert antitumor activity. EC1169 only inhibits the growth of PSMA-positive cells but has no effect on PSMA-negative cells, and enables complete recovery in mice bearing PSMA-positive tumors. EC1169 exhibits safety with no body weight loss or major organ damage induced. EC1169 is used in studies of prostate cancer and other PSMA-expressing malignancies .
|
-
- HY-156912
-
|
|
EGFR
|
Cancer
|
|
Tyrosine kinase-IN-7 (compound 13h) is an inhibitor of the tyrosine kinase EGFR. The IC50s for inhibiting EGFR(WT) and EGFR(T790M) are 0.630 μM and 0.956 μM respectively. Tyrosine kinase-IN-7 has antitumor activity against four cancer cell lines (HepG2, HCT-116, MCF-7, and A431) with IC50s of 13.02 μM, 10.14 μM, 12.68 μM, and 47.05 μM, respectively .
|
-
- HY-148918
-
|
|
β-catenin
Wnt
Bcl-2 Family
|
Inflammation/Immunology
Cancer
|
E722-2648 is an inhibitor targeting the BCL9 and β-catenin complex with antitumor activity. E722-2648 blocks complex formation by disrupting the interaction between the two proteins, thereby inhibiting β-catenin-mediated transcriptional activity and downregulating the expression of WNT target genes. E722-2648 effectively inhibits tumor growth in colon cancer xenograft models and colorectal cancer mouse models. E722-2648 can be used for the research of colon cancer and colorectal cancer .
|
-
- HY-152870
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-O-(2-Azidoethyl)adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-O-(2-Azidoethyl)adenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-137371
-
|
|
Bacterial
Apoptosis
Antibiotic
|
Infection
Cancer
|
|
Lactonic sophorolipid is an apoptosis inducer and antimicrobial surfactant with antitumor activity. Lactonic sophorolipid regulates Bax/Bcl-gene expression through caspase-3/9 and induces apoptosis in tumor cells. Lactonic sophorolipid can disrupt cell membrane permeability and exert antibacterial effects (MIC for oral pathogens is 100-400 μg/mL). Lactonic sophorolipid promotes mitochondrial membrane potential depolarization, activates the intrinsic apoptotic pathway, and can synergize with antibiotics to enhance the antibacterial effect. Lactonic sophorolipid can be used in liver cancer research and the development of oral hygiene antibacterial agents[1][2][3].
|
-
- HY-P990627
-
|
MEDI-547 antibody
|
ADC Antibody
Ephrin Receptor
|
Cancer
|
|
Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is an anti-EphA2 monoclonal antibody. Anti-EphA2 Antibody (1C1) can induce degradation of EphA2 protein. Anti-EphA2 Antibody (1C1) conjugated with McMMAF (HY-15578) can form an antibody-conjugated drugs, which has potent antitumor activity. Anti-EphA2 Antibody (1C1) can be used for the research of cancer, such as prostate cancer and glioma .
|
-
- HY-19896
-
COTI-2
4 Publications Verification
|
MDM-2/p53
Apoptosis
|
Cancer
|
|
COTI-2, an anti-cancer agent with low toxicity, is an orally available third generation activator of p53 mutant forms. COTI-2 acts both by reactivating mutant p53 and inhibiting the PI3K/AKT/mTOR pathway. COTI-2 induces apoptosis in multiple human tumor cell lines. COTI-2 exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms. COTI-2 converts mutant p53 to wild-type conformation .
|
-
- HY-154855
-
|
|
HDAC
|
Cancer
|
|
HDAC-IN-56 ((S)-17b) is an orally active class I histone deacetylase (HDAC) inhibitor with IC50 values of 56.0 ± 6.0, 90.0 ± 5.9, 422.2 ± 105.1, >10000 nM for HDAC1, HDAC2, HDAC3, and HDAC4-11, respectively. HDAC-IN-56 has potent inhibitory activity while strongly increasing intracellular levels of acetylhistone H3 and P21 and effectively inducing G1 cell cycle arrest and apoptosis.HDAC-IN-56 has antitumor activity .
|
-
- HY-101489A
-
|
|
PDGFR
Bcr-Abl
Apoptosis
|
Cancer
|
|
GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC50s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-Abl T315I inhibitor, with IC50s of 19.9 and 15.4 nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity . GZD856 (formic) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-154779R
-
|
|
Nucleoside Antimetabolite/Analog
Reference Standards
|
Cancer
|
|
5′-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine (Standard) is the analytical standard of 5′-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine. This product is intended for research and analytical applications. 5′-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![5′-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine (Standard)](//file.medchemexpress.com/product_pic/hy-154779r.gif)
- HY-13314R
-
|
XL-647 (Standard); EXEL-7647 (Standard); KD-019 (Standard)
|
EGFR
VEGFR
Src
Reference Standards
|
Cancer
|
|
Tesevatinib (Standard) is the analytical standard of Tesevatinib. This product is intended for research and analytical applications. Tesevatinib (XL-647) is an orally available, blood-brain barrier-penetrant inhibitor of the epidermal growth factor receptor (EGFR). Tesevatinib significantly reduces cellular viability, with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Tesevatinib also inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM). Tesevatinib can inhibit tumor proliferation and exhibits antitumor activity .
|
-
- HY-152737
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-azido-isocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Deoxy-3’-azido-isocytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-10181GL
-
|
BMS-354825 (GMP Like)
|
Bcr-Abl
Src
Autophagy
Apoptosis
|
Cancer
|
|
Dasatinib (GMP Like) (BMS-354825 (GMP Like)) is Dasatinib (HY-10181) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib also induces apoptosis and autophagy.
|
-
- HY-P10994
-
|
Eps8(327-335)
|
EGFR
IFNAR
Interleukin Related
TNF Receptor
Complement System
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Eps8 peptide 327 is an HLA-A*2402-restricted peptide antigen derived from Eps8 protein. Eps8 peptide 327 has potent antitumor activity with significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cells proliferation, induces apoptosis and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. Eps8 peptide 327 significantly inhibits tumor growth in HT-29 xenograft mcie models .
|
-
- HY-111015A
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
IRC-083927 is an orally effective tubulin inhibitor. IRC-083927 binds to the colchicine site on tubulin to inhibit its polymerization, thereby inducing G2-M phase cell cycle arrest in tumor cells. IRC-083927 significantly inhibits endothelial cell proliferation and in vitro angiogenesis, and exhibits remarkable antitumor activity. IRC-083927 can be widely applied in relevant studies on human cervical cancer, breast cancer, pancreatic cancer, prostate cancer, as well as small cell and non-small cell lung cancer .
|
-
- HY-120149
-
|
|
Toll-like Receptor (TLR)
MDM-2/p53
MMP
Caspase
SOD
p38 MAPK
NF-κB
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Inotodiol activates p53 signaling pathway, inhibits MMP-2/9, and exhibits antitumor activity in cancer cell HeLa. Inotodiol inhibits the generation of ROS and exhibits antioxidant and neuroprotective effects. Inotodiol inhibits the activation of MAPK and NF-κB signaling pathway, and exhibits anti-inflammatory activity. Inotodiol inhibits TLR-4 mediated TNF-α production (IC50s in BMMC and BMDM is 0.7 μM and 3.0 μM), inhibits the degranulation in mast cell, exhibits anti-allergic activity. Inotodiol is orally active .
|
-
- HY-10032R
-
|
PF 00477736 (Standard)
|
Checkpoint Kinase (Chk)
Reference Standards
VEGFR
Src
c-Fms
Aurora Kinase
FGFR
FLT3
RET
CDK
|
Cancer
|
|
PF 477736 (Standard) is the analytical standard of PF 477736 (HY-10032). This product is intended for research and analytical applications. PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of Chk1, with a Ki of 0.49 nM, it is also a Chk2 inhibitor, with a Ki of 47 nM. PF 477736 shows <100-fold selectivity for Chk1 over VEGFR2, Fms, Yes, Aurora-A, FGFR3, Flt3, and Ret (IC50=8 (Ki), 10, 14, 23, 23, 25, and 39 nM, respectively). PF 477736 can enhance Gemcitabine antitumor activity in vitro and in vivo .
|
-
- HY-15815
-
|
|
Epigenetic Reader Domain
Apoptosis
CDK
HIV
|
Cancer
|
|
Bromosporine, a chemical probe, is a potent BET inhibitor with an IC50 value of 2.1 μM for PCAF. Bromosporine can arrest cell cycle and induce apoptosis in cancer cells. Bromosporine exhibits excellent antitumor activity in xenograft mice model when combined with 5-Fluorouracil (HY-90006). Bromosporine can increase CDK9 T-loop phosphorylation in HIV-1 latency models, resulting the protection of reactivate HIV-1 replication from latency. Bromosporine can be used to research colorectal cancer, acute myeloid leukemia (AML) and AIDS .
|
-
- HY-183570
-
|
|
Photosensitizer
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Antitumor photosensitizer-11 is a type-I carbazole/benzindolium photosensitizer with antitumor activity. Antitumor photosensitizer-11 induces ROS generation via a type-I pathway, forming superoxide anions and hydroxyl radicals. Antitumor photosensitizer-11 triggers immunogenic cell death in cancer cells via enhanced oxidative stress. Antitumor photosensitizer-11 exhibits antiproliferative activity in normoxic and hypoxic environments, inhibits breast cancer tumor growth in vivo, and promotes dendritic cell maturation and T cell infiltration. Antitumor photosensitizer-11 can be used for the research of cancer, such as breast cancer .
|
-
- HY-124072
-
|
|
Cyclophilin
LPL Receptor
MDM-2/p53
Apoptosis
Reactive Oxygen Species (ROS)
|
Cancer
|
|
HL001 is an orally active small molecule inhibitor of Cyclophilin A (CypA) and a receptor antagonist of Lysophosphatidic acid 1 (LPA1). HL001 induces cell cycle arrest and apoptosis of tumor cells by p53. HL001 stabilizes p53 by down-regulating G3BP1, inducing reactive oxygen species and DNA damage. HL001 disrupts the interaction between MDM2 and p53-72R in a CypA dependent manner. HL001 has antitumor activity. HL001 can also be used to study pulmonary fibrosis .
|
-
- HY-112429
-
HJB97
2 Publications Verification
|
Ligands for Target Protein for PROTAC
Epigenetic Reader Domain
|
Cancer
|
|
HJB97 is a high-affinity BET inhibitor with Ki values of 0.9 nM (BRD2 BD1), 0.27 nM (BRD2 BD2), 0.18 nM (BRD3 BD1), 0.21 nM (BRD3 BD2), 0.5 nM (BRD4 BD1), and 1.0 nM (BRD4 BD2) . HJB97 can serve as a ligand for target protein (Ligands for Target Protein for PROTAC) for the development of PROTAC BET degraders with antitumor activity . HJB97 can be used for the synthesis of BETd-260 (HY-101519).
|
-
- HY-W739775
-
|
2’-Deoxy-3’,2-anhydro-5-methyluridine-d3
|
Isotope-Labeled Compounds
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2,3’-Anhydrothymidine-d3 (2’-Deoxy-3’,2-anhydro-5-methyluridine-d3) is the deuterium labeled 2,3’-Anhydrothymidine (HY-154340). 2,3’-Anhydrothymidine; 2’-Deoxy-3’,2-anhydro-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-50751R
-
|
ABT-869 (Standard); AL-39324 (Standard)
|
PDGFR
VEGFR
FLT3
c-Fms
c-Kit
Autophagy
Apoptosis
Reference Standards
|
Cancer
|
|
Linifanib (Standard) is the analytical standard of Linifanib. This product is intended for research and analytical applications. Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib is a specific miR-10b inhibitor that blocks miR-10b biogenesis .
|
-
- HY-152720
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
Cancer
|
|
3’-Azido-3’-deoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-176444
-
|
|
Molecular Glues
CDK
|
Cancer
|
|
CDK2 degrader 6 is an orally active and potent CDK2 molecular glue degrader with a DC50 of 46.5 nM. CDK2 degrader 6 binds to cereblon and CDK2 to induce ubiquitination and subsequent proteasomal degradation of CDK2. CDK2 degrader 6 modulates cell cycle in breast cancer cells. CDK2 degrader 6 reduces proliferation of breast cancer cells. CDK2 degrader 6 exhibits in vivo antitumor activity in gastric cancer mouse models. CDK2 degrader 6 can be used for the research of breast cancer, gastric cancer .
|
-
- HY-154054
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5′-Azido-5′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5′-Azido-5′-deoxyadenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-159642
-
|
TYRA-300
|
FGFR
ERK
|
Metabolic Disease
Cancer
|
|
Dabogratinib (TYRA-300) is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .
|
-
- HY-152868
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-O-(2-Azidoethyl)adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-O-(2-Azidoethyl)adenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-163527
-
|
|
FGFR
|
Cancer
|
|
FGFR-IN-13 (compound III-30) is an irreversible covalent fibroblast growth factor receptor (FGFR) inhibitor. FGFR-IN-13 regulates endogenous FGFR1(IC50=0.20±0.02 nM) and FGFR4(IC50=0.40±0.03 nM) mediated signaling pathways by inhibiting the expression of key proteins. FGFR-IN-13 inhibits total-PARP and Bcl-2 protein expressions, and promote Cleaved-PARP and Bax protein expressions in a dose-dependent manner. FGFR-IN-13 has significant antitumor activity and oral activity .
|
-
- HY-156730B
-
|
|
Molecular Glues
STAT
|
Cancer
|
|
KT-333 diammonium is a molecular glues that degrades STAT3 protein. KT-333 diammonium mediates the selective degradation of STAT3 through the ubiquitin-proteasome system by binding to STAT3 protein and E3 ubiquitin ligase von Hippel-Lindau protein (VHL). KT-333 diammonium has strong selectivity for STAT3 protein degradation and good antitumor activity. KT-333 diammonium can be used in the study of hematologic malignancies such as large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL) .
|
-
- HY-175646
-
|
|
Acyltransferase
mTOR
Ribosomal S6 Kinase (RSK)
Apoptosis
|
Cancer
|
|
AGPAT4-IN-1 (Compound CL26) is a covalent AGPAT4 inhibitor with an IC50 of 795 nM. AGPAT4-IN-1 covalently binds to AGPAT4 at Cys 228 and significantly inhibits acyltransferase activity, LPA-to-PA conversion and downstream mTOR/S6K pathways. AGPAT4-IN-1 sensitizes hepatocellular carcinoma (HCC) tumors to Sorafenib (HY-10201) and significantly induces apoptosis with a synergistic response. AGPAT4-IN-1 has antitumor activity and reduces tumorigenicity and stemness in HCC xenograft mouse models .
|
-
- HY-174850
-
|
|
Btk
|
Cancer
|
|
CFON-026 is a selective, orally active and non-covalent BTK inhibitor with an IC50 of 0.27 nM. CFON-026 has significant antitumor activity against wild-type BTK (TMD8 and REC-1) and all clinically relevant BTK resistance mutations (BTK C481S, T474I, L528W and V416L). CFON-026 induces complete tumor regression in TMD8 xenograft mice model. CFON-026 can be used for research of hematological cancers like chronic lymphocytic leukemia and waldenström macroglobulinemia .
|
-
- HY-19337
-
|
BAY 1896953; ORM-15341
|
Androgen Receptor
|
Cancer
|
|
Ketodarolutamide (ORM-15341) is a potent, high-affinity nonsteroidal competitive full antagonist of androgen receptor (AR). Ketodarolutamide displays a Ki value of 8 nM for rat wild-type AR and an IC50 value of 38 nM in AR-HEK293 cells . Ketodarolutamide inhibits testosterone-induced nuclear translocation of the AR and antagonizes both overexpressed and mutant ARs . Ketodarolutamide specifically suppresses the proliferation of AR-dependent prostate cancer cells and exhibits antitumor activity in models of castration-resistant prostate cancer (CRPC) . Ketodarolutamide is suitable for the mechanistic and therapeutic research of prostate cancer .
|
-
- HY-149878
-
|
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
|
BD-9136 is a potent and highly selective BRD4 PROTAC depressant. BD-9136 has low-nanomolar degradation potencies against BRD4 , and its degradation selectivity for BRD4 is 1000 times that of BRD2 and BRD3 proteins. BD-9136 has antitumor activity .(Pink: Desmethyl-QCA276 (HY-44103); Black: 3-(2-(4-Methylpiperazin-1-yl)ethyl)azetidin-3-ol; Blue: Thalidomide-4-OH (HY-103596))
|
-
- HY-W818693
-
|
|
Apoptosis
|
Cancer
|
|
3-Hydroxy-3-phenylpentanamide is a compound with neuroprotective activity. 3-Hydroxy-3-phenylpentanamide shows protective effects against ischemic brain injury and cerebral hemorrhage. 3-Hydroxy-3-phenylpentanamide is studied in psychiatry as a potential anxiety, depression and addiction suppressant compound. 3-Hydroxy-3-phenylpentanamide shows antitumor activity in oncology, acting by inducing apoptosis and inhibiting tumor growth. 3-Hydroxy-3-phenylpentanamide also has protective effects against epileptic seizures .
|
-
- HY-152663
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Mthoxy-9-beta-D-(2-C-ethynyl-ribofuranosyl) purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 6-Mthoxy-9-beta-D-(2-C-ethynyl-ribofuranosyl) purine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-W001925
-
|
|
Apoptosis
NF-κB
c-Met/HGFR
Akt
MMP
|
Cancer
|
|
7-Methoxy-1-tetralone is a potent antitumor agent. 7-Methoxy-1-tetralone inhibits cancer cell proliferation and migration, and induces hepatocellular carcinoma cell (HCC) apoptosis. 7-Methoxy-1-tetralone decreased the protein levels of NF-κB, matrix metallopeptidase 2 (MMP2)/MMP9, and p-AKT. 7-Methoxy-1-tetralone showed antitumor activity in nude mice and had no effect on body weight and liver, spleen and organ index .
|
-
- HY-154405
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Azido-5’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5’-Azido-5’-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-154666
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Azido-3’-deoxyinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxyinosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-139439
-
|
|
Ser/Thr Protease
|
Cancer
|
|
SBI-581 is an orally active and potent selective serine-threonine kinase TAO3 inhibitor, with an IC50 of 42 nM. SBI-581 promotes TKS5α accumulation at RAB11-positive vesicles. SBI-581 inhibits invadopodia formation. SBI-581 shows reasonable pharmacokinetics in mice using IP injection. SBI-581 shows antitumor activity . SBI-581 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-B1092AS
-
|
D-Gluconic acid sodium salt-1-13C; Sodium D-gluconate-1-13C; D-Gluconate sodium salt-1-13C
|
Isotope-Labeled Compounds
NO Synthase
Endogenous Metabolite
Interleukin Related
ERK
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Gluconate-1- 13C (D-Gluconic acid-1- 13C) sodium is the 13C labeled Gluconate sodium (HY-B1092A). Gluconate (D-Gluconic acid) sodium is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury .
|
-
- HY-148918A
-
|
|
β-catenin
Wnt
Bcl-2 Family
|
Cancer
|
E722-2648 TFA is an inhibitor targeting the BCL9 and β-catenin complex with antitumor activity. E722-2648 TFA blocks complex formation by disrupting the interaction between the two proteins, thereby inhibiting β-catenin-mediated transcriptional activity and downregulating the expression of WNT target genes. E722-2648 TFA effectively inhibits tumor growth in colon cancer xenograft models and colorectal cancer mouse models. E722-2648 TFA can be used for the research of colon cancer and colorectal cancer .
|
-
- HY-N0234R
-
|
7-O-Methylbavachin (Standard); Bavachinin A (Standard)
|
Amyloid-β
Reference Standards
PPAR
HIF/HIF Prolyl-Hydroxylase
|
Inflammation/Immunology
|
|
Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC50 value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .
|
-
- HY-154629
-
-
- HY-113952R
-
|
(-)-Actinonin (Standard)
|
Reference Standards
Aminopeptidase
Bacterial
MMP
Apoptosis
Antibiotic
|
Infection
Cancer
|
|
Actinonin (Standard) is the analytical standard of Actinonin. This product is intended for research and analytical applications. Actinonin ((-)-Actinonin) is a naturally occurring antibacterial agent produced by Actinomyces. Actinonin inhibits aminopeptidase M, aminopeptidase N and leucine aminopeptidase. Actinonin is a potent reversible peptide deformylase (PDF) inhibitor with a Ki of 0.28 nM. Actinonin also inhibits MMP-1, MMP-3, MMP-8, MMP-9, and hmeprin α with Ki values of 300 nM, 1,700 nM, 190 nM, 330 nM, and 20 nM, respectively. Actinonin is an apoptosis inducer. Actinonin has antiproliferative and antitumor activities[1][2][3][4][5].
|
-
- HY-152770
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-((2R,3R,4R,5R)-4-Hydroxy-5-(hydroxymethyl)-3-methoxytetrahydrofuran-2-yl)-3-(2-oxopropyl)imidazo[1,2-c]pyrimidin-5(6H)-one is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![6-(2-O-Methyl-beta-D-ribofuranosyl)-3-(2-oxo-propyl)-6H-imidazo[1,2-c]pyrimidin-5-one](//file.medchemexpress.com/product_pic/hy-152770.gif)
- HY-155005
-
|
|
EGFR
|
Cancer
|
|
EGFR mutant-IN-2 (Compound D51) is an EGFR mutant inhibitor. EGFR mutant-IN-2 inhibits the EGFR L858R/T790M/C797S mutant with an IC50 value of 14 nM. EGFR mutant-IN-2 inhibits the EGFR del19/T790M/C797S mutant with an IC50 value of 62 nM. EGFR mutant-IN-2 has favorable PK parameters, safety properties, in vivo stability, and antitumor activity .
|
-
- HY-N13201
-
|
|
Apoptosis
CDK
|
Cancer
|
|
12-Deoxyphorbol 13-palmitate is a traditional Chinese medicine monomer with antitumor activity that can be isolated from the root of Euphorbia fischeriana. 12-Deoxyphorbol 13-palmitate induces gastric cancer cell cycle arrest and apoptosis by regulating key cell cycle regulators such as cyclin B、cyclin A and CDC2. In addition, 12-Deoxyphorbol 13-palmitate can significantly weaken APOL2–SERCA2–PERK–HES1 signaling and slow liver fibrosis by targeting APOL2 .
|
-
- HY-P991634
-
|
|
CD73
TNF Receptor
Interleukin Related
IFNAR
|
Inflammation/Immunology
Cancer
|
|
IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research .
|
-
- HY-152728
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Azido-3’-deoxycytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxycytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-D0162R
-
|
MCCK1 (Standard)
|
Reference Standards
Fungal
IKK
NF-κB
Apoptosis
|
Infection
Cancer
|
|
Malachite green hemioxalate (Standard) is the analytical standard of Malachite green hemioxalate (HY-D0162). This product is intended for research and analytical applications. Malachite green hemioxalate is a triphenylmethane dye which can be used to detect the release of phosphate in enzymatic reactions. Malachite green hemioxalate has antimicrobial activity, which is attributed to inhibition of intracellular enzymes, intercalation into DNA, and/or interaction with cellular membranes. Malachite green hemioxalate is also a potent and selective inhibitor of IKBKE, and inhibits its downstream targets such as IκBα, p65 and IRF3. Malachite green hemioxalate exhibits antitumor activity in vitro and in vivo.
|
-
- HY-154055
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5′-Azido-2′,5′-dideoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5′-Azido-2′,5′-dideoxyadenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-153221
-
|
|
CDK
|
Cancer
|
|
QR-6401 is an orally active and selective macrocyclic CDK2 inhibitor with IC50 values of 0.37, 10, 22, 34 and 45 nM for CDK2/E1, CDK9/T1, CDK1/A2, CDK6/D3 and CDK4/D1, respectively. QR-6401 has potent antitumor activity in an OVCAR3 ovarian cancer xenograft model. QR-6401 has the potential to be used in the study of cancer .
|
-
- HY-B1022A
-
|
BNP-7787 free acid
|
Drug Derivative
|
Endocrinology
Cancer
|
|
Dimesna (BNP-7787) free acid, the disulfide form of Mesna (HY-13679), is a platinum-related toxicity protective agent. Dimesna free acid converts to Mesna, which in turn inactivates toxic platinum substances. Dimesna free acid does not interfere with the antitumor activity of platinum compounds. Dimesna free acid does not affect the antiproliferative effects of Cisplatin (HY-17394) or Carboplatin (HY-17393). Dimesna free acid counteracts Cisplatin-induced nephrotoxicity. Dimesna free acid exerts selective protective effects on the kidneys. Dimesna free acid can be used in studies related to ovarian cancer and Cisplatin-induced nephrotoxicity .
|
-
- HY-111077
-
|
|
JAK
STAT
|
Inflammation/Immunology
Cancer
|
|
INCB16562 is an orally active and selective inhibitor against JAK1/2 markedly selective over JAK3. INCB16562 potently inhibits interleukin-6 (IL-6)-induced phosphorylation of STAT3. Additionally, INCB16562 inhibits the proliferation and survival of myeloma cells dependent on IL-6 for growth, as well as the IL-6–induced growth of primary bone marrow-derived plasma cells. INCB16562 antagonizes the growth of myeloma xenografts in mice with antitumor activity. INCB16562 is promising for research of multiple myeloma .
|
-
- HY-159495
-
|
|
Keap1-Nrf2
|
Metabolic Disease
Cancer
|
|
Keap1-Nrf2-IN-21 (compound 4d) is a glucose metabolism inhibitor with antitumor activity. Keap1-Nrf2-IN-21 inhibits glycolytic activity of cancer cells by targeting the glycolytic pathway, especially by affecting the Keap1-Nrf2 signaling pathway, thereby inhibiting tumor growth. Keap1-Nrf2-IN-21 exhibits cytotoxicity against the HEC1A cell line (IC50=2.60 μM) .
|
-
- HY-N0256R
-
|
|
Reference Standards
COX
NF-κB
|
Cancer
|
|
Hederagenin (Standard) is the analytical standard of Hederagenin. This product is intended for research and analytical applications. Hederagenin is a triterpenoid saponin with orally active and antitumor activity. Hederagenin can inhibit the expression of iNOS, COX-2, and NF-κB in cells induced by LPS stimulation. Hederagenin also increases ROS production in cancer cells, disrupts mitochondrial membrane potential, and induces apoptosis. Hederagenin also sensitizes cancer cells to Cisplatin (HY-17394) and Paclitaxel (HY-B0015), enhancing induced apoptosis. Hederagenin also has preventive potential against alcoholic liver injury .
|
-
- HY-B0255R
-
|
GS 0840 (Standard)
|
Reference Standards
HBV
Reverse Transcriptase
Orthopoxvirus
Endogenous Metabolite
|
Infection
Cancer
|
|
Adefovir dipivoxil (Standard) is the analytical standard of Adefovir dipivoxil. This product is intended for research and analytical applications. Adefovir dipivoxil is an orally active adenosine analog and Adefovir prodrug. Adefovir dipivoxil inhibits DNA synthesis, activates the ATR signaling pathway, and disrupts the KCTD12-CDK1 interaction. Adefovir dipivoxil has antiviral activity against PRV, HBV, and orthopoxviruses. Adefovir dipivoxil has inhibitory effects on both lamivudine-resistant and wild-type strains. Adefovir dipivoxil has antitumor activity against lung and colon cancer .
|
-
- HY-172399
-
|
|
Fat Mass and Obesity-associated Protein (FTO)
Apoptosis
|
Cancer
|
|
FTO-IN-14 (Compound F97) is the inhibitor for the RNA demethylase Fat mass and obesity-associated protein FTO with IC50 of 0.45 μM. FTO-IN-14 regulates the protein expression of ASB2, RARA and MYC. FTO-IN-14 exhibits antiproliferative activity in AML cancer cells (IC50 for MOLM13, NB4, HEL, OCI-AML3, MV4-11 and MONOMAC6 is 0.7-5.5 μM), induces apoptosis in NB4 cell. FTO-IN-14 exhibits antitumor activity in mouse NB4 xenograft models .
|
-
- HY-50905R
-
|
CHIR-258 (Standard); TKI258 (Standard)
|
FLT3
c-Kit
FGFR
VEGFR
PDGFR
c-Fms
Reference Standards
|
Cancer
|
|
Dovitinib (Standard) is the analytical standard of Dovitinib. This product is intended for research and analytical applications. Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity .
|
-
- HY-152514
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Azidomethyl-2’-beta-methyl uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5-Azidomethyl-2’-beta-methyl uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-126251
-
|
|
CDK
Apoptosis
|
Cancer
|
|
CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC .
|
-
- HY-113327R
-
|
|
Drug Metabolite
Reference Standards
Endogenous Metabolite
|
Cancer
|
|
Hederagenin (Standard) is the analytical standard of Hederagenin. This product is intended for research and analytical applications. Hederagenin is a triterpenoid saponin with orally active and antitumor activity. Hederagenin can inhibit the expression of iNOS, COX-2, and NF-κB in cells induced by LPS stimulation. Hederagenin also increases ROS production in cancer cells, disrupts mitochondrial membrane potential, and induces apoptosis. Hederagenin also sensitizes cancer cells to Cisplatin (HY-17394) and Paclitaxel (HY-B0015), enhancing induced apoptosis. Hederagenin also has preventive potential against alcoholic liver injury .
|
-
- HY-108359
-
|
9-Nitropaullone; NSC 705701
|
CDK
GSK-3
Apoptosis
|
Cancer
|
|
Alsterpaullone (9-Nitropaullone) is a potent CDK inhibitor, with IC50s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively. Alsterpaullone also competes with ATP for binding to GSK-3alpha/GSK-3beta with IC50s of both 4 nM. Alsterpaullone has antitumor activity, and possesses potential for the study in neurodegenerative and proliferative disorders . Alsterpaullone induces apoptosis in leukemia cell line .
|
-
- HY-101117R
-
|
|
Histone Methyltransferase
Reference Standards
|
Cancer
|
|
EED226 (Standard) is the analytical standard of EED226 (HY-101117). This product is intended for research and analytical applications. EED226 is a polycomb repressive complex 2 (PRC2) inhibitor, which binds to the K27me3-pocket on embryonic ectoderm development (EED) and shows strong antitumor activity in xenograft mice model . EED226 is a potent, selective, and orally bioavailable EED inhibitor . EED226 inhibits PRC2 with an IC50 of 23.4 nM when the H3K27me0 peptide is used as a substrate in the in vitro enzymatic assays .
|
-
- HY-P991468
-
|
|
Interleukin Related
|
Cancer
|
|
IMM20324 is a human monoclonal antibody (mAb) targeting IL38. IMM20324 inhibits the interaction of IL-38 with human IL1RAPL1-Fc and human IL-36R-Fc with IC50 values of 1.267 nM and 1.4667 nM, respectively. IMM20324 has antitumor activity in the B16.F10 syngeneic mouse model. IMM20324 can be used in antitumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-178021
-
|
|
HDAC
DNA/RNA Synthesis
Apoptosis
RAD51
Caspase
|
Cancer
|
|
HDAC1-IN-11 (Compound 6) is a HDAC1 inhibitor with an IC50 of 106.6 nM. HDAC1-IN-11 inhibits the expression of Sp1 and RAD51, thereby inducing Caspase-dependent apoptosis. HDAC1-IN-11 has antitumor activity and sensitizes Etoposide (HY-13629) and Gemcitabine (HY-17026), promoting synergistic death of NSCLC cells through the inhibition of homologous recombination and non-homologous end joining (NHEJ) pathways involved in DNA DSB repair. HDAC1-IN-11 can be used for chemotherapy of cancers like NSCLC research .
|
-
- HY-W470101
-
|
|
HIF/HIF Prolyl-Hydroxylase
Apoptosis
HSP
Caspase
|
Cancer
|
|
HIF-2α-IN-17 is a selective hypoxia-inducible factor 2α (HIF2α) inhibitor that binds to the PAS-B domain of HIF2α. HIF-2α-IN-17 disrupts the interaction between HIF2α and the molecular chaperone Hsp70, leading to proteasomal degradation of HIF2α. HIF-2α-IN-17 exhibits antitumor activity and induces apoptosis in cancer cells. HIF-2α-IN-17 is applicable for research on cancers such as clear cell renal cell carcinoma .
|
-
- HY-152592
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Azido-3’-deoxy-beta-L-cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-beta-L-cytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-N0256
-
|
|
COX
NF-κB
E1/E2/E3 Enzyme
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Hederagenin is a triterpenoid saponin with orally active and antitumor activity. Hederagenin can inhibit the expression of iNOS, COX-2, and NF-κB in cells induced by LPS stimulation. Hederagenin also increases ROS production in cancer cells, disrupts mitochondrial membrane potential, and induces apoptosis. Hederagenin also sensitizes cancer cells to Cisplatin (HY-17394) and Paclitaxel (HY-B0015), enhancing induced apoptosis. Hederagenin can also bind to SKP2, with KD = 67.9 μM. Hederagenin also has preventive potential against alcoholic liver injury .
|
-
- HY-149250
-
|
|
MDM-2/p53
Apoptosis
|
Cancer
|
|
MDMX/MDM2-IN-2 is a potent p53-MDM2/MDMX dual inhibitors with Kis of 0.23 μM and 2.45 μM for MDM2 and MDMX, respectively. MDMX/MDM2-IN-2 inhibits the binding of p53 and MDM2 proteins. MDMX/MDM2-IN-2 restores the function of p53 and enables cell cycle arrest and apoptosis. MDMX/MDM2-IN-2 inhibits cell migration and invasion. MDMX/MDM2-IN-2 has antitumor activity .
|
-
- HY-101029R
-
|
|
NEKs
Apoptosis
Reference Standards
|
Cancer
|
|
MBM-55 (Standard) is the analytical standard of MBM-55 (HY-101029). This product is intended for research and analytical applications. MBM-55 is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 1 nM. MBM-55 shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC50=5.4 nM) and DYRK1a (IC50=6.5 nM). MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55 shows antitumor activities, and no obvious toxicity to mice .
|
-
- HY-175244
-
|
|
SOS1
Ras
Potassium Channel
|
Cancer
|
|
SOS1-IN-20 (Compound 12f) is an orally active SOS1 inhibitor with an IC50 of 5.11 nM against KRAS G12C::SOS1. By disrupting the interaction between KRAS and SOS1, SOS1-IN-20 inhibits KRAS activation and downstream signal transduction. SOS1-IN-20 has an IC50 of 253 nM for p-ERK in PC-9 cells and 16.71 μM for hERG channel . SOS1-IN-20 can inhibit the proliferation of tumor cells and has antitumor activity .
|
-
- HY-P991984
-
|
|
EGFR
PI3K
Akt
|
Cancer
|
|
SIBP-03 is a specifical anti-HER3 antibody. SIBP-03 binds strongly and specifically to recombinant HER3 protein. SIBP-03 inhibits HER3 activation, as well as the downstream PI3K/AKT signaling pathway. SIBP-03 exhibits anticancer activity against squamous cell carcinoma, non-small cell lung cancer, gastric cancer, and breast cancer. SIBP-03 synergistically enhances the antitumor activity of DS-8201 (HY-138298A) and Cetuximab (HY-P9905) .
|
-
- HY-108511A
-
|
|
Sigma Receptor
Apoptosis
SARS-CoV
|
Infection
Cancer
|
|
PB28 is a cyclohexylpiperazine derivative and a high affinity and selective sigma 2 (σ2) receptor agonist with a Ki of 0.68 nM. PB28 is also a σ1 antagonist with a Ki of 0.38 nM. PB28 is less affinity for other receptors. PB28 inhibits electrically evoked twitch in guinea pig bladder and ileum with EC50 values of 2.62 μM and 3.96 μM, respectively. PB28 can modulate SARS-CoV-2-human protein-protein interaction. PB28 induces caspase-independent apoptosis and has antitumor activity .
|
-
- HY-124586
-
-
- HY-108511
-
|
|
Sigma Receptor
Apoptosis
SARS-CoV
|
Infection
Cancer
|
|
PB28 dihydrochloride, a cyclohexylpiperazine derivative, is a high affinity and selective sigma 2 (σ2) receptor agonist with a Ki of 0.68 nM. PB28 dihydrochloride is also a σ1 antagonist with a Ki of 0.38 nM. PB28 dihydrochloride is less affinity for other receptors. PB28 dihydrochloride inhibits electrically evoked twitch in guinea pig bladder and ileum with EC50 values of 2.62 μM and 3.96 μM, respectively. PB28 dihydrochloride can modulate SARS-CoV-2-human protein-protein interaction. PB28 dihydrochloride induces caspase-independent apoptosis and has antitumor activity .
|
-
- HY-174137
-
|
|
Apoptosis
FLT3
|
Cancer
|
|
FLT3-IN-31 (compound 10q) is a potent FLT3 inhibitor with IC50 values of 0.16, 2.4 nM for FLT3, FLT3-D835Y, resprctively. FLT3-IN-31 shows antiproliferation activity. FLT3-IN-31 decreases the protein expression of p-FLT3, P-STAT5, P-ERK. FLT3-IN-31 induces apoptosis and cell cycle arrest at G1 phase. FLT3-IN-31 shows antitumor activity .
|
-
- HY-15730
-
|
HM781-36B; NOV120101
|
EGFR
Apoptosis
|
Cancer
|
|
Poziotinib (HM781-36B) is an orally active, irreversible pan-HER inhibitor, which effectively inhibits EGFR wt, HER-2 and HER-4 with IC50s of 3.2, 5.3 and 23.5 nM, respectively. Poziotinib (HM781-36B) also shows excellent inhibitory activities against mutated EGFRs, including EGFR T790M and EGFR L858R/T790M, with IC50s of 4.2 and 2.2 nM, respectively. Excellent antitumor activity .
|
-
- HY-154284
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy guanosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-168081
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1-IN-52 (Compound III-5) is an orally active PD-1/PD-L1 inhibitor that blocks the interaction between PD-1 and PD-L1, with an IC50 of 109.9 nM. PD-1/PD-L1-IN-52 exhibits antitumor activity in a C57BL/6 mouse xenograft model implanted with human PD-1-expressing MC38 colon cancer cells, with a TGI of 49.6% .
|
-
- HY-18200A
-
|
E5555 hydrochloride; ER-172594-00 hydrochloride
|
Protease Activated Receptor (PAR)
JAK
Apoptosis
|
Cardiovascular Disease
Cancer
|
|
Atopaxar hydrochloride (E5555 hydrochloride) is the hydrochloride salt form of Atopaxar (HY-18200). Atopaxar hydrochloride is an orally active, selective and reversible antagonist for thrombin receptor protease-activated receptor-1 (PAR-1). Atopaxar hydrochloride is the inhibitor for Janus kinase 1 (JAK1) and JAK2, which inhibits the JAK-STAT with EC50 of 5.90 μM in A549. Atopaxar hydrochloride inhibits the cell viability of A549 (IC50=7.02 μM), arrests the cell cycle at G1 phase and induces apoptosis. Atopaxar hydrochloride exhibits antiplatelet and antitumor activities. Atopaxar hydrochloride can be used for the research of atherothrombotic disease .
|
-
- HY-182447
-
|
DL111-IT
|
CDK
Apoptosis
|
Endocrinology
Cancer
|
|
Contragestazol (DL111-IT) is a non-hormonal antifertility agent. Contragestazol reduces the expression of Cyclin D1 and CDK4, increases the expression of total retinoblastoma protein (pRb), and decreases the level of hyperphosphorylated pRb. Contragestazol induces G0/G1 phase cell cycle arrest. Contragestazol inhibits embryonic development by inducing luteal cell apoptosis and reducing intrauterine polyamine levels. Contragestazol exhibits antitumor activity against prostate cancer, S180 tumor and H22 tumor. Contragestazol shows extremely potent activity in terminating early pregnancy in animals .
|
-
- HY-179631
-
|
|
Apoptosis
|
Cancer
|
|
2DG-ODDA is a 2-deoxyglucose (2-DG) (HY-13966) derivative with potent antitumor activity. 2DG-ODDA induces apoptosis, and reduces ATP production. 2DG-ODDA is taken up through both fatty acid and glucose transporters and is cleaved by α-Mannosidase (HY-P2950), releases 2DG to inhibit N-glycosylation and disrupt cellular metabolism. 2DG-ODDA inhibits tumor growth in a 4T1 mouse model. 2DG-ODDA can be used for the research of triple-negative breast cancer (TNBC) .
|
-
- HY-183277
-
|
|
EGFR
p38 MAPK
Akt
Apoptosis
|
Cancer
|
|
EGFR-IN-209 (Compound 6g) is an orally active, selective EGFR Del19/T790M/C797S inhibitor with an IC50 of 0.056 μM. EGFR-IN-209 blocks the phosphorylation of EGFR and its downstream effector molecules (pMAPK, pAKT). EGFR-IN-209 induces Apoptosis. EGFR-IN-209 exhibits antitumor activity against Osimertinib (HY-15772)-resistant non-small cell lung cancer. EGFR-IN-209 can be used in research related to non-small cell lung cancer .
|
-
- HY-168953
-
|
|
P-glycoprotein
Apoptosis
Bcl-2 Family
Reactive Oxygen Species (ROS)
Caspase
|
Cancer
|
|
Lysosomal P-gp targeted agent 1 (Compound 14) is an anti-tumor agent targeting lysosomal P-glycoprotein (Pgp). Lysosomal P-gp targeted agent 1 is selectively transported into lysosomes by overexpressed Pgp, release nitric oxide (NO) to generate reactive oxygen species (ROS), resulting in lysosomal membrane permeabilization (LMP) and inducing apoptosis. Lysosomal P-gp targeted agent 1 can overcome P-glycoprotein-mediated drug resistance and lead to cell cycle arrest, but relatively low toxicity to normal cells. Lysosomal P-gp targeted agent 1 has antitumor activity, significantly inhibits tumor volume .
|
-
- HY-172916
-
|
|
SHP2
FGFR
p38 MAPK
ERK
|
Cancer
|
|
LC-SF-14 is a selective dual inhibitor of SHP2 and FGFR (IC50 values are 71.6 and 8.9 nM, respectively). LC-SF-14 inhibits FGFR2-FRS2α-SHP2-MAPK signaling and ERK phosphorylation. LC-SF-14 inhibits the proliferation of KATOIII cancer cells (IC50: 9.2 nM). LC-SF-14 has antitumor activity in the SNU-16 xenograft mouse model. LC-SF-14 can be used in FGFR2-driven gastric cancer research .
|
-
- HY-152601
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Azido-3’-deoxy-beta-L-adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-beta-L-adenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-178022
-
|
|
HDAC
Apoptosis
Caspase
RAD51
DNA/RNA Synthesis
|
Cancer
|
|
HDAC6-IN-63 (Compound 7) is an orally active HDAC6 inhibitor with an IC50 of 145 nM. HDAC6-IN-63 inhibits the expression of Sp1 and RAD51, thereby inducing Caspase-dependent apoptosis. HDAC6-IN-63 has antitumor activity and sensitizes Etoposide (HY-13629) and Gemcitabine (HY-17026), promoting synergistic death of NSCLC cells through the inhibition of homologous recombination and non-homologous end joining (NHEJ) pathways involved in DNA DSB repair. HDAC6-IN-63 can be used for chemotherapy of cancers like NSCLC research .
|
-
- HY-W354252
-
|
9-Pentofuranosyl-9H-purin-2-amine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
(2R,3R,4S,5R)-2-(2-amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (9-pentofuranosyl-9H-purin-2-amine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-156730A
-
|
|
Molecular Glues
STAT
|
Cancer
|
|
KT-333 ammonium (Compound A) is a molecular glues that degrades STAT3 protein. KT-333 ammonium mediates the selective degradation of STAT3 through the ubiquitin-proteasome system by binding to STAT3 protein and E3 ubiquitin ligase von Hippel-Lindau protein (VHL). KT-333 ammonium has strong selectivity for STAT3 protein degradation and good antitumor activity. KT-333 ammonium can be used in the study of hematologic malignancies such as large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL) .
|
-
- HY-101570G
-
|
Peposertib; M3814
|
DNA-PK
BCRP
|
Cancer
|
|
Nedisertib (GMP) (Peposertib (GMP)) is Nedisertib (HY-101570) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Nedisertib is an orally active selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of less than 3 nM. Nedisertib also acts as a modulator of ABCG2, capable of reversing ABCG2-mediated multidrug resistance (MDR), thus providing new strategies for combination therapy. By inhibiting DNA double-strand break repair, Nedisertib can enhance the efficacy of chemotherapy and radiotherapy. Nedisertib exhibits antitumor activity .
|
-
- HY-176451
-
|
|
CDK
|
Cancer
|
|
CDK9 degrader-1 (Compound AZ-9) is a selective CDK9 degrader (DC50: 0.4073 µM). CDK9 degrader-1 recruits ATG101 to initiate the autophagy-lysosome pathway and forms autophagosomes by recruiting LC3, which then fuses with lysosomes to degrade CDK9 and its partner protein Cyclin T1 (DC50: 1.215 µM). CDK9 degrader-1 induces caspase 3-mediated apoptosis. CDK9 degrader-1 has antitumor activity in a mouse HCT116 xenograft model .
|
-
- HY-174384
-
|
|
c-Met/HGFR
Apoptosis
G-quadruplex
|
Cancer
|
|
MET Transcription-IN-1 (Compound C3) is an orally active MET transcription inhibitor. MET Transcription-IN-1 can efficiently bind and stabilize the G-quadruplex in the MET promoter region, thereby inhibiting c-Met expression. MET Transcription-IN-1 can also overcome drug resistance caused by specific c-Met mutations. MET Transcription-IN-1 is capable of inhibiting tumor cell proliferation, migration, and invasion, as well as inducing cell cycle arrest and apoptosis. MET Transcription-IN-1 has antitumor activity, and can be used in the research of tumors such as non-small cell lung cancer .
|
-
- HY-101925R
-
|
|
Reference Standards
Histone Methyltransferase
DNA Methyltransferase
Apoptosis
|
Cancer
|
|
CM-272 (Standard) is the analytical standard of CM-272 (HY-101925). This product is intended for research and analytical applications. CM-272 is a first-in-class, potent, selective, substrate-competitive and reversible dual G9a/DNA methyltransferases (DNMTs) inhibitor with antitumor activities. CM-272 inhibits G9a, DNMT1, DNMT3A, DNMT3B and GLP with IC50s of 8 nM, 382 nM, 85 nM, 1200 nM and 2 nM, respectively. CM-272 inhibits cell proliferation and promotes apoptosis, inducing IFN-stimulated genes and immunogenic cell death .
|
-
- HY-103181
-
|
CPA; UK-80882
|
Adenosine Receptor
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
N6-Cyclopentyladenosine (CPA) is a selective Adenosine A1 receptor agonist, with Ki values of 2.3 nM, 790 nM and 43 nM for human A1, A2A and A3 receptors, respectively. N6-cyclopentyladenosine increases Apoptosis. N6-Cyclopentyladenosine has antitumor activity against leukemia. N6-cyclopentyladenosine improves 5-fluorouracil (HY-90006)-induced hematopoietic damage, regulates sleep, and delays Aminophylline-induced clonic epileptic seizures .
|
-
- HY-B1092R
-
|
Calcium D-gluconate (Standard); Gluconic acid hemicalcium salt (Standard)
|
Reference Standards
NO Synthase
Endogenous Metabolite
Interleukin Related
ERK
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Gluconate Calcium (Standard) (Calcium D-gluconate (Standard)) is the analytical standard of Gluconate Calcium (HY-B1092). This product is intended for research and analytical applications. Gluconate (D-Gluconic acid) Calcium is an orally active glucose derivative. Gluconate Calcium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate Calcium inhibits ERK phosphorylation. Gluconate Calcium has antioxidant and antiplatelet activation activities. Gluconate Calcium has antitumor activity against colorectal cancer. Gluconate Calcium improves osteoarthritis, intestinal damage and acute lung injury .
|
-
- HY-147682
-
|
|
NF-κB
Apoptosis
|
Cancer
|
|
NF-κB-IN-5 (compound 4d) is an orally active and potent NF-κB inhibitor by interacting directly with NF-κB. NF-κB-IN-5 shows antitumor activity against human cancer cell lines (HCT116, U87-MG, HepG2, BGC823, PC9), with IC50 values of 5.35, 2.81, 2.83, 2.02 and 3.90 μM, respectively. NF-κB-IN-5 induces apoptosis in U87-MG tumor cell and cell cycle arrest in G0/G1 phase .
|
-
- HY-17499R
-
|
|
EGFR
Apoptosis
|
Cancer
|
|
EGFR-IN-12 (Standard) is the analytical standard of EGFR-IN-12. This product is intended for research and analytical applications. EGFR-IN-12 is a 4,6-disubstituted pyrimidine and is a potent, ATP-competitive, irreversible and highly selective EGFR inhibitor with an IC50of 21 nM. EGFR-IN-12 also inhibits mutant EGFRL858R and EGFRL861Q with IC50s of 63 nM and 4 nM, respectively. EGFR-IN-12 displays strong selectivity for EGFR over HER4 (IC50 = 7640 nM) and a panel of 55 other kinases. EGFR-IN-12 induces cells apoptosis and has antitumor activity .
|
-
- HY-D0214
-
|
|
Influenza Virus
Photosensitizer
Amyloid-β
|
Infection
Neurological Disease
Cancer
|
|
Acid Red 94 sodium, a synthetic fluorescein derivative, is a deep red dye primarily composed of 4,5,6,7-tetrachloro-2,4,5,7-tetraiodo fluorescein. It is widely used as an ophthalmic diagnostic agent to detect dry or damaged cells on the ocular surface. Acid Red 94 sodium exhibits antitumor activity and can inhibit Friend Leukemia Virus (FLV) infection through photodynamic action. Additionally, Acid Red 94 sodium can inhibit Aβ aggregation through light irradiation. Acid Red 94 sodium holds potential for use in cancer, viral infections, and neurodegenerative disease research .
|
-
- HY-P992396
-
|
|
c-Met/HGFR
|
Cancer
|
|
KTN0073 is a high-affinity MET receptor tyrosine kinase inhibitor. KTN0073 can be used in studies related to non-small cell lung cancer and human cancers driven by HGF, MET amplification, or exon 14 mutation. KTN0073 binds to the Sema/PSI domain to block the HGF-MET interaction, and induces ubiquitination and degradation of oncogenic MET receptors via an HGF-independent pathway, thereby inhibiting MET-dependent signal transduction. KTN0073 exhibits significant antitumor activity in vivo, and its tumor suppressive activity is superior to that of the IgG1 subtype when grafted to the IgG2 constant region .
|
-
- HY-17617
-
|
Z-360
|
Cholecystokinin Receptor
Ephrin Receptor
Interleukin Related
VEGFR
HIF/HIF Prolyl-Hydroxylase
Akt
|
Neurological Disease
Cancer
|
|
Nastorazepide (Z-360) is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide inhibits the specific binding of [ 3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide has antitumor activity against pancreatic cancer. Nastorazepide inhibits colorectal cancer liver metastasis and relieves pain .
|
-
- HY-111168
-
|
|
GSK-3
|
Cancer
|
|
MLS-2064 is a 3'-substituted 7-haloindirubin with antitumor activity. MLS-2064 induces caspase-independent cell death. MLS-2064 induces dose-dependent cell death in various human cancer cell lines. MLS-2064 shows no significant inhibitory activity against CDK1 and CDK5 kinases, and only weak inhibitory activity against GSK-3 kinase (IC50: 5 μM). MLS-2064 can be used in research related to colon cancer, breast cancer, lung cancer, prostate cancer, liver cancer, and neuroblastoma .
|
-
- HY-108239
-
|
|
Histone Methyltransferase
Autophagy
|
Cancer
|
|
BIX-01294 trihydrochloride is a reversible and highly selective G9a and GLP Histone Methyltransferase inhibitor, with IC50s of of 1.7 μM and 0.9 μM, respectively. BIX-01294 trihydrochloride inhibits G9a/GLP by competing for binding with the amino acids N-terminal of the substrate lysine residue. BIX-01294 trihydrochloride, a (1H-1,4-diazepin-1-yl)-quinazolin-4-yl amine derivative, induces necroptosis and autophagy. BIX-01294 trihydrochloride has antitumor activity in recurrent tumor cells .
|
-
- HY-10587
-
|
|
Histone Methyltransferase
Autophagy
|
Cancer
|
|
BIX-01294 is a reversible and highly selective G9a and GLP Histone Methyltransferase inhibitor, with IC50s of of 1.7 μM and 0.9 μM, respectively. BIX-01294 inhibits G9a/GLP by competing for binding with the amino acids N-terminal of the substrate lysine residue. BIX-01294, a (1H-1,4-diazepin-1-yl)-quinazolin-4-yl amine derivative, induces necroptosis and autophagy. BIX-01294 has antitumor activity in recurrent tumor cells .
|
-
- HY-164503
-
|
NEP010
|
EGFR
|
Cancer
|
|
Neptinib (NEP010) is an orally active derivative of Afatinib (HY-10261) that has stronger antitumor activity than Afatinib (HY-10261) by improving pharmacokinetics. Neptinib has a significant inhibitory effect on tumor growth in mouse non-small cell lung cancer models with different EGFR mutations. Neptinib has a certain inhibitory effect on the EGFR kinase family, with IC50 values ??of 0.24 nM, 7.25 nM, 0.46 nM and 1.79 nM for EGFR wt, EGFR L858R/T790M, EGFR L858R and EGFR T790M, respectively .
|
-
- HY-137191
-
|
|
EGFR
|
Cancer
|
|
CH7233163 is a noncovalent ATP-competitive inhibitor for EGFR-Del19/T790M/C797S. CH7233163 can overcome Osimertinib (HY-15772)-Resistant EGFR-Del19/T790M/C797S mutation. CH7233163 blocks the EGFR phosphorylation in the Del19/T790M/C797S_NIH3T3 cells. CH7233163 has antitumor activities .
|
-
- HY-158346
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
RP-2119 is an orally bioactive Polymerase Theta (Polθ) inhibitor, with an IC50 of 0.7 nM against human Polθ ATPase. RP-2119 reduces Polθ activity and exerts antiproliferative effects in BRCA2-deficient cancer cells. RP-2119 exhibits antitumor activity in BRCA2-deficient cancer cell xenograft mouse models . RP-2119 can be used for the research of cancer and homologous recombination-deficient cancers, including brca1/brca2-mutant cancers and shld2-mutant cancers .
|
-
- HY-N6818R
-
|
TMF (Standard)
|
Reference Standards
Apoptosis
Caspase
PARP
Endogenous Metabolite
CFTR
|
Cancer
|
|
5,7,4'-Trimethoxyflavone (Standard) is the analytical standard of 5,7,4'-Trimethoxyflavone. This product is intended for research and analytical applications. 5,7,4’-Trimethoxyflavone can be isolated from the medicinal plant Kaempferia parviflora (KP). 5,7,4’-Trimethoxyflavone is a CFTR activator and EC50 is 64 μM. 5,7,4’-Trimethoxyflavone induces apoptosis, increases proteolytic activation of caspase-3, and degradation of ADP-ribose polymerase (PARP) protein. 5,7,4’-Trimethoxyflavone has antitumor activity. 5,7,4’-Trimethoxyflavone can be used to prevent skin aging and oxidative stress .
|
-
- HY-154305
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5′-Azido-2′,5′-dideoxy-2′-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5′-Azido-2′,5′-dideoxy-2′-fluorouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-161769
-
|
|
PROTACs
Epigenetic Reader Domain
Apoptosis
|
Cancer
|
|
HL435 is a heterobifunctional molecule that degrades BRD4 by linking to JQ1, with DC50 of 11.9 nM and 21.9 nM, in MDA-MB-231 and MCF-7 cells, respectively. HL435 inhibits the proliferation of MDA-MB-231, MCF-7, 22Rv1 and A549, arrests the cell cycle and induces apoptosis. HL435 exhibits antitumor activity in mouse model. (Pink: ligand for target protein JQ-1 (HY-78695); Black: linker (HY-W004640); blue: ligand for E3 ligase HL389 (HY-161770))
|
-
- HY-182764A
-
|
|
CDK
|
Cancer
|
|
CDK11-IN-1 hydrochloride is a potent, highly selective, and orally active CDK11 inhibitor with an IC50 of 4 nM, showing 32.5-fold and 2700-fold selectivity over CDK7 and CDK9, respectively. CDK11-IN-1 hydrochloride binds competitively to the ATP-binding pocket of CDK11 and forms a hydrogen bond with the hinge region residue Val163. It inhibits tumor cell proliferation and exhibits antitumor activity in lung cancer xenograft models. CDK11-IN-1 hydrochloride can be used for studies on the pathophysiology of CDK11-mediated tumors, as well as research on malignant tumors such as lung cancer .
|
-
- HY-152353
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Azido-3’-deoxy-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-2-thiouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-169061
-
|
|
Histone Methyltransferase
Aminotransferases (Transaminases)
Lactate Dehydrogenase
|
Cancer
|
|
WQQ-345 is an orally active BCAT1 inhibitor with an IC50 values of 10.8 mM. WQQ-345 reduces cellular α-KG levels, upregulating H3K27me3 expression, decreasing glycolytic enzyme expression, and impairing glycolysis activity. WQQ-345 reduces colony formation, suppresses growth of BCAT1-high TKI-resistant lung cancer cells. WQQ-345 exerts in vitro and in vivo antitumor activity. WQQ-345 can be used for the research of TKI-resistant non-small cell lung cancer and TKI-resistant lung cancer .
|
-
- HY-P991461
-
|
XmAb968
|
CD38
|
Cancer
|
|
AMG-424 (XmAb968) is a human bispecific antibody (bsAb) targeting CD38 & CD3E. AMG-424 kills CD38-expressing cancer cells, triggers T-cell proliferation and attenuates cytokine release. AMG 424 has antitumor activity in a bone marrow-invasive mouse cancer model and induces peripheral B-cell depletion in cynomolgus monkeys. AMG-424 can be used in multiple myeloma research. Recommended isotype control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3 .
|
-
- HY-152802
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-O-(3-Azidopropyl)-5-azacytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-O-(3-Azidopropyl)-5-azacytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-117807
-
|
|
Ras
Farnesyl Transferase
VEGFR
|
Cancer
|
|
A-176120 is a selective inhibitor of farnesyl transferase (IC50=1.2 nM) based on a farnesyl pyrophosphate (FPP) analog, with superior selectivity against GGTaseI (IC50=423 nM), GGTaseII (IC50=3000 nM), and SSase (IC50>10 μM). A-176120 inhibits ras processing in H-ras transformed NIH3T3 cells and HCT116 K-ras mutant cells (ED50=1.6 and 0.5 μM, respectively). A-176120 has antiangiogenic and antitumor activities in vivo and reduces capillary structure formation and VEGF secretion .
|
-
- HY-173437
-
|
|
PROTACs
PARP
DNA/RNA Synthesis
|
Cancer
|
|
CW-2 is a PARP1 PROTAC degrader. CW-2 has potent antiproliferative effects against MDA-MB-231 cells (IC50 = 0.72 μM) and CDDP-resistant cells (A549/CDDP: IC50 = 3.52 μM). CW-2 has synergistic antitumor activity and enhanced membrane permeability. CW-2 exerts antitumor effects by inducing DNA damage, impairing DNA repair, and activating mitochondria-dependent apoptosis (Pink: PARP1 ligand (HY-173441); Blue: E3 CRBN ligand (HY-173439); Black: linker (HY-173440)) .
|
-
- HY-P990778
-
|
ATG-101
|
TNF Receptor
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Xirestomig (ATG-101) is a tetravalent "2+2″ PD-L1×4-1BB bispecific antibody. Xirestomig binds PD-L1 and 4-1BB concurrently, with a greater affinity for PD-L1, and potently activated 4-1BB+ T cells when cross-linked with PD-L1-positive cells. Xirestomig activates exhausted T cells upon PD-L1 binding. Xirestomig displays potent antitumor activity in numerous in vivo tumor models, including those resistant or refractory to immune checkpoint inhibitors (ICIs) .
|
-
- HY-N14001
-
|
|
TNF Receptor
Interleukin Related
Arginase
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Naamidine J is an imidazole-type alkaloids discovered in a sponge. Naamidine J inhibits inflammation by binding to the protein CSE1L (KD = 5.41 μM). Namidine J significantly inhibits the expression of pro-inflammatory factors such as TNF-α, IL-1β, and IL-6, and upregulates anti-inflammatory factors such as CD206 and Arg-1. Namidine J inhibits PD-L1 and shows antitumor activity. Namidine J significantly reduces pulmonary tissue edema, inflammatory cell infiltration and cytokine storm in mice. Namidine J can be used for the research on the immune microenvironment of acute lung injury and tumors .
|
-
- HY-152642
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Azido-2’-deoxy-5-methyl cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-Azido-2’-deoxy-5-methyl cytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-139604
-
|
|
MARK
Apoptosis
|
Cancer
|
|
PCC0208017 is a microtubule affinity regulating kinases (MARK3/MARK4) inhibitor with IC50s of 1.8 and 2.01 nM, respectively. PCC0208017 has much lower inhibitory activity against MARK1 and MARK2, with IC50s of 31.4 and 33.7 nM, respectively. PCC0208017 suppresses glioma progression in vitro and in vivo. PCC0208017 disrupts microtubule dynamics and induces G2/M phase cell cycle arrest and cell apoptosis. PCC0208017 demonstrates robust antitumor activity in vivo and displays good BBB permeability .
|
-
- HY-152724
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Azido-3’-deoxy-5-iodouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-iodouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152645
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Azido-3’-deoxy-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-methyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-13404CR
-
|
INC280 dihydrochloride hydrate (Standard); INCB-28060 dihydrochloride hydrate (Standard)
|
c-Met/HGFR
Apoptosis
Reference Standards
|
Cancer
|
|
Capmatinib (dihydrochloride hydrate) (Standard) is the analytical standard of Capmatinib (dihydrochloride hydrate). This product is intended for research and analytical applications. Capmatinib (INC280; INCB28060) dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase .
|
-
- HY-161410
-
|
|
PROTACs
Apoptosis
Bcl-2 Family
|
Cancer
|
|
WH244 is a second generation BCL-2 and BCL-xL dual depressant (PROTAC). The primary activity of WH244 is the specific degradation of BCL-2 and BCL-xL proteins (BCL-xL: DC50=0.6 nM, BCL-2: DC50=7.4 nM). WH244 promotes their ubiquitination and subsequent proteasome degradation by targeting these proteins, thereby restoring the cell's apoptosis pathway. WH244 has good antitumor activity. (Pink: BCL-2/BCL-xL ligand (HY-161415); Blue: E3 ligase ligand (HY-112078); Black: linker) .
|
-
- HY-154320
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Azido-3’-deoxy-3-deazauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-3-deazauridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-128952G
-
|
SG3249
|
Drug-Linker Conjugates for ADC
DNA Alkylator/Crosslinker
|
Cancer
|
|
Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .
|
-
- HY-116514R
-
|
|
Reference Standards
Farnesyl Transferase
Apoptosis
Endogenous Metabolite
|
Cancer
|
|
(S)-(-)-Perillyl alcohol (Standard) is the analytical standard of (S)-(-)-Perillyl alcohol (HY-116514). This product is intended for research and analytical applications. (S)-(-)-Perillyl alcohol, a monoterpene, is an orally active farnesyl transferase and geranylgeranyl transferase inhibitor. (S)-(-)-Perillyl alcohol up-regulates the mannose-6-phosphate receptor, facilitating TGF-β1 activation and cytostasis,. (S)-(-)-Perillyl alcohol induces apoptosis in cancer cells, modulates cyclin D1 and AP-1 activity. (S)-(-)-Perillyl alcohol exhibits antitumor activity against sarcoma tumors in mice. (S)-(-)-Perillyl alcohol can be used for the research of squamous cell carcinoma of the esophagus and sarcoma 180.
|
-
- HY-152713
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Azido-3’-deoxy-5-methoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-methoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-154308
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Azido-5’-deoxy-2’-O-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5’-Azido-5’-deoxy-2’-O-methyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-181752
-
|
|
FGFR
TNK1
Apoptosis
Caspase
|
Cancer
|
|
FGFR3-IN-12 is a selective fibroblast growth factor receptor 3 (FGFR3) inhibitor with an IC50 of 6.8 nM. FGFR3-IN-12 shows an IC50 of 19.2 nM against FGFR3 V555M and an IC50 of 16.9 nM against TNK1 (Thirty-eight Negative Kinase 1). FGFR3-IN-12 inhibits cancer cells proliferation and induces caspase-mediated apoptosis. FGFR3-IN-12 exhibits antitumor activity in bladder cancer xenografts mice models. FGFR3-IN-12 can be used for the research of cancer, such as bladder cancer .
|
-
- HY-154579
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Azido-N6-benzoyl-3’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-N6-benzoyl-3’-deoxyadenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-B0530A
-
|
γ-pipradol hydrochloride
|
Reactive Oxygen Species (ROS)
mAChR
NADPH Oxidase
|
Cancer
|
|
Azacyclonol (γ-pipradol) hydrochloride is a compound with promising anticancer activity, showing effectiveness in inhibiting NOX-derived ROS in A549 human lung cancer cells. Azacyclonol hydrochloride exhibits enhanced proliferation inhibition against androgen-refractory cancer cell lines, specifically DU145 and PC-3. Azacyclonol hydrochloride demonstrates antitumor activity in DU145-xenografted chorioallantoic membrane tumor models. Azacyclonol hydrochloride also acts as a ligand for the M3 muscarinic acetylcholine receptor, which is overexpressed in ARPC. Azacyclonol hydrochloride effectively blocks carbachol-induced proliferation and NOX activity in DU145 cells. Azacyclonol hydrochloride can also be utilized for the treatment of chronic schizophrenia.
|
-
- HY-154402
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Azido-2′-deoxy-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2′-Azido-2′-deoxy-5-methyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-13404R
-
|
INC280 (Standard); INCB28060 (Standard)
|
Reference Standards
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Capmatinib (Standard) is the analytical standard of Capmatinib. This product is intended for research and analytical applications. Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase .
|
-
- HY-154919
-
|
|
YTHDF
FOXO
MMP
Pyroptosis
Interleukin Related
|
Endocrinology
Cancer
|
|
DC-Y13-27 is a DC-Y13 derivative and YTHDF2 inhibitor (KD: 37.9 μM). DC-Y13-27 inhibits YTHDF2, restores FOXO3 and TIMP1 protein levels, and reduces MMP1/3/7/9 expression. DC-Y13-27 induces Pyroptosis and increases IL-1β secretion. DC-Y13-27 reduces intervertebral disc degeneration and enhances the response to radiotherapy in colon cancer and melanoma. DC-Y13-27 has antitumor activity against breast cancer .
|
-
- HY-147858A
-
|
|
PROTACs
|
Cancer
|
|
PROTAC EGFR degrader 7 (compound 13b) is a potent and selective CRBN-recruiting PROTAC EGFRL858R/T790M degrader, with a DC50 of 13 .2 nM.PROTAC EGFR degrader 7 inhibits NCI-H1975 cells proliferation, with an IC50 of 46 .82 nM.PROTAC EGFR degrader 7 significantly induces apoptosis and G2/M phase arrest in NCI-H1975 cell.PROTAC EGFR degrader 7 shows antitumor activity, and can be used for non-small cell lung cancer (NSCLC) research .
|
-
- HY-P990673
-
|
DSTP-3086S Antibody; RG-7450 Antibody
|
ADC Antibody
Transmembrane Glycoprotein
Mitosis
|
Cancer
|
|
Vandortuzumab (DSTP-3086S Antibody; RG-7450 Antibody) is a humanized anti-STEAP1 IgG1 antibody and antimitotic agent that can be conjugated with MMAE (HY-15162) to form the antibody-drug conjugate (ADC) Vandortuzumab vedotin. Vandortuzumab vedotin specifically binds to STEAP1 and drives internalization of the complex, releasing the MMAE (HY-15162) payload intracellularly. After binding to tubulin, MMAE inhibits cell division and induces cell death. Vandortuzumab exhibits antitumor activity in preclinical xenograft models of prostate cancer and can be used for research related to metastatic castration-resistant prostate cancer (mCRPC) .
|
-
- HY-15346R
-
|
BAY 80-6946 (Standard)
|
Reference Standards
PI3K
Apoptosis
|
Cancer
|
|
Copanlisib (Standard) is the analytical standard of Copanlisib. This product is intended for research and analytical applications. Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .
|
-
- HY-N0763
-
|
Isopsoralen
|
Apoptosis
Virus Protease
NF-κB
p38 MAPK
JNK
Caspase
|
Infection
Inflammation/Immunology
Cancer
|
|
Angelicin is a furanocoumarin compound that functions as an inhibitor of NF-κB and MAPK signaling pathways, exhibiting anti-inflammatory, antiviral, and antitumor activities. It suppresses the lytic replication of γ-herpesviruses, such as MHV-68, early during viral infection, potentially inhibiting RTA gene expression (IC50=28.95 μM). Angelicin also mitigates inflammation by inhibiting the phosphorylation and nuclear translocation of NF-κB, and the phosphorylation of p38 and JNK. Furthermore, it induces apoptosis in neuroblastoma cells by downregulating anti-apoptotic proteins like Bcl-2, Bcl-xL, and Mcl-1, while activating caspase-9 and caspase-3.
|
-
- HY-152315
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Azido-3’-deoxy-N6-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-N6-methyladenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-128481
-
|
|
STING
|
Inflammation/Immunology
Cancer
|
|
SB24011 is a STING modulator and a TRIM29-STING protein-protein interaction inhibitor. SB24011 blocks TRIM29-induced K48-linked specific ubiquitination by binding to STING, thereby upregulating intracellular STING protein levels. SB24011 enhances inflammatory cytokine expression and STING-mediated immune responses, and exhibits abscopal antitumor activity that promotes tumor regression and activates T cell infiltration. When combined with STING agonists or anti-PD1 antibodies, SB24011 synergistically enhances antitumor responses. SB24011 is suitable for research related to colon cancer and melanoma .
|
-
- HY-152708
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Azido-3’-deoxy-5-trifluoromethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-trifluoromethyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-174382
-
|
|
Akt
mTOR
NF-κB
ROR
Apoptosis
|
Cancer
|
|
ROR1-IN-3 (Compound 24d) is a potent and highly selective ROR1 kinase inhibitor (IC50 = 17.6 nM). ROR1-IN-3 demonstrates robust antitumor activity and inhibitory effect against ROR1 both in vitro and in vivo. ROR1-IN-3 has robust antiproliferative efficacy in vitro and in vivo. ROR1-IN-3 induces apoptosis in cancer cell lines. ROR1-IN-3 inhibits ROR1 downstream AKT/mTOR and NF-κB signaling pathway. ROR1-IN-3 can be studied in antitumor research .
|
-
- HY-178036
-
|
|
MDM-2/p53
Topoisomerase
Bcl-2 Family
Caspase
Cyclin G-associated Kinase (GAK)
|
Cancer
|
|
ZM484 is a potent dual p53-MDM2/TOP1 inhibitor that exhibits antiproliferative and antitumor activity both in vitro and in vivo. ZM484 effectively upregulates p53 and MDM2 proteins and maintains TOP1 inhibitory activity by the release of camptothecin (CPT) and a potent p53-MDM2 inhibitor. ZM484 induces cell cycle arrest and apoptosis by regulating the expression of key apoptosis- and cycle-related proteins, including caspase-3, Bcl-2, and Cyclin B1. ZM484 can be used for colorectal cancer research .
|
-
- HY-175326
-
|
|
SOS1
|
Cancer
|
|
SOS1-IN-21 is an orally active inhibitor of son of Sevenless 1 (SOS1) with an IC50 of 15 nM. SOS1 is a guanine nucleotide exchange factor (GEF) that activates KRAS by facilitating the exchange of GDP for GTP. SOS1-IN-21 exhibits potent antiproliferative activity, with IC50 values of 16 nM in NCI-H358 and 17 nM in Mia Paca-2 cell proliferation assays. SOS1-IN-21 exhibits significant antitumor activity in the Mia Paca-2 xenograft model. SOS1-IN-21 can be used for the study of KRAS mutant tumors, such as pancreatic cancer .
|
-
- HY-119009
-
|
|
JAK
STAT
NF-κB
Bcl-2 Family
|
Cancer
|
|
TM-233 is an inhibitor of the JAK/STAT and NF-κB signaling pathways, exhibiting significant antitumor activity. TM-233 reduces the expression of the anti-apoptotic protein Mcl-1 by inhibiting the phosphorylation of JAK2 and STAT3, and regulates its transcription by directly binding to the Mcl-1 gene promoter. Additionally, TM-233 prevents the translocation of NF-κB from the cytoplasm to the nucleus by inhibiting its DNA-binding activity, thereby reducing nuclear NF-κB expression. TM-233 shows potential in overcoming Bortezomib (HY-10227) resistance and can be applied in research related to multiple myeloma .
|
-
- HY-152338
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
7-Propargyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 7-Propargyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-152688
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Azido-3’-deoxy-5-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-fluorouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-154119
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Azido-3’-deoxy-6-azauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-6-azauridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-154346
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Azido-5’-deoxy-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5’-Azido-5’-deoxy-5-methyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152585
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Azido-3’-deoxy-5-fluoro-beta-L-uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-fluoro-beta-L-uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-N3005
-
|
|
Apoptosis
Autophagy
NOD-like Receptor (NLR)
Pyroptosis
|
Inflammation/Immunology
Cancer
|
|
Britannin is an NLRP3 inhibitor with an IC50 of 3.630 μM, exhibiting anti-inflammatory activity. Britannin inhibits the activation and assembly of the NLRP3 inflammasome by blocking the interaction between NLRP3 and NEK7. Additionally, Britannin demonstrates antitumor activity by inhibiting the proliferation of tumor cells through blocking the interaction between HIF-1α and Myc, thereby suppressing PD-L1 expression and enhancing cytotoxic T lymphocyte activity. Britannin can also induce apoptosis and autophagy in liver cancer cells by activating ROS-regulated AMPK. Britannin holds promise for research in the fields of anti-inflammatory and antitumor therapeutics .
|
-
- HY-100874
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
N3-PEG3-vc-PAB-MMAE is a synthesized agent-linker conjugate for ADC that incorporates the MMAE (a tubulin inhibitor ) and 3-unit PEG linker. N3-PEG3-vc-PAB-MMAE shows potent antitumor activity. N3-PEG3-vc-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152373
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy-3’-fluoro-xylo-guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy-3’-fluoro-xylo-guanosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-152448
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Azido-2’-deoxycytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-Azido-2’-deoxycytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups. 2’-Azido-2’-deoxycytidine is an azidonucleoside,and it should be phosphorylated twice to become an inhibitor of the nucleotide reductase.
|
-
- HY-172256
-
|
|
PI4K
|
Cancer
|
|
PI4KIII beta inhibitor 5 is a PI4KIIIβ inhibitor with an IC50 of 19 nM. PI4KIII beta inhibitor 5 can induce cancer cell apoptosis (Apoptosis), cell cycle arrest at the G2/M phase, and autophagy (Autophagy) by inhibiting the PI3K/AKT pathway. PI4KIII beta inhibitor 5 has also demonstrated significant antitumor activity in the H446 xenograft model of small cell lung cancer. PI4KIII beta inhibitor 5 can be used for research in the field of cancer therapy .
|
-
- HY-162772
-
|
|
Isocitrate Dehydrogenase (IDH)
Apoptosis
|
Cancer
|
|
IDH1/2-IN-1 (Compound 6b) serves as a dual inhibitor of IDH1(R132H)/IDH2(R140Q) with IC50 values of 0.22 μM and 1.6 μM, respectively. IDH1/2-IN-1 effectively inhibits tumor growth by suppressing tumor cell proliferation and enhancing host defense through the activation of antioxidant enzymes. Additionally, IDH1/2-IN-1 reduces inflammation and promotes apoptosis, demonstrating robust antitumor activity. IDH1/2-IN-1 holds potential for research in leukemia .
|
-
- HY-N0646R
-
|
|
Reference Standards
Phosphatase
Endogenous Metabolite
Tyrosinase
Apoptosis
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Silydianin (Standard) is the analytical standard of Silydianin (HY-N0646). This product is intended for research and analytical applications. Silydianin is a flavonolignan. Silydianin can be obtained from Silybum marianum. Silydianin inhibits PTP1B with an IC50 of 17.38 μM. Silydianin inhibits both monophenolase and diphenolase of tyrosinase significantly, with IC50s of 2.6 μM and 16.5 μM, respectively. Silydianin induces Apoptosis and reduces cytokines (IL-4 and IL-5). Silymarin has antioxidant, cytoprotective and immunomodulatory effects. Silydianin has antitumor activity against prostate cancer. Silymarin can be used in allergic asthma research .
|
-
- HY-152583
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Azido-3’-deoxy-5-methyl-beta-L-uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-methyl-beta-L-uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152389
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Methylpurine-β-D-(3-azido-3-deoxy)riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 6-Methylpurine-β-D-(3-azido-3-deoxy)riboside is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152364
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy-3’-fluoro guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy-3’-fluoro guanosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-14575
-
|
Z-360 hemicalcium
|
Cholecystokinin Receptor
Ephrin Receptor
Interleukin Related
VEGFR
HIF/HIF Prolyl-Hydroxylase
Akt
|
Neurological Disease
Cancer
|
|
Nastorazepide (Z-360) hemicalcium is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide hemicalcium inhibits the specific binding of [ 3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide hemicalcium inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide hemicalcium has antitumor activity against pancreatic cancer. Nastorazepide hemicalcium inhibits colorectal cancer liver metastasis and relieves pain .
|
-
- HY-175176
-
|
|
HDAC
Apoptosis
Pyroptosis
Reactive Oxygen Species (ROS)
Caspase
|
Cancer
|
|
HDAC1/6-IN-3 is a potent HDAC inhibitor. HDAC1/6-IN-3 shows excellent inhibitory activities against HDAC1 (IC50 = 1.1 nM) and HDAC6 (IC50 = 2.7 nM). HDAC1/6-IN-3 significantly arrests HepG2 cells at the G0/G1 phase and induces apoptosis and pyroptosis. HDAC1/6-IN-3 exhibits significant antitumor activity in the HepG2 xenograft mode. HDAC1/6-IN-3 can be used for the study of cancers such as liver cancer, lung cancer, colon cancer and breast cancer .
|
-
- HY-153703
-
|
|
PI3K
|
Cancer
|
|
PI3Kγ inhibitor 7 (compound 2) is a potent and orally active PI3Kγ inhibitor with IC50 values of 4768, 878.1, 3.42, 355.2 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, respectively. PI3Kγ inhibitor 7 shows antitumor activity . PI3Kγ inhibitor 7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-155075
-
|
|
PROTACs
Glutathione Peroxidase
Ferroptosis
|
Cancer
|
|
NC-R17 is a PROTAC-class, non-covalent GPX4 degrader based on RSL3, involved in ferroptosis. NC-R17 has antitumor activity and is used for non-covalent GPX4 PROTAC design . NC-R17 consists of a target protein ligand (red part) Demethyl-RSL3 (HY-135832); an E3 ubiquitin ligase ligand (blue part) Lenalidomide (HY-A0003) and a PROTAC linker (black part) (HY-169376). E3 ubiquitin ligase and linker can form Lenalidomide-C13-piperazine-Boc (HY-169377) .
|
-
- HY-D0214E
-
|
|
Influenza Virus
Photosensitizer
Amyloid-β
|
Infection
Neurological Disease
Cancer
|
|
Acid Red 94 sodium (80%), a synthetic fluorescein derivative, is a deep red dye primarily composed of 4,5,6,7-tetrachloro-2,4,5,7-tetraiodo fluorescein. Acid Red 94 sodium (80%) is widely used as an ophthalmic diagnostic agent to detect dry or damaged cells on the ocular surface. Acid Red 94 sodium (80%) exhibits antitumor activity and can inhibit Friend Leukemia Virus (FLV) infection through photodynamic action. Additionally, Acid Red 94 sodium (80%) can inhibit Aβ aggregation through light irradiation. Acid Red 94 sodium (80%) holds potential for use in cancer, viral infections, and neurodegenerative disease research .
|
-
- HY-W052289R
-
|
|
Endogenous Metabolite
Reference Standards
|
Cancer
|
|
Methyl 6-bromo-1H-indole-3-carboxylate (Standard) is the analytical standard of Methyl 6-bromo-1H-indole-3-carboxylate (HY-W052289). This product is intended for research and analytical applications. Methyl 6-bromo-1H-indole-3-carboxylate is a marine-derived natural product with antitumor activity. Methyl 6-bromo-1H-indole-3-carboxylate showed growth inhibition against Staphylococcus epidermidis, exhibiting weak or moderate minimum inhibitory concentrations (MICs) .
|
-
- HY-179381
-
|
|
FGFR
|
Cancer
|
|
FGFR4-IN-24 is a selective irreversible covalent FGFR4 inhibitor (IC50 = 1.2 nM). FGFR4-IN-24 shows much weaker activity against the other three FGFR family kinases (FGFR1-3). FGFR4-IN-24 inhibits the FGF19/FGFR4 signaling pathway, effectively suppressing the proliferation of the HuH-7 HCC cell line (GI50 = 17 nM). FGFR4-IN-24 exhibits significant antitumor activity in a HuH-7 mouse xenograft model. FGFR4-IN-24 can be used for the research of hepatocellular carcinoma .
|
-
- HY-181996
-
|
|
Btk
Caspase
Apoptosis
PARP
|
Cancer
|
|
BTK-IN-47 (Compound 9e) is a covalent, selective BTK inhibitor with an IC50 of 5.15 nM against BTK. BTK-IN-47 inhibits the BTK signaling pathway, induces cell cycle arrest, and activates the canonical Caspase-dependent Apoptotic pathway (promoting the cleavage of Caspase-3, Caspase-7 and PARP), without inducing necroptosis, pyroptosis or ferroptosis. BTK-IN-47 exerts dose-dependent antiproliferative activity against hematologic tumor cell lines. BTK-IN-47 exhibits dose-dependent in vivo antitumor activity in a Ramos cell xenograft model in BALB/c nude mice. BTK-IN-47 can be used for the research of hematologic malignancies .
|
-
- HY-152597
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Azido-3’-deoxy-5-fluoro-beta-L-cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-fluoro-beta-L-cytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-N6037R
-
|
|
Reference Standards
Apoptosis
Ornithine decarboxylase (ODC)
Reactive Oxygen Species (ROS)
Cathepsin
Deubiquitinase
Caspase
|
Inflammation/Immunology
Cancer
|
|
Gardenin B (Standard) is the analytical standard of Gardenin B (HY-N6037). This product is intended for research and analytical applications. Gardenin B is a flavonoid isolated from Gardenia jasminoides. Gardenin B is a methoxyflavone compound and an inhibitor of USP7, ODC (IC50: 6.24 μg/mL), and Cathepsin D (IC50: 5.61 μg/mL). Gardenin B exhibits antioxidant and antitumor activities. Gardenin B shows IC50 values of 8.87 and 10.59 μg/mL for DPPH and NO scavenging, respectively, and also possesses ferric ion reducing ability. Additionally, Gardenin B can inhibit tumor cell proliferation, induce cell cycle arrest and apoptosis. Gardenin B can be used in cancer research .
|
-
- HY-152595
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Azido-3’-deoxy-5-methyl-beta-L-cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-methyl-beta-L-cytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-159838
-
|
EI‐1071
|
c-Fms
Amyloid-β
|
Neurological Disease
Cancer
|
|
Enrupatinib (EI‐1071) is a potent, orally active, CNS-penetrant and selective CSF1R inhibitor. Enrupatinib inhibits macrophage proliferation and osteoclast differentiation in vitro. Enrupatinib preserves microglia distal to Aβ plaques. Enrupatinib mitigates Alzheimer's disease (AD)-related pathologies by reducing neuroinflammation, preserving neuronal integrity, lowering disease-associated microglia gene expression, and enhancing cognitive function in 5xFAD and J20 mouse models. Enrupatinib reduces tumor-associated macrophage infiltration and enhances antitumor activity of anti-PD-1 antibody in murine colorectal cancer and breast cancer models. Enrupatinib can be used for the research of AD, colorectal cancer, and breast cancer .
|
-
- HY-182937
-
|
|
FLT3
STAT
Akt
ERK
Caspase
PARP
Bcl-2 Family
Apoptosis
|
Cancer
|
|
FLC-8 is an orally active FLT3 inhibitor with IC50 values of 10.2 nM, 11.6 nM and 24.10 nM against human FLT3-WT, FLT3-G697R and FLT3-N676D, respectively. FLC-8 inhibits FLT3 autophosphorylation and downstream STAT5, AKT and ERK signaling pathways, and induces apoptosis in acute myeloid leukemia (AML) cells. FLC-8 exhibits potent antitumor activity in the MV4-11 xenograft model. FLC-8 can be used for the research of acute myeloid leukemia .
|
-
- HY-168892
-
|
|
Atg8/LC3
Autophagy
|
Cancer
|
|
LC3B recruiter 2 (34R) is an LC3B recruiter and a component of the autophagy-lysosome pathway degradation system (ATTEC, Autophagy-Tethering Compounds), which directly binds to LC3B. LC3B recruiter 2 binds to CDK9 inhibitor SNS-032 (HY-10008) through a linker, forming an ATTEC that targets the degradation of the CDK9 and Cyclin T1 complex (with inhibitory effects on both). Therefore, LC3B recruiter 2 exerts activity through the LC3B-dependent autophagy-lysosome pathway, interfering with the cell cycle of cancer cells, thus exhibiting antitumor activity .
|
-
- HY-P99463
-
|
AVB-500; AVB-S6-500
|
TAM Receptor
PI3K
Akt
p38 MAPK
|
Cancer
|
|
Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((KD <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis .
|
-
- HY-131088
-
|
|
Drug-Linker Conjugates for ADC
EGFR
|
Cancer
|
|
N3-PEG8-Phe-Lys-PABC-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (HY-50895) (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-175700
-
|
|
Topoisomerase
Apoptosis
|
Cancer
|
|
YCJ-02 is a selective Topoisomerase I (Top I) inhibitor. YCJ-02 can inhibit cell proliferation and induce apoptosis and G2/M phase arrest. YCJ-02 can induce DNA damage and increaseγ-H2AX levels. YCJ-02 can promote Top I deqradation via a ubiquitin/26S proteasome pathway. YCJ-02 increases the expressions of pro-apoptotic proteins Bad, Bax, and cleaved
caspase-3. YCJ-02 shows broad-spectrum antitumor activity. YCJ-02 can be used for the research of cancer, such as intrahepatic cholangiocarcinoma (ICC) .
|
-
- HY-152341
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
7-(Butyn-2-yl)-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 7-(Butyn-2-yl)-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-159642G
-
|
TYRA-300
|
FGFR
ERK
|
Metabolic Disease
Cancer
|
|
Dabogratinib (TYRA-300) (GMP) is Dabogratinib (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .
|
-
- HY-169006
-
|
|
Apoptosis
PKC
|
Cancer
|
|
Evo312 is a dose-dependent inhibitor of protein kinase CβⅠ (PKCβⅠ) (IC50 is 117.34 nM). Evo312 induces PANC-GR (acquired gemcitabine-resistant PC cells) cell cycle arrest and apoptosis by inhibiting PKCβ1 protein expression. Evo312 has antiproliferative effects in pancreatic cancer cells PANC-1 and PANC-GR cells with IC50 of 0.08 μM and 0.07 μM, and in human normal pancreatic ductal epithelial cells HPDE6-c7 with IC50 of 2.95 μM. Evo312 exhibits antitumor activity in a PANC-GR cell transplantation mouse model .
|
-
- HY-147245
-
|
STP1002
|
PARP
|
Cancer
|
|
Basroparib (STP1002) is a selective, orally active inhibitor of tankyrase (TNKS1/TNKS2) with IC50 of 29.94 nM and 3.68 nM for TNKS1 and TNKS2, respectively. Basroparib has an IC50 of >10 μM for PARP1. Basroparib binds to TNKS, stabilizes AXIN1/2 proteins, blocks Wnt/β-catenin signaling pathway, inhibits tumor cell proliferation and induces apoptosis, while reducing cancer stem cell properties. Basroparib can be used in colorectal cancer (CRC) studies with KRAS mutations (such as G12V/G12D) to overcome acquired resistance to MEK inhibitors. STP1002 has synergistic antitumor activity with MEK inhibitors .
|
-
- HY-19337S1
-
|
BAY 1896953-d6; ORM-15341-d6
|
Isotope-Labeled Compounds
Androgen Receptor
|
Cancer
|
|
Ketodarolutamide-d6 (BAY 1896953-d6) is the deuterium labeled Ketodarolutamide (HY-19337). Ketodarolutamide (ORM-15341) is a potent, high-affinity nonsteroidal competitive full antagonist of androgen receptor (AR). Ketodarolutamide displays a Ki value of 8 nM for rat wild-type AR and an IC50 value of 38 nM in AR-HEK293 cells . Ketodarolutamide inhibits testosterone-induced nuclear translocation of the AR and antagonizes both overexpressed and mutant ARs . Ketodarolutamide specifically suppresses the proliferation of AR-dependent prostate cancer cells and exhibits antitumor activity in models of castration-resistant prostate cancer (CRPC) . Ketodarolutamide is suitable for the mechanistic and therapeutic research of prostate cancer .
|
-
- HY-181843
-
|
|
HDAC
Apoptosis
Histone Acetyltransferase
Microtubule/Tubulin
Caspase
|
Cancer
|
|
HDAC-IN-99 is a histone deacetylase (HDAC) inhibitor with an IC50 of 37.73 nM, and it exhibits potent inhibitory activity against HDAC1 (IC50 = 48.09 nM), HDAC2 (IC50 = 300.28 nM) and HDAC6 (IC50 = 9.16 nM). HDAC-IN-99 exerts broad-spectrum antiproliferative activity in various cancer cell lines. HDAC-IN-99 induces S-phase cell cycle arrest and apoptosis in colon cancer cells, increases the acetylation levels of histone H3, histone H4 and α-tubulin, and upregulates the expression of p21 as well as the cleavage of caspase-3. HDAC-IN-99 displays antitumor activity in colon cancer xenograft models. HDAC-IN-99 can be used for the research of colon cancer .
|
-
- HY-182036
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
KWZL-7f15 (compound 7f15) is a dual CDK6/BET inhibitor with an IC50 of 31.81 nM against human CDK6. KWZL-7f15 inhibits the CDK6-RB axis and the BRD4-Myc axis. KWZL-7f15 exhibits antiproliferative activity against triple-negative breast cancer cells. KWZL-7f15 shows antitumor activity in xenograft mouse models without significant adverse effects. KWZL-7f15 can be used in studies related to triple-negative breast cancer .
|
-
- HY-179012
-
|
|
APC
CDK
Raf
Akt
HSP
|
Cancer
|
|
CDC20/HSP90-IN-1 (Compound 2b) is a Cdc20/Hsp90 inhibitor with a Kd of 16.2 μM for Cdc20 and a Kd of 0.241 μM for Hsp90α. CDC20/HSP90-IN-1 exerts potent antitumor activity through reducing p53-mediated Cdc20, upregulating Bim, downregulating Cyclin B1 expression, and disturbing B-Raf and AKT pathways via destroying Hsp90 chaperone function. CDC20/HSP90-IN-1 overcomes Vemurafenib (HY-12057)-induced resistant melanoma .
|
-
- HY-147100
-
|
|
PROTACs
Adrenergic Receptor
|
Cancer
|
|
α1A-AR Degrader 9c (compound 9c) is a potent, selective and reversible α1A-AR (Adrenergic receptor) PROTAC degrader, with a DC50 of 2.86 μM. α1A-AR Degrader 9c induces α1A-AR degradation can be attributed to proteasomal degradation. α1A-AR Degrader 9c inhibits the proliferation of PC-3 cells, with an IC50 of 6.12 μM. α1A-AR Degrader 9c shows antitumor activity, and can be used for prostate cancer research .
|
-
- HY-P3371
-
|
DS-7300a; MABX-9001a; I-DXd
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
Apoptosis
|
Cancer
|
|
Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects
|
-
- HY-154383
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Azido-5’-deoxy-2’-O-(2-methoxyethyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5’-Azido-5’-deoxy-2’-O-(2-methoxyethyl)uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-145736A
-
|
|
Drug-Linker Conjugates for ADC
Apoptosis
|
Cancer
|
|
β-Glucuronide-dPBD-PEG5-NH2 TFA is the β-glucuronide-linked pyrrolobenzodiazepine dimer, which binds to the prenylated antibody for synthesis of antibody-drug conjugate (ADC) cIRCR201-dPBD.β-glucuronide-linkage as a cleavable linker. β-Glucuronide-dPBD-PEG5-NH2 TFA, as a proagent of cIRCR201-dPBD, reduces side effects. β-Glucuronide-dPBD-PEG5-NH2 TFA can induce apoptosis and arrest cell cycle. β-Glucuronide-dPBD-PEG5-NH2 TFA has antitumor activity .
|
-
- HY-183120
-
|
|
FAK
EGFR
Apoptosis
|
Cancer
|
|
EGFR T790M/FAK-IN-2 is an orally active dual FAK and EGFR T790M kinase inhibitor, with an IC50 of 1.03 nM against FAK and an IC50 of 3.89 nM against EGFR T790M. EGFR T790M/FAK-IN-2 exerts antiproliferative effects in drug-resistant cancer cells overexpressing FAK, inducing apoptosis and cell cycle arrest. EGFR T790M/FAK-IN-2 exhibits antitumor activity in a pancreatic cancer xenograft mouse model. EGFR T790M/FAK-IN-2 can be used for the research of pancreatic cancer, breast cancer and non-small cell lung cancer .
|
-
- HY-172209
-
|
|
p38 MAPK
Apoptosis
Reactive Oxygen Species (ROS)
Caspase
Bcl-2 Family
|
Cancer
|
|
PPIA-IN-1 is a PPIA inhibitor with a Kd value of 0.52 μM. PPIA-IN-1 inhibits the PPIA/MAPK signaling pathway to exert antiproliferative activity. PPIA-IN-1 induces G0/G1 cell cycle arrest in cancer cells. PPIA-IN-1 upregulates the expression of Bax and caspase-3, downregulates Bcl-2 expression, and induces apoptosis in cancer cells. PPIA-IN-1 induces increased ROS levels, DNA damage, endoplasmic reticulum stress, and mitochondrial dysfunction in cancer cells. PPIA-IN-1 exhibits antitumor activity in a mouse colon cancer xenograft model. PPIA-IN-1 can be used for the research of colorectal cancer .
|
-
- HY-154423
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Azido-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2′-Azido-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
![2′-Azido-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxyuridine](//file.medchemexpress.com/product_pic/hy-154423.gif)
- HY-145736
-
|
|
Drug-Linker Conjugates for ADC
Apoptosis
|
Cancer
|
|
β-Glucuronide-dPBD-PEG5-NH2 is the β-glucuronide-linked pyrrolobenzodiazepine dimer, which binds to the prenylated antibody for synthesis of antibody-drug conjugate (ADC) cIRCR201-dPBD. β-glucuronide-linkage as a cleavable linker. β-Glucuronide-dPBD-PEG5-NH2, as a proagent of cIRCR201-dPBD, reduces side effects. β-Glucuronide-dPBD-PEG5-NH2 can induce apoptosis and arrest cell cycle. β-Glucuronide-dPBD-PEG5-NH2 has antitumor activity .
|
-
- HY-154283
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-7-propargyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2-Amino-7-propargyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl)purine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-154042
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Azido-5’-deoxy-2’-O,4’-C-methyleneuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5’-Azido-5’-deoxy-2’-O,4’-C-methyleneuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-182064
-
|
|
EGFR
NO Synthase
COX
NF-κB
Interleukin Related
Apoptosis
|
Cancer
|
|
EGFR-IN-206 is an orally active EGFR inhibitor. EGFR-IN-206 inhibits the phosphorylation of the key tumor growth protein EGFR, and suppresses the proliferation, migration and invasion of EGFR triple-mutant tumor cell lines. EGFR-IN-206 downregulates the expression of inflammation-related proteins iNOS, COX-2 and NF-κB (p65). EGFR-IN-206 promotes the secretion of NO. EGFR-IN-206 reduces the secretion of IL-6. EGFR-IN-206 induces apoptosis (apoptosis) of EGFR triple-mutant tumor cells. EGFR-IN-206 exerts antitumor activity in EGFR triple-mutant mice. EGFR-IN-206 is applicable to the research of non-small cell lung cancer .
|
-
- HY-P991015
-
|
JNJ-78278343; KLCB-245
|
CD3
|
Cancer
|
|
Pasritamig (JNJ-78278343; KLCB-245) is a bispecific T-cell engager (BiTE) that targets the complex of human kallikrein KLK2 and CD3 receptor. Pasritamig redirects the cytotoxicity of T cells to KLK2-expressing tumor cells and induces T cell-mediated lysis of KLK2-expressing prostate cancer cells. Administered via subcutaneous injection, subcutaneous infusion or intravenous infusion, Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig has a safety profile with an extremely low incidence of cytokine release syndrome and can be safely administered in an outpatient setting. Pasritamig is applicable to the research of metastatic castration-resistant prostate cancer .
|
-
- HY-108511R
-
|
|
Reference Standards
Sigma Receptor
Apoptosis
SARS-CoV
|
Infection
Cancer
|
|
PB28 dihydrochloride (Standard) is the analytical standard of PB28 (dihydrochloride) (HY-108511). This product is intended for research and analytical applications. PB28 dihydrochloride, a cyclohexylpiperazine derivative, is a high affinity and selective sigma 2 (σ2) receptor agonist with a Ki of 0.68 nM. PB28 dihydrochloride is also a σ1 antagonist with a Ki of 0.38 nM. PB28 dihydrochloride is less affinity for other receptors. PB28 dihydrochloride inhibits electrically evoked twitch in guinea pig bladder and ileum with EC50 values of 2.62 μM and 3.96 μM, respectively. PB28 dihydrochloride can modulate SARS-CoV-2-human protein-protein interaction. PB28 dihydrochloride induces caspase-independent apoptosis and has antitumor activity .
|
-
- HY-154733
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[5-(propyn-1-yl)pyridin-3-yl]purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[5-(propyn-1-yl)pyridin-3-yl]purine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
![9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[5-(propyn-1-yl)pyridin-3-yl]purine](//file.medchemexpress.com/product_pic/hy-154733.gif)
- HY-178819
-
|
|
Integrin
Drug Intermediate
|
Cancer
|
|
NM-001 is a theranostic prodrug that targets ανβ3 integrin. NM-001 consists of cRGD and GFLG peptides, a DCM fluorophore and Chlorambucil (HY-13593). NM-001 internalizes into lysosomes of tumor cells via the cRGD peptide, and generates NM-002 (HY-178820) and Chlorambucil through intracellular cleavage at the GFLG peptide by overexpressed Cathepsin B (CTSB). NM-001 exhibits green fluorescence under physiological conditions, and converts to NIR fluorescence by CTSB activation. NM-001 has significant antitumor activity with low toxicity in HeLa cell xenografts mouse models. NM-001 can be used for real-time drug release monitoring research .
|
-
- HY-151563A
-
|
|
Deubiquitinase
|
Cancer
|
|
OTUB1/USP8-IN-1 TFA is the TFA salt form of OTUB1/USP8-IN-1 (HY-151563). OTUB1/USP8-IN-1 TFA is a dual inhibitor for OTUB1/USP8, IC50 for OTUB1 and USP8 is 0.17 and 0.28 nM, respectively. OTUB1/USP8-IN-1 TFA inhibits proliferation of NSCLC cells. OTUB1/USP8-IN-1 TFA exhibits good pharmacokinetic characters in ICR mouse, and exhibits antitumor activity in H1975 xenograft mouse model .
|
-
- HY-168715
-
|
|
SHP2
Apoptosis
MAPKAPK2 (MK2)
|
Cancer
|
|
SHP2-IN-33 (Compound D13) is an allosteric inhibitor of SHP2 with an IC50 of 1.2 μM. In cellular studies, SHP2-IN-33 demonstrates antiproliferative activity with an IC50 of 38 μM against Huh7 cells by arresting the G0/G1 cell cycle, promoting apoptosis (Apoptosis), and suppressing the MAPK signaling pathway. In an in vivo Huh7 xenograft mouse model, SHP2-IN-33 exhibits significant antitumor activity and favorable pharmacokinetics, including 54% oral bioavailability and a half-life of 10.57 hours. SHP2-IN-33 is a promising compound for studying tumor diseases associated with SHP2 .
|
-
- HY-163028
-
|
|
Tim3
|
Cancer
|
|
ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research .
|
-
- HY-112120
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-6-chloro-9-(3-deoxy-3-fluoro-beta-D-ribofuranosyl)-9H-purine ((2R,3S,4S,5R)-2-(2-Amino-6-chloro-9H-purin-9-yl)-4-fluoro-5-(hydroxymethyl)tetrahydrofuran-3-ol) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-147826
-
|
|
EGFR
Apoptosis
|
Cancer
|
|
EGFR-IN-60 (Compound 7d) shows obvious inhibition of EGFR WT, EGFR T790M, EGFR L858R and JAK3 with IC50s of 83, 26, 53, and 69 nM, respectively. EGFR-IN-60 potently inhibits the growth of H1975 cells harboring EGFR T790M mutation (IC50=1.32 µM) over A431 cells overexpressing EGFR WT (IC50=4.96 µM). EGFR-IN-60 exhibits good oral absorption, potent and safe antitumor activity. EGFR-IN-60 induces cell death through apoptosis supported by increased Bax/Bcl-2 ratio .
|
-
- HY-180553
-
|
|
Histone Methyltransferase
|
Cancer
|
|
NSD2-IN-6 is a selective and orally active NSD2 inhibitor with IC50s of 3.8 and 274 nM for NSD2 and NSD1 respectively. NSD2-IN-6 reduces H3K36me2 levels, reverses cell plasticity by restoring the androgen receptor ( AR) signaling pathway. NSD2-IN-6 reduces a shift from cluster 2 and 3 states towards the cluster 1 state in organoids. NSD2-IN-6 exerts antitumor activity by reversing tumor cell plasticity, suppressing growth, and promoting apoptosis in vivo. NSD2-IN-6 can be used for prostate cancer research .
|
-
- HY-112749B
-
|
|
Heme Oxygenase (HO)
Reactive Oxygen Species (ROS)
Mitochondrial Metabolism
|
Cancer
|
|
(3S,4R)-ME-344 is the (3S,4R)-enantiomer of ME-344 (HY-112749). ME-344 is a mitochondrial Heme oxygenase 1 (HO-1) inhibitor. ME-344 specifically binds and alters HO-1 structure, and increases HO-1 translocation from the rough endoplasmic reticulum to mitochondria, but only in drug-sensitive cells (such as H460 and SHP-77 cells). ME-344 decreases mitochondrial ATP production and induces ROS, with subsequent disruption of redox homeostasis and mitochondrial function. ME-344 has significant antitumor activity, and can be used for cancers like breast cancer research .
|
-
- HY-P991944
-
|
|
CCR
|
Cancer
|
|
ZL-1218 is a selective humanized IgG1 antibody, targeting CCR8. ZL-1218 induces antibody-dependent cellular cytotoxicity (ADCC), leading to NK cell-mediated depletion of CCR8-expressing regulatory T cells (Tregs). ZL-1218 blocks the binding of the CCR8 ligand CCL1 to CCR8 and reduces Treg recruitment by inhibiting the chemotaxis of CCR8 + cells. ZL-1218 reduces intratumoral Treg levels in a dose-dependent manner. ZL-1218 exerts enhanced antitumor activity when combined with the anti-PD-1 antibody. ZL-1218 can be used for solid tumour research .
|
-
- HY-152319
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Azido-3’-deoxy-N6,N6-dimethyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-N6,N6-dimethyladenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-181005
-
|
|
FGFR
Akt
PERK
Reactive Oxygen Species (ROS)
Caspase
Pyroptosis
PD-1/PD-L1
|
Neurological Disease
Cancer
|
|
FGFR-IN-25 (Compound 19E) is a FGFR inhibitor (IC50s: 1.30 nM and 0.85 nM for FGFR1 and FGFR2, respectively) and radiosensitizer. FGFR-IN-25 effectively reduces the phosphorylation of FGFR1 and its key downstream effectors, pAKT and pERK. FGFR-IN-25 exerts broad-spectrum antitumor activity against gastric cancer, colorectal carcinoma, hepatocellular carcinoma, breast cancer, triple-negative breast cancer, and glioblastoma. FGFR-IN-25, when combined with radiotherapy, synergistically activates the ROS-Caspase-3-GSDME axis, downregulates PD-L1 expression, and induces immunogenic cell death (ICD). FGFR-IN-25 combined with radiotherapy improves the antitumor efficacy .
|
-
- HY-19337S
-
|
BAY 1896953-d3; ORM-15341-d3
|
Isotope-Labeled Compounds
Androgen Receptor
|
Cancer
|
|
Ketodarolutamide-d3 (BAY 1896953-d3) is the deuterium labeled Ketodarolutamide (HY-19337). Ketodarolutamide (ORM-15341) is a potent, high-affinity nonsteroidal competitive full antagonist of androgen receptor (AR). Ketodarolutamide displays a Ki value of 8 nM for rat wild-type AR and an IC50 value of 38 nM in AR-HEK293 cells . Ketodarolutamide inhibits testosterone-induced nuclear translocation of the AR and antagonizes both overexpressed and mutant ARs . Ketodarolutamide specifically suppresses the proliferation of AR-dependent prostate cancer cells and exhibits antitumor activity in models of castration-resistant prostate cancer (CRPC) . Ketodarolutamide is suitable for the mechanistic and therapeutic research of prostate cancer .
|
-
- HY-154377
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Azido-5’-deoxy-2’-O-methyl-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5'-Azido-5'-deoxy-2'-O-methyl-5-methyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-W334680
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-9-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,9-dihydro-6H-purin-6-one (9-β-D-[2'-Fluoro-2'-deoxy-arabinofuranosyl]-guanin) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![9-β-D-[2'-Fluoro-2'-deoxy-arabinofuranosyl]-guanin](//file.medchemexpress.com/product_pic/hy-w334680.gif)
- HY-17617R
-
|
Z-360 (Standard)
|
Cholecystokinin Receptor
Ephrin Receptor
Interleukin Related
VEGFR
HIF/HIF Prolyl-Hydroxylase
Akt
Reference Standards
|
Neurological Disease
Cancer
|
|
Nastorazepide (Standard) is the analytical standard of Nastorazepide. This product is intended for research and analytical applications. Nastorazepide (Z-360) is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide inhibits the specific binding of [3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide has antitumor activity against pancreatic cancer. Nastorazepide inhibits colorectal cancer liver metastasis and relieves pain .
|
-
- HY-131088A
-
|
|
Drug-Linker Conjugates for ADC
EGFR
|
Cancer
|
|
N3-PEG8-Phe-Lys-PABC-Gefitinib TFA is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (HY-50895) (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib TFA is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-154146
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Nitro-1-(3-azido-3-deoxy-β-D-ribofuranosyl)-2(1H)-pyridinone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5-Nitro-1-(3-azido-3-deoxy-β-D-ribofuranosyl)-2(1H)-pyridinone is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-162802
-
|
|
Apoptosis
PI3K
Akt
PARP
CDK
|
Cancer
|
|
PI3K/AKT-IN-4 (compound 3) is a diterpenoid that can be isolated from the roots and rhizomes of Salvia castanea Dielsf. PI3K/AKT-IN-4 has antitumor activity, inhibiting cell viability and proliferation (IC50=4.72 μM) and promoting apoptosis by blocking the G0/G1 phase of the Hep3B cell cycle, inducing mitochondrial dysfunction and oxidative stress. In addition, PI3K/AKT-IN-4 inhibits hepatocellular carcinoma by inhibiting the PI3K-Akt signaling pathway and binding to PARP1 and CDK2 targets .
|
-
- HY-12307
-
|
Indolactam V
|
PKC
|
Cancer
|
|
(-)-Indolactam V is a PKC activator, with Kis of 3.36 nM, 1.03 μM for η-CRD2 (PKCη surrogate peptide), γ-CRD2 (PKCγ surrogate peptide), and Kds of 5.5 nM (η-C1B), 7.7 nM (ε-C1B), 8.3 nM (δ-C1B), 18.9 nM (β-C1A-long), 20.8 nM (α-C1A-long), 137 nM (β-C1B), 138 nM (γ-C1A), 213 nM (γ-C1B), and has antitumor activity.
|
-
- HY-154386
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Azido-5’-deoxy-2’-O-(2-methoxyethyl)-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5’-Azido-5’-deoxy-2’-O-(2-methoxyethyl)-5-methyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-129440
-
|
|
NF-κB
Toll-like Receptor (TLR)
p38 MAPK
NO Synthase
COX
ERK
Caspase
PDGFR
MyD88
Reactive Oxygen Species (ROS)
Apoptosis
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
N-(p-Coumaroyl) Serotonin is an orally active polyphenol found in safflower seeds with potent anti-inflammatory, antioxidant, and antitumor activities. N-(p-Coumaroyl) Serotonin suppresses NF‑κB, TLR4/MyD88 and MAPK signaling, activates NQO1/HO‑1 pathways, and inhibits pro‑inflammatory cytokines, iNOS and COX‑2 and ROS production. N-(p-Coumaroyl) Serotonin induces S‑phase arrest and apoptosis in glioblastoma cells, reduces atherosclerotic lesions, and alleviates renal and vascular injuries. N-(p-Coumaroyl) Serotonin acts as a vasodilator, regulates calcium dynamics. N-(p-Coumaroyl) Serotonin can be used for the research of neurodegenerative diseases, atherosclerosis, glioblastoma, and acute renal failure .
|
-
- HY-172158
-
|
|
Anaplastic lymphoma kinase (ALK)
Caspase
|
Cancer
|
|
ALKBH5-IN-5 is a highly selective ALKBH5 (IC50 = 0.62 μM, Kd = 804 nM). ALKBH5-IN-5 disrupts ALKBH5 binding to m 6A-RNA and 6mA-DNA substrates. ALKBH5-IN-5 promotes differentiation, induces apoptosis, cause G2-M phase arrest and exerts strong antiproliferative effects in cancer cells. ALKBH5-IN-5 reduces TACC3 and MYC protein levels and increases cleaved caspase-3 levels. ALKBH5-IN-5 exerts antitumor activity in tumor xenograft mice models. ALKBH5-IN-5 can be used for the research of acute myeloid leukemia .
|
-
- HY-183327
-
|
|
PI3K
mTOR
Akt
Apoptosis
Reactive Oxygen Species (ROS)
Mitochondrial Metabolism
Bcl-2 Family
Caspase
|
Cancer
|
|
PI3K/mTOR-IN-22 is an orally active PI3K/mTOR kinase dual inhibitor with IC50 values of 400.5 nM and 8.2 nM. PI3K/mTOR-IN-22 downregulates phosphorylation of the AKT and mTOR, upregulates pro-apoptotic proteins Bax and caspase-3 and downregulates anti-apoptotic protein Bcl-2. PI3K/mTOR-IN-22 exhibits antiproliferative activity against cancer cells, induces apoptosis and ROS production, and reduces mitochondrial membrane potential. PI3K/mTOR-IN-22 exhibits antitumor activity in breast cancer mice models .
|
-
- HY-120406
-
|
|
Btk
Akt
mTOR
p38 MAPK
ERK
CCR
Apoptosis
|
Cancer
|
|
LPS-123 is a covalently irreversible BTK inhibitor with an IC50 of < 5 nM. LPS-123 simultaneously inhibits the catalytic activity of BTK at Tyr551 and its self-activation at Tyr223. LPS-123 inhibits phosphorylation of the AKT/mTOR and MAPK signaling pathways, activation of PLCγ2, ERK1/2, p38, AKT, and mTOR, and blocks the production of CCL3 and CCL4 chemokines. LPS-123 exhibits significant anti-proliferative activity against various B-cell lymphoma cell lines and effectively induces apoptosis via a caspase-dependent pathway. LPS-123 also demonstrates significant antitumor activity in the OCI-Ly7 xenograft model. LPS-123 can be used for lymphoma research .
|
-
- HY-W018604
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone is a purine nucleoside analog. 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone can be synthesized from D-ribose by reacting with methanol under Fischer glycosylation conditions. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone exerts anticancer activities through inhibition of DNA synthesis, induction of apoptosis, etc. 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone can be studied in anticancer research for lymphoid malignancies .
|
-
- HY-10587R
-
|
|
Reference Standards
Histone Methyltransferase
Autophagy
|
Cancer
|
|
BIX-01294 (Standard) is the analytical standard of BIX-01294 (HY-10587). This product is intended for research and analytical applications. BIX-01294 is a reversible and highly selective G9a and GLP Histone Methyltransferase inhibitor, with IC50s of of 1.7 μM and 0.9 μM, respectively. BIX-01294 inhibits G9a/GLP by competing for binding with the amino acids N-terminal of the substrate lysine residue. BIX-01294, a (1H-1,4-diazepin-1-yl)-quinazolin-4-yl amine derivative, induces necroptosis and autophagy. BIX-01294 has antitumor activity in recurrent tumor cells .
|
-
- HY-152438
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Amino-3-ethynyl-4-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 6-Amino-3-ethynyl-4-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
![6-Amino-3-ethynyl-4-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine](//file.medchemexpress.com/product_pic/hy-152438.gif)
- HY-173250
-
|
|
PROTACs
Ras
Apoptosis
|
Cancer
|
|
YN14-H is a PROTAC degrader targeting KRAS G12C. YN14-H inhibits cell growth in NCI-H358 and MIA PaCa-2 cells (IC50 values of 0.042, 0.021 μM, DC50 values of 28.9, 18.1 nM, respectively). YN14-H significantly induces apoptosis and inhibits migration. YN14-H demonstrates favorable pharmacokinetic properties and excellent antitumor activity in vivo. (Structure Note: Pink: target protein ligand (HY-173252); Blue: E3 ligase ligand (HY-125905); Black: linker (HY-Y0840); E3 ligase ligand + linker (HY-173253) .
|
-
- HY-103181R
-
|
CPA (Standard); UK-80882 (Standard)
|
Reference Standards
Adenosine Receptor
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
N6-Cyclopentyladenosine (Standard) is the analytical standard of N6-Cyclopentyladenosine (HY-103181). This product is intended for research and analytical applications. N6-Cyclopentyladenosine (CPA) is a selective Adenosine A1 receptor agonist, with Ki values of 2.3 nM, 790 nM and 43 nM for human A1, A2A and A3 receptors, respectively. N6-cyclopentyladenosine increases Apoptosis. N6-Cyclopentyladenosine has antitumor activity against leukemia. N6-cyclopentyladenosine improves 5-fluorouracil (HY-90006)-induced hematopoietic damage, regulates sleep, and delays Aminophylline-induced clonic epileptic seizures .
|
-
- HY-112411
-
|
|
EGFR
ERK
PDGFR
FGFR
|
Neurological Disease
Inflammation/Immunology
|
|
PD 174265 is a highly selective, reversible EGFR/ErbB2 tyrosine kinase inhibitor (IC50=0.45 nM) and cell differentiation inducer. By blocking receptor autophosphorylation and the downstream ERK signaling pathway (with an IC50 of 0.45 μM for full-length ERK), PD 174265 effectively inhibits tumor growth and exhibits antitumor activity without obvious toxicity in in vivo models. PD 174265 drives oligodendrocyte precursor cells to switch from a proliferative state to a differentiated state, significantly upregulates the expression of myelin proteins such as CNP, PLP and MBP, and induces neurite branching. PD 174265 shows no inhibitory effect on other kinases including insulin, PDGF and basic FGF receptors, and serves as a crucial tool molecule for investigating the treatment of human epidermoid carcinoma and the mechanism of myelin repair in multiple sclerosis .
|
-
- HY-108239R
-
|
|
Reference Standards
Histone Methyltransferase
Autophagy
|
Cancer
|
|
BIX-01294 trihydrochloride (Standard) is the analytical standard of BIX-01294 (trihydrochloride) (HY-108239). This product is intended for research and analytical applications. BIX-01294 trihydrochloride is a reversible and highly selective G9a and GLP Histone Methyltransferase inhibitor, with IC50s of of 1.7 μM and 0.9 μM, respectively. BIX-01294 trihydrochloride inhibits G9a/GLP by competing for binding with the amino acids N-terminal of the substrate lysine residue. BIX-01294 trihydrochloride, a (1H-1,4-diazepin-1-yl)-quinazolin-4-yl amine derivative, induces necroptosis and autophagy. BIX-01294 trihydrochloride has antitumor activity in recurrent tumor cells .
|
-
- HY-154334
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Acetyl-3’-azido-5’-O-(4-methylbenzoyl)-3’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-O-Acetyl-3’-azido-5’-O-(4-methylbenzoyl)-3’-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-168954
-
|
|
c-Fms
Apoptosis
Akt
ERK
STAT
|
Inflammation/Immunology
Cancer
|
|
CSF1R-IN-26 (Compound III-1) is the inhibitor for CSF-1R with an IC50 of 20.07 nM. CSF1R-IN-26 promotes the polarization of M2 macrophages to M1 macrophages, thereby inducing apoptosis in MC-38 cancer cell. CSF1R-IN-26 inhibits the activation of AKT/ERK/STAT3 signaling pathway. CSF1R-IN-26 reconstructs the tumor immune microenvironment and exhibits antitumor activity in mouse models. CSF1R-IN-26 exhibits pharmacokinetics characteristics in SD rats with a half-life 1.86 hours, and an oral bioavailability of 79.22% .
|
-
- HY-P991911
-
|
|
Scavenger Receptor Class B type I (SR-BI）
|
Cancer
|
|
PLT012 is a humanized IgG4 antibody targeting CD36. PLT012 inhibits the lipid-binding domain of CD36. PLT012 blocks CD36-mediated metabolic adaptation in regulatory T cells (Tregs) and CD8 + tumor-infiltrating lymphocytes (TILs), thereby inhibiting tumor growth and shifting the tumor microenvironment from immunosuppressive to immunosupportive. PLT012 reduces intratumoral Tregs, enhances CD8 + T cell infiltration and cytotoxic function, and increases the abundance of progenitor-exhausted T cells. PLT012 exerts robust antitumor activity and synergizes with anti-PD-L1 or standard-of-care regimens (anti-VEGF + anti-PD-L1). PLT012 can be used for hepatocellular carcinoma, colorectal cancer and solid tumor research .
|
-
- HY-178466
-
|
|
Microtubule/Tubulin
P-glycoprotein
Apoptosis
|
Cancer
|
|
Tubulin polymerization/P-gp-IN-1 is a Tubulin polymerization/P-gp dual inhibitor. Tubulin polymerization/P-gp-IN-1 inhibits tubulin polymerization and induces G2/M arrest and apoptosis. Tubulin polymerization/P-gp-IN-1 reverses MDR by inhibiting P-gp efflux function. Tubulin polymerization/P-gp-IN-1 has dual functions: direct antitumor activity and reversal of P-gp-mediated Cisplatin (HY-17394) resistance. Tubulin polymerization/P-gp-IN-1 stable binds to the tubulin CBS (ΔG = −12.4 kcal/mol) and the P-gp hydrophobic lumen (ΔG = −10.8 kcal/mol). Tubulin polymerization/P-gp-IN-1 can be used for the study of drug-resistant cervical cancer .
|
-
- HY-P990953
-
|
Gen1047
|
CD3
|
Cancer
|
|
Zubotamig (Gen1047) is an CD3E/VTCN1-targeting Ig(G1 -κ_G1 -λ2) type chimeric human antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zubotamig induces T-cell mediated cytotoxicity of B7H4-positive tumor cells, triggers T-cell activation, and induces cytokine release from T cells in the presence of B7H4-expressing tumor cells. Zubotamig demonstrates antitumor activity in mouse patient-derived xenograft (PDX) models. Zubotamig can be used for the research of solid cancers (including breast, ovarian and lung cancer) .
|
-
- HY-147858
-
|
|
PROTACs
EGFR
Apoptosis
|
Cancer
|
|
PROTAC EGFR degrader 7 (compound 13b) is a potent and selective CRBN-recruiting PROTAC EGFR L858R/T790M degrader, with a DC50 of 13.2 nM. PROTAC EGFR degrader 7 inhibits NCI–H1975 cells proliferation, with an IC50 of 46.82 nM. PROTAC EGFR degrader 7 significantly induces apoptosis and G2/M phase arrest in NCI–H1975 cell. PROTAC EGFR degrader 7 shows antitumor activity, and can be used for non-small cell lung cancer (NSCLC) research . PROTAC EGFR degrader 7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-154425
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-7-propargyl-7,8-dihydro-8-oxo-9-(beta-D-3-deoxy-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2-Amino-7-propargyl-7,8-dihydro-8-oxo-9-(beta-D-3-deoxy-ribofuranosyl)purine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-N16377
-
|
|
Others
|
Cancer
|
|
1-Butyl-3,5,8-trihydroxy-9,10-anthracenedione (Compound 2) is an anthraquinone analog. 1-Butyl-3,5,8-trihydroxy-9,10-anthracenedione can be isolated from soil Actinomycete Streptomyces. 1-Butyl-3,5,8-trihydroxy-9,10-anthracenedione has potent cytotoxicity against HepG2, A875, BGC-823 and MCF-7 cells with IC50s of 2.29, 4.90, 0.99 and 1.66 μg/mL, respectively. 1-Butyl-3,5,8-trihydroxy-9,10-anthracenedione has an antitumor activity .
|
-
- HY-154310
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,2-Di-O-acetyl-3-azido-3-deoxy-5-O-(4-methyl) benzoyl-L-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 1,2-Di-O-acetyl-3-azido-3-deoxy-5-O-(4-methyl) benzoyl-L-ribofuranose is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-124295
-
|
ABT-301; MPT0E028; TMU-C-0012
|
HDAC
Akt
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Imofinostat (ABT-301; MPT0E028) is an orally active and selective HDAC inhibitor with IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6, respectively. Imofinostat has a weak inhibitory effect on HDAC8 (IC50 of 2.5 μM), but no inhibitory effect on HDAC4 (IC50>10 μM). Imofinostat reduces the viability of B-cell lymphomas by inducing apoptosis and possesses potent direct Akt targeting ability and reduces Akt phosphorylation in B-cell lymphoma. Imofinostat has a broad-spectrum antitumor activity, including colorectal cancer, B-cell lymphoma, non-small cell lung carcinoma (NSCLC), and pancreatic cancer, while also showing therapeutic potential in non-tumor diseases like emphysema and pulmonary fibrosis .
|
-
- HY-154318
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,2-Di-O-acetyl-3-azido-3-deoxy-5-O-(4-methyl)benzoyl-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 1,2-Di-O-acetyl-3-azido-3-deoxy-5-O-(4-methyl)benzoyl-D-ribofuranose is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-154678
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’-Azido-3’-O-benzoyl-5’-O-(m-chlorobenzoyl)-2’-deoxy-2’-fluoro-beta-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 4’-Azido-3’-O-benzoyl-5’-O-(m-chlorobenzoyl)-2’-deoxy-2’-fluoro-beta-D-arabinouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-176428
-
|
P11-2
|
PROTACs
MNK
Apoptosis
Eukaryotic Initiation Factor (eIF)
|
Cancer
|
|
PROTAC MNK1 degrader-1 is a selective MNK1 PROTAC degrader with a DC50 of 11.92 nM, and a Dmax > 96% in MV4-11 cells. PROTAC MNK1 degrader-1 significantly reduces p-eIF4E (IC50: 22.07 nM), induces apoptosis, and arrests the cell cycle at the G1 phase. PROTAC MNK1 degrader-1 has potent antitumor activity. PROTAC MNK1 degrader-1 has robust antileukemic efficacy in MV4-11 xenograft mice model with acceptable drug safety . Pink: MNK1 ligand (HY-176429); Blue: CRBN ligase ligand (HY-A0003); Black: linker (HY-Y1139); CRBN + linker: HY-176430
|
-
- HY-P99974
-
|
Nanoparticle albumin-bound Paclitaxel; Nanoparticle albumin-bound ABI-007
|
Microtubule/Tubulin
Apoptosis
Autophagy
|
Cancer
|
|
Nab-Paclitaxel (Nanoparticle albumin-bound Paclitaxel) is an albumin-bound nanoparticle formulation of Paclitaxel (HY-B0015). Nab-Paclitaxel is composed of albumin and the active pharmaceutical ingredient Paclitaxel, in which human albumin is used as an excipient to disperse and stabilize particles and carry the main drug. Nab-Paclitaxel is a solvent-free taxane with higher response rates and improved tolerability. Nab-Paclitaxel displays less toxicity and greater antitumor activity. Nab-Paclitaxel is more readily available for tumor cell uptake in three rhabdomyosarcoma, seven neuroblastoma cell lines, and one ostersarcoma cell line Nab-Paclitaxel can be studied in cancer research for example breast cancer and solid tumors. (The product specifications below only indicate the effective content of Paditaxel, the actual albumin quality depends on the batch; the ratio of each ingredient in this product is Paditaxel: albumin -1:7~1:11) .
|
-
- HY-154341
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-[2'-O-Acetyl-3'-azido-3'-deoxy-5'-O-toluoyl-b-L-ribofuranosyl)-6-chloropurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 9-[2'-O-Acetyl-3'-azido-3'-deoxy-5'-O-toluoyl-b-L-ribofuranosyl)-6-chloropurine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-13590
-
|
|
VEGFR
|
Cancer
|
|
CEP-7055 (compound 21) is a novel vascular endothelial growth factor R2 (VEGF-R2) tyrosine kinase inhibitor with potent inhibitory activity. Studies have found that the inhibitor activity can be significantly improved by optimizing the R9 substituent. Compound 21 has potent low nanomolar inhibition of human VEGF-R tyrosine kinase and shows good selectivity against multiple tyrosine and serine/threonine kinases. N,N-dimethylglycine ester 40 was prepared to improve its water solubility and oral bioavailability. In animal pharmacokinetic studies, a significant increase in the plasma level of 21 was observed after oral administration of 40. Compound 21 showed significant in vivo antitumor activity in multiple tumor models and has entered phase I clinical trials as a water-soluble N,N-dimethylglycine ester proagent of 40 (CEP-7055).
|
-
- HY-15334
-
|
|
VEGFR
|
Cancer
|
|
CEP-5214, derived from a new indenopyrrolocarbazole template, is a potent inhibitor of vascular endothelial growth factor R2 (VEGF-R2) tyrosine kinase. Structurally, it features optimal substitutions at positions 9 (ethoxymethyl) and 12 (hydroxypropyl) on the indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-one scaffold, leading to high potency against VEGF-R2 (IC50 8 nM). Compound 21 (CEP-5214) exhibits low-nanomolar inhibition of human VEGF-R tyrosine kinases (IC50 4 nM for VEGF-R2/KDR), with good selectivity over other kinases. The compound demonstrated significant cellular and in vivo antitumor activity across various models and advanced into phase I clinical trials as a water-soluble prodrug (CEP-7055) to enhance oral bioavailability .
|
-
- HY-177434
-
|
Precem-TcT; M 9140
|
Antibody-Drug Conjugates (ADCs)
Transmembrane Glycoprotein
Topoisomerase
|
Cancer
|
|
Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonal antibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC .
|
-
- HY-N8146
-
|
|
STAT
Bcl-2 Family
Ser/Thr Kinase
Survivin
c-Myc
Apoptosis
Necroptosis
CDK
|
Infection
Cancer
|
|
Bruceantinol is a quassinoid that can be isolated from Brucea javanica, inhibits pepper mottle virus (PepMoV) in pepper. Bruceantinol is a STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models. Bruceantinol has potent anti-leukemic activity. Bruceantinol strongly inhibits STAT3 DNA-binding ability (IC50 = 2.4 pM), blocks the constitutive and IL-6-induced STAT3 activation, and suppresses transcription of MCL-1, PTTG1, survivin and c-Myc. Bruceantinol binds with CDK2/4/6 to facilitate protein degradation through proteasome pathway. Bruceantinol can dose- and time-dependently reduces the cell growth, impede cell proliferation, disrupts the cell cycle, and induces necrosis in MCF-7 cells and apoptosis in MDA-MB-231 cells .
|
-
- HY-12875
-
|
|
Ras
|
Cancer
|
|
BQU57 is a selective inhibitor of RalA/RalB small GTPases, with a binding potency (Kb) of 7.7 μM for RalB-GDP. BQU57 can block its interaction with effector proteins (such as SEC5 and EXO84), inhibiting tumor cell migration, invasion and non-adherent growth. BQU57 downregulates the NF-κB signaling pathway, reduces the expression of IL-6, IL-8 and MMP-13, and inhibits apoptosis by regulating the Bcl-2/Bax balance. BQU57 also protects the extracellular matrix by inhibiting the Ral/NF-κB pathway and can be used for the study of degenerative diseases. BQU57 exhibits significant antitumor activity in triple-negative breast cancer (TNBC) models, inhibiting orthotopic tumor growth and lung metastasis and enhancing paclitaxel chemotherapy sensitivity .
|
-
- HY-174981
-
|
|
PROTACs
FGFR
ATP Synthase
|
Cancer
|
|
LC-MF-4 is a selective FGFR3 PROTAC degrader with a DC50 of 30.89 nM in KMS-11 cells. LC-MF-4 inhibits the metabolic function of FGFR3-TACC3 fusion positive cancers with reduction of ATP synthesis and inhibition of mitochondrial biogenesis genes. LC-MF-4 has potent antitumor activity in the Ba/F3-FGFR3-TACC3 xenograft mice model. LC-MF-4 can be used for FGFR3-altered cancers like bladder cancer and urothelial carcinoma (UC) research . Pink: FGFR3 ligand (HY-175414); Blue: VHL ligase ligand (HY-125905); Black: linker (HY-Y1224)
|
-
- HY-167854
-
|
|
Aurora Kinase
Apoptosis
IGF-1R
|
Cancer
|
|
KW-2450 Free base is a potent multikinase inhibitor targeting Aurora A and B kinases, demonstrating significant antitumor activity against triple-negative breast cancer (TNBC). KW-2450 Free base effectively reduces cell viability, promotes apoptosis, and inhibits colony formation and mammosphere formation in TNBC cells. KW-2450 Free base significantly suppresses the growth of TNBC xenografts, leading to tetraploid accumulation followed by apoptosis or the survival of octaploid cells. KW-2450 Free base enhances the efficacy of combination therapy with the MEK inhibitor selumetinib, resulting in a synergistic antitumor effect in TNBC models. KW-2450 Free base also acts as an orally bioavailable inhibitor of IGF-1R and IR tyrosine kinases, contributing to its potential antineoplastic activity by inhibiting tumor cell proliferation and inducing apoptosis.
|
-
- HY-174086
-
|
|
Glutathione Peroxidase
Ferroptosis
ROS Kinase
PROTACs
|
Cancer
|
|
PROTAC GPX4 degrader-4 is a GPX4 PROTAC degrader (DC50: 5.32 nM). PROTAC GPX4 degrader-4 inhibits the activity of RT4, T24, and J82 cancer cells (IC50 values are 0.09, 2.97, and 7.58 μM, respectively). PROTAC GPX4 degrader-4 increases lipid ROS levels and induces ferroptosis in T24 and RT4 cells. PROTAC GPX4 degrader-4 has antitumor activity in T24 tumor-bearing BALB/c nude mouse model. PROTAC GPX4 degrader-4 can be used for bladder cancer research. (Pink: target protein ligand (HY-N0193); blue: E3 ligase ligand (HY-1035960); black: linker (HY-W013907); E3 ligase ligand + linker (HY-174087)) .
|
-
- HY-129440R
-
|
|
Reference Standards
PDGFR
ERK
Caspase
NF-κB
Toll-like Receptor (TLR)
p38 MAPK
NO Synthase
COX
MyD88
Reactive Oxygen Species (ROS)
Apoptosis
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
N-(p-Coumaroyl) Serotonin (Standard) is the analytical standard of N-(p-Coumaroyl) Serotonin (HY-129440). This product is intended for research and analytical applications. N-(p-Coumaroyl) Serotonin is an orally active polyphenol found in safflower seeds with potent anti-inflammatory, antioxidant, and antitumor activities. N-(p-Coumaroyl) Serotonin suppresses NF‑κB, TLR4/MyD88 and MAPK signaling, activates NQO1/HO‑1 pathways, and inhibits pro‑inflammatory cytokines, iNOS and COX‑2 and ROS production. N-(p-Coumaroyl) Serotonin induces S‑phase arrest and apoptosis in glioblastoma cells, reduces atherosclerotic lesions, and alleviates renal and vascular injuries. N-(p-Coumaroyl) Serotonin acts as a vasodilator, regulates calcium dynamics. N-(p-Coumaroyl) Serotonin can be used for the research of neurodegenerative diseases, atherosclerosis, glioblastoma, and acute renal failure .
|
-
- HY-181687
-
|
|
HSP
CDK
|
Cancer
|
|
Hsp90-IN-46 is a Hsp90 inhibitor. Hsp90-IN-46 exhibits broad-spectrum antiproliferative activity against tumor cell lines. Hsp90-IN-46 inhibits breast cancer cell proliferation by reducing colony formation and downregulating the proliferation marker Ki-67. Hsp90-IN-46 inhibits Hsp90 and its ATPase activity, downregulates the downstream substrate oncoproteins HER2 and CDK4, and moderately induces the heat shock response. Hsp90-IN-46 shows significant antitumor activity in a mouse model of triple-negative breast cancer tumor xenografts. Hsp90-IN-46 can be used for research on various cancers including triple-negative breast cancer, leukemia, non-small cell lung cancer, colon cancer, ovarian cancer, renal cancer, prostate cancer .
|
-
- HY-157213
-
|
|
Apoptosis
PROTACs
FLT3
|
Cancer
|
|
LWY713 is a PROTAC-class FLT3 degrader (DC50=0.64 nM), which selectively induces FLT3 degradation via cereblon and proteasome-dependent pathways. LWY713 inhibits cell proliferation and induces G0/G1 phase arrest and apoptosis in MV4-11 cells. LWY713 shows effective in vivo antitumor activity in MV4-11 xenograft models . LWY713 consists of a target protein ligand (red part) Gilteritinib (HY-12432), an E3 ubiquitin ligase ligand (blue part) Lenalidomide-F (HY-W039233), and a PROTAC linker (black part) Glycolic acid (HY-W015967). E3 ubiquitin ligase and linker can form Lenalidomide-Glycolic acid (HY-169373); the active control for the target protein ligand is Naproxen Gilteritinib (HY-169374).
|
-
- HY-164490
-
|
|
EGFR
Apoptosis
|
Cancer
|
|
LS-106 is an orally active and potent inhibitor against epidermal growth factor receptor (EGFR) . LS-106 exhibits antitumor activities both in vitro and in vivo. LS-106 inhibits the kinase activities of EGFR 19del/T790M/C797S and EGFR L858R/T790M/C797S with IC50 values of 2.4 nmol/L and 3.1 nmol/L, respectively, which is more potent than Osimertinib (HY-15772). LS-106 induces Apoptosis, suppresses cell proliferation of tumor cells harboring EGFR 19del/T790M/C797S and leas to significant tumor regression in a C797S-mutant xenograft model .
|
-
- HY-176149
-
|
|
CaMK
MMP
AMPK
Apoptosis
Autophagy
|
Cancer
|
|
Fluoxetine-Conjugated Platinum(IV) prodrug-1 (Compound 8) is an eEF2K inhibitor. Fluoxetine-Conjugated Platinum(IV) prodrug-1 inhibits cancer cell proliferation, induces DNA damage, cell cycle arrest at S phase and apoptosis. Fluoxetine-Conjugated Platinum(IV) prodrug-1 induces ROS accumulation and mitochondrial dysfunction. Fluoxetine-Conjugated Platinum(IV) prodrug-1 inhibits TNBC cell migration and invasion by inhibiting MMP-2 activity. Fluoxetine-Conjugated Platinum(IV) prodrug-1 induces autophagy in TNBC cells by activating AMPK. Fluoxetine-Conjugated Platinum(IV) prodrug-1 has antitumor activity and activates immunosuppression in the 4T1-Luc mouse model. Fluoxetine-Conjugated Platinum(IV) prodrug-1 can be used in triple-negative breast cancer (TNBC) research .
|
-
- HY-174396
-
|
|
PI3K
HDAC
Bcl-2 Family
Caspase
Reactive Oxygen Species (ROS)
Apoptosis
Histone Methyltransferase
Microtubule/Tubulin
|
Cancer
|
|
PI3Kδ/HDAC6-IN-1 (Compound 22E) is an orally active and dual inhibitor of PI3Kδ and HDAC6 with IC50 values of 2.4 nM and 6.2 nM, respectively. PI3Kδ/HDAC6-IN-1 exhibits potent antiproliferative effects on non-Hodgkin lymphoma (NHL) cells and possesses in vivo antitumor activity without significant toxicity. PI3Kδ/HDAC6-IN-1 arrests the cell cycle at the G0/G1 phase and induces apoptosis. PI3Kδ/HDAC6-IN-1 blocks the PI3K/AKT/mTOR signaling pathway and increases the acetylation levels of α-tubulin and histone H3 .
|
-
- HY-N15378
-
|
|
IAP
Bcl-2 Family
COX
TNF Receptor
Caspase
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
β-carotene-15,15ʹ-epoxide is a XIAP antagonist with apoptosis-inducing and antitumor activity, found in the leaves of Spondias mombin. In a DMBA (HY-W011845)-induced rat model of breast cancer, β-carotene-15,15ʹ-epoxide binds to the BIR3 domain of the anti-apoptotic protein XIAP, blocking its interaction with caspase-9 and thereby promoting tumor cell apoptosis. In addition, β-carotene-15,15ʹ-epoxide significantly downregulates the expression of BCL-2, COX-2, and TNF-α in tumor tissues, reduces MDA levels, increases catalase activity, and modulates serum levels of LDH, ALP, and ALT, demonstrating strong antioxidant, anti-inflammatory, and metabolic protective effects. β-carotene-15,15ʹ-epoxide may be used in research on inflammation-related conditions and cancers such as breast cancer .
|
-
- HY-N0863
-
|
NSC-698790; Smilax saponin B
|
Bcl-2 Family
Apoptosis
Akt
c-Myc
ERK
p38 MAPK
JNK
FOXO
|
Cancer
|
|
Methyl protodioscin (NSC-698790; Smilax saponin B) is a multi-target, selective, steroidal diglycoside inhibitor with antitumor activity that induces cell cycle arrest. The mechanism of action of Methyl protodioscin is complex, involving the induction of G2/M cell cycle arrest, regulation of the Bcl-2/Bax apoptotic pathway, inhibition of the Akt1/c-Myc axis and MAPK/ERK signaling, while simultaneously downregulating ADAM15 and inducing FOXO1 to reduce cholesterol synthesis. It also inhibits the JNK/c-Jun pathway, reducing the production of inflammatory factors (IL-6, TNF-α). Methyl protodioscin exhibits significant antitumor (inhibiting proliferation, migration, invasion, and inducing apoptosis), anti-inflammatory, and anti-restenosis activities. Methyl protodioscin can be used in research on lung cancer, prostate cancer, pancreatic cancer, and other tumors, as well as inflammatory diseases such as airway inflammation and enteritis .
|
-
- HY-177442
-
|
DS-3939
|
Antibody-Drug Conjugates (ADCs)
Mucin
Topoisomerase
Apoptosis
|
Cancer
|
|
DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers .
|
-
- HY-164392
-
|
|
EGFR
Apoptosis
|
Cancer
|
|
TAS-121 is an orally active, selective, covalent, third-generation mutant EGFR-tyrosine kinase inhibitor (EGFR-TKI). TAS-121 inhibits the L858R mutation (IC50=1.7 nM), Ex19del mutation (IC50=2.7 nM), L858R/T790M mutation (IC50=0.56 nM) and Ex19del/T790M mutation (IC50=1.1 nM) and wild-type EGFR (IC50=8.2 nM). TAS-121 inhibits HER2 and HER4 with IC50s of 110 and 2.6 nM, respectively. TAS-121 inhibits phosphorylation of EGFR and its downstream signaling targets to block cell proliferation. TAS-121 induces apoptosis and displays antitumor activity in SW48 (EGFR G719S) and NCI-H1975 (EGFR L858R/T790M) xenograft models .
|
-
- HY-128586A
-
|
|
NEDD8-activating Enzyme
Carbonic Anhydrase
Apoptosis
|
Cancer
|
|
TAS4464 hydrochloride is a long-acting, highly selective covalent inhibitor targeting NEDD8-activating enzyme (NAE) (IC50=0.955 nM), and also inhibits CAII with an IC50 of 0.73 μM, which is less potent than MLN4924 (HY-70062). The IC50 values of TAS4464 hydrochloride against other E1 enzymes UAE and SAE are 449 nM and 1280 nM, respectively. TAS4464 hydrochloride targets NEDD8 in an ATP-dependent manner to inhibit NAE, blocks the neddylation pathway, causes accumulation of CRL ubiquitin ligase substrates (such as CDT1, p27, phosphorylated IκBα), and further induces tumor cell apoptosis. TAS4464 hydrochloride exhibits antiproliferative and cytotoxic effects, and has broad-spectrum antitumor activity against various hematologic and solid tumor cell lines as well as patient-derived tumor cells. TAS4464 hydrochloride has a wide therapeutic window, without obvious toxicity. TAS4464 hydrochloride can be used in the research of hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.) and solid tumors (small cell lung cancer, colorectal cancer, sarcoma, endometrial cancer, ovarian cancer, etc.) .
|
-
- HY-128586
-
|
|
Apoptosis
Carbonic Anhydrase
NEDD8-activating Enzyme
|
Cancer
|
|
TAS4464 is a long-acting, highly selective covalent inhibitor targeting NEDD8-activating enzyme (NAE) (IC50=0.955 nM), and also inhibits CAII with an IC50 of 0.73 μM, which is less potent than MLN4924 (HY-70062). The IC50 values of TAS4464 against other E1 enzymes UAE and SAE are 449 nM and 1280 nM, respectively. TAS4464 targets NEDD8 in an ATP-dependent manner to inhibit NAE, blocks the neddylation pathway, causes accumulation of CRL ubiquitin ligase substrates (such as CDT1, p27, phosphorylated IκBα), and further induces tumor cell apoptosis. TAS4464 exhibits antiproliferative and cytotoxic effects, and has broad-spectrum antitumor activity against various hematologic and solid tumor cell lines as well as patient-derived tumor cells. TAS4464 has a wide selcetive window, without obvious toxicity. TAS4464 can be used in the research of hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.) and solid tumors (small cell lung cancer, colorectal cancer, sarcoma, endometrial cancer, ovarian cancer, etc.) .
|
-
- HY-109061A
-
|
YH25448 mesylate hydrate; GNS-1480 mesylate hydrate
|
Apoptosis
Akt
TRP Channel
EGFR
ERK
|
Cancer
|
|
Lazertinib (YH25448; GNS-1480) mesylate hydrate is an orally active, blood-brain barrier permeable third-generation EGFR tyrosine kinase inhibitor, as well as an ABCB1/ABCG2 inhibitor and a TRPA1 activator. Lazertinib mesylate hydrate exhibits IC50 values of 0.4 mM and 0.2 mM against human ABCB1 and ABCG2, respectively. By inhibiting mutant EGFR signaling, EGFR phosphorylation and the downstream ERK/AKT pathway, as well as upregulating surface expression of EGFR/MET, Lazertinib mesylate hydrate induces cell cycle arrest, apoptosis, spontaneous calcium responses, hyperexcitability of dorsal root ganglion (DRG) neurons, and TRPA1-dependent pain-like behaviors. Lazertinib mesylate hydrate competitively binds to the substrate-binding sites of ABCB1/ABCG2, stimulates their ATPase activity without altering their expression or plasma membrane localization, thereby enhancing ADCC activity, acting as a chemosensitizer, and reversing ABCB1-mediated multidrug resistance. It exerts antitumor activity as a single agent or in combination with other drugs. Lazertinib mesylate hydrate is applicable to research related to non-small cell lung cancer, multidrug-resistant cancers, and paresthesia .
|
-
- HY-181163
-
|
|
Caspase
COX
Cytochrome P450
Steroid Sulfatase
Apoptosis
|
Cancer
|
|
Caspase-3/7 activator 4 is a caspase-3 activator and caspase-7 activator. Caspase-3/7 activator 4 inhibits key enzymes in estrogen biosynthesis, including aromatase (IC50 = 38.3 nM) and steroid sulfatase (IC50 = 12.7 µM), and selectively suppresses COX-2 (IC50 = 5.38 µM). Caspase-3/7 activator 4 shows strong antioxidant activity (DPPH: IC50 = 16.26 µM). Caspase-3/7 activator 4 inhibits estrogen synthesis, suppresses estrogen availability, reduces prostaglandin production, increases caspase-3/7 expression, induces G0/G1 cell cycle arrest, induces apoptotic cell death, reduces circulating TNF-α and VEGFR-II levels, restores hepatorenal function markers and histoarchitecture, restores antioxidant defense enzyme activity, reduces lipid peroxidation, exerts antiproliferative activity against breast cancer cells, exerts antitumor activity in the Ehrlich ascites carcinoma models. Caspase-3/7 activator 4 can be used for the research of breast cancer, ehrlich ascites carcinoma .
|
-
- HY-109061B
-
|
YH25448 mesylate; GNS-1480 mesylate
|
TRP Channel
EGFR
Akt
ERK
Apoptosis
|
Cancer
|
|
Lazertinib (YH25448; GNS-1480) mesylate is an orally active, blood-brain barrier permeable third-generation EGFR tyrosine kinase inhibitor, as well as an ABCB1/ABCG2 inhibitor and a TRPA1 activator. Lazertinib mesylate exhibits IC50 values of 0.4 mM and 0.2 mM against human ABCB1 and ABCG2, respectively. By inhibiting mutant EGFR signaling, EGFR phosphorylation and the downstream ERK/AKT pathway, as well as upregulating surface expression of EGFR/MET, Lazertinib mesylate induces cell cycle arrest, apoptosis, spontaneous calcium responses, hyperexcitability of dorsal root ganglion (DRG) neurons, and TRPA1-dependent pain-like behaviors. Lazertinib mesylate competitively binds to the substrate-binding sites of ABCB1/ABCG2, stimulates their ATPase activity without altering their expression or plasma membrane localization, thereby enhancing ADCC activity, acting as a chemosensitizer, and reversing ABCB1-mediated multidrug resistance. It exerts antitumor activity as a single agent or in combination with other drugs. Lazertinib mesylate is applicable to research related to non-small cell lung cancer, multidrug-resistant cancers, and paresthesia .
|
-
- HY-109061
-
|
YH25448; GNS-1480
|
Apoptosis
Akt
TRP Channel
EGFR
ERK
|
Infection
Neurological Disease
Metabolic Disease
Cancer
|
|
Lazertinib (YH25448; GNS-1480) is an orally active, blood-brain barrier permeable third-generation EGFR tyrosine kinase inhibitor, as well as an ABCB1/ABCG2 inhibitor and a TRPA1 activator. Lazertinib exhibits IC50 values of 0.4 mM and 0.2 mM against human ABCB1 and ABCG2, respectively. By inhibiting mutant EGFR signaling, EGFR phosphorylation and the downstream ERK/AKT pathway, as well as upregulating surface expression of EGFR/MET, Lazertinib induces cell cycle arrest, apoptosis, spontaneous calcium responses, hyperexcitability of dorsal root ganglion (DRG) neurons, and TRPA1-dependent pain-like behaviors. Lazertinib competitively binds to the substrate-binding sites of ABCB1/ABCG2, stimulates their ATPase activity without altering their expression or plasma membrane localization, thereby enhancing ADCC activity, acting as a chemosensitizer, and reversing ABCB1-mediated multidrug resistance. It exerts antitumor activity as a single agent or in combination with other drugs. Lazertinib is applicable to research related to non-small cell lung cancer, multidrug-resistant cancers, and paresthesia .
|
-
- HY-170576
-
|
|
FLT3
STAT
Apoptosis
|
Cancer
|
|
FLT3-IN-28 (Compound 12y) is an orally active FLT3 inhibitor with antitumor activity. FLT3-IN-28 selectively inhibits cancer cells harboring the FLT3 internal tandem duplication (ITD) mutation, with IC50 values of 85, 290, 130, 65, and 220 nM for BaF3-FLT3-ITD, BaF3-TEL-VEGFR2, MV4-11, MOLM-13, and MOLM-14 cell lines respectively (MV4-11 and MOLM-13/14 are acute myeloid leukemia (AML) cell lines carrying the FLT3-ITD mutation). Additionally, FLT3-IN-28 can downregulate the phosphorylation levels of FLT3 and STAT5 in MOLM-13 cells and induce cell cycle arrest and Apoptosis. FLT3-IN-28 has an oral bioavailability of 19.2% in SD rats and can prolong survival in a dose-dependent manner in NSG mice xenografted with MOLM-13 cells. FLT3-IN-28 holds promise for research in cancer fields related to FLT3-ITD .
|
-
- HY-173119
-
|
|
ERK
Autophagy
Apoptosis
p62
mTOR
Reactive Oxygen Species (ROS)
Ferroptosis
|
Cancer
|
|
SKLB-D18 is an orally active ERK1/2/ERK5 inhibitor, with an IC50 of 38.69 nM and a Kd of 126.9 nM against human ERK1, an IC50 of 40.12 nM and a Kd of 209.8 nM against ERK2, and an IC50 of 59.72 nM and a Kd of 468.2 nM against ERK5. SKLB-D18 inhibits cancer cell proliferation, induces G0/G1 cell cycle arrest and apoptosis. SKLB-D18 reduces the levels of p-ERK5, p-RSKp90, p-c-Myc and c-Myc, and upregulates the level of p-ERK1/2, thereby inhibiting the ERK1/2/5 pathway in cells. SKLB-D18 increases LC3B-II accumulation, and decreases the levels of p62, p-mTOR and p-p70S6K. SKLB-D18 elevates the levels of ROS, lipid peroxidation and free ferrous ions, reduces the levels of NCOA4 and GPX4, and induces ferritin autophagy-dependent ferroptosis in cancer cells. SKLB-D18 exhibits antitumor activity in a triple-negative breast cancer xenograft mouse model. SKLB-D18 can be used in research related to triple-negative breast cancer .
|
-
- HY-178172
-
|
|
Histone Methyltransferase
c-Myc
Epigenetic Reader Domain
HOXA
|
Cancer
|
|
AF9/ENL-DOT1L/AF4 PPI-IN-1 is a potent AF9/ENL and histone methyltransferase DOT1L/AF4 protein-protein interactions (PPI) inhibitor. AF9/ENL-DOT1L/AF4 PPI-IN-1 can inhibit the AF9-DOT1L (IC50 = 1.5 μM), AF9-AF4 (IC50 = 1 μM), ENL-AF4 (IC50 = 1.2 μM) interactions. AF9/ENL-DOT1L/AF4 PPI-IN-1 can suppress the expression of Mixed lineage leukemia (MLL) target genes Myc and Meis1 and selectively block the proliferation of MLL-r and several other leukemia cells. AF9/ENL-DOT1L/AF4 PPI-IN-1 exhibits significant antitumor activities in a mouse model of MLL-r leukemia without overt toxicities. AF9/ENL-DOT1L/AF4 PPI-IN-1 can be used for the study of MLL-r leukemia .
|
-
- HY-116538
-
|
trans-10,cis-12 CLA2
|
Endogenous Metabolite
PPAR
NF-κB
Stearoyl-CoA Desaturase (SCD)
Lipase
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
(10E,12Z)-Octadeca-10,12-dienoic acid (trans-10,cis-12 CLA2) is an orally active PPARα activator and inhibits adipocyte differentiation. (10E,12Z)-Octadeca-10,12-dienoic acid and its downstream metabolites have various antioxidant and antitumor activities. (10E,12Z)-Octadeca-10,12-dienoic acid can induce proinflammatory cytokines and chemokines, which would lead to decreased adipogenesis and insulin resistance in adipose tissue. (10E,12Z)-Octadeca-10,12-dienoic acid can affect many aspects of milk fat synthesis. (10E,12Z)-Octadeca-10,12-dienoic acid reduces expression of lipogenic enzymes and inhibits the desaturation of fatty acids. (10E,12Z)-Octadeca-10,12-dienoic acid can reduce lipoprotein lipase (LPL) activity in cultured 3T3-L1 adipocytes and enhance triacylglycerol release from these cells. (10E,12Z)-Octadeca-10,12-dienoic acid decreases the expression of hepatic stearoyl-CoA desatyrase mRNA in mice. (10E,12Z)-Octadeca-10,12-dienoic acid is associated with changes in mucosal NF-κB and Cyclin D1 protein levels in mice .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D0214
-
|
|
Fluorescent Dyes
|
|
Acid Red 94 sodium, a synthetic fluorescein derivative, is a deep red dye primarily composed of 4,5,6,7-tetrachloro-2,4,5,7-tetraiodo fluorescein. It is widely used as an ophthalmic diagnostic agent to detect dry or damaged cells on the ocular surface. Acid Red 94 sodium exhibits antitumor activity and can inhibit Friend Leukemia Virus (FLV) infection through photodynamic action. Additionally, Acid Red 94 sodium can inhibit Aβ aggregation through light irradiation. Acid Red 94 sodium holds potential for use in cancer, viral infections, and neurodegenerative disease research .
|
-
- HY-P3371
-
|
DS-7300a; MABX-9001a; I-DXd
|
Fluorescent Dyes
|
|
Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects
|
-
- HY-141601
-
|
ABBV-399
|
Fluorescent Dyes
|
|
Telisotuzumab vedotin (ABBV-399) (Teliso-V) is an anti-c-Met antibody-drug conjugate. Telisotuzumab vedotin consists of an anti-c-Met monoclonal antibody Telisotuzumab (ABT-700) (HY-P99391) and Monomethyl Auristatin E (HY-15162). Telisotuzumab vedotin exerts antitumor activity with acceptable toxicity in vivo. Telisotuzumab vedotin can be used for non-small cell lung cancer (NSCLC) research .
|
-
- HY-15096
-
MKT-077
Maximum Cited Publications
16 Publications Verification
FJ-776
|
Fluorescent Dyes
|
|
MKT-077 (FJ-776), a highly water-soluble mitochondrial dye, has significant antitumor activity . MKT-077 exhibits low cytotoxicity, and inhibits broad-spectrum human cancer cell lines (colon cancer, breast cancer, pancreatic cancer). MKT-077 inhibits the growth of tumor in nude mice enograft tumor model. Ex/Em=488/543 nm .
|
-
- HY-171135
-
|
|
Fluorescent Dyes
|
|
Cetuximab MMAE is an antibody-drug conjugate (ADC) consisting of the EGFR-targeting humanized monoclonal antibody Cetuximab (HY-P9905) conjugated to VcMMAE (HY-15575). Cetuximab MMAE exhibits antitumor activity .
|
-
- HY-177434
-
|
Precem-TcT; M 9140
|
Fluorescent Dyes
|
|
Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonal antibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC .
|
-
- HY-177442
-
|
DS-3939
|
Fluorescent Dyes
|
|
DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers .
|
-
- HY-D0162
-
|
MCCK1
|
Fluorescent Dyes
|
|
Malachite green hemioxalate (MCCK1) is a triphenylmethane dye which can be used to detect the release of phosphate in enzymatic reactions. Malachite green hemioxalate has antibacterial activity, which is attributed to inhibition of intracellular enzymes, insertion into DNA and/or interaction with cell membranes. Malachite green hemioxalate is also a potent and selective inhibitor of IKBKE, and inhibits its downstream targets such as IκBα, p65 and IRF3. Malachite green hemioxalate exhibits antitumor activity in vitro and in vivo .
|
-
- HY-171747
-
|
|
Fluorescent Dyes
|
|
AMT-562 is an antibody-drug conjugate (ADC) consisting of a novel anti-HER3 antibody Ab562 (HY-P991505) conjugated to the linker MC-VA-PAB and the topoisomerase I inhibitor Exatecan (HY-13631). The ADC toxic molecule and linker portion are MC-VA-PAB-Exatecan (HY-147270). AMT-562 can induce apoptosis and has antitumor activity against pancreatic, esophageal, and gastric cancers .
|
-
- HY-111783G
-
|
|
Fluorescent Dyes
|
|
AZD-7648 (GMP) is AZD-7648 (HY-111783) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AZD-7648 is a potent, orally active, selective DNA-PK inhibitor with an IC50 of 0.6 nM. AZD-7648 induces apoptosis and shows antitumor activity .
|
-
- HY-159642G
-
|
TYRA-300
|
Fluorescent Dyes
|
|
Dabogratinib (TYRA-300) (GMP) is Dabogratinib (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .
|
-
- HY-128952G
-
|
SG3249
|
Fluorescent Dyes
|
|
Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .
|
-
- HY-D2095
-
|
|
Fluorescent Dyes
|
|
Medical fluorophore 33 is a novel quinoline-isoquinoline salt. Medical fluorophore 33 exhibits a strong fluorescent signal, good microsomal stability and high biocompatibility in vivo. Medical fluorophore 33 has antitumor activity in colorectal cancer mice .
|
-
- HY-B0342GL
-
|
Methylglucamine (GMP Like); Meglumin (GMP Like); Methylglucamin (GMP Like)
|
Fluorescent Dyes
|
|
Meglumine (GMP Like) (Methylglucamine (GMP Like)) is the GMP Like class Meglumine (HY-B0342) that can be used as pharmaceutical excipients. Meglumine (Methylglucamine) is an orally active amino sugar derived from sorbitol. Meglumine has anti-inflammatory and antitumor activity. Meglumine is often used as an excipient in active molecules and with iodinated compounds in contrast agents such as meglumine and meglumine iodide .
|
-
- HY-15794G
-
|
Methoxymorpholinyl doxorubicin; FCE 23762; PNU 152243
|
Fluorescent Dyes
|
|
Nemorubicin (Methoxymorpholinyl doxorubicin) GMP is a GMP-class Nemorubicin (HY-15794). Nemorubicin is a Doxorubicin derivative with potent antitumor activity. Nemorubicin is highly cytotoxic to a variety of tumor cell lines presenting a multidrug-resistant phenotype. Nemorubicin not only intercalate into the duplex DNA, but also result in significant ligands for G-quadruplex DNA segments, stabilizing their structure. Nemorubicin requirs an intact nucleotide excision repair (NER) system to exert its activity .
|
-
- HY-D2380
-
|
|
Fluorescent Dyes
|
|
H2S probe 1 (compound 1NND) is a derivative of nitrobenzoxadiazole (NBD) with antitumor activity. H2S probe 1 is cytotoxic to human pancreatic cancer cell MIA PaCa-2 (IC50=77.9 nM) and has a high affinity for human telomeric G-quadruplex (G4) (Kd=1.72 μM). H2S probe 1 can be used in cancer research .
|
-
- HY-D0162R
-
|
MCCK1 (Standard)
|
Fluorescent Dyes
|
|
Malachite green hemioxalate (Standard) is the analytical standard of Malachite green hemioxalate (HY-D0162). This product is intended for research and analytical applications. Malachite green hemioxalate is a triphenylmethane dye which can be used to detect the release of phosphate in enzymatic reactions. Malachite green hemioxalate has antimicrobial activity, which is attributed to inhibition of intracellular enzymes, intercalation into DNA, and/or interaction with cellular membranes. Malachite green hemioxalate is also a potent and selective inhibitor of IKBKE, and inhibits its downstream targets such as IκBα, p65 and IRF3. Malachite green hemioxalate exhibits antitumor activity in vitro and in vivo.
|
-
- HY-10181GL
-
|
BMS-354825 (GMP Like)
|
Fluorescent Dyes
|
|
Dasatinib (GMP Like) (BMS-354825 (GMP Like)) is Dasatinib (HY-10181) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib also induces apoptosis and autophagy.
|
-
- HY-D0214E
-
|
|
Fluorescent Dyes
|
|
Acid Red 94 sodium (80%), a synthetic fluorescein derivative, is a deep red dye primarily composed of 4,5,6,7-tetrachloro-2,4,5,7-tetraiodo fluorescein. Acid Red 94 sodium (80%) is widely used as an ophthalmic diagnostic agent to detect dry or damaged cells on the ocular surface. Acid Red 94 sodium (80%) exhibits antitumor activity and can inhibit Friend Leukemia Virus (FLV) infection through photodynamic action. Additionally, Acid Red 94 sodium (80%) can inhibit Aβ aggregation through light irradiation. Acid Red 94 sodium (80%) holds potential for use in cancer, viral infections, and neurodegenerative disease research .
|
| Cat. No. |
Product Name |
Type |
-
- HY-143692
-
|
|
Biochemical Assay Reagents
|
|
SQDG inhibits topoisomerase I and P-selectin receptor, exhibits anti-inflammatory, antiviral and antitumor activities. SQDG is a glycolipid that possesses sugar moieties in their head groups. SQDG is a membrane lipid that can be used to investigate the effects of structural lipid in LNP formulations .
|
-
- HY-111783G
-
|
|
Biochemical Assay Reagents
|
|
AZD-7648 (GMP) is AZD-7648 (HY-111783) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AZD-7648 is a potent, orally active, selective DNA-PK inhibitor with an IC50 of 0.6 nM. AZD-7648 induces apoptosis and shows antitumor activity .
|
-
- HY-W001925
-
|
|
Biochemical Assay Reagents
|
|
7-Methoxy-1-tetralone is a potent antitumor agent. 7-Methoxy-1-tetralone inhibits cancer cell proliferation and migration, and induces hepatocellular carcinoma cell (HCC) apoptosis. 7-Methoxy-1-tetralone decreased the protein levels of NF-κB, matrix metallopeptidase 2 (MMP2)/MMP9, and p-AKT. 7-Methoxy-1-tetralone showed antitumor activity in nude mice and had no effect on body weight and liver, spleen and organ index .
|
-
- HY-159642G
-
|
TYRA-300
|
Biochemical Assay Reagents
|
|
Dabogratinib (TYRA-300) (GMP) is Dabogratinib (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .
|
-
- HY-172497
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .
|
-
- HY-128952G
-
|
SG3249
|
Biochemical Assay Reagents
|
|
Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .
|
-
- HY-W052750
-
|
|
Biochemical Assay Reagents
|
|
5-Carboxy-2-thiouracil is a compound with antitumor activity that can form complexes with metal ions, thereby exhibiting significant biological effects.
|
-
- HY-172496
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .
|
-
- HY-172498
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .
|
-
- HY-172497A
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG3400-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG3400-CREKA can be used for drug delivery .
|
-
- HY-172280C
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG3400-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG3400-Octreotide can be used for drug delivery .
|
-
- HY-172280B
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG5000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG5000-Octreotide can be used for drug delivery .
|
-
- HY-172280A
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG21000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG2000-Octreotide can be used for drug delivery .
|
-
- HY-B0342GL
-
|
Methylglucamine (GMP Like); Meglumin (GMP Like); Methylglucamin (GMP Like)
|
Biochemical Assay Reagents
|
|
Meglumine (GMP Like) (Methylglucamine (GMP Like)) is the GMP Like class Meglumine (HY-B0342) that can be used as pharmaceutical excipients. Meglumine (Methylglucamine) is an orally active amino sugar derived from sorbitol. Meglumine has anti-inflammatory and antitumor activity. Meglumine is often used as an excipient in active molecules and with iodinated compounds in contrast agents such as meglumine and meglumine iodide .
|
-
- HY-15794G
-
|
Methoxymorpholinyl doxorubicin; FCE 23762; PNU 152243
|
Biochemical Assay Reagents
|
|
Nemorubicin (Methoxymorpholinyl doxorubicin) GMP is a GMP-class Nemorubicin (HY-15794). Nemorubicin is a Doxorubicin derivative with potent antitumor activity. Nemorubicin is highly cytotoxic to a variety of tumor cell lines presenting a multidrug-resistant phenotype. Nemorubicin not only intercalate into the duplex DNA, but also result in significant ligands for G-quadruplex DNA segments, stabilizing their structure. Nemorubicin requirs an intact nucleotide excision repair (NER) system to exert its activity .
|
-
- HY-172280
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG1000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG1000-Octreotide can be used for drug delivery .
|
-
- HY-10181GL
-
|
BMS-354825 (GMP Like)
|
Biochemical Assay Reagents
|
|
Dasatinib (GMP Like) (BMS-354825 (GMP Like)) is Dasatinib (HY-10181) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib also induces apoptosis and autophagy.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P0036
-
Octreotide
Maximum Cited Publications
16 Publications Verification
SMS 201-995
|
Somatostatin Receptor
Apoptosis
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .
|
-
- HY-P2322
-
-
- HY-P2657
-
|
|
HIF/HIF Prolyl-Hydroxylase
Proton Pump
Endogenous Metabolite
|
Cancer
|
|
Verucopeptin is a potent HIF-1 (IC50=0.22 μM) inhibitor and decreases the expression of HIF-1 target genes and HIF-1α protein levels. Verucopeptin strongly inhibits v-ATPase activity by directly targeting the v-ATPase ATP6V1G subunit but not ATP1V1B2 or ATP6V1D. Verucopeptin exhibits antitumor activity against multidrug resistance (MDR) cancers and can be used for cancer research.
|
-
- HY-P1613A
-
|
Cyclo(RGDfV) TFA; C(RGDfV) TFA
|
Integrin
Apoptosis
|
Cancer
|
|
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .
|
-
- HY-P10762
-
|
CBP-1008; LDC 10B
|
Peptide-Drug Conjugates (PDCs)
Folate Receptor (FR)
TRP Channel
|
Cancer
|
|
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .
|
-
- HY-P10201A
-
|
|
STAT
|
Cancer
|
|
Ac-GpYLPQTV-NH2 acetate is a STAT3 inhibitor with an IC50 value of 0.33 μM. Ac-GpYLPQTV-NH2 acetate has antitumor activity .
|
-
- HY-P1791
-
|
Lactoferricin B; Lfcin B
|
Bacterial
Fungal
Apoptosis
|
Infection
Cancer
|
|
Lactoferrin 17-41 (Lactoferricin B), a peptide corresponding to residues 17-41 of bovine lactoferrin, has antimicrobial activity against a wide range of microorganisms, including Gram-positive and Gramnegative bacteria, viruses, protozoa, and fungi. Lactoferrin 17-41 has antitumor activities .
|
-
- HY-N6748
-
-
- HY-P1812
-
AUNP-12
3 Publications Verification
NP-12
|
PD-1/PD-L1
|
Cancer
|
|
AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .
|
-
- HY-105019
-
|
Melphalan flufenamide
|
DNA Alkylator/Crosslinker
Apoptosis
|
Cancer
|
|
Melflufen (Melphalan flufenamide), a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen induces irreversible DNA damage and cytotoxicity in MM cells .
|
-
- HY-P1791B
-
|
Lactoferricin B acetate; Lfcin B acetate
|
Bacterial
Fungal
Apoptosis
|
Infection
Cancer
|
|
Lactoferrin 17-41 (Lactoferricin B) acetate, a peptide corresponding to residues 17-41 of bovine lactoferrin, has antimicrobial activity against a wide range of microorganisms, including Gram-positive and Gramnegative bacteria, viruses, protozoa, and fungi. Lactoferrin 17-41 acetate has antitumor activities .
|
-
- HY-P2282
-
|
|
STAT
|
Cancer
|
|
APTSTAT3-9R, a specific STAT3-binding peptide, inhibits STAT3 activation and downstream signaling by specifically blocking STAT3 phosphorylation. APTSTAT3-9R exerts antiproliferative effects and antitumor activity .
|
-
- HY-P1755
-
|
|
MDM-2/p53
|
Cancer
|
|
p53 (17-26) is a peptide derived from the P53 MDM2 binding domain, with a Kd of 50 nM for MDM2. p53 (17-26) causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) exhibits antitumor activity and is applicable to research related to pancreatic cancer .
|
-
- HY-P10950A
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
PD-L1 inhibitory peptide TFA is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide TFA binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide TFA is promising for research of cancers .
|
-
- HY-P10201
-
|
|
STAT
|
Cancer
|
|
Ac-GpYLPQTV-NH2 is a STAT3 inhibitor with an IC50 value of 0.33 μM. Ac-GpYLPQTV-NH2 has antitumor activity .
|
-
- HY-P11211A
-
|
|
Bacterial
|
Infection
Cancer
|
|
D2A21 TFA is an antimicrobial peptide with significant antimicrobial activity against Pseudomonas and bactericidal effect on burn scabs. D2A21 TFA has antitumor activity and can be used in prostate cancer research .
|
-
- HY-P10709A
-
|
|
Biochemical Assay Reagents
|
Cardiovascular Disease
Cancer
|
|
CREKA peptide acetate is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. CREKA peptide acetate can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .
|
-
- HY-106263B
-
|
|
PTEN
PDK-1
MDM-2/p53
Apoptosis
Akt
|
Cancer
|
|
Tyroserleutide hydrochloride is a tripeptide isolated from the degradation products of porcine spleen with antitumor activity. Tyroserleutide hydrochloride can upregulate the expression of the tumor suppressor gene PTEN and inhibit the activity of AKT and PDK1. Tyroserleutide hydrochloride inhibits tumor cell proliferation and MDM2 phosphorylation by inhibiting the PI3K/AKT pathway, and also upregulates P21, P27, P53, and induces mitochondrial damage and cell apoptosis .
|
-
- HY-P10841
-
|
|
Amino Acid Derivatives
|
Cancer
|
|
CyPep-1 is a novel cationic lytic peptide with antitumor activity. CyPep-1 is highly cytotoxic by interacting with the negatively charged cell membrane of cancer cells. CyPep-1 has strong cytolytic activity on cancer cells both in vivo and in vitro, and can be used in the study of solid tumors .
|
-
- HY-P0036A
-
|
SMS 201-995 dihydrochloride
|
Somatostatin Receptor
Apoptosis
|
Inflammation/Immunology
Endocrinology
Cancer
|
|
Octreotide (SMS 201-995) hydrochloride is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide hydrochloride can bind to the somatostatin receptors which are mainly subtypes 2, 3 and 5. Octreotide hydrochloride increases Gi activity and reduces intracellular cAMP production. Octreotide hydrochloride has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .
|
-
- HY-P3116
-
|
|
Bacterial
|
Cancer
|
|
Thiocoraline is a depsipeptide that can be isolated by marine Micromonospora. Thiocoraline has antitumor activity with IC50s of 0.002, 0.002, 0.01 and 0.002 μg/mL in P388, A549, HT-29 and MEL-28 cells, respectively. Thiocoraline also a strong antimicrobial activity against Gram-positive microorganisms .
|
-
- HY-P11097
-
|
|
CD47
|
Cancer
|
|
Pep-20 is a CD47/SIRPα blocking peptide with KD values of 2.91 and 3.63 μM for human and mouse CD47, respectively. IC50 values for blocking the human and mouse CD47/SIRPα interaction are 24.56 and 12.03 μM, respectively. Pep-20 has antitumor activity .
|
-
- HY-P10950
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
PD-L1 inhibitory peptide is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide is promising for research of cancers .
|
-
- HY-P1755F
-
|
|
MDM-2/p53
|
Cancer
|
|
p53 (17-26), FITC labeled is a biological active peptide. p53 (17-26) is a peptide derived from the P53 MDM2 binding domain, with a Kd of 50 nM for MDM2. p53 (17-26) causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) exhibits antitumor activity and is applicable to research related to pancreatic cancer.
|
-
- HY-P1613
-
|
Cyclo(RGDfV); C(RGDfV)
|
Integrin
Apoptosis
|
Cancer
|
|
Cyclo(Arg-Gly-Asp-D-Phe-Val) (Cyclo(RGDfV)) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia .
|
-
- HY-P1755A
-
|
|
MDM-2/p53
|
Cancer
|
|
p53 (17-26) acetate is a peptide derived from the P53 MDM2 binding domain, with a Kd of 50 nM for MDM2. p53 (17-26) acetate causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) acetate exhibits antitumor activity and is applicable to research related to pancreatic cancer .
|
-
- HY-P10847
-
|
|
Ras
|
Cancer
|
|
KS-58 is a KRpep-2d (HY-P3277) derivative. KS-58 is a K-Ras (G12D) inhibitory peptide that selectively binds K-Ras. KS-58 can enter cells and block intracellular Ras interaction with effector proteins. KS-58 inhibits the proliferation of tumor cells and has antitumor activity .
|
-
- HY-P10994
-
|
Eps8(327-335)
|
EGFR
IFNAR
Interleukin Related
TNF Receptor
Complement System
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Eps8 peptide 327 is an HLA-A*2402-restricted peptide antigen derived from Eps8 protein. Eps8 peptide 327 has potent antitumor activity with significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cells proliferation, induces apoptosis and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. Eps8 peptide 327 significantly inhibits tumor growth in HT-29 xenograft mcie models .
|
-
- HY-131374
-
|
|
CXCR
|
Cancer
|
|
TN14003 is a CXCR4 inhibitor. TN14003 has antitumor activity .
|
-
- HY-P10951
-
|
(R)-PSMA I&T; (R)-PNT-2002
|
PSMA
|
Cancer
|
|
Zadavotide guraxetan (PSMA I&T; PNT-2002) is a prostate-specific membrane antigen (PSMA) inhibitor. Zadavotide guraxetan has antitumor activity and can be used in prostate cancer-targeted research .
|
-
- HY-169232
-
|
|
PROTACs
|
Cancer
|
|
PCC16 chloride is a CRBN-based cp-PCC with an IC50 value of 102 nM for the degradation of DHHC3. PCC16 chloride has antitumor activity. (Target protein ligand: HY-169235, linker: HY-169236, E3 ligase ligand: HY-10984) .
|
-
- HY-P5702
-
|
|
Bacterial
Apoptosis
Fungal
|
Infection
|
|
EP3 is an antimicrobial peptide. EP3 has antibacterial and antifungal activities. EP3 inhibits E. gallinarum, P. pyocyanea, A. baumanii, K. terrigena with a MIC value of 12.85 μg/mL. EP3 also shows antitumor activity against cancer cells, and induces cell apoptosis .
|
-
- HY-P0036B
-
|
SMS 201-995 pamoate
|
Somatostatin Receptor
Apoptosis
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Octreotide (SMS 201-995) pamoate is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide pamoate can bind to the somatostatin receptors which are mainly subtypes 2, 3 and 5. Octreotide pamoate increases Gi activity and reduces intracellular cAMP production. Octreotide pamoate has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .
|
-
- HY-P1812A
-
|
NP-12 TFA
|
PD-1/PD-L1
|
Cancer
|
|
AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .
|
-
- HY-P11076
-
|
|
Complement System
|
Cancer
|
|
CP-EPS8-NLS is a peptide with anti-AML property. CP-EPS8-NLS interferes with EPS8-associated signaling and exerts anti-AML activity in various AML cell types. CP-EPS8-NLS has potent antitumor activity in xenograft tumor models. CP-EPS8-NLS downregulates EPS8 expression and its downstream pathway .
|
-
- HY-P10992
-
|
|
PI3K
Akt
mTOR
Caspase
Apoptosis
Bcl-2 Family
|
Cancer
|
|
YVPGP is an oligopeptide exacted from Anthopleura anjunae. YVPGP has a significant antitumor activity by mediating PI3K/AKT/mTOR signaling pathway. YVPGP arrests DU-145 cells in the S phase and induces apoptosis via mitochondrial and death receptor pathways (caspase3, 7, 8, 9). YVPGP effectively inhibits tumor growth in DU-145 xenografts mice model, promising for prostate cancer research .
|
-
- HY-P2157
-
|
|
Ras
|
Cancer
|
|
Ras Inhibitory Peptide (VPPPVPPRRR) is a Ras inhibitor with antitumor activity .
|
-
- HY-136728
-
|
|
Caspase
|
Cancer
|
|
Ac-YVAD-AOM is the inhibitor of caspase-1 that shows antitumor activity .
|
-
- HY-P5955
-
|
|
Caspase
|
Cancer
|
|
Ac-AAVALLPAVLLALLAP-LEVD-CHO is a cell-permeable caspase-4 inhibitor that has antitumor activity .
|
-
- HY-P5938
-
|
|
Caspase
|
Cancer
|
|
Ac-AAVALLPAVLLALLAP-YVAD-CHO is a cell-permeable caspase-1 inhibitor that has antitumor activity .
|
-
- HY-P1808
-
|
|
GnRH Receptor
|
Cancer
|
|
LGnRH-III, lamprey, an isoform of GnRH isolated from the sea lamprey, is a weak GnRH agonist with antitumor activities .
|
-
- HY-P10418
-
|
|
c-Myc
|
Cancer
|
|
VGN50 is a bioactive molecule that mimics the function of K-Rta and down-regulates MYC-mediated gene transcription. VGN50 has antitumor activity .
|
-
- HY-P10656
-
|
|
Apoptosis
Pyroptosis
|
Cancer
|
|
Ac-DEVDD-TPP is a porphyrin derivative that can be converted into D-TPP by caspase-3 cleavage and laser irradiation. The formed porphyrin nanofibers can effectively induce Apoptosis and Pyroptosis. Ac-DEVDD-TPP has antitumor activity .
|
-
- HY-P10705
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
KGFRWR is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. KGFRWR can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .
|
-
- HY-P10286
-
|
|
MDM-2/p53
|
Cancer
|
|
Phage-derived 12/1 peptide exhibits antitumor activity by targeting MDM2 and MDMX, an thus disrupt the MDM2-p53 and MDMX-p53 interaction, with IC50 of 0.15 and 1.25 μM .
|
-
- HY-P3627
-
|
|
Drug Derivative
|
Cancer
|
|
Nagrestipen, a human macrophage inflammatory protein-1 alpha (MIP-1α) variant, also known as ECI 301. Nagrestipen has antitumor activity and can be used in therapeutic trials to study cancer, tumors, metastases, radiation oncology, and tumor metastasis .
|
-
- HY-P5703
-
|
|
Bacterial
Apoptosis
Fungal
|
Infection
|
|
EP5-1 is an antimicrobial peptide. EP5-1 has antibacterial and antifungal activities. EP5-1 also shows antitumor activity against cancer cells, and induces cell apoptosis. EP5-1 has antiviral activity against pseudorabies virus (PRV) .
|
-
- HY-P10511
-
|
|
Apoptosis
|
Infection
Cancer
|
|
Pantinin-3 is an antimicrobial peptide with antitumor activity found in the venom of the emperor scorpion (Pandinus imperator). Pantinin-3 shows selective toxicity against breast cancer cells (MDA-MB-231) and prostate cancer cells (DU-145). Pantinin-3 can induce apoptosis in tumor cells. Pantinin-3 can be used in cancer research .
|
-
- HY-P10513
-
|
AP1-Z1
|
Bacterial
Fungal
Apoptosis
|
Infection
Cancer
|
|
AcrAP1 (AP1-Z1) is an antimicrobial peptide found in the venom of the Arabian scorpion (Androctonus crassicauda). AcrAP1 has antimicrobial activity and can inhibit the growth of Gram-positive and Gram-negative bacteria as well as yeast. AcrAP1 exerts antitumor activity by promoting apoptosis of cancer cells and inhibiting angiogenesis. AcrAP1 can be used in cancer therapy research .
|
-
- HY-P10596
-
|
|
Bacterial
Fungal
|
Infection
Cancer
|
|
Lasioglossin-III is an antimicrobial peptide that can be isolated from the venom of wild bees. Lasioglossin-III has high antibacterial activity against Gram-positive and Gram-negative bacteria, antifungal activity and antitumor activity. Lasioglossin-III has certain cytotoxicity against three cancer cell lines (HeLa S3, CRC SW 480 and CCRF-CEM T) with IC50 values of 4, 18 and 5 μM, respectively .
|
- HY-P11182
-
|
|
Bacterial
|
Infection
Cancer
|
|
ChMAP-28 is an antimicrobial peptide. ChMAP-28 can be derived from goat Capra hircus. ChMAP-28 can initiate necrotic death. ChMAP-28 is effective in killing many bacteria, including strains resistant to Polymyxin and Meropenem (HY-13678). ChMAP-28 shows antitumor activity against acute promyelocytic leukemia, epidermoid carcinoma, melanoma, breast adenocarcinoma .
|
- HY-P10995
-
|
|
EGFR
IFNAR
Interleukin Related
TNF Receptor
Complement System
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
TAT-327 is cell-penetrating peptide. TAT-327 selectively inserts into cancer cell membranes and shows potent antitumor activity. TAT-327 effectively inhibits cancer cells proliferation, induces apoptosis and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. TAT-327 significantly inhibits tumor growth in HT-29 xenograft mcie models .
|
- HY-P10521
-
|
|
VEGFR
|
Cancer
|
|
Apolipoprotein KV domain (67-77) is an 11-amino acid peptide identified from the KV domain of human apolipoprotein a (ApoA) with antiangiogenic and antitumor activities. Apolipoprotein KV domain (67-77) targets the angiogenic c-Src/ERK pathway by blocking activation signals received from vascular endothelial growth factor (VEGF). Apolipoprotein KV domain (67-77) can be used in cancer research .
|
- HY-P11658
-
|
Peptoid 1
|
Peptides
|
Cancer
|
|
Anticancer peptoid 1 (Peptoid 1) is a peptoid with antitumor activity. Anticancer peptoid 1 exerts cytotoxicity primarily via plasma membrane damage. Anticancer peptoid 1 exerts cytotoxicity against a broad range of cancer cell lines, including those with multidrug resistance. Anticancer peptoid 1 inhibits tumor growth in a human breast cancer xenotransplantation mouse model without noticeable acute adverse effects. Anticancer peptoid 1 can be used for the research of cancer, such as breast cancer, and prostate cancer .
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P9905
-
Cetuximab
Maximum Cited Publications
53 Publications Verification
C225; IMC-C225
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
|
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
|
-
(5)
-
- HY-P99055
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
|
-
(5)
-
- HY-P99974
-
|
Nanoparticle albumin-bound Paclitaxel; Nanoparticle albumin-bound ABI-007
|
Microtubule/Tubulin
Apoptosis
Autophagy
|
Cancer
|
|
Nab-Paclitaxel (Nanoparticle albumin-bound Paclitaxel) is an albumin-bound nanoparticle formulation of Paclitaxel (HY-B0015). Nab-Paclitaxel is composed of albumin and the active pharmaceutical ingredient Paclitaxel, in which human albumin is used as an excipient to disperse and stabilize particles and carry the main drug. Nab-Paclitaxel is a solvent-free taxane with higher response rates and improved tolerability. Nab-Paclitaxel displays less toxicity and greater antitumor activity. Nab-Paclitaxel is more readily available for tumor cell uptake in three rhabdomyosarcoma, seven neuroblastoma cell lines, and one ostersarcoma cell line Nab-Paclitaxel can be studied in cancer research for example breast cancer and solid tumors. (The product specifications below only indicate the effective content of Paditaxel, the actual albumin quality depends on the batch; the ratio of each ingredient in this product is Paditaxel: albumin -1:7~1:11) .
|
-
(5)
-
- HY-P3371
-
|
DS-7300a; MABX-9001a; I-DXd
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
Apoptosis
|
Cancer
|
|
Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects
|
-
(5)
-
- HY-P9956
-
|
CNTO-328
|
Interleukin Related
|
Cancer
|
|
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research .
|
-
(5)
-
- HY-P99250
-
|
MetMAb
|
c-Met/HGFR
|
Cancer
|
|
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity .
|
-
(5)
-
- HY-P99205
-
|
|
ADC Antibody
|
Cancer
|
|
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
|
-
(5)
-
- HY-P9976
-
|
ch38SB19; hu38SB19; SAR-650984
|
CD38
Apoptosis
|
Cancer
|
|
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions .
|
-
(5)
-
- HY-P990673
-
|
DSTP-3086S Antibody; RG-7450 Antibody
|
ADC Antibody
Transmembrane Glycoprotein
Mitosis
|
Cancer
|
|
Vandortuzumab (DSTP-3086S Antibody; RG-7450 Antibody) is a humanized anti-STEAP1 IgG1 antibody and antimitotic agent that can be conjugated with MMAE (HY-15162) to form the antibody-drug conjugate (ADC) Vandortuzumab vedotin. Vandortuzumab vedotin specifically binds to STEAP1 and drives internalization of the complex, releasing the MMAE (HY-15162) payload intracellularly. After binding to tubulin, MMAE inhibits cell division and induces cell death. Vandortuzumab exhibits antitumor activity in preclinical xenograft models of prostate cancer and can be used for research related to metastatic castration-resistant prostate cancer (mCRPC) .
|
-
(5)
-
- HY-P991015
-
|
JNJ-78278343; KLCB-245
|
CD3
|
Cancer
|
|
Pasritamig (JNJ-78278343; KLCB-245) is a bispecific T-cell engager (BiTE) that targets the complex of human kallikrein KLK2 and CD3 receptor. Pasritamig redirects the cytotoxicity of T cells to KLK2-expressing tumor cells and induces T cell-mediated lysis of KLK2-expressing prostate cancer cells. Administered via subcutaneous injection, subcutaneous infusion or intravenous infusion, Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig has a safety profile with an extremely low incidence of cytokine release syndrome and can be safely administered in an outpatient setting. Pasritamig is applicable to the research of metastatic castration-resistant prostate cancer .
|
-
(5)
-
- HY-P99539
-
|
REGN4018
|
CD3
|
Cancer
|
|
Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and CD3. Ubamatamab demonstrates potent antitumor activity .
|
-
(5)
-
- HY-P9965
-
|
HuLuc 63; PDL 063; BMS 901608
|
Transmembrane Glycoprotein
|
Cancer
|
|
Elotuzumab (HuLuc 63) is an IgG1 monoclonal antibody targeting the SLAMF7 receptor. Elotuzumab exerts antitumor activity by activating natural killer cells and inducing antibody-dependent cell-mediated cytotoxicity. Elotuzumab can be combined with Lenalidomide (HY-A0003), Dexamethasone (HY-14648), etc., for the research of tumors such as multiple myeloma .
|
-
(5)
-
- HY-P99394
-
|
JNJ-64407564
|
CD3
|
Cancer
|
|
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .
|
-
(5)
-
- HY-P99455
-
|
EMB-01
|
EGFR
c-Met/HGFR
|
Cancer
|
|
Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity .
|
-
(5)
-
- HY-P990028
-
|
|
ADC Antibody
Transmembrane Glycoprotein
|
Cancer
|
|
Raludotatug is a humanized anti-CDH6 IgG1 monoclonal antibody. Raludotatug has antitumor activity and can be used to synthesize the ADC molecule Raludotatug deruxtecan (HY-164734) .
|
-
(5)
-
- HY-P99101
-
|
AEX-4089; MGC026 antibody
|
ADC Antibody
|
Cancer
|
|
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .
|
-
(5)
-
- HY-P9922
-
|
IMC-3G3; LY3012207
|
PDGFR
|
Cancer
|
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .
|
-
(5)
-
- HY-P99010
-
|
|
FGFR
|
Cancer
|
|
Bemarituzumab is a humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer .
|
-
(5)
-
- HY-P99175
-
|
|
CD47
|
Cancer
|
|
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research .
|
-
(5)
-
- HY-P99333
-
|
M200; Eos 200-4
|
Integrin
|
Cardiovascular Disease
Cancer
|
|
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .
|
-
(5)
-
- HY-P990534
-
|
K1-70
|
TSH Receptor
|
Endocrinology
Cancer
|
|
Anti-TSHR Antibody (K1-70) is an anti-TSHR monoclonal antibody. Anti-TSHR Antibody (K1-70) incorporates a single-chain variable fragment into a chimeric antigen receptor to redirect T cells to TSHR-expressing cells. Anti-TSHR Antibody (K1-70) shows antitumor activity with no apparent toxicity. Anti-TSHR Antibody (K1-70) can be used for the research of differentiated thyroid cancer (DTC) .
|
-
(5)
-
- HY-P99286
-
|
PRO 95780; rhuMAb-DR 5; Anti-Human DR5 Recombinant Antibody
|
Apoptosis
|
Cancer
|
|
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma .
|
-
(5)
-
- HY-P99758
-
|
CS1003
|
PD-1/PD-L1
|
Cancer
|
|
Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab shows antitumor activity and can be used for the research of unresectable or metastatic hepatocellular carcinoma .
|
-
(5)
-
- HY-P99422
-
|
SHR-1316
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .
|
-
(5)
-
- HY-P99711
-
|
RB4v1.2
|
CD19
ADC Antibody
|
Cancer
|
|
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349) .
|
-
(5)
-
- HY-P99777
-
|
TTI-621
|
CD47
|
Cancer
|
|
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .
|
-
(5)
-
- HY-P991501
-
|
HcHAb18
|
ADC Antibody
Transmembrane Glycoprotein
SARS-CoV
|
Infection
Cancer
|
|
Meplazumab (HcHAb18) is a humanized anti-CD147 IgG1 antibody a Kd of 0.47 nM. Meplazumab shows anti-SARS-CoV-2 and antitumor activity. Meplazumab conjugated with DM1 can form an antibody-conjugated drug ( HcHAb18-DM1), which induces G2/M phase cell cycle arrest and exerts antiproliferative activity in cancer cells. Meplazumab can be used for the researches of COVID-19 pneumonia and non-small cell lung cancer .
|
-
(5)
-
- HY-P990627
-
|
MEDI-547 antibody
|
ADC Antibody
Ephrin Receptor
|
Cancer
|
|
Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is an anti-EphA2 monoclonal antibody. Anti-EphA2 Antibody (1C1) can induce degradation of EphA2 protein. Anti-EphA2 Antibody (1C1) conjugated with McMMAF (HY-15578) can form an antibody-conjugated drugs, which has potent antitumor activity. Anti-EphA2 Antibody (1C1) can be used for the research of cancer, such as prostate cancer and glioma .
|
-
(5)
-
- HY-P99108
-
-
(5)
-
- HY-P99208
-
|
IPH2102
|
Transmembrane Glycoprotein
|
Cancer
|
|
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research .
|
-
(5)
-
- HY-P99202
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research .
|
-
(5)
-
- HY-P99272
-
|
BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody
|
CXCR
|
Cancer
|
|
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .
|
-
(5)
-
- HY-P99284
-
|
MK-0646; h7C10
|
IGF-1R
Apoptosis
|
Cancer
|
|
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo .
|
-
(5)
-
- HY-P990981
-
|
ALPS-12; RG-6524; RO 7616789
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Clesitamig (ALPS-12) is a trispecific T cell engager with two CD3/CD137 dual-specific Fabs and one DLL3 Fab. Clesitamig engages CD3 and CD137 on T cells to activate and co-stimulate T cells, promoting their proliferation, survival, and antitumor activity. Clesitamig binds to DLL3 on tumor cells for tumor-specific recognition. Clesitamig can be used for the research of small cell lung cancer (SCLC) .
|
-
(5)
-
- HY-P99603
-
|
SEA-CD40
|
Inhibitory Antibodies
|
Cancer
|
|
Cifurtilimab (SEA-CD40) is an agonistic nonfucosylated, human IgG1 monoclonal antibody directed against CD40. Cifurtilimab shows antitumor activities .
|
-
(5)
-
- HY-P99906
-
|
DKN-01; LY-2812176
|
β-catenin
|
Cancer
|
|
Sirexatamab (DKN-01) is a humanized IgG4 monoclonal antibody that can bind to and neutralize circulating DKK1. Sirexatamab exhibits antitumor activity in tumor models expressing DKK1 .
|
-
(5)
-
- HY-P99914
-
|
GNC-038
|
PD-1/PD-L1
CD19
TNF Receptor
CD3
Interleukin Related
IFNAR
|
Inflammation/Immunology
Cancer
|
|
Emfizatamab (GNC-038) is a monoclonal antibody against CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3 and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia .
|
-
(5)
-
- HY-P991588
-
|
AC101
|
EGFR
Apoptosis
|
Cancer
|
|
HLX-22 is a humanized monoclonal antibody targeting HER2. HLX-22 induces apoptosis in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab (HY-P9907). HLX-22 has potent antitumor activity against advanced solid tumors .
|
-
(5)
-
- HY-P99249
-
|
Pogalizumab; MOXR 0916
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models .
|
-
(5)
-
- HY-P99293
-
|
IDEC 114; Anti-Human CD80 Recombinant Antibody
|
CD28
Apoptosis
|
Cancer
|
|
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors .
|
-
(5)
-
- HY-P99463
-
|
AVB-500; AVB-S6-500
|
TAM Receptor
PI3K
Akt
p38 MAPK
|
Cancer
|
|
Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((KD <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis .
|
-
(5)
-
- HY-P99630
-
|
MM-302 antibody
|
EGFR
|
Cancer
|
|
Gancotamab antibody (MM-302) is a HER2-targeted antibody with antitumor activity .
|
-
(5)
-
- HY-P991143
-
|
TORL-1-23 Antibody
|
Claudin
|
Cancer
|
|
Ixotatug is a monoclonal antibody targeting human CLDN6 (claudin-6). Ixotatug specifically binds to CLDN6, interfering with relevant signaling pathways in tumor cells and exerting antitumor activity. Ixotatug is promising for research of cancers .
|
-
(5)
-
- HY-P99836
-
|
IBI101
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
|
Cudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research .
|
-
(5)
-
- HY-145627
-
|
BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Ozuriftamab vedotin (BA3021), an antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities .
|
-
(5)
-
- HY-P99969
-
|
CMAB-302; Cipterbin
|
EGFR
|
Cancer
|
|
Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities .
|
-
(5)
-
- HY-P99109
-
|
GLS-010; AB-122; WBP-3055
|
PD-1/PD-L1
|
Cancer
|
|
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
|
-
(5)
-
- HY-P990953
-
|
Gen1047
|
CD3
|
Cancer
|
|
Zubotamig (Gen1047) is an CD3E/VTCN1-targeting Ig(G1 -κ_G1 -λ2) type chimeric human antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zubotamig induces T-cell mediated cytotoxicity of B7H4-positive tumor cells, triggers T-cell activation, and induces cytokine release from T cells in the presence of B7H4-expressing tumor cells. Zubotamig demonstrates antitumor activity in mouse patient-derived xenograft (PDX) models. Zubotamig can be used for the research of solid cancers (including breast, ovarian and lung cancer) .
|
-
(5)
-
- HY-P991697
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Lenipagrusin alfa is a naturally occurring homotetrameric variant of Maackia amurensis seed lectin (1-258), the glycoform alfa. Lenipagrusin alfa exhibits antitumor activity .
|
-
(5)
-
- HY-P99633
-
|
BGB-A333
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity .
|
-
(5)
- HY-P991665
-
|
OBT357NF; OBT357
|
Transmembrane Glycoprotein
|
Cancer
|
|
MEN1112 (OBT357NF) is a selective humanized monoclonal antibody targeting the Bst1/CD157 antigen (EC50=1 nM). MEN1112 exerts potent antitumor activity against acute myeloid leukemia (AML) cells. MEN1112 is promising for research of hematological malignancies such as AML .
|
-
(5)
- HY-P991610
-
|
Sym025
|
C-type Lectin-like Receptors (CTLRs)
|
Cancer
|
|
S-095029 is a humanized IgG1 monoclonal antibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells .
|
-
(5)
- HY-P990778
-
|
ATG-101
|
TNF Receptor
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Xirestomig (ATG-101) is a tetravalent "2+2″ PD-L1×4-1BB bispecific antibody. Xirestomig binds PD-L1 and 4-1BB concurrently, with a greater affinity for PD-L1, and potently activated 4-1BB+ T cells when cross-linked with PD-L1-positive cells. Xirestomig activates exhausted T cells upon PD-L1 binding. Xirestomig displays potent antitumor activity in numerous in vivo tumor models, including those resistant or refractory to immune checkpoint inhibitors (ICIs) .
|
-
(5)
- HY-P99799
-
|
CX-072
|
PD-1/PD-L1
|
Cancer
|
|
Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity .
|
-
(5)
- HY-P99306
-
|
DS 1024; Zatuximab
|
EGFR
|
Cancer
|
|
Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo .
|
-
(5)
- HY-P991448
-
|
|
Glycoprotein VI
|
Cancer
|
|
MDX-1414 is a human IgG1 monoclonal antibody (mAb) targeting GPC3. MDX-1414 has antitumor activity in the HepG2 xenograft model. MDX-1414 can be used in liver cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991311
-
|
|
LPL Receptor
Wnt
|
Cancer
|
|
GSK3178022 is a human IgG1 monoclonal antibody (mAb) targeting LRP6. GSK3178022 inhibits the expression of WNT target genes SP5 and AXIN2. GSK3178022 has antitumor activity in the RSPO fusion model of colorectal cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991062
-
|
Gensci-059
|
CD47
|
Cancer
|
|
Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets CD47. Gentulizumab displays strong binding to CD47 in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P991779
-
|
|
EGFR
|
Cancer
|
|
Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19) reacts with domain III of human and canine HER2. Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19) exerts antitumor activity in mouse oral cancer xenografts. Recommend Isotype Controls: Mouse IgG2b kappa, Isotype Control (HY-P99982) .
|
-
(5)
- HY-P991582
-
|
|
Fc Receptor (FcR)
|
Cancer
|
|
BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcγRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab (HY-P9907) .
|
-
(5)
- HY-P991561
-
|
|
CD47
|
Cancer
|
|
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .
|
-
(5)
- HY-P991634
-
|
|
CD73
TNF Receptor
Interleukin Related
IFNAR
|
Inflammation/Immunology
Cancer
|
|
IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research .
|
-
(5)
- HY-P991461
-
|
XmAb968
|
CD38
|
Cancer
|
|
AMG-424 (XmAb968) is a human bispecific antibody (bsAb) targeting CD38 & CD3E. AMG-424 kills CD38-expressing cancer cells, triggers T-cell proliferation and attenuates cytokine release. AMG 424 has antitumor activity in a bone marrow-invasive mouse cancer model and induces peripheral B-cell depletion in cynomolgus monkeys. AMG-424 can be used in multiple myeloma research. Recommended isotype control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3 .
|
-
(5)
- HY-P991140
-
|
|
Claudin
|
Cancer
|
|
Garetatug is a humanized monoclonal antibody targeting human CLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity .
|
-
(5)
- HY-P991605
-
|
|
LAG-3
|
Cancer
|
|
HLX26 is a humanised anti-LAG-3 monoclonal antibody. HLX26 has antitumor activity especially advanced solid tumours. HLX26 can be used for lymphoma research .
|
-
(5)
- HY-P991726
-
|
|
Orphan GPCR
|
Cancer
|
|
Vemzatatug is a humanized IgG1κ monoclonal antibody inhibitor targeting GPRC5D. Vemzatatug has an antitumor activity. Vemzatatug can be used for cancers like multiple myeloma (MM) research .
|
-
(5)
- HY-P991126
-
|
YH003
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy .
|
-
(5)
- HY-P991160
-
|
IMM-47
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Suvonstobart is a monoclonal antibody targeting human CD24 (signal transducer CD24). Suvonstobart specifically binds to CD24, activating relevant immune cell signaling pathways and exerting immunostimulatory and antitumor activities .
|
-
(5)
- HY-P991145
-
|
|
SLC39 (Zinc Transporter)
|
Cancer
|
|
Laventatug is a humanized monoclonal antibody targeting human SLC39A6. Laventatug specifically binds to SLC39A6, interfering with the intracellular zinc ion transport process and thus exerting antitumor activity. Laventatug is promising for research of cancers .
|
-
(5)
- HY-P991125
-
|
YH-002
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy .
|
-
(5)
- HY-P991556
-
|
|
TNF Receptor
|
Cancer
|
|
TQB2916 is a humanized IgG2 monoclonal antibody agonist targeting CD40. TQB2916 has a significant antitumor activity with CD40 occupancy and immune activation. TQB2916 can be used for advanced solid tumors and lymphomas research .
|
-
(5)
- HY-P991141
-
|
|
VEGFR
|
Cancer
|
|
Inlecitug is a chimeric monoclonal antibody targeting human KDR (kinase insert domain receptor). Inlecitug specifically binds to KDR, blocking the binding of vascular endothelial growth factor (VEGF) to KDR and inhibiting angiogenesis, thus exerting antitumor activity. Inlecitug is promising for research of cancers .
|
-
(5)
- HY-P991606
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Infection
Inflammation/Immunology
Cancer
|
|
TRX585 is a humanised anti-immunoglobulin-like transcript 5 (ILT5) monoclonal antibody. TRX585 has a potent immunoregulatory activity. TRX585 significantly activates human T cells and upregulates NKG2D and Fas ligand, followed by enhancing antitumor activity with potent cytotoxicity. TRX585 can be used for viral infections and malignancies research .
|
-
(5)
- HY-P990986
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Efdelikofusp alfa is a bispecific Fc fusion protein. Efdelikofusp alfa is formed by fusing the N-terminal extracellular domain of human CD80 (B7.1) with the Fc fragment of human immunoglobulin G4 (IgG4), and is linked to an interleukin-2 variant (IL-2v) as the C-terminal part. Efdelikofusp alfa exhibits potential immunostimulatory, immune checkpoint inhibitory, and antitumor activities.
|
-
(5)
- HY-P991587
-
|
|
Orphan GPCR
|
Cancer
|
|
SAR-446523 is a humanized IgG1 monoclonal antibody inhibitor targeting GPRC5D. SAR-446523 significantly induces antibody-dependent cell-mediated cytotoxicity (ADCC). SAR-446523 has potent antitumor activity with improvement of mouse survival in NK humanized NOG huIL15 transgenic mice model bearing MM cells. SAR-446523 can be used for multiple myeloma (MM) research .
|
-
(5)
- HY-P990992
-
|
GI-102
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Efzilonkofusp alfa is a bispecific Fc fusion protein. Efzilonkofusp alfa is formed by fusing the N-terminal extracellular domain of human CD80 (B7.1) with the Fc fragment of human immunoglobulin G4 (IgG4), and is linked to an interleukin-2 variant (IL-2v) as the C-terminal part. Efzilonkofusp alfa exhibits potential immunostimulatory, immune checkpoint inhibitory, and antitumor activities.
|
-
(5)
- HY-P990649
-
|
TRU-015
|
CD20
|
Inflammation/Immunology
|
|
PF-5212374 (TRU-015) is a humanized antibody expressed in CHO, targeting CD20/MS4A1. PF-5212374 exhibits potent direct signaling and antibody-dependent cellular cytotoxicity, with complement-mediated cytotoxicity lower than that of Rituximab (HY-P9913). PF-5212374 has antitumor activity and can be used in the research of tumors such as lymphoma and inflammatory diseases .
|
-
(5)
- HY-P991095
-
|
APV-527; ATOR-1016
|
Transmembrane Glycoprotein
|
Cancer
|
|
ALG.APV-527 (APV-527) is a bispecific 4-1BB (CD137) and 5T4 antibody. ALG.APV-527 is designed to activate 4-1BB on T and natural killer (NK) cells only when simultaneously bound to 5T4-expressing tumor cells. ALG.APV-527 has a potent antitumor activity .
|
-
(5)
- HY-P991366
-
|
AL008
|
CD47
|
Cancer
|
|
IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research .
|
-
(5)
- HY-P991430
-
|
TB-403
|
VEGFR
|
Cancer
|
|
RO5323441 (TB-403) is a human IgG1 monoclonal antibody (mAb) targeting PlGF. RO5323441 inhibits the binding of human PlGF-1 or PlGF-2 to VEGFR-1 (IC50 values are 0.1 and 0.2 nM, respectively). RO5323441 blocks PlGF-induced VEGFR-1 phosphorylation in Flt-1-transfected HEK293 cells. RO5323441 has antitumor activity .
|
-
(5)
- HY-P991585
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
MORAb-028 is a humanized IgG1 monoclonal antibody inhibitor targeting GD2. MORAb-028 has a potent antitumor activity and kills GD2-expressing target cells via complement-mediated cytotoxicity (CDC). MORAb-028 significantly inhibits tumor growth in EL-4-luc xenograft mice model. MORAb-028 can be used for melanoma cancer research .
|
-
(5)
- HY-P991432
-
|
|
TNF Receptor
NF-κB
c-Myc
|
Cancer
|
|
VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma .
|
-
(5)
- HY-P991425
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
AT-1413 is a human monoclonal antibody (mAb) targeting CD43. AT-1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. AT-1413 has antitumor activity in AML mouse models. AT-1413 can be used in Acute myeloid leukaemia, Breast cancer, Malignant melanoma and Myelodysplastic syndromes research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991468
-
|
|
Interleukin Related
|
Cancer
|
|
IMM20324 is a human monoclonal antibody (mAb) targeting IL38. IMM20324 inhibits the interaction of IL-38 with human IL1RAPL1-Fc and human IL-36R-Fc with IC50 values of 1.267 nM and 1.4667 nM, respectively. IMM20324 has antitumor activity in the B16.F10 syngeneic mouse model. IMM20324 can be used in antitumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P992110
-
|
DB-1311 Antibody; BNT324 Antibody
|
CD276/B7-H3
|
Cancer
|
|
Elfetabart is a humanized monoclonal antibody targeting CD276 with antitumor activity. The antibody isotype of Elfetabart is human IgG1κ, and the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992125
-
|
HFB-200603
|
CD28
|
Cancer
|
|
Radanstobart is a humanized monoclonal antibody targeting CD272 with antitumor activity. Radanstobart is of the human IgG4κ isotype, and the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P992005
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
DS-1055a is an anti-human GARP antibody. DS-1055a effectively depletes GARP-positive regulatory T cells in the tumor microenvironment, and activates effector T cells. DS-1055a exhibits antitumor activity and can be used for the research of cancer, such as colon cancer .
|
-
(5)
- HY-P992086
-
|
|
VEGFR
|
Cancer
|
|
Anti-Mouse VEGF Antibody (G6-31) is a anti-mouse VEGF antibody. Anti-Mouse VEGF Antibody (G6-31) blocks VEGF-A-mediated angiogenesis and shows antitumor activity. Anti-Mouse VEGF Antibody (G6-31) can be used for the research of cancer, such as multiple endocrine neoplasia type 1 .
|
-
(5)
- HY-P991902
-
|
|
CD20
|
Cancer
|
|
NAV006 is an anti-CD20 antibody variant of Rituximab (HY-P9913) with a Kd of 30.5 nM to CD20. NAV006 exhibits reduced interaction with CA125 and demonstrates enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activity. NAV006 displays antitumor activity against lymphoma and can be used in research on non-Hodgkin lymphoma .
|
-
(5)
- HY-P991528
-
|
|
NF-κB
|
Inflammation/Immunology
Cancer
|
|
PE0116 is a fully human CD137 agonistic monoclonal antibody generated from immunized harbor H2L2 human transgenic mice. PE0116 is a ligand block. PE0116 activates NF-κB signaling which significantly promotes T-cell proliferation and increases cytokine secretion in vitro. PE0116 exhibits robust antitumor activity in MC38 tumor model .
|
-
(5)
- HY-P99528
-
|
DSTP 3086S; RG 7450; MSTP2109A
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Vandortuzumab vedotin (DSTP 3086S; RG 7450) is a STEAP1-targeted antibody-drug conjugate (ADC). Vandortuzumab vedotin binds specifically to STEAP1, triggers internalization of the conjugate complex, mediates intracellular release of monomethyl auristatin E, inhibits cell division, and induces cell death. Vandortuzumab vedotin exhibits antitumor activity in preclinical prostate cancer xenografts. Vandortuzumab vedotin can be used for the research of metastatic castration-resistant prostate cancer .
|
-
(5)
- HY-P992462
-
|
|
Orexin Receptor (OX Receptor)
NF-κB
|
Cancer
|
|
SHR-1806 is a OX40 agonist and a NF-κB activator, with antitumor activity. SHR-1806 mediates ADCC and CDC effects, enhances the function and expansion of effector T cells, suppresses regulatory T cells, and increases γ-interferon secretion. SHR-1806 exhibits typical pharmacokinetic characteristics and favorable safety profiles. SHR-1806 can be used in studies related to solid tumors and colon cancer .
|
-
(5)
- HY-P992012
-
|
|
Opioid Receptor
|
Neurological Disease
Cancer
|
|
CA1001 is a small-molecule ZNF74 inhibitor and a peripherally restricted κ/δ dual opioid receptor agonist. CA1001 exhibits potent antitumor activity both in vitro and in vivo. CA1001, in combination with immune checkpoint inhibitors, significantly enhances tumor regression. CA1001 activates peripherally restricted κ/δ dual opioid receptors and exerts analgesic effects under conditions of inflammatory pain, neuropathic pain, and mechanical hyperalgesia. CA1001 can be used in research related to melanoma, mechanical hyperalgesia, neuropathic pain, and inflammatory arthritis pain.
|
-
(5)
- HY-P991984
-
|
|
EGFR
PI3K
Akt
|
Cancer
|
|
SIBP-03 is a specifical anti-HER3 antibody. SIBP-03 binds strongly and specifically to recombinant HER3 protein. SIBP-03 inhibits HER3 activation, as well as the downstream PI3K/AKT signaling pathway. SIBP-03 exhibits anticancer activity against squamous cell carcinoma, non-small cell lung cancer, gastric cancer, and breast cancer. SIBP-03 synergistically enhances the antitumor activity of DS-8201 (HY-138298A) and Cetuximab (HY-P9905) .
|
-
(5)
- HY-P992396
-
|
|
c-Met/HGFR
|
Cancer
|
|
KTN0073 is a high-affinity MET receptor tyrosine kinase inhibitor. KTN0073 can be used in studies related to non-small cell lung cancer and human cancers driven by HGF, MET amplification, or exon 14 mutation. KTN0073 binds to the Sema/PSI domain to block the HGF-MET interaction, and induces ubiquitination and degradation of oncogenic MET receptors via an HGF-independent pathway, thereby inhibiting MET-dependent signal transduction. KTN0073 exhibits significant antitumor activity in vivo, and its tumor suppressive activity is superior to that of the IgG1 subtype when grafted to the IgG2 constant region .
|
-
(5)
- HY-P991944
-
|
|
CCR
|
Cancer
|
|
ZL-1218 is a selective humanized IgG1 antibody, targeting CCR8. ZL-1218 induces antibody-dependent cellular cytotoxicity (ADCC), leading to NK cell-mediated depletion of CCR8-expressing regulatory T cells (Tregs). ZL-1218 blocks the binding of the CCR8 ligand CCL1 to CCR8 and reduces Treg recruitment by inhibiting the chemotaxis of CCR8 + cells. ZL-1218 reduces intratumoral Treg levels in a dose-dependent manner. ZL-1218 exerts enhanced antitumor activity when combined with the anti-PD-1 antibody. ZL-1218 can be used for solid tumour research .
|
-
(5)
- HY-P991911
-
|
|
Scavenger Receptor Class B type I (SR-BI）
|
Cancer
|
|
PLT012 is a humanized IgG4 antibody targeting CD36. PLT012 inhibits the lipid-binding domain of CD36. PLT012 blocks CD36-mediated metabolic adaptation in regulatory T cells (Tregs) and CD8 + tumor-infiltrating lymphocytes (TILs), thereby inhibiting tumor growth and shifting the tumor microenvironment from immunosuppressive to immunosupportive. PLT012 reduces intratumoral Tregs, enhances CD8 + T cell infiltration and cytotoxic function, and increases the abundance of progenitor-exhausted T cells. PLT012 exerts robust antitumor activity and synergizes with anti-PD-L1 or standard-of-care regimens (anti-VEGF + anti-PD-L1). PLT012 can be used for hepatocellular carcinoma, colorectal cancer and solid tumor research .
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
- HY-N7235
-
-
- HY-121245
-
-
- HY-122146
-
-
- HY-129339
-
-
- HY-N4304
-
-
- HY-N14832
-
-
- HY-N5122
-
-
- HY-119675
-
-
- HY-N13900
-
-
- HY-N8975
-
-
- HY-125395
-
-
- HY-N12145
-
-
- HY-169500
-
-
- HY-129728
-
-
- HY-N3268
-
-
- HY-156393
-
-
- HY-123887
-
-
- HY-N14410
-
-
- HY-129673
-
-
- HY-N15371
-
-
- HY-130072
-
-
- HY-129291
-
-
- HY-N8449
-
-
- HY-N12371
-
-
- HY-N9292
-
-
- HY-N10391
-
-
- HY-N11010
-
-
- HY-N11777
-
-
- HY-136293
-
-
- HY-N14781
-
-
- HY-N12364
-
-
- HY-122474
-
-
- HY-N1265
-
-
- HY-N14677
-
-
- HY-122108
-
|
LL-Z 1272-alpha
|
Microorganisms
Phenols
Polyphenols
Source Classification
|
Apoptosis
|
|
Ilicicolin A is a potent anticancer agent. Ilicicolin A induces apoptosis. Ilicicolin A inhibits cell growth and colony formation. Ilicicolin A shows antitumor activity. Ilicicolin A has the potential for the research of prostate cancer .
|
-
- HY-N13894
-
-
- HY-N0878R
-
-
- HY-N15597
-
-
- HY-N14822
-
-
- HY-N2322R
-
-
- HY-135176
-
-
- HY-B1071R
-
-
- HY-N13895
-
-
- HY-N2227
-
-
- HY-N9647
-
-
- HY-N0661R
-
-
- HY-N10542
-
-
- HY-N17754
-
-
- HY-N9844
-
-
- HY-120787
-
-
- HY-N0379
-
-
- HY-125665
-
|
|
Microorganisms
Ketones, Aldehydes, Acids
Source Classification
|
Apoptosis
|
|
Pheophorbide A is an intermediate product in the chlorophyll degradation pathway. Pheophorbide A can be used as a photosensitizer. Pheophorbide A is a lymphatic vascular activator. Pheophorbide A has antitumor activity. Pheophorbide A can be used for human lymphatic vascular insufficiencies research .
|
-
- HY-N2389R
-
-
- HY-N10541
-
-
- HY-N6952
-
-
- HY-13744
-
-
- HY-N6949
-
-
- HY-N6011
-
-
- HY-75161
-
-
- HY-N0174R
-
-
- HY-N2682
-
-
- HY-N13571
-
-
- HY-W083376A
-
-
- HY-N12534
-
|
|
Natural Products
Microorganisms
Source Classification
|
Apoptosis
|
|
Monaspin B is a natural product produced by the co-culture of Monascus purpureus and Aspergillus oryzae. Monaspin B exerts anti-proliferation activity by inducing apoptosis of HL-60 cells, IC50 160 nM. Monaspin B has antitumor activity .
|
-
- HY-N15458
-
-
- HY-B1000R
-
-
- HY-N11435
-
-
- HY-B1320
-
-
- HY-119458
-
-
- HY-N15263
-
-
- HY-135765
-
-
- HY-N0697
-
-
- HY-N4227
-
-
- HY-N8253R
-
-
- HY-N10188
-
-
- HY-N4251
-
-
- HY-19829
-
-
- HY-101414R
-
-
- HY-N8473
-
|
(+)-Pericosine A
|
Natural Products
Microorganisms
Source Classification
|
Topoisomerase
|
|
Pericosine A ((+)-Pericosine A) is a topoisomerase II (Topoisomerase II) inhibitor that can be isolated from the Periconia byssoides strain. Pericosine A has significant antitumor activity in vitro and in vivo and can be used in cancer research. Pericosine A also inhibits the protein kinase epidermal growth factor receptor .
|
-
- HY-B0508
-
-
- HY-123325
-
-
- HY-N6074R
-
-
- HY-125827
-
-
- HY-N13163
-
-
- HY-128425R
-
-
- HY-13680
-
-
- HY-N0611
-
-
- HY-N2232
-
-
- HY-N12137
-
-
- HY-N7022R
-
-
- HY-N17781
-
-
- HY-126803
-
-
- HY-N0585R
-
-
- HY-N14959
-
|
|
Natural Products
Microorganisms
Source Classification
|
Antibiotic
Bacterial
|
|
Deacetylravidomycin N-oxide is an antibiotic that can be produced by Streptomyces ravidus S50905. Deacetylravidomycin N-oxide is active against Gram-positive bacteria but inactive against Gram-negative bacteria. Deacetylravidomycin N-oxide has antitumor activity against P388 leukemia and methamphetamine A fibrosarcoma .
|
-
- HY-W004284
-
-
- HY-137139
-
-
- HY-N0189
-
-
- HY-B0719
-
|
Ingenol 3-angelate; PEP005
|
Classification of Application Fields
Terpenoids
Euphorbia peplus Linn.
Diterpenoids
Euphorbiaceae
Plants
Inflammation/Immunology
Disease Research Fields
|
PKC
|
|
Ingenol Mebutate is an active ingredient in Euphorbia peplus, acts as a potent PKC modulator, with Kis of 0.3, 0.105, 0.162, 0.376, and 0.171 nM for PKC-α, PKC-β, PKC-γ, PKC-δ, and PKC-ε, respectively, and has antiinflammatory and antitumor activity.
|
-
- HY-130430
-
|
(-)-Neplanocin A
|
Natural Products
Microorganisms
Source Classification
|
Antibiotic
Orthopoxvirus
|
|
Neplanocin A ((-)-Neplanocin A) is an antitumor antibiotic with significant antitumor activity against murine L1210 leukemia. Neplanocin A is also an irreversible inhibitor of AdoHcy hydrolase (Ki=8.39 nM). Neplanocin A also has antiviral activity and is effective against vaccinia virus. Neplanocin A is obtained from Ampulariella regularis .
|
-
- HY-129252
-
|
|
Alkaloids
Microorganisms
Pyrrole Alkaloids
Source Classification
|
Antibiotic
Bacterial
|
|
Prothracarcin is an antibiotic with antitumor activity that exerts its tumor cell toxicity by covalently binding to the C-2 amino group of guanine residues in the minor groove of DNA. Prothracarcin also shows antibacterial activity against Gram-positive bacteria and some Gram-negative bacteria such as Escherichia coli .
|
-
- HY-N15497
-
-
- HY-19474R
-
-
- HY-111934
-
-
- HY-17411R
-
-
- HY-N0446
-
-
- HY-N12209
-
-
- HY-P5702
-
-
- HY-107324R
-
-
- HY-N7028R
-
-
- HY-N1984
-
-
- HY-125300
-
|
|
Natural Products
Microorganisms
Source Classification
|
Fungal
Antibiotic
|
|
Oligomycin E is a antitumor antibiotic that can be isolated from Streptomyces. Oligomycin E has significant antifungal activity, showing minimal inhibitory concentrations (MICs) values between 2 and 75μg/mL. Oligomycin E has strong antitumor activity against HeLa cells, with an IC50 of 0.014 μg/mL .
|
-
- HY-N3862
-
-
- HY-N3028
-
-
- HY-B0986
-
-
- HY-N0379R
-
-
- HY-119789
-
-
- HY-N3149
-
-
- HY-N0171B
-
-
- HY-B1320R
-
-
- HY-P5703
-
-
- HY-N6949R
-
-
- HY-N6656R
-
-
- HY-N0284
-
-
- HY-N0697R
-
-
- HY-N6748
-
-
- HY-125037
-
-
- HY-N6031
-
-
- HY-75161R
-
-
- HY-N0750
-
-
- HY-N0750R
-
-
- HY-N6961
-
-
- HY-N13162
-
|
|
Triterpenes
Terpenoids
Cucurbitaceae
Plants
Hemsleya pengxianensis W. J. Chang
Source Classification
|
Others
|
|
Hemsleyadin D is a triterpenoid compound derived from Hemsleya penxianensis with antitumor activity. Its IC50 values against K562, MGC-803, U118, HepG2, A549, and MCF-7 cells are 93.9, 47.1, 25.9, 56.1, 66.3, and 67.6 μM, respectively .
|
-
- HY-N8487
-
-
- HY-13680R
-
-
- HY-B0508R
-
-
- HY-121716
-
|
Antibiotic 2088A; LL-14I352α
|
Antibiotics
Marine natural products
Source Classification
|
Bacterial
|
|
Pelagiomicin A is a novel phenazine antibiotic produced by the marine bacterium Pelagiobacter variabilis. The compound is unstable in water and small alcohols. The absolute structure of its major component, Pelagiomicin A, as well as the properties of minor amounts of other structures, were determined by spectroscopic data and synthesis. Pelagiomicin A is active against both Gram-positive and Gram-negative bacteria and exhibits antitumor activity in vitro and in vivo.
|
-
- HY-N9093
-
|
|
Phenols
Curcuma kwangsiensis S. K. Lee & C. F. Liang
Plants
Source Classification
Zingiberaceae
|
Others
|
|
(3R,5R)-3,5-Diacetoxy-1-(3,4-dihydroxyphenyl)-7-(4-hydroxyphenyl)heptane, a diarylheptanoid from the rhizomes of Curcuma kwangsiensis, possesses a variety of biological and pharmacological activities including antioxidant, antihepa totoxic, anti-inflammatory, antiproliferative, antiemetic, and antitumor activities .
|
-
- HY-W267446
-
-
- HY-N1839
-
-
- HY-W004284R
-
-
- HY-W012531
-
-
- HY-125927
-
-
- HY-17583
-
-
- HY-N2274
-
|
12-Oleanene-3β,16β,23,28-tetrol; 3β,16β-12-Oleanene-3, 16,23,28-tetrol
|
Triterpenes
Classification of Application Fields
Terpenoids
Asclepiadaceae
Lysimachia heterogenea Klatt
Plants
Primulaceae
Disease Research Fields
Gymnema sylvestre (Retz.) Schult.
Source Classification
Cancer
|
Others
|
|
23-Hydroxylongispinogenin (12-Oleanene-3β,16β,23,28-tetrol) is extracted from Lysimachia heterogenea Klatt. Lysimachia heterogenea Klatt is a perennial herb, which is used as a folk medicine in subduing swelling and detoxicating in China. The effective fraction LH-1 of L. heterogene has antitumor activity .
|
-
- HY-113612
-
-
- HY-120241
-
|
K 251-1
|
Microorganisms
Phenols
Polyphenols
Source Classification
|
Phosphodiesterase (PDE)
|
|
Reticulol (K 251-1) is an inhibitor of cyclic adenosine 3', 5'-monophosphate phosphodiesterase. Reticulol shows antitumor activity independent with cell cycle arrest or apoptosis. Reticulol inhibits cell growth of murine melanoma cells and human lung tumor cells. Reticulol protects its lung metastasis via the bloodstream by inhibiting the growth of B16F10 melanoma .
|
-
- HY-17408
-
-
- HY-N2108
-
-
- HY-N0611R
-
-
- HY-N6015
-
-
- HY-B0719R
-
|
Ingenol 3-angelate (Standard); PEP005 (Standard)
|
Structural Classification
Terpenoids
Euphorbia peplus Linn.
Diterpenoids
Euphorbiaceae
Plants
|
Reference Standards
PKC
|
|
Ingenol Mebutate (Standard) is the analytical standard of Ingenol Mebutate. This product is intended for research and analytical applications. Ingenol Mebutate is an active ingredient in Euphorbia peplus, acts as a potent PKC modulator, with Kis of 0.3, 0.105, 0.162, 0.376, and 0.171 nM for PKC-α, PKC-β, PKC-γ, PKC-δ, and PKC-ε, respectively, and has antiinflammatory and antitumor activity.
|
-
- HY-105463
-
|
|
Quinones
Structural Classification
Microorganisms
Anthraquinones
Source Classification
|
Antibiotic
Bacterial
|
|
Saptomycin D is an antibiotic with antitumor activity isolated from the Streptomyces sp. HP530 strain. Saptomycin D exhibits potent inhibitory effects against Gram-positive bacteria, while demonstrating weaker inhibitory activities against certain Gram-negative bacteria and yeasts. Saptomycin D also displays remarkable antitumor properties. Saptomycin D is applicable in research within the field of oncology .
|
-
- HY-W047478
-
-
- HY-N9942
-
-
- HY-N9666
-
|
|
Structural Classification
Microorganisms
Antibiotics
Source Classification
|
Antibiotic
Bacterial
|
|
Chromomycin A4, a major byproduct of Chromomycin A3 (HY-W040129)'s manufacture, is an antibiotic produced by Streptomyces griseus No. 7. Chromomycin A4 exhibits cancerostatic and antitumor activity. Chromomycin A4 shows strong growth inhibition against Gram-positive bacteria and and activity against tuberculous bacilli. Chromomycin A4 can be used for the research of bacterial infection .
|
-
- HY-B0986R
-
-
- HY-N0841
-
-
- HY-130596
-
-
- HY-128741
-
-
- HY-N0446R
-
-
- HY-112661
-
-
- HY-126490
-
-
- HY-125916
-
-
- HY-B1092A
-
-
- HY-N0284R
-
-
- HY-119413R
-
|
|
Natural Products
Microorganisms
Source Classification
|
Reference Standards
Endogenous Metabolite
|
|
Loxoprofen (sodium) (Standard) is the analytical standard of Loxoprofen (sodium). This product is intended for research and analytical applications. Loxoprofen sodium is a non-steroidal, orally active anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen sodium is a nonselective COX inhibitor with IC50s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively. Loxoprofen sodium can reduce atherosclerosis and shows antitumor activity .
|
-
- HY-N1984R
-
-
- HY-13502B
-
-
- HY-13502
-
-
- HY-N15614
-
|
|
Alkaloids
Erythrophleum fordii Oliv.
Leguminosae
Other Alkaloids
Plants
Source Classification
|
Others
|
|
Cassamine is a diterpenoid compound that can be isolated from the bark of Erythrophleum fordii. Cassamine exhibits certain cytotoxicity against non-small cell lung cancer cell lines, with IC50 values of 3.4, 2.1, and 1.9 μM against A549, NCI-H1975, and NCI-H1299, respectively. Cassamine has antitumor activity and can be used in the research of lung cancer and other tumors .
|
-
- HY-125135
-
-
- HY-N7719
-
-
- HY-119906
-
-
- HY-N6961R
-
-
- HY-13502A
-
-
- HY-125780R
-
|
|
Microorganisms
Source Classification
|
Drug Metabolite
Reference Standards
|
|
Dasatinib (monohydrate) (Standard) is the analytical standard of Dasatinib (monohydrate). This product is intended for research and analytical applications. Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib monohydrate inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib monohydrate also induces apoptosis and autophagy.
|
-
- HY-N13115A
-
|
(E)-21-Angeloyl-protoaescigenin
|
Aesculus chinensis Bunge
Triterpenes
Terpenoids
Hippocastanaceae
Plants
Source Classification
|
Others
|
|
Protoescigenin 21-tiglate (compound 10) is a glycosidic oleanane-type triterpenoid (BAT) that can be isolated from the acid hydrolysis product (AHP) of the crude extract of Aesculus chinensis seeds. Aesculus-derived triterpenoids (BAT) generally exhibit good antitumor, anti-inflammatory, and anti-Alzheimer's activities. However, the antitumor activity of Protoescigenin 21-tiglate is relatively weak, with IC50 values of >80 μM and 80 μM against MCF-7 and HeLa cells, respectively .
|
-
- HY-N14221
-
-
- HY-N13115
-
|
(Z)-Protoescigenin 21-tiglate
|
Aesculus chinensis Bunge
Triterpenes
Terpenoids
Hippocastanaceae
Plants
Source Classification
|
Others
|
|
21-Angeloyl-protoaescigenin (compound 11) is a glycosidic oleanane-type triterpenoid (BAT) that can be isolated from the acid hydrolysis product (AHP) of the crude extract of Aesculus chinensis seeds. Aesculus-derived triterpenoids (BAT) generally exhibit good antitumor, anti-inflammatory, and anti-Alzheimer's activities. Protoescigenin 21-tiglate has antitumor activity, with IC50 values of 38.2 μM and 33 μM against MCF-7 and HeLa cells, respectively .
|
-
- HY-128912
-
|
|
Alkaloids
Animals
Source Classification
|
Histone Demethylase
|
|
Arborinine is a potent and orally activeLSD1 inhibitor. Arborinine increases the expression of H3K4me1/2, H3K9me1/2, E-cad protein and decreases the expression of UBE2O protein level. Arborinine induces cell cycle arrest at S phase. Arborinine shows antitumor activity .
|
-
- HY-N4095
-
-
- HY-B1092
-
-
- HY-N12537
-
-
- HY-W012531R
-
-
- HY-N0542
-
-
- HY-113952
-
|
(-)-Actinonin
|
Infection
Natural Products
Microorganisms
Classification of Application Fields
Marine natural products
Disease Research Fields
Source Classification
|
Aminopeptidase
Bacterial
MMP
Apoptosis
Antibiotic
|
|
Actinonin ((-)-Actinonin) is a naturally occurring antibacterial agent produced by Actinomyces. Actinonin inhibits aminopeptidase M, aminopeptidase N and leucine aminopeptidase. Actinonin is a potent reversible peptide deformylase (PDF) inhibitor with a Ki of 0.28 nM. Actinonin also inhibits MMP-1, MMP-3, MMP-8, MMP-9, and hmeprin α with Ki values of 300 nM, 1,700 nM, 190 nM, 330 nM, and 20 nM, respectively. Actinonin is an apoptosis inducer. Actinonin has antiproliferative and antitumor activities .
|
-
- HY-N12004
-
-
- HY-N8487R
-
|
|
Flavonoids
Flavones
Leguminosae
Zornia brasiliensis
Plants
Source Classification
|
Reference Standards
Cytochrome P450
|
|
7-Methoxyflavone (Standard) is the analytical standard of 7-Methoxyflavone (HY-N8487). This product is intended for research and analytical applications. 7-Methoxyflavone is a flavonoid compound that can be isolated from Zornia brasiliensis. 7-Methoxyflavone can bind to human serum albumin and is an aromatase inhibitor. 7-Methoxyflavone has peripheral analgesic and certain antitumor activities. 7-Methoxyflavone is effective against chemical pain but has no significant effect on thermal pain .
|
-
- HY-N7175
-
|
9,11-Dehydroergosterol peroxide; 9(11)-DHEP
|
Classification of Application Fields
Solanum lyratum Thunberg
Solanaceae
Plants
Disease Research Fields
Steroids
Source Classification
Cancer
|
Apoptosis
Endogenous Metabolite
|
|
5,8-Epidioxyergosta-6,9(11),22-trien-3-ol (9,11-Dehydroergosterol peroxide), an important steroid from medicinal mushroom, exerts antitumor activity in several tumor types. 5,8-Epidioxyergosta-6,9(11),22-trien-3-ol inhibits HT29 cell growth by inducing CDKN1A expression, thus causing cell cycle arrest and apoptosis .
|
-
- HY-N7719R
-
-
- HY-128741R
-
-
- HY-N0234
-
-
- HY-N0617
-
-
- HY-N3405
-
-
- HY-W047478R
-
|
NSC 10154 (Standard)
|
Alkaloids
Structural Classification
other families
Plants
Indole Alkaloids
Source Classification
|
Reference Standards
Interleukin Related
Fungal
|
|
3-Methylcarbazole (NSC 10154) Standard is the analytical standard of 3-Methylcarbazole (HY-W047478). This product is intended for research and analytical applications. 3-Methylcarbazole (NSC 10154) is a carbazole alkaloid with an IC50 of 25 μg/mL against human fibrosarcoma cells. 3-Methylcarbazole inhibits mycelial growth and conidial germination of a variety of phytopathogenic fungi. 3-Methylcarbazole exhibits anti-inflammatory and antitumor activities. 3-Methylcarbazole can be used in studies related to fibrosarcoma, phytopathogenic fungal infections and inflammatory diseases.
|
-
- HY-N6037
-
-
- HY-13502AR
-
|
Mitozantrone dihydrochloride (Standard); NSC 301739 dihydrochloride (Standard)
|
Quinones
Structural Classification
Anthraquinones
Endogenous metabolite
Source Classification
|
Reference Standards
Topoisomerase
PKC
Orthopoxvirus
Apoptosis
Endogenous Metabolite
|
|
Mitoxantrone (dihydrochloride) (Standard) is the analytical standard of Mitoxantrone (dihydrochloride). This product is intended for research and analytical applications. Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .
|
-
- HY-N6818
-
|
TMF
|
Structural Classification
Flavonoids
Classification of Application Fields
Flavones
Kaempferia parviflora Wall. ex Baker
Plants
Disease Research Fields
Source Classification
Zingiberaceae
Cancer
|
Apoptosis
Caspase
PARP
Endogenous Metabolite
CFTR
|
|
5,7,4’-Trimethoxyflavone can be isolated from the medicinal plant Kaempferia parviflora (KP). 5,7,4’-Trimethoxyflavone is a CFTR activator and EC50 is 64 μM. 5,7,4’-Trimethoxyflavone induces apoptosis, increases proteolytic activation of caspase-3, and degradation of ADP-ribose polymerase (PARP) protein. 5,7,4’-Trimethoxyflavone has antitumor activity. 5,7,4’-Trimethoxyflavone can be used to prevent skin aging and oxidative stress .
|
-
- HY-B0255
-
-
- HY-13502R
-
-
- HY-N6015R
-
-
- HY-N9284
-
-
- HY-16468
-
-
- HY-116514
-
-
- HY-N2187
-
-
- HY-N13772
-
|
(+)-Dihydroisorhamnetin
|
Flavanonols
Flavonoids
Pulicaria jaubertii E.Gamal-Eldin
Asteraceae
Plants
Source Classification
|
Apoptosis
|
|
3'-O-Methyltaxifolin ((+)-Dihydroisorhamnetin) is a dihydroflavanol found in Pulicaria jaubertii. A mixture of these alcohol compounds including 3'-O-Methyltaxifolin found in Pulicaria jaubertii exhibits antitumor activity with IC50 values of 19.1 μg, 20.0 μg, and 24.1 μg against prostate cancer (PC-3), breast cancer (MCF-7), and hepatocellular carcinoma (HepG-2) cell lines, respectively. Furthermore, 3'-O-Methyltaxifolin can induce cell apoptosis, making it a promising candidate for anticancer research. .
|
-
- HY-N0646
-
-
- HY-N4095R
-
-
- HY-B1092AR
-
-
- HY-120149
-
-
- HY-W001925
-
-
- HY-N0234R
-
-
- HY-113952R
-
|
(-)-Actinonin (Standard)
|
Natural Products
Microorganisms
Source Classification
|
Reference Standards
Aminopeptidase
Bacterial
MMP
Apoptosis
Antibiotic
|
|
Actinonin (Standard) is the analytical standard of Actinonin. This product is intended for research and analytical applications. Actinonin ((-)-Actinonin) is a naturally occurring antibacterial agent produced by Actinomyces. Actinonin inhibits aminopeptidase M, aminopeptidase N and leucine aminopeptidase. Actinonin is a potent reversible peptide deformylase (PDF) inhibitor with a Ki of 0.28 nM. Actinonin also inhibits MMP-1, MMP-3, MMP-8, MMP-9, and hmeprin α with Ki values of 300 nM, 1,700 nM, 190 nM, 330 nM, and 20 nM, respectively. Actinonin is an apoptosis inducer. Actinonin has antiproliferative and antitumor activities[1][2][3][4][5].
|
-
- HY-N13201
-
-
- HY-N0256R
-
-
- HY-B0255R
-
-
- HY-113327R
-
|
|
Natural Products
Human Gut Microbiota Metabolites
Microorganisms
Endogenous metabolite
Source Classification
|
Drug Metabolite
Reference Standards
Endogenous Metabolite
|
|
Hederagenin (Standard) is the analytical standard of Hederagenin. This product is intended for research and analytical applications. Hederagenin is a triterpenoid saponin with orally active and antitumor activity. Hederagenin can inhibit the expression of iNOS, COX-2, and NF-κB in cells induced by LPS stimulation. Hederagenin also increases ROS production in cancer cells, disrupts mitochondrial membrane potential, and induces apoptosis. Hederagenin also sensitizes cancer cells to Cisplatin (HY-17394) and Paclitaxel (HY-B0015), enhancing induced apoptosis. Hederagenin also has preventive potential against alcoholic liver injury .
|
-
- HY-N0256
-
-
- HY-124586
-
-
- HY-B1092R
-
|
Calcium D-gluconate (Standard); Gluconic acid hemicalcium salt (Standard)
|
Structural Classification
Endogenous metabolite
Saccharides
Monosaccharides
Source Classification
|
Reference Standards
NO Synthase
Endogenous Metabolite
Interleukin Related
ERK
|
|
Gluconate Calcium (Standard) (Calcium D-gluconate (Standard)) is the analytical standard of Gluconate Calcium (HY-B1092). This product is intended for research and analytical applications. Gluconate (D-Gluconic acid) Calcium is an orally active glucose derivative. Gluconate Calcium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate Calcium inhibits ERK phosphorylation. Gluconate Calcium has antioxidant and antiplatelet activation activities. Gluconate Calcium has antitumor activity against colorectal cancer. Gluconate Calcium improves osteoarthritis, intestinal damage and acute lung injury .
|
-
- HY-N6818R
-
|
TMF (Standard)
|
Structural Classification
Flavonoids
Flavones
Kaempferia parviflora Wall. ex Baker
Plants
Source Classification
Zingiberaceae
|
Reference Standards
Apoptosis
Caspase
PARP
Endogenous Metabolite
CFTR
|
|
5,7,4'-Trimethoxyflavone (Standard) is the analytical standard of 5,7,4'-Trimethoxyflavone. This product is intended for research and analytical applications. 5,7,4’-Trimethoxyflavone can be isolated from the medicinal plant Kaempferia parviflora (KP). 5,7,4’-Trimethoxyflavone is a CFTR activator and EC50 is 64 μM. 5,7,4’-Trimethoxyflavone induces apoptosis, increases proteolytic activation of caspase-3, and degradation of ADP-ribose polymerase (PARP) protein. 5,7,4’-Trimethoxyflavone has antitumor activity. 5,7,4’-Trimethoxyflavone can be used to prevent skin aging and oxidative stress .
|
-
- HY-N14001
-
|
|
Structural Classification
Alkaloids
Marine natural products
Sponge
Imidazole Alkaloids
Source Classification
|
TNF Receptor
Interleukin Related
Arginase
PD-1/PD-L1
|
|
Naamidine J is an imidazole-type alkaloids discovered in a sponge. Naamidine J inhibits inflammation by binding to the protein CSE1L (KD = 5.41 μM). Namidine J significantly inhibits the expression of pro-inflammatory factors such as TNF-α, IL-1β, and IL-6, and upregulates anti-inflammatory factors such as CD206 and Arg-1. Namidine J inhibits PD-L1 and shows antitumor activity. Namidine J significantly reduces pulmonary tissue edema, inflammatory cell infiltration and cytokine storm in mice. Namidine J can be used for the research on the immune microenvironment of acute lung injury and tumors .
|
-
- HY-116514R
-
-
- HY-N0763
-
|
Isopsoralen
|
Classification of Application Fields
Leguminosae
Coumarins
Phenylpropanoids
Psoralea corylifolia L.
Plants
Disease Research Fields
Source Classification
Cancer
|
Apoptosis
Virus Protease
NF-κB
p38 MAPK
JNK
Caspase
|
|
Angelicin is a furanocoumarin compound that functions as an inhibitor of NF-κB and MAPK signaling pathways, exhibiting anti-inflammatory, antiviral, and antitumor activities. It suppresses the lytic replication of γ-herpesviruses, such as MHV-68, early during viral infection, potentially inhibiting RTA gene expression (IC50=28.95 μM). Angelicin also mitigates inflammation by inhibiting the phosphorylation and nuclear translocation of NF-κB, and the phosphorylation of p38 and JNK. Furthermore, it induces apoptosis in neuroblastoma cells by downregulating anti-apoptotic proteins like Bcl-2, Bcl-xL, and Mcl-1, while activating caspase-9 and caspase-3.
|
-
- HY-N3005
-
-
- HY-N0646R
-
-
- HY-W052289R
-
-
- HY-N6037R
-
-
- HY-129440
-
|
|
Structural Classification
Classification of Application Fields
Carthamus tinctorius L.
Phenols
Polyphenols
Plants
Compositae
Inflammation/Immunology
Disease Research Fields
Source Classification
|
NF-κB
Toll-like Receptor (TLR)
p38 MAPK
NO Synthase
COX
ERK
Caspase
PDGFR
MyD88
Reactive Oxygen Species (ROS)
Apoptosis
|
|
N-(p-Coumaroyl) Serotonin is an orally active polyphenol found in safflower seeds with potent anti-inflammatory, antioxidant, and antitumor activities. N-(p-Coumaroyl) Serotonin suppresses NF‑κB, TLR4/MyD88 and MAPK signaling, activates NQO1/HO‑1 pathways, and inhibits pro‑inflammatory cytokines, iNOS and COX‑2 and ROS production. N-(p-Coumaroyl) Serotonin induces S‑phase arrest and apoptosis in glioblastoma cells, reduces atherosclerotic lesions, and alleviates renal and vascular injuries. N-(p-Coumaroyl) Serotonin acts as a vasodilator, regulates calcium dynamics. N-(p-Coumaroyl) Serotonin can be used for the research of neurodegenerative diseases, atherosclerosis, glioblastoma, and acute renal failure .
|
-
- HY-N16377
-
|
|
Quinones
Microorganisms
Anthraquinones
Source Classification
|
Others
|
|
1-Butyl-3,5,8-trihydroxy-9,10-anthracenedione (Compound 2) is an anthraquinone analog. 1-Butyl-3,5,8-trihydroxy-9,10-anthracenedione can be isolated from soil Actinomycete Streptomyces. 1-Butyl-3,5,8-trihydroxy-9,10-anthracenedione has potent cytotoxicity against HepG2, A875, BGC-823 and MCF-7 cells with IC50s of 2.29, 4.90, 0.99 and 1.66 μg/mL, respectively. 1-Butyl-3,5,8-trihydroxy-9,10-anthracenedione has an antitumor activity .
|
-
- HY-N8146
-
-
- HY-129440R
-
|
|
Structural Classification
Carthamus tinctorius L.
Phenols
Polyphenols
Plants
Compositae
Source Classification
|
Reference Standards
PDGFR
ERK
Caspase
NF-κB
Toll-like Receptor (TLR)
p38 MAPK
NO Synthase
COX
MyD88
Reactive Oxygen Species (ROS)
Apoptosis
|
|
N-(p-Coumaroyl) Serotonin (Standard) is the analytical standard of N-(p-Coumaroyl) Serotonin (HY-129440). This product is intended for research and analytical applications. N-(p-Coumaroyl) Serotonin is an orally active polyphenol found in safflower seeds with potent anti-inflammatory, antioxidant, and antitumor activities. N-(p-Coumaroyl) Serotonin suppresses NF‑κB, TLR4/MyD88 and MAPK signaling, activates NQO1/HO‑1 pathways, and inhibits pro‑inflammatory cytokines, iNOS and COX‑2 and ROS production. N-(p-Coumaroyl) Serotonin induces S‑phase arrest and apoptosis in glioblastoma cells, reduces atherosclerotic lesions, and alleviates renal and vascular injuries. N-(p-Coumaroyl) Serotonin acts as a vasodilator, regulates calcium dynamics. N-(p-Coumaroyl) Serotonin can be used for the research of neurodegenerative diseases, atherosclerosis, glioblastoma, and acute renal failure .
|
-
- HY-N15378
-
|
|
Structural Classification
Natural Products
Spondias mombin L.
Plants
Anacardiaceae
Source Classification
|
IAP
Bcl-2 Family
COX
TNF Receptor
Caspase
Apoptosis
|
|
β-carotene-15,15ʹ-epoxide is a XIAP antagonist with apoptosis-inducing and antitumor activity, found in the leaves of Spondias mombin. In a DMBA (HY-W011845)-induced rat model of breast cancer, β-carotene-15,15ʹ-epoxide binds to the BIR3 domain of the anti-apoptotic protein XIAP, blocking its interaction with caspase-9 and thereby promoting tumor cell apoptosis. In addition, β-carotene-15,15ʹ-epoxide significantly downregulates the expression of BCL-2, COX-2, and TNF-α in tumor tissues, reduces MDA levels, increases catalase activity, and modulates serum levels of LDH, ALP, and ALT, demonstrating strong antioxidant, anti-inflammatory, and metabolic protective effects. β-carotene-15,15ʹ-epoxide may be used in research on inflammation-related conditions and cancers such as breast cancer .
|
-
- HY-N0863
-
|
NSC-698790; Smilax saponin B
|
Structural Classification
other families
Classification of Application Fields
Plants
Disease Research Fields
Steroids
Source Classification
Cancer
|
Bcl-2 Family
Apoptosis
Akt
c-Myc
ERK
p38 MAPK
JNK
FOXO
|
|
Methyl protodioscin (NSC-698790; Smilax saponin B) is a multi-target, selective, steroidal diglycoside inhibitor with antitumor activity that induces cell cycle arrest. The mechanism of action of Methyl protodioscin is complex, involving the induction of G2/M cell cycle arrest, regulation of the Bcl-2/Bax apoptotic pathway, inhibition of the Akt1/c-Myc axis and MAPK/ERK signaling, while simultaneously downregulating ADAM15 and inducing FOXO1 to reduce cholesterol synthesis. It also inhibits the JNK/c-Jun pathway, reducing the production of inflammatory factors (IL-6, TNF-α). Methyl protodioscin exhibits significant antitumor (inhibiting proliferation, migration, invasion, and inducing apoptosis), anti-inflammatory, and anti-restenosis activities. Methyl protodioscin can be used in research on lung cancer, prostate cancer, pancreatic cancer, and other tumors, as well as inflammatory diseases such as airway inflammation and enteritis .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-128995AS
-
|
|
|
Glycyl-Exatecan-d5 (Glycyl-DX-8951-d5) hydrochloride is deuterium labeled Glycyl-Exatecan (HY-128995A). Glycyl-Exatecan (Glycyl-DX-8951), a derivative of Exatecan (HY-13631), is an anticancer agent. Glycyl-Exatecan has significantly antitumor activity. Glycyl-Exatecan can be used for cancers like solid tumors research.
|
-
-
- HY-15575S
-
|
|
|
VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .
|
-
-
- HY-B0413S
-
5 Publications Verification
|
|
Fenbendazole-d3 is a deuterium labeled Fenbendazole. Fenbendazole-d3 is a HIF-1α agonist and activates the HIF-1α-related GLUT1 pathway. Fenbendazole is an orally active benzimidazole anthelmintic agent, with a broad antiparasitic range. Fenbendazole is a microtubule destabilizing agent. Fenbendazole causes cell-cycle arrest and mitotic cell death, and has antitumor activity in mice xenografted with wild-type p53 .
|
-
-
- HY-169326S
-
|
|
|
JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with IC50 ≤10 nM against JH2 BIND WT/V617F. JAK2-IN-11 has antitumor activity .
|
-
-
- HY-10981S
-
|
|
|
Lenvatinib-d4 is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
|
-
-
- HY-15582S
-
|
|
|
Auristatin E-d8 is the deuterium labeled Auristatin E (HY-15582). Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids .
|
-
-
- HY-W768336
-
|
|
|
Gluconate sodium- 13C6 (D-Gluconic acid sodium salt- 13C6) is the 13C-labeled Gluconate sodium (HY-B1092A). Gluconate sodium (D-Gluconic acid sodium salt) is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury .
|
-
-
- HY-13582S
-
|
|
|
Carbendazim-d4 is the deuterium labeled Carbendazim. Carbendazim is a potent and orally active broad-spectrum?benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria,?Fusarium?and?Sclerotina . Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma .
|
-
-
- HY-50936S
-
|
|
|
Trabectedin D3 (Ecteinascidin 743 D3) is deuterium labeled Trabectedin. Trabectedin is a tetrahydroisoquinoline alkaloid with potent antitumor activity. Trabectedin binds to the minor groove of DNA, blocks transcription of stress-induced proteins, induces DNA backbone cleavage and cancer cells apoptosis, and increases the generation of ROS in MCF-7 and MDA-MB-453 cells. Trabectedin has tje potential for soft tissue sarcoma and ovarian cancer treatment .
|
-
-
- HY-10181S1
-
|
|
|
Dasatinib-d4 (BMS-354825-d4) is deuterium labeled Dasatinib. Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib also induces apoptosis and autophagy.
|
-
-
- HY-B1092AS
-
|
|
|
Gluconate-1- 13C (D-Gluconic acid-1- 13C) sodium is the 13C labeled Gluconate sodium (HY-B1092A). Gluconate (D-Gluconic acid) sodium is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury .
|
-
-
- HY-112582S
-
|
|
|
N1-Methylpseudouridine-d3 is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
-
- HY-W782079
-
|
|
|
Geraniol-d6 (Major) is the deuterated labeled Geraniol (Major). Geraniol is an olefin terpene with oral activity. Geraniol inhibits cell proliferation and promotes apoptosis. Geraniol has antibacterial, antifungal, antioxidant, anti-inflammatory and antitumor activities. Geraniol can be used to study diabetes .
|
-
-
- HY-16106S1
-
|
|
|
Talazoparib-d4 (BMN-673-d4) is deuterium labeled Talazoparib. Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity .
|
-
-
- HY-10981S1
-
|
|
|
Lenvatinib-d5 is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
|
-
-
- HY-B1000S1
-
|
|
|
Selenomethionine- 77Se (Seleno-DL-methionine- 77Se) is the 77Se- labeled Selenomethionine (HY-B1000). Selenomethionine is a naturally occurring amino acid containing selenium that has oral activity and is a common natural food source. Selenomethionine has antitumor activity .
|
-
-
- HY-10981S2
-
|
|
|
Lenvatinib- 15N,d4 is 15N and deuterated labeled Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
|
-
-
- HY-113341S
-
|
|
|
7ß-Hydroxycholesterol-d7 is the deuterium labeled 7α-Hydroxycholesterol. 7β-Hydroxycholesterol is an oxysterol that derived by the oxidation of cholesterol. 7β-hydroxycholesterol can induce cellular oxidative stress, apoptosis, and necrosis, resulting in cytotoxicity. 7β-hydroxycholesterol has antitumor activity .
|
-
-
- HY-126534S
-
|
|
|
Abemaciclib metabolite M18-d8 is the deuterium labeled Abemaciclib metabolite M18. Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .
|
-
-
- HY-B0508S1
-
|
|
|
Ornidazole- 13C2, 15N2 is the 13C, 15N labeled Ornidazole. Ornidazole (Ro 7-0207) is a nitroimidazole derivative with anti-trichomonad activity and in vitro activity against a variety of anaerobic bacteria. Ornidazole inhibits Sonic hedgehog (Shh) signaling pathway, exhibits antitumor activity. Ornidazole can be used in research of Crohn’s disease .
|
-
-
- HY-W768839
-
|
|
|
5-(Hydroxymethyl)cytidine- 13C,d2 is the deuterium labeled and 13C-labeled 5-(Hydroxymethyl)cytidine (HY-152854). 5-(Hydroxymethyl)cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
-
- HY-B1490AS
-
|
|
|
Imipramine-d6 is the deuterium labeled Imipramine hydrochloride. Imipramine is an orally active tertiary amine tricyclic antidepressant. Imipramine is a Fascin1 inhibitor with antitumor activities. Imipramine also inhibits serotonin transporter with an IC50 value of 32 nM. Imipramine stimulates U-87MG glioma cells autophagy and induces HL-60 cell apoptosis. Imipramine shows neuroprotective and immunomodulatory effects .
|
-
-
- HY-B1490S1
-
|
|
|
Imipramine-d3 (hydrochloride) is deuterium labeled Imipramine (hydrochloride). Imipramine is an orally active tertiary amine tricyclic antidepressant. Imipramine is a Fascin1 inhibitor with antitumor activities. Imipramine also inhibits serotonin transporter with an IC50 value of 32 nM. Imipramine stimulates U-87MG glioma cells autophagy and induces HL-60 cell apoptosis. Imipramine shows neuroprotective and immunomodulatory effects .
|
-
-
- HY-P0036S4
-
|
|
|
Octreotide-d8 (acetate) (SMS 201-995-d8 (acetate)) is deuterium labeled Octreotide. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .
|
-
-
- HY-128741S
-
|
|
|
D-Allose- 13C is the 13C labeled D-Allose (HY-128741). D-Allose exhibits antitumor activity against various cancer cells. D-Allose scavenges reactive oxygen species (ROS) and reduces oxidative stress damage. D-Allose exhibits anti-inflammatory and neuroprotective through inhibition of TLR4/PI3K/AKT signaling pathway. D-Allose exhibits antihypertensive, cryoprotective, and anti-osteoporotic activities .
|
-
-
- HY-12678S
-
|
|
|
Entrectinib-d4 (NMS-E628-d4; RXDX-101-d4) is the deuterium labeled Entrectinib (HY-12678). Entrectinib is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC50 values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice .
|
-
-
- HY-W754911
-
|
|
|
Avapritinib-d3 (BLU-285-d3) is deuterium labeled Avapritinib. Avapritinib (BLU-285) is a highly potent, selective, and orally active KIT and PDGFRA activation loop mutant kinases inhibitor with IC50s of 0.27 and 0.24 nM for KIT D816V and PDGFRA D842V, respectively. Avapritinib (BLU-285) binds the active conformation of the kinase and shows antitumor activity. Avapritinib (BLU-285) attenuates the transport function of both ABCB1 and ABCG2 .
|
-
-
- HY-W701673
-
|
|
|
Thio-TEPA-d12 is the deuterium labeled Thio-TEPA (HY-17574). Thio-TEPA is a DNA alkylating agent, with antitumor activity.
|
-
-
- HY-W698934
-
|
|
|
DL-Alanosine- 15N2 is the 15N-labeled DL-Alanosine (HY-13548). DL-Alanosine is an amino acid analogue with antitumor activities .
|
-
-
- HY-B0431S
-
|
|
|
Phenoxybenzamine-d5 is the deuterium labeled Phenoxybenzamine . Phenoxybenzamine is a nonselective, irreversible, orally active α-adrenoceptor antagonist that is commonly used for the research of hypertension, specifically caused by pheochromocytoma. Phenoxybenzamine also shows antitumor activity .
|
-
-
- HY-B0431AS
-
|
|
|
Phenoxybenzamine-d5 (hydrochloride) is the deuterium labeled Phenoxybenzamine hydrochloride. Phenoxybenzamine hydrochloride is a nonselective, irreversible, orally active α-adrenoceptor antagonist that is commonly used for the research of hypertension, specifically caused by pheochromocytoma. Phenoxybenzamine hydrochloride also shows antitumor activity[1][2][3].
|
-
-
- HY-100760S
-
|
|
|
Toxoflavin- 13C4 is the 13C-labeled Toxoflavin. Toxoflavin (Xanthothricin) is an antagonist of transcription factor 4 (TCF4)/β-catenin complex, also acts as an inhibitor of KDM4A, with antitumor activity . Antibiotic properties.
|
-
-
- HY-N8253S
-
|
|
|
Quercetin 4'-Glucoside-d3 (Spiraeoside-d3) is deuterium labeled Spiraeoside. Spiraeoside, an orally active natural compound, exerts antioxidant activity, inhibits reactive oxygen species (ROS) and malondialdehyde production. Spiraeoside possesses antiallergic, anti-inflammatory and antitumor activities .
|
-
-
- HY-145989S
-
|
|
|
Aminobenzenesulfonic auristatin E-d8 is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .
|
-
-
- HY-12643S
-
|
|
|
Eprinomectin-d3 (MK-397-d3) is the deuterium-labeled Eprinomectin (HY-12643). Eprinomectin is a type of avermectin. Eprinomectin, as a broad-spectrum fungicide, has insecticidal, insecticidal and acaricidal activities. Eprinomectin induces apoptosis and autophagy in prostate cancer cells and has antitumor activity .
|
-
-
- HY-B0431AS1
-
|
|
|
Phenoxybenzamine (benzyl-2,3,4,5,6-d5) (hydrochloride) is the deuterium labeled Phenoxybenzamine hydrochloride. Phenoxybenzamine hydrochloride is a nonselective, irreversible, orally active α-adrenoceptor antagonist that is commonly used for the research of hypertension, specifically caused by pheochromocytoma. Phenoxybenzamine hydrochloride also shows antitumor activity[1][2][3].
|
-
-
- HY-B0508S
-
|
|
|
Ornidazole-d5 is deuterium labeled Ornidazole. Ornidazole (Ro 7-0207) is a nitroimidazole derivative with anti-trichomonad activity and in vitro activity against a variety of anaerobic bacteria. Ornidazole inhibits Sonic hedgehog (Shh) signaling pathway, exhibits antitumor activity. Ornidazole can be used in research of Crohn’s disease .
|
-
-
- HY-W711474
-
|
|
|
(-)-Menthol-d4 is the deuterium labeled (-)-Menthol (HY-75161). (-)-Menthol is a key component of peppermint oil that binds and activates transient receptor potential melastatin 8 (TRPM8), a Ca2+-permeable nonselective cation channel, to increase [Ca2+]i . Antitumor activity .
|
-
-
- HY-N8525S
-
|
|
|
3'-O-Acetylthymidine- 13C is the 13C-labeled 3'-O-Acetylthymidine (HY-N8525). 3'-O-Acetylthymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
-
- HY-13582S1
-
|
|
|
Carbendazimb-d3 is the deuterium labeled Carbendazimb (HY-13582). Carbendazim is a potent and orally active broad-spectrum?benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria,?Fusarium?and?Sclerotina . Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma .
|
-
-
- HY-159176
-
|
|
|
Antitumor agent-183 (compound 3f) has antitumor activity with metabolic stability. Antitumor agent-183 inhibits cancer cell growth, with IC50s less than 5 nM for A549, HCT116, and HS578T cells. The albumin-bound nanoparticle formulation of Antitumor agent-183 has prolonged retention in the tumor tissues .
|
-
-
- HY-W654009
-
|
|
|
Loxoprofen-d3 is deuterium labeled Loxoprofen. Loxoprofen is a non-steroidal, orally active anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen is a nonselective COX inhibitor with IC50s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively. Loxoprofen can reduce atherosclerosis and shows antitumor activity .
|
-
-
- HY-B1490S
-
|
|
|
Imipramine-d4 (hydrochloride) is the deuterium labeled Imipramine hydrochloride. Imipramine hydrochloride is an orally active tertiary amine tricyclic antidepressant. Imipramine hydrochloride is a Fascin1 inhibitor with antitumor activities. Imipramine hydrochloride also inhibits serotonin transporter with an IC50 value of 32 nM. Imipramine hydrochloride stimulates U-87MG glioma cells autophagy and induces HL-60 cell apoptosis. Imipramine hydrochloride shows neuroprotective and immunomodulatory effects .
|
-
-
- HY-B1490AS1
-
|
|
|
Imipramine-d4 is deuterium labeled Imipramine. Imipramine is an orally active tertiary amine tricyclic antidepressant. Imipramine is a Fascin1 inhibitor with antitumor activities. Imipramine also inhibits serotonin transporter with an IC50 value of 32 nM. Imipramine stimulates U-87MG glioma cells autophagy and induces HL-60 cell apoptosis. Imipramine shows neuroprotective and immunomodulatory effects .
|
-
-
- HY-B1490AS3
-
|
|
|
Imipramine-d4-1 is the deuterium labeled Imipramine (HY-W010179). Imipramine is an orally active tertiary amine tricyclic antidepressant. Imipramine is a Fascin1 inhibitor with antitumor activities. Imipramine also inhibits serotonin transporter with an IC50 value of 32 nM. Imipramine stimulates U-87MG glioma cells autophagy and induces HL-60 cell apoptosis. Imipramine shows neuroprotective and immunomodulatory effects .
|
-
-
- HY-W012531S2
-
|
|
|
2-Hydroxycinnamic acid-d4 is deuterium labeled 2-Hydroxycinnamic acid. 2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against Staphylococcus aureus and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of HIV/SARS-CoV S pseudovirus with an IC50 of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity .
|
-
-
- HY-P0036S2
-
|
|
|
Octreotide-d8 (SMS 201-995-d8) is deuterium labeled Octreotide. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .
|
-
-
- HY-W011577S1
-
|
|
|
Dibenzo[a,c]anthracene- 13C6 (2,3-Benzotriphenylene- 13C6) is 13C labeled Benzo[f]tetraphene. Benzo[f]tetraphene (Dibenz[a,c]anthracene) is a polycyclic aromatic hydrocarbon with significant antitumor activity. Benzo[f]tetraphene is used as a luminescent probe in cell biology research and can effectively detect reactive oxygen species in biological systems. Benzo[f]tetraphene can also be used as a potential photosensitizer and shows good application prospects in photodynamic inhibition.
|
-
-
- HY-18986S
-
|
|
|
SAR405838-d10 (MI-77301-d10) is the deuterium labeled SAR405838 (HY-18986). SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective MDM2-p53 interaction inhibitor. SAR405838 binds to MDM2 with a Ki of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity .
|
-
-
- HY-128741S2
-
|
|
|
D-Allose- 13C-2 is the 13C labeled D-Allose (HY-128741). D-Allose exhibits antitumor activity against various cancer cells. D-Allose scavenges reactive oxygen species (ROS) and reduces oxidative stress damage. D-Allose exhibits anti-inflammatory and neuroprotective through inhibition of TLR4/PI3K/AKT signaling pathway. D-Allose exhibits antihypertensive, cryoprotective, and anti-osteoporotic activities .
|
-
- HY-13502AS
-
|
|
|
Mitoxantrone-d8 dihydrochloride is deuterated labeled Mitoxantrone dihydrochloride (HY-13502A). Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .
|
-
- HY-128741S1
-
|
|
|
D-Allose- 13C-1 is the 13C labeled D-Allose (HY-128741). D-Allose exhibits antitumor activity against various cancer cells. D-Allose scavenges reactive oxygen species (ROS) and reduces oxidative stress damage. D-Allose exhibits anti-inflammatory and neuroprotective through inhibition of TLR4/PI3K/AKT signaling pathway. D-Allose exhibits antihypertensive, cryoprotective, and anti-osteoporotic activities .
|
-
- HY-13502AS1
-
|
|
|
Mitoxantrone-d8 (hydrochloride) (Mitozantrone-d8 (hydrochloride)) is deuterium labeled Mitoxantrone (dihydrochloride). Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .
|
-
- HY-P0036S3
-
|
|
|
Octreotide- 13C9, 15N (SMS 201-995- 13C9, 15N) is 13C and 15N labeled Octreotide. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .
|
-
- HY-W739775
-
|
|
|
2,3’-Anhydrothymidine-d3 (2’-Deoxy-3’,2-anhydro-5-methyluridine-d3) is the deuterium labeled 2,3’-Anhydrothymidine (HY-154340). 2,3’-Anhydrothymidine; 2’-Deoxy-3’,2-anhydro-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-159846S
-
|
|
|
Luvometinib-d is the deuterium labeled Luvometinib (HY-159846). Luvometinib is a mitogen-activated protein kinase (MEK) inhibitor with antitumor activity .
|
-
- HY-119696S1
-
|
|
|
MTIC- 13C is the 13C-labeled MTIC (HY-119696). MTIC, the active metabolite of Temozolomide (TMZ), is a DNA alkylating agent. MTIC has antitumor activity
|
-
- HY-B1000S
-
|
|
|
Selenomethionine- 76Se (Seleno-DL-methionine- 76Se) is the 76Se- labeled Selenomethionine (HY-B1000). Selenomethionine is a naturally occurring amino acid containing selenium that has oral activity and is a common natural food source. Selenomethionine has antitumor activity .
|
-
- HY-112581S
-
|
|
|
5-Methoxyuridine-d3 is the deuterium labeled 5-Methoxyuridine (HY-112581). 5-Methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-136270S
-
|
|
|
Gartisertib-d8 (VX-803-d8) is the deuterium labeled Gartisertib (HY-136270). Gartisertib (VX-803) is an ATP-competitive, orally active, and selective ATR inhibitor, with a Ki of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC50 of 8 nM. Antitumor activity .
|
-
- HY-N6748S
-
|
|
|
Roquefortine C- 13C22 is the 13C-labeled Roquefortine C (HY-N6748). Roquefortine C is a mycotoxin that can be isolated from Penicillium species. Roquefortine C is an agonist of P-gp and an inhibitor of P450 3A and P450 1A. Roquefortine C can inhibit Gram-positive bacteria and also has certain neurotoxicity. Additionally, Roquefortine C can exert antitumor activity .
|
-
- HY-P0036S
-
|
|
|
Octreotide-d8 (SMS 201-995-d8) TFA is the deuterium labeled Octreotide TFA. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly.
|
-
- HY-W040293S
-
|
|
|
06:0 PE-d22 (PE(6:0/6:0)-d22) is the deuterium labeled 06:0 PE (HY-W040293). 06:0 PE (PE(6:0/6:0)) is a water-soluble phospholipid characterized by its short acyl chains, exhibiting notable antitumor activity and the ability to inhibit tumor progression in vivo, alongside antiproliferative and proapoptotic effects, while serving as a precursor for phosphatidylcholine and phosphatidylethanolamine.
|
-
- HY-B1092AS2
-
|
|
|
Gluconate-d6 sodium (D-Gluconic acid sodium salt-d6) is the deuterium labeled Gluconate sodium (HY-B1092A). Gluconate sodium (D-Gluconic acid sodium salt) is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury .
|
-
- HY-19337S1
-
|
|
|
Ketodarolutamide-d6 (BAY 1896953-d6) is the deuterium labeled Ketodarolutamide (HY-19337). Ketodarolutamide (ORM-15341) is a potent, high-affinity nonsteroidal competitive full antagonist of androgen receptor (AR). Ketodarolutamide displays a Ki value of 8 nM for rat wild-type AR and an IC50 value of 38 nM in AR-HEK293 cells . Ketodarolutamide inhibits testosterone-induced nuclear translocation of the AR and antagonizes both overexpressed and mutant ARs . Ketodarolutamide specifically suppresses the proliferation of AR-dependent prostate cancer cells and exhibits antitumor activity in models of castration-resistant prostate cancer (CRPC) . Ketodarolutamide is suitable for the mechanistic and therapeutic research of prostate cancer .
|
-
- HY-19337S
-
|
|
|
Ketodarolutamide-d3 (BAY 1896953-d3) is the deuterium labeled Ketodarolutamide (HY-19337). Ketodarolutamide (ORM-15341) is a potent, high-affinity nonsteroidal competitive full antagonist of androgen receptor (AR). Ketodarolutamide displays a Ki value of 8 nM for rat wild-type AR and an IC50 value of 38 nM in AR-HEK293 cells . Ketodarolutamide inhibits testosterone-induced nuclear translocation of the AR and antagonizes both overexpressed and mutant ARs . Ketodarolutamide specifically suppresses the proliferation of AR-dependent prostate cancer cells and exhibits antitumor activity in models of castration-resistant prostate cancer (CRPC) . Ketodarolutamide is suitable for the mechanistic and therapeutic research of prostate cancer .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-10446
-
Pralatrexate
Maximum Cited Publications
9 Publications Verification
|
|
Alkynes
|
|
Pralatrexate is an antifolate and is a potent dihydrofolate reductasean (DHFR) inhibitor with a Ki of 13.4 pM. Pralatrexate is a substrate for folylpolyglutamate synthetase with improved cellular uptake and retention. Pralatrexate has antitumor activities and has the potential for relapsed/refractory T-cell lymphoma treatment . Pralatrexate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-134723
-
|
|
|
ADC Synthesis
DBCO
|
|
DBCO-PEG4-GGFG-Dxd is a agent-linker conjugate for ADC with potent antitumor activity by using Dxd (a DNA topoisomerase I inhibitor), linked via the cleavable ADC linker DBCO-PEG4-GGFG . DBCO-PEG4-GGFG-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-133492
-
|
|
|
ADC Synthesis
DBCO
|
|
DBCO-PEG4-MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the linker DBCO-PEG4. DBCO-PEG4-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-100874
-
|
|
|
Azide
ADC Synthesis
|
|
N3-PEG3-vc-PAB-MMAE is a synthesized agent-linker conjugate for ADC that incorporates the MMAE (a tubulin inhibitor ) and 3-unit PEG linker. N3-PEG3-vc-PAB-MMAE shows potent antitumor activity. N3-PEG3-vc-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-147858
-
|
|
|
Alkynes
PROTAC Synthesis
|
|
PROTAC EGFR degrader 7 (compound 13b) is a potent and selective CRBN-recruiting PROTAC EGFR L858R/T790M degrader, with a DC50 of 13.2 nM. PROTAC EGFR degrader 7 inhibits NCI–H1975 cells proliferation, with an IC50 of 46.82 nM. PROTAC EGFR degrader 7 significantly induces apoptosis and G2/M phase arrest in NCI–H1975 cell. PROTAC EGFR degrader 7 shows antitumor activity, and can be used for non-small cell lung cancer (NSCLC) research . PROTAC EGFR degrader 7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-175247
-
|
|
|
Alkynes
|
|
DDO-4033 is a SPOP inhibitor (IC50 = 16.9 μM, Kd = 15.1 μM). DDO-4033 impairs the malignant migration, invasion, and proliferation of clear cell renal cell carcinoma (ccRCC) cell lines. DDO-4033 disrupts SPOP recruitment to its substrate LATS1, inhibits its polyubiquitination and subsequent degradation, and upregulates LATS1 expression. DDO-4033 has promising antitumor activity and is promising for renal cell carcinoma research .
|
-
- HY-131088
-
|
|
|
ADC Synthesis
Azide
|
|
N3-PEG8-Phe-Lys-PABC-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (HY-50895) (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-P10950
-
|
|
|
Alkynes
|
|
PD-L1 inhibitory peptide is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide is promising for research of cancers .
|
-
- HY-152720
-
|
|
|
Azide
|
|
3’-Azido-3’-deoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-154054
-
|
|
|
Azide
|
|
5′-Azido-5′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5′-Azido-5′-deoxyadenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152448
-
|
|
|
Azide
|
|
2’-Azido-2’-deoxycytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-Azido-2’-deoxycytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups. 2’-Azido-2’-deoxycytidine is an azidonucleoside,and it should be phosphorylated twice to become an inhibitor of the nucleotide reductase.
|
-
- HY-176495
-
|
|
|
Alkynes
|
|
SG3683 is a DNA-targeted cytotoxic agent belonging to pyrrolobenzodiazepine (PBD) dimers. SG3683 exerts antitumor activity with an IC50 value of 0.74 nM in MDA-MB-436 cells. SG3683 is promising for research of cancers, such as breast cancer .
|
-
- HY-W130901
-
|
Pent-4-ynylbenzene
|
|
Alkynes
|
|
5-Phenyl-1-pentyne (Pent-4-ynylbenzene) is a compound with antibacterial and antitumor activity, which can effectively inhibit the growth of certain cancer cells. 5-Phenyl-1-pentyne is often used as a reaction intermediate in organic synthesis to promote a variety of chemical reactions. 5-Phenyl-1-pentyne is also used in the synthesis of new compounds to improve the bioavailability and inhibitory effect of the compounds.
|
-
- HY-152601
-
|
|
|
Azide
|
|
3’-Azido-3’-deoxy-beta-L-adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-beta-L-adenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-154678
-
|
|
|
Azide
|
|
4’-Azido-3’-O-benzoyl-5’-O-(m-chlorobenzoyl)-2’-deoxy-2’-fluoro-beta-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 4’-Azido-3’-O-benzoyl-5’-O-(m-chlorobenzoyl)-2’-deoxy-2’-fluoro-beta-D-arabinouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-131088A
-
|
|
|
Azide
|
|
N3-PEG8-Phe-Lys-PABC-Gefitinib TFA is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (HY-50895) (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib TFA is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152474
-
|
|
|
Alkynes
|
|
2’-β-C-Ethynylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-β-C-Ethynylcytidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-152475
-
|
|
|
Alkynes
|
|
2’-β-C-Ethynyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-β-C-Ethynyladenosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-152447
-
|
|
|
Alkynes
|
|
3’-beta-C-Ethynyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-beta-C-Ethynyl inosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-152625
-
|
|
|
Alkynes
|
|
2’-Beta-C-Ethynyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-Beta-C-Ethynyl inosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-152659
-
|
|
|
Alkynes
|
|
N1-Propargylpseudouridine (see GL102032) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . N1-Propargylpseudouridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-154142
-
|
|
|
Alkynes
|
|
3’-Beta-C-Ethynyl-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Beta-C-Ethynyl-5-methoxyuridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-152442
-
|
|
|
Alkynes
|
|
3’-beta-C-Ethynyl-3-deazauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-beta-C-Ethynyl-3-deazauridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-154314
-
|
|
|
Alkynes
|
|
N2-(Isopropylphenoxyacetyl)-2’-O-propargylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . N2-(Isopropylphenoxyacetyl)-2’-O-propargylguanosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-154141
-
|
|
|
Alkynes
|
|
3’-Beta-C-Ethynyl-5-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Beta-C-Ethynyl-5-fluorouridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-154202
-
|
|
|
Alkynes
|
|
2’-beta-C-Ethynyl-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-beta-C-Ethynyl-5-methyluridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-154143
-
|
|
|
Alkynes
|
|
3’-Beta-C-Ethynyl-4-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Beta-C-Ethynyl-4-deoxyuridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-152627
-
|
|
|
Alkynes
|
|
N6-Methyl-2’-beta-C-ethynyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . N6-Methyl-2’-beta-C-ethynyl adenosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-152626
-
|
|
|
Alkynes
|
|
N6-Ethyl-2’-beta-C-ethynyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . N6-Ethyl-2’-beta-C-ethynyl adenosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-154256
-
|
|
|
Azide
|
|
5-(2-Azidoethyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5-(2-Azidoethyl)uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152352
-
|
|
|
Alkynes
|
|
7,8-Dihydro-8-oxo-7-propargyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 7,8-Dihydro-8-oxo-7-propargyl guanosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-152746
-
|
|
|
Alkynes
|
|
2-Amino-6-chloropurine-9-(2’-O-propargyl)riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2-Amino-6-chloropurine-9-(2’-O-propargyl)riboside is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-152870
-
|
|
|
Azide
|
|
2’-O-(2-Azidoethyl)adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-O-(2-Azidoethyl)adenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152737
-
|
|
|
Azide
|
|
3’-Deoxy-3’-azido-isocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Deoxy-3’-azido-isocytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152868
-
|
|
|
Azide
|
|
3’-O-(2-Azidoethyl)adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-O-(2-Azidoethyl)adenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152663
-
|
|
|
Alkynes
|
|
6-Mthoxy-9-beta-D-(2-C-ethynyl-ribofuranosyl) purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 6-Mthoxy-9-beta-D-(2-C-ethynyl-ribofuranosyl) purine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-154405
-
|
|
|
Azide
|
|
5’-Azido-5’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5’-Azido-5’-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-154666
-
|
|
|
Azide
|
|
3’-Azido-3’-deoxyinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxyinosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152728
-
|
|
|
Azide
|
|
3’-Azido-3’-deoxycytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxycytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-154055
-
|
|
|
Azide
|
|
5′-Azido-2′,5′-dideoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5′-Azido-2′,5′-dideoxyadenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-159495
-
|
|
|
Azide
|
|
Keap1-Nrf2-IN-21 (compound 4d) is a glucose metabolism inhibitor with antitumor activity. Keap1-Nrf2-IN-21 inhibits glycolytic activity of cancer cells by targeting the glycolytic pathway, especially by affecting the Keap1-Nrf2 signaling pathway, thereby inhibiting tumor growth. Keap1-Nrf2-IN-21 exhibits cytotoxicity against the HEC1A cell line (IC50=2.60 μM) .
|
-
- HY-152514
-
|
|
|
Azide
|
|
5-Azidomethyl-2’-beta-methyl uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5-Azidomethyl-2’-beta-methyl uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152592
-
|
|
|
Azide
|
|
3’-Azido-3’-deoxy-beta-L-cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-beta-L-cytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-154284
-
|
|
|
Alkynes
|
|
7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy guanosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-154305
-
|
|
|
Azide
|
|
5′-Azido-2′,5′-dideoxy-2′-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5′-Azido-2′,5′-dideoxy-2′-fluorouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152353
-
|
|
|
Azide
|
|
3’-Azido-3’-deoxy-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-2-thiouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152802
-
|
|
|
Azide
|
|
2’-O-(3-Azidopropyl)-5-azacytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-O-(3-Azidopropyl)-5-azacytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152642
-
|
|
|
Azide
|
|
2’-Azido-2’-deoxy-5-methyl cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-Azido-2’-deoxy-5-methyl cytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152724
-
|
|
|
Azide
|
|
3’-Azido-3’-deoxy-5-iodouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-iodouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152645
-
|
|
|
Azide
|
|
3’-Azido-3’-deoxy-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-methyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154320
-
|
|
|
Azide
|
|
3’-Azido-3’-deoxy-3-deazauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-3-deazauridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152713
-
|
|
|
Azide
|
|
3’-Azido-3’-deoxy-5-methoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-methoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154308
-
|
|
|
Azide
|
|
5’-Azido-5’-deoxy-2’-O-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5’-Azido-5’-deoxy-2’-O-methyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154579
-
|
|
|
Azide
|
|
3’-Azido-N6-benzoyl-3’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-N6-benzoyl-3’-deoxyadenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154402
-
|
|
|
Azide
|
|
2′-Azido-2′-deoxy-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2′-Azido-2′-deoxy-5-methyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152315
-
|
|
|
Azide
|
|
3’-Azido-3’-deoxy-N6-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-N6-methyladenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152708
-
|
|
|
Azide
|
|
3’-Azido-3’-deoxy-5-trifluoromethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-trifluoromethyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152338
-
|
|
|
Alkynes
|
|
7-Propargyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 7-Propargyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-152688
-
|
|
|
Azide
|
|
3’-Azido-3’-deoxy-5-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-fluorouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154119
-
|
|
|
Azide
|
|
3’-Azido-3’-deoxy-6-azauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-6-azauridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154346
-
|
|
|
Azide
|
|
5’-Azido-5’-deoxy-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5’-Azido-5’-deoxy-5-methyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152585
-
|
|
|
Azide
|
|
3’-Azido-3’-deoxy-5-fluoro-beta-L-uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-fluoro-beta-L-uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152373
-
|
|
|
Alkynes
|
|
7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy-3’-fluoro-xylo-guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy-3’-fluoro-xylo-guanosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-152583
-
|
|
|
Azide
|
|
3’-Azido-3’-deoxy-5-methyl-beta-L-uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-methyl-beta-L-uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152389
-
|
|
|
Azide
|
|
6-Methylpurine-β-D-(3-azido-3-deoxy)riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 6-Methylpurine-β-D-(3-azido-3-deoxy)riboside is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152364
-
|
|
|
Alkynes
|
|
7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy-3’-fluoro guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy-3’-fluoro guanosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-152597
-
|
|
|
Azide
|
|
3’-Azido-3’-deoxy-5-fluoro-beta-L-cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-fluoro-beta-L-cytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152595
-
|
|
|
Azide
|
|
3’-Azido-3’-deoxy-5-methyl-beta-L-cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-methyl-beta-L-cytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154383
-
|
|
|
Azide
|
|
5’-Azido-5’-deoxy-2’-O-(2-methoxyethyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5’-Azido-5’-deoxy-2’-O-(2-methoxyethyl)uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154423
-
|
|
|
Azide
|
|
2′-Azido-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2′-Azido-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154283
-
|
|
|
Alkynes
|
|
2-Amino-7-propargyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2-Amino-7-propargyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl)purine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-154042
-
|
|
|
Azide
|
|
5’-Azido-5’-deoxy-2’-O,4’-C-methyleneuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5’-Azido-5’-deoxy-2’-O,4’-C-methyleneuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152319
-
|
|
|
Azide
|
|
3’-Azido-3’-deoxy-N6,N6-dimethyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-N6,N6-dimethyladenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154377
-
|
|
|
Azide
|
|
5’-Azido-5’-deoxy-2’-O-methyl-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5'-Azido-5'-deoxy-2'-O-methyl-5-methyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154146
-
|
|
|
Azide
|
|
5-Nitro-1-(3-azido-3-deoxy-β-D-ribofuranosyl)-2(1H)-pyridinone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5-Nitro-1-(3-azido-3-deoxy-β-D-ribofuranosyl)-2(1H)-pyridinone is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154386
-
|
|
|
Azide
|
|
5’-Azido-5’-deoxy-2’-O-(2-methoxyethyl)-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5’-Azido-5’-deoxy-2’-O-(2-methoxyethyl)-5-methyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152438
-
|
|
|
Alkynes
|
|
6-Amino-3-ethynyl-4-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 6-Amino-3-ethynyl-4-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-154334
-
|
|
|
Azide
|
|
2’-O-Acetyl-3’-azido-5’-O-(4-methylbenzoyl)-3’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-O-Acetyl-3’-azido-5’-O-(4-methylbenzoyl)-3’-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154425
-
|
|
|
Alkynes
|
|
2-Amino-7-propargyl-7,8-dihydro-8-oxo-9-(beta-D-3-deoxy-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2-Amino-7-propargyl-7,8-dihydro-8-oxo-9-(beta-D-3-deoxy-ribofuranosyl)purine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-154310
-
|
|
|
Azide
|
|
1,2-Di-O-acetyl-3-azido-3-deoxy-5-O-(4-methyl) benzoyl-L-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 1,2-Di-O-acetyl-3-azido-3-deoxy-5-O-(4-methyl) benzoyl-L-ribofuranose is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154318
-
|
|
|
Azide
|
|
1,2-Di-O-acetyl-3-azido-3-deoxy-5-O-(4-methyl)benzoyl-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 1,2-Di-O-acetyl-3-azido-3-deoxy-5-O-(4-methyl)benzoyl-D-ribofuranose is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154341
-
|
|
|
Azide
|
|
9-[2'-O-Acetyl-3'-azido-3'-deoxy-5'-O-toluoyl-b-L-ribofuranosyl)-6-chloropurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 9-[2'-O-Acetyl-3'-azido-3'-deoxy-5'-O-toluoyl-b-L-ribofuranosyl)-6-chloropurine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-W741987
-
|
6,7-Didehydronorethisterone
|
|
Alkynes
|
|
6,7-Dehydro Norethindrone (6,7-Didehydronorethisterone) (Compound 26) is a Norethisterone (HY-B0554) metabolite. 6,7-Dehydro Norethindrone can be produced by the biotransformation of Norethisterone using Rhizopus microsporus PT2906. 6,7-Dehydro Norethindrone induces Apoptosis, binds to p53 and inhibits the degradation of p53. 6,7-Dehydro Norethindrone selectively exhibits antitumor activity against cervical cancer .
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-75161
-
|
|
|
Flavoring Agents
|
|
(-)-Menthol is a key component of peppermint oil that binds and activates transient receptor potential melastatin 8 (TRPM8), a Ca 2+-permeable nonselective cation channel, to increase [Ca 2+]i . Antitumor activity .
|
-
- HY-W009163
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Bromouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W244398
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2-Thiocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W587829
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
4-Thiothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-131795
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Methylthioadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W154568
-
|
6-MPR
|
|
Nucleoside Analogs
|
|
6-Methylpurine riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154534
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
Alpha-Adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-151414
-
|
|
|
Nucleoside Analogs
Inosine
|
|
3'-Deoxyinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W014306
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2',3'-Dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-106689
-
|
DHAC; NSC 264880
|
|
Nucleoside Analogs
Cytidine
|
|
Dihydro-5-azacytidine (DHAC), the nucleoside analog, is incorporated into DNA and inhibits DNA methylation. Dihydro-5-azacytidine has an antitumor activity .
|
-
- HY-W013259
-
|
|
|
Nucleoside Analogs
|
|
6-Methylmercaptopurine riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154530
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
DMTr-TNA-C(Bz)-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W130204
-
|
N4-Acetyl-2'-deoxycytidine
|
|
Nucleoside Analogs
Cytidine
|
|
N-Acetyl-2′-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152682
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Ethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152617
-
|
|
|
Nucleoside Analogs
Inosine
|
|
4’-Thioinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154329
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2-Deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152368
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
8-Hydrazinoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152544
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
8-Allylthioguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W609639
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2’-Deoxyisocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152510
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-(Aminomethyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152794
-
|
|
|
Nucleoside Analogs
|
|
7-Methyl wyosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152586
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2′,3′-Anhydroadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152318
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
Adenosine-2-carboxamide is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154537
-
|
|
|
Nucleoside Analogs
Inosine
|
|
3’-O-Methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154616
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-O-Phthalimidopropyl uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154620
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2′-O-Hexadecyl-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154674
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N1-Allylpseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154528
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2’-O-Phthalimidopropyl cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W550365
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
1-(alpha-L-Threofuranosyl)thymine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152767
-
|
|
|
Nucleoside Analogs
|
|
N1-Ethylpseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-177633
-
|
LY 2181308
|
|
Antisense Oligonucleotides
|
|
Gataparsen is an antisense oligonucleotide directed against survivin mRNA with potential antitumor activity.
|
-
- HY-177614
-
|
AD3133 sodium
|
|
siRNAs
siRNA drugs
|
|
ALN-3133 sodium is a siRNA that targets VEGF, and it is one of the siRNAs in ALN-VSP.ALN-VSP is a lipid nanoparticle formulation containing two siRNAs for kinesin spindle protein (KSP) and VEGF with potential antitumor activity.
|
-
- HY-177613
-
|
AD12115
|
|
siRNAs
siRNA drugs
|
|
ALN-12115 is a siRNA that targets kinesin spindle protein (KSP), and it is one of the siRNAs in ALN-VSP.ALN-VSP is a lipid nanoparticle formulation containing two siRNAs for KSP and VEGF with potential antitumor activity.
|
-
- HY-177613A
-
|
AD12115 sodium
|
|
siRNAs
siRNA drugs
|
|
ALN-12115 sodium is a siRNA that targets kinesin spindle protein (KSP), and it is one of the siRNAs in ALN-VSP.ALN-VSP is a lipid nanoparticle formulation containing two siRNAs for KSP and VEGF with potential antitumor activity.
|
-
- HY-W022290
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
5-Bromocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152654
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
4′-Thiocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154242
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
8-Methylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152807
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
4’-Thioadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152321
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Hydroxy-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-177633A
-
|
LY 2181308 sodium
|
|
CpG ODNs
|
|
Gataparsen sodium is an antisense oligonucleotide directed against survivin mRNA with potential antitumor activity.
|
-
- HY-139096
-
|
|
|
Phospholipids
|
|
4-Pentadecylbenzylphosphonic acid is an Autotaxin (ATX) inhibitor. 4-Pentadecylbenzylphosphonic acid has antitumor activity .
|
-
- HY-106689A
-
|
DHAC acetate; NSC 264880 acetate
|
|
Nucleoside Analogs
Cytidine
|
|
Dihydro-5-azacytidine acetate (DHAC), the nucleoside analog, is incorporated into DNA and inhibits DNA methylation. Dihydro-5-azacytidine acetate has an antitumor activity .
|
-
- HY-124092
-
|
935U83
|
|
Nucleoside Analogs
Uridine
|
|
Raluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152995
-
|
|
|
Nucleoside Analogs
|
|
Confidential is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154269
-
|
|
|
Nucleoside Analogs
|
|
Confiden is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154270
-
|
|
|
Nucleoside Analogs
|
|
Confident is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154668
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
5'- Homocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-134295
-
|
|
|
Nucleoside Analogs
Inosine
|
|
8-Chloroinosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154536
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
Alpha-Guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152314
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Cyanoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152599
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
4’-Methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152546
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
8-Allyloxyguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154732
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2-Thiopseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-157339
-
|
|
|
Phosphoramidites
Adenine
|
|
MMT-2'-O-Methyl adenosine (n-bz) CED phosphoramidite (compound 1) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies .
|
- HY-152643
-
|
|
|
Nucleoside Analogs
Uridine
|
|
6-Methylpseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154535
-
|
|
|
Nucleoside Analogs
Inosine
|
|
Alpha-inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152615
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
4’-Methylguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152383
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Difluoromethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154268
-
|
|
|
Nucleoside Analogs
|
|
Confidential-2 is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152462
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
8-Azaguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154670
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
5’-Homoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-131792
-
|
|
|
Nucleoside Analogs
Inosine
|
|
2-Chloroinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W100215
-
|
5-Methylcyclocytidine hydrochlorine
|
|
Nucleoside Analogs
Cytidine
|
|
5-Methylcyclocytidine hydrochloride is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154275
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
4’-Methylthymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152740
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Pyrrolidinomethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W412546
-
|
4-[1-[(2-Methylphenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine
|
|
Nucleoside Analogs
Uridine
|
|
3’-O-Methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154421
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,5’-Dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152375
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
8-Hydroxy-xyloguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152327
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Methylthio isopentenyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152602
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
1,3'-Dimethylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152441
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Aminomethyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152387
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
8-Chloro-arabinoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154131
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3-Deaza-xylouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152869
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
5-(Trifluoromethyl)cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152420
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Trifluoromethyl adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154474
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’,4-Dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152867
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-(Trifluoromethyl)uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152594
-
|
|
|
Nucleoside Analogs
Uridine
|
|
Uridine-5-oxyacetic acid is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152613
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
N2-Ethylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152649
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N1-Cyclopropylmethylpseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154626
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2’-O-Hexadecanyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152384
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
5’(R)-C-Methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152837
-
|
|
|
Nucleoside Analogs
Uridine
|
|
1,3-Dimethyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154109
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N1-Aminopseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152871
-
|
|
|
Nucleoside Analogs
Uridine
|
|
Uridine 5-oxyacetic acid methyl ester is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154110
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-Aminopseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154453
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4-Deoxy-xylo-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154187
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Pivaloyloxymethyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154356
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
1-(alpha-L-Threofuranosyl)cytosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W556301
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2′,3′-O-Isopropylideneisocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152313
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Bromoadenosine, antimalarial agent is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152454
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
4’-α-C-Methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-137589
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Dimethyldeoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154398
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
5-Aza-xylo-cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154621
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-O-Hexadecanyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152344
-
|
|
|
Nucleoside Analogs
|
|
2’-β-C-Methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152795
-
|
|
|
Nucleoside Analogs
|
|
N4-Desmethyl wyosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152608
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-iso-Propyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-185372
-
|
Liposomal mitoxantrone
|
|
Liposome
|
|
Mitoxantrone hydrochloride liposome is a liposome-encapsulated Mitoxantrone hydrochloride (HY-13502A) (a topoisomerase II inhibitor). Compared to regular Mitoxantrone hydrochloride, Mitoxantrone hydrochloride liposome enhances antitumor activity and prolongs drug circulation time in the body.
|
- HY-185371
-
|
Irinotecan hydrochlorid liposomee; Liposomal irinotecan
|
|
Liposome
|
|
Irinotecan liposome is a liposome-encapsulated form of Irinotecan hydrochlorid (HY-16562A) (a topoisomerase I inhibitor). Compared with Irinotecan, Irinotecan liposome enhances antitumor activity, reduces drug release rate, and avoids neutropenia.
|
- HY-152814
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2′-β-C-Methyl isoguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152725
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N1-Benzyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154354
-
|
|
|
Nucleoside Analogs
|
|
Methyl 3’-O-benzyl xyloriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152345
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N1-Ethoxymethyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152464
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N1-Methyl-arabinoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-137848
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
Thymine 1-β-D-arabinofuranoside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152598
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
N1-Methylxylo-guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154722
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
N6-Dimethylaminomethylidene isoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152417
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-Ethyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152346
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N1-Benzoyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152459
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-(n-Propylidene hydrazino) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152609
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N1-Cyanomethyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154553
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
3’,5’-Di-O-acetylthymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152411
-
|
|
|
Nucleoside Analogs
Inosine
|
|
3’-Beta-C-Methyl-inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152323
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N1-Methylsulfonyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152342
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N1-Methoxymethyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152385
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5,6-Dihydro-ara-uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-77644
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5'-Deoxy-5'-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154717
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2-Deoxy-2’-fluoroisocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152298
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Fluoro-4’-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152701
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Aminocarbonylmethyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152743
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
8-Aza-7-deazguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-482934
-
|
2'-Fluoro-2'-deoxyinosine
|
|
Nucleoside Analogs
Inosine
|
|
2’-Deoxy-2’-fluoroinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152622
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154559
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2′-Deoxy-2-hydrazinyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154241
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
8-Methyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154347
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
5′-Deoxy-5′-iodothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152540
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Methoxy-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152505
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Methyl-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152731
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
3′-Deoxy-3′-methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154491
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-Deoxy-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154011
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
8-Amino-2′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152666
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
5-Methyl-4’-thiocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154153
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Methyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154088
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
3′-Deoxy-3′-iodothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W460267
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
N2,2'-O-Dimethylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-149160
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
5′-Amino-5′-deoxythymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152367
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
8-Hydroxy-3’-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152630
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-5-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152771
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
3′-Deoxy-3′-fluorocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154364
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-5-trifluoromethyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154327
-
|
|
|
Nucleoside Analogs
Uridine
|
|
DMTr-dH2U-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154214
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-(3-Methyln-propylidene hydrazino) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154025
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
8-Azido-2′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154589
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3',5'-Di-O-benzoyl fialuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154520
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Chloro-3′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154467
-
|
|
|
Nucleoside Analogs
Inosine
|
|
2′-Deoxy-6-thioinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154243
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
8-Methyl-2’-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152445
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Amino-3’-deoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152354
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
8-Benzyloxy-3’-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154200
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
3’-Deoxy-5-methycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152452
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2′-Amino-2′-deoxycytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152821
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Methoxy-4’-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154540
-
|
|
|
Nucleoside Analogs
Uridine
|
|
Alpha-5-Methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152628
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-3-deazauridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152465
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Carboxymethyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154554
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
3’,5’-Di-O-benzoyl thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152700
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Methoxy-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154215
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-(P-Cyanophenyl methylidene hydrazino) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152320
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
Adenosine-2-carboxy methyl amide is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154087
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
3′-Bromo-3′-deoxythymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152519
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-(Aminomethyl)-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154443
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
Rev dC(Bz)-5'-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154300
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N-Benzoyl-3′-O-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W154172
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2′-Chloro-2′-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152533
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Ethyl-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-137600
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
1,N6-Ethenoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152631
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-5-methoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154470
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
8-Aza-2’-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152351
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
8-Bromo-3’-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154001
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2'-Deoxy-8-methylthioguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-149220
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5'-Protected 2,2'-anhydrouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154114
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2′-Deoxy-2-iodoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152295
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-2’-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152334
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2’-Chloro-2’-deoxyadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W141338
-
|
2'-Bromo-2'-deoxy-D-uridine
|
|
Nucleoside Analogs
Uridine
|
|
2′-Bromo-2′-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W114787
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
N4-Benzoyl-2’-O-methylcytidine is a natural cytidine nucleoside analog. Cytidine analogs have the mechanism of inhibiting DNA methyltransferase (such as Zebularine (HY-13420)) and have potential antimetabolite and antitumor activities .
|
- HY-102018
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3'-Deoxy-3'-fluoroadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154324
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2′-Deoxy-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152591
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’-Methyl-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152730
-
|
|
|
Nucleoside Analogs
Inosine
|
|
3’-Deoxy-3’-fluoroinosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154740
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
3′-Chloro-3′-deoxythymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W039275
-
|
5'-Iodo-5'-deoxyguanosine
|
|
Nucleoside Analogs
Guanosine
|
|
5'-Deoxy-5'-iodoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152765
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3′-Deoxy-3′-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152710
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Methoxycarbonylmethyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154692
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2′-Deoxy-5-methylisocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152440
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
3’-Amino-3’-deoxycytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152793
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
7-Cyano-7-deazaguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154294
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N1-Methyl ara-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154120
-
|
|
|
Nucleoside Analogs
Uridine
|
|
6-Aza-2'-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W251781
-
|
2′-Deoxy-4-thiouridine; 4-Thiodeoxyuridine
|
|
Nucleoside Analogs
Uridine
|
|
4-Thio-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W013052
-
|
8-Bromo-9-(2-deoxypentofuranosyl)-9H-purin-6-amine
|
|
Nucleoside Analogs
Adenosine
|
|
8-Bromo-2'-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152739
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-(N-Isopentenyl-N-trifluoroacetyl) aminomethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154399
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
5-Aza-3’-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154232
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
4′,5′-Didehydro-5′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152759
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
3’-Deoxy-3’-fluoro-xylocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154012
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2'-Deoxy-8-methylamino-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152308
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
3’-Deoxy-3’,5-difluorocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154248
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-3’,2-anhydrouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154147
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2’-Deoxy-N1-methylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154624
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2’-O-Hexadecanyl-2-aminoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152662
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2’,3’-Dideoxy-5-fluorocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154038
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2′,3′-Dideoxy-3′-fluoroadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154400
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
5-Aza-3’-beta-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152707
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Amino-2′-C-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154239
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-O-Triphenylmethyl-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152593
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
3’-Deoxy-N1-methylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152379
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-methyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154374
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-Azido-2’,5’-dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W603690
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2'-Deoxy-N6-phenoxyacetyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W550918
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Bromo-2’-O-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152433
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N1-(1,1-Difluoroethyl)pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152752
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2’,3’-Dideoxy-3’-fluorocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154333
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2′-Deoxy-8-(phenylmethoxy)guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W560803
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
5'-DMTr-2,2'-anhydrothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154625
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-O-Hexadecanyl-2-aminoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152551
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’-C-Methyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154569
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
5’-Deoxy-5’-furfurylamino thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-77645
-
|
1-(5-Deoxy-beta-D-erythro-pent-4-enofuranosyl)uracil
|
|
Nucleoside Analogs
Uridine
|
|
4',5'-Didehydro-5'-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154564
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
5’-Deoxy-5’-N-methylaminothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152836
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-O-Methyl-5-hydroxymethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154289
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’-Isopropylidene-5-hydroxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152516
-
|
|
|
Nucleoside Analogs
Inosine
|
|
2’-O-(2-Methoxyethyl) inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154420
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’-Bis-(O-t-butyldimethylsilyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154026
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Amino-2'-deoxyuridine (monohydrochloride) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152717
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-O-Methyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152499
-
|
|
|
Nucleoside Analogs
Inosine
|
|
1-Methyl-2'-O-methylinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154303
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-O-Levulinyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154204
-
|
|
|
Nucleoside Analogs
Inosine
|
|
2’-Deoxy-2’-fluoroarabino inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152996
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2′-Deoxy-8-(methylthio)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152854
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
5-(Hydroxymethyl)cytidine is a purine nucleoside analog that can be used in oligonucleotide synthesis. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154602
-
|
|
|
Phosphoramidites
Guanine
|
|
2’-dG (iBu)-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152584
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
3’-Deoxy-3’-fluoro-xyloguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152336
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N1-(2-Methyl)propyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152590
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-Deoxy-N6-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154372
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2′,5′-Dideoxy-5′-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154496
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2’-Deoxy-N3-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154558
-
|
|
|
Nucleoside Analogs
Inosine
|
|
2′-Deoxy-6-O-methylinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152316
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Chloro-N6-isopropyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152866
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
N,N-Dimethyl-2’-O-methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154052
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5′-Amino-2′,5′-dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154392
-
|
|
|
Nucleoside Analogs
Inosine
|
|
2-Chloro-2’-deoxy inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W392809
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
5-Methyl-2′-O-methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154533
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-O-Acetyl-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154456
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2’-Deoxy-N6-cyclopentyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154237
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-O-DMTr-3’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154556
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2′,3′-Dideoxy-5-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152548
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’-C-Methyl-4-deoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152377
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Hydroxy-2’-O-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152865
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
7-(N-Acetylaminomethyl)-7-deazaguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154697
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
3-epi-Azido-3-deoxythymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152640
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
5-Fluoro-4’-thio-cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W415119
-
|
acetic acid 4-acetoxy-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2-hydroxymethyl-tetrahydrofuran-3-yl ester
|
|
Nucleoside Analogs
Uridine
|
|
2',3'-Di-O-acetyl-D-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152607
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N,N-Dimethyl-2′-O-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152307
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Chloro-N6-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154293
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-Deoxy-N6-ethyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152577
-
|
|
|
Nucleoside Analogs
Inosine
|
|
3’-O-(2-Methoxyethyl) inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152554
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-Deoxy-3’-fluoro-xyloadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154510
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2’-Deoxy-N4-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152638
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Amino-3’-O-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152588
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-Deoxy-N1-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152325
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N1-(N,N-Dimethylaminocarbonyl)-pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W347492
-
|
O6-Methyl-2′-deoxyguanosine
|
|
Nucleoside Analogs
Guanosine
|
|
O6-Methyldeoxy guanosine; DNA adduct is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152425
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Methylamino-N6-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152513
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-O-Methyl-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154544
-
|
|
|
Phosphoramidites
Uracil
|
|
3’-O-MOE-U-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152561
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’(R)-C-Methyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W357202
-
|
PMO Thymidine Precusor
|
|
Nucleoside Analogs
Thymidine
|
|
7’-OH-N-trityl morpholinothymine (PMO Thymidine Precusor) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152397
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-Deoxy-N6-isopentenyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152317
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Methyl-2-thio-xylo-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154136
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Fluoro-3’-beta-C-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152715
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-C-β-Methyl-4-deoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152749
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-β-C-methyl-5-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154130
-
|
|
|
Nucleoside Analogs
Uridine
|
|
1-(b-D-Xylofuranosyl)-5-trifluoromethyluracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154292
-
|
|
|
Nucleoside Analogs
Inosine
|
|
3’-Deoxy-N1-Methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154262
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Ethyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152635
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
8-Chloro-2’-O-methyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152467
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
8-Aza-2’-beta-C-methylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152880
-
|
T 70179
|
|
Nucleoside Analogs
|
|
2’-Deoxy-2’-fluoro-arabino-tubercidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154468
-
|
|
|
Nucleoside Analogs
Inosine
|
|
6-O-Methyl-2’-O-methylinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154129
-
|
|
|
Nucleoside Analogs
Uridine
|
|
1-(b-D-Xylofuranosyl)-5-methoxyuracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154348
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
4’,5’-Didehydro-5’-deoxy thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152530
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-beta-C-Methyl-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154296
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-ara-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152729
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-(2-Amino-2-oxoethyl)uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154018
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
N4-Benzoyl-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154161
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-(2-Hydroxyethyl)-2’-deoxy uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152721
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-O-Methyl-4-deoxy uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152497
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-β-C-Methyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152629
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-β-C-Methyl-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152428
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
3’-Deoxy-3’-α-C-methylguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154600
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
N4-Benzoyl-3’-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152768
-
|
|
|
Nucleoside Analogs
|
|
N1-(1,1,1-Trifluoroethyl)pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152651
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’(R)-C-Methyl-3-deazauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152745
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-β-C-Methyl-5-trifluoromethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154430
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2’-Deoxy-N2-cyclopentyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W008615
-
|
5-Iodo-D-cytidine
|
|
Nucleoside Analogs
Cytidine
|
|
5-Iodo-cytidine (5-Iodo-D-cytidine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W010681A
-
|
|
|
Phosphoramidites
Thymine
|
|
3’-O-DMTr-thymidine 5’-CE phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W394419
-
|
|
|
Phosphoramidites
Cytosine
|
|
3’-dC(Bz)-2’-phosphor amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152322
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Chloro-N6-iso-pentenyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154373
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4′,5′-Didehydro-2′,5′-dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154138
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-beta-C-Methyl-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152501
-
|
|
|
Nucleoside Analogs
Inosine
|
|
8-Chloro-2’-O-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152500
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4-Deoxy-3’-β-C-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-49200
-
|
|
|
Phosphoramidites
Cytosine
|
|
DMT-2'-F-dC(Bz)-CE-Phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154201
-
|
|
|
Nucleoside Analogs
Inosine
|
|
3’-Deoxy-O6-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W013728
-
|
|
|
Nucleoside Analogs
|
|
1,3,5-Tri-O-benzoyl-a-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152326
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-β-C-Methyl-6-azauridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154568
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
5’-Deoxy-5’-(4-morpholinyl)thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-148019
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2′-Deoxy-2′-fluoro-N-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154472
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
N4-Ethyl-2’-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154233
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-O-TBDPS-2,2’-anhydrouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154428
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2’-Deoxy-N2-isopropyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154496A
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2’-Deoxy-N3-methylcytidine hydriodide is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154128
-
|
|
|
Nucleoside Analogs
Uridine
|
|
1-(b-D-Xylofuranosyl)-5-fluorouracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154495
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-Methyl-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W377454
-
|
|
|
Nucleoside Analogs
Uridine
|
|
1-Beta-D-arabinofuranosyl-5-iodouracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152369
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
1,N6-Etheno-ara-adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154330
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3'-beta-Azido-2',3'-dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152863
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Furfuryl-2-aminoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W048512
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2',3'-Didehydro-2',3'-dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152741
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-β-C-Methyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152644
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-β-C-Methyl-5-methoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154432
-
|
|
|
Nucleoside Analogs
Inosine
|
|
N1-Methyl-2’-deoxyinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152415
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-Deoxy-3’-α-C-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152466
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2’-O-Methyl-N1-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152343
-
|
|
|
Nucleoside Analogs
Uridine
|
|
1-(β-D-Xylofuranosyl)-2-thiouracil is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154231
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2’-Deoxy-2’-fluoro-alpha-D-arabinoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154081
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-O-DMTr-2’-OMeU-methyl phosphonamidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154457
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2’-Deoxy-N6-(4-methoxybenzyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154406
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2’-Deoxy-N2-methylguanosine, DNA adduct is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152650
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Methyl-2-methyl thioadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152400
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
8-Bromo-9-(β-D-xylofuranosyl) guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152872
-
|
|
|
Nucleoside Analogs
Uridine
|
|
Uridine-5-oxo-acetyl-(9-fluorenylmethyl) ester is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154261
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
Rev 2’-O-MOE-A(Bz)-5’-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152675
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Amino-2’-deoxy-β-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152624
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Methyl-4’-thio-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152508
-
|
|
|
Nucleoside Analogs
Inosine
|
|
8-Chloro-2’-beta-C-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154323
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
5’-DMTr-3’dA(Bz)-methylphosphonami dite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154566
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
5’-Deoxy-5’-N,N-diethylamino thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152339
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
N4-Amino-2'-C-methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152606
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Ethyl-2’-C-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154516
-
|
|
|
Nucleoside Analogs
|
|
2-Chloro-9-(beta-D-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152621
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Ethyl-4’-thio-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152413
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Furfuryl-2’-C-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152461
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-(3-Trifluoromethylbenzyl)-3’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154458
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2’-Deoxy-N6-(3-methoxybenzyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152738
-
|
|
|
Nucleoside Analogs
|
|
2’-β-C-Methyl-3-deazauri dine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152648
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Ethyl-2’-O-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154481
-
|
|
|
Phosphoramidites
Cytosine
|
|
3’-O-Me-C(Bz)-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152324
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Chloro-N6-(2-hydroxyethyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154064
-
|
|
|
Phosphoramidites
Adenine
|
|
3’-O-MOE-A(Bz)-2’-CED-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152805
-
|
|
|
Nucleoside Analogs
|
|
9-(2-β-C-Methyl-β-D-ribofuranosyl)purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154198
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
5′-O-[Bis(4-methoxyphenyl)phenylmethyl]cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154257
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
N2-iso-Butyryl-8-azaguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154529
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
5’-O-DMTr-3’-O-phthalimidopropyl cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154565
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
5’-Deoxy-5’-N,N-dimethylamino thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154395
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Chloro-2′-deoxy-N,N-dimethyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152421
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
8-Benzyloxy-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154297
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
N6-Dimethylamino methylidene-2’-deoxyisoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-145791
-
|
2′,3′-Didehydro-2′,3′-dideoxycytidine
|
|
Nucleoside Analogs
Cytidine
|
|
Dideoxycytidinene (2′,3′-Didehydro-2′,3′-dideoxycytidine) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W128788
-
|
4-amino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)pyrimidin-2(1H)-one
|
|
Nucleoside Analogs
Cytidine
|
|
2’-Deoxy-2’-fluoro-b-D-arabinocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152494
-
|
|
|
Nucleoside Analogs
|
|
6-Methyl-9-(β-D-xylofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154082
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Caroxy uracil-1-yl acetic acid benzyl ester is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152804
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
5-Iodo-2’-β-C-methyl cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154417
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’-Bis(O-t-butyldimethylsilyl)-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154170
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2',3',5'-Tri-O-acetyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152873
-
|
|
|
Nucleoside Analogs
Uridine
|
|
Uridine-5-(N-Fmoc-methylamino)-acetyl (9-fluorenylmethyl) ester is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152747
-
|
|
|
Nucleoside Analogs
|
|
5-β-D-Ribofuranosyl-2(1H)-pyridinone is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152332
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2’-Chloro-N6-(4-methoxy)benzyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154418
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’-Bis(O-(t-butyldimethylsilyl)-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154595
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’,5’-Tri-O-benzoyl-4-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154344
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5′-Deoxy-5′-iodo-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154609
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Bromo-2’-deoxy-5-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154646
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’,5’-Tri-O-benzoyl-4’-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152723
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Amino-N,N-dimethyl-2′-C-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152330
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2’-Chloro-N6-(3-methoxy)benzyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152302
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
3’-Deoxy-3’-fluoro-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154396
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
8-Chloro-2’-deoxy-2’-fluoroadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152362
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
8-Hydroxy-3’-deoxy-3’-fluoroguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154599
-
|
|
|
Phosphoramidites
Uracil
|
|
5-Me-3’-dU-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152803
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Iodo-3’-deoxy-3’-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W010917
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2′,3′,5′-Tri-O-acetyl-6-chloroguanosine diacetate is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154288
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’,5’-Tri-O-benzoyl-5-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154066
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-3’-flluoro-3-deazauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W054074
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Bromo-2',3',5'-tri-O-acetyluridine diacetate is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154573
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2’-Deoxy-O6-[2-(4-nitrophenylethyl)]guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152761
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-3’-fluoro-5-methoxyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154642
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Bromo-2’-deoxy-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152359
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
8-Benzyloxy-3’-deoxy-3’-fluoroguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152335
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2’-Chloro-N6-(3-trifluoromethyl)benzyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152439
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Amino-3’-deoxy-5-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154513
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2’-Deoxy-5,N4-dimethylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152482
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-O-(2-Methoxyethyl)-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152329
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-3’-fluoro-6-azauridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154156
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2’-Deoxy-2’-fluoroadenosine 5’-monophosphate (triethylammonium) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152712
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Bromo-3’-deoxy-3’-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152653
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-iso-Propyl-2’-O-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154578
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N1-Methyl-2'-deoxyadenosine, DNA adduct is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152457
-
|
|
|
Nucleoside Analogs
Inosine
|
|
3’-Deoxy-3’-fluoro-beta-D-xylo-inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152757
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-3’-fluoro-5-trifluoromethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W551974
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’,5’-Tri-O-benzoyl-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154415
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’,5’-Tri-O-benzoyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154213
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
5’-O-DMTr-5-MedC (Ac)-methyl phosphonamidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154085
-
|
|
|
Nucleoside Analogs
Uridine
|
|
(2’,3’,5’-Tri-O-acetyl)uridine 5-carboxylic acid is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152455
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-Deoxy-N6-(m-methoxy benzyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152549
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2’-O-(2-Methoxyethyl)-2-aminoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152693
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
N4-Methyl-2’-O-methyl-cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152611
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N1-Methyl-5-methyl ara-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152754
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-3’-fluoro-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152487
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Amino-3’-deoxy-3’-fluoroadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152753
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-3’-fluoro-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152760
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-3’-fluoro-5-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W539754
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2'-Deoxy-2'-fluoro-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154230
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
Rev 2’-O-MOE-C(Bz)-5’-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152337
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2’-Chloro-N6-(4-trifluoromethyl)benzyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152664
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
1-(2,3-Dideoxy-β-D-erythro-hexo pyranosyl)cytosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152778
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Chloro-3’-deoxy-3’-fluoroadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152356
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
8-Bromo-3’-deoxy-3’-fluoroguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152306
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N1,N3-Bis(cyanomethyl)pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154190
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2',3',5'-Tri-O-benzoyl-6-azauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154259
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
Rev 2’-O-MOE-G(iBu)-5’-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152456
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2’-Amino-2’-deoxy-5-methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152733
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
8-Aza-7-bromo-7-deazaguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154121
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2’-O-(2-Methoxyethyl)guanosine 5’-triphosphate (ammonium) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W397503
-
|
2'-Deoxy-5'-O-DMT-5-iodouridine
|
|
Nucleoside Analogs
Uridine
|
|
5’-O-DMTr-5-iodo-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154167
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-O-(4,4’-Dimethoxytrityl)-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152566
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
N7-Methyl-2’-beta-C-methyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154526
-
|
|
|
Nucleoside Analogs
Uridine
|
|
1-(3’-O-[4,4’-dimethoxytrityl]-alpha-L-threofuranosyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154545
-
|
|
|
Phosphoramidites
Uracil
|
|
3’-O-MOE-5MeU-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154473
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2’-Deoxy-N4-ethyl-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152563
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
N1-Methyl-2’-beta-C-methyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154291
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-3’-fluoro-N1-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154133
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-3’-fluoro-xylo-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154059
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluorouridine 5’-monophosphate triethyl ammonium is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-131818
-
|
NH2dAdo; Nsc 238990
|
|
Nucleoside Analogs
Adenosine
|
|
5'-Amino-5'-deoxyadenosine (NH2dAdo; Nsc 238990) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152340
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Amino-2’-deoxy-5-fluoro-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152507
-
|
|
|
Nucleoside Analogs
Inosine
|
|
N1-Methyl-2’-beta-C-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154465
-
|
|
|
Phosphoramidites
Guanine
|
|
3’-F-3’-dG(iBu)-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154319
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
1-(3’-O-[4,4’-Dimethoxytrityl]-alpha-L-threofuranosyl)-thymine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152633
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-Deoxy-N6,N6-dimethyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154394
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Chloro-N6-methyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154407
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2’-Deoxy-N2,N2-dimethylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154511
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2’-Deoxy-N4,N4-dimethylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154295
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-N1-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154159
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2’-O,4’-C-Methyleneadenosine 5’-monophosphate (triethylammonium) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154391
-
|
|
|
Nucleoside Analogs
|
|
5-O-(tert-Butyldiphenylsilyl)-2,3-isopropylidene-D-ribonolactone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152518
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-O-Methyl-5-methyl-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152817
-
|
|
|
Nucleoside Analogs
|
|
2′-β-C-Methyl-beta-D-6-methylpurine riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152301
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-Deoxy-3’-fluoro-N6-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152489
-
|
|
|
Nucleoside Analogs
Inosine
|
|
8-Chloro-2’-deoxy-2’-fluoro inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154370
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’-Bis-O-(t-butyldimethylsilyl)-N1-methylpseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152403
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
3’-Deoxy-3’-fluoro-xylo-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152504
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2’-Deoxy-2’-fluoro-N1-methyladensoine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154355
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Chloro-N6-cyclopentyl 2’-deoxy- adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152444
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Hydroxymethyl-2’-O-(2-methoxyethyl)uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154531
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2′,3′-Dideoxy-3′-fluoro-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154203
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4-Deoxy-3’-deoxy-3’-fluoro uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-149070
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3′-Azido-2′,3′-dideoxy-5-hydroxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152813
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2′-Deoxy-2′-fluoro-4-deoxy-arabinouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154218
-
|
|
|
Nucleoside Analogs
|
|
2-O-Benzoyl-3-O-t-butyldiphenylsilyl-L-threono lactone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152435
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Amino-2’-deoxy-5-methyl uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152509
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N1-Methyl-2’-beta-C-methyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152618
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-N-Acetyl-3’-amino-3’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152424
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-(4-Methoxybenzyl)-2’-C-methyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152815
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2′-Deoxy-2′-fluoro-3-deaza-arabinouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154132
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
1-(b-D-Xylofuranosyl)-N6-(p-methoxybenzyl) adenine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154246
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2’-Fluoro-2’-deoxy-arabinoadenosine 5’-triphosphate (triethylamine) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152311
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Chloro-N6,N6-dimethyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154404
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’,5’-Tri-O-benzyl-4’-thio-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154345
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4′,5′-Didehydro-5′-deoxy-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154134
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-3’-fluoro-xylo-5-trifluoromethyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154158
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2’-Deoxy-2’-fluoroguanosine 5’-monophosphate triethyl ammonium is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154306
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-Deoxy-5’-iodo-2’-O-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152390
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2’-Fluoro-2’-deoxy-N6-methylarabinoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154238
-
|
|
|
Phosphoramidites
Uracil
|
|
5’-O-DMTr-3’-deoxyuridine 2’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154660
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
N4-Benzoyl-2’-deoxy-5-iodocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154266
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Amino-2’-deoxy-N6-ethyl-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152484
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
N7-Methyl-2’-deoxy-2’-fluoroarabinoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154205
-
|
|
|
Nucleoside Analogs
Inosine
|
|
2’-Deoxy-2’-fluoroarabino-O6-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154235
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
N2-iBu-2’,3’-bis-O-TBDMS guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152634
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
8-Chloro-2’-deoxy-2’-fluoro-arabino adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-172496
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .
|
- HY-154307
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4′,5′-Didehydro-5′-deoxy-2′-O-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154050
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
3′-Chloro-3′-deoxy-5′-O-(triphenylmethyl)thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154331
-
|
|
|
Nucleoside Analogs
Uridine
|
|
1-(5-O-Methoxytrityl-2-deoxy-β-D-xylofuranosyl)uracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154343
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
3′-Azido-3′-deoxy-5′-O-(triphenylmethyl)thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152647
-
|
|
|
Nucleoside Analogs
|
|
6-Methoxypurine-9-beta-D-(3-methoxy riboside) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152412
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-3’-α-C-methyl-5-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-172498
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .
|
- HY-152492
-
|
|
|
Nucleoside Analogs
Inosine
|
|
2’-Deoxy-2’-fluoro-N1-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-172497A
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG3400-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG3400-CREKA can be used for drug delivery .
|
- HY-152393
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-3’-α-C-methyl-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W555976
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Hydroxymethyl-2',3'-O-isopropylidene-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W564313
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2',3'-O-Isopropylidene-5-pyrrolidinomethyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154557
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2′,3′-Didehydro-2′,3′-dideoxy-5-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154382
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’,5’-Didehydro-2’-O-(2-methoxyethyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154234
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-O-TBDPS-5-methyl-2,2’-anhydrouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154376
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’,5’-Didehydro-2’-O-methyl-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W342904
-
|
5'-O-[Bis(4-methoxyphenyl)phenylmethyl]-5-iodo-2'-O-methyl-uridine
|
|
Nucleoside Analogs
Uridine
|
|
2’-O-Methyl-5’-O-DMTr-5-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154304
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’,5’-Didehydro-2’,5’-dideoxy-2’-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154429
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2’-Deoxy-N2,N2-diethyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154612
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-4’-thio-a-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152796
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Furan-2-yl-2’-O-methyl uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154371
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-O-Benzoyl-2’-O,4’-C-methyleneuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152486
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
N1-Methyl-2’-deoxy-2’-fluoroarabinoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152736
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-3’-fluoro-5-methyl-xylo-uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-172497
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .
|
- HY-152481
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N1-Methyl-2’-deoxy-2’-fluoroarabinoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154408
-
|
|
|
Phosphoramidites
Uracil
|
|
2’-O-Me-5-I-U-3’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-41793
-
|
2'-Deoxy-3'-O-[(1,1-dimethylethyl)dimethylsilyl]-2'-fluorouridine
|
|
Nucleoside Analogs
Uridine
|
|
3'-O-(t-Butyldimethylsilyl)-2'-deoxy-2'-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154258
-
|
|
|
Nucleoside Analogs
Uridine
|
|
Rev 2’-O-MOE-5MeU-5’-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154677
-
|
|
|
Nucleoside Analogs
|
|
2-Aminopurine-9-beta-D-(2’-deoxy)riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154123
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Benzoyl-2’-chloro-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154263
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
5’-O-DMTr-N6-ethyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154567
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
5’-Deoxy-5’-N-(2-chloroethyl)amino thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154575
-
|
|
|
Nucleoside Analogs
Inosine
|
|
2-[(3-Pyridyl) pyrrolidin-1-yl]-2’-deoxyinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154086
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
5’-O-DMTr-2’,2’-difluoro-dC(Bz)-methyl phosphonamidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154779
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
5′-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152503
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Benzoyl-3’-O-(2-methoxyethyl)adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152706
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2’-O-Methyl-N2,N2-dimethyl-guanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154442
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
Rev 2’-O-MOE-5MeC(Bz)-5’-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154037
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Benzoyl-3'-fluoro-2',3'-dideoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152571
-
|
|
|
Nucleoside Analogs
Inosine
|
|
N1-Methyl-2’-O-(2-methoxyethyl) inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154309
-
|
|
|
Phosphoramidites
Adenine
|
|
3'-O-tert-Butyldimethylsilyl-5'-O-DMT-2'-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152378
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-β-D-arabino-6-azauridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152569
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N1-Methyl-2’-O-(2-methoxyethyl) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154024
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
N4-Benzoyl-2’-O-(2-methoxyethyl)cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154148
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Isopentenyl-2’-deoxy adenosine, 2’-deoxy riboprine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154240
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Amino-2’,3’-bis-O-(2-methoxyethyl) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152350
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-4’-thio-β-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152570
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Methyl-2’-O-(2-methoxyethyl) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152864
-
|
|
|
Nucleoside Analogs
|
|
6-Methylpurine-2’-deoxy-2’-fluoro-beta-D-arabinoriboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W553730
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-iodouridine; 2’-Iodo-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W394293
-
|
2-Thio-5-methyluridine
|
|
Nucleoside Analogs
Uridine
|
|
5-Methyl-2-thiouridine (2-Thio-5-methyluridine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W395015
-
|
5'-O-(DIMETHOXYTRITYL)-2'-O-METHYLINOSINE
|
|
Phosphoramidites
Hypoxanthine
|
|
5’-O-(4,4-Dimethoxytrityl)-2’-O-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152567
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
N1-Methyl-2’-O-(2-methoxyethyl) guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154587
-
|
|
|
Nucleoside Analogs
Uridine
|
|
1-[6-(Diethoxyphosphinyl)-2-O-methyl-β-D-ribo-hexofuranosyl]uracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154546
-
|
|
|
Phosphoramidites
Cytosine
|
|
3’-O-MOE-5Me-C(Bz)-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154325
-
|
|
|
Nucleoside Analogs
|
|
1-(2-Deoxy-β-D-erythro-pentofuranosyl)-4(1H)-pyrimidinone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154499
-
|
|
|
Nucleoside Analogs
|
|
Methyl 4-C-hydroxymethyl-2,3-O-isopropylidene-beta-D-ribofuranoside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154220
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
N4-Benzoyl-2’-deoxy-2’,2’-diflurocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152349
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-β-D-arabino-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154454
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
3’-Deoxy-2’,5’-di-O-acetyl-8-hydroxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152619
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6,N6-Dimethyl-4’-thio-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154588
-
|
|
|
Nucleoside Analogs
Uridine
|
|
1-[6-Phosphono-2-O-methyl-β-D-ribo-hexofuranosyl]uracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154680
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-N3-(4-nitrobenzyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154727
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-N3-(3-aminopropyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154541
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N2,N2-Dimethylamino-6-deamino adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154363
-
|
|
|
Phosphoramidites
|
|
3-Cyanovinyl-9-(5’-O-DMT-2’-deoxyribofuranosyl)carbazole is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152587
-
|
|
|
Nucleoside Analogs
Inosine
|
|
N1-Methyl-3’-O-(2-methoxyethyl) inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154251
-
|
|
|
Nucleoside Analogs
|
|
2-Methoxy-9-β-D-ribofuranosyl-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154605
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
N2-iso-Butyroyl-2’-fluoro-2’-deoxyarabinoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152769
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Methoxy-2’-deoxy-2’-fluoro-beta-D-arabinoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154729
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-O-Methyl-2’-O-acetyl-5’-O-benzoyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152575
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Methyl-3’-O-(2-methoxyethyl) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152874
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-N-(t-Butyloxycarbonylmethyl)-N-trifluoro acetyl-aminomethyl-2’-O-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152371
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
1,N6-Etheno-9-(β-D-xylofuranosyl)adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154224
-
|
|
|
Phosphoramidites
Uracil
|
|
2’-O-Me-2-thio-U-3’-phos phoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154682
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-N3-(n-dodecyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154489
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Bromo-2’-deoxy-2’-fluoro-β-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154723
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-N3-(4-hydroxybenzyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154326
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2-Deoxy-2’-deoxy-5’-(4,4’-dimethoxytrityl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152426
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
1-Amino-8-benzyloxy-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152568
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
N7-Methyl-2’-O-(2-methoxyethyl) guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152573
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N1-Methyl-3’-O-(2-methoxyethyl) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152527
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-4-thio-beta-D-arabinouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-23790
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Benzoyl-2'-O-(2-methoxyethyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W565157
-
|
|
|
Nucleoside Analogs
|
|
3,5-O-Ditoluoyl 6-chloropurine-9-β-D-deoxyriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154437
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-β-Amino-2’,3’-dideoxy-5’-O-methoxy trityluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152785
-
|
|
|
Nucleoside Analogs
|
|
9-(3-Deoxy-3-fluoro-beta-D-ribofuranosyl)-9H-Purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154360
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2’,3’-Di-O-acetyl-8-benzyloxy-3’-deoxy guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152831
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2-Amino-8-aza-7-deaza-7-iodoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152735
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-[[Methyl(2,2,2-trifluoroacetyl)amino]methyl]-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154023
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-O-Benzoyl-2’,3’-di-O-acetyl-4’-C-fluoromethyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154514
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2’-Deoxy-5,N4,N4-trimethylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154667
-
|
|
|
Nucleoside Analogs
|
|
1,2-Di-O-acetyl-3,5-di-O-benzyl-D-xylofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154469
-
|
|
|
Nucleoside Analogs
Inosine
|
|
5’-O-DMTr-2’-O-MOE inosine 3’-P-methyl phosphonamidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154610
-
|
|
|
Nucleoside Analogs
|
|
6-Amino-9-[2-deoxy-β-D-ribofuranosyl]-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152994
-
|
|
|
Nucleoside Analogs
|
|
1,2-Di-O-acetyl-3,5-di-O-benzoyl-D-xylofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154412
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
N4-Benzoyl-2’-deoxy-2’-fluoro-β-D-arabinocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154622
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Bz-5’-O-DMTr-2’-O-hexadecanyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152877
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2-Amino-1-β-D-ribofuranosyl-4(1H)-pyrimidinone is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154206
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
N4-Benzo yl-5’-O-(4,4’-dimethoxytrityl)-aracytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152555
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Amino-2’-deoxy-β-D-arabino-5-methyl uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152661
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Hydroxy-2’-de oxy-2’-fluoro-beta-D-arabino adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154276
-
|
|
|
Nucleoside Analogs
|
|
1-O-Acetyl-2-O-benzoyl-3-O-tert-butyldiphenylsilyl-L-threofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152660
-
|
|
|
Nucleoside Analogs
|
|
2-Amino-6-O-methyl-2’-O-methyl purine riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-N0171B
-
|
β-Sitosterol (purity>75%); 22,23-Dihydrostigmasterol (purity>75%)
|
|
Cholesterol
|
|
Beta-Sitosterol (purity>75%) is a phytosterol with oral activity. Beta-Sitosterol (purity>75%) interferes with a variety of cell signaling pathways, including the cell cycle, apoptosis and cell proliferation. Beta-Sitosterol (purity>75%) has anti-inflammatory, antioxidant, and antitumor activities .
|
- HY-W354644
-
|
|
|
Nucleoside Analogs
|
|
1-(β-D-Ribofuranosyl)-5-nitropyrine-2(1H)-one is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154607
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-3’-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-49198
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2'-Deoxy-2'-fluoro-N4-benzoyl-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154381
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-Deoxy-5’-iodo-2’-O-(2-methoxyethyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152392
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2’-Fluoro-2’-deoxy-N6,N6-dimethylarabinoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152998
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’,5’-Tri-O-acetyl-5-methoxycarbonylmethyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152655
-
|
|
|
Nucleoside Analogs
Inosine
|
|
6-Ethoxy-9-beta-D-(2-C-methyl-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152711
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Chloro-2’-β-C-methyl-6-N,N-dimethyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154478
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
3’-O-Acetyl-N2-iso-Butyroyl-2’-deoxy-guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154627
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
N2-iBu-5’-O-DMTr-2’-O-hexadecanyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152689
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-N3-(4-nitrobenzyl)-beta-D-arabinouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154463
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
N2-iso-Butyroyl-3’-deoxy-3’-fluoro guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W559353
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
1-(3-Beta-amino-2,3-dideoxy-beta-d-threopenta-furanosyl)thymine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152762
-
|
|
|
Nucleoside Analogs
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-phenylpurine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154298
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N-Benzoyl-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-3′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152780
-
|
|
|
Nucleoside Analogs
|
|
9-(2’-Deoxy-2’-fluoro-β-D-arabinofuranosyl)-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154594
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-(Aminomethyl)-2′,3′-O-(1-methylethylidene)-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154725
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-N3-[3-(tert-butoxycarbonyl) amino]propyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152374
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-Deoxy-3’-fluoro-N6,N6-dimethyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154366
-
|
N1-Methylpseudouridine CEP
|
|
Phosphoramidites
Uracil
|
|
5'-DMT-2'-O-TBDMS-N1-Methyl-PseudoUridine-CE-Phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154160
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-(2-Hydroxyethyl)-2’,3’-di-O-toluoyl-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154267
-
|
|
|
Phosphoramidites
Uracil
|
|
5'-O-DMT-2-thio-2'-dU-3'-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152808
-
|
|
|
Nucleoside Analogs
|
|
6-(2-Furanyl)-9-β-D-ribofuranosyl-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154385
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’,5’-Didehydro-2’-O-(2-methoxyethyl)-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154561
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’,5’-Di-O-acetyl-2’-deoxy-N3-methyl uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154340
-
|
2’-Deoxy-3’,2-anhydro-5-methyluridine
|
|
Nucleoside Analogs
Thymidine
|
|
2,3’-Anhydrothymidine; 2’-Deoxy-3’,2-anhydro-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152437
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Amino-3’-deoxy-5-methyl uridine, Anticancer antiviral agent is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154135
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-Deoxy-3’-fluoro-xylo-N6-(p-methoxybenzyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154375
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-Deoxy-5’-iodo-2’-O-methyl-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152404
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-Deoxy-3’-fluoro-xylo-N6-(m-methoxybenzyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154236
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-3’,5’-bis-O-TBDMS-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154045
-
|
|
|
Nucleoside Analogs
|
|
3’-Deoxy-1,2-O-isopropylidene-5-O-(p-toluoyl)-L-arabinofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154290
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3,5-Dimethyl-2’-O-(2-methoxyethyl) uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152380
-
|
|
|
Nucleoside Analogs
|
|
1,2,4-Triazine-3,5-dione 2-β-D-xylopyranoside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154512
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
5’-Deoxy-N4,N4-dimethyl-5-fluorocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152347
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
1-Amino-3’-deoxy-7,8-dihydro-8-oxoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152579
-
|
|
|
Nucleoside Analogs
|
|
6-(1-Piperazinyl)-9-β-D-ribofuranosyl-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154542
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-O-Acetyl-2’,3’-dideoxy-2’,3’-didehydro-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152878
-
|
NSC 529488
|
|
Nucleoside Analogs
Cytidine
|
|
2-Amino-1-β-D-arabinofuranosyl-4(1H)-pyrimidinone is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152572
-
|
|
|
Nucleoside Analogs
|
|
6-(4-Morpholinyl)-9-β-D-ribofuranosyl-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154222
-
|
|
|
Phosphoramidites
Cytosine
|
|
5’-O-DMTr-2’,2’-difluoro-dC(Bz)-3’-CED-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W555583
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’,5’-Di-O-acetyl-2’-deoxy-2’-fluoro-5-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W556276
-
|
|
|
Nucleoside Analogs
|
|
1,4-Anhydro-2,3-di-O-isopropylidene-4-thio-D-ribitol is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152824
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
(R)-N-(2,3-Dihydro-1H-indenyl)-2-amino adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W394793
-
|
|
|
Nucleoside Analogs
|
|
2-Amino-6-chloropurine-9-beta-D-(2’-deoxy)riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154264
-
|
|
|
Phosphoramidites
Adenine
|
|
5’-O-DMTr-N6-ethyl-2’-deoxyadenosine 3’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154424
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2′-Amino-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154490
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-(Furan-2-yl)-2’-O-methyl-5’-O-DMTr-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154683
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
3',5'-Di-O-benzoyl-2'-deoxy-2'-fluoro-beta-D-arabinocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154654
-
|
|
|
Nucleoside Analogs
|
|
9-(2-β-C-Methyl-2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154583
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’,5’-Bis-O-benzoyl-2’-deoxy-2’-fluoro-β-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154154
-
|
|
|
Nucleoside Analogs
|
|
3,5-Bis-O-(4-methylbenzoyl)-2-C-methyl-D-ribonic acid gama-lactone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154229
-
|
|
|
Phosphoramidites
Guanine
|
|
3’-O-DMT-N2-isobutyryl-2’-O-(2-methoxyethyl)guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154543
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-O-(4,4’-Dimethoxytrityl)-3’-O-(2-methoxyethyl) uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154681
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-N3-[(pyrid-4-yl)methyl]uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-172280C
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG3400-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG3400-Octreotide can be used for drug delivery .
|
- HY-154571
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2’,3’,5’-Tri-O-acetyl-6-S-methyl-6-thio-guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154611
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-5-methyl-4’-thio-a-D-arabino uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152423
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-Deoxy-3’-α-C-methyl-N6,N6-dimethyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154721
-
|
|
|
Phosphoramidites
Uracil
|
|
5’-O-DMTr-5-iodo-2’-dU-3’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154720
-
|
|
|
Nucleoside Analogs
|
|
3-O-Benzoyl-1,2: 5,6-bis(di-O-isopropylidene)-alpha-D-galactofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154117
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2',3',5'-Tri-O-benzoyl-2'-beta-C-methyl-6-azauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152695
-
|
|
|
Nucleoside Analogs
|
|
6-Methoxy purine-9-beta-D-(3’-deoxy-3’-fluoro)riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154562
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’,5’-Di-O-acetyl-2’-deoxy-5,N3-dimethyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154223
-
|
|
|
Phosphoramidites
Uracil
|
|
5'-O-(4,4'-Dimethoxytrityl)-2'-O-methyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154365
-
|
|
|
Nucleoside Analogs
Inosine
|
|
5’-O-(4,4’-Dimethoxy trityl)-2’-O-(2-methoxyethyl) inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152604
-
|
|
|
Nucleoside Analogs
|
|
3,4-Dihydro-3-oxo-4-β-D-ribofuranosyl-2-pyrazinecarboxamide is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154449
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
N4-Benzoyl-3’-O-(2-methoxyethyl)-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154718
-
|
|
|
Nucleoside Analogs
|
|
2-Amino-6-chloropurine-3’,5’-di-O-acetyl-2’-deoxyriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154592
-
|
|
|
Nucleoside Analogs
|
|
DMTr-TNA-G(O6-CONPh2)(N2Ac)-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154030
-
|
|
|
Phosphoramidites
Adenine
|
|
N6-Benzoyl-3'-deoxy-5'-O-DMT-3'-fluoroadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-172280B
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG5000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG5000-Octreotide can be used for drug delivery .
|
- HY-154061
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’,5’-Tri-O-benzoyl-2’-β-C-methyl-5-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154581
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
5-(Furan-2-yl)-2’-O-methyl-5’-O-DMTr-cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154035
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
N4-Acetyl-5’-O-(4,4’-dimethoxytrityl)-2’-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154302
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
5’-O-(4,4’-Dimethoxytrityl)-3’-O-levulinyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-172280A
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG21000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG2000-Octreotide can be used for drug delivery .
|
- HY-172280
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG1000-Octreotide can be used for drug delivery .
|
- HY-154057
-
|
|
|
Nucleoside Analogs
|
|
5-(2,3,5-Tri-O-benzyl-beta-D-ribofuranosyl)-2(1H)-pyridinone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154145
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’,5’-Tri-O-benzoyl-2’-β-C-methyl-5-methoxy uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152532
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2’-Deoxy-2’-fluoro-6-S-Methyl-6-thio-ara-guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154359
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-O-Acetyl-3’,5’-bis-O-benzoyl-6-aza-xylo uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154426
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
2’,3’-Di-O-acetyl-8-benzyloxy-3’-deoxy-3’-fluoroguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152605
-
|
|
|
Nucleoside Analogs
Inosine
|
|
2’-Deoxy-2’-fluoro-6-S-methyl-6-thio-arabino-inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154056
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’,5’-Tri-O-benzoyl-2’-β-C-methyl-3-deazauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152521
-
|
|
|
Nucleoside Analogs
|
|
2-Amino-6-meThythio-9-(β-D-ribofuranosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W601637
-
|
|
|
Nucleoside Analogs
|
|
1,2-Di-O-acetyl-5-Benzoyl-3-O-Methyl-D-ribofuranose diacetate is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-146245C
-
|
CpG 1826 sodium
|
|
CpG ODNs
|
|
ODN 1826 sodium is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 sodium induces NO and iNOS production and enhances Apoptosis. ODN 1826 sodium enhances immune surveillance. ODN 1826 sodium increases aortic atherosclerotic plaque size. ODN 1826 sodium has antitumor activity against lung cancer, glioma and melanoma .
|
- HY-154089
-
|
|
|
Nucleoside Analogs
|
|
3-Deoxy-1,2:5,6-bis-O-(1-methylethylidene)-α-D-ribo-hexofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154221
-
|
|
|
Phosphoramidites
Cytosine
|
|
N4-Benzoyl-2'-deoxy-5'-O-DMT-2',2'-difluorocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152372
-
|
|
|
Nucleoside Analogs
|
|
Methyl 6-amino-9-β-D-ribofuranosyl-9H-purine-2-carboxylate is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152348
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-5-methyl-4’-thio-β-D-arabino uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154601
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
N4-Benzoyl-5’-O-(4,4-dimethoxytrityl)-3’-deoxy cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154628
-
|
|
|
Phosphoramidites
Guanine
|
|
N2-iBu-5’-O-DMTr-2’-O-hexadecanyl guanosine 3’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152734
-
|
|
|
Nucleoside Analogs
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-(pyridine-4-yl)purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152491
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
7-Cyclopropyl methyl-7,8-dihydro-8-oxo-9-(β-D-ribofuranosyl)guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154555
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-O-Acetyl-2’,3’-dideoxy-2’,3’-didehydro-5-fluoro-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154384
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-Deoxy-5’-iodo-2’-O-(2-methoxyethyl)-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154477
-
|
|
|
Nucleoside Analogs
|
|
2-Amino-6-chloro-9-(3-deoxy-beta-D-ribofuanosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154439
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-β-Amino-2’,3’-dideoxy-5’-O-trityl-5-methyl uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154416
-
|
|
|
Nucleoside Analogs
|
|
5-(2,3,5-Tri-O-benzyl-beta-D-ribofuranosyl)-3-methyl-2-benzyloxypyridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154260
-
|
|
|
Phosphoramidites
Adenine
|
|
N6-Benzoyl-3'-O-DMT-2'-O-(2-methoxyethyl) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154342
-
|
|
|
Phosphoramidites
Thymine
|
|
N1-Ethyl-2’-O-TBDMS-5’-O-DMTr-3’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152809
-
|
|
|
Nucleoside Analogs
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-(furan-2-yl)purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152331
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
7-n-Propyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152328
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
7-Ethyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154328
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-beta-Azido-2’,3’-dideoxy-5’-O-(4-methoxy-trityl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154315
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3',5'-Bis-O-benzoyl-2'-deoxy-2'-fluoro-4-deoxy-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152531
-
|
|
|
Nucleoside Analogs
|
|
2-Amino-6-allyl thio-9-(beta-D-ribofuranosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154422
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Amino-2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152766
-
|
|
|
Nucleoside Analogs
|
|
6-(Thiophen-3-yl)purine-beta-D-(3’-deoxy-3’-fluoro)riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152297
-
|
|
|
Nucleoside Analogs
|
|
(1S)-1,4-Anhydro-1-C-(2,4-difluorophenyl)-D-ribitol is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152727
-
|
|
|
Nucleoside Analogs
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-(naphthalen-1-yl)purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-16200
-
|
ECyD; TAS-106; 3'-C-Ethynylcytidine
|
|
Nucleoside Analogs
Cytidine
|
|
Ethynylcytidine (ECyD), a nucleoside analog and a potent inhibitor of RNA synthesis, inhibits RNA polymerases I, II and II. Ethynylcytidine has robust antitumor activity in a wide range of models of cancer . Ethynylcytidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-154593
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
N4-Benzoyl-5’-O-DMTr-2’-O-(N3-trifluoroacetyl) aminopropyl cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154686
-
|
|
|
Nucleoside Analogs
Thymidine
|
|
1-(3-β-Azido-2,3-dideoxy-5-O-trityl-D-threopenta-furanosyl)thymine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154501
-
|
|
|
Nucleoside Analogs
|
|
5-O-Benzoyl-1,2,3-tri-O-acetyl-4-C-methyl-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152460
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Chloro-N6-cyclopentyl-2’-deoxy-2’-fluoro-beta-D-arabinoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154207
-
|
|
|
Phosphoramidites
Cytosine
|
|
2’-O-Acetyl-N4-benzoyl-5’-O-DMT arabinocytidine 3’-O-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154403
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Azido-2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152436
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
7-Cyclopropylmethyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl) guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154658
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-N3-[(pyrid-4-yl)methyl]-beta-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154003
-
|
|
|
Nucleoside Analogs
|
|
7-(2-Deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152853
-
|
|
|
Nucleoside Analogs
|
|
3-Methyl-5-β-D-ribofuranosyl-2,4(1H,3H)-pyrimidinedione is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154379
-
|
|
|
Nucleoside Analogs
|
|
3',5'-Di-O-acetyl-2'-O-methyl-6-chloro-2-aminopurine riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152381
-
|
|
|
Nucleoside Analogs
|
|
1,9-Dihydro-9-β-D-xylofuranosyl-6H-purin-6-one is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154623
-
|
|
|
Phosphoramidites
Adenine
|
|
N6-Bz-5’-O-DMTr-2’-O-hexadecanyl adenosine 3’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154643
-
|
|
|
Nucleoside Analogs
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-9H-purin-2-amine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154515
-
|
|
|
Nucleoside Analogs
|
|
2-Chloro-9-[(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)]-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152810
-
|
|
|
Nucleoside Analogs
|
|
2-Ami no-9-(2-β-C-methyl-β-D-ribofuranosyl)-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154532
-
|
|
|
Nucleoside Analogs
|
|
9-(5(R)-C-Methyl-2,3,5-tri-O-benzoyl-D-ribofuranosyl)-6-chloropurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152333
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
7-n-Butyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-146245
-
ODN 1826
Maximum Cited Publications
10 Publications Verification
CpG 1826
|
|
CpG ODNs
|
|
ODN 1826 is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 induces NO and iNOS production and enhances Apoptosis. ODN 1826 enhances immune surveillance. ODN 1826 increases aortic atherosclerotic plaque size. ODN 1826 has antitumor activity against lung cancer, glioma and melanoma .
|
- HY-154570
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-N-Acetyl-3’-amino-3’-deoxy-2’,5’-di-O-acetyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152776
-
|
|
|
Nucleoside Analogs
|
|
2-Amino-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154316
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’,5’-Di-O-benzoyl-2’-deoxy-2’-fluoro-3-Deaza-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154265
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Amino-2’-deoxy-N6,N6-dimethyl-2’-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152791
-
|
|
|
Nucleoside Analogs
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-methyl-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W061531
-
|
|
|
Nucleoside Analogs
|
|
5-O-TBDPS-1,2-di-O-isopropy lidene-3-keto-alpha-D-xylofuranoside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154116
-
|
|
|
Nucleoside Analogs
|
|
6-Chloro-2-hydroxy-9-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154663
-
|
|
|
Nucleoside Analogs
|
|
1-β-D-Arabinofuranosyl-5-bromo-2,4(1H,3H)-pyrimidinedione is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152690
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-N3-[(pyrid-2-yl)methyl]-beta-D-arabinouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154312
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3,5-Di-O-benzoyl-2-deoxy-2-fluoro-5-trifluoromethyl-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152603
-
|
|
|
Nucleoside Analogs
|
|
2-Amino-1-β-D-arabinofuranosyl-5-methyl-4(1H)-pyrimidinone is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152407
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
7-Allyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl) guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152431
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
1-Amino-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl) guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154029
-
|
|
|
Nucleoside Analogs
|
|
3-β-D-Ribofuranosyl-6-hydroxymethyl-furano[2,3-d]-pyrimidin-2-one is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W556327
-
|
|
|
Nucleoside Analogs
|
|
5-Nitro-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-2(1H)-pyridinone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152408
-
|
|
|
Nucleoside Analogs
|
|
2-β-D-Ribofuranosyl-2H-pyrazolo[3,4-d]pyrimidine-4,6-diamine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154078
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-O-Acetyl-5’-O-(p-toluoyl)-3’-deoxy-3’-fluoro-5-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154459
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
N4-Benzoyl-2’-deoxy-5’-O-DMTr-2’-fluoro- 5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154726
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro- N3-(2S)-(2-amino-3-carbonyl)-propyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154369
-
|
|
|
Nucleoside Analogs
|
|
1,4-Anhydro-2,3-O-isopropylidene-5-O-t-butyldiphenylsilyl-4-thio-D-ribitol is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154655
-
|
|
|
Nucleoside Analogs
|
|
6-Methyl-9-(2-β-C-methyl-2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154212
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
N4-Acetyl-5’-O-(4,4’-dimethoxytrityl)-5-methyl-2’-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154633
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
3,5-O-[1,1,3,3-Tetrakis(1-methylethyl)-1,3-disiloxanediyl] cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154185
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’,5’-Di-O-benzoyl-2’-deoxy-2’-fluoro-5-methyl-β-D-arabino-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154286
-
|
|
|
Nucleoside Analogs
|
|
1-O-Acetyl-2,3,5-tri-O-benzoyl-5(R)-C-methyl-D-ribo furanose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154228
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-O-(4,4’-Dimethoxy trityl)-2’-O-(2-methoxyethyl)-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154040
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-O-Benzoyl-3’-O-(4-methoxybenzyl)-2’-O,4’-C-methyleneuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152709
-
|
|
|
Nucleoside Analogs
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-(5-phenylpyridin-3-yl)purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154440
-
|
|
|
Nucleoside Analogs
|
|
2-Amino-6-chloro-9-(3’-O-methyl-beta-D-ribofuranosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154676
-
|
|
|
Nucleoside Analogs
|
|
Purine-9-b-D-(3’,5’-di-O-benzoyl-2’-deoxy-2’-fluoro)arabinoriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154503
-
|
|
|
Nucleoside Analogs
|
|
3-O-(4-Methoxybenzyl)-4-C-hydroxymethyl-1,2-O-isopropylidine-alpha-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154071
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-O-Acetyl-5’-O-(p-toluoyl)-3’-deoxy-3’-fluoro-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-14392
-
|
DRB
|
|
Nucleoside Analogs
|
|
5,6-Dichlorobenzimidazole riboside (DRB) is a nucleoside analog that inhibits several carboxyl-terminal domain kinases, including casein kinase II and cell cycle-dependent kinases (CDK). 5, 6-dichlorobenzimidazole riboside has antitumor activity. 5, 6-dichlorobenzimidazole riboside can induce apoptosis .
|
- HY-154335
-
|
|
|
Nucleoside Analogs
|
|
1-(3-Deoxy-3-fluoro-β-D-xylofuranosyl)-2,4(1H,3H)-pyrimidinedione is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154083
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-O-Acetyl-5’-O-(p-toluoyl)-3’-deoxy-3’-fluoro-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154730
-
|
|
|
Nucleoside Analogs
|
|
9-(2’-O-Acetyl-5’-O-benzoyl-3’-O-methyl-beta-D-ribofuranosyl)-6-chloropurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152858
-
|
|
|
Nucleoside Analogs
Uridine
|
|
Methyl 1,2,3,4-tetrahydro-2,4-dioxo-1-β-D-ribofuranosyl-5-pyrimidineacetate is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154124
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Benzoyl-2'-chloro-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152876
-
|
|
|
Nucleoside Analogs
|
|
6-Chloro-9-(2-O-methyl-beta-D-ribofuranosyl)-9H-purin-2-amine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W048245
-
|
|
|
Nucleoside Analogs
|
|
(2R,3S,4R)-2-(Hydroxymethyl)tetrahydrothiophene-3,4-diol is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154118
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3',5'-Bis-O-benzoyl-2'-deoxy-2'-fluoro-beta-D-arabino-6-azidouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154498
-
|
|
|
Nucleoside Analogs
|
|
1,2-Di-O-acetyl-3,5-di-O-benzoyl-3-beta-C-methyl-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W547585
-
|
|
|
Nucleoside Analogs
|
|
4-Hydroxy-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-2(1H)-pyridinone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154072
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-O-Acetyl-5’-O-(p-toluoyl)-3’-deoxy-3’-fluoro-5-trifluoromethyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152981
-
|
|
|
Nucleoside Analogs
|
|
Di-O-Toluoyl-1,2-dideoxy-D-ribose-6-chloro-7-iodo-7-deazapurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152828
-
|
|
|
Nucleoside Analogs
|
|
1-β-D-Ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154475
-
|
|
|
Nucleoside Analogs
|
|
9-(2'-O-Acetyl-5'-O-benzoyl-3'-deoxy-beta-D-ribofuranosyl)-6-chloropurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154447
-
|
|
|
Nucleoside Analogs
Inosine
|
|
5’-O-(p-Toluoyl)-2’-O-acetyl-3’-deoxy-3’-fluoro-6-chloroinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152772
-
|
|
|
Nucleoside Analogs
|
|
2-Amino-6-chloropurine-9-beta-D-(2’-deoxy-2’-fluoro)-arabinoriboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152806
-
|
|
|
Nucleoside Analogs
|
|
2-Amino -6-chloro-9-(2-β-C-methyl-β-D-ribofuranosyl)-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154044
-
|
|
|
Nucleoside Analogs
|
|
3-Deoxy-1,2-O-isopropylidene-5-p-toluoyl-a-D-glycero-pent-3-enofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152485
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2-Amino-N6,N6-dimethyl-2’-deoxy-2’-fluoro-beta-D-arabino-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152410
-
|
|
|
Nucleoside Analogs
|
|
6-Amino-4-hydrozino-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154380
-
|
|
|
Nucleoside Analogs
|
|
6-Chloro-9-(3,5-di-O-acetyl-2-O-methyl-β-D-ribofuranosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154679
-
|
|
|
Nucleoside Analogs
|
|
2-Chloro-6-(thiophen-3-yl)purine-beta-D-(3’-deoxy-3’-fluoro)riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152414
-
|
|
|
Nucleoside Analogs
|
|
6-Amino-4-hydroxyamino-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152582
-
|
|
|
Nucleoside Analogs
|
|
7-(3-Deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152680
-
|
|
|
Nucleoside Analogs
|
|
4-Amino-5-cyano-1- (β-D-ribofuranosyl)-7H-pyrrolo[2,3-d] pyrimidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152305
-
|
|
|
Nucleoside Analogs
|
|
(1S)-1,4-Anhydro-1-C-(2,4-difluoro-5-methylphenyl)-D-ribitol is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154112
-
|
|
|
Nucleoside Analogs
|
|
2-Bromo-6-chloro-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154731
-
|
|
|
Nucleoside Analogs
|
|
9-(2’-O-Acetyl-5’-O-benzoyl-3’-O-methyl-beta-D-ribofuranosyl)-2,6-dichloropurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152687
-
|
|
|
Nucleoside Analogs
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[6-(4-methylpiperazinyl) pyridin-3-yl]purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152685
-
|
|
|
Nucleoside Analogs
|
|
4-Amino-1-(β-D-ribofurano syl)-7H-pyrrolo [2.3-d] pyrimidine-5-carboxamide is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152827
-
|
|
|
Nucleoside Analogs
|
|
4-Methoxy-1-β-D-ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152578
-
|
|
|
Nucleoside Analogs
|
|
7-(2,3-Anhydro-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152704
-
|
|
|
Nucleoside Analogs
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[6-(4-morpholinyl)pyridin-3-yl]purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154617
-
|
|
|
Phosphoramidites
Guanine
|
|
6-S-(2-Cyanoethyl)-2’-deoxy-5’-O-DMTr--6-thioguanosine 3’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W544504
-
|
|
|
Nucleoside Analogs
|
|
2,6-Dichloro-9-(2-c-methyl-2,3,5-tri-O-benzoyl-beta-D-ribofuranosyl)purine dibenzoate is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152818
-
|
|
|
Nucleoside Analogs
|
|
4-Chloro-7-(2-β-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d] pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152657
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N1-Methyl-N3-[(2S)-2-(t-butoxycarbonyl)amino-3-(t-butoxycarbonyl)] propylpseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152432
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
1-Amino-7-cyclopropyl methyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154675
-
|
|
|
Nucleoside Analogs
|
|
2-Aminopurine-9-beta-D-(3’,5’-di-O-benzoyl-2’-deoxy-2’-fluoro)arabinoriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154572
-
|
|
|
Nucleoside Analogs
|
|
9-(2-O-Acetyl-3,5-di-O-benzoyl-β-D-xylofuranosyl)-6-chloro-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152398
-
|
|
|
Nucleoside Analogs
|
|
6-Amino-4-methoxy-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154669
-
|
|
|
Nucleoside Analogs
|
|
9-(2,3-Di-O-acetyl-6-O-benzoyl-5-deoxy-D-ribo-exofuranoyl)-6-chloropurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152686
-
|
|
|
Nucleoside Analogs
|
|
2-Chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-6-methoxy-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152788
-
|
|
|
Nucleoside Analogs
|
|
2-Chloro-6-(furan-2-yl) purine-beta-D-(3’-deoxy-3’-fluoro)-riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154060
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-3'-O-(2-methoxyethyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154662
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-N3-(2S)-(2-amino-3-carbonyl] propyl-beta-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W551230
-
|
|
|
Nucleoside Analogs
|
|
2-Amino-6-chloropurine-9-beta-D-(2’-deoxy-3’,5’-di-O-(p-toluoyl))riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154653
-
|
|
|
Nucleoside Analogs
|
|
9-(2,3,5-Tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)-9H-purin-2-amine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154362
-
|
|
|
Nucleoside Analogs
|
|
1,2-Di-O-acetyl-3-deoxy-3-fluoro-5-O-(4-methyl)benzoyl-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154724
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-N3-(2S)-[2-(tert-butoxy-carbonyl)-amino-3-carbonyl]propyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W020361
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2'-C-Ethynyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2'-C-Ethynyluridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-154125
-
|
|
|
Nucleoside Analogs
|
|
6-Chloro-2-fluoropurine-9-b-D-(3,5-bis-O-(p-toluoyl)-2-deoxy)riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W544503
-
|
|
|
Nucleoside Analogs
|
|
6-Chloro-9-(2,3,5-tri-O-benzoyl-2-C-methyl-beta-D-ribofuranosyl)-9H-purine dibenzoate is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152819
-
|
|
|
Nucleoside Analogs
|
|
4-Amino-5-iodo-7-(2-β-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152474
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2’-β-C-Ethynylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-β-C-Ethynylcytidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-152475
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2’-β-C-Ethynyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-β-C-Ethynyladenosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-W020420
-
|
|
|
Nucleoside Analogs
|
|
6-Chloro-9-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152718
-
|
|
|
Nucleoside Analogs
|
|
4-Amino-5-cyano-1-(2-β-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2.3-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W550484
-
|
|
|
Nucleoside Analogs
|
|
2,6-Dichloro-9-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-D-arabinofuranosyl)-9H-purine arabinoriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-21978
-
|
|
|
Nucleoside Analogs
|
|
9H-Purine, 6-chloro-2-iodo-9-β-D-ribofuranosyl- (6-CHLORO-2-IODOPURINE-9-RIBOSIDE) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-W605935
-
|
|
|
Nucleoside Analogs
|
|
2-Amino-6-chloropurine -9-beta-D-(2’-deoxy-3’,5’-di-O-benzoyl-2’-fluoro)arabinoriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152556
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3-Deaza-4’-C-methyluridine, 4-Hydroxy-1-β-D-(4-C-methylribofuranosyl)-2(1H)-pyridinone is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152405
-
|
|
|
Nucleoside Analogs
|
|
6-Amino-1,2-dihydro-2-β-D-ribofuranosyl-4H-pyrazolo[3,4-d]pyrimidin-4-one is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152447
-
|
|
|
Nucleoside Analogs
Inosine
|
|
3’-beta-C-Ethynyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-beta-C-Ethynyl inosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-152625
-
|
|
|
Nucleoside Analogs
Inosine
|
|
2’-Beta-C-Ethynyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-Beta-C-Ethynyl inosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-152659
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N1-Propargylpseudouridine (see GL102032) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . N1-Propargylpseudouridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-152443
-
|
|
|
Nucleoside Analogs
|
|
6-Amino-3-(furan-2-yl)-4-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152616
-
|
|
|
Nucleoside Analogs
|
|
2-Amino-3,7-dihydro-5-iodo-7-β-D-ribofuranosyl-4H-pyrrolo[2,3-d]pyrimidin-4-one is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154613
-
|
|
|
Nucleoside Analogs
|
|
(2R-cis)-5-[Tetrahydro-5-(hydroxymethyl)-4-oxo-2-furanyl]-2,4(1H,3H)-pyrimidinedione is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152703
-
|
|
|
Nucleoside Analogs
|
|
2-Amino-7-cyclopropyl methyl-7,8-dihydro-8-oxo-9-(beta-D-xylo furanosyl)purine (G159-82) PTPD-2 Confidential is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154142
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Beta-C-Ethynyl-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Beta-C-Ethynyl-5-methoxyuridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-152442
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-beta-C-Ethynyl-3-deazauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-beta-C-Ethynyl-3-deazauridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-154314
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
N2-(Isopropylphenoxyacetyl)-2’-O-propargylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . N2-(Isopropylphenoxyacetyl)-2’-O-propargylguanosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-154141
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Beta-C-Ethynyl-5-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Beta-C-Ethynyl-5-fluorouridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-154202
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-beta-C-Ethynyl-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-beta-C-Ethynyl-5-methyluridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-154143
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Beta-C-Ethynyl-4-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Beta-C-Ethynyl-4-deoxyuridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-152627
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Methyl-2’-beta-C-ethynyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . N6-Methyl-2’-beta-C-ethynyl adenosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-W012293
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
4-Amino-1-((2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (3'-Deoxycytidine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152626
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
N6-Ethyl-2’-beta-C-ethynyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . N6-Ethyl-2’-beta-C-ethynyl adenosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-154256
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-(2-Azidoethyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5-(2-Azidoethyl)uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-W394432
-
|
|
|
Nucleoside Analogs
|
|
(2R,3S,5R)-2-(hydroxymethyl)-5-(6-methyl-9H-purin-9-yl)tetrahydrofuran-3-ol (9-(2-Deoxy-beta-D-ribofuranosyl)-6-methylpurine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152352
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
7,8-Dihydro-8-oxo-7-propargyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 7,8-Dihydro-8-oxo-7-propargyl guanosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-152746
-
|
|
|
Nucleoside Analogs
|
|
2-Amino-6-chloropurine-9-(2’-O-propargyl)riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2-Amino-6-chloropurine-9-(2’-O-propargyl)riboside is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-W013289
-
|
|
|
Nucleoside Analogs
Inosine
|
|
9-((2R,3R,4R,5R)-4-Hydroxy-5-(hydroxymethyl)-3-methoxytetrahydrofuran-2-yl)-9H-purin-6-ol (2'-O-methylinosine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152870
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
2’-O-(2-Azidoethyl)adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-O-(2-Azidoethyl)adenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152737
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
3’-Deoxy-3’-azido-isocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Deoxy-3’-azido-isocytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152720
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Azido-3’-deoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154054
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
5′-Azido-5′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5′-Azido-5′-deoxyadenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152868
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-O-(2-Azidoethyl)adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-O-(2-Azidoethyl)adenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152663
-
|
|
|
Nucleoside Analogs
|
|
6-Mthoxy-9-beta-D-(2-C-ethynyl-ribofuranosyl) purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 6-Mthoxy-9-beta-D-(2-C-ethynyl-ribofuranosyl) purine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-154405
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-Azido-5’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5’-Azido-5’-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154666
-
|
|
|
Nucleoside Analogs
Inosine
|
|
3’-Azido-3’-deoxyinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxyinosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154629
-
|
|
|
Solvents
|
|
Sesame Oil is a vegetable oil. Sesame Oil can be extracted from the seeds of Sesamum indicum L. Sesame Oil decreases NF-κB, aspartate aminotransferase, alanine aminotransferase, IL-1β, IL-4 and nitric oxide. Sesame Oil has antitumor activity against malignant melanoma. Sesame Oil has protective effects against liver damage caused by various agents such as Cisplatin (HY-17394) and Acetaminophen (HY-66005). Sesame Oil shows antinociceptive and anti-inflammatory activities .
|
- HY-152770
-
|
|
|
Nucleoside Analogs
|
|
6-((2R,3R,4R,5R)-4-Hydroxy-5-(hydroxymethyl)-3-methoxytetrahydrofuran-2-yl)-3-(2-oxopropyl)imidazo[1,2-c]pyrimidin-5(6H)-one is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152728
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
3’-Azido-3’-deoxycytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxycytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154055
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
5′-Azido-2′,5′-dideoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5′-Azido-2′,5′-dideoxyadenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152514
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Azidomethyl-2’-beta-methyl uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5-Azidomethyl-2’-beta-methyl uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152592
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
3’-Azido-3’-deoxy-beta-L-cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-beta-L-cytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154284
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy guanosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-152601
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-Azido-3’-deoxy-beta-L-adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-beta-L-adenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-W354252
-
|
9-Pentofuranosyl-9H-purin-2-amine
|
|
Nucleoside Analogs
|
|
(2R,3R,4S,5R)-2-(2-amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (9-pentofuranosyl-9H-purin-2-amine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154305
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5′-Azido-2′,5′-dideoxy-2′-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5′-Azido-2′,5′-dideoxy-2′-fluorouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152353
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Azido-3’-deoxy-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-2-thiouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152802
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2’-O-(3-Azidopropyl)-5-azacytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-O-(3-Azidopropyl)-5-azacytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152642
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2’-Azido-2’-deoxy-5-methyl cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-Azido-2’-deoxy-5-methyl cytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152724
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Azido-3’-deoxy-5-iodouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-iodouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152645
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Azido-3’-deoxy-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-methyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154320
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Azido-3’-deoxy-3-deazauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-3-deazauridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152713
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Azido-3’-deoxy-5-methoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-methoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154308
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-Azido-5’-deoxy-2’-O-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5’-Azido-5’-deoxy-2’-O-methyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154579
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-Azido-N6-benzoyl-3’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-N6-benzoyl-3’-deoxyadenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154402
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2′-Azido-2′-deoxy-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2′-Azido-2′-deoxy-5-methyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152315
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-Azido-3’-deoxy-N6-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-N6-methyladenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152708
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Azido-3’-deoxy-5-trifluoromethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-trifluoromethyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152338
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
7-Propargyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 7-Propargyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-152688
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Azido-3’-deoxy-5-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-fluorouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154119
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Azido-3’-deoxy-6-azauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-6-azauridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154346
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-Azido-5’-deoxy-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5’-Azido-5’-deoxy-5-methyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152585
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Azido-3’-deoxy-5-fluoro-beta-L-uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-fluoro-beta-L-uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152373
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy-3’-fluoro-xylo-guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy-3’-fluoro-xylo-guanosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-152448
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
2’-Azido-2’-deoxycytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-Azido-2’-deoxycytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups. 2’-Azido-2’-deoxycytidine is an azidonucleoside,and it should be phosphorylated twice to become an inhibitor of the nucleotide reductase.
|
- HY-152583
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-Azido-3’-deoxy-5-methyl-beta-L-uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-methyl-beta-L-uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152389
-
|
|
|
Nucleoside Analogs
|
|
6-Methylpurine-β-D-(3-azido-3-deoxy)riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 6-Methylpurine-β-D-(3-azido-3-deoxy)riboside is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152364
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy-3’-fluoro guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy-3’-fluoro guanosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-152597
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
3’-Azido-3’-deoxy-5-fluoro-beta-L-cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-fluoro-beta-L-cytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152595
-
|
|
|
Nucleoside Analogs
Cytidine
|
|
3’-Azido-3’-deoxy-5-methyl-beta-L-cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-5-methyl-beta-L-cytidine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152341
-
|
|
|
Nucleoside Analogs
Guanosine
|
|
7-(Butyn-2-yl)-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 7-(Butyn-2-yl)-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-154383
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-Azido-5’-deoxy-2’-O-(2-methoxyethyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5’-Azido-5’-deoxy-2’-O-(2-methoxyethyl)uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154423
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2′-Azido-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2′-Azido-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154283
-
|
|
|
Nucleoside Analogs
|
|
2-Amino-7-propargyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2-Amino-7-propargyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl)purine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-154042
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-Azido-5’-deoxy-2’-O,4’-C-methyleneuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5’-Azido-5’-deoxy-2’-O,4’-C-methyleneuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154733
-
|
|
|
Nucleoside Analogs
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[5-(propyn-1-yl)pyridin-3-yl]purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[5-(propyn-1-yl)pyridin-3-yl]purine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-112120
-
|
|
|
Nucleoside Analogs
|
|
2-Amino-6-chloro-9-(3-deoxy-3-fluoro-beta-D-ribofuranosyl)-9H-purine ((2R,3S,4S,5R)-2-(2-Amino-6-chloro-9H-purin-9-yl)-4-fluoro-5-(hydroxymethyl)tetrahydrofuran-3-ol) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-152319
-
|
|
|
Nucleoside Analogs
Adenosine
|
|
3’-Azido-3’-deoxy-N6,N6-dimethyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-N6,N6-dimethyladenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154377
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-Azido-5’-deoxy-2’-O-methyl-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5'-Azido-5'-deoxy-2'-O-methyl-5-methyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-W334680
-
|
|
|
Nucleoside Analogs
|
|
2-Amino-9-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,9-dihydro-6H-purin-6-one (9-β-D-[2'-Fluoro-2'-deoxy-arabinofuranosyl]-guanin) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
- HY-154146
-
|
|
|
Nucleoside Analogs
|
|
5-Nitro-1-(3-azido-3-deoxy-β-D-ribofuranosyl)-2(1H)-pyridinone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5-Nitro-1-(3-azido-3-deoxy-β-D-ribofuranosyl)-2(1H)-pyridinone is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154386
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-Azido-5’-deoxy-2’-O-(2-methoxyethyl)-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 5’-Azido-5’-deoxy-2’-O-(2-methoxyethyl)-5-methyluridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-W018604
-
|
|
|
Nucleoside Analogs
|
|
2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone is a purine nucleoside analog. 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone can be synthesized from D-ribose by reacting with methanol under Fischer glycosylation conditions. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone exerts anticancer activities through inhibition of DNA synthesis, induction of apoptosis, etc. 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone can be studied in anticancer research for lymphoid malignancies .
|
- HY-152438
-
|
|
|
Nucleoside Analogs
|
|
6-Amino-3-ethynyl-4-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 6-Amino-3-ethynyl-4-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-154334
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-O-Acetyl-3’-azido-5’-O-(4-methylbenzoyl)-3’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-O-Acetyl-3’-azido-5’-O-(4-methylbenzoyl)-3’-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154425
-
|
|
|
Nucleoside Analogs
|
|
2-Amino-7-propargyl-7,8-dihydro-8-oxo-9-(beta-D-3-deoxy-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2-Amino-7-propargyl-7,8-dihydro-8-oxo-9-(beta-D-3-deoxy-ribofuranosyl)purine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-154310
-
|
|
|
Nucleoside Analogs
|
|
1,2-Di-O-acetyl-3-azido-3-deoxy-5-O-(4-methyl) benzoyl-L-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 1,2-Di-O-acetyl-3-azido-3-deoxy-5-O-(4-methyl) benzoyl-L-ribofuranose is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154318
-
|
|
|
Nucleoside Analogs
|
|
1,2-Di-O-acetyl-3-azido-3-deoxy-5-O-(4-methyl)benzoyl-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 1,2-Di-O-acetyl-3-azido-3-deoxy-5-O-(4-methyl)benzoyl-D-ribofuranose is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154678
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’-Azido-3’-O-benzoyl-5’-O-(m-chlorobenzoyl)-2’-deoxy-2’-fluoro-beta-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 4’-Azido-3’-O-benzoyl-5’-O-(m-chlorobenzoyl)-2’-deoxy-2’-fluoro-beta-D-arabinouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154341
-
|
|
|
Nucleoside Analogs
|
|
9-[2'-O-Acetyl-3'-azido-3'-deoxy-5'-O-toluoyl-b-L-ribofuranosyl)-6-chloropurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 9-[2'-O-Acetyl-3'-azido-3'-deoxy-5'-O-toluoyl-b-L-ribofuranosyl)-6-chloropurine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-111783G
-
|
|
DNA-PK
ATM/ATR
PI3K
Apoptosis
|
Cancer
|
|
AZD-7648 (GMP) is AZD-7648 (HY-111783) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AZD-7648 is a potent, orally active, selective DNA-PK inhibitor with an IC50 of 0.6 nM. AZD-7648 induces apoptosis and shows antitumor activity .
|
-
-
- HY-B0342GL
-
|
Methylglucamine (GMP Like); Meglumin (GMP Like); Methylglucamin (GMP Like)
|
Biochemical Assay Reagents
|
Cancer
|
|
Meglumine (GMP Like) (Methylglucamine (GMP Like)) is the GMP Like class Meglumine (HY-B0342) that can be used as pharmaceutical excipients. Meglumine (Methylglucamine) is an orally active amino sugar derived from sorbitol. Meglumine has anti-inflammatory and antitumor activity. Meglumine is often used as an excipient in active molecules and with iodinated compounds in contrast agents such as meglumine and meglumine iodide .
|
-
-
- HY-15794G
-
|
Methoxymorpholinyl doxorubicin; FCE 23762; PNU 152243
|
G-quadruplex
|
Cancer
|
|
Nemorubicin (Methoxymorpholinyl doxorubicin) GMP is a GMP-class Nemorubicin (HY-15794). Nemorubicin is a Doxorubicin derivative with potent antitumor activity. Nemorubicin is highly cytotoxic to a variety of tumor cell lines presenting a multidrug-resistant phenotype. Nemorubicin not only intercalate into the duplex DNA, but also result in significant ligands for G-quadruplex DNA segments, stabilizing their structure. Nemorubicin requirs an intact nucleotide excision repair (NER) system to exert its activity .
|
-
-
- HY-10181G
-
|
BMS-354825 (GMP)
|
Src
Bcr-Abl
Apoptosis
Autophagy
|
Cancer
|
|
Dasatinib (BMS-354825) (GMP) is a GMP-grade Dasatinib (HY-10181). GMP-grade small molecules can be used as adjuvant agents in cell therapy. Dasatinib (BMS-354825) is an orally active, ATP-competitive, dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Ki values for Src and Bcr-Abl are 16 pM and 30 pM, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50 values of less than 1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy .
|
-
-
- HY-10181GL
-
|
BMS-354825 (GMP Like)
|
Bcr-Abl
Src
Autophagy
Apoptosis
|
Cancer
|
|
Dasatinib (GMP Like) (BMS-354825 (GMP Like)) is Dasatinib (HY-10181) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib also induces apoptosis and autophagy.
|
-
-
- HY-101570G
-
|
Peposertib; M3814
|
DNA-PK
BCRP
|
Cancer
|
|
Nedisertib (GMP) (Peposertib (GMP)) is Nedisertib (HY-101570) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Nedisertib is an orally active selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of less than 3 nM. Nedisertib also acts as a modulator of ABCG2, capable of reversing ABCG2-mediated multidrug resistance (MDR), thus providing new strategies for combination therapy. By inhibiting DNA double-strand break repair, Nedisertib can enhance the efficacy of chemotherapy and radiotherapy. Nedisertib exhibits antitumor activity .
|
-
-
- HY-128952G
-
|
SG3249
|
Drug-Linker Conjugates for ADC
DNA Alkylator/Crosslinker
|
Cancer
|
|
Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .
|
-
-
- HY-159642G
-
|
TYRA-300
|
FGFR
ERK
|
Metabolic Disease
Cancer
|
|
Dabogratinib (TYRA-300) (GMP) is Dabogratinib (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
![5′-O-[Bis(4-methoxyphenyl)phenylmethyl]cytidine](http://file.medchemexpress.com/product_pic/hy-154198.gif)
![2’-Deoxy-O6-[2-(4-nitrophenylethyl)]guanosine](http://file.medchemexpress.com/product_pic/hy-154573.gif)
![1-(3’-O-[4,4’-Dimethoxytrityl]-alpha-L-threofuranosyl)uridine](http://file.medchemexpress.com/product_pic/hy-154526.gif)
![1-(3’-O-[4,4’-Dimethoxytrityl]-alpha-L-threofuranosyl)-thymine](http://file.medchemexpress.com/product_pic/hy-154319.gif)
![2-[(3-Pyridyl) pyrrolidin-1-yl]-2’-deoxyinosine](http://file.medchemexpress.com/product_pic/hy-154575.gif)
![5′-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine](http://file.medchemexpress.com/product_pic/hy-154779.gif)
![1-[6-(Diethoxyphosphinyl)-2-O-methyl-β-D-ribo-hexofuranosyl]uracil](http://file.medchemexpress.com/product_pic/hy-154587.gif)
![1-[6-Phosphono-2-O-methyl-β-D-ribo-hexofuranosyl]uracil](http://file.medchemexpress.com/product_pic/hy-154588.gif)
![5-[[Methyl(2,2,2-trifluoroacetyl)amino]methyl]-2-thiouridine](http://file.medchemexpress.com/product_pic/hy-152735.gif)
![6-Amino-9-[2-deoxy-β-D-ribofuranosyl]-9H-purine](http://file.medchemexpress.com/product_pic/hy-154610.gif)
![N-Benzoyl-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-3′-deoxyadenosine](http://file.medchemexpress.com/product_pic/hy-154298.gif)
![2’-Deoxy-2’-fluoro-N3-[3-(tert-butoxycarbonyl) amino]propyluridine](http://file.medchemexpress.com/product_pic/hy-154725.gif)
![2′-Amino-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxyuridine](http://file.medchemexpress.com/product_pic/hy-154424.gif)
![Benzo[f]tetraphene](http://file.medchemexpress.com/product_pic/hy-w011577.gif)
![2’-Deoxy-2’-fluoro-N3-[(pyrid-4-yl)methyl]uridine](http://file.medchemexpress.com/product_pic/hy-154681.gif)
![2’-Deoxy-2’-fluoro-N3-[(pyrid-4-yl)methyl]-beta-D-arabinouridine](http://file.medchemexpress.com/product_pic/hy-154658.gif)
![7-(2-Deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine](http://file.medchemexpress.com/product_pic/hy-154003.gif)
![2-Chloro-9-[(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)]-9H-purine](http://file.medchemexpress.com/product_pic/hy-154515.gif)
![2’-Deoxy-2’-fluoro-N3-[(pyrid-2-yl)methyl]-beta-D-arabinouridine](http://file.medchemexpress.com/product_pic/hy-152690.gif)
![3-β-D-Ribofuranosyl-6-hydroxymethyl-furano[2,3-d]-pyrimidin-2-one](http://file.medchemexpress.com/product_pic/hy-154029.gif)
![2-β-D-Ribofuranosyl-2H-pyrazolo[3,4-d]pyrimidine-4,6-diamine](http://file.medchemexpress.com/product_pic/hy-152408.gif)
![4,10-Dioxatri cyclo[5.2. 1.02.6]dec-8-ene-3,5-dione](http://file.medchemexpress.com/product_pic/hy-w102981.gif)
![3,5-O-[1,1,3,3-Tetrakis(1-methylethyl)-1,3-disiloxanediyl] cytidine](http://file.medchemexpress.com/product_pic/hy-154633.gif)
![1-β-D-Ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine](http://file.medchemexpress.com/product_pic/hy-152828.gif)
![6-Amino-4-hydrozino-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine](http://file.medchemexpress.com/product_pic/hy-152410.gif)
![6-Amino-4-hydroxyamino-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine](http://file.medchemexpress.com/product_pic/hy-152414.gif)
![7-(3-Deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine](http://file.medchemexpress.com/product_pic/hy-152582.gif)
![4-Amino-5-cyano-1- (β-D-ribofuranosyl)-7H-pyrrolo[2,3-d] pyrimidine](http://file.medchemexpress.com/product_pic/hy-152680.gif)
![9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[6-(4-methylpiperazinyl) pyridin-3-yl]purine](http://file.medchemexpress.com/product_pic/hy-152687.gif)
![4-Amino-1-(β-D-ribofuranosyl)-7H-pyrrolo[2.3-d]pyrimidine-5-carboxamide](http://file.medchemexpress.com/product_pic/hy-152685.gif)
![4-Methoxy-1-β-D-ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine](http://file.medchemexpress.com/product_pic/hy-152827.gif)
![7-(2,3-Anhydro-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine](http://file.medchemexpress.com/product_pic/hy-152578.gif)
![9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[6-(4-morpholinyl)pyridin-3-yl]purine](http://file.medchemexpress.com/product_pic/hy-152704.gif)
![4-Chloro-7-(2-β-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d] pyrimidine](http://file.medchemexpress.com/product_pic/hy-152818.gif)
![N1-Methyl-N3-[(2S)-2-(t-butoxycarbonyl)amino-3-(t-butoxycarbonyl)] propylpseudouridine](http://file.medchemexpress.com/product_pic/hy-152657.gif)
![6-Amino-4-methoxy-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine](http://file.medchemexpress.com/product_pic/hy-152398.gif)
![2’-Deoxy-2’-fluoro-N3-(2S)-(2-amino-3-carbonyl] propyl-beta-D-arabinouridine](http://file.medchemexpress.com/product_pic/hy-154662.gif)
![2’-Deoxy-2’-fluoro-N3-(2S)-[2-(tert-butoxy-carbonyl)-amino-3-carbonyl]propyluridine](http://file.medchemexpress.com/product_pic/hy-154724.gif)
![4-Amino-5-iodo-7-(2-β-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine](http://file.medchemexpress.com/product_pic/hy-152819.gif)
![4-Amino-1-(2-C-methyl-β-D-ribofuranosyl)-1H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile](http://file.medchemexpress.com/product_pic/hy-152718.gif)
![6-Amino-1,2-dihydro-2-β-D-ribofuranosyl-4H-pyrazolo[3,4-d]pyrimidin-4-one](http://file.medchemexpress.com/product_pic/hy-152405.gif)
![6-Amino-3-(furan-2-yl)-4-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine](http://file.medchemexpress.com/product_pic/hy-152443.gif)
![2-Amino-3,7-dihydro-5-iodo-7-β-D-ribofuranosyl-4H-pyrrolo[2,3-d]pyrimidin-4-one](http://file.medchemexpress.com/product_pic/hy-152616.gif)
![(2R-cis)-5-[Tetrahydro-5-(hydroxymethyl)-4-oxo-2-furanyl]-2,4(1H,3H)-pyrimidinedione](http://file.medchemexpress.com/product_pic/hy-154613.gif)
![Dibenzo[a,c]anthracene-13C6](http://file.medchemexpress.com/product_pic/hy-w011577s1.gif)
![5′-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine (Standard)](http://file.medchemexpress.com/product_pic/hy-154779r.gif)
![6-(2-O-Methyl-beta-D-ribofuranosyl)-3-(2-oxo-propyl)-6H-imidazo[1,2-c]pyrimidin-5-one](http://file.medchemexpress.com/product_pic/hy-152770.gif)
![2′-Azido-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxyuridine](http://file.medchemexpress.com/product_pic/hy-154423.gif)
![9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[5-(propyn-1-yl)pyridin-3-yl]purine](http://file.medchemexpress.com/product_pic/hy-154733.gif)
![9-β-D-[2'-Fluoro-2'-deoxy-arabinofuranosyl]-guanin](http://file.medchemexpress.com/product_pic/hy-w334680.gif)
![6-Amino-3-ethynyl-4-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine](http://file.medchemexpress.com/product_pic/hy-152438.gif)
